<SEC-DOCUMENT>0000950123-17-008682.txt : 20171006
<SEC-HEADER>0000950123-17-008682.hdr.sgml : 20171006
<ACCEPTANCE-DATETIME>20170929101106
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-17-008682
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20170929
<PUBLIC-REL-DATE>20171006
DATE AS OF CHANGE:		20170929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701108
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01690
		FILM NUMBER:		171109435

	BUSINESS ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-242-1600

	MAIL ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spero Therapeutics, LLC
		DATE OF NAME CHANGE:	20170316
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on
September&nbsp;29, 2017, pursuant to Section 6(e) of the Securities Act of 1933, as amended, as Amendment No. 2 to the draft registration statement. </B></P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>This Amendment No. 2 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all
information herein remains strictly confidential. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF&nbsp;1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-4590683</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">incorporation or</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">Identification Number)</P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857) <FONT STYLE="white-space:nowrap">242-1600</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ankit Mahadevia, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Spero Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857) 242-1600 </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Name,
address, including zip code, and telephone number, including area code, of agent for service) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Copies to:</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Matthew J. Gardella, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Lewis J. Geffen, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>One Financial Center</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02111</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">542-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Peter N. Handrinos, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">948-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an
offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum<BR>Aggregate Offering<BR>Price(1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration<BR>Fee(1)(2)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Includes shares of common stock that the underwriters have the option to purchase. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule&nbsp;457(o) under the
Securities Act of 1933, as amended. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule&nbsp;457(o) based on an estimate of the proposed maximum aggregate initial public offering price. </TD></TR></TABLE>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until this registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128"><B>Subject to Completion </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128"><B>Preliminary Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </B></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>PROSPECTUS</B> </U></P>
<P STYLE="margin-top:15pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g74a40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This is Spero
Therapeutics, Inc.&#146;s initial public offering. We are selling&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Currently, no public market exists for our common stock. We have applied to list our common stock on The NASDAQ Global Market under the symbol &#147;SPRO.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; under the federal securities laws and are subject to reduced public company disclosure
standards. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company.&#148; </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common
stock involves risks. See &#147;<A HREF="#toc431217_2">Risk Factors</A>&#148; beginning on page 15 of this prospectus. </B></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:34.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:7%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We refer you to &#147;<A HREF="#toc431217_18a">Underwriting</A>&#148; beginning on page&nbsp;178 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares will be ready
for delivery on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_6">Reorganization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_9">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_13">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_18">Material U.S. Federal Income and Estate Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_18a">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_21">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc431217_22">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we may authorize to be
delivered or made available to you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of
common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, or other earlier date stated in this prospectus, regardless of
the time of delivery of this prospectus or any sale of shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of shares of our common stock and the distribution of this prospectus outside of the United States.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain industry data and market data included in this prospectus were obtained from independent
third-party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. All of management&#146;s estimates presented herein are based upon management&#146;s review of independent
third-party surveys and industry publications prepared by a number of sources and other publicly available information. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to
give undue weight to such estimates. We believe that the information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a
variety of factors, including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth
under the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Unless the context otherwise requires or as otherwise noted, we use the
terms &#147;Spero Therapeutics,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Spero Therapeutics, Inc. and its subsidiaries taken as a whole. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum
oral carbapenem-class antibiotic for use in adults to treat multi-drug resistant, or MDR, Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier,
more convenient and cost-effective treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of
existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat
MDR Gram-negative infections in the hospital setting. In addition, we are developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We believe that
our novel product candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic-resistant bacteria are one of the largest threats to global health, and their prevalence is increasing. While the majority of
life-threatening infections historically resulting from antibiotic-resistant bacteria are acquired in the hospital setting, there is an increasing incidence of MDR pathogens in the community setting. Antibiotics used currently for first-line empiric
treatment of MDR bacterial infections suffer from significant limitations and risks, including narrow spectrums of coverage and safety and tolerability concerns, and they can be associated with serious adverse effects. In addition, there are no oral
antibiotics commercially available that can reliably be used in adults with MDR Gram-negative bacterial infections, which limits the ability of physicians to prevent hospitalizations and transition patients home from the hospital after receiving <FONT
STYLE="white-space:nowrap">IV-administered</FONT> therapy. This increasing prevalence of drug resistance and MDR Gram-negative bacteria, as well as the limitations of existing therapies and traditional drug development approaches, highlights the
critical need for novel therapies, and in particular orally administrable agents, that are capable of overcoming these obstacles to effective patient treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To address the
foregoing, we are developing a portfolio of novel product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994: Novel Antibiotic with Potential to be the First Broad-Spectrum Oral Carbapenem for Use in Adults</I></B>.<B><I> </I></B>SPR994 is our novel oral formulation of tebipenem pivoxil, or tebipenem, a
carbapenem-class antibiotic marketed by Meiji Seika Pharma Co. Ltd., or Meiji, in Japan as Orapenem since 2009 for common pediatric infections. While we are developing SPR994 to be effective against a broad spectrum of MDR bacterial infections, our
initial focus is on the treatment of complicated urinary tract infections, or cUTIs. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Based on our <FONT STYLE="white-space:nowrap">pre-investigational</FONT> new drug
application meeting, or <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting, with the U.S. Food and Drug Administration, or FDA, and subject to our receiving favorable results from our Phase 1 clinical trial of SPR994 acceptable to the FDA, we
believe we will be able to progress directly to a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI. We filed a Clinical Trial Notification, or CTN, in Australia in September 2017 and plan to initiate in the fourth quarter of 2017 a
Phase 1 dose-selection clinical trial of SPR994 in Australia. A CTN enables conduct of clinical trials in Australia similar to an investigational new drug application, or IND, in the United States. We expect to report
<FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> Thereafter, we plan to hold a <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA to confirm no
additional clinical trials or preclinical studies are required prior to initiating a Phase 3 clinical trial. Subject to feedback from the FDA, we plan to submit an IND and commence in the second half of 2018 a pivotal Phase 3 clinical trial of
SPR994 for the treatment of cUTI in support of a new drug application, or NDA. We expect to receive data from the planned <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort evaluating the pharmacokinetics and safety of SPR994 in cUTI patients in
the first half of 2019 and to receive <FONT STYLE="white-space:nowrap">top-line</FONT> data from our planned pivotal Phase 3 clinical trial in <FONT STYLE="white-space:nowrap">mid-2020.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Our clinical strategy is supported by extensive safety data underlying tebipenem&#146;s regulatory approval in Japan and long-standing use in
Japan for common pediatric infections. Approximately 1,200 subjects, including approximately 741 adults, have been dosed with tebipenem at a range of doses in clinical and pharmacologic studies. We have rights to use all clinical data generated by
Meiji, including two exploratory Phase 2 trials that were conducted in Japan in patients with cUTI, the first indication in which we intend to study SPR994. Further, we have received Qualified Infectious Disease Product, or QIDP, designation from
the FDA for SPR994 for the treatment of cUTI, community-acquired bacterial pneumonia, or CABP, and moderate to severe diabetic foot infections, or DFI, which provides priority review of SPR994 for regulatory approval by the FDA. The QIDP designation
for SPR994, however, does not guarantee a faster development process or ensure FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Given the observed activity of SPR994
against MDR Gram-negative bacteria, we view the market opportunity for SPR994, if successfully developed and approved, to be substantial. Urinary tract infections, or UTIs, are among the most common bacterial diseases worldwide, with significant
clinical and economic burden. QuintilesIMS estimates that between 33 to 34 million patients either visit their physician or are hospitalized for a UTI or otherwise suspected of experiencing a UTI in the United States annually. Our initial study for
SPR994 will focus on patients who suffer from a subset of UTIs called cUTIs, which affect approximately 4.9 million patients in the United States annually. A significant majority of UTIs, including cUTIs, are caused by a group of MDR Gram-negative
bacteria called <I>Enterobacteriaceae</I>. Nearly 30% to 35% of UTIs are resistant to the oral antibiotics currently used for treatment, which has led to increased use of IV-administered therapeutics such as carbapenems. We believe SPR994 is well
positioned to address the unmet need for an oral therapy for community-acquired UTIs and may offer physicians an option for treating MDR UTIs while avoiding patient hospitalization. In addition, we believe SPR994 has the potential to accelerate
hospital discharge and obviate the need for continued IV-administered therapy at home by transitioning discharged patients to an at-home oral therapy. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Potentiator Platform (SPR741 and SPR206): Our Technology Designed to Enhance the Effectiveness of Existing
Antibiotics Against MDR Gram-Negative Bacterial Infections</I></B>.<B><I> </I></B>Our Potentiator Platform is our novel and proprietary technology that we believe will enable us to develop drugs to expand the spectrum and potency of existing
antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Gram-negative bacteria are a subset of bacterial organisms distinguished by the presence of an outer cell membrane. Our Potentiator
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Platform relies on our chemical and biological insights that enable us to design molecules that have demonstrated the ability to specifically enhance the permeability of this outer cell membrane.
Our Potentiator Platform molecules are designed to treat Gram-negative bacterial infections through interactions with the bacteria&#146;s outer cell membrane either as a monotherapy or by <FONT STYLE="white-space:nowrap">co-administering</FONT> our
potentiator molecules with existing antibiotics, thereby making the existing antibiotics more effective by clearing a path for them to enter and kill the bacteria. Specifically, our Potentiator Platform molecules utilize a mechanism of action
whereby they interact with constituents of the outer cell membrane called lipopolysaccharides, or LPS, resulting in a loss of outer membrane integrity and increased permeability, thereby potentially allowing antibiotics that were previously excluded
to enter the Gram-negative bacteria where they become active. Since we began work on our Potentiator Platform in 2015, we have generated two development-stage product candidates: SPR741 and SPR206. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Our lead potentiator product candidate is SPR741, an IV-administered agent that has demonstrated <I>in vitro</I> the ability to expand the
spectrum and increase the potency of a co-administered antibiotic against Gram-negative bacteria, including organisms identified by the Centers for Disease Control and Prevention, or the CDC, and the World Health Organization, or the WHO, as urgent
and serious threats to human health. SPR741 has demonstrated an ability to potentiate over two dozen existing antibiotics by expanding their activity against Gram-negative pathogens. While previous attempts by others to develop agents that interact
with the bacteria&#146;s outer membrane using the mechanism of action employed by SPR741 have, to our knowledge, failed in preclinical testing and Phase&nbsp;1 clinical trials due to safety concerns, data from our Phase 1 single-ascending dose, or
SAD, clinical trial of SPR741 demonstrate it was well tolerated at doses up to and including 800 mg. We expect to report full data from our Phase&nbsp;1 clinical trial of SPR741 in the fourth quarter of 2017 and hold a pre-IND meeting with the FDA
shortly thereafter. We plan to submit a Clinical Trial Authorisation application, or CTA, in the United Kingdom in the fourth quarter of 2017 and thereafter initiate a Phase&nbsp;1b drug-drug interaction clinical trial of SPR741 in the United
Kingdom. Subject to the outcome of our pre-IND meeting and the results of our Phase&nbsp;1b drug-drug interaction clinical trial of SPR741, we expect to submit an IND and initiate a Phase&nbsp;2 combination clinical trial of SPR741 with a generic
antibiotic for the treatment of cUTI in the first half of 2018. We also intend to apply to the FDA for QIDP designation for SPR741 during the fourth quarter of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In addition, we are developing next-generation potentiator molecules, exemplified by our product candidate SPR206. SPR206 is designed to also
have antibiotic activity as a single agent against certain MDR and extremely drug resistant, or XDR, bacterial strains. SPR206 is currently in preclinical development. We intend to initiate scale-up manufacturing to support the initiation of FDA
good laboratory practice, or GLP, toxicology and safety pharmacology studies in 2018. Pending successful results from such studies, we plan to submit an IND (or foreign equivalent) and begin our Phase 1 clinical trial of SPR206 during the second
half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">There is a need to expand the clinical utility of widely used antibiotic agents by addressing the loss of potency of such
drugs against Gram-negative strains of bacteria in high-risk patients. We believe SPR741 has the key characteristics to be developed as a potentiator to be used in combination with multiple first-line empiric therapies for a wide variety of
life-threatening infections caused by Gram-negative pathogens. We believe SPR206 has the potential, if successfully developed and approved, to become a new standard of care for Gram-negative infections given the lack of coverage of these infections
by generic and recently approved agents, and even new agents in development. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR720: Novel Antibiotic with Potential to be the First Oral Treatment for Pulmonary <FONT STYLE="white-space:nowrap">Non-tuberculous</FONT> Mycobacterial Infections</I></B>.<B><I> </I></B>SPR720 is our novel oral
therapy product candidate designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections, or NTM, a rare lung infection often occurring in patients with compromised immune systems, including
human immunodeficiency virus, or HIV, or respiratory conditions, such as cystic fibrosis, chronic obstructive pulmonary disease, asthma and bronchiectasis. The annual prevalence of NTM is increasing at an estimated rate of 8% per year. The current
treatment for NTM is lengthy and involves combination therapy, often including three or more antibiotics, including injectables. None of these treatments are approved for use in NTM. Treatment failure is common and is often due to poor compliance or
patients&#146; inability to tolerate the regimen. Many patients experience progressive lung disease and mortality is high. We believe SPR720, if successfully developed, has the potential to be the first oral antibiotic approved for the treatment of
this debilitating orphan disease. <I>In vitro </I>and <I>in vivo </I>studies have demonstrated the potency of SPR720 against a range of bacteria causing NTM, including <I>Mycobacterium abscessus</I>, a highly resistant strain causing infections with
high mortality. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">SPR720 is currently in preclinical development. We have conducted
<FONT STYLE="white-space:nowrap">28-day</FONT> toxicity studies in rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates in accordance with GLP regulations. We have also observed activity as good as or better than positive controls in
<I>in vitro </I>and <I>in vivo</I> studies, including in an acute model infection caused by <I>Mycobacterium abscessus</I> murine pneumonia. We are currently testing SPR720 in <I>in vivo</I> studies to assess activity across other pathogens of
interest. Pending further evidence of <I>in vivo</I> activity and positive results from our additional toxicity studies, we plan to initiate a Phase&nbsp;1 clinical trial of SPR720 in the first half of 2019. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our product candidates, their status, our current estimated development timeline and anticipated milestones. We
have distinguished between ongoing development activities and planned development activities that have yet to occur. Our ability to advance our product candidates and achieve our anticipated milestones on the timeline depicted in the table will
depend on our successful completion of preclinical and clinical studies with results that are satisfactory to the FDA or comparable foreign regulatory authorities. See &#147;Risk Factors&#151;Risks Related to Product Development and
Commercialization.&#148; Without such success, our planned development activities and anticipated milestones will not occur on the timeline depicted in the table, or at all. Our planned development activities and anticipated milestones are based on
our current assumptions, estimates and plans, which may change. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g58u08.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to identify, develop and commercialize novel treatments for MDR bacterial infections, focusing on areas of high unmet medical need
for safe and effective antibiotic treatments. Key elements of our strategy are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Rapidly advance our lead product candidate SPR994 through clinical development and regulatory approval</I></B>.<B><I> </I></B>We intend to initiate a Phase 1 dose-selection clinical trial of SPR994 in Australia in
the fourth quarter of 2017, and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> Following completion of this trial, leveraging data and <FONT
STYLE="white-space:nowrap">know-how</FONT> we have licensed from Meiji, we intend to hold a pre-Phase 3 meeting with the FDA, file an IND and commence in the second half of 2018 a pivotal Phase&nbsp;3 clinical trial of SPR994 for the treatment of
cUTI in support of an NDA. We expect to receive data from the planned <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort evaluating the pharmacokinetics and safety of SPR994 in cUTI patients in the first half of 2019 and to receive <FONT
STYLE="white-space:nowrap">top-line</FONT> data from our planned pivotal Phase 3 clinical trial in mid-2020. In addition to cUTI, we believe SPR994 has the potential to treat other serious and life-threatening infections. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Rapidly advance our lead potentiator product candidate SPR741 through clinical development and regulatory approval and advance our other product candidates</I></B>. We recently completed a Phase 1, <FONT
STYLE="white-space:nowrap">two-part,</FONT> randomized, double-blind, placebo-controlled, dose-escalation clinical trial of SPR741. The SAD data from this clinical trial indicated that SPR741 was well tolerated at single doses up to and including
800 mg. We expect to report full data from the Phase&nbsp;1 clinical trial in the fourth quarter of 2017 and hold a pre-IND meeting with the FDA shortly thereafter. We plan to submit a CTA in the United Kingdom in the fourth quarter of 2017 and
thereafter initiate a Phase&nbsp;1b drug-drug interaction clinical trial of SPR741 in the United Kingdom. Subject to the outcome of our pre-IND meeting and the results of our Phase&nbsp;1b drug-drug interaction clinical trial of SPR741, we expect to
submit an IND and initiate a Phase&nbsp;2 combination clinical trial of SPR741 with a generic antibiotic for the treatment of cUTI in the first half of 2018. In addition, we expect to continue to advance our other product candidates, including
SPR206 and SPR720, through preclinical and clinical development. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize the value of our Potentiator Platform through collaborations with other pharmaceutical companies</I></B>.<B><I> </I></B>We intend to pursue strategic collaborations with other pharmaceutical companies to
leverage our Potentiator Platform. These collaborations may include global collaborations to advance the entire Potentiator Platform, or product-specific deals pairing our product candidates with collaborators&#146; antibiotics, whether generic or
novel, with the intention of enhancing those antibiotics&#146; performance and efficacy. We believe this approach will facilitate the capital-efficient development and commercialization of our Potentiator Platform. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to pursue collaborations with <FONT STYLE="white-space:nowrap">non-commercial</FONT> organizations for scientific expertise and funding support</I></B>.<B><I> </I></B>We are currently receiving funding
support of up to an aggregate of $15.0&nbsp;million from the U.S. National Institute of Allergy and Infectious Diseases, or NIAID, the U.S. Department of Defense, or DoD, and the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator,
or <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a public-private partnership funded by the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services. We intend to continue to
collaborate with government agencies and <FONT STYLE="white-space:nowrap">non-profit</FONT> foundations to support the development of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Expand our portfolio of product candidates for the treatment of MDR infections</I></B>.&nbsp;Since our inception, we have focused on identifying and developing antibiotics to treat MDR infections, and we are using
our expertise to aggressively build and expand a portfolio of product candidates for the treatment of such infections. Our management team has deep-rooted relationships in the academic, medical and corporate infectious disease community, which
provide us visibility into new and innovative therapies under development. We believe the greatest unmet medical needs for safe and effective antibiotic treatments lie among infections due to MDR bacteria, as patients with these infections often
have limited or inadequate therapeutic options, leading to high rates of mortality. The increasing prevalence of drug resistance and MDR bacteria, and the limitations of existing therapies and traditional drug development approaches, highlight the
critical need for novel therapies capable of overcoming resistance, particularly orally administrable agents. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Establish global commercialization and marketing capabilities</I></B><I>.</I><B><I> </I></B>We have global
commercialization rights to all of our product candidates, with the exception of SPR994 in certain contractually specified Asian countries. Our management team has significant expertise in the commercialization of infectious disease treatments.
Prior to joining us, members of our management team have collectively played leading roles in the approval and launch of 11 infectious disease products. We intend to build a targeted sales force and directly commercialize our product
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
candidates in the United States in both hospital and community settings. Outside the United States, we intend to enter into collaborations with third parties to develop and market our product
candidates in targeted geographical markets. By collaborating with companies that have an existing commercial presence and experience in such markets, we believe we can efficiently maximize the commercial potential of our product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Problem: Growing Antibiotic Resistance in the Hospital and Community Setting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are drugs used to treat infections that are caused by bacteria. Prior to the introduction of the first antibiotics in the 1930s
and 1940s, bacterial infections were often fatal. Today, antibiotics are used routinely to treat and prevent infections. There are two main varieties of bacteria, Gram-negative bacteria and Gram-positive bacteria, which are distinguished by
structural differences in their cell envelope. Gram-positive bacteria are surrounded by a single lipid membrane and a thick cell wall, while Gram-negative bacteria are encircled by two lipid membranes, an inner membrane and an outer membrane, with a
thinner cell wall in between. Antibiotics that target Gram-negative bacteria must be specifically designed to cross both the inner and outer membranes to enter the bacteria. The outer membrane, with its lipopolysaccharide, or <FONT
STYLE="white-space:nowrap">LPS,-containing</FONT> outer leaflet, represents a significant barrier to the entry into the bacteria by antibiotics and is a significant contributor toward reduced potency of many agents in treating Gram-negative
bacterial infections. A study of 13,796 patients in intensive care units around the world reported in 2009 that 51% of patients experienced bacterial infections, and of these patients 62% were infected by Gram-negative organisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic resistance is one of the largest threats to global health, and resistance rates are increasing. Antibiotic resistance can affect
anyone, of any age and in any country. According to the CDC, each year in the United States at least 2&nbsp;million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of
these infections. Approximately 70% of the pathogens that cause these infections are resistant to at least one drug, meaning the incidence rate of serious infections is increasing and the proportion of the infections caused by MDR pathogens is
increasingly seen as an emerging threat to world health. The CDC estimates that the excess annual cost resulting from these infections in the United States is as high as $20&nbsp;billion. According to the CDC, among all of the bacterial resistance
problems, Gram-negative pathogens, which cause a majority of all bacterial infections, are particularly worrisome because they are becoming resistant to nearly all drugs that would be considered for treatment. In February 2017, the WHO published a
list of Gram-negative bacteria based on the urgency of need for new antibiotics and highlighted a critical group of MDR Gram-negative bacteria that pose a particular threat to human health, including <I>Acinetobacter, Pseudomonas</I> and various
<I>Enterobacteriaceae</I> (including <I>Klebsiella</I>, <I>E. coli</I>, <I>Serratia</I> and <I>Proteus</I>). These pathogens are associated with significant mortality because the increased incidence of antibiotic resistance has limited the number of
effective treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is an acute need for new antibiotics to treat MDR bacterial infections, as few new antibiotics capable
of addressing such infections have been approved recently for commercialization or are in clinical development. Further, the majority of MDR bacterial infections historically have been acquired in the hospital setting, where they have been treated
using <FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics. However, increasingly such infections are being acquired in the community setting, emphasizing the need for orally administrable antibiotics that can effectively treat such
infections. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates Overcome Limitations of Available Treatment Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics currently used for first-line empiric treatment of MDR bacterial infections and NTM suffer from significant limitations. We
believe that our product candidates will overcome these limitations, as described below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994 is designed to address the lack of orally administrable antibiotics to prevent hospitalization and permit <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> switch
therapy in resistant Gram-negative infections</I></B>. Many of the most commonly used antibiotics for MDR Gram-negative infections are only available in an <FONT STYLE="white-space:nowrap">IV-administered</FONT> formulation. Treatment with effective
orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective treatment of patients following hospitalization. However, currently there are no oral antibiotics
commercially available that can reliably be used in adults with MDR Gram-negative infections. SPR994 is an orally administrable tablet that has the potential to treat such infections in both the community and hospital settings, thereby preventing
certain hospitalizations and enabling patients to transition to oral treatment. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR741 and SPR206 are designed to address the decline of novel and effective <FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics to treat MDR Gram-negative infections in the hospital
setting</I></B>. First-line empiric antibiotics, such as levofloxacin, ceftazidime and <FONT STYLE="white-space:nowrap">piperacillin-tazobactam,</FONT> have experienced diminished utility as the number of bacterial strains resistant to these
antibiotics has increased. Due to gaps in the spectrum of coverage of antibiotics currently on the market, physicians are often confronted with the need to design complicated multi-drug cocktails for patients with serious infections. We believe that
SPR741 will address the need for more effective treatments against MDR Gram-negative bacterial infections by expanding the spectrum and potency of existing antibiotics, including formerly inactive antibiotics. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR720 is designed to be the first oral treatment of NTM where treatment failure is common and no approved therapies exist</I></B>. The current treatment for NTM is lengthy and involves combination therapy, often
including three or more antibiotics, including injectables. None of these combination treatments are currently approved for use in NTM. Treatment failure is common and is often due to poor compliance or patients&#146; inability to tolerate the
regimen. Many patients experience progressive lung disease as a result of NTM, and mortality rates are high, ranging from 29% to 69% within five years of diagnosis. We believe SPR720, if successfully developed, has the potential to be the first
approved oral agent for NTM, and it has demonstrated effectiveness <I>in vitro</I> and <I>in vivo</I> against a range of pathogens, including <I>Mycobacterium abscessus</I>, a highly resistant organism causing NTM with a high rate of mortality.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more
fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history, have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We do not expect to generate
any product revenue for the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are heavily dependent on the success of our lead product candidates SPR994 and SPR741, both of which are still
under development. Our ability to generate product revenue is substantially </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
dependent on our ability to further develop, obtain marketing approval for and successfully commercialize SPR994 and SPR741. Even if we receive regulatory approval to market product candidates,
the market may not be receptive to our product candidates upon their commercial introduction, which will prevent us from becoming profitable. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect that we will need substantial additional funding. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our clinical program for SPR994 is subject to a number of specific risks, including our use of a new formulation of the active pharmaceutical ingredient of SPR994 and our reliance, in part, on clinical data from two
exploratory Phase 2 clinical trials conducted by Meiji in Japan, which were not conducted in accordance with FDA guidance for clinical trials in patients with cUTI, as support for our clinical plan to proceed from a Phase 1 dosage-selection clinical
trial directly to a pivotal Phase 3 clinical trial. If the FDA were to discount significantly the value of this clinical data, our clinical path for SPR994 could be materially delayed and we could incur material costs associated with conducting
additional clinical trials. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If our planned clinical trials of SPR994, SPR741 or any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not
otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on third parties to conduct our preclinical studies and clinical trials and to manufacture preclinical and clinical supplies of SPR994 and SPR741. If the third parties do not perform satisfactorily, we may not
be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our success depends in large part on our ability to obtain and maintain patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally, with respect to our
proprietary chemistry technology and our product candidates. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position will be harmed. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this
prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June 30, 2017, through a series
of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a Delaware corporation. Our principal executive offices are located at 675 Massachusetts Avenue, Cambridge, Massachusetts
02139, and our telephone number is (857) <FONT STYLE="white-space:nowrap">242-1600.</FONT> Our website address is <I>www.sperotherapeutics.com</I>. The information contained on, or that can be accessed through, our website is not part of this
prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The mark &#147;Spero
Therapeutics&#148; is our common law trademark. All other service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or
</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
display of other companies&#146; trade names, trademarks or service marks to imply a relationship with, or an endorsement or sponsorship of us by, these other companies. Solely for convenience,
trademarks and tradenames referred to in this prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended
to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reorganization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As more fully described
in the section titled &#147;Reorganization&#148;, on June&nbsp;30, 2017, we completed a series of transactions pursuant to which Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc., with Spero Therapeutics, Inc. continuing as the
surviving corporation. In connection with this reorganization, by operation of law, we acquired all of the assets of Spero Therapeutics, LLC and assumed all of its liabilities and obligations. Further, each issued and outstanding preferred and
common unit of Spero Therapeutics, LLC outstanding immediately prior to the reorganization was converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series. These transactions are collectively
referred to in this prospectus as the Reorganization. The purpose of the Reorganization was to reorganize our corporate structure so that Spero Therapeutics, Inc. would continue as a corporation and so that our existing investors would own our
capital stock rather than equity interests in a limited liability company. Except as context otherwise requires, all information included in this prospectus is presented giving effect to the Reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain
an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the completion of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at
least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Securities Exchange Act of 1934,
as amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such
fiscal year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of
specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may present in this prospectus only two years of audited financial statements, in addition to any required unaudited financial statements, with correspondingly reduced Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of
2002, or the Sarbanes-Oxley Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may provide reduced disclosure about our executive compensation arrangements; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute arrangements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have chosen to opt out of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new
or revised accounting standards. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition periods for complying with new or revised accounting standards is irrevocable. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have an option within 30 days of the date of this prospectus to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock in this offering.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase
additional shares in full), assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our planned Phase&nbsp;1 clinical trial of SPR994 and initiate our planned pivotal Phase 3 clinical
trial of SPR994; to fund additional preclinical activities relating to SPR741 and our planned Phase&nbsp;2 clinical trial of SPR741; to fund additional preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies to develop SPR206
and SPR720; and for working capital and other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the section titled &#147;Risk Factors&#148; beginning on page&nbsp;15 of this prospectus and other information included in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of
our common stock. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed NASDAQ Global Market symbol </P></TD>
<TD>&#147;SPRO&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
51,036,137 shares of our common stock outstanding as of August&nbsp;31, 2017, after giving effect to the automatic conversion of all outstanding shares of preferred stock into an aggregate of 48,998,475 shares of common stock immediately prior to
the completion of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">9,368,492 shares of common stock issuable upon the exercise of outstanding stock options as of August 31, 2017, at an exercise price of $0.97 per share; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,482,201&nbsp;shares of common stock available for future issuance as of August 31, 2017 under our 2017 Stock Incentive Plan, or the 2017 Plan; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock that will become available for future issuance under the 2017 Plan in connection
with this offering, as well as any automatic increases in the number of shares of our common stock reserved for issuance under the 2017 Plan. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes or gives effect
to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options described above after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in
this offering; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all of our outstanding shares of our preferred stock into an aggregate of 48,998,475&nbsp;shares of common stock immediately prior to the completion of this offering; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> prior to the completion of this
offering; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a <FONT STYLE="white-space:nowrap">one-for-</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reverse stock split of our common stock effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read the following summary consolidated financial data together with our consolidated financial statements and the related notes
appearing elsewhere in this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived
the consolidated statement of operations data for the years ended December&nbsp;31, 2015 and 2016 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data for the six
months ended June&nbsp;30, 2016 and 2017 and the consolidated balance sheet data as of June&nbsp;30, 2017 have been derived from our unaudited consolidated financial statements appearing elsewhere in this prospectus and have been prepared on the
same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal, recurring adjustments, necessary for a fair statement of the financial information in
those statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units and redeemable convertible preferred shares to redemption value</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders of Spero Therapeutics, Inc.,
basic and diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares outstanding, basic and diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 15 to our consolidated financial statements appearing elsewhere in this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders of Spero
Therapeutics, Inc. and on the calculation of pro forma basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data give effect to (i) our issuance and sale in July 2017 of 61,880 shares of Series C preferred stock for gross proceeds of $0.1 million and the resulting change to the conversion ratios of
our Series A and Series B preferred stock, (ii) the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 48,998,475 shares of common stock immediately prior to the completion of this offering and (iii) our
payment of $2.6 million to Northern Antibiotics Oy Ltd., or Northern, upon the completion of this offering under our license and exchange agreement with Northern. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give further effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in
this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information discussed
above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents,
working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the
assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
together with all of the other information in this prospectus, including our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face.
Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be
materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Our Financial Position and Need for Additional Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each year since our inception and anticipate that we will
continue to incur significant losses for the foreseeable future, and if we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating history. We have not generated any revenue from the sale of
products and have incurred losses in each year since our inception in 2013. As of June&nbsp;30, 2017, we had an accumulated deficit of $72.0&nbsp;million. All of our product candidates are in development, none have been approved for sale and we may
never have a product candidate approved for commercialization. We have financed our operations primarily through private placements of our preferred stock, collaborations and government funding for research and development. We have devoted
substantially all of our financial resources and efforts to research and development, including preclinical and clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we conduct planned clinical trials of our lead product candidate, SPR994, and our lead potentiator product candidate, SPR741, seek
marketing approval for SPR994 and SPR741 if clinical trials are successful, and continue to advance our other product candidates, including SPR206 and SPR720, through preclinical and clinical development. Our expenses will also increase
substantially if and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional clinical trials of our product candidates, including the commencement of clinical trials for SPR994 and SPR741, which include our planned Phase 1 clinical trial of SPR994 in the fourth quarter of
2017, our planned pivotal Phase 3 clinical trial of SPR994 in the second half of 2018 and our planned Phase 2 clinical trial of SPR741 in the first half of 2018; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to discover and develop additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a
public reporting company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If our product candidates fail to demonstrate safety and efficacy in clinical trials, do not gain
regulatory approval, or do not achieve market acceptance following regulatory approval and commercialization, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; equity and working capital. If we are unable to achieve and sustain profitability, the market value of
our common stock will likely decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with developing biopharmaceutical
products, we are unable to predict the extent of any future losses or when, if ever, we will become profitable. Our expenses could increase if we are required by the FDA, or any comparable foreign regulatory authority to perform studies in addition
to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
expect that we will need substantial additional funding. If we are unable to raise capital when needed, or do not receive payment under our government awards, we could be forced to delay, reduce or eliminate our product development programs or
commercialization efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a
time-consuming, expensive and uncertain process that takes years to complete. We expect that our expenses will increase substantially as we commence and advance our planned clinical trials of SPR994 and SPR741, seek marketing approval for SPR994 and
SPR741 if clinical trials are successful, and continue to advance our other product candidates, including SPR206 and SPR720, through preclinical and clinical development. If we obtain marketing approval for SPR994, SPR741 or any other product
candidate, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Some of these expenses may be incurred in advance of marketing approval, and could be substantial. Accordingly,
we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or
at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our
operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . Our cash forecasts are based on assumptions that may prove to be wrong, and we
could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of
circumstances beyond our control. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trial of SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trial of SPR741; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of our other product candidates and potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government awards that we have applied for; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for SPR994, SPR741 and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and
manufacturing capabilities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of SPR994 or SPR741; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our <FONT STYLE="white-space:nowrap">non-dilutive</FONT> sources of funding are expected to be awards from <FONT
STYLE="white-space:nowrap">CARB-X</FONT> and the DoD that provide partial funding for the development of our potentiator product candidates, including SPR741, and an award from NIAID for our SPR720 program. Our DoD cooperative agreement is
structured as a single, <FONT STYLE="white-space:nowrap">two-year</FONT> $1.5&nbsp;million award. We are eligible for the full funding from the DoD and there are no options to be exercised at a later date. The NIAID award is structured as a base
period followed by a single option. For the base period of March&nbsp;1, 2017 through February&nbsp;28, 2018, NIAID committed funding of approximately $0.6&nbsp;million for the SPR720 program. If exercised by NIAID, the approximately
$0.4&nbsp;million option will have a period of performance from March&nbsp;1, 2018 through February&nbsp;28, 2019. The <FONT STYLE="white-space:nowrap">CARB-X</FONT> award is structured as a base period followed by two sequential options. In March
2017, <FONT STYLE="white-space:nowrap">CARB-X</FONT> committed funds of $1.5&nbsp;million to support SPR741 development efforts for the period from April&nbsp;1, 2017 to March&nbsp;31, 2018. <FONT STYLE="white-space:nowrap">CARB-X</FONT> has
subsequent <FONT STYLE="white-space:nowrap">12-month</FONT> options for $3.9&nbsp;million and $1.4&nbsp;million that it can exercise at its discretion on April&nbsp;1, 2018 and April&nbsp;1, 2019, respectively. The NIAID and <FONT
STYLE="white-space:nowrap">CARB-X</FONT> awards are subject to termination for convenience at any time by NIAID and <FONT STYLE="white-space:nowrap">CARB-X.</FONT> Neither organization is obligated to provide funding to Spero beyond the base period
amounts from Congressionally approved annual appropriations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including
purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs
through public or private equity offerings, debt financings or collaborations, licensing arrangements and government funding arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations,
even if we believe that we have sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional
capital through the sale of common stock, convertible securities or other equity securities, your ownership interest may be materially diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution
protections that could adversely affect your rights as a common stockholder. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our
ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely affect our ability to conduct our business. In addition, securing additional financing would require a
substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may
adversely affect our management&#146;s ability to oversee the development of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its
report on our audited financial statements included in this prospectus. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The report from our independent registered public
accounting firm for the year ended December&nbsp;31, 2016 includes an explanatory paragraph stating that our recurring losses from operations since inception and required additional funding to finance our operations raise substantial doubt about our
ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going
concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or
a part of their investment. After this offering, future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional
financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially
reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards may be limited. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had U.S. federal, state and foreign net operating loss carryforwards, or NOLs, of $39.8&nbsp;million,
$39.6&nbsp;million and $3.8&nbsp;million, respectively. Our NOLs begin to expire in 2033. Utilization of these NOLs depends on many factors, including our future income, which cannot be assured. These NOLs could expire unused and be unavailable to
offset our future income tax liabilities. In addition, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an &#147;ownership change,&#148; which
is generally defined as a greater than 50% change, by value, in its equity ownership by 5% stockholders over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income may be limited. We have not determined if we have experienced Section&nbsp;382 ownership changes in the past and if a portion of our NOLs is subject to an
annual limitation under Section&nbsp;382. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, including this offering, some of which may be outside of our control. If we determine
that an ownership change has occurred and our ability to use our historical NOLs is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for
our future viability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were established in 2013 and began operations in 2014. Our operations to date have been limited to
financing and staffing our company, developing our technology and developing SPR994, SPR741 and our other product candidates. We have not yet demonstrated an ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing
approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success
or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to transition from a development-focused company to a company with commercial activities, and
we may experience difficulties in managing this transition, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen
expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial
activities. We may not be successful in such a transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect our financial condition and operating results to continue to
fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future
operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development and Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of SPR994 and SPR741, both of which are still under development, and our ability to develop, obtain marketing
approval for and successfully commercialize SPR994 and SPR741. If we are unable to develop, obtain marketing approval for and successfully commercialize SPR994 or SPR741, or if we experience significant delays in doing so, our business could be
materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and have invested a significant portion of our efforts and
financial resources in the development of SPR994 and SPR741 as product candidates for the treatment of MDR bacterial infections. Our near-term prospects are substantially dependent on our ability to develop, obtain marketing approval for and
successfully commercialize either or both of SPR994 and SPR741. The success of SPR994 and SPR741 will depend on several factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third-party manufacturers to obtain manufacturing supply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtainment and maintenance of patent, trade secret protection and regulatory exclusivity, both in the United States and internationally, including our ability to maintain our license agreement with Meiji with respect to
SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales of SPR994 and SPR741, if approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of SPR994 and SPR741, if approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition with other therapies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of SPR994 and SPR741 following approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Successful
development of SPR994 and SPR741 for any additional indications would be subject to these same risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond our control, including clinical development, the regulatory
submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for, or successfully commercialize
SPR994 or SPR741, or if we experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no
experience as a company in obtaining regulatory approval for a drug. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a company, we have never obtained regulatory approval
for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for
any current or future product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical, nonclinical or manufacturing validation studies before it will reconsider our applications.
Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT> studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend
more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing SPR994 or SPR741, generating revenues and achieving and sustaining profitability. It is also possible that additional
studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which
would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of SPR994, SPR741 or any other product candidate that we may advance to clinical trials fail to demonstrate safety and efficacy to
the satisfaction of the FDA or comparable foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of SPR994, SPR741 or any other product candidate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may not commercialize, market, promote, or sell any
product candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities, such as the European Medicines Agency, or EMA, and we may
never receive such approvals. We must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. Clinical testing is
expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted an NDA to the FDA or similar applications to comparable foreign regulatory authorities for any
of our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The clinical development of SPR994, SPR741 and any of our other product candidates is susceptible to the
risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a trial or across a broad population of patients, the occurrence of severe adverse events, failure to comply with protocols or applicable
regulatory requirements, and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered
significant setbacks in clinical trials, even after promising results in earlier nonclinical studies or clinical trials. The results of preclinical and other nonclinical studies and/or early clinical trials of our product candidates may not be
predictive of the results of later-stage clinical trials. Notwithstanding any promising results in early nonclinical studies or clinical trials, we cannot be certain that we will not face similar setbacks. For example, although SPR994 is a new
formulation of the active pharmaceutical ingredient tebipenem that exhibited a favorable safety and efficacy profile during Phase&nbsp;2 clinical trials conducted by Meiji and a global pharmaceutical company, which we refer to as Global Pharma, in
Japan, we may nonetheless fail to achieve success in our clinical trials. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, preclinical and clinical data are often susceptible to varying interpretations and
analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results
of our clinical trials warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among
clinical trial participants, among others. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one of the factors listed or otherwise.
Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to detect
toxicity of or intolerability of our product candidates or may determine that our product candidates are toxic or not well tolerated when that is not in fact the case. In the case of our clinical trials, results may differ on the basis of the type
of bacteria with which patients are infected. We cannot assure you that any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen events prior to, during, or as a result of, clinical trials that could delay or
prevent us from obtaining regulatory approval for SPR994, SPR741 or any of our other product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly
among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce unfavorable or inconclusive results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate participants may drop out of these
clinical trials at a higher rate than we anticipate or we may fail to recruit suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us
in a timely manner, or at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or
other unexpected characteristics of the product candidate; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements
or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs, of the
institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, if any, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of
factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, or changes in governmental regulations or administrative actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of SPR994, SPR741 or any other product candidate beyond the trials
and testing that we contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these trials or tests are unfavorable or are only modestly favorable or if there are safety
concerns associated with SPR994, SPR741 or any other product candidate, we may: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional unplanned costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to remove the product from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
failure to successfully initiate and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.
Our product candidate development costs will also increase if we experience delays in testing or marketing approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will
begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to
commercialize our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and
results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of SPR994, SPR741 or any other product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, clinical development activities could be delayed or otherwise
adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on
our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may not be able to initiate, continue or complete clinical trials of SPR994, SPR741 or any other product candidate that we develop if we are
unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the EMA. Patient enrollment is a significant factor in the timing of
clinical trials, and is affected by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to clinical sites; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the eligibility criteria for participation in the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit clinical trial investigators with appropriate experience; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new
drugs that may be approved for the indications that we are investigating; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain patient consents; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The inclusion and exclusion criteria for our contemplated Phase 3 clinical trials of SPR994 and SPR741 may adversely affect our enrollment
rates for patients in these trials. In addition, many of our competitors also have ongoing clinical trials for product candidates that would treat the same indications as we contemplate for SPR994 and SPR741, and patients who would otherwise be
eligible for our clinical trials may instead enroll in clinical trials of our competitors&#146; product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our inability to
enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development
costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would
cause the value of our company to decline and limit our ability to obtain additional financing if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future legislation, and/or regulations
and policies adopted by the FDA, the EMA or similar regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials of SPR994, SPR741 and our other product candidates and potential product candidates.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities.
The policies of the FDA and other regulatory authorities may change and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional laws may be enacted or government regulations may be promulgated that could prevent, limit, delay but also accelerate regulatory review of our product candidates. For example, in
December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but all of its provisions have not yet been implemented. Among
other things, the Cures Act provides a new &#147;limited population&#148; pathway for certain antibacterial and antifungal drugs, or LPAD, but the FDA has not yet issued guidance regarding the LPAD. Additionally, in August 2017, FDA issued final
guidance setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. We cannot predict what if any effect the
Cures Act or any existing or future guidance from FDA will have on the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical program for SPR994 is
subject to a number of specific risks that may affect the outcome of the trial, including the use of a new formulation of the active pharmaceutical ingredient, tebipenem. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our planned pivotal Phase 3 clinical trial of SPR994 is subject to a number of specific risks arising from our clinical program and the design
of the trial. We have not conducted a clinical trial of SPR994 in patients with cUTI, who will be the subjects of the clinical trial, and we have no direct clinical evidence that SPR994 is effective in treating cUTIs in humans. Although we believe
that SPR994 has the potential to treat cUTI in humans based on the results of our nonclinical <I>in vitro</I> and <I>in vivo</I> animal model studies, together with Meiji&#146;s and Global Pharma&#146;s Phase 2 clinical trial results, these results
are not necessarily predictive of the results of our planned clinical trials and we cannot guarantee that SPR994 will demonstrate the expected efficacy in our planned pivotal Phase 3 clinical trial patients. We also cannot guarantee that the
projections made from the pharmacokinetic and pharmacodynamic models that we developed from our nonclinical and clinical SPR994 studies will be validated in our planned pivotal Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may face competition in enrolling suitable patients as a result of other companies conducting clinical trials for antibiotic
product candidates that are intended to treat similar infections, resulting in slower than anticipated enrollment in our trials. Enrollment delays in the trial may result in increased development costs for SPR994, or slow down or halt our product
development for SPR994. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>To support our accelerated clinical development strategy for SPR994, we are relying, in part, on clinical data from two
exploratory Phase 2 clinical trials conducted by Meiji (ME1211) and Global Pharma <FONT STYLE="white-space:nowrap">(L-084</FONT> 04) in Japan, which were not conducted in accordance with FDA guidance for clinical trials in patients with cUTI. To the
extent that these clinical trial design differences limit our use of the clinical data, our proposed clinical trial plan for SPR994 with the FDA could be materially delayed and we may incur material additional costs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are significant differences in the trial design for the two exploratory Phase 2 clinical trials conducted by Meiji and Global Pharma in
Japan compared to the clinical trial design described by the FDA in its guidance for clinical trials in patients with cUTI, including: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The studies were not randomized and were open-label and had no comparator arm. Treatment assignments were made by the investigators. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The inclusion criteria specified complicated UTI as an entry criterion, but other than retained residual volume (100 ml) there were no other criteria defining &#147;complicated&#148; UTI. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While <FONT STYLE="white-space:nowrap">L-084</FONT> 04 excluded patients who received prior antibiotics and who had no clinical response, there were no parameters or limits for inclusion (e.g., less than 24 hours of a
potentially effective antibiotic or number of doses). ME1211 did not specifically mention prior antibiotic use. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While urine cultures were obtained at baseline, these were not quantitative, and there was no minimum requirement for bacterial load for entry. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While microbiological outcome was assessed, the definitions did not include a minimum reduction in bacterial counts (i.e., a reduction to less than 10<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> cfu/ml).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical outcomes were global assessments by the investigators and did not specifically mention the resolution of baseline signs and symptoms. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint was not a composite of both clinical and microbiological outcomes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If
the FDA were to discount significantly the value of these clinical data as support for our clinical plan to proceed from a Phase 1 dosage-selection clinical trial directly to a pivotal Phase 3 clinical trial of SPR994, then our clinical pathway for
SPR994 could be materially delayed and we could incur material costs associated with conducting additional clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our planned Phase 2
clinical trial of SPR741 is subject to a number of specific risks that may affect the outcome of the trials, including the need to <FONT STYLE="white-space:nowrap">co-administer</FONT> SPR741 with a companion antibiotic. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our planned Phase 2 clinical trial of SPR741 is subject to a number of specific risks arising from our clinical program and the design of the
trial. We have not conducted a clinical trial of SPR741 in patients with cUTI, who will be the subjects of the clinical trial, and we have no direct clinical evidence that SPR741 as a potentiator in combination with a partner antibiotic has the
potential to treat cUTI in humans. Although we believe that SPR741 as a potentiator in combination with a partner antibiotic has the potential to treat cUTI in humans based upon our nonclinical <I>in vitro</I> and <I>in vivo</I> animal model study
results, these results are not necessarily predictive of the results in humans. We cannot guarantee that SPR741 as a potentiator in combination with a partner antibiotic will demonstrate the efficacy we expect to observe in patients in our planned
Phase&nbsp;2 clinical trial. We also cannot guarantee that the projections made from the pharmacokinetic and pharmacodynamic models that we developed from our nonclinical and clinical SPR741 studies will be validated in our planned Phase&nbsp;2
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may face competition in enrolling suitable patients as a result of other companies conducting clinical
trials for antibiotic product candidates that are intended to treat similar infections, resulting in slower than anticipated enrollment in our trials. Enrollment delays in the trials may result in increased development costs for SPR741, or slow down
or halt our product development and approval process for SPR741. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Serious adverse events or undesirable side effects or other unexpected properties
of SPR994, SPR741 or any other product candidate may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative
consequences following marketing approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Serious adverse events or undesirable side effects caused by, or other unexpected
properties of, our product candidates could cause us, an institutional review board, or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label, the imposition of distribution or use
restrictions or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If SPR994, SPR741 or any of our other product candidates is associated with serious or unexpected adverse events or undesirable side
effects, the FDA, the IRBs at the institutions in which our studies are conducted, or a DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny
approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.
Any of these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While the active pharmaceutical
ingredient in SPR994, tebipenem, is approved in Japan, our formulation of tebipenem, SPR994, has not yet been tested extensively in patients. There may be unforeseen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serious adverse events or side effects that differ from those seen in the Japanese studies. To date, patients treated with the active ingredient in SPR994 have experienced drug-related side
effects including diarrhea, temporary increases in hepatic enzymes, allergic reactions, rash, and convulsions. To date, SPR741 has generally been well tolerated in clinical trials conducted in healthy subjects and there have been no reports of
serious adverse events related to SPR741. Our planned Phase 2 clinical trial, however, will involve dosing a larger population of patients than were included in the ongoing Phase 1 clinical trial and additional adverse events may emerge in
subsequent clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If unexpected adverse events occur in any of our planned clinical trials, we may need to abandon development
of our product candidates, or limit development to lower doses or to certain uses or subpopulations in which the undesirable side effects or other unfavorable characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Undesirable side effects or other unexpected adverse events or properties of SPR994, SPR741 or any of our other product candidates could arise
or become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our trials could be suspended or terminated and the FDA or comparable foreign regulatory
authorities could order us to cease further development of, or could deny approval of, SPR994, SPR741 or our other product candidates. If such an event occurs after such product candidates are approved, a number of potentially significant negative
consequences may result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw the approval of such product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to recall a product or change the way such product is administered to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require one or more post-market studies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of a &#147;black box&#148; warning; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to implement a REMS including the creation of a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product may become less competitive; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if a product candidate does obtain regulatory approval, it may never achieve the market acceptance by physicians,
patients, hospitals, third-party payors and others in the medical community that is necessary for commercial success and the market opportunity may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we obtain FDA or other regulatory approvals and are able to launch SPR994, SPR741 or any other product candidate commercially, the
product candidate may not achieve market acceptance among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
physicians, patients, hospitals (including pharmacy directors) and third-party payors and, ultimately, may not be commercially successful. For example, physicians are often reluctant to switch
their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their
physicians recommend switching products or they are required to switch therapies due to lack of coverage and reimbursement for existing therapies. Market acceptance of any product candidate for which we receive approval depends on a number of
factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of the product candidate as demonstrated in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of physicians to prescribe the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of hospital pharmacy directors to purchase the product for their formularies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance by physicians, patients, operators of hospitals and treatment facilities and parties responsible for coverage and reimbursement of the product; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings, including distribution or use restrictions, contained in the product&#146;s approved labeling or an approved risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of other new products for the same indications; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of the approved product as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about the product or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of bacterial resistance to the product;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate at which resistance to other drugs in the target infections grows. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any failure by
SPR994, SPR741 or any other product candidate that obtains regulatory approval to achieve market acceptance or commercial success would adversely affect our business prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to
capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that
we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove
to have greater commercial potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the
commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more
advantageous for us to retain sole development and commercialization rights to the product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales,
marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing SPR994, SPR741 or any other product candidate if such product candidate is approved.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not have a sales, marketing or distribution infrastructure and we have no experience in the sale, marketing or distribution
of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource those functions to third parties. We intend to build a commercial organization in the United
States and recruit experienced sales, marketing and distribution professionals. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the
commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization costs. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire a sales force in the United States that is sufficient in size
or has adequate expertise in the medical markets that we intend to target. If we are unable to establish a sales force and marketing and distribution capabilities, our operating results may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our products on our own include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use collaborators to assist with the commercialization of SPR994, SPR741 and any other product candidate outside the United
States. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us would likely be lower than if we were to directly
market and sell products in those markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we likely would have
little control over such third parties, and any of them might fail to devote the necessary resources and attention to sell and market our products effectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be
successful in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from other pharmaceutical and biotechnology companies and our
operating results may suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is
highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to SPR994, SPR741 and our other product candidates that we may seek to develop and
commercialize in the future. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of resistant infections. Potential
competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less
costly than SPR994, SPR741 or any other product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are a variety of available oral therapies marketed for the treatment of multi-drug resistant infections that we would expect would
compete with SPR994, such as Levaquin, Cipro and Bactrim. Many of the available therapies are well established and widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of
generic products, for example in the fluoroquinolone class. If SPR994 is approved, the pricing may be at a significant premium over other competitive products. This may make it difficult for SPR994 to compete with these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are also a number of oral product candidates in clinical development by third parties that are intended to treat UTIs. Some <FONT
STYLE="white-space:nowrap">mid-</FONT> to late-stage product candidates include <FONT STYLE="white-space:nowrap">C-Scape</FONT> from Achaogen, Inc., sulopenem from Iterum Therapeutics Limited, eravacycline from Tetraphase Pharmaceuticals, Inc. and
omadacycline from Paratek Pharmaceuticals, Inc. If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing
a strong market position before we are able to enter the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are several IV-administered products marketed for the treatment of
infections resistant to first-line therapy for Gram-negative infections, including Avycaz from Allergan plc and Pfizer Inc. and Zerbaxa from Merck &amp; Co. There are also a number of IV-administered product candidates in late-stage clinical
development that are intended to treat resistant Gram-negative infections, including plazomicin from Achaogen, Inc., meropenem vaborbactam from The Medicines Company, cefiderocol from Shionogi &amp; Co. Ltd., eravacycline IV from Tetraphase
Pharmaceuticals, Inc. and relabactam from Merck &amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which
included the Generating Antibiotics Incentives Now Act, or the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products. In December 2016, the Cures Act was passed, providing
additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources than we have
to shift their efforts towards the development of product candidates that could be competitive with SPR994, SPR741 and our other product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize SPR994, SPR741 or any other product candidate, the product may become subject to unfavorable pricing regulations,
or third-party payor coverage and reimbursement policies that could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Marketing approvals, pricing, coverage and
reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing
approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a
particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which may negatively affect the revenues that we are able to generate from the sale of the product in
that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently expect that some of our product candidates, if approved, will be administered in a hospital inpatient setting. In the United
States, governmental and other third-party payors generally reimburse hospitals a single bundled payment established on a prospective basis intended to cover all items and services provided to the patient during a single hospitalization. Hospitals
bill third-party payors for all or a portion of the fees associated with the patient&#146;s hospitalization and bill patients for any deductibles or <FONT STYLE="white-space:nowrap">co-payments.</FONT> Because there is typically no separate
reimbursement for drugs administered in a hospital inpatient setting, some of our target customers may be unwilling to adopt our product candidates in light of the additional associated cost. If we are forced to lower the price we charge for our
product candidates, if approved, our gross margins may decrease, which would adversely affect our ability to invest in and grow our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent SPR994, SPR741 or any other product candidate we develop is used in an outpatient setting, the commercial success of our product
candidates will depend substantially, both domestically and abroad, on the extent to which coverage and reimbursement for these products and related treatments are available from government health programs and third-party payors. If coverage is not
available, or reimbursement is limited, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing
sufficient to realize a sufficient return on our investments. Government authorities and third-party payors, such as health insurers and managed care organizations, publish formularies that identify the medications they will cover and the related
payment levels. The healthcare industry is focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications, which could affect our ability to sell our product candidates profitably. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are
requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for SPR994, SPR741 or any other product candidate that we
commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for outpatient drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs
from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any approved products used on an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outpatient basis that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot predict whether bacteria may develop resistance to SPR994, SPR741 or our other product candidates, which could affect their revenue
potential. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing SPR994 and SPR741 to treat drug-resistant bacterial infections. The bacteria responsible for these
infections evolve quickly and readily transfer their resistance mechanisms within and between species. We cannot predict whether or when bacterial resistance to SPR994 or SPR741 may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Specifically, neither SPR994 nor SPR741 (as a potentiator in combination with a partner antibiotic) are highly active against infections
caused by <I>Pseudomonas aeruginosa</I>. As with some commercially available carbapenems, SPR994 is not active against organisms expressing a resistance mechanism mediated by enzymes known as carbapenemases. Although occurrence of this resistance
mechanism is currently rare, we cannot predict whether carbapenemase-mediated resistance will become widespread in regions where we intend to market SPR994 if it is approved. The growth of drug resistant infections in community settings or in
countries with poor public health infrastructures, or the potential use of SPR994 and SPR741 outside of controlled hospital settings, could contribute to the rise of resistance. If resistance to SPR994 or SPR741 becomes prevalent, our ability to
generate revenue from SPR994 or SPR741 could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not successful in discovering, developing and commercializing additional product
candidates, our ability to expand our business and achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although a substantial
amount of our efforts will focus on planned clinical trials and potential approval of our lead product candidate, SPR994, and our lead potentiator product candidate, SPR741, a key element of our strategy is to discover, develop and commercialize a
portfolio of therapeutics to treat drug resistant bacterial infections. We are seeking to do so through our internal research programs and are exploring, and intend to explore in the future, strategic partnerships for the development of new product
candidates. Other than SPR741, all of our potential product candidates remain in the discovery and preclinical stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research programs
to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product
candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to successfully modify candidate compounds to be active in Gram-negative bacteria or defeat bacterial resistance mechanisms or identify viable product candidates in our screening campaigns;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of bacterial resistance to potential product candidates may render them ineffective against target infections. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products
that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability claims as a result of the clinical testing of our product
candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we obtain marketing approval for and commercially sell SPR994, SPR741 or any other product candidate. For example,
we may be sued if any product that we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in
manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend
ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced resources for our management to pursue our business strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation of investigations by regulators; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend resulting litigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we maintain general
liability insurance and clinical trial liability insurance, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be
substantial. We will need to increase our insurance coverage if and when we receive marketing approval for and begin selling SPR994, SPR741 or any other product candidate. In addition, insurance coverage is becoming increasingly expensive. If we are
unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product
candidates, which could adversely affect our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may
involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and wastes, we cannot
completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability
could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees
resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. Moreover, we do not currently maintain insurance for environmental liability or toxic tort claims that may be asserted
against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws
and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition,
failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or
those of our contract research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our contract research organizations and other
contractors and consultants are vulnerable to damage or disruption from hacking, computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. While we have not, to
our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss
of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To
the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, the further development of our
product candidates could be delayed or our competitive position could be compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to depend on collaborations with third parties for the development and commercialization of some of our product candidates. Our prospects with
respect to those product candidates will depend in part on the success of those collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we expect to
commercialize SPR994 and SPR741 ourselves in the United States, we intend to commercialize both product candidates outside the United States through collaboration arrangements. If we develop SPR741 to be
<FONT STYLE="white-space:nowrap">co-administered</FONT> in combination with branded and not generic antibiotic compounds, then we will be required to obtain and maintain rights from third-party collaborators for the development and commercialization
of SPR741 <FONT STYLE="white-space:nowrap">co-administered</FONT> with such other branded antibiotic compounds. In addition, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may seek third-party collaborators for development and commercialization of other product candidates. Our likely collaborators for any marketing, distribution, development, licensing or broader
collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not currently party to any such arrangements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may derive revenue from research and development fees, license fees, milestone payments and royalties under any collaborative
arrangement into which we enter. Our ability to generate revenue from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. In addition, our collaborators
may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. As a result, we can expect to relinquish some or all of the
control over the future success of a product candidate that we license to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking and
obtaining appropriate collaborators. Collaborations involving our product candidates may pose a number of risks, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the
collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates
in the most efficient manner or at all. If a collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have to alter our development and commercialization plans if we are not able to establish collaborations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will require additional funds to complete the development and potential commercialization of SPR994, SPR741 and our other product
candidates. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. For SPR741, if we develop such product
candidate to be <FONT STYLE="white-space:nowrap">co-administered</FONT> in combination with branded and not generic antibiotic compounds, we will be required to obtain and maintain rights from third-party collaborators for such development and
commercialization of SPR741 <FONT STYLE="white-space:nowrap">co-administered</FONT> with such collaborator&#146;s branded antibiotic compound. Moreover, we intend to utilize a variety of types of collaboration arrangements for commercialization
outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking and obtaining appropriate collaborators. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation
of a number of factors. Those factors may include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design or results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market for the subject product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and complexities of manufacturing and delivering such product candidate to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for competing products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patent position protecting the product candidate, including any uncertainty with respect to our ownership of our technology or our licensor&#146;s ownership of technology we license from them, which can exist if
there is a challenge to such ownership without regard to the merits of the challenge; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to seek licenses or <FONT STYLE="white-space:nowrap">sub-licenses</FONT> to third-party intellectual property;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">industry and market conditions generally. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future
license agreements from entering into agreements on certain terms with potential collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced
number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unable to reach agreements with suitable collaborators on a timely basis, on
acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities, or increase our expenditures and undertake development or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and
additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may
not be able to further develop our product candidates or bring them to market and our business may be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
third parties to conduct some of our preclinical studies and all of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or
commercialize any of our product candidates. If they do not perform satisfactorily, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do
not independently conduct nonclinical studies that comply with GLP requirements. We also do not have the ability to independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research
organizations, clinical data management organizations, medical institutions, and clinical investigators, to conduct our clinical trials of SPR994 and SPR741 and expect to rely on these third parties to conduct clinical trials of our other product
candidates and potential product candidates. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for clinical development activities limits our control over these activities but we remain responsible for
ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a contract research organization for a trial of one of our product
candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. While we will have agreements governing their activities, we control only
certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP studies and our clinical trials play a significant role in the conduct of these studies
and trials and the subsequent collection and analysis of data. Although we rely on these third parties to conduct our <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> nonclinical studies and clinical trials, we remain responsible for ensuring
that each of our nonclinical studies and clinical trials are conducted in accordance with applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. The FDA and regulatory authorities in
other jurisdictions also require us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are
accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and
institutional review boards. If we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials
before approving our product candidates, which would delay the regulatory approval process. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register
clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under
our agreements with such contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties do not successfully carry out their
contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product
candidates. If that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurs, we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects for
SPR994, SPR741 or our other product candidates could be harmed, our costs could increase and our ability to generate revenue could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of preclinical and clinical supplies of SPR994 and SPR741 and expect to continue to do so in
connection with any future commercialization and for any future clinical trials and commercialization of our other product candidates and potential product candidates. This reliance on third parties increases the risk that we will not have
sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not currently have nor do we plan to build the internal infrastructure or capability to manufacture SPR994, SPR741 or our other product
candidates for use in the conduct of our preclinical research, our clinical trials or for commercial supply. We currently rely on and expect to continue to rely on third-party contract manufacturers to manufacture supplies of SPR994 and SPR741 and
our other product candidates, and we expect to rely on third-party contract manufacturers to manufacture commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities, if
any. Reliance on third-party manufacturers entails risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement
between us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of the third-party manufacturer to comply with applicable regulatory requirements;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently rely on a small number of third-party contract manufacturers for all of our required raw materials, drug substance and finished
product for our preclinical research and clinical trials. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of any of our product
candidates. If any of our existing manufacturers should become unavailable to us for any reason, we may incur delays in identifying or qualifying replacements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved by any regulatory agency, we intend to enter into agreements with third-party contract
manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under
cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements
outside the United States. Facilities used by our third-party manufacturers must be approved by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply to manufacturers of our product
candidates for use or sale in foreign countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our product
candidates. If our manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for
their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable product candidate. In
addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply
with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply and
criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of SPR994, SPR741 and our other product candidates and potential
product candidates may adversely affect our future profit margins and our ability to commercialize any products for which we receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire development or
commercialization rights to products, technology or data from third parties, including those for SPR994, we could lose such rights that are important to our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to agreements with Meiji for SPR994, Northern for SPR741, Vertex Pharmaceuticals for SPR720 and PBB Distributions Limited for
SPR206, and we may enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations on
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, we have an exclusive <FONT STYLE="white-space:nowrap">know-how</FONT> license with Meiji, or the Meiji License, that
gives Spero rights outside of specified countries in Asia to develop, manufacture, and commercialize SPR994 as well as the right to use, cross-reference, file or incorporate by reference any information and relevant Meiji regulatory documentation to
support any regulatory filings outside of Asia. In addition, Spero has the right to develop, manufacture and have manufactured SPR994 in Asia solely for the purpose of furthering development, manufacturing and commercialization of SPR994 outside of
Asia. In exchange for those rights, Spero is obligated to satisfy diligence requirements, including using commercially reasonable efforts to develop and commercialize SPR994 and to implement a specified development plan, meeting specified
development milestones and providing an update on progress on an annual basis. The Meiji License requires us to pay milestone payments of up to $3.0 million upon the achievement of specified clinical and regulatory milestones and royalties of a low
single-digit percentage on net sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations to Meiji or any of our other partners, our counterparties may have the right to terminate these
agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could materially adversely affect the value of the product candidate being developed under any such
agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these
agreements, including our rights to important intellectual property or technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on government funding for certain of our programs adds uncertainty to our research and
commercialization efforts with respect to those programs and may impose requirements that increase the costs of commercialization and production of product candidates developed under those government-funded programs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Aspects of our development programs are currently being supported, in part, with funding from <FONT STYLE="white-space:nowrap">CARB-X,</FONT>
the DoD and NIAID. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Contracts and grants awarded by the U.S. government, its agencies, and its partners, including our awards from <FONT
STYLE="white-space:nowrap">CARB-X,</FONT> the DoD and NIAID, include provisions that reflect the government&#146;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate agreements, in whole or in part, for any reason or no reason; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce or modify the government&#146;s obligations under such agreements without the consent of the other party; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">claim rights, including intellectual property rights, in products and data developed under such agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">audit contract-related costs and fees, including allocated indirect costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or debar the contractor or grantee from doing future business with the government; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">control and potentially prohibit the export of products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue criminal or civil remedies under the False Claims Act, False Statements Act and similar remedy provisions specific to government agreements;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the government&#146;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it
has been funded for an initial period. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may not have the right to prohibit the U.S. government from using certain
technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the
position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition,
government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to
liability for failure to comply with these terms and conditions. These requirements include, for example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specialized accounting systems unique to government awards; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adhering to stewardship principals imposed by <FONT STYLE="white-space:nowrap">CARB-X</FONT> as a condition of the award; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public disclosures of certain award information, which may enable competitors to gain insights into our research program;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandatory socioeconomic compliance requirements, including labor standards, <FONT STYLE="white-space:nowrap">non-discrimination</FONT> and affirmative action programs and environmental compliance requirements.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that
such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on
their contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs. Although
adjustments arising from government audits and reviews have not had a material adverse effect on our financial condition or results of operations in the past, we cannot assure you that future audits and reviews will not have those effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain sufficient patent protection for our technology or our product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products
similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our proprietary chemistry technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which
could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our
business. The patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify
patentable aspects of our research and development before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent position of
biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign
jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a
result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope,
strength and enforceability of our patent rights or the nature of proceedings which may be brought by us related to our patent rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our pending and future patent applications may not result in patents being issued which protect
our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States
and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The laws of foreign countries may
not protect our rights to the same extent or in the same manner as the laws of the United States. For example, even assuming the other requirements for patentability are met, currently, in the United States, the first to make the claimed invention
is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending
patent applications, or that we were the first to file for patent protection of such inventions. As a result of the America Invents Act of 2011, the United States transitioned to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system in March 2013, under which, assuming the other requirements for patentability are met, the first inventor to file a patent application is
entitled to the patent. However, as a result of the lag in the publication of patent applications following filing in the United States, we are still not be able to be certain upon filing that we are the first to file for patent protection for any
invention. Moreover, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, <I>inter partes</I> review or interference proceedings,
in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third
parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may seek to market generic versions of any approved products by submitting Abbreviated New Drug Applications to the FDA in which they claim that patents owned or licensed by us
are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our
patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents,
these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in
loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and
products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or
other intellectual property, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents,
trademarks, copyrights or other intellectual property, or those of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part,
and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do
not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our
patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business
position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted
trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we
will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the
diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are sued for infringing intellectual property rights of third parties, or otherwise become involved in disputes regarding our intellectual property rights, such litigation could be costly and time consuming and could prevent or delay us from
developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop,
manufacture, market and sell our product candidates and use our proprietary chemistry technology without infringing the intellectual property and other proprietary rights of third parties. Numerous third-party U.S. and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending applications exist in the area of antibacterial treatment, including compounds, formulations, treatment methods and synthetic processes that may be applied towards the
synthesis of antibiotics. If any of their patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the U.S. Patent and Trademark Office.
Intellectual property disputes arise in a number of areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future
intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. With respect to our Meiji License of certain know-how used in SPR994, we are neither a party
to, nor an express third-party beneficiary of, the letter agreement between Meiji and Global Pharma consenting to Meiji&#146;s arrangement with us. As such, if any dispute among the parties were to occur, our direct enforcement rights with respect
to the letter agreement may be limited or uncertain. A termination or early expiration of the head license between Meiji and Global Pharma (which currently by its terms is set to expire in January 2022) or any restriction on our ability to use the
Global Pharma know-how could have a negative impact on our development of SPR994 and adversely affect our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are found
to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product
candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement
could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third
parties could have a similar negative effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees have misappropriated the
intellectual property of a third party, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our
employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the intellectual property and other
proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed such intellectual property or other proprietary information.
Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, while we typically require our employees, consultants and
contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual
property that we regard as our own. To the extent that we fail to obtain such assignments or such assignments are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the
ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in
prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our
business would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and products, we also rely on trade secrets,
including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, in seeking to develop and maintain a competitive position. We seek to protect these trade secrets, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our consultants, independent contractors, advisors, corporate collaborators, outside scientific collaborators, contract
manufacturers, suppliers and other third parties. We, as well as our licensors, also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. Any party with whom we have executed such an
agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a
trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third
party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and
competitive position could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet registered our trademarks. Failure to secure those registrations could adversely affect our
business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not yet registered our trademarks in the United States or other countries. If we do not secure registrations
for our trademarks, we may encounter more difficulty in enforcing them against third parties than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we otherwise would, which could adversely affect our business. We have also not yet registered trademarks for any of our product candidates in any jurisdiction. When we file trademark
applications for our product candidates those applications may not be allowed for registration, and registered trademarks may not be obtained, maintained or enforced. During trademark registration proceedings in the United States and foreign
jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the United States Patent and Trademark Office and in comparable agencies in
many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks
may not survive such proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, any proprietary name we propose to use with SPR994, SPR741 or any other product candidate
in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for
confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify
under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval
and Other Legal Compliance Matters </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will
not be able to commercialize SPR994, SPR741 or our other product candidates, and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our product candidates, including SPR994 and SPR741, and the activities associated with their development and commercialization, including
their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States
and by comparable foreign regulatory authorities, with regulations differing from country to country. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We currently do not have
any products approved for sale in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in
this process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval, if any, by the FDA and comparable foreign authorities is unpredictable but typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our
existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until
we or they receive regulatory approval of an NDA from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to commercialize a product candidate in the
United States or abroad, we or our collaborators must demonstrate to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and
clinical trials can be interpreted in different ways. Even if we believe that the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities.
The FDA may also require us to conduct additional nonclinical studies or clinical trials for our product candidates either prior to or post-approval, and it may otherwise object to elements of our clinical development program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not submitted an NDA for any of our product candidates. An NDA must include extensive
preclinical and clinical data and supporting information to establish the product candidate&#146;s safety and efficacy for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls
for the product candidate. Obtaining approval of an NDA is a lengthy, expensive and uncertain process. The FDA has substantial discretion in the review and approval process and may refuse to accept for filing any application or may decide that our
data are insufficient for approval and require additional nonclinical, clinical or other studies. Foreign regulatory authorities have differing requirements for approval of drugs with which we must comply prior to marketing. Obtaining marketing
approval for marketing of a product candidate in one country does not ensure that we will be able to obtain marketing approval in other countries, but the failure to obtain marketing approval in one jurisdiction could negatively affect our ability
to obtain marketing approval in other jurisdictions. The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or abandon a program for
many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or the applicable foreign regulatory agency&#146;s disagreement with the design or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement with the interpretation of data from nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s requirement for additional nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement regarding the formulation, labeling and/or the specifications for our product candidates; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage complete the FDA or foreign regulatory approval processes and are
successfully commercialized. The lengthy review process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval, which would significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we eventually receive approval of an NDA or foreign marketing application for our product
candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, often referred to as Phase 4 clinical trials, and the FDA may require the implementation of a Risk
Evaluation and Mitigation Strategy, or REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient
population than we originally requested, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in
obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek fast track designation for SPR994, SPR741 or one or more of our other product candidates, but we might not receive such designation, and in
any case, such designation may not actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a drug is
intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a drug sponsor may apply for fast track designation by the FDA for the particular
indication under study. If fast track designation is obtained, the FDA may initiate review of sections of an NDA before the application is complete. This &#147;rolling review&#148; is available if the applicant provides and the FDA approves a
schedule for the remaining information. If we seek fast track designation for a product candidate, we may not receive it from the FDA. However, even if we receive fast track designation, fast track designation does not ensure that we will receive
marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with fast track designation compared to conventional FDA procedures. In
addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#146;s priority
review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain marketing approval in international jurisdictions, we will not be able to market our product
candidates abroad. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to market and sell SPR994, SPR741 or our other product candidates in the European Union and many
other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval
by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The approval procedure varies among countries and can involve additional testing. In
addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval
process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product
can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we receive regulatory approval for any product candidate, including SPR994 or SPR741, we will be subject to ongoing obligations and continuing
regulatory review, which may result in significant additional expense. Our product candidates, including SPR994 and SPR741, if approved, could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to
comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any product candidate, including SPR994 or SPR741, for which we obtain marketing approval will also be subject to ongoing regulatory
requirements for labeling, packaging, storage, distribution, advertising, promotion, record-keeping and submission of safety and other post-market information. For example, approved products, manufacturers and manufacturers&#146; facilities are
required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs. As such, we and our contract manufacturers will be subject to continual review and periodic inspections to
assess compliance with cGMPs. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses
for which the product may be marketed, may be subject to significant conditions of approval or may impose requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA may also require a
REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and
regulatory requirements. The FDA also imposes stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we do not restrict the marketing of our products only to their approved
indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a regulatory
agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a
product, it may impose restrictions on that product or us. In addition, if any product fails to comply with applicable regulatory requirements, a regulatory agency may: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue fines, warning letters, untitled letters or impose holds on clinical trials if any are still <FONT STYLE="white-space:nowrap">on-going;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandate modifications to promotional materials or require provision of corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the product or its manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the labeling or marketing of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require post-marketing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require withdrawal of the product from the market; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require recall of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific
actions and penalties for noncompliance; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to permit the import or export of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain supplies of the product;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue injunctions or impose civil or criminal penalties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud
and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product
candidates, including SPR994 and SPR741, for which we may obtain marketing approval. Our future arrangements with third-party payors and customers will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that
may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. These laws and regulations include, for example, the false claims and
anti-kickback statutes and regulations. At such time as we market, sell and distribute any products for which we obtain marketing approval, it is possible that our business activities could be subject to challenge under one or more of these laws and
regulations. Restrictions under applicable federal and state healthcare laws and regulations include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal healthcare Anti-Kickback Statute, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federally funded healthcare programs such as Medicare and Medicaid. A person or entity
does not need to have actual knowledge of the statute or specific intent to violate the statute in order to have committed a violation. In addition, the government may assert that a claim that includes items or services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes criminal and civil penalties, which can be enforced by private citizens through civil whistleblower and qui tam actions, against individuals or entities for knowingly presenting, or
causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or for making any false statements
relating to healthcare matters; as in the case of the federal healthcare Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate the statute in order to have committed a
violation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, also imposes obligations on certain covered entities as well as their business associates that perform certain services
involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require
notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, requires manufacturers of drugs, devices, biologics and medical supplies to report to the U.S. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests;&nbsp;and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and some state laws require pharmaceutical companies to implement compliance programs and to track and report gifts, compensation and other
remuneration provided to physicians, in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information. State laws also govern the
privacy and security of health information in some circumstances, and many such state laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will be required to spend substantial time and money to ensure that our business arrangements with third parties, and our business
generally, comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices, including arrangements we may have with physicians and other healthcare providers, some of whom may
receive stock options as compensation for services provided, do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that
our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, imprisonment, fines, exclusion from government funded
healthcare programs, such as Medicare and Medicaid, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could
affect our operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business
remains uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future policies and legislation may increase the difficulty and cost for us to obtain marketing approval of
and commercialize our product candidates and may affect the reimbursement made for any product candidate for which we receive marketing approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pricing and reimbursement environment may become more challenging due to, among other reasons, policies advanced by the new presidential
administration, federal agencies, new healthcare legislation passed by the U.S. Congress or fiscal challenges faced by all levels of government health administration authorities. Among policy makers and payors in the United States and foreign
countries, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products for which we obtain marketing approval, due to the
trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. Resulting legislative, administrative, or policy changes from payors may reduce payments for any products for which
we obtain marketing approval and could affect future revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ACA became law in the United States in March 2010 with the goals of
broadening access to health insurance, reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for the health care and health insurance industries and imposing
additional health policy reforms. Provisions of ACA may negatively affect our future revenues. For example, the ACA requires, among other things, that annual fees be paid by manufacturers for certain branded prescription drugs, that manufacturers
participate in a discount program for certain outpatient drugs under Medicare Part D, and that manufacturers provide increased rebates under the Medicaid Drug Rebate Program for outpatient drugs dispensed to Medicaid recipients. The ACA also
addresses a new methodology by which rebates owed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers under the Medicaid Drug Rebate Program are calculated for line extensions and expands oversight and support for the federal government&#146;s comparative effectiveness research of
services and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. As a
result, there have been delays in the implementation of certain aspects of the ACA. Congress and President Trump have expressed their intentions to repeal or repeal and replace the Affordable Care Act. The President issued an Executive Order and
both chambers of Congress passed bills all with the goal of fulfilling their intentions, however, to date the Executive Order has had limited effect and the Congressional activities have not resulted in passage of a law. If a law is enacted, many if
not all of the provisions of the Affordable Care Act may no longer apply to prescription drugs. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beginning on April&nbsp;1, 2013, Medicare payments for all items and services under Part&nbsp;A and&nbsp;B, including drugs and biologicals,
and most payments to plans under Medicare Part&nbsp;D were reduced by 2%, or automatic spending reductions, required by the Budget Control Act of 2011, or BCA, as amended by the American Taxpayer Relief Act of 2012. The BCA requires sequestration
for most federal programs, excluding Medicaid, Social Security, and certain other programs. The BCA caps the cuts to Medicare payments for items and services and payments to Part&nbsp;D plans at 2%. Subsequent legislation extended the 2% reduction,
on average, to 2025. As long as these cuts remain in effect, they could adversely affect payment for our product candidates. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could
limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. There
have been several U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and
restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the effect of such
changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to
more stringent product labeling and post-marketing testing and other requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we successfully commercialize one of our product candidates,
failure to comply with our reporting and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we participate in the Medicaid Drug Rebate Program if and when we successfully commercialize a product candidate, we will be required to
report certain pricing information for our product to the Centers for Medicare&nbsp;&amp; Medicaid Services, the federal agency that administers the Medicaid and Medicare programs. We may also be required to report pricing information to the U.S.
Department of Veterans Affairs. If we become subject to these reporting requirements, we will be liable for errors associated with our submission of pricing data, for failure to report pricing data in a timely manner, and for overcharging government
payers, which can result in civil monetary penalties under the Medicaid statute, the federal civil False Claims Act, and other laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, contract research organizations,
consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, principal investigators, contract research organizations, consultants
or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: FDA regulations, including those
laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal and state healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of
financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper
use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not
always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none
occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and
administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished potential profits and future earnings, and
curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Employee Matters and Managing Growth </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our chief executive officer and other key
executives and to attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of
management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of Ankit Mahadevia, M.D., our President and Chief Executive Officer, as well as the other principal
members of our management, scientific and clinical team. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be
seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to
develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms
given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we
rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have
commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates
will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to grow our organization, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of
our operations, particularly in the areas of product candidate development, regulatory affairs and sales, marketing and distribution. Our management may need to divert a disproportionate amount of its attention away from our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities to devote time to managing these growth activities. To manage these growth activities, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such
anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our inability to effectively manage the expansion of our operations may result in weaknesses in our
infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial
resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our potential ability to generate revenue
could be reduced and we may not be able to implement our business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If foreign approvals are obtained, we will be subject to additional
risks in conducting business in international markets. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain approval for commercialization of a product
candidate in a foreign country, we will be subject to additional risks related to international business operations, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with
low or lower prices) rather than buying them locally; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and
fires;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce
our financial resources. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies. If
we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or
investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We
could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel,
technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future
acquisitions or the effect that any such transactions might have on our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and This Offering
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution in the book value of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share
of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. Based on the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this offering and the initial public offering price. Purchasers of
common stock in this offering will have contributed approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate consideration paid by all purchasers of our stock but will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock
outstanding after this offering, excluding any shares of our common stock that they may have acquired prior to this offering. Furthermore, if the underwriters exercise their option to purchase additional shares in this offering or our previously
granted options to acquire common stock at prices below the assumed initial public offering price are exercised, you will experience further dilution. For a further description of the dilution that you will experience immediately after this
offering, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. This price may not reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. Although we have applied to list our common stock on The
NASDAQ Global Market, an active trading market for our shares may never develop or, if developed, be maintained following this offering. If an active market for our common stock does not develop or is not maintained, it may be difficult for you to
sell shares you purchase in this offering without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our
ability to acquire other companies or technologies by using our shares as consideration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and
fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our stock
price may be volatile. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. The market price
for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of existing or new competitive products or technologies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of clinical trials of SPR994, SPR741 and any other product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of SPR994, SPR741 and any other product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of product candidates of our competitors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or products; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders or other stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the pharmaceutical and biotechnology sectors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this &#147;Risk Factors&#148; section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry
analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our
business. We do not have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts downgrade our stock or change their opinion of our stock, our share price would
likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them
effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend
the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on
our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act and may remain an
emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not
emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation
related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and we will therefore be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our
management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a
public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of
effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase
our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer
liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are
currently evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to
their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, we will be required
to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the Securities and Exchange Commission, or the SEC,
after we become a public company. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.
To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to
continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be
able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in
the financial markets due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding
shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in
the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering, we will
have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding based on
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding as of August&nbsp;31, 2017 and giving effect to the automatic conversion of all outstanding shares of our preferred
stock into 48,998,475&nbsp;shares of our common stock immediately prior to the completion of this offering. Of these shares, the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold
by us in this offering may be resold in the public market immediately, unless purchased by our affiliates. The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are currently
restricted under securities laws or as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, but will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this
prospectus. Moreover, after this offering, holders of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, will have rights, subject to conditions, to
require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register
all&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we may issue under the 2017 Plan. Once we register these shares, they can be freely sold in the public market
upon issuance and once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; section of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital
appreciation, if any, for any return on their investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We
currently intend to retain all of our future earnings, if any, to finance the operation, development and growth of our business. To the extent that we enter into any future debt agreements, the terms of such agreements may also preclude us from
paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After
this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to control all matters submitted to stockholders for approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our executive officers and directors, combined with our stockholders who owned more than 5% of our
outstanding common stock before this offering will, in the aggregate, beneficially own shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our capital stock. As a result, if these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these
persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, defer or prevent a change in control; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrench our management and/or our board of directors;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more
difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and
restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the completion of this offering may discourage, delay or prevent a merger, acquisition or other change in
control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for
shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts
by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors such that all members of the board are not elected at one time; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of our directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the manner in which stockholders can remove directors from our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved by our board of directors;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws.</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the
person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired
by, or beneficial to, our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to advance product candidates into, and successfully complete, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory filings and approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercialization of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing, coverage and reimbursement of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the implementation of our business model, strategic plans for our business and product candidates and our Potentiator Platform; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our Potentiator Platform; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into strategic arrangements and/or collaborations and the potential benefits of such arrangements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks
emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could
differ materially and adversely from those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to
new information, actual results or to changes in our expectations, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the
documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and
events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million from our sale of
common stock in this offering, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price stays the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our planned Phase 1 clinical trial of SPR994 and initiate our planned pivotal Phase 3 clinical trial of SPR994; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund additional preclinical activities relating to SPR741 and our planned Phase 2 clinical trial of SPR741; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund additional preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies to develop SPR206 and SPR720; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder, if any, balance for working capital and other general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
believe opportunities may exist from time to time to expand our current business through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of complementary companies, medicines or technologies. While we have no current agreements,
commitments or understandings for any specific acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> at this time, we may use a portion of the net proceeds for these purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we currently anticipate that we will use the net proceeds from this offering as described above, there may be circumstances where a
reallocation of funds is necessary. Due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes.
The amounts and timing of our actual expenditures will depend upon numerous factors, including the factors described in &#147;Risk Factors.&#148; Accordingly, our management will have broad discretion in applying the net proceeds from this offering.
An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be
sufficient to enable us to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have based this estimate on assumptions that may prove to be wrong, and
we could use our available capital resources sooner than we currently expect. We do not expect the net proceeds from this offering and our existing cash and cash equivalents to be sufficient to fund development of our product candidates through
regulatory approval and commercialization. We believe the amount of net proceeds from this offering currently allocated to SPR206 and SPR720 would only be sufficient to fund those programs to the point
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
where we would be in a position to file an IND with respect to each. We will need to raise substantial additional funds before we can expect to commercialize any products. We may satisfy our
future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or
more of these sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we plan to invest the net proceeds from this offering in short-term,
interest-bearing obligations, investment-grade instruments, certificates of deposit or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of
directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors
may deem relevant. Additionally, our ability to pay dividends on our capital stock could be limited by terms and covenants of any future indebtedness. Investors should not purchase our common stock with the expectation of receiving cash dividends.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_6"></A>REORGANIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, we completed a series of transactions pursuant to which Spero Therapeutics, LLC, our former sole stockholder and
holding company parent, merged with and into Spero Therapeutics, Inc., a Delaware corporation (formerly known as Spero OpCo, Inc.), which continued to exist as the surviving corporation. Throughout this prospectus, we refer to these transactions and
the related transactions enumerated below collectively as the Reorganization. To consummate the Reorganization, we filed a certificate of merger with the Secretary of State of the State of Delaware. In connection with the Reorganization: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Spero Therapeutics, LLC&#146;s outstanding Class C preferred units received one share of our Series C preferred stock for each Class&nbsp;C preferred unit held immediately prior to the Reorganization, with an
aggregate of 29,647,582 shares of our Series C preferred stock issued in the Reorganization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Spero Therapeutics, LLC&#146;s outstanding Class&nbsp;B preferred units received one share of our Series B preferred stock for each Class&nbsp;B preferred unit held immediately prior to the Reorganization,
with an aggregate of 5,909,089 shares of our Series B preferred stock issued in the Reorganization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Spero Therapeutics, LLC&#146;s outstanding Class&nbsp;A preferred units received one share of our Series A preferred stock for each Class&nbsp;A preferred unit held immediately prior to the Reorganization,
with an aggregate of 4,202,278 shares of our Series A preferred stock issued in the Reorganization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Spero Therapeutics, LLC&#146;s outstanding Junior preferred units received one share of our Junior preferred stock for each Junior Preferred Unit held immediately prior to the Reorganization, with an
aggregate of 3,438,318 shares of our Junior preferred stock issued in the Reorganization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holders of Spero Therapeutics, LLC&#146;s outstanding common units received one share of our common stock for each common unit held immediately prior to the Reorganization, with an aggregate of 2,037,662 shares of our
common stock issued in the Reorganization; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as all incentive units issued by Spero Therapeutics LLC were intended to be profits interest within the meaning of Internal Revenue Service Revenue Procedures <FONT STYLE="white-space:nowrap">93-27</FONT> and <FONT
STYLE="white-space:nowrap">2001-43,</FONT> such incentive units were cancelled as they were deemed to be valueless based on a liquidation valuation basis for federal income tax purposes and pursuant to contractual rights under the operating
agreement of Spero Therapeutics, LLC. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our Series C preferred stock, Series B preferred stock, Series A preferred stock and
Junior preferred stock are designated as preferred stock under our amended and restated certificate of incorporation. All outstanding shares of our preferred stock convert to shares of common stock at the then-effective conversion ratios. In
connection with the Reorganization, by operation of law, we acquired all assets of Spero Therapeutics, LLC and assumed all of its liabilities and obligations. The purpose of the Reorganization was to reorganize our corporate structure so that Spero
Therapeutics, Inc. would continue as a corporation and so that our existing investors would own our capital stock rather than equity interests in a limited liability company. For the convenience of the reader, except as context otherwise requires,
all information included in this prospectus is presented giving effect to the Reorganization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to give effect to (i) our issuance and sale in July 2017 of 61,880 shares of Series C preferred stock for gross proceeds of $0.1 million and the resulting change to the conversion ratios of our
Series A and Series B preferred stock; (ii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 48,998,475 shares of common stock immediately prior to the completion of this offering; (iii)&nbsp;our
payment of $2.6&nbsp;million to Northern upon the completion of this offering under our license and exchange agreement with Northern; and (iv)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to give further effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information below is illustrative
only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table together with our
consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#147;Reorganization,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; sections of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro&nbsp;Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:42.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A, B, C and Junior), $0.001 par value; 43,297,267
shares authorized, 43,197,267 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; no shares authorized, issued or outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 61,917,986 shares authorized, 2,037,662 shares issued and
outstanding, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, 51,036,137 shares issued and outstanding, pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Spero Therapeutics, Inc. stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents,
total stockholders&#146; equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would
increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed
initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table above does not include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">10,850,693 shares of our common stock available for future issuance under the 2017 Plan as of June&nbsp;30, 2017 (of which options to purchase an aggregate of 9,373,425 shares of common stock, at an exercise price of
$0.97 per share, were granted in July 2017);&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock that will become available for future issuance under the 2017 Plan in
connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2017 Plan.<B> </B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of common stock and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of June&nbsp;30, 2017 was $(70.8)&nbsp;million, or $(34.73) per share of common stock. Our
historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and the carrying value of our redeemable convertible preferred stock, which is not included within stockholders&#146; equity
(deficit). Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the 2,037,662 shares of common stock outstanding as of June&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of June&nbsp;30, 2017 was $30.5&nbsp;million, or $0.60 per share of our common stock. Pro forma net
tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;our issuance and sale in July 2017 of 61,880 shares of Series C preferred stock for gross proceeds of $0.1 million and
the resulting change to the conversion ratios of our Series A and Series B preferred stock, (ii)&nbsp;the automatic conversion immediately prior to the completion of this offering of all outstanding shares of our preferred stock into an aggregate of
48,998,475 shares of common stock and (iii)&nbsp;our payment of $2.6 million to Northern upon the completion of this offering under our license and exchange agreement with Northern. Pro forma net tangible book value per share represents pro forma
net tangible book value divided by the total number of shares outstanding as of June&nbsp;30, 2017, after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After giving further effect to our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of
June&nbsp;30, 2017 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in pro forma as adjusted net tangible book value per
share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in pro forma as adjusted net tangible book value per share to new investors purchasing
common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share paid by new
investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual initial
public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution per share to new
investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1,000,000 shares in the number of
shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease the dilution per
share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per
share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase the dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in
the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share
after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing
stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering, assuming an initial public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of June&nbsp;30, 2017, on the pro forma as adjusted basis described above, the total number of shares of
common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this offering at an assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Average<BR>Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,036,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,337,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease)
the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by percentage points, assuming no change in the
assumed initial public offering price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase
additional shares in this offering. If the underwriters exercise their option to purchase additional shares in full, the number of shares of our common stock held by existing stockholders would be reduced to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participating in this offering would be increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The tables and discussion above are based on the number of shares of our common stock outstanding as of June&nbsp;30, 2017, and exclude: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">10,850,693 shares of our common stock available for future issuance under the 2017 Plan as of June&nbsp;30, 2017 (of which options to purchase an aggregate of 9,373,425 shares of common stock, at an exercise price of
$0.97 per share, were granted in July 2017);&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock that will become available for future issuance under the 2017 Plan in
connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2017 Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>You should read the following selected consolidated financial data together with our consolidated financial statements and the related
notes appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. The selected consolidated financial data contained in this
section are not intended to replace our consolidated financial statements and the related notes. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2015 and 2016 and the consolidated balance sheet
data as of December&nbsp;31, 2015 and 2016 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data for the six months ended June&nbsp;30, 2016 and 2017 and the
consolidated balance sheet data as of June&nbsp;30, 2017 have been derived from our unaudited consolidated financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial
statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not
necessarily indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units and redeemable convertible preferred shares to redemption value</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted(1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders of Spero Therapeutics, Inc.,
basic and diluted (unaudited)(1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares outstanding, basic and diluted (unaudited)(1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 15 to our consolidated financial statements appearing elsewhere in this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders of Spero
Therapeutics, Inc. and on the calculation of pro forma basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:46.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital (deficit) as current assets less current liabilities.<B> </B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the &#147;Selected
Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere
in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors
set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral
carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective
treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly
inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two <FONT STYLE="white-space:nowrap">IV-administered</FONT> agents, SPR741 and SPR206, designed to treat MDR Gram-negative
infections in the hospital setting. In addition, we are developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We believe that our novel product
candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception in 2013, we have focused substantially all of our efforts and financial resources on organizing and staffing our company,
business planning, raising capital, acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development activities for our product candidates. We do not have any products
approved for sale and have not generated any revenue from product sales. To date, we have funded our operations with proceeds from the sale of preferred units and bridge units and payments received under a concluded collaboration agreement and
funding from government contracts. Through June&nbsp;30, 2017, we received gross proceeds of $96.2&nbsp;million from sales of our preferred units (including proceeds from bridge units, which later converted into preferred units), $3.0&nbsp;million
under a concluded collaboration agreement and $0.5&nbsp;million from government contracts. Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend
heavily on the successful development and eventual commercialization of one or more of our product candidates. As of June&nbsp;30, 2017, we had an accumulated deficit of $72.0&nbsp;million. We expect to continue to incur significant expenses and
increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional clinical trials for our product candidates, including the commencement of clinical trials of SPR994 and SPR741, which include our planned Phase 1 clinical trial of SPR994 in the fourth quarter of
2017, our planned pivotal Phase 3 clinical trial of SPR994 in the second half of 2018 and our planned Phase 2 clinical trial of SPR741 in the first half of 2018; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to discover and develop additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a
public reporting company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval
for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization
capability to support product sales, marketing and distribution. Further, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time
as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding arrangements, collaborations, strategic alliances and marketing,
distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when,
needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the
timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain
profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, we had cash and cash equivalents of $36.3&nbsp;million. We believe that the net proceeds from this offering,
together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Reorganization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As more fully
described in the section of this prospectus titled &#147;Reorganization,&#148; on June&nbsp;30, 2017, we completed a series of transactions pursuant to which Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc., a Delaware
corporation (formerly known as Spero OpCo, Inc.), with Spero Therapeutics, Inc. continuing as the surviving corporation. As part of the transactions, each issued and outstanding preferred and common unit of Spero Therapeutics, LLC outstanding
immediately prior to the Reorganization was converted into and exchanged for shares of Spero Therapeutics, Inc. capital stock of the same class and/or series on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, and previously outstanding incentive units of Spero Therapeutics, LLC were cancelled. In July 2017, previous holders of the cancelled incentive units
who were still employed by us at the time of the Reorganization received stock options under our 2017 Stock Incentive Plan. Such stock options were granted for the same number of shares of our common stock as the number of incentive units cancelled,
and the stock options were granted on the same vesting terms as the incentive units. All such stock options have an exercise price of $0.97 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon consummation of the Reorganization, the historical consolidated financial statements of
Spero Therapeutics, LLC became the historical consolidated financial statements of Spero Therapeutics, Inc., the entity whose shares are being offered in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated or the context otherwise requires, all information included in this prospectus is presented giving effect to the
Reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may
generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To date, all of our revenue has been derived from government awards. We expect that our revenue for the next
several years will be derived primarily from payments under our government awards that we may enter into in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>U.S.
Department of Defense </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2016, we were awarded a cooperative agreement with the DoD to further develop anti-infective
agents to combat Gram-negative bacteria. The agreement is structured as a single, <FONT STYLE="white-space:nowrap">two-year</FONT> $1.5&nbsp;million award. We are eligible for the full funding from DoD and there are no options to be exercised at a
later date. The DoD funding supports next-generation potentiator discovery and screening of SPR741 partner antibiotics. We receive funding under the DoD award as we incur qualifying expenses. During the year ended December&nbsp;31, 2016 and the six
months ended June&nbsp;30, 2017, we recognized revenue of $0.3&nbsp;million and $0.3&nbsp;million, respectively, under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>NIAID </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2017,
we received an award from NIAID to conduct additional preclinical studies of SPR720. The award is structured as a <FONT STYLE="white-space:nowrap">12-month</FONT> $0.6&nbsp;million base period and $0.4&nbsp;million option period. To date, only the
base period funds have been committed. We receive funding under the NIAID award as we incur qualifying expenses. During the six months ended June&nbsp;30, 2017, we recognized less than $0.1&nbsp;million of revenue under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">CARB-X</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2017, we received an award from CARB-X, a public-private partnership funded by BARDA, within the U.S. Department of Health and Human
Services,<B> </B>to be used to screen, identify and complete Phase 1 clinical trials with at least one partner compound for SPR741, our lead potentiator product candidate. The award commits to funding of $1.5&nbsp;million over a <FONT
STYLE="white-space:nowrap">12-month</FONT> period, with the possibility of up to a total of $6.8&nbsp;million in funding over 36 months based on the successful achievement of specified milestones. We receive funding from <FONT
STYLE="white-space:nowrap">CARB-X</FONT> as we incur qualifying expenses. During the six months ended June&nbsp;30, 2017, we recognized $0.1&nbsp;million of revenue under this award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and
the development of our product candidates, which include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and development functions; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with CROs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of consultants and contract manufacturing organizations, or CMOs, that manufacture drug products for use in our preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payments made under third-party licensing agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into a
research and development services and support agreement and an option agreement with <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche, Inc. and certain of its affiliates, or Roche, whereby we were required to use our best efforts to
research and develop a specified asset while Roche would provide partial funding as well as participate in a joint steering committee for the development of this asset. The nonrefundable payments we received in 2014 and 2015 from Roche were
recognized as reductions to research and development expense. We terminated our agreement with Roche in August 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, we
entered into agreements with Pro Bono Bio PLC, or PBB, a corporation organized under the laws of England, and certain of its affiliates, including PBB Distributions Limited and Cantab Anti-Infectives Limited, or CAI, in order to acquire certain
intellectual property and government funding arrangements relating to SPR206. Under these agreements, CAI agreed to submit a request to NIAID to assign the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID contract to us. The NIAID contract
provides for development funding of up to $5.7&nbsp;million over a base period and three option periods. As of June 30, 2017, the base funding amount of $1.7&nbsp;million and the first option of $1.6&nbsp;million had been committed to CAI by NIAID.
Under our agreements with PBB and certain of its affiliates, CAI continues to perform research and development at our direction. We pay CAI for such research and development services at an agreed-upon rate that takes into consideration costs
incurred by CAI, net of amounts reimbursed to CAI by NIAID. Thus, prior to assignment of the NIAID contract to us, the amount we record as research and development expenses is net of the NIAID reimbursement amount that CAI receives. We also pay CAI
a portion of the NIAID reimbursement received at rates specified in the agreement, which we also record as research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, we have recorded research and development expenses for our SPR741 program conducted by our Australian
subsidiary net of a 43.5% research and development tax incentive we receive for qualified expenses from the Australian government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
expense research and development costs as incurred. Nonrefundable advance payments we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are
expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our direct research and development expenses are tracked on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis and consist primarily of external costs, such as fees paid to consultants, contractors, CMOs and CROs in connection with our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preclinical and clinical development activities. License fees and other costs incurred after a product candidate has been designated and that are directly related to the product candidate are
included in direct research and development expenses for that program. License fees and other costs incurred prior to designating a product candidate are included in early stage research programs. We do not allocate employee costs, costs associated
with our preclinical programs or facility expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple product development programs and, as such, are not
separately classified. The table below summarizes our research and development expenses incurred by development program: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206 and other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Product candidates in later stages of clinical development generally have higher development costs than those
in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical and
preclinical development activities in the near term and in the future. In particular, we intend to conduct additional clinical trials for our product candidates, including the commencement of our planned Phase 1 clinical trial of SPR994 in the
fourth quarter of 2017, our planned pivotal Phase 3 clinical trial of SPR994 in the second half of 2018 and our planned Phase 2 clinical trial of SPR741 in the first half of 2018, continue to discover and develop additional product candidates, hire
additional clinical, scientific and commercial personnel and acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies. As a result, we expect our research and development expenses will be higher in the
second half of 2017 compared to the first half of 2017 and will increase further in 2018. This expected increase in expenses includes the impact of an anticipated total payment to Northern of $2.6&nbsp;million upon the completion of this offering
and an anticipated payment of $1.0 million to Meiji upon the enrollment of the first patient in clinical trials. See &#147;&#151;Contractual Obligations and Commitments.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
preclinical and clinical development of any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third-party manufacturers to obtain manufacturing supply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtainment and maintenance of patent, trade secret protection and regulatory exclusivity, both in the United States and internationally, including our ability to maintain our license agreement with Meiji with respect to
SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales of SPR994 and SPR741, if approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of SPR994 and SPR741, if approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition with other therapies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of SPR994 and SPR741 following approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A change in
the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining
regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related costs, including share-based compensation, for personnel in
executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting and
audit services. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we
will incur increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Change
in Fair Value of Derivative Liabilities </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Tranche Rights</I>.<I> </I>Our Class&nbsp;A preferred units and Class&nbsp;B preferred
units provided our investors with the right to participate in subsequent offerings of Class&nbsp;A and Class&nbsp;B preferred units in the event that specified milestones were achieved, which we refer to as tranche rights. We classified the tranche
rights as derivative liabilities on our consolidated balance sheet that we remeasured to fair value at each reporting date, and we recognized changes in the fair value of the derivative associated with the tranche rights as a component of other
income (expense) in our consolidated statement of operations and comprehensive loss.&nbsp;The tranche rights were settled in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Anti-Dilution Rights</I>.<I> </I>In connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in
certain of our subsidiaries, specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., we granted the minority investors the right to maintain ownership interests at no additional cost, subject to a maximum ownership
percentage, which rights we refer to collectively as anti-dilution rights. We classify the anti-dilution rights as derivative liabilities on our consolidated balance sheet that we remeasure to fair value at each reporting date, and we recognize
changes in the fair value of the derivative liabilities associated with the anti-dilution rights as a component of other income (expense) in our consolidated statement of operations and comprehensive loss.&nbsp;As of December&nbsp;31, 2016,
anti-dilution rights related to Spero Potentiator, Inc. were fully settled as the maximum number of shares to be issued to the minority investor had been reached in August 2016. In May 2017, we repurchased 100% of the minority investor&#146;s
outstanding shares in Spero Europe, Ltd. and settled the anti-dilution rights associated with the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Contingent Prepayment
Options</I>.<I> </I>Bridge units issued to our investors in 2015 and 2016 were automatically convertible into equity units sold in a subsequent round of qualified financing at a discounted rate. We refer to these automatic conversion features as
contingent prepayment options. We classified the contingent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prepayment options as derivative liabilities on our consolidated balance sheet that we remeasured to fair value at each reporting date, and we recognized changes in the fair value of the
derivative liabilities associated with the contingent prepayment options as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. The contingent prepayment option associated with the bridge units
issued in 2015 was settled in 2015 upon the issuance of Class&nbsp;A preferred units. The contingent prepayment option associated with the bridge units issued in 2016 was settled in the first quarter of 2017 upon the issuance of Class&nbsp;C
preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Investment Option</I>.<I> </I>Our concluded collaboration agreement provided our collaboration partner with the
option to participate in our next round of financing subsequent to April 2014 in an amount up to $2.0&nbsp;million at 90.0% of the per unit price of the related financing, which option we referred to as the investment option. We classified the
investment option as a derivative liability on our consolidated balance sheet that we remeasured to fair value at each reporting date, and we recognized changes in the fair value of the derivative liability associated with the investment option as a
component of other income (expense) in our consolidated statement of operations and comprehensive loss. The subsequent financing occurred in June 2015 and our collaboration partner elected not to exercise the investment option, which then expired.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, the derivative liability of $0.2&nbsp;million recorded on our consolidated balance sheet relates only to the
anti-dilution rights held by the minority investor in Spero Gyrase, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Interest Income and Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on our cash equivalents, which are invested in money market accounts. Our interest income has not
been significant due to nominal investment balances and low interest earned on those balances.&nbsp;Other income (expense), net, consists of insignificant amounts of miscellaneous income and expenses unrelated to our core operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than
not that all of our net operating loss carryforwards and tax credits will not be realized. As of December&nbsp;31, 2016, we had federal and state net operating loss carryforwards of $39.8&nbsp;million and $39.6&nbsp;million, respectively, which may
be available to offset future income tax liabilities and begin to expire in 2033. In addition, as of December&nbsp;31, 2016, we had foreign net operating loss carryforwards of $3.8&nbsp;million, which may be available to offset future income tax
liabilities and do not expire. As of December&nbsp;31, 2016, we also had federal and state research and development tax credit carryforwards of $0.6&nbsp;million and $0.2&nbsp;million, respectively, which begin to expire in 2033 and 2028,
respectively. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the
Reorganization, our former parent company, Spero Therapeutics, LLC, was treated as a partnership for federal income tax purposes and, therefore, its owners, and not itself, were subject to U.S. federal or state income taxation on the income of Spero
Therapeutics, LLC. Prior to the Reorganization, all of Spero Therapeutics, LLC&#146;s directly held subsidiaries (including Spero Therapeutics, Inc.) were treated as corporations for U.S. federal income tax purposes and were subject to taxation in
the United States or in other countries. Upon the Reorganization, Spero Therapeutics, Inc., whose consolidated financial statements are presented in this prospectus, became the parent company for Spero Therapeutics, LLC&#146;s former subsidiaries
and these entities continue to be subject to taxation in the United States or in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Attributable to <FONT
STYLE="white-space:nowrap">Non-Controlling</FONT> Interests </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in our consolidated statement of operations and comprehensive loss is a result of minority investments in our subsidiaries, Spero Europe, Ltd., Spero
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Potentiator, Inc., Spero Cantab, Inc. and Spero Gyrase, Inc., and consists of the portion of the net income or loss of these subsidiaries that is not allocated to us. Changes in the amount of net
income (loss) attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests are directly impacted by changes in the net income or loss of our consolidated subsidiaries and by the ownership percentage of the minority investors.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, we repurchased 100% of the issued and outstanding shares of Spero Europe, Ltd. held by the minority investor. In June
2017, we repurchased 100% of the issued and outstanding shares of Spero Potentiator, Inc. held by the minority investor. In July 2017, we repurchased 100% of the issued and outstanding shares of Spero Cantab, Inc. held by the minority investor. As a
result of these repurchases of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests, for periods subsequent to each repurchase, we no longer attribute net income (loss) to the <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest. As of August&nbsp;31, 2017, the remaining non-controlling interest relates only to Spero Gyrase, Inc. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2016 and 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the six months ended June&nbsp;30, 2016 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Revenue recognized during the six months ended June&nbsp;30, 2017 of $0.4&nbsp;million was primarily due to the reimbursement of qualifying
expenses incurred in connection with the SPR741 program under our research and development award from the DoD and, to a lesser extent, revenue recognized under our awards from <FONT STYLE="white-space:nowrap">CARB-X</FONT> and NIAID related to our
SPR741 program and SPR720 program, respectively. No revenue was recognized during the six months ended June&nbsp;30, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206 and other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR994 as a product candidate in the second half of 2016. Direct costs related to our SPR994
program during the six months ended June&nbsp;30, 2017 were primarily due to preclinical and manufacturing costs as we focused efforts on formulation development, manufacturing process and manufacturing of clinical trial material in anticipation of
a Phase 1 clinical trial. We also incurred $0.6&nbsp;million of research and development expense for an upfront license fee paid to Meiji. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR741 program decreased by $2.1&nbsp;million primarily due to a decrease in preclinical costs resulting from
costs incurred in the prior year to support our clinical trial notification, or CTN, filing in Australia in the fourth quarter of 2016, partially offset by an increase in clinical trial costs and manufacturing costs. The increase in clinical trial
costs and manufacturing costs was due to our Phase 1 clinical trial of SPR741, which was initiated in the fourth quarter of 2016. Research and development expenses for our SPR741 program conducted by our Australian subsidiary were recorded net of a
43.5% research and development tax incentive for qualified expenses from the Australian government of $0.7&nbsp;million in the six months ended June&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR720 as a product candidate in the second half of 2016. Direct costs related to our SPR720 program during the six months ended
June&nbsp;30, 2017 were primarily due to preclinical and manufacturing costs related to IND-enabling toxicology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs
related to our SPR206 program and other preclinical programs decreased by $4.3&nbsp;million due primarily to the cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology incurred in the first half of 2016 of $5.1&nbsp;million,
partially offset by an increase in spending on our preclinical programs in the first half of 2017. The cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology incurred in the first half of 2016 of $5.1&nbsp;million was a result of
the issuance of equity and anti-dilution rights to Promiliad Biopharma Inc., or Promiliad, Biota Pharmaceuticals, Inc. (now Aviragen Therapeutics, Inc.), or Aviragen, and PBB, and a license fee payment of $0.5&nbsp;million we made to Vertex
Pharmaceuticals Inc., or Vertex, during the first half of 2016. We incurred increased research and development expenses related to our preclinical programs in the first half of 2017 as we focused development efforts on our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> technology. Direct costs related to our preclinical programs were recorded net of the recognition of funding received from a concluded collaboration agreement of $0.7&nbsp;million during the six months
ended June&nbsp;30, 2016. In July 2017, we designated SPR206 as a product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs of
$1.3&nbsp;million included in unallocated expenses was due to an increase in headcount in our research and development function. Personnel-related costs for each of the six months ended June&nbsp;30, 2016 and 2017 included share-based compensation
expense of less than $0.1&nbsp;million. The increase in facility-related and other costs of $0.4&nbsp;million was primarily due to new laboratory space and the increased costs of supporting a larger group of research and development personnel and
their research efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:79.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;&nbsp;&nbsp;&nbsp;<BR>June&nbsp;
30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs of $0.7&nbsp;million was primarily a result of an increase in
headcount in our general and administrative function. Personnel-related costs for the six months ended June&nbsp;30, 2016 and 2017 included share-based compensation expense of less than $0.1&nbsp;million and $0.1 million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in professional and consultant fees of $0.9&nbsp;million primarily consisted of an increase in professional fees, including
accounting, audit and legal fees as well as costs associated with ongoing business activities and our preparations to operate as a public company.&nbsp;We also incurred increased legal fees in connection with the Reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $1.6&nbsp;million for the six months ended June&nbsp;30, 2017, compared to less than $0.1&nbsp;million of other expense,
net for the six months ended June&nbsp;30, 2016. The increase in other income was primarily due to a decrease of $1.6&nbsp;million in the fair value of the derivative liability for anti-dilution rights granted to minority investors in Spero Gyrase
Inc. and Spero Europe Ltd. resulting from our discontinuation of the underlying development programs of these subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years
Ended December&nbsp;31, 2015 and 2016 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended
December&nbsp;31, 2015 and 2016: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, all recognized revenue related to the reimbursement of qualifying expenses incurred in
connection with our SPR741 program under our research and development award from the DoD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:77.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206 and other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR994 as a product candidate in the second half of 2016. Direct costs related to our SPR994
program during the year ended December&nbsp;31, 2016 were primarily due to preclinical and manufacturing costs as we focused efforts on formulation development, manufacturing process and manufacturing of clinical trial material in anticipation of a
Phase 1 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR741 program increased by $5.6&nbsp;million, primarily due to an increase of
$8.4&nbsp;million in preclinical costs, partially offset by the cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology under the program incurred in 2015 of $3.5&nbsp;million. The increase in preclinical costs was primarily due to
costs incurred to support our CTN filing in Australia in the fourth quarter of 2016. The cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology under the SPR741 program incurred in 2015 of $3.5&nbsp;million was a result of the
issuance of equity and anti-dilution rights to Northern Antibiotics Oy Ltd., or Northern. Research and development expenses for our SPR741 program conducted by our Australian subsidiary were recorded net of a 43.5% research and development tax
incentive from the Australian government of $0.1&nbsp;million in the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR720 as a product
candidate in the second half of 2016. Direct costs related to our SPR720 program during the year ended December&nbsp;31, 2016 were primarily due to preclinical costs related to <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies
and other preclinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR206 program and other preclinical programs increased by $4.0&nbsp;million
primarily due to the cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology of $5.1&nbsp;million, partially offset by a decrease in preclinical costs as we increased our focus on our more advanced programs, including SPR994 and
SPR720, which we designated as product candidates in the second half of 2016. The cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology incurred in 2016 of $5.1&nbsp;million was a result of the issuance of equity and anti-dilution
rights to Promiliad, Aviragen and PBB and a license fee payment of $0.5&nbsp;million we made to Vertex in the first half of 2016. Our preclinical programs expense was recorded net of the recognition of funding received from a concluded collaboration
agreement of $1.5&nbsp;million and $0.9&nbsp;million in the years ended December&nbsp;31, 2015 and 2016, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in
personnel-related costs included in unallocated expenses of $1.9&nbsp;million was due to an increase in headcount in our research and development function. Personnel-related costs for the years ended December&nbsp;31, 2015 and 2016 included
share-based compensation expense of less than $0.1&nbsp;million and $0.1 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
million, respectively. The increase in facility-related and other costs was primarily due to new laboratory space and the increased costs of supporting a larger group of research and development
personnel and their research efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in professional and consultant fees of $3.0&nbsp;million was primarily due to increases in legal
fees relating to business development, regulatory and patent costs, accounting and audit fees and public and investor relations fees due to ongoing business activities. Personnel-related costs increased by $1.3&nbsp;million as a result of an
increase in headcount in our general and administrative function. Personnel-related costs for the years ended December&nbsp;31, 2015 and 2016 included share-based compensation expense of less than $0.1&nbsp;million and $0.1&nbsp;million,
respectively. The increase in facility-related and other costs of $0.6&nbsp;million was primarily due to the lease of office space that we entered into at the end of 2015, software costs and general support costs for the increase in headcount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $0.6&nbsp;million for the year ended December&nbsp;31, 2016, compared to $0.2&nbsp;million for the year ended
December&nbsp;31, 2015. The increase of $0.4&nbsp;million was primarily due to a decrease of $0.6&nbsp;million in the fair value of the derivative liability associated with the Class&nbsp;B tranche rights resulting from a decrease in the fair value
of our Class&nbsp;B preferred units over the same period, partially offset by an increase of $0.2&nbsp;million in the fair value of the derivative liability associated with the investment option held by our former collaboration partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since
our inception, we have incurred significant operating losses. We have generated limited revenue to date from funding arrangements with the DoD, NIAID and <FONT STYLE="white-space:nowrap">CARB-X.</FONT> We have not yet commercialized any of our
product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. To date, we have funded our operations with proceeds from the sales of preferred units and bridge units, payments received
under a concluded collaboration agreement and funding from government contracts. Through June&nbsp;30, 2017, we had received gross proceeds of $96.2&nbsp;million from our sales of preferred units (including proceeds from bridge units, which later
converted into preferred units), $3.0&nbsp;million under a concluded collaboration agreement and $0.5&nbsp;million from government contracts. As of June&nbsp;30, 2017, we had cash and cash equivalents of $36.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash for each of the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2017, operating activities used $15.9&nbsp;million of cash, primarily resulting from our net loss of
$16.2&nbsp;million and net <FONT STYLE="white-space:nowrap">non-cash</FONT> income of $1.3&nbsp;million, partially offset by cash provided by changes in our operating assets and liabilities of $1.6&nbsp;million. Net cash provided by changes in our
operating assets and liabilities for the six months ended June&nbsp;30, 2017 consisted primarily of a $1.8&nbsp;million increase in accrued expenses and other current liabilities, a $0.3&nbsp;million decrease in prepaid expenses and other current
assets, partially offset by a $0.6&nbsp;million increase in receivables related to the Australian research and development tax incentive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2016, operating activities used $13.2&nbsp;million of cash, primarily resulting from our net loss of
$16.5&nbsp;million and cash used by changes in our operating assets and liabilities of $1.5&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.8&nbsp;million. Net cash used by changes in our operating
assets and liabilities for the six months ended June&nbsp;30, 2016 consisted primarily of a $0.5&nbsp;million increase in prepaid expenses and other current assets, a $0.7&nbsp;million decrease in advance payments from collaborator and a
$0.8&nbsp;million decrease in accounts payable, partially offset by a $0.6&nbsp;million increase in accrued expenses and other current liabilities. The decrease in advance payments from collaborator was a result of the recognition of research
funding received in prior periods as an offset to research and development expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016,
operating activities used $29.0&nbsp;million of cash, primarily resulting from our net loss of $32.6&nbsp;million and cash used by changes in our operating assets and liabilities of $0.8&nbsp;million, partially offset by net <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $4.5&nbsp;million. Net cash used by changes in our operating assets and liabilities for the year ended December&nbsp;31, 2016 consisted primarily of a $1.0&nbsp;million increase in prepaid
expenses and other current assets, a $0.9&nbsp;million decrease in advance payments from collaborator, a $0.6&nbsp;million decrease in accounts payable, a $0.4&nbsp;million increase in receivables related to our government awards and the Australian
research and development tax incentive, partially offset by a $2.3&nbsp;million increase in accrued expenses and other current liabilities. The decrease in advance payments from collaborator was primarily a result of the recognition of research
funding received in prior periods as an offset to research and development expense as well as the termination of our collaboration agreement in August 2016, at which time we recognized the remaining portion of the liability that had been recorded in
a prior year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, operating activities used $9.6&nbsp;million of cash, primarily resulting from
our net loss of $13.2&nbsp;million, partially offset by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $3.4&nbsp;million and cash provided by changes in our operating assets and liabilities of $0.2&nbsp;million. Net cash provided by
changes in our operating assets and liabilities for the year ended December&nbsp;31, 2015 consisted primarily of a $0.7&nbsp;million increase in accounts payable and a $0.4&nbsp;million increase in accrued expenses and other current liabilities,
partially offset by a decrease in advance payments from collaborator of $0.5&nbsp;million as a result of the recognition of payments received in 2014 as an offset to research and development expenses, an increase in prepaid expenses and other
current assets of $0.3&nbsp;million and an increase in deposits of $0.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Changes in accounts payable, accrued expenses and other current liabilities, and prepaid expenses
and other current assets in all periods were generally due to growth in our business, the advancement of our development programs and the timing of vendor invoicing and payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
did not use any cash for investing activities during the six months ended June&nbsp;30, 2017. During the six months ended June&nbsp;30, 2016, net cash used in investing activities was $0.4&nbsp;million, consisting of purchases of property and
equipment, primarily for our new office and laboratory spaces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2016 and 2015, net cash used in
investing activities was $0.8&nbsp;million and $0.2&nbsp;million, respectively, consisting of purchases of property and equipment, primarily for our new office and laboratory spaces. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2017, net cash provided by financing activities was $41.8&nbsp;million, consisting primarily of net
proceeds of $43.0&nbsp;million from the sale of our Class&nbsp;C preferred units, partially offset by $1.0&nbsp;million of cash used to purchase outstanding shares of Spero Potentiator, Inc. from the minority interest holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2016, net cash provided by financing activities was $25.9&nbsp;million, consisting of net proceeds
from the sale of our Class&nbsp;B preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, net cash provided by financing
activities was $34.4&nbsp;million, consisting of net proceeds of $25.9&nbsp;million from the sale of our Class&nbsp;B preferred units and proceeds of $8.5&nbsp;million the sale of our 2016 bridge units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, net cash provided by financing activities was $15.3&nbsp;million, consisting primarily of
proceeds of $8.0&nbsp;million from the sale of our 2015 bridge units and net proceeds of $7.3&nbsp;million from the sale of our Class&nbsp;A preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect
our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. In addition, upon the completion of this offering,
we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trials of SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trials of SPR741; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of our other product candidates and potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government contracts that we have applied for; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for SPR994, SPR741 and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and
manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of SPR994 or SPR741; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our
operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available
capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working
capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Without giving effect to the anticipated net proceeds from this offering, we expect that our existing cash and cash equivalents will be
sufficient to fund our operating expenses and capital expenditure requirements through February 2018. To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. We have concluded that this
circumstance raises substantial doubt about our ability to continue as a going concern within one year after the August&nbsp;25, 2017 issuance date of our consolidated financial statements for the year ended December&nbsp;31, 2016 and the six months
ended June&nbsp;30, 2017. See Note&nbsp;1 to our consolidated financial statements included elsewhere in this prospectus for additional information on our assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Similarly, in its report on our financial statements for the year ended December&nbsp;31, 2016, our independent registered public accounting
firm included an explanatory paragraph stating that our recurring losses from operations since inception and required additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity
offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred
equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed,
we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2016 and the effects that such obligations are expected to
have on our liquidity and cash flows in future periods: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;Than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;to&nbsp;3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>4&nbsp;to&nbsp;5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;Than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Reflects payments due for our leases of office and laboratory space under operating lease agreements that expire in 2019 and 2020. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As further described below, under various licensing and related agreements with third parties, we have agreed to make milestone payments and
pay royalties to third parties. We have not included any contingent payment obligations, such as milestones or royalties, in the table above as the amount, timing and likelihood of such payments are not known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Meiji, we are obligated (i)&nbsp;to make milestone payments of up to $3.0&nbsp;million upon the achievement
of specified clinical and regulatory milestones, (ii)&nbsp;to pay royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net sales of products licensed under the agreement and (iii)&nbsp;to pay to Meiji a low double-digit
percentage of any sublicense fees received by us up to $7.5&nbsp;million. A payment of $1.0 million will be due by us to Meiji upon the enrollment of the first patient in clinical trials, which we anticipate will occur in the fourth quarter of 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Northern, we are obligated to make milestone payments of up to an aggregate of $7.0&nbsp;million upon
the achievement of specified clinical, commercial and other milestones, including a total payment of $2.5&nbsp;million upon the completion of this offering. In addition, under an exchange agreement we entered into with Northern, we are obligated to
make a payment to Northern of $0.1&nbsp;million upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under an agreement we entered into with PBB, we are
obligated to make milestone payments of up to $5.8 million upon the achievement of specified clinical milestones and a payment of &pound;5.0 million ($6.5&nbsp;million as of June 30, 2017) upon the achievement of a specified commercial milestone. In
addition, we have agreed to pay to PBB royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our agreement with Vertex, we are obligated to make milestone payments of up to $81.1&nbsp;million upon the achievement of specified
clinical, regulatory and commercial milestones and to pay to Vertex tiered royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a mid single-digit to low double-digit percentage based on net sales of products licensed under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our agreement with Aviragen, we are obligated to make milestone payments of up to an
aggregate of $12.0&nbsp;million upon the achievement of specified clinical, regulatory and commercial milestones and to pay royalties of low single-digit percentages based on net sales of products we acquired under the agreement. We are no longer
pursuing development of the technology acquired under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs,
CMOs and other third parties for clinical trials, preclinical research studies and testing, manufacturing and other services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for
services provided or expenses incurred, including <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations
and commitments above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP.
The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial
statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Received from Government Contracts, Tax Incentives and Collaborations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception, we have been able to obtain partial funding for our research and development activities from government contracts,
government tax incentives and a collaboration arrangement. The classification within our statement of operations and comprehensive loss of the funding received under these arrangements is subject to management judgment based on the nature of the
arrangements we enter into, the source of the funding and whether the funding is considered central to our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Government Contracts </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
generate revenue from government contracts that reimburse us for certain allowable costs for funded projects. For contracts with government agencies, when we have concluded that we are the principal in conducting the research and development
expenses and where the funding arrangement is considered central to our ongoing operations, we classify the recognized funding received as revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have concluded to recognize funding received from the DoD, NIAID and <FONT STYLE="white-space:nowrap">CARB-X</FONT> as revenue, rather than
as a reduction of research and development expenses, because we are the principal in conducting the research and development activities and these contracts are central to our ongoing operations. Revenue is recognized as the qualifying expenses
related to the contracts are incurred. Revenue recognition commences only once persuasive evidence of a contract exists, services have been rendered, the reimbursement amounts under the contract are fixed or determinable, and collectibility is
reasonably assured. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in our consolidated balance sheet as other receivables. The related costs incurred by us are included in research and development
expenses in our consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Government Tax Incentives </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For available government tax incentives that we may earn without regard to the existence of taxable income and that require us to forego tax
deductions or the use of future tax credits and net operating loss carryforwards, we classify the funding recognized as a reduction of the related qualifying research and development expenses incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, our operating subsidiary in Australia has met the eligibility requirements to receive a 43.5% tax incentive
for qualifying research and development activities. We recognize these incentives as a reduction of research and development expenses in our consolidated statements of operations in the same period that the related qualifying expenses are incurred.
Reductions of research and development expense recognized upon incurring qualifying expenses in advance of receipt of tax incentive payments are recorded in our consolidated balance sheet as tax incentive receivables. Related to these incentives, we
recognized reductions of research and development expense of $0.1&nbsp;million during the year ended December&nbsp;31, 2016 and of $0.7&nbsp;million during the six months ended June&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For collaboration agreements with a third party, to determine the appropriate statement of operations classification of the recognized
funding, we first assess whether the collaboration arrangement is within the scope of the accounting guidance for collaboration arrangements. If it is, we evaluate the collaborative arrangement for proper classification in the statement of
operations based on the nature of the underlying activity and we assess the payments to and from the collaborative partner. If the payments to and from the collaborative partner are not within the scope of other authoritative accounting guidance, we
base the statement of operations classification for the payments received on a reasonable, rational analogy to authoritative accounting guidance, applied in a consistent manner. Conversely, if the collaboration arrangement is not within the scope of
accounting guidance for collaboration arrangements, we assess whether the collaboration arrangement represents a vendor/customer relationship. If the collaborative arrangement does not represent a vendor/customer relationship, we then classify the
funding payments received in our statement of operations and comprehensive loss as a reduction of the related expense that is incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, in 2014, we entered into a research and development services and support agreement with Roche and concluded that the agreements
were not within the scope of the accounting guidance for collaboration arrangements. Due to the <FONT STYLE="white-space:nowrap">co-funded</FONT> nature of the payments and our assessment that we did not have a vendor/customer relationship with
Roche, we recognized the nonrefundable payments received under the agreement as a reduction to the research and development expenses incurred. We terminated our agreement with Roche in August 2016. Related to payments received under this concluded
collaboration, we recognized reductions of research and development expense of $1.5&nbsp;million and $0.9&nbsp;million during the years ended December&nbsp;31, 2015 and 2016, respectively, and of $0.7&nbsp;million during the six months ended
June&nbsp;30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated
cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT>
schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at
that time. We periodically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with the preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CMOs in connection with the production of preclinical and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs in connection with preclinical and clinical studies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigative sites in connection with clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We base our expenses related to
preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on
our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and
timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to
our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization, our former parent company, Spero Therapeutics, LLC, had granted incentive units, which we accounted for as
equity-classified awards. Subsequent to the Reorganization on June&nbsp;30, 2017, we began granting common stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We measure all
share-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model, and we recognize compensation expense of those awards over the requisite service period, which is
generally the vesting period of the respective award. Generally, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For share-based awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants, we recognize compensation expense over the
period during which services are rendered by such consultants until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of our
common stock or common units and updated assumption inputs in the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing
model uses as inputs the fair value of our common stock or common units and assumptions we make for the volatility of our common stock or common units, the expected term of our common stock options and incentive units, the risk-free interest rate
for a period that approximates the expected term of our common stock options and incentive units, and our expected dividend yield. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of Common Units and Common Stock </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common units and common stock to date, the estimated fair value of our common units and common
stock has been determined by our board of directors as of the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each award grant, with input from management, considering our most recently available third-party valuations and our board of directors&#146; assessment of additional objective and subjective
factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American
Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common unit and common stock valuations were prepared using the option pricing
method, or OPM, which used a market approach to estimate our enterprise value. The OPM treats the company&#146;s securities as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the
allocation among the various holders of a company&#146;s securities changes. Under this method, the common stock and, prior to the Reorganization, the common units, have value only if the funds available for distribution to stockholders exceeded the
value of the preferred share liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common units or common stock is then applied to arrive at an indication of
value for the common units or common stock. These third-party valuations were performed at various dates, which resulted in valuations of our common units of $0.67 per unit as of February&nbsp;26, 2016 and $0.32 per unit as of March&nbsp;10, 2017,
and a valuation of our common stock of $0.97 per share as of June&nbsp;30, 2017. In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair
value of our common units and common stock as of each grant date, which may be a date later than the most recent third-party valuation date, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices at which we sold preferred units and the superior rights and preferences of the preferred stock and preferred units relative to our common stock and common units at the time of each grant; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of our research and development programs, including the status of preclinical studies and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development and commercialization and our business strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">external market conditions affecting the biotechnology industry, and trends within the biotechnology industry; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial position, including cash on hand, and our historical and forecasted performance and operating results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of an active public market for our common and preferred stock and our common units and preferred units; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or a sale of our company in light of prevailing market conditions;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the
application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our share-based compensation expense could be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, the fair value of our common stock will be determined based on the quoted market price of our
common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Grants of Stock-Based Awards </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth by grant date the number of incentive units or the number of shares of common stock subject to awards granted
between October&nbsp;1, 2016 and August&nbsp;31, 2017, the per share exercise price of the options or strike price of the incentive units, the fair value per share of common stock or common unit on each grant date and the per share/unit estimated
fair value of the award: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:86.85pt; font-size:8pt; font-family:Times New Roman"><B>Grant
Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Type of</B><br><B>Award</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:43.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR>Shares/Units<BR>Underlying<BR>Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per<BR>Share/Unit<BR>Exercise<BR>Price or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Strike<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair&nbsp;Value<BR>of&nbsp;Common<BR>Units or<BR>Common<BR>Stock per<BR>Share/Unit<BR>on
Grant<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per<BR>Share/Unit<BR>Estimated<BR>Fair
Value<BR>of Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Incentive&nbsp;unit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;7, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Incentive unit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;6, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,187,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;17, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Derivative Liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Tranche Rights </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
Class&nbsp;A preferred units and Class&nbsp;B preferred units provided our investors with tranche rights, which provided these investors the right to participate in subsequent offerings of Class&nbsp;A and Class&nbsp;B preferred units in the event
certain milestones were achieved. We classified each of the tranche rights as a derivative liability on our consolidated balance sheet because they met the definition of freestanding financial instruments that may require us to transfer assets upon
exercise. We remeasured to fair value of the derivative liabilities associated with the tranche rights at each reporting date, and we recognized changes in the fair value of the derivative liabilities as a component of other income (expense) in our
consolidated statement of operations and comprehensive loss. The tranche rights were settled in 2016, and we stopped recognizing changes in the fair value of the derivative liability related to the tranche rights at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the probability-weighted expected return method, or PWERM, which
considered as inputs the probability and time that a milestone would be achieved, the potential fair value of our preferred stock upon the exercise of the tranche right and the risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Anti-Dilution Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in certain of our subsidiaries,
specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., we granted anti-dilution rights to the minority investors. We classify the anti-dilution rights as derivative liabilities on our consolidated balance sheet because they
are freestanding instruments that represent a conditional obligation to issue a variable number of shares. We remeasure the derivative liabilities associated with the anti-dilution rights to fair value at each reporting date, and we recognize
changes in the fair value of the derivative liabilities as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. As of December&nbsp;31, 2016, anti-dilution rights related to Spero Potentiator,
Inc. were fully settled as the maximum number of shares to be issued to the minority investor had been reached in August 2016. In May 2017, we repurchased 100% of the minority investor&#146;s outstanding shares in Spero Europe, Ltd., at which time
the anti-dilution rights were settled. In periods subsequent to the settlement of any anti-dilution rights, we no longer recognize changes in the fair value of the derivative liability related to the settled anti-dilution right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using a discounted cash flow model.
The most significant assumption in the discounted cash flow model impacting the fair value of the anti-dilution rights is the probability that we would fund the maximum amount of investment providing anti-dilution protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Contingent Prepayment Option</I><B><I></I></B><I></I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Bridge units issued to our investors in 2015 and 2016 contained contingent prepayment options, whereby such units were automatically
convertible into equity units sold in a subsequent round of qualified financing at a discounted rate. We classified the contingent prepayment options as derivative liabilities on our consolidated balance sheet because the bridge units were deemed to
be more akin to debt than equity and the embedded prepayment options were at a substantial discount, thus meeting the definition of derivative liabilities. We remeasured the fair value of the derivative liabilities at each reporting date, and we
recognized changes in the fair value of the derivative liabilities associated with the contingent prepayment options as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. The contingent
prepayment option associated with the bridge units issued in 2015 was settled in 2015 upon the issuance of Class&nbsp;A preferred units. The contingent prepayment option associated with the bridge units issued in 2016 was settled in the first
quarter of 2017 upon the issuance of Class&nbsp;C preferred units in March 2017.&nbsp;In periods subsequent to the settlement of any contingent prepayment option, we no longer recognize changes in the fair value of the derivative liability related
to the settled contingent prepayment option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the PWERM, which
considered as inputs the probability and time that a subsequent round of preferred stock financing would occur and the risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Investment Option</I><B><I></I></B><I></I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our concluded collaboration agreement provided our collaboration partner with an investment option, whereby the collaboration partner could
participate in our next round of financing subsequent to April 2014 in an amount up to $2.0&nbsp;million at 90.0% of the per unit price of the related financing. We classified the investment option as a derivative liability on our consolidated
balance sheet because it met the definition of a freestanding financial instrument that may require us to transfer assets upon exercise. We remeasured the fair value of the derivative liability at each reporting date, and we recognized changes in
the fair value of the derivative liability associated with the investment option as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. The subsequent financing occurred in June 2015 and our
collaboration partner elected not to exercise the investment option, which then expired. We stopped recognizing changes in the fair value of the derivative liability related to the investment option at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of this derivative liability was determined using the PWERM, which considered as inputs the probability and time that a
qualified round of preferred stock financing would occur and the risk-adjusted discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT>
Sheet Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and
Adopted Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our
financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our cash and cash equivalents as of June&nbsp;30, 2017 consisted of cash and money market accounts. Our primary exposure to market risk is
interest income sensitivity, which is affected by changes in the general level of interest rates. Because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material
impact on our financial position or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#147;emerging growth company&#148; such as us to take advantage
of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#147;opt out&#148; of this provision
and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For so long as we are an emerging growth company we expect that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will present in this prospectus only two years of audited financial statements, in addition to any required unaudited financial statements, with correspondingly reduced Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will avail ourselves of the exemption from the requirement to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#146;s report
providing additional information about the audit and the financial statements; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley
Act;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will provide less extensive disclosure about our executive compensation arrangements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
will remain an emerging growth company for up to five years, although we will cease to be an &#147;emerging growth company&#148; upon the earliest of: (i)&nbsp;the last day of the fiscal year following the fifth anniversary of this offering,
(ii)&nbsp;the last day of the first fiscal year in which our annual revenues are $1.07&nbsp;billion or more, (iii)&nbsp;the date on which we have, during the previous rolling three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities or (iv)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; as defined in the Exchange Act.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral
carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective
treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly
inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two <FONT STYLE="white-space:nowrap">IV-administered</FONT> agents, SPR741 and SPR206, designed to treat MDR Gram-negative
infections in the hospital setting. In addition, we are developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We believe that our novel product
candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic-resistant bacteria are one of the largest threats to global health, and their prevalence is increasing. While the majority of
life-threatening infections historically resulting from antibiotic-resistant bacteria are acquired in the hospital setting, there is an increasing incidence of MDR pathogens in the community setting. Antibiotics used currently for first-line empiric
treatment of MDR bacterial infections suffer from significant limitations and risks, including narrow spectrums of coverage and safety and tolerability concerns, and they can be associated with serious adverse effects. In addition, there are no oral
antibiotics commercially available that can reliably be used in adults with MDR Gram-negative bacterial infections, which limits the ability of physicians to prevent hospitalizations and transition patients home from the hospital after receiving <FONT
STYLE="white-space:nowrap">IV-administered</FONT> therapy. This increasing prevalence of drug resistance and MDR Gram-negative bacteria, as well as the limitations of existing therapies and traditional drug development approaches, highlights the
critical need for novel therapies, and in particular orally administrable agents, that are capable of overcoming these obstacles to effective patient treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To address the foregoing, we are developing a portfolio of novel product candidates, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994: Novel Antibiotic with Potential to be the First Broad-Spectrum Oral Carbapenem for Use in Adults</I></B>.<B><I> </I></B>SPR994 is our novel oral formulation of tebipenem, a carbapenem-class antibiotic
marketed by Meiji in Japan as Orapenem since 2009 for common pediatric infections. While we are developing SPR994 to be effective against a broad spectrum of MDR bacterial infections, our initial focus is on the treatment of cUTIs. Carbapenems are
an important class of antibiotics because they are safe and effective against MDR bacterial infections. Carbapenems have emerged as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for many MDR and
other bacterial infections, but they have been available to date only intravenously for such indications. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Based on our
pre-IND meeting with the FDA, and subject to our receiving favorable results from our Phase&nbsp;1 clinical trial of SPR994 acceptable to the FDA, we believe we will be able to progress directly to a pivotal Phase&nbsp;3 clinical trial of SPR994 for
the treatment of cUTI. We filed a CTN in Australia in September 2017 and plan to initiate in the fourth quarter of 2017 a Phase&nbsp;1 dose-selection clinical trial of SPR994 in Australia. A CTN enables conduct of clinical trials in Australia
similar to an IND in the United States. We expect to report top-line data from this trial in mid-2018. Thereafter, we plan to hold a pre-Phase&nbsp;3 meeting with the FDA to confirm no additional clinical trials or preclinical studies are required
prior to initiating a Phase&nbsp;3 clinical trial. Subject to feedback from the FDA, we plan to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">
submit an IND and commence in the second half of 2018 a pivotal Phase&nbsp;3 clinical trial of SPR994 for the treatment of cUTI in support of an NDA. We expect to receive data from the planned
lead-in cohort evaluating the pharmacokinetics and safety of SPR994 in cUTI patients in the first half of 2019 and to receive top-line data from our planned pivotal Phase&nbsp;3 clinical trial in mid-2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Our clinical strategy is supported by extensive safety data underlying tebipenem&#146;s regulatory approval in Japan and long-standing use in
Japan for common pediatric infections. Approximately 1,200&nbsp;subjects, including approximately 741&nbsp;adults, have been dosed with tebipenem at a range of doses in clinical and pharmacologic studies. We have rights to use all clinical data
generated by Meiji, including two exploratory Phase&nbsp;2 trials that were conducted in Japan in patients with cUTI, the first indication in which we intend to study SPR994. Further, we have received QIDP designation from the FDA for SPR994 for the
treatment of cUTI, CABP and moderate to severe DFI, which provides priority review of SPR994 for regulatory approval by the FDA. The QIDP designation for SPR994, however, does not guarantee a faster development process or ensure FDA approval. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We have global commercialization rights to SPR994, except in certain contractually specified Asian countries. We believe that our
intellectual property portfolio will provide SPR994 protection globally, including in the United States and Europe, through 2038. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potentiator Platform (SPR741 and SPR206): Our Technology Designed to Enhance the Effectiveness of Existing Antibiotics Against MDR Gram-Negative Bacterial Infections</I></B>.<B><I> </I></B>Our Potentiator Platform
is our novel and proprietary technology that we believe will enable us to develop drugs to expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Gram-negative bacteria are a
subset of bacterial organisms distinguished by the presence of an outer cell membrane. Our Potentiator Platform relies on our unique chemical and biological insights that enable us to design molecules that specifically increase the permeability of
this outer cell membrane. Our Potentiator Platform molecules are designed to treat Gram-negative bacterial infections through interactions with the bacteria&#146;s outer cell membrane as a monotherapy or by
<FONT STYLE="white-space:nowrap">co-administering</FONT> our potentiator molecules with existing antibiotics, thereby making the existing antibiotics more effective by clearing a path for them to enter and kill the bacteria. Specifically, our
Potentiator Platform molecules utilize a mechanism of action whereby they interact with constituents of the outer cell membrane called LPS, resulting in a loss of outer membrane integrity and increased permeability, thereby potentially allowing
antibiotics that were previously excluded to enter the Gram-negative bacteria where they become active. Since we began work on our Potentiator Platform in 2015, we have generated two development-stage product candidates: SPR741 and SPR206.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Our lead potentiator product candidate is SPR741, an <FONT STYLE="white-space:nowrap">IV-administered</FONT> agent that
has demonstrated <I>in vitro</I> the ability to expand the spectrum and increase the potency of a <FONT STYLE="white-space:nowrap">co-administered</FONT> antibiotic against Gram-negative bacteria, including organisms identified by the CDC and the
WHO as urgent and serious threats to human health. SPR741 has demonstrated an ability to potentiate over two dozen existing antibiotics by expanding their activity against Gram-negative pathogens. While previous attempts by others to develop agents
that interact with the bacteria&#146;s outer membrane using the mechanism of action employed by SPR741 have, to our knowledge, failed in preclinical testing and Phase 1 clinical trials due to safety concerns, data from our Phase 1 SAD clinical trial
of SPR741 demonstrate it was well tolerated at doses up to and including 800&nbsp;mg. We expect to report full data from our Phase 1 clinical trial of SPR741 in the fourth quarter of 2017 and hold a <FONT STYLE="white-space:nowrap">pre-IND</FONT>
meeting with the FDA shortly thereafter. We plan to submit a CTA in the United Kingdom in the fourth quarter of 2017 and thereafter initiate a Phase 1b drug-drug interaction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">
clinical trial of SPR741 in the United Kingdom. Subject to the outcome of our pre-IND meeting and the results of our Phase 1b drug-drug interaction clinical trial of SPR741, we expect to submit
an IND and initiate a Phase 2 combination clinical trial of SPR741 with a generic antibiotic for the treatment of cUTI in the first half of 2018. We also intend to apply to the FDA for QIDP designation for SPR741 during the fourth quarter of 2017.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">In addition, we are developing next-generation potentiator molecules, exemplified by our product candidate SPR206. SPR206 is
designed to also have antibiotic activity as a single agent against MDR and XDR bacterial strains, including variants isolated in <I>Pseudomonas aeruginosa </I>and<I> Acinetobacter baumannii</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We believe that our intellectual property portfolio for SPR741 will provide SPR741 protection globally, including in the United States and
Europe, through 2038. Additionally, we have multiple patent applications pending for SPR206 that we believe will provide SPR206 protection globally, including in the United States and Europe, through 2035. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR720: Novel Antibiotic with Potential to be the First Oral Treatment for Pulmonary <FONT STYLE="white-space:nowrap">Non-tuberculous</FONT> Mycobacterial Infections</I></B>.<B><I> </I></B>SPR720 is our novel oral
therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, chronic obstructive pulmonary disease,
asthma and bronchiectasis. The annual prevalence of NTM is increasing at an estimated rate of 8% per year. The current treatment for NTM is lengthy and involves combination therapy, often including three or more antibiotics, including injectables.
None of these treatments are approved for use in NTM. Treatment failure is common and is often due to poor compliance or patients&#146; inability to tolerate the regimen. Many patients experience progressive lung disease and mortality is high. We
believe SPR720, if successfully developed, has the potential to be the first oral antibiotic approved for the treatment of this debilitating orphan disease. <I>In vitro</I> and <I>in vivo </I>studies have demonstrated the potency of SPR720 against a
range of bacteria causing NTM, including <I>Mycobacterium abscessus</I>, a highly resistant strain causing infections with high mortality. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">SPR720 is currently in preclinical development. We have conducted <FONT STYLE="white-space:nowrap">28-day</FONT> toxicity studies in rats and
<FONT STYLE="white-space:nowrap">non-human</FONT> primates in accordance with GLP regulations. We have also observed activity as good as or better than positive controls in <I>in vitro</I> and <I>in vivo</I> studies, including in an acute model
infection caused by <I>Mycobacterium abscessus</I> murine pneumonia.<I> </I>We are currently testing SPR720 in <I>in vivo</I> studies to assess activity across other pathogens of interest. Pending further evidence of <I>in vivo</I> activity and
positive results from our additional toxicity studies, we plan to initiate a Phase&nbsp;1 clinical trial of SPR720 in the first half of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We believe that our intellectual property portfolio for SPR720 will provide protection globally, including in the United States and Europe,
through 2033. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our product candidates, their status, our current estimated development timeline and anticipated milestones. We
have distinguished between ongoing development activities and planned development activities that have yet to occur. Our ability to advance our product candidates and achieve our anticipated milestones on the timeline depicted in the table will
depend on our successful completion of preclinical and clinical studies with results that are satisfactory to the FDA or comparable foreign regulatory authorities. See &#147;Risk Factors&#151;Risks Related to Product Development and
Commercialization.&#148; Without such success, our planned development activities and anticipated milestones will not occur on the timeline depicted in the table, or at all. Our planned development activities and anticipated milestones are based on
our current assumptions, estimates and plans, which may change. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g58u08.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to identify, develop and commercialize novel treatments for MDR bacterial infections, focusing on areas of high unmet medical need
for safe and effective antibiotic treatments. Key elements of our strategy are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Rapidly advance our lead product candidate SPR994 through clinical development and regulatory approval</I></B>.<B><I> </I></B>We intend to initiate a Phase 1 dose-selection clinical trial of SPR994 in Australia in
the fourth quarter of 2017, and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> Following completion of this trial, leveraging data and <FONT
STYLE="white-space:nowrap">know-how</FONT> we have licensed from Meiji, we intend to hold a pre-Phase 3 meeting with the FDA, file an IND and commence in the second half of 2018 a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI in
support of an NDA. We expect to receive data from the planned <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort assessing the pharmacokinetics and safety of SPR994 in cUTI patients in the first half of 2019 and to receive <FONT
STYLE="white-space:nowrap">top-line</FONT> data from our Phase 3 clinical trial in mid-2020. In addition to cUTI, we believe SPR994 has the potential to treat other serious and life-threatening infections. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Rapidly advance our lead potentiator product candidate SPR741 through clinical development and regulatory approval and advance our other product candidates</I></B>.<B><I></I></B> We recently completed a Phase 1, <FONT
STYLE="white-space:nowrap">two-part,</FONT> randomized, double-blind, placebo-controlled, dose-escalation clinical trial of SPR741. The SAD data from this clinical trial indicated that SPR741 was well tolerated at single doses up to and including
800 mg. We expect to report full data from the Phase 1 clinical trial in the fourth quarter of 2017 and hold a <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA shortly thereafter. We plan to submit a CTA in the United Kingdom in
the fourth quarter of 2017 and thereafter initiate a Phase 1b drug-drug interaction clinical trial of SPR741 in the United Kingdom. Subject to the outcome of our pre-IND meeting and the results of our Phase 1b drug-drug interaction clinical trial of
SPR741, we expect to submit an IND and initiate a Phase 2 combination clinical trial of SPR741 with a generic antibiotic for the treatment of cUTI in the first half of 2018. In addition, we expect to continue to advance our other product candidates,
including SPR206 and SPR720, through preclinical and clinical development. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize the value of our Potentiator Platform through collaborations with other pharmaceutical companies</I></B>.<B><I> </I></B>We intend to pursue strategic collaborations with other pharmaceutical companies to
leverage our Potentiator Platform. These may include global collaborations to advance the entire Potentiator Platform, or product-specific deals pairing our product candidates with collaborators&#146; antibiotics, whether generic or novel, with the
intention of enhancing those antibiotics&#146; performance and efficacy. We believe this approach will facilitate the capital-efficient development and commercialization of our Potentiator Platform. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to pursue collaborations with <FONT STYLE="white-space:nowrap">non-commercial</FONT> organizations for scientific expertise and funding support</I></B>.<B><I> </I></B>We are currently receiving funding
support of up to an aggregate of $15.0&nbsp;million from NIAID, the DoD and <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a public-private partnership funded by BARDA within the U.S. Department of Health and Human Services. We intend to continue
to collaborate with government agencies and <FONT STYLE="white-space:nowrap">non-profit</FONT> foundations to support the development of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Expand our portfolio of product candidates for the treatment of MDR infections</I></B>.<B><I></I></B><B><I></I></B><B><I>&nbsp;</I></B>Since our inception, we have focused on identifying and developing antibiotics
to treat MDR infections, and we are using our expertise to aggressively build and expand a portfolio of product candidates for the treatment of such infections. Our management team has deep-rooted relationships in the academic, medical and corporate
infectious disease community, which provide us visibility into new and innovative therapies under development. We believe the greatest unmet medical needs for safe and effective antibiotic treatments lie among infections due to MDR bacteria, as
patients with these infections often have limited or inadequate therapeutic options, leading to high rates of mortality. The increasing prevalence of drug resistance and MDR bacteria, and the limitations of existing therapies and traditional drug
development approaches, highlight the critical need for novel therapies capable of overcoming resistance, particularly orally administrable agents. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Establish global commercialization and marketing capabilities</I></B><I>.</I><B><I> </I></B>We have global commercialization rights to all of our product candidates, with the exception of SPR994 in certain
contractually specified Asian countries. Our management team has significant expertise in the commercialization of infectious disease treatments. Prior to joining us, members of our management team have collectively played leading roles in the
approval and launch of 11 infectious disease products. We intend to build a targeted sales force and directly commercialize our product candidates in the United States in both hospital and community settings. Outside the United States, we intend to
enter into collaborations with third parties to develop and market our product candidates in targeted geographical markets. By collaborating with companies that have an existing commercial presence and experience in such markets, we believe we can
efficiently maximize the commercial potential of our product candidates. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Problem: Antibiotics and Drug Resistance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antibiotic Background </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are drugs used to treat infections that are caused by bacteria. Prior to the introduction of the first antibiotics in the 1930s
and 1940s, bacterial infections were often fatal. Today, antibiotics are used routinely to treat and prevent infections. There are two main varieties of bacteria, Gram-negative bacteria and Gram-positive bacteria, which are distinguished by
structural differences in their cell envelope. Gram-positive bacteria are surrounded by a single lipid membrane and a thick cell wall, while Gram-negative bacteria are encircled by two lipid membranes, an inner membrane and an outer membrane, with a
thinner cell wall in between, as shown in the illustration below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g96e78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics that target Gram-negative bacteria must be specifically designed to cross both the inner and
outer membranes to enter the bacteria. The outer membrane, with its <FONT STYLE="white-space:nowrap">LPS-containing</FONT> outer leaflet, represents a significant barrier to the entry into the bacteria by antibiotics and is a significant contributor
toward reduced potency of many agents in treating Gram-negative bacterial infections. A study of 13,796 patients in intensive care units around the world reported in 2009 that 51% of patients experienced bacterial infections, and of these patients
62% were infected by Gram-negative organisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are evaluated according to several criteria, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Spectrum</I></B>. Antibiotics that are effective against a wide variety of bacteria are considered to be broad-spectrum, while those that act upon only a limited number of bacteria are considered to be
narrow-spectrum. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potency</I></B>.<B><I> </I></B>Potency is the measure of the microbiological ability of an antibiotic to kill or inhibit growth of bacteria <I>in vitro</I>. Potency is commonly expressed as the minimum inhibitory
concentration, or MIC, in &micro;g/mL, which is the lowest concentration at which the drug inhibits growth of the bacteria. Antibiotics with lower MICs are considered to be more potent. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Resistance</I></B>. Antibiotic resistance refers to the inability of an antibiotic to effectively control bacterial growth. Some bacteria are naturally resistant to certain types of antibiotics. Antibiotic
resistance can also occur due to genetic mutations or changes in gene expression. There are numerous mechanisms responsible for antibiotic resistance, and resistance mechanisms are often found together and can be transferred between different
bacteria, leading to multi-drug resistance. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Growing Antibiotic Resistance in the Hospital and Community Settings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic resistance is one of the largest threats to global health, and resistance rates are increasing. Antibiotic resistance can affect
anyone, of any age and in any country. According to the CDC, each year in the United States at least 2&nbsp;million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 people die each year as a direct result
of these infections. Approximately 70% of the pathogens that cause these infections are resistant to at least one drug, meaning the incidence rate of serious infections is increasing and the proportion of the infections caused by MDR pathogens is
increasingly seen as an emerging threat to world health. The CDC estimates that the excess annual cost resulting from these infections in the United States is as high as $20&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">According to the CDC, among all of the bacterial resistance problems, Gram-negative pathogens, which cause a majority of all bacterial
infections, are particularly worrisome because they are becoming resistant to nearly all drugs that would be considered for treatment. In February 2017,<I> </I>the WHO published a list of Gram-negative bacteria based on the urgency of need for new
antibiotics and highlighted a critical group of MDR Gram-negative bacteria that pose a particular threat to human health, including <I>Acinetobacter</I>, <I>Pseudomonas</I> and various <I>Enterobacteriaceae</I> (including <I>Klebsiella</I>, <I>E.
coli</I>, <I>Serratia</I> and <I>Proteus</I>). These pathogens are associated with significant mortality because the increased incidence of antibiotic resistance has limited the number of effective treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is an acute need for new antibiotics to treat MDR bacterial infections, as few new antibiotics capable of addressing such infections
have been approved recently for commercialization or are in clinical development. Further, the majority of MDR bacterial infections historically have been acquired in the hospital setting, where they have been treated using <FONT
STYLE="white-space:nowrap">IV-administered</FONT> antibiotics. However, increasingly such infections are being acquired in the community setting, emphasizing the need for orally administrable antibiotics that can effectively treat such infections.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates Overcome Limitations of Available Treatment Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics currently used for first-line empiric treatment of MDR bacterial infections and NTM suffer from significant limitations. We
believe that our product candidates will overcome these limitations, as described below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994 is designed to address the lack of orally administrable antibiotics to prevent hospitalization and permit <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> switch
therapy in resistant Gram-negative infections</I></B>.<B><I></I></B> Many of the most commonly used antibiotics for MDR Gram-negative infections are only available in an <FONT STYLE="white-space:nowrap">IV-administered</FONT> formulation. Treatment
with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective treatment of patients following hospitalization. However, currently there are no oral
antibiotics commercially available that can reliably be used in adults with MDR Gram-negative infections. SPR994 is an orally administrable tablet that we believe has the potential to treat such infections in both the community and hospital
settings, thereby preventing certain hospitalizations and enabling patients to transition to oral treatment. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR741 and SPR206 are designed to address the decline of novel and effective <FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics to treat MDR Gram-negative infections in the hospital
setting</I></B>.<B><I></I></B> First-line empiric antibiotics, such as levofloxacin, ceftazidime and <FONT STYLE="white-space:nowrap">piperacillin-tazobactam,</FONT> have experienced diminished utility as the number of bacterial strains resistant to
these antibiotics has increased. Due to gaps in the spectrum of coverage of antibiotics currently on the market, physicians are often confronted with the need to design complicated multi-drug cocktails for patients with serious infections. We
believe that SPR741 has the potential to address the need for more effective treatments against MDR Gram-negative bacterial infections by expanding the spectrum and potency of existing antibiotics, including formerly inactive antibiotics.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR720 is designed to be the first oral treatment for NTM where treatment failure is common and no approved therapies exist</I></B>.<B><I></I></B> The current treatment for NTM is lengthy and involves combination
therapy, often including three or more antibiotics, including injectables. None of these combination treatments are currently approved for use in NTM. Treatment failure is common and is often due to poor compliance or patients&#146; inability to
tolerate the regimen. Many patients experience progressive lung disease as a result of NTM, and mortality rates are high, ranging from 29% to 69% within five years of diagnosis. We believe SPR720, if successfully developed, has the potential to be
the first approved oral agent for NTM, and it has demonstrated effectiveness <I>in vitro</I> and <I>in vivo</I> against a range of pathogens, including <I>Mycobacterium abscessus</I>, a highly resistant organism causing NTM with a high rate of
mortality. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 (Tebipenem Pivoxil Extended Release) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, SPR994, is designed to be a broad-spectrum oral carbapenem for use in adults to treat MDR Gram-negative
infections. Currently, there are no commercially available oral carbapenems for use in adults, and we believe SPR994 has the potential to address this unmet need. Carbapenems have been utilized for over 30 years and are considered the standard of
care for many serious MDR Gram-negative bacterial infections, but to date they have only been available as <FONT STYLE="white-space:nowrap">IV-administered</FONT> formulations. SPR994 is an oral extended-release tablet formulation of tebipenem.
Tebipenem was approved in 2009 in Japan for sale under the name Orapenem for pediatric use in common infections, including pneumonia, otitis media and sinusitis. It has been sold by Meiji in Japan as a granule presentation for children that is
combined with food and dosed twice per day. To accelerate our clinical development of SPR994, in June 2017 we exclusively licensed certain data and <FONT STYLE="white-space:nowrap">know-how</FONT> from Meiji and Global Pharma, which we intend to use
to support our clinical development of SPR994. The FDA has designated SPR994 as a QIDP for the treatment of cUTI, CABP and DFI under the GAIN Act, which provides priority review for regulatory approval by the FDA. The QIDP designation for SPR994,
however, does not guarantee a faster development process or ensure FDA approval. We believe, if approved, that SPR994, which incorporates our proprietary formulation technology and benefits from <FONT STYLE="white-space:nowrap">know-how</FONT> and
data we have licensed from Meiji, has the potential to further increase the clinical demand for the carbapenem class of antibiotics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have global commercialization rights to SPR994, except in certain contractually specified Asian countries. If SPR994 is approved for
treatment of cUTI, CABP or DFI, the QIDP designation for SPR994 will extend by an additional five years any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity period awarded for SPR994 in the United States, such as a five-year New
Chemical Entity, or NCE, exclusivity granted under the Hatch-Waxman Act, for a total of 10 years. In Europe, exclusivity for NCEs is 10 years (eight years for data exclusivity and an additional two years for market exclusivity), with the possibility
of a <FONT STYLE="white-space:nowrap">one-year</FONT> extension if the chemical entity is approved for use in an additional indication. Additionally, we believe that our intellectual property portfolio for SPR994, which includes multiple patent
applications pending, will provide SPR994 protection globally, including in the United States and Europe, through 2038. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Potential
Advantages of SPR994 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the following key attributes differentiate SPR994 from other antibiotics targeting MDR
Gram-negative infections. We believe these attributes have the potential to make SPR994 a safe and effective treatment for cUTI and other serious and life-threatening infections for which we may develop SPR994. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Potential to be the first oral carbapenem in adults</I></B>.&nbsp;SPR994 is designed to be the first
broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Unlike other carbapenems, which are only available as <FONT STYLE="white-space:nowrap">IV-administered</FONT> infusions, SPR994 is an orally
administered tablet. Oral administration may potentially allow physicians to avoid </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics for otherwise healthy or stable patients and/or allow for a reduction in costs associated with avoiding or shortening
hospitalization. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety, efficacy and tolerability profile suggested by clinical studies of tebipenem in Japanese populations</I></B>.<B></B><B> </B>A granule formulation of tebipenem has been approved for use in Japan
in pediatric patients since 2009, where it has demonstrated a favorable safety and efficacy profile. Approximately 1,200 subjects have been dosed with the active pharmaceutical ingredient of SPR994, tebipenem, in clinical and pharmacologic studies
during development of this drug by Meiji and Global Pharma in Japan. This data set includes 741 adults, including 88 patients with cUTIs, the initial indication for which we plan to develop SPR994. In each case tebipenem has demonstrated a favorable
safety, pharmacokinetic and tolerability profile. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Broad spectrum of activity against a variety of MDR Gram-negative, Gram-positive and anaerobic bacteria, with a potency consistent with certain <FONT STYLE="white-space:nowrap">IV-administered</FONT>
carbapenems</I></B>.<B><I> </I></B>In<I>&nbsp;in vitro</I><I></I>&nbsp;studies, SPR994 displayed potent antibiotic activity against Gram-negative bacteria, including <I>E. coli </I>producing extended spectrum beta lactamases, or ESBLs,
and&nbsp;ESBL-producing<I>&nbsp;Klebsiella pneumoniae. </I>ESBL-producing bacteria are Gram-negative bacteria that hydrolyze, or break down, cephalosporins and render them ineffective for treatment. ESBL-producing pathogens are associated with poor
clinical outcomes in severe infections. Further, SPR994&#146;s potency against <I>Enterobacteriaceae</I> has been observed to be similar to <FONT STYLE="white-space:nowrap">IV-administered</FONT> ertapenem and imipenem. As a result, we believe that
SPR994 has the potential to be used for the treatment of cUTI and other serious and life-threatening infections caused by resistant Gram-negative pathogens. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable pharmacokinetic profile</I></B>.<B><I> </I></B>SPR994 is a novel, proprietary form and formulation of tebipenem that extends residence time of tebipenem in plasma, which we believe increases the
potential efficacy of tebipenem for a given dose and reduces the frequency of dose administration. In primate studies, SPR994 has shown bioavailability of 50%. In addition, in Meiji&#146;s studies of tebipenem in which adult patients received doses
of tebipenem at or above our intended commercial dose, at doses up to and including 500 mg, dose linearity and urine concentrations of tebipenem exceeded the level required to eradicate <I>E. coli</I>.<I> </I>As a result, we believe that SPR994 has
the potential to maintain a favorable safety and efficacy profile for the treatment of cUTI at a variety of dose levels. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to enable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> transition of antibiotic treatment to assist with reduction in hospital stays and/or eliminate the
need for hospitalization</I></B>.<B></B>&nbsp;We believe SPR994&#146;s unique oral formulation may enable patients who begin <FONT STYLE="white-space:nowrap">IV-administered</FONT> treatment for ESBLs in the hospital setting to transition to oral
dosing of SPR994 either in the hospital or upon discharge for convenient home-based care. We believe that the availability and use of an oral carbapenem as a transition therapy may eliminate hospitalization or reduce the length of a patient&#146;s
hospital stay and the overall cost of care. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe the foregoing advantages of SPR994 also significantly differentiate
SPR994 from fluoroquinolones. Fluoroquinolones are the most widely used antibiotic class in treating community and hospital Gram-negative infections, but they have encountered increasing resistance among MDR Gram-negative bacteria and are associated
with significant adverse effects. The table below reflects resistance rates in the United States in the community and hospital settings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.70pt; font-size:8pt; font-family:Times New Roman"><B>cUTIs in the&nbsp;United States</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2013-2014&nbsp;</FONT></B><B><I>E.&nbsp;coli</I></B><B>&nbsp;Resistance</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:95.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rates&nbsp;to&nbsp;Fluoroquinolones</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:95.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2000-2004&nbsp;</FONT></B><B><I>E.&nbsp;
coli</I></B><B>&nbsp;Resistance<BR>Rates to Fluoroquinolones</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Community Setting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospital Setting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Currently, fluoroquinolones are the most frequently selected antibiotic for empirical UTI
treatment in the community and hospital settings. Current UTI treatment guidelines published by the Infectious Diseases Society of America identify fluoroquinolones as an appropriate empirical therapy option. This recommendation, however, is
contingent on local resistance rates being less than 10%. The endemicity (high rates) of fluoroquinolone-resistant <I>E. coli</I> found in the United States today in the community and hospital settings based on the table above would suggest that
fluoroquinolones should not be used empirically for cUTI patients. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table highlights the observed <I>in vitro</I>
potency differences between SPR994 and levofloxacin, the most widely used fluoroquinolone. As shown below, SPR994 has a MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90 </SUB>value of 0.03 &micro;g/mL, which compares favorably (i.e., at or
below) to the potency value obtained by levofloxacin. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="38%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.25pt; font-size:8pt; font-family:Times New Roman"><B>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>E. coli</I></B><B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:29.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(&micro;g&nbsp;/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Levofloxacin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the FDA has issued several warnings against the use of fluoroquinolones in certain patients. In
particular, an FDA Advisory Committee stated in November 2015 that the risk of serious side effects caused by fluoroquinolones generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and
uncomplicated UTIs. The FDA has determined that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options. In Japan, Orapenem (tebipenem pivoxil) does not have a black box warning and has
been studied in approximately 1,200 subjects. We believe SPR994 could become a potential alternative to oral fluoroquinolones based on its safety and efficacy profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Market Opportunity for SPR994 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Given the observed activity of SPR994 against different bacteria, we view the market opportunity for SPR994, if approved, to be substantial,
including for the following uses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Treating urinary tract infections acquired in the community setting without the need for patient hospitalization. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Transitioning patients hospitalized for UTIs or cUTIs to an oral therapy as they are discharged from the hospital. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Transitioning other patients hospitalized with complicated Gram-negative infections, such as cIAI, hospital-acquired, or nosocomial, pneumonia and blood stream infections as they are discharged from the hospital.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">UTIs are among the most common bacterial diseases worldwide, with significant clinical and economic burden. QuintilesIMS
estimates that between 33 and 34&nbsp;million patients either visit their physician or are hospitalized for a UTI or otherwise suspected of experiencing a UTI in the United States annually. While drugs such as trimethoprim/sulfamethoxazole
(Bactrim/Septra) and fluoroquinolones (levofloxacin, ciprofloxacin) have been the primary oral options for treatment of UTIs caused by Gram-negative organisms, nearly 30% to 35% of UTIs are resistant, which has led to increased use of <FONT
STYLE="white-space:nowrap">IV-administered</FONT> therapeutics such as carbapenems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">QuintilesIMS completed a market assessment in August
2017 in the community and hospital settings in which it estimated that there were 11 to 12&nbsp;million patients annually who presented in the community physician&#146;s office with a UTI and 3.5 to 4.5&nbsp;million patients annually in the hospital
with a UTI in the United States alone. Of these UTIs, 10 to 11&nbsp;million are suspected to be caused by Gram-negative bacteria, and 4 to 5&nbsp;million of these patients had an infection that is resistant to or failed first-line therapy, such as
the fluoroquinolone class, or require IV therapy due to the severity of infection. Physicians in the survey reported high concern with growing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluoroquinolone resistance and lack of oral options for MDR Gram-negative infections. We believe SPR994 is well positioned to meet the unmet need for an oral therapy for community-acquired UTI
and may offer physicians an option for treating MDR UTIs while avoiding patient hospitalization. In addition, we believe SPR994 has the potential to accelerate hospital discharge and obviate the need for continued
<FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy at home by transitioning discharged patients to an <FONT STYLE="white-space:nowrap">at-home</FONT> oral therapy. Our initial study for SPR994 will focus on patients who suffer from a
subset of UTIs called cUTIs, which affect approximately 4.9 million patients in the United States annually. A significant majority of UTIs, including cUTIs, are caused by a group of MDR Gram-negative bacteria called <I>Enterobacteriaceae</I>. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 Clinical Development Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA, we intend to initiate a Phase 1 pharmacokinetics and safety
clinical trial in Australia of SPR994 in the fourth quarter of 2017, and expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> Following completion of this trial
to select a dose for pivotal trials, we intend to hold a pre-Phase 3 meeting with the FDA to confirm no additional clinical trials or preclinical studies are required prior to initiating a Phase 3 clinical trial. Subject to feedback from the FDA,
and using know-how we have licensed from Meiji, we plan to submit an IND and commence in the second half of 2018 a pivotal Phase 3 clinical trial with a <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort for the treatment of cUTI in support of
an NDA. We expect to review data from our <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort evaluating pharmacokinetics and safety of SPR994 in cUTI patients in the first half of 2019 and to receive
<FONT STYLE="white-space:nowrap">top-line</FONT> data from our Phase 3 clinical trial in mid-2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has designated SPR994 as a
QIDP for the treatment of cUTI, CABP and DFI under the GAIN Act, which provides priority review for regulatory approval by the FDA. The QIDP designation for SPR994, however, does not guarantee a faster development process or ensure FDA approval.
Further, if SPR994 is successfully developed and approved for the treatment of CUTI, CABP or DFI, the FDA&#146;s QIDP designation for SPR994 should extend any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity period awarded to SPR994 in
the United States for five years, such as a five-year New Chemical Entity data exclusivity granted under The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Planned SPR994 Phase 1 Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We filed a Clinical Trial Notification, or CTN, in Australia in September 2017 and plan to initiate in the fourth quarter of 2017 a Phase 1
clinical trial in Australia of SPR994 in approximately 60 healthy volunteers. A CTN enables conduct of a clinical trial in Australia similar to an IND in the United States. The Phase 1 clinical trial will evaluate our proprietary extended release
oral tablet formulation of SPR994 across SAD cohorts and multiple dose cohorts. The objectives of the trial include pharmacokinetics, safety and tolerability for up to 14 days and food effect. Data from the clinical trial will support dose selection
for our planned pivotal Phase 3 clinical trial. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 1 clinical trial in mid-2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Planned Pivotal SPR994 Phase 3 Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA, we believe that results from our planned Phase 1 clinical
trial of SPR994, together with nonclinical studies, PK/PD, and other supporting data, will be acceptable to FDA to allow us to commence a pivotal Phase 3 clinical trial of SPR994 under a U.S. IND. After we report top-line data from our Phase 1
clinical trial, we plan to hold a pre-Phase 3 meeting with the FDA to confirm no additional clinical trials or preclinical studies are required prior to initiating our Phase 3 clinical trial. Subject to feedback from the FDA, we plan to submit an
IND and commence the pivotal Phase 3 trial in the second half of 2018. Clinical trial applications will also be submitted in Europe and other regions, as needed, to support study enrollment. Our planned pivotal Phase 3 clinical trial of the efficacy
and safety of SPR994 is currently designed as a double-blind, double-dummy trial to compare SPR994 with an <FONT STYLE="white-space:nowrap">IV-administered</FONT> carbapenem in approximately 1,100 patients randomized 1:1 in each arm. We believe that
the primary endpoint of the trial will be <FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus a standard of care antibiotic, with a 10% <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin. We intend to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commence our pivotal Phase 3 clinical trial with a <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort with intensive pharmacokinetics in order to analyze exposure prior to initiating the
pivotal Phase 3 clinical trial cohort. We believe that efficacy of SPR994 in the Phase 3 clinical trial will be determined by assessments of clinical response and microbiological response, with the primary efficacy endpoint being microbiological
clearance and test of cure and with secondary efficacy parameters that include medical judgment, which is an endpoint that European regulators require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to receive data from the <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort of our Phase 3 clinical trial evaluating the
pharmacokinetics and safety of SPR994 in cUTI patients in the first half of 2019 and to receive <FONT STYLE="white-space:nowrap">top-line</FONT> data from our Phase 3 clinical trial in mid-2020. Following receipt of
<FONT STYLE="white-space:nowrap">top-line</FONT> data from this pivotal Phase 3 clinical trial, with requisite safety data, drug-drug interaction studies and other studies, we intend to submit to the FDA an NDA for SPR994 to treat cUTI including
acute pyelonephritis. These data, if positive, may also support marketing applications in other global regions. We also intend to reach an agreement with the FDA on a Pediatric Study Plan and initiate development of SPR994 in pediatrics for cUTI
upon receipt of <FONT STYLE="white-space:nowrap">top-line</FONT> data in adult patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Data Supporting the Use of SPR994 for the
Treatment of cUTI </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have tested SPR994 <I>in vitro </I>and&nbsp;in animal models. We believe that nonclinical assays are
generally predictive of clinical efficacy for antibiotics, particularly in the case of a well-understood class such as carbapenems. In addition, approximately 1,200 subjects have been dosed with tebipenem in clinical and pharmacologic studies during
the development of this drug by Meiji in Japan. The data set from these studies includes 741 adults, including 88 patients with cUTIs, the initial indication for which we plan to develop SPR994. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In vitro Activity Against MDR Enterobacteriaceae, Including CRE </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple susceptibility testing studies against MDR <I>Enterobacteriaceae</I> demonstrate that SPR994 remained potent against
strains resistant to several other classes of antibiotics, including aminoglycosides and fluoroquinolones. In these studies, we measured the potency, or MIC, of each drug by determining the concentration of drug required to inhibit the growth of 50%
and 90% of the isolate set (i.e., the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> or MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB>). The graph below depicts the <I>in vitro </I>activity of SPR994 compared to two
commercially available intravenously delivered antibiotics commonly used to treat cUTI against a large number of clinical isolates, namely Invanz (ertapenem, or ETP) from Merck and generically available imipenem, or IMI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPR994 Activity Against Contemporary Isolates of</B><B><I> E. coli</I></B><B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g81r65.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">SPR994 has showed MIC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> and MIC<SUB
STYLE="font-size:85%; vertical-align:bottom">90</SUB> values of less than or equal to 0.015 &micro;g/mL and 0.03 &micro;g/mL, which compare favorably (i.e., at or below) to the values obtained by competitive agents ertapenem and imipenem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Regarding a more resistant set of <I>E. coli</I> isolates, including fluoroquinolone-resistant strains, SPR994 again showed <I>in vitro</I>
activity similar to commercially available intravenously delivered drugs such as Merrem (meropenem), as shown in the graph below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPR994 is Active Against </B><B><I>E. coli</I></B><B>, Including Fluoroquinolone-Resistant Isolates </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g14o23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe this data shows the ability of orally available SPR994 to deliver similar activity to
comparative <FONT STYLE="white-space:nowrap">IV-administered</FONT> agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Tebipenem Phase 1 Clinical Trial Data Support Development of SPR994 for the Treatment of cUTI
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Tebipenem was also tested by Meiji in healthy volunteers to determine urinary concentrations as a predictor of efficacy in the cUTI
population. Results from this single-ascending dose study are shown in the graph below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Single-Ascending Dose Calculated Urine Levels
of Tebipenem </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g74g36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In early clinical studies in Japan, healthy volunteers received doses up to 600 mg/day. At each dose level,
and in a dose dependent manner, the urine concentration of tebipenem exceeded the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> for <I>E.&nbsp;coli </I>of 0.03 &micro;g/ml (defined as the level that is expected&nbsp;to inhibit 90% of
<I>E.&nbsp;coli </I>isolates). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Primate Data Support BID Dosing of SPR994 for the Treatment of cUTI </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also administered doses of SPR994 in monkeys and measured the concentration over time in plasma samples. As shown in the graph below, the
plasma concentration achieved by SPR994 exceeded the 30 ng/ml level required to eradicate <I>E. coli</I> beyond 15 hours and compared favorably to the immediate release formulation. We believe these data indicate human BID dosing for SPR994 and the
possibility for daily dosing as well, given that half-life measurements in primates typically translate to higher values in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Concentration from Dosing SPR994 in Monkey Plasma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g42o58.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Meiji Phase 2 Clinical Trial Data of Tebipenem in cUTI </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Meiji and Global Pharma conducted two exploratory, dose-ranging Phase 2 clinical trials of tebipenem in patients with cUTI including patients
with acute pyelonephritis. These trials were conducted in Japan between 2001 and 2004. Study <FONT STYLE="white-space:nowrap">L-084</FONT> 04 (report date 2003), a multicenter <FONT STYLE="white-space:nowrap">open-label</FONT> study to evaluate the
efficacy (clinical and microbiological) and safety (adverse events and laboratory tests) of tebipenem at doses of 100 mg administered TID (Group A), 150 mg administered BID (Group B), and 150 mg administered TID (Group C), for seven days in patients
with cUTI. There were 51 adult patients, aged <FONT STYLE="white-space:nowrap">20-74</FONT> years inclusive, enrolled with 40 being evaluable for efficacy (14 in Group A; 17 in Group B; 9 in Group C). Study ME1211 (report date 2004), a multicenter, <FONT
STYLE="white-space:nowrap">open-label</FONT> study to evaluate efficacy (early and late assessments) and safety (adverse events and laboratory tests) of tebipenem at doses of 250 mg administered BID (500 mg Group) and 300 mg administered TID (900 mg
Group) for seven days in patients with cUTI. There were 37 adult patients, aged 20 to 74 years inclusive, enrolled with all being evaluable for efficacy (19 in <FONT STYLE="white-space:nowrap">500-mg</FONT> Group; 18 in <FONT
STYLE="white-space:nowrap">900-mg</FONT> Group). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although the design of the Phase 2 clinical trials in Japan was different from what
is recommended in FDA guidance for clinical trials in patients with cUTI, including acute pyelonephritis, we believe these results support our plan to develop SPR994 in cUTI. With respect to these results, which are summarized in the chart below,
the efficacy rate refers to the proportion of subjects judged to have experienced a &#147;markedly effective&#148; or &#147;effective&#148; tebipenem dosage versus the total number of subjects tested, and the negative conversion rate refers to the
proportion of subjects with negative urine cultures versus the total number of subjects tested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Observed Efficacy of Tebipenem in Meiji Phase 2 Trials in cUTI </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>Study <FONT STYLE="white-space:nowrap">L-084</FONT> 04</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subjects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Efficacy<BR>Rate*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Negative<BR>Conversion<BR>Rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">300-mg</FONT> group A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(100 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">300-mg</FONT> group B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(150 mg administered BID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94.1</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94.1</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">450-mg</FONT> group C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(150 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Based on overall clinical outcome. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>Study ME1211</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Subjects</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Early<BR>Efficacy<BR>Assessment*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Negative<BR>Conversion<BR>Rate**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">500-mg</FONT> group A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(250 mg administered BID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">87.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>900 mg group B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(300 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Based on overall clinical effect at the end of therapy. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Early assessment, at end of therapy. For the purpose of this assessment, negative conversion rate is defined as the rate of subjects with negative urine cultures. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">&#147;Markedly effective&#148; or &#147;effective.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Safety of Tebipenem </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Tebipenem pivoxil is a prodrug that is metabolized to tebipenem, its therapeutically active form. We view the clinical safety profile of
tebipenem pivoxil established by Meiji as relevant and supportive of SPR994 because both metabolize to the active metabolite, tebipenem, in plasma. The extended release formulation has been designed to improve target concentration while maintaining
the exposure per dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Tebipenem pivoxil is an orally administered carbapenem, which is a sub-group of the beta-lactam class of
antibiotics.&nbsp;The safety of tebipenem pivoxil was evaluated in approximately 1,200 subjects supporting the application for approval in Japan. In this safety data set, there are 741 adult subjects across 17 trials and 440&nbsp;pediatric subjects
across six trials. These 23 trials in total, included one double-blind, comparator-controlled trial in children, five open-label trials in children, five trials enrolling adult patients (including two open-label cUTI trials), and
12&nbsp;Phase&nbsp;1 clinical pharmacology trials. Among the pharmacology trials, tebipenem pivoxil was studied for an effect on QT interval, and for the known effect of the pivoxil prodrug on serum carnitine concentrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In these studies, tebipenem pivoxil was generally safe and well tolerated, with an adverse event, or AE, profile comparable to common,
approved oral beta lactam antibiotics and IV-administered carbapenems.&nbsp;The most common AEs were gastrointestinal (e.g., diarrhea, loose stools) in both children and adults, and in the Phase 3 clinical trial of otitis media, the incidence was
similar to that reported for the comparator, cefditoren (also a pivoxil prodrug), an oral cephalosporin antibiotic.&nbsp;No effect of the administration of tebipenem pivoxil on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prolongation of the QT interval was observed, and the effect on serum carnitine concentrations was reversed post treatment and not associated with AEs. A side effect seen with beta-lactam
antibiotics is seizures; however, there have been no reports of inducement of seizures due to the administration of tebipenem pivoxil in clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Potentiator Platform (SPR741 and SPR206) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our lead potentiator product candidate is SPR741, an <FONT STYLE="white-space:nowrap">IV-administered</FONT> derivative of Polymyxin B, or
PMB, that has demonstrated <I>in vitro</I> the ability to expand the spectrum and increase the potency of a <FONT STYLE="white-space:nowrap">co-administered</FONT> antibiotic against Gram-negative bacteria, including organisms identified by the CDC
and the WHO as urgent and serious threats to human health. In preclinical studies, SPR741 has shown an ability to potentiate over two dozen existing antibiotics and enable activity against Gram-negative pathogens. SPR741 has also shown an ability to
make active formerly inactive antibiotics. In addition, we are developing next-generation potentiator molecules, such as our product candidate SPR206. SPR206 is designed to have antibiotic activity as a single agent against MDR and XDR bacterial
strains, including variants isolated in <I>Pseudomonas aeruginosa </I>and<I> Acinetobacter baumannii</I>. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We recently completed a
Phase 1, two part, randomized, double-blind, placebo-controlled, dose- escalation trial of SPR741. We expect to report full data from our Phase 1 clinical trial in the fourth quarter of 2017 and hold a <FONT STYLE="white-space:nowrap">pre-IND</FONT>
meeting with the FDA shortly thereafter. We plan to submit a CTA in the United Kingdom in the fourth quarter of 2017 and thereafter initiate a Phase 1b drug-drug interaction clinical trial of SPR741 in the United Kingdom. Subject to the outcome of
our pre-IND meeting and the results of our Phase 1b drug-drug interaction clinical trial of SPR741, we expect to submit an IND and initiate a Phase 2 combination clinical trial of SPR741 with a generic antibiotic for the treatment of cUTI in the
first half of 2018. We also intend to apply to the FDA for QIDP designation for SPR741 during the fourth quarter of 2017. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe
that our intellectual property portfolio for SPR741, which includes multiple issued patents and patent applications pending, will provide SPR741 protection globally, including in the United States and Europe, through 2038. Additionally, we have
multiple patent applications pending for SPR206 that we believe will provide SPR206 protection globally, including in the United States and Europe, through 2035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>How Our Potentiator Molecules Are Designed to Work </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Gram-positive and Gram-negative bacteria are classified by the lab staining test known as the &#147;Gram stain&#148;, but their nature is due
to structural differences in their cell envelope, with Gram-positive bacteria surrounded by a single lipid membrane and a thick cell wall and Gram-negative bacteria encircled by two lipid membranes, an inner membrane and an outer membrane, with a
thinner cell wall in between. The outer membrane, with its <FONT STYLE="white-space:nowrap">LPS-containing</FONT> outer leaflet, represents a significant barrier to the entry into the bacteria by antibiotics and is a significant contributor to
reduced potency of many agents in treating Gram-negative bacterial infections. Each membrane in Gram-negative bacteria excludes different types of chemical entities, requiring Gram-negative active antibiotics to be specifically designed to permeate
both membranes. Gram-negative bacteria include <I>Pseudomonas aeruginosa</I>, <I>Acinetobacter baumannii</I>, and the <I>Enterobacteriaceae</I>, a family of related organisms that includes <I>E.</I><I></I><I>&nbsp;coli</I>, <I>Klebsiella
pneumoniae</I>, <I>Enterobacter, Salmonella,</I> and <I>Shigella</I> species. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our potentiator molecules are charged cyclic peptides
designed to specifically interact with the outer membrane of Gram-negative bacteria, thereby permitting access for antibiotics that otherwise, and traditionally, would only exhibit activity against Gram-positive bacteria. Specifically, our
positively charged potentiator molecules are designed to interact with the negatively charged core of LPS via an electrostatic interaction, resulting in a loss of outer membrane integrity. This destabilization of the outer membrane is visible in
electron micrographs and other forms of microscopy and is what enables the increased permeability of the affected bacterial membrane. The increase in permeability potentially allows antibiotics that were previously excluded to enter the
Gram-negative bacteria where they become active. Additionally, this increase in permeability may also enhance the potency of antibiotics that have existing Gram-negative activity by maximizing the amount of antibiotic in the cell and offsetting
specific class based mechanisms of resistance and other common mechanisms of resistance, such as efflux. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potentiators May Allow Entry of Antibiotics into Gram-Negative Bacteria </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g74p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to leverage our Potentiator Platform to develop multiple potentiator molecules to be <FONT
STYLE="white-space:nowrap">co-administered</FONT> with multiple antibiotics. Each combination is designed to have unique antibiotic and pharmacokinetic capabilities, creating a complementary set of combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of our Potentiator Platform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the following key attributes of our Potentiator Platform generally, and of SPR741 in particular, have the potential to support
the clinical utility and commercial value of our Potentiator Platform for the safe and effective treatment of serious infections: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to Expand the Potency of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Standard-of-Care</FONT></FONT> Antibiotics</I></B>.<B><I> </I></B>We believe SPR741 has the potential to expand
the potency of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> antibiotics by restoring and expanding their Gram-negative activity, thereby improving therapeutic outcomes, decreasing physicians&#146;
reliance on drugs of last resort and encouraging improved antibiotic stewardship. We believe SPR741-based combinations have the potential to meet a significant need in the market to expand and prolong the utility of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> agents for Gram-negative infections and preserve agents such as colistin as drugs of last resort. We believe the ability to add SPR741 to older standard therapies, such as
piperacillin/tazobactam or ceftazidime, has the potential to not only expand their spectrum and increase their potency, but also prolong their life and utility, allowing the newer agents to be preserved for special clinical circumstances.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Broad Applicability of Potentiator Platform</I></B>.<B><I> </I></B>We have seen that our potentiators are capable of potentiating the activity of many generic and novel antibiotics from various classes in
preclinical studies. In multiple animal models of varying infection types, this potentiation effect has resulted in a significant reduction in the bacterial burden of infections caused by several common drug-resistant pathogens, including <I>E.
coli, Acinetobacter baumannii</I>, and <I>Klebsiella pneumoniae</I>.<I> </I>We believe that forms of drug-resistant bacteria specifically targeting the mechanism of action of our potentiator molecules will not impact the activity of SPR741. Our
studies have shown that SPR741 is capable of potentiating a range of antibiotics and antibiotic classes that include some cephalosporins, extended-spectrum penicillins, some BL/BLIs, rifamycins, pleuromutilins, macrolides, fusidic acid, clindamycin,
iclaprim, synercid, quinolones, oxazolidinones, glycopeptides, novobiocin and fidaxomycin. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our potentiator molecules have a proven record of being well tolerated</I></B>.<B><I> </I></B>Data from our Phase 1 SAD clinical trial of SPR741 demonstrate SPR741 was well tolerated at doses up to and including
800 mg. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our potentiator molecules may result in decreased reliance on drugs of last resort</I></B>. The emergence of resistance to ESBL-producing bacteria has led to broader use of agents such as carbapenems and drugs of
last resort, such as colistin. These drugs of last resort are often associated with serious safety issues such as increased kidney toxicity. As a result, physicians are faced with a dilemma of choosing efficacy over safety to treat these
Gram-negative MDR infections. Greater reliance on drugs of last resort is leading to a rise in resistance to these drugs, and if this trend continues, there will be even fewer options to treat MDR and XDR organisms. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Resistance to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> agents is increasing at an alarming rate</I></B>. The rate of antibiotic resistance to many of the
commonly used antibiotics has increased dramatically over the last decade. This is primarily due to the increase in the number of ESBL-producing organisms, which renders many of these drugs ineffective. According to Study for Monitoring Antibiotic
Resistance Trends, or SMART, published in 2016, the rate of increase in ESBL-producing organisms doubled from 2010 to 2014 to approximately 20%. We believe this increase will continue to erode the utility of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> antibiotics. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our next-generation molecule SPR206 may potentially be a safe and potent <FONT STYLE="white-space:nowrap">IV-administered</FONT> direct-acting agent</I></B>.<B><I> </I></B>Like SPR741, our next-generation
potentiator candidate SPR206 is designed to interact with LPS to disrupt the outer membrane. However, SPR206 is designed to have direct antibiotic activity, while retaining potentiator activity, including activity against <I>Pseudomonas</I> and
<I>Acinetobacter</I>. We are developing SPR206 as a treatment for high-risk patients with suspected or known Gram-negative infections such as carbapenem-resistant <I>Enterobacteriaceae</I>, or CRE, carbapenem resistant <I>Acinetobacter
baumannii</I>, or CRAB, and MDR <I>Pseudomonas aeruginosa</I>, or MDR PA, to prevent mortality and reduce the length of stay in the hospital setting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Market Opportunity for SPR741, including Gram-Negative IV Market </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe SPR741 has the key characteristics to be developed as a potentiator to be used in combination with multiple first-line empiric
therapies for a wide variety of life-threatening infections caused by Gram-negative pathogens. We believe SPR741, when combined with such other approved drugs, will potentiate the safe and effective treatment of cUTI infections and a wide range of
other infections caused by drug-resistant <I>Enterobacteriaceae</I>. Based on our discussions with key opinion leaders, there is a need to expand the clinical utility of widely used antibiotic agents such as cephalosporins and BL/BLIs by addressing
the loss of potency of such drugs against Gram-negative strains of bacteria in high-risk patients. In the United States, the Decision Resources&#146; Hospital Gram-Negative Infections Report from 2015 estimates that Gram-negative infections make up
more than 45&nbsp;million days of therapy, or DOT, annually. Approximately 45% of infections are treated with first-line agents such as cephalosporins (i.e., ceftazidime), and <FONT STYLE="white-space:nowrap">piperacillin-tazobactam.</FONT> Over 64%
of these infections are treated empirically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR741&#151;Phase 1 Clinical Trial and Clinical Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Data from our Phase 1 SAD clinical trial of SPR741 show SPR741 was well tolerated at doses up to and including 800&nbsp;mg. As shown in the
chart below, the pharmacokinetics observed were dose linear with a half-life of between two and four hours, consistent with expectations from preclinical modeling. There have been no safety signals observed that triggered <FONT
STYLE="white-space:nowrap">pre-specified</FONT> stopping rules. </P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g32y96.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to hold a <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA later in the
fourth quarter of 2017. We intend to study SPR741 administered in combination with compounds from the beta-lactam class of antibiotics, including cephalosporins (such as ceftazidime), monobactams (such as aztreonam) and BL/BLIs (such as
pipercillin/tazobactam). We believe that this multiple-compound testing strategy will be initiated with a Phase 1b <FONT STYLE="white-space:nowrap">drug-drug</FONT> interaction clinical trial that will be used to assess the impact, if any, on the
standalone pharmacokinetics of SPR741 or the standalone pharmacokinetics of the beta-lactam combination drug when the two are dosed together. We plan to submit a CTA in the United Kingdom for such clinical trial in the fourth quarter of 2017 and
thereafter initiate such trial in the United Kingdom. Subject to the outcome of our pre-IND meeting and receipt of favorable safety and combination pharmacokinetics data from our Phase 1b drug-drug interaction clinical trial, we intend to submit an
IND and investigate the efficacy of SPR741 in combination with a beta-lactam antibiotic in cUTI patients in a Phase 2 clinical trial beginning in the first half of 2018. We anticipate top-line data from this first SPR741 combination trial during the
second half of 2018. We will then engage with regulatory authorities on the final design of a pivotal Phase 3 trial. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to
apply to the FDA for QIDP designation by the end of 2017 for the development and regulatory review of SPR741 to treat serious and life-threatening CRE infections. Our Potentiator Platform is funded in part with
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding from the DoD and <FONT STYLE="white-space:nowrap">CARB-X,</FONT> consisting of $1.5&nbsp;million over a <FONT STYLE="white-space:nowrap">one-year</FONT> period with the possibility of up
to a total of $6.8&nbsp;million in funding based on the successful progression of specified milestones. We have global commercialization rights to SPR741, which has global patent protection extending through 2038. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Data Supporting the Use of SPR741 for the Treatment of Gram-Negative Infections
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Nonclinical Data Supporting Use of SPR741 for the Treatment of Gram-Negative Infections </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have tested <I>in vitro</I> SPR741 combined with numerous Gram-positive and Gram-negative antibiotics in order to assess improved potency
and spectrum of activity of the combination against representative Gram-negative pathogens. We have also tested combinations of SPR741 with numerous Gram-positive and Gram-negative antibiotics in animal models of infection in order to assess <I>in
vivo</I> efficacy and to establish pharmacokinetic/pharmacodynamic relationships. We have also conducted <FONT STYLE="white-space:nowrap">GLP-toxicology</FONT> studies of SPR741 to further support our clinical development of SPR741 for the treatment
of Gram-negative infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In Vitro Activity of SPR741 Against MDR Gram-Negative Bacteria </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple susceptibility testing studies against MDR <I>Enterobacteriaceae</I> suggests that SPR741 is capable of potentiating the
activity of several classes of antibiotics, including some beta-lactams and macrolides. We ascertained the potential clinical profile of combinations of SPR741 against MDR <I>Enterobacteriaceae</I> encountered in the hospital setting by testing the
combinations against a large number of clinical isolates collected from unique patients with different types of infections from hospitals around the world. In one such study, we measured the ability of SPR741 to enhance the activity of ceftazidime,
or CAZ, or piperacillin-tazobactam (Zosyn, or TZP) against a large collection of clinical isolates expressing the drug-resistant phenotype ESBL. In each case, as shown in the graph and summarized in the table below, SPR741 potentiated the activity
of the antibiotics resulting in an MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> shift from 256 to 8 for CAZ and from 256 to 1 for TZP. We believe that this data demonstrates SPR741&#146;s ability to restore the combined
antibiotic&#146;s therapeutic activity against a resistant strain of bacteria. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potency of <FONT STYLE="white-space:nowrap">Piperacillin-Tazobactam</FONT> and Ceftazidime with and without SPR741 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in Global Set of Clinical Isolates Classified as ESBL Producers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g41w64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> and % of Bacteria Susceptible to <FONT
STYLE="white-space:nowrap">Piperacillin-Tazobactam</FONT> and Ceftazidime </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with and without SPR741 in Global Set of Clinical Isolates
Classified as ESBL Producers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>MIC90</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:30.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(mg/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>%<BR>Susceptible(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CAZ</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CAZ+SPR741</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TZP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TZP+SPR741</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>98</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Breakpoints for CAZ+SPR741 and TZP+SPR741 are defined by regulatory bodies only upon approval of NDA(s) and as such none exist today. As a surrogate, we have used the clinically approved breakpoints for CAZ and TZP to
define anticipated susceptibility for our combinations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I></I><B></B><I>In Vivo Activity of SPR741 Against Drug-Resistant
Gram-Negative Bacteria </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple mouse infection studies using MDR <I>Enterobacteriaceae</I> as the infecting pathogen
also suggest that SPR741 is capable of potentiating the activity of several classes of antibiotics, including beta-lactams and macrolides. We have assessed combinations for efficacy in models of thigh, pneumonia, and urinary tract infection with
pathogens exhibiting different resistant phenotypes and have observed positive results in these models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In one such study, we measured
the ability of SPR741 to enhance the activity of CAZ in a mouse thigh infection study where the infecting organism was a <I>Klebsiella pneumoniae</I> expressing ESBL <I>bla</I><SUB STYLE="font-size:85%; vertical-align:bottom"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CTX-M-25</FONT></FONT></SUB>. CAZ administered alone at 50 mg/kg, TID (orange bar) resulted in ~1 log cfu/g of growth in burden, compared to the starting inoculum. SPR741 administered alone
at either 40 mg/kg or 60 mg/kg, TID (blue bars) resulted in ~1.5 log cfu/g of growth in burden, compared to the starting inoculum. However, when CAZ at 50 mg/kg, TID and SPR741 at 40 mg/kg or 60 mg/kg, TID were administered in combination (green
bars), the growth in burden was reduced by ~1.6 log and 2.8 log cfu/g, respectively compared to the starting inoculum. For comparison, tigecycline administered alone at a high dose of 40 mg/kg TID (purple bar) reduced burden by ~2.5 log cfu/g
compared to the starting inoculum. We believe that these data demonstrate <I>in vitro</I> SPR741&#146;s ability to restore the combined antibiotic&#146;s therapeutic activity against a resistant strain of bacteria, and also demonstrate that a
first-line antibiotic like CAZ can achieve efficacy in line with a reserve agent like tigecycline when used in combination with SPR741. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>In Vivo</I></B><B> Effect of Administration of SPR741 and Ceftazidime in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Klebsiella Pneumonia </I></B><B>Mouse Thigh Infection Model</B><B><I> </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g19n51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPR206&#151;Next-Generation Potentiator Product Candidate </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our next-generation potentiator candidate, SPR206, like SPR741, is an agent that is designed to interact with the LPS to disrupt the outer
membrane of Gram-negative bacteria. SPR206, unlike SPR741, has been observed to have direct antibiotic activity, while retaining potentiator activity, and has shown antibiotic activity against <I>Pseudomonas</I> and <I>Acinetobacter</I>. We are
developing SPR206 as a treatment for high-risk patients with suspected or known Gram-negative infections such as CRE, CRAB and MDR PA to prevent mortality and reduce the length of stay in the hospital setting. We believe SPR206 has the potential, if
successfully developed and approved, to become a new standard of care for these infections given the lack of coverage of these infections by generic and recently approved agents, and even new agents in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR206 Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In preclinical studies to date, SPR206 has demonstrated a favorable nephrotoxicity profile and toxicity profile. SPR206 has also shown
favorable efficacy in multiple models of Gram-negative infection, including <I>Pseudomonas </I>and <I>Acinetobacter</I> lung models in mice. Our current plans for SPR206 are to initiate the <FONT STYLE="white-space:nowrap">scale-up</FONT>
manufacturing to support the initiation of GLP toxicology and safety pharmacology studies in 2018. Pending successful results, we plan to file an IND (or foreign equivalent) and begin Phase 1 clinical trials during the second half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Market Opportunity for SPR206 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The need for new antibiotics to treat CRE, CRAB and MDR PA is particularly acute, as together these represent among the top global threats in
infectious disease. In February 2017,<I> </I>the WHO published a list of Gram-negative bacteria based on the urgency of need for new antibiotics: critical, high and medium priority. The most critical group of all includes MDR bacteria that pose a
particular threat including <I>Acinetobacter</I>, <I>Pseudomonas</I> and various <I>Enterobacteriaceae</I> (including <I>Klebsiella</I>, <I>E. coli</I>, <I>Serratia</I>, and <I>Proteus</I>). These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bacteria can cause severe and often deadly infections. As such, there is an acute need for new drugs to treat MDR Gram-negative bacteria. Currently approved products are increasingly ineffective
against Gram-negative bacteria due to increasing resistance, resulting in limited treatment options for patients with MDR infections. Few new therapeutic agents have been approved or are in clinical development to treat infections caused by
Gram-negative bacteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Carbapenem-Resistant Acinetobacter Baumannii </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Acinetobacter baumannii</I> is an opportunistic bacterial pathogen primarily associated with hospital-acquired infections. The recent
increase in incidence, largely associated with infected combat troops returning from conflict zones, coupled with a dramatic increase in the incidence of MDR strains, has significantly raised the profile of this emerging opportunistic pathogen. It
is estimated between 50,000 to 80,000 infections annually in the United States and approximately 63% of isolates are MDR. Mortality rates for patients with <I>Acinetobacter baumannii</I> have been reported as high as 43%. Currently the only drugs to
treat these resistant organisms are colistin and tigecycline, both of which have significant safety and tolerability issues. SPR206 would provide a much needed addition to the treatment of these very serious infections. The activity of SPR206
against a carbapenem resistant strain of <I>Acinetobacter baumannii</I> was superior to that of polymyxin B and tigecycline in a mouse lung infection model as shown below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Activity of SPR206 vs. Comparators in a Mouse Lung Infection Model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g78m75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Carbapenem Resistant Pseudomonas Aeruginosa </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Pseudomonas</I> is one of the most common Gram-negative organisms in the hospital setting. Incidence ranges from 13% in UTIs and as high as
25% in respiratory tract infections. Resistance to commonly used agents such as cephalosporins, piperacillin/tazobactam and quinolones ranges from 10% in the <FONT STYLE="white-space:nowrap">non-ICU</FONT> setting to upwards of 35% in the ICU. Even
more problematic is the increase in resistance to carbapenems, which is reported to be as high as 19% in the ICU. <I>Pseudomonas</I> is a serious cause of infection with morbidity and mortality rates of 18% to 61%. In preclinical studies to date,
SPR206 has demonstrated potent activity across a broad range of resistant strains of <I>Pseudomonas aeruginosa</I>.<I> </I>There are limited treatment options available today to treat these resistant organisms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>CRE infections and need for new approaches </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">CRE infections are associated with significant mortality, with up to 50% mortality observed in patients with bloodstream infections. With
limited treatment options available for CRE infections, physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime/avibactam. However, there is evidence that these antibiotics are failing
patients. For example, in bloodstream infections due to carbapenemase-producing <I>Klebsiella pneumoniae</I>, <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality for treatment with colistin, tigecycline, or combinations of antibiotics that
do not include a carbapenem active <I>in vitro </I>against the infecting isolate was reported to be 46%, 47%, and 37%, respectively. Recently, resistance to even these last-resort treatments has begun to be reported, further increasing the urgency
for new therapeutic options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>SPR206, if successfully developed, could become the first novel monotherapy approach to treat the growing
threat of carbapenem resistant Gram-negative organisms </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In our <I>in vitro</I> studies, SPR206 has covered a wide variety of these
bacteria. We are developing SPR206 as a monotherapy because of its observed broad-spectrum coverage. The safety profile observed to date is also a key differentiator in treating these life-threatening infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pulmonary <FONT STYLE="white-space:nowrap">Non-Tuberculous</FONT> Mycobacterial Infection Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A third area of our focus is anti-infective orphan disease. We are developing SPR720, a novel mechanism of action therapeutic candidate for
the treatment of NTM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Non-tuberculous mycobacteria are typically found in water and soil. NTM is a rare infection of the lung that is
acquired through inhalation of this microbe. There are approximately 150 types of mycobacteria, with <I>Mycobacterium avium complex</I>, or<I> </I>MAC, and <I>Mycobacterium abscessus</I> the most common cause of NTM, together comprising almost 90%
of all NTM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">NTM occurs in many different types of patients. NTM often occurs in people with compromised immune systems, such as those
with HIV, or those with respiratory conditions such as cystic fibrosis, chronic obstructive pulmonary disease, asthma or bronchiectasis. According to Strollo <I>et al. </I>and Adjemian <I>et al.</I>, the diagnosed patient population is approximately
86,000 in the United States. The annual prevalence of NTM is increasing at an estimated rate of 8% per year. While NTM can affect people of any age, it mostly affects adults middle-aged to elderly, and is increasing among patients over 65, a
population expected to nearly double by 2030. While relatively rare compared to other infectious diseases, the prevalence of NTM has more than doubled since 1997. By comparison, the prevalence of tuberculosis has declined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutics indicated for NTM. The current treatment for NTM is
lengthy and involves combination therapy, often including three or more drugs including an injectable. Treatment failure is common and is often due to poor compliance or inability to tolerate the regimen. Many patients experience progressive lung
disease and mortality is high. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that our intellectual property portfolio for SPR720, which includes multiple issued patents and
patent applications pending, will provide SPR720 protection globally, including in the United States and Europe, through 2033. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Our
SPR720 Development Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop SPR720 to become the first oral treatment
<FONT STYLE="white-space:nowrap">FDA-indicated</FONT> for NTM, and to enable refractory patients to regain a better quality of life. SPR720 is currently in preclinical development. We have conducted <FONT STYLE="white-space:nowrap">28-day</FONT> GLP
toxicity studies in rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates. We have also observed activity as good as or better than positive controls in <I>in vitro</I> and <I>in vivo</I> testing, including in an acute model infection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
caused by <I>Mycobacterium abscessus</I>. The activity observed was similar to and in some cases better than clarithromycin in other <I>in vitro</I> assays (macrophage and biofilm). We are
currently testing SPR720 in <I>in vivo</I> studies to assess activity across other pathogens of interest. Pending further evidence of <I>in vivo</I> activity and positive results from our additional toxicity studies, we plan to initiate Phase 1
clinical trials by the first half of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to our own patents and patent applications, we have acquired or licensed patents, patent applications and <FONT
STYLE="white-space:nowrap">know-how</FONT> from various third parties to access intellectual property covering product candidates that we are exploring and developing. We have certain obligations under these acquisition or licensing agreements,
including diligence obligations and payments, that are contingent upon achieving various development, regulatory and commercial milestones. Also, pursuant to the terms of some of these license agreements, when and if commercial sales of a product
commence, we may be obligated to pay royalties to such third parties on net sales of the respective products. Some of our license agreements include sublicenses of rights owned by third-party head licensors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meiji Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To support our
development of SPR994, in June 2017 we entered into an exclusive License Agreement with Meiji Seika Pharma Co., Ltd., or the Meiji License. Pursuant to the Meiji License, we obtained <FONT STYLE="white-space:nowrap">know-how,</FONT> data and
regulatory documents that will support the development of SPR994. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We retain exclusive rights to commercialize SPR994 throughout the
world, except in Japan, Bangladesh, Brunei, Cambodia, China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, where Meiji will have exclusive rights to commercialize SPR994. With Meiji, we will
establish a joint development committee for the management of the development of SPR994, including any joint, cross-territory studies that may be undertaken by the parties, if any. In addition, the parties will establish a joint commercialization
committee to coordinate information sharing relative to commercialization of the new formulation. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Meiji and we have granted each
other exclusive cross licenses to our respective tebipenem intellectual property, including <FONT STYLE="white-space:nowrap">know-how</FONT> and regulatory documentation. The license granted to us by Meiji includes certain know-how that Meiji
received from Global Pharma, as described below. As such, our rights to the Global Pharma know-how component are non-exclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Meiji License, we have paid Meiji a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of $0.6&nbsp;million
and are obligated to pay Meiji future clinical and regulatory milestone payments up to an aggregate of $3.0&nbsp;million and royalties of a low single-digit percentage based on net sales of SPR994. Additionally, we are obligated to pay Meiji a
percentage of certain amounts received from any sublicensees, up to an aggregate of $7.5&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the know-how that we
received under the Meiji License to support SPR994 development was originally obtained by Meiji through a license from Global Pharma, which we refer to as the head license. Prior to entering into the Meiji License with us, Meiji received written
approval from Global Pharma permitting Meiji to enter into the Meiji License with us. Specifically, in a letter agreement between Global Pharma and Meiji entered into in January 2017, Global Pharma consented to Meiji assisting us with the transfer
or license of the Global Pharma know-how and Meiji know-how on a non-exclusive basis outside of those Asian countries identified above, as well as certain related matters. This letter agreement does not contemplate us having any right to sublicense
the Global Pharma know-how. Global Pharma retains rights to its know-how outside of those Asian countries identified above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Meiji License continues in effect until the expiration of all payment obligations
thereunder (including royalty payments and licensee revenue) on a product-by-product and country-by-country basis, unless earlier terminated by the parties. Pursuant to the terms of the Meiji License, in addition to each party&#146;s right to
terminate the agreement upon the other party&#146;s material breach (if not cured within a specified period after receipt of notice) or insolvency, we also have unilateral termination rights (i) in the event that we abandon the development and
commercialization of SPR994 for efficacy, safety, legal or business factors, and (ii) under certain circumstances arising out of the head license with Global Pharma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Northern License
Agreement </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2015, our subsidiary, Spero Potentiator, Inc., or Spero Potentiator, entered into a license agreement, or
the 2015 Northern License Agreement, with Northern Antibiotics Oy (Ltd.) of Finland pursuant to which Northern granted to Spero Potentiator an exclusive, worldwide, perpetual and irrevocable license to develop and commercialize certain licensed
compounds under certain patents, patent applications and <FONT STYLE="white-space:nowrap">know-how</FONT> of Northern. In exchange for such exclusive license, Spero Potentiator issued an equity interest in Spero Potentiator and entered into a
subscription agreement and shareholders agreement with Northern. In June 2017, we repurchased Northern&#146;s minority equity interest in Spero Potentiator in exchange for a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee
of $1.0&nbsp;million immediately and agreed to pay Northern $0.1&nbsp;million within five days of the consummation of our initial public offering, and we also amended and restated the 2015 Northern License Agreement, which, as amended, we refer to
as the 2017 Northern License Agreement, to include certain contingent cash payments as described below. The 2017 Northern License Agreement has a perpetual term and no express termination rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the 2017 Northern License Agreement, Northern granted to Spero Potentiator an exclusive, perpetual, irrevocable, worldwide license to
develop and commercialize certain licensed compounds under certain Northern patents, patent applications and <FONT STYLE="white-space:nowrap">know-how</FONT> in consideration for one or more near-term milestone payments up to an aggregate of
$2.5&nbsp;million based on either clinical milestones or the completion of our initial public offering, or a combination thereof, and in consideration for up to an aggregate of $4.5&nbsp;million upon receipt of marketing approval of SPR741 or other
compounds licensed from Northern which, in either case, is approved to be <FONT STYLE="white-space:nowrap">co-administered</FONT> with a different antibiotic agent. With Northern, we have established a joint development committee for the exchange of
information and ideas regarding development of the licensed compounds, to monitor conduct of activities and to provide and receive updates regarding new inventions. In addition, we provide periodic reports to Northern describing the development and
commercialization of the licensed compounds, including SPR741. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cantab Agreements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into a stock purchase agreement, or the Cantab Agreement, with Pro Bono Bio PLC, a corporation organized under the
laws of England, and its affiliates, including PBB Distributions Limited, or PBB, Cantab Anti-Infectives Ltd., or CAI and New Pharma License Holdings Limited, or NPLH, in order to acquire NPLH and its intellectual property rights and assets relating
to our Potentiator Platform, and our next-generation potentiating agents in particular. The intellectual property portfolio we acquired includes patents which cover SPR206 as well as other novel potentiating agents, polymyxin derivatives and other
LPS or outer-membrane bacterial disrupting agents. In exchange for the acquisition of NPLH, we paid PBB upfront consideration in the amount of $0.3&nbsp;million and also agreed to pay a total of up to $5.8&nbsp;million upon the achievement of
specified clinical and regulatory milestones and to pay &pound;5.0&nbsp;million ($6.5&nbsp;million as of June&nbsp;30, 2017) upon the achievement of a specified commercial milestone. We also agreed to pay royalties of a low single-digit percentage
based on net sales of products licensed under the agreement. In addition, Spero Cantab issued an equity interest in Spero Cantab and entered into a subscription agreement and shareholders agreement with PBB. In July 2017, we repurchased PBB&#146;s
minority equity interest in Spero Cantab in exchange for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of approximately $0.2&nbsp;million and we also amended the Cantab Agreement to increase the contingent milestone
payments to PBB by an aggregate of $0.1&nbsp;million. The Cantab Agreement continues indefinitely, with royalty payment obligations thereunder continuing on a product-by-product and country-by-country basis until the later of ten years after the
first commercial sale of such product in such country or the expiration in such country of the last to expire valid claim of any of the applicable patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, CAI is party to a certain NIAID contract that partially funds the next-generation potentiating agent development program, which
is in the process of being novated to us pursuant to the terms of the Cantab Agreement. CAI has submitted a request to NIAID with respect to such novation and we believe that such novation should be completed during 2017. If NIAID exercises future
contract options and we receive further funding from NIAID, then we will pay a portion of the proceeds to PBB pursuant to the Cantab Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vertex
Assignment and License Agreement </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2016, we entered into an agreement with Vertex Pharmaceuticals Incorporated, or Vertex,
pursuant to which Vertex assigned to us rights to patents relating to SPR720 and SPR719 (an active metabolite). The acquired patent portfolio includes protection for composition of matter, method of use, and specific key intermediates used in the
manufacture of SPR719 and SPR720. We also obtained certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a license to research, develop, manufacture and sell products for a proprietary compound, as well as a transfer of materials as part of
the transaction. In return, we granted Vertex an exclusive license to the assigned patents and <FONT STYLE="white-space:nowrap">know-how</FONT> for use outside of the diagnosis, treatment or prevention of bacterial infections. In exchange for the
assigned patents, we paid Vertex an upfront, <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.5&nbsp;million, which was
recognized as research and development expense, and we also agreed to pay Vertex future clinical, regulatory and commercial milestones up to $81.1&nbsp;million in the aggregate and a royalty on the net sales of licensed products ranging from
mid-single digits to low double digits. The agreement continues in effect until the expiration of all payment obligations thereunder, with royalty payment obligations continuing on a product-by-product and country-by-country basis until the later of
a specified period after the first commercial sale of such product in such country or the date of expiration in such country of the last to expire applicable patent. Further, Vertex has the right to terminate the agreement if provided with
notification from us of our intent to cease all development or if no material development or commercialization efforts occur for a period of 12 consecutive months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Awards </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have commitments
of up to an aggregate of $15.0&nbsp;million in <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding from NIAID, the DoD and <FONT STYLE="white-space:nowrap">CARB-X.</FONT> As noted above, our potentiator program is partially funded by a
$1.5&nbsp;million award from the DoD and an award of up to $6.8&nbsp;million from <FONT STYLE="white-space:nowrap">CARB-X.</FONT> The DoD funding supports next-generation potentiator discovery and screening of SPR741 partner antibiotics. The <FONT
STYLE="white-space:nowrap">CARB-X</FONT> award supports screening and selection of SPR741 partner antibiotics (with the exception of azithromycin) with the goal of taking one SPR741/partner combination through
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, culminating in the completion of a Phase 1 clinical trial. Our NIAID award provides up to $1.0&nbsp;million of support for our SPR720 program. The scope of the program includes <I>in
vitro</I> and <I>in vivo</I> assessments of SPR720 against tuberculous as well as nonclinical and manufacturing activities in support of both tuberculous and NTM indications. Finally, NIAID is providing up to $5.7&nbsp;million of funding for our
next-generation potentiator molecules. CAI is the current contract holder, although novation of the contract to us is in progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual
Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technology that we believe is important to our business, including seeking and
maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture and any other inventions that are commercially important to the development of our business. We also rely on
trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success will significantly depend on our ability to obtain and maintain patent and other
proprietary protection for commercially important technology and inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate
without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our proprietary position.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero-Owned Intellectual Property Relating to SPR994 and Other Compounds Under Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have patent applications directed to the composition of matter, formulation and/or use of SPR994, SPR741, SPR206 and SPR720 pending in the
United States, Europe, Japan and other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our SPR994 program contains three pending U.S. provisional applications covering novel preparations of tebipenem pivoxil as of August&nbsp;31,
2017, all wholly owned by us. The provisional patent applications will be converted to Patent Cooperation Treaty, or PCT, applications within one year of their filing dates. U.S. and foreign patents issuing from our tebipenem pivoxil patent
applications will have statutory expiration dates of December 2037 and February 2038. Patent term adjustments or patent term extensions could result in later expiration dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Platform (Including SPR741) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolio for our Potentiator Platform contains patent applications and issued patents directed to composition of
matter for SPR741 and analogs thereof, composition of matter with different structural features, combinations of SPR741 or other potentiators with other anti-bacterial compounds, and methods of use for these novel compounds and compositions. As of
August&nbsp;31, 2017, we owned or were exclusively licensed eight U.S. patents and one U.S. provisional application; 28 foreign patents and nine pending foreign patent applications in a number of jurisdictions, including Australia, Brazil, Canada,
China, the European Union, Israel, India, Indonesia, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa, and Taiwan; four pending PCT applications; and two pending U.S. provisional patent applications directed to our
Potentiator Platform. Issued U.S. or foreign patents and any patents issuing any pending U.S., foreign or PCT applications covering SPR741 will have a statutory expiration date of August 2027, February 2029, April 2037, May 2037, May 2038 and July
2038. Patent term adjustments or patent term extensions could result in later expiration dates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Next-Generation Polymyxin Program (Including
SPR206) </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolio for our next-generation polymyxin program contains patent applications and issued
patents directed to composition of matter for polymyxin-like compounds with different structural features, pharmaceutical compositions comprising the same, and methods of use for these novel compounds and compositions. As of August&nbsp;31, 2017, we
owned one U.S. patent, three pending U.S. applications, four foreign patents and 47 pending foreign patent applications in a number of jurisdictions including Argentina, Australia, Brazil, Canada, China, Colombia, Eurasia, the European Union, the
Gulf Coast Cooperation Treaty, Hong Kong, Israel, India, Indonesia, Japan, South Korea, Mexico, Russia, Singapore, South Africa, Taiwan and Vietnam. Issued U.S. or foreign patents and any patents issuing any pending U.S., foreign or PCT applications
covering our next-generation polymyxin program will have a statutory expiration date of November 2032, May 2034, March 2035 and November 2035. Patent term adjustments or patent term extensions could result in later expiration dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DNA Gyrase Inhibitor Program (SPR720) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our intellectual property portfolio for our DNA Gyrase Inhibitor program includes issued patents and pending patent applications directed to
composition of matter for SPR720, and its close analogs and prodrugs, novel solid forms of SPR720 and its prodrugs, methods of manufacture, and methods of treatment using SPR720 alone and in combination with other antibiotic compounds. All patents
and patent applications in the portfolio are wholly owned by us. As of August&nbsp;31, 2017, we owned ten issued U.S. patents, one pending U.S. patent application, 52 issued foreign patents, and 38 pending foreign patent applications. The issued and
foreign patents are in a number of jurisdictions including the European Union and its member states, Argentina, Australia, Brazil, Canada, China, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, the Philippines, Russia,
Singapore, South Africa, and Taiwan. Issued U.S. and foreign patents, and patents issuing from pending U.S. and foreign applications will have statutory expiration dates of January 2032, June 2032 and July 2033. Patent term adjustments or patent
term extensions could result in later expiration dates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term and Patent Term Extensions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#146;s term may be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a
patent that covers a drug, biological product or medical device approved pursuant to a <FONT STYLE="white-space:nowrap">pre-market</FONT> approval may also be eligible for patent term extension when FDA approval is granted, provided statutory and
regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the
Hatch-Waxman Act, permits a patent term extension of up to five&nbsp;years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval,
only one patent applicable to each regulatory review period may be granted an extension and only those claims reading on the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of
a patent that covers an approved drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We rely, in some circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect. We
seek to protect our trade secrets and proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of
our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached. We may not have adequate remedies for any breach and could lose our trade secrets through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent
that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and
inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
biopharmaceutical industry is characterized by intense competition and rapid innovation. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our
potential competitors have greater financial, technical human resources than we do, as well as greater experience in the discovery and development of product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly, our potential competitors may be more successful than us in
obtaining FDA approval drugs and achieving widespread market acceptance. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the development of new
treatment methods for the diseases we are targeting could render our product candidates <FONT STYLE="white-space:nowrap">non-competitive</FONT> or obsolete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors that will affect the development and commercial success of most advanced product candidate, SPR994, if
approved, will be efficacy, coverage of drug-resistant strains bacteria, safety and tolerability profile, reliability, convenience of oral dosing, price, availability of reimbursement from governmental and other third-party payers and susceptibility
to drug resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing SPR994 as an oral antibiotic for use as a monotherapy for the treatment of resistant and MDR
infections. If approved, SPR994 would compete with several antibiotics currently in clinical development, including <FONT STYLE="white-space:nowrap">C-Scape</FONT> from Achaogen, Inc., sulopenem from Iterum Therapeutics Limited, eravacycline from
Tetraphase Pharmaceuticals, Inc. and omadacycline from Paratek Pharmaceuticals, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also expect that SPR994, if approved, would
compete with future and current generic versions marketed antibiotics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If approved, we believe that SPR994 would compete effectively
against these compounds on the basis of SPR994&#146;s potential: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broad range of activity against a wide variety of resistant and MDR Gram-negative bacteria; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low probability of drug resistance; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a convenient oral dosing regimen and opportunity to step-down from <FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a monotherapy treatment for MDR Gram-negative infections. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also developing
SPR741 through our Potentiator Platform, an <FONT STYLE="white-space:nowrap">IV-administered</FONT> agent that has demonstrated <I>in vitro</I> the ability to expand the spectrum and increase the potency of
<FONT STYLE="white-space:nowrap">co-administered</FONT> antibiotics. If approved, SPR741 would compete with several IV-administered product candidates marketed for the treatment of Gram-negative infections, including Avycaz from Allergan plc and
Pfizer Inc. and Zerbaxa from Merck &amp; Co. There are also a number of IV-administered product candidates in late-stage clinical development that are intended to treat Gram-negative infections, including plazomicin from Achaogen Inc.,
meropenem-vaborbactam from The Medicines Company, cefiderocol from Shionogi &amp; Co. Ltd., eravacycline IV from Tetraphase Pharmaceuticals Inc. and relabactam from Merck &amp; Co. Each of these products and product candidates employs a mechanism of
action that differs from the mechanism of action employed by SPR741. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If approved, we believe that SPR741 would compete effectively
and potentially occupy an earlier place in treatment against these compounds on the basis of SPR741&#146;s potential, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">novel mechanism of action and ability to expand the utility of multiple antibiotics including many generic standard of care antibiotics and prolong the use of these agents to lessen the burden on newer expensive agents;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broad-spectrum activity against a wide variety of multi-drug resistant Gram-negative bacteria; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low probability of drug resistance; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other
things, the research, development, clinical trials, testing, manufacture, including any manufacturing changes, authorization, pharmacovigilance, adverse event reporting, recalls, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, marketing, import and export of pharmaceutical products and product candidates such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent
compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Changes in the
Regulatory Landscape </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s Division of Anti-Infective Products, or DAIP, has undergone evolution in recent years,
primarily driven by concerns that increasingly less effective antibiotics may have been approved in the last 10 to 15 years and a desire to bring what DAIP perceives to be greater statistical rigor to their analyses. The impact of this was a
rethinking of how antibiotic efficacy is measured in clinical trials, and a review of the statistical tools used to analyze the data. In February 2015, the FDA published guidance documents for industry entitled &#147;Complicated Urinary Tract
Infections: Developing Drugs for Treatment&#148; and guidance entitled &#147;Complicated Intra-Abdominal Infections: Developing Drugs for Treatment.&#148; The purpose of these guidance documents is to address considerations surrounding the clinical
development of drugs for cUTI and cIAI indications, including clinical trial design and efficacy. Additionally, in August 2017, the FDA published a guidance document entitled &#147;Antibacterial Therapies for Patients With an Unmet Medical Need for
the Treatment of Serious Bacterial Diseases,&#148; setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, President Obama signed into law the Cures Act, which is intended to accelerate medal product development.
Section&nbsp;3042 of the Cures Act establishes the limited population pathway for certain antibacterial or antifungal drugs intended to treat targeted groups of patients suffering from serious or life-threatening infections where unmet need exists.
Approvals of these limited population drugs are expected to rely on data from smaller clinical trials than would ordinarily be required by the FDA. To date, the FDA has not approved any drugs utilizing the limited population pathway. For drugs
approved through this pathway, the statement &#147;Limited Population&#148; will appear prominently next to the drug&#146;s name in labeling, which is intended to provide notice to healthcare providers that the drug is indicated for use in a limited
and specific population of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the
applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending
NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil and/or criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally
involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with GLP regulations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials in accordance with GCP to establish the safety and efficacy of the proposed drug product for each indication; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good
manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of clinical data; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of user fees and securing FDA review and approval of the NDA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess
potential safety and efficacy. Preclinical tests intended for submission to the FDA to support the safety of a product candidate must be conducted in compliance with GLP regulations and the United States Department of Agriculture&#146;s Animal
Welfare Act. A drug sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical
testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places
the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to
commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed
consent in writing for their participation in any clinical trial along with the requirement to ensure that the data and results reported from the clinical trials are credible and accurate. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the trial, the criteria for determining subject eligibility, the dosing plan, the parameters to be used in monitoring safety, the procedure for timely reporting of adverse events, and the effectiveness criteria
to be evaluated. A protocol for each clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve
the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their <I>www.clinicaltrials.gov </I>website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1</I></B>: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug&#146;s or
biological product&#146;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2</I></B>: The drug is administered to a larger, but still limited patient population to identify possible adverse effects and
safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dosage tolerance and optimal dosage. Phase 2 clinical trials are typically well-controlled and closely monitored. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 3</I></B>: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites,
in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the
labeling of the product. Phase 3 clinical trials usually involve a larger number of participants than a Phase 2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any
specified period, or at all. Results from one trial may not be predictive of results from subsequent trials. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the
research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s
requirements or if the drug has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed
information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases,
the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision.
Furthermore, the FDA is not required to complete its review within the established <FONT STYLE="white-space:nowrap">ten-month</FONT> timeframe and may extend the review process by issuing requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain
data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe
and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric
data requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by regulation, the pediatric data requirements do not apply to products
with orphan designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any
identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk
minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them
for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA
reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facilities in which it is manufactured, processed, packaged or held meet standards designed to assure the product&#146;s continued safety,
quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of
independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of
an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically
will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign
clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCPs and the FDA is able to validate the data through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole
basis for marketing approval if (1)&nbsp;the foreign data are applicable to the U.S. population and U.S. medical practice, (2)&nbsp;the studies were performed by clinical investigators with recognized competence, and (3)&nbsp;the data may be
considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The testing and approval process for an NDA
requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could
delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and
all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response
letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the
application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or
precautions be included in the product labeling&nbsp;, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor
the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA
may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and
additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special FDA Expedited Review and Approval
Programs </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including fast track designation, accelerated approval and priority review, that are intended
to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of
these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To be eligible for a fast
track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug
qualifies as a QIDP under the GAIN Act. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy
or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#146;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a
schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. The FDA
may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may give a
priority review designation to drugs that offer major advances in treatment for a serious condition, or provide a treatment where no adequate therapy exists. Most products that are eligible for fast track designation are also likely to be considered
appropriate to receive a priority review. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement,
these six and ten month review periods are measured from the &#147;filing&#148; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the
date of submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, meaning that it may be approved on (i)&nbsp;the basis of adequate and well-controlled clinical trials establishing that the drug product has
an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or (ii)&nbsp;on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality and that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may
require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated
withdrawal procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or
FDASIA, enacted in 2012, a sponsor can request designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to
expedite the development and review of an application for approval of a breakthrough therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more
of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution,
advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also
are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require
post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers
that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of drug products that are placed on the market. A product cannot
be commercially promoted before it is approved, and approved drugs may generally be promoted only for their approved indications. Promotional claims must also be consistent with the product&#146;s <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
label, including claims related to safety and effectiveness. The FDA and other federal agencies also closely regulate the promotion of drugs in specific contexts such as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, industry-sponsored scientific and education activities, and promotional activities involving the Internet and social media. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market
studies or clinical trials to assess new safety risks; or imposition of distribution or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other restrictions under a REMS program. Other potential consequences of regulatory <FONT STYLE="white-space:nowrap">non-compliance</FONT> include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on, or suspensions of, the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interruption of production processes, including the shutdown of manufacturing facilities or production lines or the imposition of new manufacturing requirements; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or other enforcement letters or holds on post-approval clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the distribution
of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of
drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusivity and Approval of Competing Products </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Market and data exclusivity provisions under the FDCA can delay the submission or the approval of certain applications for competing products.
The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the
FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. We believe that our product candidates are new chemical entities. During the
exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or 505(b)(2) NDA may be submitted
after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing NDA
or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three year exclusivity
may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and
effectiveness. For drug products that contain an &#147;antibiotic&#148; ingredient approved prior to 1997, the statute imposes certain limitations on the award of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity. However, we do not
believe these limitations would apply to SPR994 or any of our other investigational antibiotics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Qualified Infectious Disease Product Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the GAIN Act provisions of FDASIA, which was signed into law in July 2012, the FDA may designate a product as a qualified infectious
disease product, or QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (i)&nbsp;an antibiotic
or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;qualifying pathogen&#148; found on a list of potentially dangerous, drug-resistant organisms
to be established and maintained by the FDA under the new law. A sponsor must request such designation before submitting a marketing application. We obtained a QIDP designation for the oral formulation of SPR994 for cUTI in November 2016 and CABP
and DFI in April 2017, and expect to request QIDP designations for our other product candidates prior to submitting a marketing application for such product candidates, as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon approving an application for a qualified infectious disease product, the FDA will extend by an additional five years any <FONT
STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular entity. This extension is in addition to any pediatric exclusivity extension awarded, and the
extension will be awarded only to a drug first approved on or after the date of enactment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The GAIN Act provisions prohibit the grant of
an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or is an application for a product that
does not meet the definition of qualified infectious disease product based on the uses for which it is ultimately approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical
trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union
and Australia, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product authorization, pricing and reimbursement vary greatly from
place to place, and the time may be longer or shorter than that required for FDA approval. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under European Union regulatory systems,
a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new
active substances for specific indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the
centralized procedure, a marketing application is submitted to the European Medicines Agency where it will be evaluated by the Committee for Medicinal Products for Human Use and a favorable opinion typically results in the grant by the European
Commission of a&nbsp;single marketing authorization that is valid for all European Union member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an
unlimited period. The decentralized procedure provides for approval by one or more &#147;concerned&#148; member states based on an assessment of an application performed by one member state, known as the &#147;reference&#148; member state. Under the
decentralized approval procedure, an applicant submits&nbsp;an application, or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related
materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#146;s assessment report, each concerned member state must decide whether to approve the assessment report and related materials.
If a member state does not recognize the marketing authorization, the disputed&nbsp;points are eventually referred to the European Commission, whose decision is binding on all member states. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Coverage and Reimbursement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of our products will depend, in part, on the availability and extent of coverage and reimbursement by third-party payors, such as
government health programs, including Medicare and Medicaid, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging the price and limiting the coverage and reimbursement amounts for medical
products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal and state governments, and the prices of
drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement,
and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and
results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our
sales, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the federal government provides health insurance for people
who are 65 or older, and certain people with disabilities or certain conditions irrespective of their age, through the Medicare program, which is administered by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. Coverage and
reimbursement for products and services under Medicare are determined in accordance with the Social Security Act and pursuant to regulations promulgated by CMS, as well as the agency&#146;s subregulatory coverage and reimbursement guidance and
determinations. Drugs and other products that are utilized within the hospital <FONT STYLE="white-space:nowrap">in-patient</FONT> setting are typically reimbursed under a prospective payment system, or a predetermined payment amount that is based on
diagnosis related groups, or DRGs for Medicare patients and under a bundled payment for commercially insured patients. These payment amounts differ by type of diagnoses, procedures performed and the severity of the patient&#146;s condition, among
other things. A drug that is used in a treatment or procedure under a specific DRG or bundled payment is generally not eligible for any separate payment. For catastrophic cases where costs greatly exceed the bundled payment amount, the hospital may
be eligible for an outlier payment that is intended to cover part of the expense above the standard payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Medicaid is a health
insurance program for <FONT STYLE="white-space:nowrap">low-income</FONT> children, families, pregnant women, and people with disabilities that is jointly funded by the federal and state governments, but administered by the states. In general, state
Medicaid programs are required to cover drugs and biologicals of manufacturers that have entered into a Medicaid Drug Rebate Agreement, although such drugs and biologicals may be subject to prior authorization or other utilization controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The U.S. Congress and state legislatures from time to time propose and adopt initiatives aimed at cost containment, which could impact our
ability to sell our products profitably. For example, the federal Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, known collectively as the ACA, among other things, contains
provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D
beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing
controls and measures, could limit payments for pharmaceutical drugs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health
and Human Services as a condition for states to receive federal matching funds for manufacturers&#146; outpatient drugs furnished to Medicaid patients. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring
pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of
the ACA. Congress and President Trump have expressed their intentions to repeal and replace the ACA. President Trump issued an Executive Order and both chambers of Congress passed bills all with the goal of fulfilling their intentions. However, to
date, the Executive Order has had limited effect and the Congressional activities have not resulted in the passage of a law. If a law is enacted, many if not all of the provisions of the ACA may no longer apply to prescription drugs. We cannot
predict the full impact of the ACA or future reform measures on our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed
pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, in the EU, the sole legal instrument at the EU level governing the pricing and
reimbursement of medicinal products is Council Directive 89/105/EEC, or the Price Transparency Directive. The aim of this Directive is to ensure that pricing and reimbursement mechanisms established in the EU Member States are transparent and
objective, do not hinder the free movement of and trade in medicinal products in the EU, and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not provide any guidance&nbsp;concerning the specific
criteria on the basis of which pricing and reimbursement decisions are to be made in individual EU Member States, nor does it have any direct consequence for pricing or reimbursement levels in individual EU Member States. The EU Member States are
free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement, and to control the prices and/or reimbursement levels of medicinal products for human use. An EU Member State may approve a
specific price or level of reimbursement for the medicinal product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the market, including
volume-based&nbsp;arrangements, caps and reference pricing mechanisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Health Technology Assessment, or HTA, of medicinal products is
becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including the United Kingdom, France, Germany, Ireland, Italy and Sweden. The HTA process in the EU Member States is governed by the national
laws of these countries. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the
individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those
elements of medicinal products are compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products
by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between EU Member States. A negative HTA of one of our products by
a leading and recognized HTA body, such as the National Institute for Health and Care Excellence in the United Kingdom, could not only undermine our ability to obtain reimbursement for such product in the EU Member State in which such negative
assessment was issued, but also in other EU Member States. For example, EU Member States that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in countries with a developed HTA framework, such as the United
Kingdom, when adopting decisions concerning the pricing and reimbursement of a specific medicinal product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Healthcare Laws </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we currently do not have any products on the market, if our product candidates are approved and we begin commercialization, we may be
subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal
anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be
subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not own or operate
manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for
all of our required raw materials, drug substance, and finished drug product for our preclinical research and clinical trials. We currently employ internal resources to manage our manufacturing. We intend to have two suppliers for SPR994&#146;s
active pharmaceutical ingredient, with each is capable of producing kilogram quantities for commercial scale and has produced over 10kg of active pharmaceutical ingredient under cGMP conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are not party to
any material legal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in Cambridge, Massachusetts, where we lease approximately 7,800 square feet of office space. Our lease extends
through December 2020, and we have the option to extend the term of the lease for such space through January 2026. We also sublease approximately 7,000 square feet of laboratory space in Watertown, Massachusetts. Our sublease extends through
November 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
August 31, 2017, we had 28 <FONT STYLE="white-space:nowrap">full-time</FONT> employees, including a total of 12 employees with M.D. or Ph.D. degrees. Twenty employees were primarily engaged in research and development activities, with the rest
providing administrative, business and operations support. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our employee relations to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers, Key Employees and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our executive officers, key employees and directors as of the date of this prospectus: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:13.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Sendek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key Employees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Garbacz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance and Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy Keutzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vikas Goyal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reza Halse, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr. Halse has notified the Company that he will resign from our board of directors immediately prior to the effectiveness of the resignation statement of which this prospectus forms a part. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Ankit
Mahadevia, M.D.</I></B> has served as our Chief Executive Officer since March 2015 and has been a member of our board of directors since September 2013. He <FONT STYLE="white-space:nowrap">co-founded</FONT> the company in 2013. Prior to joining us,
Dr.&nbsp;Mahadevia was a Venture Partner in the life sciences group at Atlas Venture in Cambridge, Massachusetts, where he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including
Synlogic Therapeutics and Translate Bio. He has led three of these companies as acting or full-time CEO. Prior to joining Atlas Venture in 2008, Dr.&nbsp;Mahadevia worked on product and business development with the founding team at Arcion
Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey&nbsp;&amp; Company and Monitor Group. Dr.&nbsp;Mahadevia
began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. Dr.&nbsp;Mahadevia holds an M.D. from
the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Joel Sendek</I></B> has served as our Chief Financial Officer since May 2017. Mr.&nbsp;Sendek has more than 25 years of experience in
the life sciences sector, including 18 years as a senior sell-side research analyst covering biotechnology. Prior to joining us, Mr. Sendek was the Chief Financial Officer at Forward Pharma A/S since August 2014. As an analyst, he served as a
Managing Director at Stifel Financial Corp. from January 2012 to July 2014, where he led the firm&#146;s healthcare equity research group, and previously he was a Managing Director at Lazard Ltd. since January 2000, where he established the
firm&#146;s healthcare equity research effort. Prior to his career in equity research, Mr.&nbsp;Sendek worked as a Senior Director of Corporate Development at Progenics Pharmaceuticals, Inc. and as an investment banking analyst at Goldman,
Sachs&nbsp;&amp; Co. Mr.&nbsp;Sendek holds a B.A. in Biochemistry from Rice University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Cristina Larkin</I></B> was promoted to Chief Operating Officer as of September 2017
and had served as our Chief Commercial Officer since March 2016. Ms.&nbsp;Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance,
Teflaro, Levaquin and Floxin. Prior to joining us, Ms.&nbsp;Larkin founded CLC Insights, LLC. Prior to that, since 2004, she worked at Actavis, plc, formerly Forest Laboratories, Inc., where she served in various positions, including Assistant Vice
President from 2014 to 2015. During that time, Ms.&nbsp;Larkin led the commercial hospital antibiotic franchise team and was responsible for the U.S. launch and execution strategy for several antibiotics. Additionally, she was a member of the
business assessments and business development team and played an integral role in several strategic ventures, including the <FONT STYLE="white-space:nowrap">out-licensing</FONT> of ceftaroline to AstraZeneca plc and the acquisition of Durata. From
1996 to 2002, Ms.&nbsp;Larkin served in various roles at Ortho-McNeil Pharmaceutical, LLC. Ms.&nbsp;Larkin received a bachelor&#146;s degree from Florida State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Thomas Parr Jr., Ph.D</I></B><I>.</I>, has served as our Chief Scientific Officer since April 2014. He has more than 26 years of drug
discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining us, from 2012 to 2014, Dr.&nbsp;Parr was the Chief Scientific Officer at Fedora Pharmaceuticals, Inc. where the company moved novel
diazabicyclooctane beta-lactramase inhibitors toward development partnerships. Prior to Fedora, he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. Dr.&nbsp;Parr earned his Ph.D. from the University of
Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development
career. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Employees </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Stephen Garbacz, CPA</I></B>,<B><I></I></B> has served as our Vice President of Finance and Operations since July 2015. He has over 20
years of senior finance experience in biotechnology and consumer products. Prior to joining us, he was the Executive Director at Epizyme, Inc. where he played a leading role in that company&#146;s IPO. Before joining Epizyme in 2012,
Mr.&nbsp;Garbacz held senior financial positions at Biogen, Inc., including Controller of International (based in Switzerland), Director of Operations and Technology and Director of Accounting. Mr.&nbsp;Garbacz has also held senior financial
positions at Kraft Foods Group, Inc., including mergers and acquisitions, treasury, financial planning and analysis, and international. He has an M.B.A. in Finance from the Stern Graduate School of Business at New York University and a B.S. in
Economics from George Mason University. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Timothy Keutzer</I></B> was promoted to Senior Vice President of Development as of
September 2017 and had served as our Vice President of Development since September 2015. He has over 20 years of experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining us, Mr.&nbsp;Keutzer was
employed by Cubist Pharmaceuticals, Inc. from 2008 to 2015. He was Vice President of Program and Portfolio Management from 2014-2015. While at Cubist, he was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to
Phase 3 clinical trials, and was approved in the United States in December 2014. Prior to that role, he also led several of Cubist&#146;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> development programs, and also led the commercial supply
chain for Cubicin. His experience before Cubist spans the drug development continuum across multiple drug classes, and includes preclinical PK/PD and clinical operations at Genetics Institute, Inc., as well as global strategic marketing and program
management at Wyeth. Mr.&nbsp;Keutzer began his career in contract toxicology laboratories. He studied English and microbiology at the University of Kentucky. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Casper Breum</I></B> has served on our board of directors since June 2015. Mr.&nbsp;Breum is a Senior Partner at Lundbeckfond Ventures,
where he has been since 2009. Previously, Mr.&nbsp;Breum was Chief Executive Officer of Ilochip A/S, a venture-backed company focused on the development of diagnostic biochips. Prior to Ilochip, Mr.&nbsp;Breum held different positions at H. Lundbeck
A/S, most recently in corporate business development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and&nbsp;strategy. While working at H. Lundbeck A/S, he was a member of the board of directors of&nbsp;Lundbeckfond and Lundbeckfond Invest A/S, the main shareholder of H. Lundbeck A/S and <FONT
STYLE="white-space:nowrap">ALK-Abello</FONT> A/S, as an employee representative. Mr.&nbsp;Breum is currently a member of the board of directors of Atox Bio Inc.,&nbsp;Biom&#146;Up SA,&nbsp;Dysis Medical Ltd., and&nbsp;Laboratoris Sanifit, S.L.
Mr.&nbsp;Breum obtained an MSc in Organic Chemistry and an M.B.A. in Management of Technology, both from the Technical University of Denmark. We believe Mr.&nbsp;Breum is qualified to serve on our board of directors because of his extensive
operational experience within the pharmaceutical industry, his experience as a chief executive officer and his experience as a venture capitalist serving on other boards of directors in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Milind Deshpande, Ph.D.</I></B>,<B><I></I></B> has served on our board of directors since January 2014 and currently serves as chairman
of our board of directors. Dr.&nbsp;Deshpande joined Achillion Pharmaceuticals, Inc. in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior
Vice President and Chief Scientific Officer in December 2004 and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President of Research and Development in October 2010. In May 2013,
Dr.&nbsp;Deshpande was appointed President and Chief Executive Officer of Achillion and joined its board of directors on which he continues to serve. Prior to joining Achillion, Dr.&nbsp;Deshpande was Associate Director of Lead Discovery and Early
Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a
faculty position at Boston University Medical School. Dr.&nbsp;Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India. We believe that Dr.&nbsp;Deshpande is qualified to serve on our
board of directors due to his extensive experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Jean-Fran&ccedil;ois Formela,
M.D.</I></B>,<B><I></I></B> has served on our board of directors since March 2013. Dr.&nbsp;Formela is currently a partner at Atlas Venture and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.
Dr.&nbsp;Formela joined Atlas Venture in 1993 to build its U.S. life sciences franchise. Prior to joining Atlas, he worked at Schering-Plough Corporation, where he directed U.S. Phase 4 clinical trials in all therapeutic areas. Before that, he was
responsible for the marketing of Intron A, Schering-Plough&#146;s alpha-interferon. Dr.&nbsp;Formela began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Dr.&nbsp;Formela serves as chair of
the board of directors of IFM Therapeutics, and serves on the boards of directors of Intellia Therapeutics, F-Star Biotechnology Ltd., Kyn Therapeutics, Inc. and Translate Bio, which he co-founded. Dr.&nbsp;Formela received his M.D. from Paris
University School of Medicine and his M.B.A. from Columbia University. We believe Dr.&nbsp;Formela&#146;s experience in the life sciences industry, as well as his practice of medicine, provides him with the qualifications and skills to serve as a
director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Vikas Goyal</I></B> has served on our board of directors since September 2013. Mr.&nbsp;Goyal is currently
a Principal at S.R. One, Limited, the corporate venture capital arm of GlaxoSmithKline plc, in Cambridge, Massachusetts, where he manages investments in innovative drug discovery and development companies. He joined S.R. One, Limited in January
2011. Prior to joining S.R. One, Limited, Mr.&nbsp;Goyal was a consultant in the pharmaceutical and medical products practice at McKinsey and Company, a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Extera Partners, where he advised public
and private life sciences companies, and a business development manager at Infinity Pharmaceuticals, Inc. Over his career, Mr.&nbsp;Goyal has supported business and corporate development activities for nearly 50 large and small public,
venture-backed, and angel funded life science companies. He received his B.A. in Neurobiology from Harvard University and his M.B.A. in Health Care Management from the Wharton School of the University of Pennsylvania. We believe that Mr.&nbsp;Goyal
is qualified to serve on our board of directors due to his extensive investment and operations experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Reza Halse, Ph.D.</I></B>,<B><I></I></B> has served on our board of directors since March 2013. Dr.&nbsp;Halse currently serves as
President of MRL Ventures Fund, the global corporate venture arm of Merck&nbsp;&amp; Co. Previously, he was Head of the Merck European Innovation Hub, based in London, leading business development and licensing activities in Europe. Prior to Merck,
he was a Partner with the corporate venture capital arm of Partners HealthCare System, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inc., a large academic medical center and Harvard Medical School affiliate, based in Boston, Massachusetts. He has also had management roles in large pharmaceutical and private life-science
companies in both the United Kingdom and the United States. He has served on the boards of numerous private life science companies. Mr.&nbsp;Halse holds a B.Sc. and Ph.D. from Newcastle University in the United Kingdom. We believe that
Mr.&nbsp;Halse is qualified to serve on our board of directors due to his extensive experience in the life sciences industry and venture capital involvement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Frank Thomas</I></B> has served on our board of directors since July 2017. Mr.&nbsp;Thomas served as the President and Chief Operating
Officer of AMAG Pharmaceuticals, Inc., a publicly traded commercial-stage pharmaceutical company, from April 2015 to April 2017, and previously served as AMAG&#146;s Executive Vice President and Chief Operating Officer from May 2012 through April
2015 and Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to joining AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics,
Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr.&nbsp;Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from April 2004 to March 2008,
where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008.
Prior to 2004, Mr.&nbsp;Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr.&nbsp;Thomas was a member of the board of directors of
the Massachusetts Biotechnology Council from 2007 to 2015 and currently serves as a member of the board of directors of Zafgen, Inc., a public biopharmaceutical company, which he joined in June 2014. Mr.&nbsp;Thomas holds a B.B.A. from the
University of Michigan, Ann Arbor. We believe that Mr.&nbsp;Thomas&#146; extensive commercial and operational management experience at biopharmaceutical companies and with financial matters qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Patrick Vink, M.D.</I></B>,<B><I></I></B> has served on our board of directors since September 2015. Dr.&nbsp;Vink has been an advisor
to the pharmaceutical industry since 2015 and <FONT STYLE="white-space:nowrap">non-executive</FONT> board member of several companies. Previously, Dr.&nbsp;Vink was employed at Cubist Pharmaceuticals, Inc. Most recently he served as Executive
Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company&#146;s profit and loss. He joined Cubist in 2012 as Senior Vice-president and
Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr.&nbsp;Vink served as Senior Vice President, Global Head of Hospital
Business and Global Head of Biologics for Mylan Inc. In this role, Dr.&nbsp;Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining
Mylan, Dr.&nbsp;Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Business for Biogen, Inc.; and Head of Worldwide Marketing,
Cardiovascular and Thrombosis for Sanofi-Synth&eacute;labo SA. Dr.&nbsp;Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr.&nbsp;Vink
graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr.&nbsp;Vink has served on the board of directors of Concordia International Corp., Santhera
Pharmaceuticals Ag. and Arch Biopartners. We believe that Dr.&nbsp;Vink is qualified to serve on our board of directors because of his extensive operational business experience, significant knowledge of the activities of our company, and diverse
background serving on the board of directors of various public and private life science companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors consists of eight members, all of whom are members pursuant to the board composition provisions of our voting
agreement, which agreement is described under &#147;Certain Relationships and Related Party Transactions&#148; in this prospectus. These board composition provisions will terminate upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate
governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees, which may include diversity, which is not only limited to race, gender or national origin. We
have no formal policy regarding board diversity. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will further the interests of our
stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and
professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. Our amended and
restated certificate of incorporation and amended and restated by-laws that will become effective upon the completion of this offering also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least
75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only
by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Director Independence</I>. Rule 5605 of the NASDAQ Listing Rules requires a
majority of a listed company&#146;s board of directors to be comprised of independent directors within one year of listing. In addition, the NASDAQ Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s
audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange
Act of 1934, as amended, or the Exchange Act. Under Rule 5605(a)(2), a director will only qualify as an &#147;independent director&#148; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may
not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of
its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has
determined that all members of our board of directors, except Ankit Mahadevia, M.D., are independent directors, including for purposes of the rules of The NASDAQ Stock Market and relevant federal securities<B> </B>laws and regulations. There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Staggered Board. </I>In accordance with the terms of our
amended and restated certificate of incorporation and amended and restated by-laws that will become effective upon the completion of this offering, our board of directors will be divided into three staggered classes of directors of the same or
nearly the same number and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are
then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2018 for Class&nbsp;I directors, 2019 for Class&nbsp;II directors and
2020 for Class&nbsp;III directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;I directors will be Casper Breum and Vikas Goyal; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;II directors will be Frank Thomas and Patrick Vink, M.D.; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;III directors will be Ankit Mahadevia, M.D., Jean-Fran&ccedil;ois Formela, M.D., and Milind Deshpande, Ph.D. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that
the number of our directors shall be fixed from time to time by a resolution of the majority of our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist
of one third of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The division of our board of directors into three classes with staggered three-year terms may
delay or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
will have the composition and responsibilities described below upon completion of this offering. Each of the below committees will have a written charter approved by our board of directors, effective upon completion of this offering. Each of the
committees will report to our board of directors as such committee deems appropriate and as our board of directors may request. Upon completion of this offering, copies of each charter will be posted on the investor relations section of our website.
Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective upon completion of this offering, our audit committee will be comprised of Frank Thomas,&nbsp;Vikas Goyal and Patrick Vink, M.D.,
with Mr. Thomas serving as chairman of the committee. Our board of directors has determined that&nbsp;each member of the audit committee meets the independence requirements of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the
Exchange Act and the applicable NASDAQ Stock Market rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has determined that Frank Thomas is an &#147;audit committee financial
expert&#148; within the meaning of Securities and Exchange Commission&#146;s regulations and the applicable rules of The NASDAQ Stock Market. The audit committee&#146;s responsibilities upon completion of this offering will include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensuring the independence of the independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT>
operating results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considering the effectiveness of our internal controls and internal audit function; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing material related-party transactions or those that require disclosure; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting
firm. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective upon completion of this offering, our compensation committee is comprised of Patrick Vink, M.D., Casper Breum and
Jean-Fran&ccedil;ois Formela, M.D., with Dr. Vink serving as chairman of the committee. Each member of this committee is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by
<FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1986, as amended. Our board of directors has determined that each member of the compensation committee is &#147;independent&#148; as defined in the rules of The NASDAQ Stock Market. The
composition of our compensation committee meets the requirements for independence under the listing standards of The NASDAQ Stock Market, including the applicable transition rules. Our board of directors intends to cause our compensation committee
to be comprised of only directors that are independent under the rules of The NASDAQ Stock Market within one year of the date of this prospectus. The compensation committee&#146;s responsibilities upon completion of this offering will include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the terms of any compensatory agreements with our executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our stock and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing all overall compensation policies and practices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective upon completion of this offering, our nominating and governance committee will be comprised of Milind Deshpande
Ph.D., Jean-Fran&ccedil;ois Formela, M.D. and Frank Thomas, with Dr. Deshpande as the chairman of the committee. Our board of directors has determined that each member of the nominating and corporate governance committee is &#147;independent&#148;
as defined in the applicable rules of The NASDAQ Stock Market. The nominating and corporate governance committee&#146;s responsibilities upon completion of this offering will include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and recommending candidates for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending directors to serve on board committees; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending our corporate governance guidelines and policies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing proposed waivers of the code of conduct for directors and executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual directors; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisting our board of directors on corporate governance matters. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leadership Structure and Risk
Oversight </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors is currently chaired by Dr.&nbsp;Deshpande. As a general policy, our board of directors believes
that separation of the positions of chairman and chief executive officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of management&#146;s performance and enhances
the effectiveness of our board of directors as a whole. As such, Dr.&nbsp;Mahadevia serves as our Chief Executive Officer while Dr.&nbsp;Deshpande serves as the chairman of our board of directors but is not an officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors oversees the management of risks inherent in the operation of our business
and the implementation of our business strategies. Our board of directors performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate functions of our company, our board of
directors addresses the primary risks associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated with our company&#146;s business strategies periodically throughout the year as part of
its consideration of undertaking any such business strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each of our board committees also oversees the management of our
company&#146;s risk that falls within the committee&#146;s areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Executive Officer reports to the
audit committee and is responsible for identifying, evaluating and implementing risk management controls and methodologies to address any identified risks. In connection with its risk management role, our audit committee meets privately with
representatives from our independent registered public accounting firm and our Chief Executive Officer. The audit committee oversees the operation of our risk management program, including the identification of the primary risks associated with our
business and periodic updates to such risks, and reports to our board of directors regarding these activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks
and Insider Participation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has at any time during the prior three years been one
of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of our board of directors or compensation committee of any entity that has one or more executive officers serving on
our board of directors or compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, see &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
plan to adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting, which will be effective upon completion of this offering. Upon the
completion of this offering, our code of business conduct and ethics will be available on our website at <I>www.sperotherapeutics.com</I>. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a
Current Report on Form&nbsp;8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
following table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2016, to our Chief Executive Officer and our two next most highly compensated executive officers who earned more than $100,000 during the
fiscal year ended December&nbsp;31, 2016<B> </B>and were serving as executive officers as of such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Salary<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:21.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bonus<BR>($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:26.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock<BR>Awards<BR>($)(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:49.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All
Other<BR>Compensation<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Tomayko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,264</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Medical Officer</I>(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr, Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,664</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent cash bonuses earned for the <FONT STYLE="white-space:nowrap">12-month</FONT> period from January&nbsp;1, 2016 to December&nbsp;31, 2016, and exclude payments made in 2016 for 2015 bonuses.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These amounts represent the aggregate grant date fair value for stock awards for the fiscal year ended December&nbsp;31, 2016, computed in accordance with Financial Accounting Standards Board Accounting Standards
Codification Topic 718, or ASC 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 8 to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes the dollar value of life insurance premiums the company paid with respect to term life insurance for the benefit of Dr.&nbsp;Mahadevia. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Tomayko terminated his service as Chief Medical Officer of the company, effective as of May&nbsp;14, 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes the dollar value of life insurance premiums the company paid with respect to term life insurance for the benefit of Dr.&nbsp;Tomayko. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes reimbursement during the fiscal year ended December 31, 2016 of $29,506 for housing costs and $1,158 for life insurance premiums the company paid with respect to term life insurance for the benefit of
Dr.&nbsp;Parr. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into offer letters with each of our named executive officers in connection with their employment with us, the material terms
of which are described below. Except as noted below, these offer letters provide for &#147;at will&#148; employment and were each subject to execution of our standard proprietary information and invention assignment agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ankit Mahadevia, M.D. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;2, 2015, Dr.&nbsp;Mahadevia executed an offer letter with respect to his employment as our Chief Executive Officer beginning on the same date. Employment under the offer letter continues until terminated by us or Dr.&nbsp;Mahadevia. Under
the terms of the offer letter, Dr.&nbsp;Mahadevia&#146;s annual base salary was $350,000 in 2015 and was increased to $360,500 in 2016. Under the offer letter, he is eligible to receive an annual incentive bonus determined at the discretion of our
board of directors or compensation committee, with a target bonus opportunity of 30% of his then-current base salary. Dr.&nbsp;Mahadevia&#146;s bonus was $108,150 in 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2015, Dr.&nbsp;Mahadevia was awarded 135,000&nbsp;incentive units of Spero
Therapeutics, LLC, 25% of which vested on August 24, 2016, with the remainder vesting in 36 equal monthly installments thereafter. On July 29, 2016, he received a grant of 616,792 incentive units of Spero Therapeutics, LLC, 25% of which vested on
April&nbsp;28, 2017, with the remainder vesting in 36 equal monthly installments thereafter. As set forth in Dr. Mahadevia&#146;s incentive unit agreements, these awards were subject to accelerated vesting in the event Dr.&nbsp;Mahadevia is
terminated without cause following a sale event as described under &#147;Outstanding Equity Awards at 2016 Fiscal Year-End&#148; below. The incentive units were intended to qualify as a &#147;profits interest&#148; for U.S. federal income tax
purposes and would only have value to the extent the equity value of Spero Therapeutics, LLC increased beyond the value at issuance. Dr.&nbsp;Mahadevia&#146;s incentive units were terminated in connection with the Reorganization. Thereafter, he was
granted options to purchase our common stock in connection with the Reorganization in June 2017, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mahadevia&#146;s offer letter also provided that, in the event that his employment is terminated by us without cause, subject to the
execution and effectiveness of a separation agreement and release, he is entitled to receive severance consisting of (a)&nbsp;continued base salary, as then in effect, for a period of six months from the date of such termination, plus
(b)&nbsp;payment of the employer portion of medical insurance premiums at the rate in effect on the date of such termination until the earlier of six months from the date of termination or eligibility with a subsequent employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mahadevia&#146;s offer letter was subsequently amended and restated in connection with our June 2017 Reorganization pursuant to an
employment agreement dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. Under the terms of the new agreement, Dr.&nbsp;Mahadevia&#146;s annual base salary increased to $400,000 effective on
May&nbsp;19, 2017. Further, the new employment agreement provides for an increase in the severance period from six months from the date of termination to nine months from the date of termination. Dr.&nbsp;Mahadevia&#146;s employment agreement also
provides that all unvested options shall accelerate and become fully vested in the event his employment is terminated without cause within the <FONT STYLE="white-space:nowrap">30-day</FONT> period prior to a change of control or within the <FONT
STYLE="white-space:nowrap">12-month</FONT> period following a change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John Tomayko, M.D. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2015, Dr.&nbsp;Tomayko executed an offer letter with respect to his employment as our Chief Medical Officer beginning on
August&nbsp;5, 2015. Employment under the offer letter continues until terminated by us or Dr.&nbsp;Tomayko. Under the terms of the offer letter, Dr.&nbsp;Tomayko&#146;s annual base salary was $325,000 in 2015 and was increased to $328,964 in 2016
and to $340,478 effective January&nbsp;1, 2017. Under the offer letter, he was eligible to receive an annual incentive bonus to be determined at the discretion of our board of directors, with a target bonus opportunity of up to 20% of his
then-current base salary. Dr.&nbsp;Tomayko&#146;s bonus was $98,689 in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Tomayko was awarded 165,000&nbsp;incentive units of
Spero Therapeutics, LLC on October&nbsp;1, 2015, 25% of which vested on August&nbsp;5, 2016, one year from his commencement of employment, with the remainder vesting in 36 equal monthly installments thereafter. In July 2016, he received a grant of
24,827&nbsp;incentive units of Spero Therapeutics, LLC, 25% of which vested on April&nbsp;28, 2017, with the remainder vesting in 36 equal monthly installments thereafter. As set forth in Dr. Tomayko&#146;s incentive unit agreements, these awards
were subject to accelerated vesting in the event Dr.&nbsp;Tomayko was terminated without cause following a sale event as described under &#147;Outstanding Equity Awards at 2016 Fiscal Year-End&#148; below. However, as described in the section of
this prospectus titled &#147;Reorganization,&#148; we completed the Reorganization in June 2017, and all of Dr.&nbsp;Tomayko&#146;s incentive units were cancelled upon consummation of the Reorganization. Dr.&nbsp;Tomayko was not granted any stock
options of Spero Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Tomayko&#146;s offer letter also provides that, in the event that his employment is
terminated by us without cause, subject to the execution and effectiveness of a separation agreement and release, he is entitled to receive severance consisting of (a)&nbsp;continued base salary, as then in effect, for a period of six months from
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of such termination, plus (b)&nbsp;payment of the employer portion of medical insurance premiums at the rate in effect on the date of such termination until the earlier of six months from
the date of termination or eligibility with a subsequent employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Tomayko terminated his service as our Chief Medical Officer
effective as of May&nbsp;14, 2017. In connection with his termination, we entered into a separation agreement and general release of claims with Dr.&nbsp;Tomayko, whereby he became entitled to the severance payments provided for in his offer letter,
as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Thomas R. Parr Jr., Ph.D. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2014, Dr.&nbsp;Parr executed an offer letter with respect to his employment as our Chief Scientific Officer beginning on
April&nbsp;9, 2014. Employment under the offer letter continues until terminated by us or Dr.&nbsp;Parr. Under the terms of the offer letter, Dr.&nbsp;Parr&#146;s annual base salary was $275,000 in 2015 and was increased to $283,250 in 2016. Under
the offer letter, he is eligible to receive an annual incentive bonus in the amount of up to 25% of his then-current base salary to be determined at the discretion of our board of directors. Dr.&nbsp;Parr&#146;s bonus was $84,975 in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July 1, 2014 Dr.&nbsp;Parr was awarded 83,187 incentive units of Spero Therapeutics, LLC, 25% of which vested on April 14, 2015, with the
remainder vesting in 36 equal monthly installments thereafter. Dr.&nbsp;Parr received additional grants of (i)&nbsp;82,000 incentive units of Spero Therapeutics, LLC in September 2015, 25% of which vested on August 24, 2016, with the remainder
vesting in 36 equal monthly installments thereafter, (ii)&nbsp;5,000 incentive units of Spero Therapeutics, LLC in December 2015, 25% of which vested on December&nbsp;1, 2016, with the remainder vesting in 36 equal monthly installments thereafter,
and (iii)&nbsp;92,940 incentive units of Spero Therapeutics, LLC in July 2016, 25% of which vested on April&nbsp;28, 2017, with the remainder vesting in 36&nbsp;equal monthly installments thereafter. As set forth in Dr. Parr&#146;s applicable
incentive unit agreements, the incentive units granted in September 2015 and July 2016 were subject to accelerated vesting in the event Dr.&nbsp;Parr was terminated without cause following a sale event as described under &#147;Outstanding Equity
Awards at 2016 Fiscal Year-End&#148; below. The incentive units were intended to qualify as a &#147;profits interest&#148; for U.S. federal income tax purposes and would only have value to the extent the equity value of Spero Therapeutics, LLC
increased beyond the value at issuance. Dr.&nbsp;Parr&#146;s incentive units were terminated in connection with the Reorganization. Thereafter, he was granted options to purchase our common stock in connection with the Reorganization in June 2017,
as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Parr&#146;s offer letter also provides that, in the event that his employment is terminated by us without
cause or by Dr.&nbsp;Parr for good reason, subject to the execution and effectiveness of a separation agreement and release, he is entitled to receive severance consisting of (a)&nbsp;continued base salary, as then in effect, for a period of six
months from the date of such termination, plus (b)&nbsp;payment of the employer portion of medical insurance premiums at the rate in effect on the date of such termination until the earlier of six months from the date of termination or eligibility
with a subsequent employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Parr&#146;s offer letter was subsequently amended and restated in connection with the Reorganization
pursuant to an employment agreement dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. Under the terms of the new agreement, Dr.&nbsp;Parr&#146;s annual base salary
increased to $293,164 beginning on January&nbsp;1, 2017, and his annual incentive bonus target increased to 30% of his then-current base salary. The new employment also reflects our arrangement with Dr.&nbsp;Parr whereby we have agreed to reimburse
the amount of his rental payments for housing in Cambridge, Massachusetts. Further, the new employment agreement provides for an increase in the severance period from six months from the date of termination to nine months from the date of
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Parr&#146;s employment agreement also provides that all unvested options shall accelerate and become fully vested
in the event his employment is terminated without cause within the <FONT STYLE="white-space:nowrap">30-day</FONT> period prior to a change of control or within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following a change of
control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2016 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth all grants of equity awards outstanding on the last day of the fiscal year ended December&nbsp;31, 2016 to each
of the named executive officers. All equity awards set forth in the table below were granted pursuant to the operating agreement of Spero Therapeutics, LLC, as amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:70.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR>Incentive&nbsp;Units&nbsp;That<BR>Have&nbsp;Not&nbsp;
Vested</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Market&nbsp;Value&nbsp;of<BR>Incentive&nbsp;Units&nbsp;That&nbsp;Have</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Not Vested ($)(9)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">616,792</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Tomayko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,827</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr, Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">27,729<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">54,667</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3,750</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">92,940</P></TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(6)&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(7)&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(8)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">10,814<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&#151;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&#151;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">42,752</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on September&nbsp;28, 2015, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested
on August&nbsp;24, 2016, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until
all of the incentive units are vested. In addition, if Dr.&nbsp;Mahadevia&#146;s employment is terminated by us without cause within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms
of the incentive unit agreement. Such incentive units have a threshold price of $0.96 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Mahadevia was granted options to purchase common stock of Spero
Therapeutics, Inc. with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on July&nbsp;29, 2016, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on
April&nbsp;28, 2017, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of the remaining unvested incentive units will vest until all of the
incentive units are vested. In addition, if Dr.&nbsp;Mahadevia&#146;s employment is terminated by us without cause within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms of the
incentive unit agreement. Such incentive units have a threshold price of $0.21 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Mahadevia was granted options to purchase common stock of Spero Therapeutics,
Inc. with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on October&nbsp;1, 2015, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on
August&nbsp;5, 2016, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until all of
the incentive units are vested. In addition, in the event Dr. Tomayko&#146;s employment is terminated by us without cause within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms of
the incentive unit agreement. Such incentive units have a threshold price of $0.96 per unit. All of Dr.&nbsp;Tomayko&#146;s incentive units were cancelled upon consummation of the Reorganization in June 2017 and, in light of his termination, he was
not granted stock options in Spero Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Represents incentive units of Spero Therapeutics, LLC granted on July&nbsp;29, 2016, <FONT
STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on April&nbsp;28, 2017, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until all of the incentive units are vested. In addition, in the event Dr. Tomayko&#146;s employment is terminated by us without cause
within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the incentive unit agreement. Such incentive units have a threshold price of $0.21 per unit. All of Dr.&nbsp;Tomayko&#146;s incentive units were cancelled upon consummation of the
Reorganization in June 2017 and, in light of his termination, he was not granted stock options in Spero Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on July&nbsp;1, 2014, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on
April&nbsp;14, 2015, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until all of
the incentive units are vested. Such incentive units have a threshold price of $0.28 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Parr was granted options to purchase common stock of Spero Therapeutics,
Inc., with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on September&nbsp;28, 2015, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested
on August&nbsp;24, 2016, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until
all of the incentive units are vested. In addition, if Dr.&nbsp;Parr&#146;s employment is terminated by us without cause within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms of the
incentive unit agreement. Such incentive units have a threshold price of $0.96 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Parr was granted options to purchase common stock of Spero Therapeutics, Inc.,
with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted in December 2015, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on
December&nbsp;1, 2016, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until all
of the incentive units are vested. Such incentive units have a threshold price of $0.96 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Parr was granted options to purchase common stock of Spero
Therapeutics, Inc., with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Represents incentive units of Spero Therapeutics, LLC granted on July&nbsp;29, 2016, <FONT STYLE="white-space:nowrap">one-fourth</FONT> (1/4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) of which vested on
April&nbsp;28, 2017, and on the same day of each succeeding calendar month thereafter, an additional one thirty-sixth (1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;of the remaining unvested incentive units will vest until all of
the incentive units are vested. In addition, if Dr.&nbsp;Parr&#146;s employment is terminated by us without cause within one year following a sale event, the vesting of these incentive units will accelerate in accordance with the terms of the
incentive unit agreement. Such incentive units have a threshold price of $0.21 per unit. As part of the Reorganization, these incentive units were cancelled and Dr.&nbsp;Parr was granted options to purchase common stock of Spero Therapeutics, Inc.,
with continued vesting on the same terms as the incentive units. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">The fair value of the common units as of December&nbsp;31, 2016 was $0.67 per unit. The incentive units only have value when the fair market value of Spero Therapeutics, LLC&#146;s common units exceeds the threshold
price for such incentive unit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As discussed above in the section of this prospectus titled &#147;Reorganization,&#148; on
June&nbsp;30, 2017, we completed a series of transactions pursuant to which Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc., with Spero Therapeutics, Inc. continuing as the surviving corporation. As part of the Reorganization,
each of the capital units of Spero Therapeutics, LLC issued and outstanding prior to the Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series, and each
of the incentive units of Spero Therapeutics, LLC was terminated and cancelled. Promptly after the Reorganization, previous holders of incentive units who were still employed by us at the time of the Reorganization received stock options under the
2017 Plan. Such stock options were granted for the same number of shares of our common stock as the number of incentive units cancelled, and the stock options were granted with continued vesting on the same terms and with similar rights and
restrictions as the incentive units. All such stock options have an exercise price of $0.97. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, in addition to the stock options granted in exchange for the incentive units in
connection with the Reorganization, on July&nbsp;6, 2017, we granted additional stock options to certain of our employees and consultants under the 2017 Plan.<B> </B>The named executive officers were granted the following additional stock options on
July&nbsp;6, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017&nbsp;Option&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:35.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of&nbsp;Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:55.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vesting<BR>Commencement<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:30.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vesting<BR>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;6,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,806,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;6, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Tomayko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;6, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;6, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">100% of the options will vest on the vesting commencement date. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">25% of the options will vest on the first anniversary of the vesting commencement date, with the balance to vest in equal monthly installments for 36 months beginning on such first anniversary. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following
table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2016,<B> </B>to each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Directors who are employed by us are not compensated for
their service on our board of directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:54.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock&nbsp;Awards<BR>($)(1)(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vikas Goyal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reza Halse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">These amounts represent the grant date fair value of stock awards granted to each director in the fiscal year ended December&nbsp;31, 2016, computed in accordance with ASC 718. A discussion of the assumptions used in
determining grant date fair value may be found in Note&nbsp;8 to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016, the aggregate number of incentive units of Spero Therapeutics, LLC held by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director was as follows: Mr.&nbsp;Vink, 56,391, and
Mr.&nbsp;Deshpande, 20,000. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not currently have a director compensation policy and none of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors received any compensation for service during 2016 other than Mr.&nbsp;Vink, who received 29,191 incentive units of Spero Therapeutics, LLC on July&nbsp;29, 2016, having a threshold price of
$0.21 per unit, 25% of which vested on May&nbsp;13, 2017, with the remainder vesting in 36 equal monthly installments thereafter. Additionally, on October&nbsp;21, 2015, Mr.&nbsp;Vink was granted 27,200 incentive units of Spero Therapeutics, LLC,
having a threshold price of $0.96 per unit, 25% of which vested on August&nbsp;24, 2016, with the remainder vesting in 36 equal monthly installments thereafter. As part of the Reorganization in June 2017, Mr.&nbsp;Vink&#146;s incentive units were
cancelled and he was granted options to purchase common stock of Spero Therapeutics, Inc. with continued vesting on the same terms as the incentive units. Further, on July&nbsp;6, 2017, Mr.&nbsp;Vink was granted a stock option under the 2017 Plan to
purchase 129,063 shares of our common stock at an exercise price of $0.97 per share, which vests over four years with 25% of the options vesting on the first anniversary of the grant date, and the remainder vesting in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal monthly installments for 36 months thereafter. No incentive units were granted to Mr.&nbsp;Deshpande in 2016, but he received 20,000 incentive units of Spero Therapeutics, LLC on
October&nbsp;2, 2015, having a threshold price of $0.96 per unit, 25% of which vested on August&nbsp;24, 2016, with the remainder vesting in 36 equal monthly installments thereafter. As part of the Reorganization in June 2017, Mr. Deshpande&#146;s
incentive units were cancelled and he was granted options to purchase common stock of Spero Therapeutics, Inc., with continued vesting on the same terms as the incentive units. On July 6, 2017, Mr. Deshpande was granted a stock option under the 2017
Plan to purchase 274,647&nbsp;shares of common stock of the company at an exercise price of $0.97 per share, which vest over four years with 25% of the options vesting on the first anniversary of the grant date, and the remainder vesting in equal
monthly installments for 36 months thereafter. We provide reimbursement to all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred for attending meetings of our board of directors or any committees thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to adopt a policy with respect to the compensation payable to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors,
which will become effective upon the completion of this offering. Under this policy, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be eligible to receive compensation for his or her service consisting of annual cash
retainers and equity awards. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will receive the following annual retainers for their service: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Retainer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Chairperson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Equity awards for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will consist of (i)&nbsp;an
initial equity award consisting of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upon first appointment to our board of directors and vesting
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued service on our board of directors, and (ii)&nbsp;annual
equity awards consisting of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vesting &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, subject to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued service on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Directors may be reimbursed
for travel, food, lodging and other expenses directly related to their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our current certificate of
incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> as well as our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the
completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans and Other Benefit Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benefits Programs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each named
executive employee is eligible to participate in our benefits programs, which include health, life, disability and dental insurance and a 401(k) retirement savings plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Therapeutics, LLC&#146;s Incentive Units </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, LLC&#146;s operating agreement provided for the issuance of incentive units to employees, executive officers, directors,
and consultants. Pursuant to the terms of the operating agreement, all incentive units were subject to time-based vesting, with the first 25% vesting after 12 months of continued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment or service, and the remainder vesting in equal monthly installments over the following 36 months. Each incentive unit was intended to be a &#147;profits interest&#148; within the
meaning of IRS Revenue Procedures <FONT STYLE="white-space:nowrap">93-27</FONT> and <FONT STYLE="white-space:nowrap">2001-43</FONT> for federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the operating agreement, incentive units may be issued subject to vesting, forfeiture and repurchase pursuant to
separate agreements, the provisions of which may be determined, altered, or waived in the sole discretion of Spero Therapeutics, LLC&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As described in the section of this prospectus titled &#147;Reorganization,&#148; all incentive units issued under Spero Therapeutics,
LLC&#146;s operating agreement were cancelled as they were deemed to be valueless based on a liquidation valuation basis for federal income tax purposes and pursuant to contractual rights under the operating agreement. Any incentive unit holders who
were employees, directors or consultants of the Company at the time of the Reorganization were issued options under the 2017 Plan with continued vesting on the same schedule and the same terms as such person&#146;s incentive units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Therapeutics, Inc.&#146;s 2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We adopted the Spero Therapeutics, Inc. 2017 Stock Incentive Plan on June&nbsp;30, 2017. The 2017 Plan will expire on June&nbsp;30, 2027.
Under the 2017 Plan, we may grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and unrestricted stock awards and other stock-based awards. There are 10,850,693 shares of our common stock
authorized for issuance under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to amend the 2017 Plan in connection with the completion of this offering, and
upon such amendment, there will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock authorized for issuance under such amended plan. In addition, we intend to add an
&#147;evergreen&#148; provision, which will allow for an annual increase in the number of shares of our common stock available for issuance under the 2017 Plan on the first day of each fiscal year during the period beginning in fiscal year 2018 and
ending in fiscal year 2027. The annual increase in the number of shares shall be equal to the lowest of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;% of the number of shares of our common stock outstanding as of such date; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an amount determined by our board of directors or compensation committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of
directors is authorized to administer the 2017 Plan. In accordance with the provisions of the 2017 Plan, our board of directors determines the terms of the options and other awards issued pursuant thereto, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">which employees, directors and consultants shall be granted awards; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock subject to options and other awards; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date of grant; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the termination or cancellation provisions applicable to the options; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and repurchase price; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other terms and conditions upon which each award may be granted in accordance with the 2017 Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No participant may receive awards for more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in any fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our
board of directors or any committee to which our board of directors delegates authority may, with the consent of the affected plan participants, <FONT STYLE="white-space:nowrap">re-price</FONT> or otherwise amend outstanding awards consistent with
the terms of the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon a merger, consolidation, or sale of all or substantially all of our assets, our board of directors or
any committee to which our board of directors delegates authority, or the board of directors of any corporation assuming the our obligations, may, in its sole discretion, take any one or more of the following actions pursuant to the 2017 Plan, as to
some or all outstanding awards, to the extent not otherwise agreed under any individual agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding options will be assumed or substituted for options of the successor corporation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the outstanding options must be exercised within a certain number of days, either to the extent the options are then exercisable, or at our board of directors&#146; discretion, any such options being made
partially or fully exercisable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate outstanding options in exchange for a cash payment of an amount equal to the difference between (a)&nbsp;the consideration payable upon consummation of the corporate transaction to a holder of the number of
shares into which such option would have been exercisable to the extent then exercisable, or in our board of directors&#146; discretion, any such options being made partially or fully exercisable, and (b)&nbsp;the aggregate exercise price of those
options; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding stock grants will be substituted for shares of the successor corporation or consideration payable with respect to our outstanding stock in connection with the corporate transaction; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate outstanding stock grants in exchange for payment of an amount equal to the consideration payable upon consummation of the corporate transaction to a holder of the same number of shares comprising the stock
grant, to the extent the stock grant is no longer subject to any forfeiture or repurchase rights, or at our board of directors&#146; discretion, all forfeiture and repurchase rights being waived upon the corporate transaction. For purposes of
determining such payments, in the case of a corporate transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair market value thereof as determined in good faith by
our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which
they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer
when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional shares of our
common stock outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions since January&nbsp;1, 2014, to which we have been a party, in which the amount involved exceeds
$120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. We refer to such
transactions as &#147;related party transactions&#148; and such persons as &#147;related parties.&#148; With the approval of our board of directors, we have engaged in the related party transactions described below. We believe the terms obtained or
consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions to
which we have been or will be a party other than compensation arrangements, which are described where required under &#147;Executive and Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Financings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Bridge Unit Financing
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2014, we issued and sold 1,531,148 bridge units to investors upon the conversion of convertible notes in a total
amount of $1,531,148. The following table sets forth the number of bridge units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price
paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a member of our board of directors, is a
Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Junior Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 3,438,318 junior preferred units, consisting of (i) 1,500,000 junior preferred units issued and sold
at a price per unit of $1.00 for an aggregate purchase price of $1.5&nbsp;million, and (ii) 1,938,318 junior preferred units issued upon the conversion of the 2014 bridge units. The following table sets forth the number of junior preferred units
issued to our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:37.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exchanged</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Junior&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:59.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Received&nbsp;in<BR>Exchange&nbsp;for<BR>Bridge&nbsp;Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Junior&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:57.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">833,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. Jean-Fran&ccedil;ois Formela, M.D., a
member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. Vikas Goyal, a member of our board of directors, is
a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Bridge Unit Financing </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
January 2015, we issued and sold 8,000 bridge units to existing investors at a price per unit of $1,000 for an aggregate purchase price of $8.0&nbsp;million. The following table sets forth the number of bridge units purchased by our directors,
executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a member of our board of directors, is a
Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, we issued an aggregate of 4,202,278 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units, consisting of (i)
2,279,202 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued to existing investors in exchange for 8,000 bridge units, and (ii) 1,923,076 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued and
sold at a price per unit of $3.90 for an aggregate purchase price of approximately $7.5&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units were subsequently reclassified as Class&nbsp;A preferred units. The
following table sets forth the number of Class&nbsp;A preferred units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for
such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge<BR>Units<BR>Exchanged</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:94.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Received&nbsp;in&nbsp;Exchange<BR>for Bridge Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:61.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,153,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Vikas Goyal, a member of our board of
directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Casper Breum, a member of our board
of directors, is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest&nbsp;A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Reza Halse, a member of our board of
directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, we issued and sold 5,909,089 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units at a price per unit of
$4.40, for an aggregate purchase price of approximately $26.0&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units were subsequently reclassified as Class&nbsp;B preferred units. The following table sets forth the
number of Class&nbsp;B preferred units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;B&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:60.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Vikas Goyal, a member of our board of
directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at
the time of or as a result of the Class&nbsp;B preferred unit financing. Casper Breum, a member of our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
board of directors, is a Senior Partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest&nbsp;A/S. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Reza Halse, a member of our board of
directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Bridge Unit Financing </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
December 2016, we issued and sold 8,500 bridge units at a price per unit of $1,000 for an aggregate purchase price of approximately $8.5&nbsp;million. The following table sets forth the number of bridge units purchased by our directors, executive
officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a member of our board of directors, is a
Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Casper Breum, a member of our board of directors,
is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Reza Halse, a member of our board of directors,
serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;C Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we issued an aggregate of 29,647,582 Class&nbsp;C preferred units, consisting of (i) 5,321,112 Class&nbsp;C preferred units in
exchange for 8,500 bridge units and (ii) 24,326,470 Class&nbsp;C preferred units </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at a price per unit of $1.7749 for an aggregate purchase price of approximately $43,177,052. The following table sets forth the number of Class&nbsp;C preferred units purchased by our directors,
executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:37.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exchanged</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;C&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:70.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units Received in<BR>Exchange&nbsp;for&nbsp;Bridge<BR>Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;C&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:61.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GV 2015, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,760,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,519,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,971,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,299,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,390,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">469,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">762,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">724,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, L.P.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">GV 2015, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">RA Capital Healthcare Fund, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Vikas Goyal, a member of our board of
directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Casper Breum, a member of our board
of directors, is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Reza Halse, a member of our board of
directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund X, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reorganization </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, as part of the Reorganization, each of the capital units of Spero Therapeutics, LLC issued and outstanding prior to the
Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, after the consummation of the Reorganization, we sold to Joel Sendek, our Chief Financial Officer, 61,880 shares of Series C
preferred stock of Spero Therapeutics, Inc., at a purchase price of $1.7749 per share, for an aggregate purchase price of $109,831. Such purchase and sale was made in accordance with the terms of Mr.&nbsp;Sendek&#146;s offer letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Stockholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors&#146;
Rights Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into an investors&#146; rights agreement with the purchasers of our outstanding preferred stock,
including entities with which certain of our directors are affiliated. The investors&#146; rights agreement provides these holders the right, following the date that is 180&nbsp;days after the date of this prospectus, to demand that we file&nbsp;a
registration statement or request that their shares be covered by a registration statement that we are otherwise filing. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into a right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with certain holders of our common
stock and preferred stock, including entities with which certain of our directors are affiliated. This agreement provides for rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> relating to the shares of our common stock held
by the parties to the agreement. Upon the consummation of this offering, the right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into
a voting agreement with certain holders of our common stock and preferred stock, including entities with which certain of our directors are affiliated. Under this agreement, our stockholders that are party to the agreement have agreed to vote their
shares to elect to our board of directors: (i)&nbsp;one director designated by Atlas Venture Fund IX, L.P. and Atlas Venture Fund X, L.P., (ii) one director designated by S.R. One, Limited, (iii)&nbsp;one director designated by Lundbeckfond Invest
A/S, (iv)&nbsp;one director designated by MRL Ventures Fund, LLC, (v)&nbsp;after delivery of written notice from GV 2015, L.P. to the company informing the company that GV 2015, L.P. will designate a member of our board of directors, one director
designated by GV 2015, L.P., (vi)&nbsp;the person who is the company&#146;s then-serving Chief Executive Officer, (vii)&nbsp;one director with relevant industry experience who is reasonably acceptable to a majority of the other directors then
serving on our board of directors and (viii)&nbsp;two directors designated by the stockholders holding a majority of shares voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. Upon the
consummation of this offering, the voting agreement will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Executive Officer Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See &#147;Executive and Director Compensation&#148; for a discussion of payments and options granted to our named executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our executive officers. For more information regarding these agreements, see &#147;Executive
and Director Compensation&#151;Narrative Disclosure to Summary Compensation Table.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements with Officers and Directors and Directors&#146; and Officers&#146; Liability
Insurance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we have entered into indemnification agreements with each of our executive officers and
directors. The indemnification agreements, our amended and restated certificate of incorporation and our amended and restated by-laws that will become effective upon the completion of this offering will require us to indemnify our directors to the
fullest extent not prohibited by Delaware law. Subject to certain limitations, our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> also require us to advance expenses incurred by our directors and officers. We also maintain a
general liability insurance policy which covers certain liabilities of directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we plan to adopt a written policy, effective upon completion of this offering, that requires all future
transactions between us and any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in
Item&nbsp;404 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K,</FONT> or their affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our audit committee. Any request for such a transaction
must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to the audit
committee, including, but not limited to, the extent of the related party&#146;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third
party under the same or similar circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at August&nbsp;31, 2017 by:
</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The column titled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; is based on a total of 51,036,137 shares of our
common stock outstanding as of August&nbsp;31, 2017, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 48,998,475 shares of our common stock immediately prior to the completion of this offering.
The column titled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be
outstanding after this offering, including the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that we are selling in this offering, but not including any
additional shares issuable upon exercise of outstanding options or any exercise by the underwriters of their option to purchase additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with
respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days after August&nbsp;31, 2017 are considered outstanding and beneficially owned by the person holding the options
for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and
investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o Spero
Therapeutics, Inc., 675 Massachusetts Avenue, Cambridge, Massachusetts 02139. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Beneficially&nbsp;Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Before<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>After<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Principal Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,662,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,368,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GV 2015, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,760,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,332,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,516,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, LLC(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,554,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,332,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D.(2)(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,030,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vikas Goyal(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,662,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reza Halse(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,516,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr Jr., Ph.D.(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Tomayko, M.D.(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (12 persons)(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,550,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,662,941 shares of common stock issuable upon the conversion of 1,483,784 shares of Junior preferred stock, 1,496,694 shares of Series A preferred stock, 1,999,418 shares of Series B preferred stock,
3,683,045 shares of Series C preferred stock held by S.R. One, Limited, or S.R. One, an indirect wholly owned subsidiary of GlaxoSmithKline plc. Vikas Goyal, a member of our board of directors, is a principal at S.R. One and disclaims beneficial
ownership of the shares held by S.R. One, except to the extent of his pecuniary interest therein. The address for S.R. One is 161 Washington Street, Suite 500, Eight Tower Bridge, Conshohocken, Pennsylvania 19428. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 260,000 shares of common stock and (ii) 8,108,390 shares of common stock issuable upon the conversion of 1,492,645 shares of Junior preferred stock, 1,496,694 shares of Series A preferred stock,
1,999,418 shares of Series B preferred stock, and 3,119,633 shares of Series C preferred stock held by Atlas Venture Fund IX, L.P. , or Atlas Fund IX. All shares are held directly by Atlas Venture Fund IX. Atlas Venture Associates IX, L.P., or AVA
IX LP, is the general partner of Atlas Venture Fund IX, and Atlas Venture Associates IX, LLC, or AVA IX LLC, is the general partner of AVA IX LP. Peter Barrett, Bruce Booth, Jean-Fran&ccedil;ois Formela, Jeff Fagnan, and Ryan Moore are the members
of AVA IX LLC and collectively make investment decisions on behalf of Atlas Venture Fund IX. Dr.&nbsp;Formela is also a member of our board of directors, Dr.&nbsp;Formela disclaims beneficial ownership of such shares, except to the extent of his
pecuniary interest therein, if any. The address for Atlas Venture Fund IX, is 25 First Street, Suite 303, Cambridge, Massachusetts 02141. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consists of 6,760,944 shares of common stock issuable upon the conversion of 6,760,944 shares of Series C
preferred stock held by GV 2015, L.P. GV 2015 GP, L.L.C., the general partner of GV 2015, L.P., Alphabet Holdings LLC, the sole member of GV 2015 GP, L.L.C., Google Inc., the sole member of Alphabet Holdings LLC, and Alphabet Inc., the sole member
of Google Inc., may be deemed to have sole power to vote or dispose of the shares held by GV 2015, L.P. The address for GV 2015, L.P., GV 2015 GP, L.L.C., </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Alphabet Holdings LLC, Google Inc., and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View, CA 94043. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 5,332,851 shares of common stock issuable upon the conversion of 1,756,988 shares of Series A preferred stock, 1,090,591 shares of Series B preferred stock, and 2,485,272 shares of Series C preferred stock
held by Lundbeckfond Invest A/S. The board of directors of Lundbeckfond Invest A/S consists of J&oslash;rgen Huno Rasmussen, Steffen Kragh, Lars Holmqvist, Susanne Kr&uuml;ger Kj&aelig;r, Michael Kj&aelig;r, Peter Sch&uuml;tze, Gunhild Waldemar,
Vagn Flink M&oslash;ller Pedersen, Henrik Sindal Jensen, and Peter Adler W&uuml;rtzen, who have shared investment and voting control with respect to the shares held by Lundbeckfond Invest A/S and may exercise such control only with the support of a
majority of the members of the Lundbeckfond Invest Ventures A/S board of directors. No individual member of the Lundbeckfond Invest A/S board of directors is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held
by Lundbeckfond Invest A/S. Casper Breum, one of our directors, is a partner of Lundbeckfond Ventures, a division within Lundbeckfond Invest A/S, and is not deemed to beneficially own the shares held by Lundbeckfond Invest A/S. The address for
Lundbeckfond Invest A/S is Scherfigsvej 7, 2100 Copenhagen &Oslash;, Denmark. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,516,030 shares of common stock issuable upon the conversion of 585,662 shares of Series A preferred stock, 1,999,418 shares of Series B preferred stock, and 1,930,950 shares of Series C preferred stock
held by MRL Ventures Fund, LLC, or MRL Ventures Fund. All shares are held directly by MRL Ventures Fund, which is a subsidiary of Merck Sharp&nbsp;&amp; Dohme Corp. Reza Halse is the President of MRL Ventures. Dr.&nbsp;Halse is also a member of our
board of directors. Dr.&nbsp;Halse disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The address for MRL Ventures Fund, LLC is 320 Bent Street, Cambridge, Massachusetts 02141.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,673,446 shares of common stock issuable upon the conversion of 3,673,446 shares of Series C preferred stock held by RA Capital Healthcare Fund, L.P. RA Capital Management, LLC is the investment advisor and
sole general partner of RA Capital Healthcare Fund, L.P. The address of RA Capital Management, LLC is 20 Park Plaza, Suite 1200, Boston, Massachusetts 02116. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,662,178 shares of common stock issuable upon the conversion of 3,662,178 shares of Series C preferred stock held by Atlas Venture Fund X, LLC, or Atlas Fund X. All shares are held directly by Atlas Venture
Fund X. Atlas Venture Associates X, L.P., or AVA X LP, is the general partner of Atlas Venture Fund X, and Atlas Venture Associates X, LLC, or AVA X LLC, is the general partner of AVA X LP. Peter Barrett, Bruce Booth, Jean-Fran&ccedil;ois Formela,
David Gragzel and Jason Rhodes are the members of AVA X LLC and collectively make investment decisions on behalf of Atlas Venture Fund X. Dr.&nbsp;Formela is also a member of our board of directors. Dr.&nbsp;Formela disclaims beneficial ownership of
such shares, except to the extent of his pecuniary interest therein, if any. The address for Atlas Venture Fund X, is 400 Technology Square, 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Floor, Cambridge, MA 02139.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,554,137 shares of common stock issuable upon the conversion of 1,363,238 shares of Series B preferred stock and 1,190,899 shares of Series C preferred stock held by Osage University Partners II, L.P. Osage
University GP, LP is the general partner of Osage University Partners II, L.P. Osage Partners, LLC is the general partner of Osage University GP, LP. The address for Osage Partners, LLC is 50 Monument Road, Suite 201, Bala Cynwyd, Pennsylvania
19004. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 400,000 shares of common stock and (ii) 1,055,373 shares of common stock underlying options that are exercisable as of August&nbsp;31, 2017 or will become exercisable within 60 days after such date held
by Dr.&nbsp;Mahadevia. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Mr. Breum is a partner at Lundbeckfond Ventures, a division within Lundbeckfond Invest A/S, but has no voting or investment power with respect to the shares described in footnote 4. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 100,000 shares of common stock and 10,833 shares of common stock underlying options that are exercisable as of August&nbsp;31, 2017 or will become exercisable within 60 days after such date held by
Mr.&nbsp;Deshpande. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Thomas is a member of our board of directors and holds no voting or investment power with respect to our securities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 25,071 shares of common stock underlying options that are exercisable as of August&nbsp;31, 2017 or will become exercisable within 60 days after such date held by Mr.&nbsp;Vink. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 281,565 shares of common stock underlying options that are exercisable as of August&nbsp;31, 2017 or will become exercisable within 60 days after such date held by Dr.&nbsp;Parr. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Tomayko formerly served as our Chief Medical Officer and holds no voting or investment power with respect to our securities. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">See footnotes 1, 2, 5, 7 and 9 through 15. Includes 73,574 shares of common stock underlying options that are exercisable as of August&nbsp;31, 2017 or will become exercisable within 60 days after such date held by
Cristina Larkin, our Chief Operating Officer, and 61,880 shares of Series C preferred stock held by Joel Sendek, our Chief Financial Officer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_16"></A>DESCRIPTION OF CAPITAL STOCK </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this
offering, our authorized capital stock will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.001 per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, par value $0.001 per share, all of which will be undesignated, and there will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding and no shares of preferred stock outstanding. As of August&nbsp;31, 2017, we had approximately 21 record
holders of our capital stock. All of our outstanding shares of preferred stock will automatically convert into shares of our common stock immediately prior to the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and
restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the completion of this offering are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of
incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part. The descriptions of our common stock
and preferred stock reflect the content of the amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of
this offering, we will be authorized to issue one class of common stock. Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote of
stockholders. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then
outstanding. Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights
of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Except as described under &#147;&#151;Antitakeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate
of Incorporation and Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws&#148;</FONT> below, a majority vote of the holders of common stock is generally required to take action under our amended and restated certificate of incorporation
and amended and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our board of directors will be authorized, without action by the stockholders, to designate and issue up
to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and
privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or
other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect
of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of our company, which might harm the market
price of our common stock. See also &#147;Antitakeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated <FONT STYLE="white-space:nowrap">By-laws&#151;Provisions</FONT> of Our
Amended and Restated Certificate of Incorporation and Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws&#151;Undesignated</FONT> Preferred Stock&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors will make any determination to issue such shares based on its judgment as
to our company&#146;s best interests and the best interests of our stockholders. Upon the completion of this offering, we will have no shares of preferred stock outstanding and we have no current plans to issue any shares of preferred stock
following completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2017, options to purchase 9,368,492 shares of our common stock at an exercise price of $0.97 were outstanding, of which
options to purchase 1,980,341 shares of our common stock were exercisable at an exercise price of $0.97 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into an Investors&#146; Rights Agreement dated as of June&nbsp;30, 2017, or the Investors&#146; Rights Agreement, with certain
holders of our capital stock. These shares will represent approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock after this offering, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% if the underwriters exercise their option to purchase
additional shares in full. These shares also may be sold under Rule&nbsp;144 under the Securities Act of 1933, as amended, depending on their holding period and subject to restrictions in the case of shares held by persons deemed to be our
affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Investors&#146; Rights Agreement holders of registrable shares can demand that we file&nbsp;a registration
statement or request that their shares be included on a registration statement that we are otherwise filing, in either case, registering the resale of their shares of common stock. These registration rights are subject to conditions and limitations,
including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration and our right, in certain circumstances, not to effect a requested
<FONT STYLE="white-space:nowrap">S-1</FONT> registration within 60&nbsp;days before or 180&nbsp;days following any offering of our securities, including this offering, or a requested <FONT STYLE="white-space:nowrap">S-3</FONT> registration within
30&nbsp;days before or 90&nbsp;days following any offering of our securities, including this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the date that is 180 days after the date of this prospectus, the holders of at least 60% of the registrable securities then
outstanding under the Investors&#146; Rights Agreement may require us to file a registration statement under the Securities Act on a <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> at our expense, subject to certain exceptions, with respect to
the resale of their registrable shares, and we are required to use commercially reasonable efforts to effect the registration. At any time after we are eligible to use a registration statement under the Securities Act on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of at least 25% of the registrable securities then outstanding under the Investors&#146; Rights Agreement may require us to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> at our expense, subject to certain exceptions, with respect to the resale of their registrable shares, and we are required to use commercially reasonable efforts to effect the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If
we propose to register any of our securities under the Securities Act for our own account or the account of any other holder, the holders of registrable shares are entitled to notice of such registration and to request that we include registrable
shares for resale on such registration statement, subject to the right of any underwriter to limit the number of shares included in such registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will
pay all registration expenses, other than underwriting discounts and commissions, related to any demand or piggyback registration. The Investors&#146; Rights Agreement contains customary cross-indemnification
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions, pursuant to which we are obligated to indemnify the selling stockholders, in the event of misstatements or omissions in the registration statement attributable to us except in the
event of fraud, and they are obligated to indemnify us for misstatements or omissions attributable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The registration rights will terminate upon the later of the date on which all registrable shares have been sold, the closing of
certain liquidation events, and the fifth anniversary of the closing date of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Delaware Law and Provisions of
our Amended and Restated Certificate of Incorporation and Our Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will
become effective upon the completion of this offering include a number of provisions that may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of
directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with our amended and restated certificate of incorporation, our board is divided into three classes serving three-year terms,
with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled
to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our
directors then in office, even if less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of
Stockholders </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that only a majority of the members
of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated <FONT
STYLE="white-space:nowrap">by-laws</FONT> limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before
meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be
received at our principal executive offices not less than 90&nbsp;days or more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in the amended
and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a
potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As required by the Delaware General Corporation Law, any amendment of our amended and restated certificate of incorporation must first be
approved by a majority of our board of directors and, if required by law or our amended and restated certificate of incorporation, thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of
the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, directors, limitation of liability, exclusive jurisdiction of Delaware Courts and the amendment of
our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> and amended and restated certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the amendment, and not less than 75%
of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended by the affirmative vote of a majority of the directors then in office, subject to
any limitations set forth in the amended and restated <FONT STYLE="white-space:nowrap">by-laws;</FONT> and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if our board of
directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Blank Check Preferred Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation provides for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may
enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of
directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or
other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power
to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock.
The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In
general, Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an
interested stockholder, unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the
interested stockholder. An &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the
corporation&#146;s voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is
prohibited unless it satisfies one of the following conditions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">before the stockholder became interested, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee
stock plans, in some instances; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the
affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or
an express provision in its amended and restated certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have
not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Jurisdiction of Certain Actions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our
name, actions against our directors, officers and employees for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, unless we otherwise consent. Although we believe this provision
benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market Listing </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
have applied to list our common stock on The NASDAQ Global Market under the symbol &#147;SPRO.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_17"></A>SHARES ELIGIBLE FOR FUTURE SALE</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. Future sales of our common stock, including shares issued upon
the exercise of outstanding options, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital in the
future. As described below, only a limited number of shares of our common stock will be available for sale in the public market for a period of several months after completion of this offering due to contractual and legal restrictions on resale.
Future sales of our common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such
time and our ability to raise equity capital at a time and price we deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Restricted Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, based on the number of shares of our common stock outstanding as of August&nbsp;31, 2017, and assuming
(i)&nbsp;the conversion of our outstanding preferred stock into common stock, (ii)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of common stock and (iii)&nbsp;no exercise of outstanding options, we will have
outstanding an aggregate of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. Of these shares, all of
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be sold in this offering, and any shares sold upon exercise of the underwriters&#146; option to purchase
additional shares will be freely tradable in the public market without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, unless the shares are held by any of our &#147;affiliates&#148; as such
term is defined in Rule&nbsp;144 of the Securities Act. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be &#147;restricted securities&#148; as such term is defined in
Rule&nbsp;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from
registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule&nbsp;701, which rules are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to below and the provisions of Rule&nbsp;144 and
Rule&nbsp;701 under the Securities Act, the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:160.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares and % of Total
Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:145.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date&nbsp;Available&nbsp;for&nbsp;Sale&nbsp;into&nbsp;Public&nbsp;
Market</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On the date of this prospectus</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">90&nbsp;days after the date of this prospectus</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">180&nbsp;days after the date of this prospectus, due to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the holders of these shares and the underwriters. However, the representative of the underwriters can
waive the provisions of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and allow these stockholders to sell their shares at any time.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated
and Cowen and Company, LLC. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lend or otherwise dispose of or transfer any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock, or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other
securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock
and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement
later acquires the power of disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the lock-up agreements described above, upon the completion of this offering, the holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of
these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See &#147;Description of Capital Stock&#151; Registration
Rights&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of lock-up agreements applicable to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, under
Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act, for at least 90&nbsp;days, a person (or persons whose shares are required to be aggregated) who is not deemed to have
been one of our &#147;affiliates&#148; for purposes of Rule&nbsp;144 at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including
the holding period of any prior owner other than one of our &#147;affiliates,&#148; is entitled to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable)
without complying with the manner of sale, volume limitations or notice provisions of Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially owned the shares proposed to
be sold for at least one year, including the holding period of any prior owner other than &#147;affiliates,&#148; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&nbsp;144
(subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable). In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the
Exchange Act for at least 90&nbsp;days, our &#147;affiliates,&#148; as defined in Rule&nbsp;144, who have beneficially owned the shares proposed to be sold for at least six months are entitled to sell in the public market, upon expiration of any
applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any three-month period, a number of those shares of our common stock that does not exceed the greater of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of common stock then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
immediately after this offering (calculated on the basis of the number of shares of our common stock outstanding as of June&nbsp;30, 2017, the assumptions described above and assuming no exercise of the underwriters&#146; option to purchase
additional shares and no exercise of outstanding options);&nbsp;or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Such sales under Rule&nbsp;144 by our &#147;affiliates&#148; or persons selling shares on behalf of our &#147;affiliates&#148; are also
subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the availability of Rule&nbsp;144, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our restricted securities have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as referenced above and their restricted securities will become
eligible for sale (subject to the above limitations under Rule&nbsp;144) upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, under
Rule&nbsp;701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with
Rule&nbsp;701 under the Securities Act before the effective date of the registration statement of which this prospectus is a part (to the extent such common stock is not subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) is
entitled to rely on Rule&nbsp;701 to resell such shares beginning 90&nbsp;days after we become subject to the public company reporting requirements of the Exchange Act in reliance on Rule&nbsp;144, but without compliance with the holding period
requirements contained in Rule&nbsp;144. Accordingly, subject to any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, beginning 90&nbsp;days after we become subject to the public company reporting requirements of the Exchange
Act, under Rule&nbsp;701 persons who are not our &#147;affiliates,&#148; as defined in Rule&nbsp;144, may resell those shares without complying with the minimum holding period or public information requirements of Rule&nbsp;144, and persons who are
our &#147;affiliates&#148; may resell those shares without compliance with Rule&nbsp;144&#146;s minimum holding period requirements (subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if
applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Stock Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to file with the SEC a registration statement under the Securities Act covering the shares of common stock that we may issue upon
exercise of outstanding options reserved for issuance under the 2017 Plan. Such registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under
such registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_18"></A>MATERIAL U.S. FEDERAL INCOME AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ESTATE TAX CONSEQUENCES TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our common stock to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of
1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed or subject to differing interpretations, possibly with retroactive
effect, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought and will not seek any ruling from the Internal Revenue Service, or the IRS, with respect to the statements made and the
conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This summary also does not address the tax considerations arising under the laws of any U.S. state or local or any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction, the 3.8% Medicare tax on net investment income or any alternative minimum tax consequences. In addition, this discussion does not address tax considerations applicable to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances or to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that may be subject to special tax rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or government organizations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers of or dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than five percent of our capital stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain U.S. expatriates, citizens or former long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction,&#148; synthetic security, other integrated investment, or other risk reduction transaction;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts or regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships, or other entities or arrangements treated as partnerships for U.S. federal income tax purposes, or investors in any such entities); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons for whom our stock constitutes &#147;qualified small business stock&#148; within the meaning of Section&nbsp;1202 of the Code; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">integral parts or controlled entities of foreign sovereigns; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that acquire our common stock as compensation for services. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if a
partnership, including any entity or arrangement classified as a partnership for U.S. federal income tax purposes, holds our common stock, the tax treatment of a partner generally will depend on the status of the partner, the activities of the
partnership, and certain determinations made at the partner level. Accordingly, partnerships that hold our common stock, and partners in such partnerships, should consult their tax advisors regarding the U.S. federal income tax consequences to them
of the purchase, ownership, and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You are urged to consult your tax advisor with respect to the
application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal estate or gift tax rules or under the laws of
any U.S. state or local or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other taxing jurisdiction or under any applicable tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common
stock that is not a &#147;U.S. person,&#148; and is not a partnership, or an entity disregarded from its owner, each for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as
any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in
effect to be treated as a U.S. person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As discussed under &#147;Dividend Policy,&#148; above, we do not anticipate paying any dividends on our common stock in the foreseeable
future. If we make distributions on our common stock, those payments will constitute dividends for U.S. income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, they will constitute a return of capital and will first reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s basis in
our common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;Gain on Sale or Other Disposition of Common Stock.&#148; Any such distributions would be subject to the discussions
below regarding backup withholding and FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, any dividend paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must
provide us or our agent with an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> or another appropriate version of IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> (or a successor form), which must be updated periodically, and which, in each case, must certify qualification for the reduced rate. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should
consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a U.S. trade or business within the United States (and, if required by an applicable
income tax treaty, are attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States) generally are exempt from the withholding tax described above. In order to obtain this
exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must provide the applicable withholding agent with an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> or successor form or other applicable IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. Such effectively
connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if
you are <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation, dividends you receive that are effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies, are attributable to a
permanent establishment maintained by the you in the United States) may also be subject to a branch profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as
adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you are eligible for a reduced rate of withholding tax pursuant to a tax treaty, you may be able to obtain
a refund of any excess amounts currently withheld if you timely file an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Disposition
of Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax on any gain realized upon the sale or other disposition of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if an income tax treaty applies, the gain is
attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States), in which case the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal
income tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and for a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder may also be subject to the branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States for a period or periods aggregating 183&nbsp;days or more during the calendar year in which the sale or
disposition occurs and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal income tax at a flat 30% rate on the gain derived from the sale, which tax may be
offset by U.S. source capital losses (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States) (subject to applicable income tax or other treaties); or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest by reason of our status as a &#147;U.S. real property
holding corporation&#148; for U.S. federal income tax purposes, a USRPHC, at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period for our
common stock. We believe we are not currently and do not anticipate becoming a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market
value of our other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, gain arising from the sale or other taxable disposition by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax as long as our common stock is regularly traded on an established securities market and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder does not, actually or constructively, hold more than five percent of our common stock at any time during the applicable period that is specified in the Code. If the foregoing exception does not
apply, then if we are or were to become a USRPHC a purchaser may be required to withhold 15% of the proceeds payable to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder from a sale of our common stock and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be subject to U.S. federal income tax on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined
in the Code). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Generally, we must file information returns annually to the IRS in connection with any dividends on our common stock paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. A similar report will be sent to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. Pursuant to applicable income tax treaties or other
agreements, the IRS may make these reports available to tax authorities in the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Payments of dividends or of proceeds on the disposition of stock made to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be
subject to additional information reporting and backup withholding at a current rate of 28% unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder establishes an exemption, for example by properly certifying its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status on an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E,</FONT></FONT> IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> or another appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> (or a successor form). Notwithstanding the foregoing, backup withholding and information reporting may
apply if either we or our paying agent has actual knowledge, or reason to know, that a holder is a U.S. person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Backup withholding is not
an additional tax; rather, the U.S. income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the
IRS, provided that the required information is furnished to the IRS in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, imposes withholding tax on certain types of payments made to foreign financial institutions
and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. The legislation imposes a 30% withholding tax on dividends on, or, on or after January&nbsp;1, 2019, gross proceeds from the sale or other disposition of, our common stock
paid to a &#147;foreign financial institution&#148; or to certain <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entities&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain
diligence and reporting obligations, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes
identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If
the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Treasury requiring, among other things, that it undertake to identify accounts
held by &#147;specified United States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on payments to account holders whose
actions prevent it from complying with these reporting and other requirements. If the country in which a payee is resident has entered into an &#147;intergovernmental agreement&#148; with the United States regarding FATCA, that agreement may permit
the payee to report to that country rather than to the U.S. Department of the Treasury. Prospective investors should consult their own tax advisors regarding the possible impact of these rules on their investment in our common stock, and the
possible impact of these rules on the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding tax under
FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Common stock owned (or treated as owned) by an individual who is not a citizen or a resident of the United States (as defined for U.S. federal
estate tax purposes) at the time of death will be included in the individual&#146;s gross estate for U.S. federal estate tax purposes unless an applicable estate or other tax treaty provides otherwise, and therefore may be subject to U.S. federal
estate tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice. Each
prospective investor should consult its tax advisor regarding the particular U.S. federal, state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common stock, including the
consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_18a"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company, LLC are acting as representatives of each of the
underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to
purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:31.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner &amp; Smith<BR>Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus &amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer &amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering, the public offering price, concession or any other
term of this offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before
expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The expenses of this offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and are payable by us. We have also agreed to reimburse the underwriters for certain of their expenses, in an amount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, incurred in connection
with the review and clearance by the Financial Industry Regulatory Authority, Inc. of the terms of this offering, as set forth in the underwriting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions
contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the
date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company, LLC. Specifically, we and these other persons have agreed, with certain limited exceptions, not
to directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lend or otherwise dispose of or transfer any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock, or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other
securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock
and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement
later acquires the power of disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The NASDAQ Global Market under the symbol &#147;SPRO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will be determined through
negotiations between us and the representative. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation multiples of publicly traded companies that the representative believes to be comparable to us, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial information, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the history of, and the prospects for, our company and the industry in which we compete, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the present state of our development, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval for our product candidates, and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after this offering the shares of our common stock will not
trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to sell more than 5% of the
shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representative may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in this offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on The NASDAQ Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic
Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of this offering has
been, or will be made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representative for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no
such offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the Company or the representative to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article
16 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any
communication in respect of an offer of shares, or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with the representative and the company that (1)&nbsp;it is a &#147;qualified
investor&#148; within the meaning of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the
Prospectus Directive, the shares acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is
defined in the Prospectus Directive, or in circumstances in which the prior consent of the representatives has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified
investors, the offer of those shares to it is not treated under the Prospectus Directive as having been made to such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
company, the representatives and their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Member State will
be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject of
this offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer.
Neither the company nor either of the representatives has authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the representatives to publish a prospectus for such
offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied
in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member
State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order
(all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment
activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating
to our common stock or this offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither this
document nor any other offering or marketing material relating to this offering, the company or our shares of common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed
with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes,
or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
DFSA. This prospectus is intended for distribution only to persons of a type </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in
connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this prospectus. The shares to which this prospectus relates may be illiquid and/or
subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission in relation to this offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not purport to
include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under this offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese Person, except
in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148;
shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors
in Singapore </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an
invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to
a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA
by a relevant person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that
trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>.<I> </I>Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with
remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_19"></A>LEGAL MATTERS</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Mintz, Levin, Cohn, Ferris,
Glovsky&nbsp;&amp; Popeo, P.C., Boston, Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_20"></A>EXPERTS </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2016 and 2015 and for each of the two years in the period ended December&nbsp;31, 2016
included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note 1 to the consolidated financial
statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGES IN CERTIFYING ACCOUNTANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On March 6, 2015, KPMG LLP, or KPMG, was engaged as our principal accountant to issue an auditor&#146;s report on our consolidated financial
statements as of December 31, 2014 and for the year then ended. We dismissed KPMG as our principal accountant on June&nbsp;30, 2016, effective as of that date. Our board of directors participated in and approved our change in certifying accountants.
KPMG did not issue a report on our financial statements for either of the two fiscal years ended December 31, 2016. During the period from March&nbsp;6, 2015, when we engaged KPMG as our principal accountant, to June&nbsp;30, 2016, (i) there were no
disagreements (as that term is used in Item 304(a)(1)(iv) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> and the related instructions, or Regulation S-K) with KPMG on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of KPMG would have caused KPMG to make reference thereto in their report on our audited consolidated financial statements as of
December&nbsp;31, 2014 and for the year then ended, and (ii)&nbsp;there were no reportable events as such term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We provided KPMG with a copy of the disclosures set forth above and requested that KPMG furnish a letter addressed to the SEC stating whether
or not KPMG agrees with statements related to them made by us in the disclosures above. KPMG has furnished such letter dated August&nbsp;25, 2017, a copy of which is filed as Exhibit&nbsp;16.1 to the registration statement of which this prospectus
forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We engaged PricewaterhouseCoopers LLP, or PwC, as our independent registered public accounting firm on June 30, 2016. The
decision to change our independent registered public accounting firm was approved by our board of directors. During the period from January&nbsp;1, 2014 to December&nbsp;31, 2015 and the subsequent period preceding our engagement of PwC as our
independent registered public accounting firm on June&nbsp;30, 2016, neither we nor anyone acting on our behalf consulted with PwC regarding: (i)&nbsp;the application of accounting principles to a specific completed or contemplated transaction, or
the type of audit opinion that might be rendered on our consolidated financial statements, and PwC did not provide any written report or oral advice that PwC concluded was an important factor considered by us in reaching a decision as to any such
accounting, auditing or financial reporting issue; or (ii)&nbsp;any matter that was either the subject of a disagreement, as that term is defined in Item&nbsp;304(a)(1)(iv) of Regulation S-K and the related instructions to Item&nbsp;304 of
Regulation S-K, or a reportable event, as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc431217_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> including exhibits and
schedules, under the Securities Act that registers the shares of our common stock to be sold in this offering. This prospectus does not contain all the information contained in the registration statement and the exhibits and schedules filed as part
of the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. Statements contained in this
prospectus as to the contents of any contract or other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copies of the contract or document that has been
filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the consummation of this offering, we will file annual, quarterly and current reports, proxy statements and other information with the
SEC under the Exchange Act. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You may read and copy this information at the SEC&#146;s Public Reference Room at 100&nbsp;F Street, N.E., Washington D.C. 20549, at
prescribed rates. You may obtain information regarding the operation of the public reference room by calling the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains a website (<I>http://www.sec.gov</I>) that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our website address is
<I>www.sperotherapeutics.com</I>. The information contained in, and that can be accessed through, our website is not incorporated into and is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc431217_22"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_4">Consolidated Statements of Bridge Units, Redeemable Convertible Preferred Shares
 and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin431217_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spero
Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and
comprehensive loss, of bridge units, redeemable convertible preferred shares and stockholders&#146; deficit and of cash flows present fairly, in all material respects, the financial position of Spero Therapeutics, Inc. and its subsidiaries as of
December&nbsp;31, 2016 and 2015, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these financial statements in accordance with the standards of the Public
Company Accounting Oversight Board (United States) and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the Company has incurred recurring losses from operations since inception, has an accumulated deficit, and will require additional financing to fund future operations that raise substantial doubt
about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers&nbsp;LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 25, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit, share and per share amounts) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B><br><B>June&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tax incentive receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities, Bridge Units, Redeemable Convertible Preferred Shares and Stockholders&#146; Equity
(Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Advance payments from collaborator</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Advance payments from collaborator, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Redeemable convertible preferred units (Class A, B, C and Junior); 7,640,596 and 13,549,685 units
issued and outstanding as of December&nbsp;31, 2015 and 2016, respectively; aggregate liquidation preference of $50,326 as of December&nbsp;31, 2016; no units authorized, issued or outstanding as of June&nbsp;30, 2017 (unaudited) or pro forma as of
June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A, B, C and Junior), $0.001 par value; no shares
authorized, issued or outstanding as of December&nbsp;31, 2015 or 2016; 43,297,267 shares authorized and 43,197,267 shares issued and outstanding as of June&nbsp;30, 2017 (unaudited); aggregate liquidation preference of $106,208 as of June&nbsp;30,
2017 (unaudited); no shares issued or outstanding, pro forma as of June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common units; 2,165,995 and 2,037,662 units issued and outstanding as of December&nbsp;31, 2015 and
2016, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.001 par value; no shares authorized, issued or outstanding as of December&nbsp;31,
2015 and 2016; 61,917,986 shares authorized and 2,037,662 shares issued and outstanding as of June&nbsp;30, 2017 (unaudited); 50,967,293 shares issued and outstanding, pro forma as of June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total Spero Therapeutics, Inc. stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Non-controlling interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities, bridge units, redeemable convertible preferred shares and stockholders&#146;
equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to non-controlling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units and redeemable convertible preferred shares to redemption value</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders of Spero Therapeutics, Inc.,
basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,886,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,140,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_4"></A>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>Controlling</B><br><B>Interests</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,165,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of bridge units, net of derivative liability of $2,307</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed contribution of capital for reduction in conversion discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of bridge units into Class&nbsp;A preferred units, net of tranche rights derivative
liability of $1,301</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,279,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class&nbsp;A preferred units, net of tranche rights derivative liability of $1,100 and
offering costs of $170</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,923,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 49.9% non-controlling interest in Spero Potentiator in exchange for licensed
technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of additional shares of Spero Potentiator to minority investor under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,165,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>Controlling</B><br><B>Interests</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed contribution of capital for settlement of Class&nbsp;A preferred unit tranche
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class B preferred units, net of tranche rights derivative liability of $909 and
offering costs of $112</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of bridge units, net of contingent prepayment option derivative liability of $908</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested restricted common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(938</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 20% non-controlling interest in Spero Gyrase in exchange for acquired
technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 5% non-controlling interest in Spero Europe in exchange for licensed
technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 12.5% non-controlling interest in Spero Cantab in exchange for licensed
technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of additional shares of Spero Potentiator to minority investor under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>Controlling</B><br><B>Interests</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;$</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of bridge units into Class C preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class C preferred units, net of issuance costs of $176</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,326,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of non-controlling interest in Spero Europe</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of non-controlling interest in Spero Potentiator</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange of units of Spero Therapeutics, LLC for shares of Spero Therapeutics, Inc. on a
one-for-one basis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,197,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,197,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,037,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at June&nbsp;30, 2017 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,197,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency transaction gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payments from collaborator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;A preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs related to 2016 issuance of Class B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class B preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class C preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs related to probable 2017 equity financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payment for repurchase of Spero Potentiator non-controlling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of non-cash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of bridge units into preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of derivative liabilities upon issuance of preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of tranche rights with preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed contribution of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of derivative liability upon issuance of bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of contingent prepayment option with bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of additional shares of common stock to minority investors under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of non-controlling interest balance upon repurchase of non-controlling
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable, accrued expenses and deferred
rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of
these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin431217_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc., together with its consolidated subsidiaries (the&nbsp;&#147;Company&#148;), is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (&#147;MDR&#148;) bacterial infections. The Company&#146;s most advanced product candidate, SPR994, is designed to be the
first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more
convenient and cost-effective treatment of patients after hospitalization. The Company also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of
existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. The Company&#146;s lead product candidates generated from its Potentiator Platform are two IV-administered agents, SPR741 and SPR206, designed to treat
MDR Gram-negative infections in the hospital setting. In addition, the Company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary non-tuberculous mycobacterial infections. The Company believes that its novel product
candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June&nbsp;30, 2017, through a
series of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a Delaware corporation. As part of the transactions, holders of preferred units and common units of Spero
Therapeutics, LLC exchanged their units for shares of Spero Therapeutics, Inc. on a one-for-one basis. These transactions are collectively referred to as the Reorganization. Upon completion of the Reorganization, the historical consolidated
financial statements of Spero Therapeutics, LLC became the historical consolidated financial statements of Spero Therapeutics, Inc. because the Reorganization was accounted for as a reorganization of entities under common control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product
candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of
additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant
revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of the Company have been prepared in conformity with
accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance
with Accounting Standards Update (&#147;ASU&#148;) 2014-15,&nbsp;<I>Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic 205-40)</I>, the Company has evaluated whether there are conditions and events,
considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has funded its operations with proceeds from sales of preferred
units (including bridge units, which converted into preferred units), payments received in connection with a concluded collaboration agreement and funding from government contracts. The Company has incurred recurring losses since inception,
including net losses attributable to Spero Therapeutics, Inc. of $10.2&nbsp;million and $25.5&nbsp;million for the years ended December&nbsp;31, 2015 and 2016, respectively, and $15.0&nbsp;million for the six months ended June&nbsp;30, 2017
(unaudited). In addition, as of December&nbsp;31, 2016 and June&nbsp;30, 2017 (unaudited), the Company had an accumulated deficit of $45.4 million and $72.0 million, respectively. The Company expects to continue to generate operating losses for the
foreseeable future. As of August&nbsp;25, 2017, the issuance date of the annual consolidated financial statements for the year ended December&nbsp;31, 2016 and the interim consolidated financial statements for the six months ended June&nbsp;30,
2017, the Company expects that its cash and cash equivalents of $36.3 million as of June&nbsp;30, 2017 (unaudited), will be sufficient to fund its operating expenses and capital expenditure requirements through February 2018. The future viability of
the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is seeking
to complete an initial public offering (&#147;IPO&#148;) of its common stock. Upon the closing of a qualified public offering on specified terms, the Company&#146;s outstanding redeemable convertible preferred stock will automatically convert into
shares of common stock (see Note 6).&nbsp;In the event the Company does not complete an IPO, the Company expects to seek additional funding through private equity financings, debt financings, or other capital sources, including collaborations with
other companies, government funding arrangements or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the
Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some
or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to
pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future,
and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial
statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements do not include any adjustments that might result from the
outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities
and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development
expenses, the valuation of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares, the valuation of share-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other <FONT
STYLE="white-space:nowrap">market-specific</FONT> or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and
experience. Actual results may differ from those estimates or assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated balance sheet as of June&nbsp;30, 2017, the consolidated statements of operations and comprehensive loss and of
cash flows for the six months ended June&nbsp;30, 2016 and 2017, and the consolidated statement of bridge units, redeemable convertible preferred shares and stockholders&#146; deficit for the six months ended June&nbsp;30, 2017 are unaudited. The
unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring
adjustments, necessary for the fair statement of the Company&#146;s financial position as of June&nbsp;30, 2017 and the results of its operations and its cash flows for the six months ended June&nbsp;30, 2016 and 2017. The financial data and other
information disclosed in these notes related to the six months ended June&nbsp;30, 2016 and 2017 are also unaudited. The results for the six months ended June&nbsp;30, 2017 are not necessarily indicative of results to be expected for the year ending
December&nbsp;31, 2017, any other interim periods, or any future year or period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro forma consolidated balance sheet as of June&nbsp;30, 2017 has been prepared to give effect, upon the closing of
a qualified initial public offering (see Note 6), to the automatic conversion of all shares of redeemable convertible preferred stock outstanding as of June&nbsp;30, 2017 into 48,929,631 shares of common stock as if the proposed initial public
offering had occurred on June&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the accompanying consolidated statements of operations and comprehensive loss, the
unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2016 and the six months ended June&nbsp;30, 2017 have been prepared to give effect, upon the closing of a qualified
initial public offering, to the automatic conversion of all shares of redeemable convertible preferred stock into common stock as if the proposed initial public offering had occurred on the later of January&nbsp;1, 2016 or the issuance date of the
redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company consolidates entities in which it has a controlling financial interest. The Company evaluates each of its subsidiaries to
determine whether the entity represents a variable interest entity (&#147;VIE&#148;), for which consolidation should be evaluated under the VIE model, or, alternatively, if the entity is a voting interest entity, for which consolidation should be
evaluated using the voting interest model. The Company has concluded that none of its subsidiaries is a VIE and has consolidated each subsidiary under the voting interest model because it has majority voting control of each subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Ownership interests in the Company&#146;s subsidiaries that are held by entities other than the Company are reported as non-controlling
interests in the consolidated balance sheets. Losses attributed to non-controlling interests and to the Company are reported separately in the consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015 and 2016, the Company consolidated the following subsidiaries
that were not wholly owned: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Relationship</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Country</B><br><B>Domiciled</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year of<BR>Inclusion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Potentiator, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Europe, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling&nbsp;interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">United&nbsp;Kingdom</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Gyrase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Cantab, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All of the non-controlling interests in Spero Europe, Ltd. and Spero Potentiator, Inc. were repurchased by the
Company during the six months ended June&nbsp;30, 2017. All of the non-controlling interests in Spero Cantab, Inc. were repurchased by the Company in July 2017 (see Notes&nbsp;9 and 17). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk and of Significant Suppliers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In
particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be
adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with
in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of additional paid-in capital generated
as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company
considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds at June&nbsp;30, 2017 (unaudited). The Company did not have any
cash equivalents as of December&nbsp;31, 2015 and 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized
using the straight-line method over the estimated useful life of each asset as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:130.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Estimated&nbsp;Useful&nbsp;Life&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;life&nbsp;of&nbsp;lease&nbsp;or&nbsp;5&nbsp;years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Costs for capital assets not yet placed into service are capitalized as construction in progress and are
depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or
loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived
Assets </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability
whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset
group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated
undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined
based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&nbsp;31, 2015 or 2016 or during the six months ended June&nbsp;30, 2016 and 2017 (unaudited). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and
liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets
or liabilities, or other inputs that are observable or can be corroborated by observable market data. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow
methodologies and similar techniques. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash equivalents and derivative liabilities are carried at fair
value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&#146;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with certain equity financings, licensing transactions and research collaborations, the Company has identified certain embedded and freestanding derivatives, which are recorded as liabilities on the Company&#146;s consolidated balance
sheet and are remeasured to fair value at each reporting date until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification and Accretion of Bridge Units and Redeemable Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has classified bridge units and redeemable convertible&nbsp;preferred shares outside of stockholders&#146; equity (deficit)
because the shares contain certain redemption features that are not solely within the control of the Company. The carrying values of these instruments are accreted to their respective redemption values from the date of issuance through the earliest
date of redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The
Company&#146;s singular focus is on identifying, developing and commercializing novel treatments for MDR bacterial infections. All of the Company&#146;s tangible assets are held in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Contracts and Revenue Recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects. For
contracts with government agencies, when the Company has concluded that it is the principal in conducting the research and development expenses and where the funding arrangement is considered central to the Company&#146;s ongoing operations, the
Company classifies the recognized funding received as revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has concluded to recognize funding received from the U.S.
Department of Defense (&#147;DoD&#148;), the National Institute of Allergy and Infectious Diseases (&#147;NIAID&#148;) of the National Institutes of Health (&#147;NIH&#148;) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator
(&#147;CARB-X&#148;) as revenue, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations.
Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognition commences only once persuasive evidence of a contract exists, services have been rendered, the reimbursement amounts under the contract are
fixed or determinable, and collectibility is reasonably assured. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#146;s consolidated balance sheet as other receivables. The related
costs incurred by the Company are included in research and development expense in the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Tax Incentives</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For available government tax incentives that the Company may earn without regard to the existence of taxable income and that require the
Company to forego tax deductions or the use of future tax credits and net operating loss carryforwards, the Company classifies the funding recognized as a reduction of the related qualifying research and development expenses incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, the Company&#146;s operating subsidiary in Australia has met the eligibility requirements to receive a 43.5%
tax incentive for qualifying research and development activities (see Note 14). The Company recognizes these incentives as a reduction of research and development expenses in the consolidated statements of operations and comprehensive loss in the
same period that the related qualifying expenses are incurred. Reductions of research and development expense recognized upon incurring qualifying expenses in advance of receipt of tax incentive payments are recorded in the consolidated balance
sheet as tax incentive receivables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For collaboration agreements with a third party, to determine the appropriate statement of operations classification of the recognized
funding, the Company first assesses whether the collaboration arrangement is within the scope of the accounting guidance for collaboration arrangements. If it is, the Company evaluates the collaborative arrangement for proper classification in the
statement of operations based on the nature of the underlying activity and the Company assesses the payments to and from the collaborative partner. If the payments to and from the collaborative partner are not within the scope of other authoritative
accounting guidance, the Company bases the statement of operations classification for the payments received on a reasonable, rational analogy to authoritative accounting guidance, applied in a consistent manner. Conversely, if the collaboration
arrangement is not within the scope of accounting guidance for collaboration arrangements, the Company assesses whether the collaboration arrangement represents a vendor/customer relationship. If the collaborative arrangement does not represent a
vendor/customer relationship, the Company then classifies the funding payments received in the statement of operations and comprehensive loss as a reduction of the related expense that is incurred. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a research and development services and support agreement with Hoffmann-La Roche Inc. and certain of its
affiliates (&#147;Roche&#148;) and concluded that the agreements were not within the scope of the accounting guidance for collaboration arrangements (see Note 13). Due to the co-funded nature of the payments and the Company&#146;s assessment that it
did not have a vendor/customer relationship with Roche, the Company recognized the nonrefundable payments received under the agreement as a reduction to the research and development expenses incurred, based on a proportional methodology comparing
the total expenses incurred in the period under the project to the total expenses expected to be incurred under the project. The Company terminated the agreement with Roche in August 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing
research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, manufacturing expenses and external costs of outside vendors engaged to conduct preclinical development activities and
trials as well as the cost of licensing technology. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Nonrefundable advance payments for
goods </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or
the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Contract Costs and Accruals </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside
of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of
the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at
the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company measures all share-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service
period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For share-based awards granted to non-employee consultants, compensation expense is recognized over the period during which services are
rendered by such consultants until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of the Company&#146;s common shares and
updated assumption inputs in the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company classifies share-based compensation expense in its
consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipient&#146;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Comprehensive
loss includes net loss as well as other changes in stockholders&#146; equity (deficit) that result from transactions and economic events other than those with shareholders. There was no difference between net loss and comprehensive loss for each of
the periods presented in the accompanying consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) per Share Attributable to Spero Therapeutics, Inc.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company follows the two-class method when computing net income (loss) per share, as the Company has issued shares that meet
the definition of participating securities. The two-class method determines </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class
method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Net
income (loss) per share attributable to common stockholders is calculated based on net income (loss) attributable to Spero Therapeutics, Inc. and excludes net income (loss) attributable to non-controlling interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common
stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to
reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders
by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually
require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a
net loss attributable to common stockholders of Spero Therapeutics, Inc., diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the same as basic net loss per share attributable to common stockholders of Spero
Therapeutics, Inc., since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders of Spero Therapeutics, Inc. for the years ended
December&nbsp;31, 2015 and 2016 and the six months ended June&nbsp;30, 2016 and 2017 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#146;s tax returns. Deferred tax assets and liabilities are determined on the basis of the
differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not
that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits
expected and considering prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in
the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination
by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that
may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are
considered appropriate as well as the related net interest and penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU No.&nbsp;2014-15, <I>Disclosure of Uncertainties about
an Entity&#146;s Ability to Continue as a Going Concern</I> (&#147;ASU 2014-15&#148;). The amendments in this update explicitly require a company&#146;s management to assess an entity&#146;s ability to continue as a going concern and to provide
related footnote disclosures in certain circumstances. The new standard is effective for annual periods ending after December&nbsp;15, 2016 and for interim periods thereafter. The Company adopted ASU 2014-15 as of the required effective date of
December&nbsp;31, 2016. This guidance relates to footnote disclosure only, and its adoption had no impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2014, the FASB issued ASU No.&nbsp;2014-16, <I>Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in
the Form of a Share Is More Akin to Debt or to Equity</I> (&#147;ASU 2014-16&#148;). The guidance requires an entity to determine the nature of the host contract by considering all stated and implied substantive terms and features of the hybrid
financial instrument, weighing each term and feature on the basis of the relevant facts and circumstances (commonly referred to as the whole-instrument approach). The Company adopted the standard retrospectively to all periods presented on the
required effective date of January&nbsp;1, 2016, and its adoption had no impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2015,&nbsp;the FASB&nbsp;issued ASU No.&nbsp;2015-17,&nbsp;<I>Income Taxes (Topic 740): Balance Sheet Classification of Deferred
Taxes</I>&nbsp;(&#147;ASU 2015-17&#148;), which requires deferred tax liabilities and assets to be classified as non-current in the consolidated balance sheet. ASU&nbsp;2015-17 is required to be adopted for annual periods beginning after
December&nbsp;15, 2016, including interim periods within those fiscal years.&nbsp;The amendment may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.&nbsp;The Company elected to
early adopt the standard on January&nbsp;1, 2016 and has reflected the adoption retrospectively to all periods presented. The adoption of ASU 2016-09 had no material impact on the Company&#146;s financial position, results of operations or cash
flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting</I> (&#147;ASU 2016-09&#148;). ASU 2016-09 involves several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, an
option to recognize gross share compensation expense with actual forfeitures recognized as they occur and certain classifications on the statement of cash flows. Certain of these changes are required to be applied retrospectively, while other
changes are required to be applied prospectively. The Company adopted ASU 2016-09 as of the required effective date of January&nbsp;1, 2017 and has elected to account for forfeitures as they occur rather than apply an estimated forfeiture rate to
share-based compensation expense. The adoption of ASU 2016-09 had no material impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I> (&#147;ASU 2014-09&#148;), which
supersedes existing revenue recognition guidance under GAAP. The standard&#146;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which
the company expects to be entitled in exchange for those goods or services. The standard outlines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance.
The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction
price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU 2015-14, <I>Revenue from Contracts with Customers (Topic 606): Deferral of
the Effective Date</I>, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December&nbsp;15, 2017 and for interim periods within those fiscal years. In March
2016, the FASB issued ASU No.&nbsp;2016-08, <I>Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</I> (&#147;ASU 2016-08&#148;), which further clarifies the implementation guidance on principal versus agent
considerations in ASU 2014-09. In April 2016, the FASB issued ASU No.&nbsp;2016-10, <I>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensin</I>g, clarifying the implementation guidance on identifying
performance obligations and licensing. Specifically, the amendments in this update reduce the cost and complexity of identifying promised goods or services and improve the guidance for determining whether promises are separately identifiable. The
amendments in this update also provide implementation guidance on determining whether an entity&#146;s promise to grant a license provides a customer with either a right to use the entity&#146;s intellectual property (which is satisfied at a point
in time) or a right to access the entity&#146;s intellectual property (which is satisfied over time). In May 2016, the FASB issued ASU No.&nbsp;2016-12, <I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical
Expedients</I> (&#147;ASU 2016-12&#148;), which clarifies the objective of the collectability criterion, presentation of taxes collected from customers, non-cash consideration, contract modifications at transition, completed contracts at transition
and how guidance in ASU 2014-09 is retrospectively applied. ASU 2016-08, ASU 2016-10 and ASU 2016-12 have the same effective dates and transition requirements as ASU 2014-09. The Company plans to adopt this standard using the modified retrospective
approach and is currently evaluating the impact that the adoption will have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016,
the FASB issued ASU No.&nbsp;2016-02, <I>Leases (Topic 842</I>) (&#147;ASU 2016-02&#148;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e.,&nbsp;lessees and
lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification
will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all
leases with a term of greater than 12&nbsp;months regardless of their classification. Leases with a term of 12&nbsp;months or less will be accounted for similar to existing guidance for operating leases today. The guidance is effective for public
entities for annual reporting periods beginning after December&nbsp;15, 2018 and for interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will
have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU No.&nbsp;2016-15, <I>Statement of Cash Flows:
Classification of Certain Cash Receipts and Cash Payments</I> (&#147;ASU 2016-15&#148;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is
effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2016-15 will have on its consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU 2016-18 <I>Statement of Cash Flows (Topic 230) </I>(&#147;ASU <FONT
STYLE="white-space:nowrap">2016-18&#148;),</FONT> which requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and
end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after December&nbsp;15, 2017 and interim periods within those fiscal years and should be applied using a retrospective transition
method to each period presented. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-18 on its consolidated financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2017, FASB issued ASU No.&nbsp;2017-01, <I>Business Combinations (Topic 805):
Clarifying the Definition of a Business</I> (&#147;ASU 2017-01&#148;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be
accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The standard is effective for annual periods beginning
after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-01 will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, the FASB issued ASU No.&nbsp;2017-09, <I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting</I>
(&#147;ASU 2017-09&#148;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting
conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within
those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2017-09 will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU 2017-11, <I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives
and Hedging (Topic 815) I. Accounting for Certain Financial</I> <I>Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily
Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the
indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these
mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the
adoption of ASU 2017-11 will have on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value of Financial Assets and Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2015&nbsp;Using:&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level 2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level 3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2016&nbsp;Using:&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent prepayment option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;June&nbsp;30,&nbsp;2017&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015 and 2016 and the six months ended June&nbsp;30, 2017
(unaudited), there were no transfers between Level 1, Level 2 and Level 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tranche Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sales of Class&nbsp;A-1 preferred units (&#147;Class A preferred units&#148;) and Class B-1 preferred units (&#147;Class B
preferred units&#148;) (see Note 6) provided investors with the right to participate in subsequent offerings of Class&nbsp;A and Class B preferred units in the event specified development and regulatory milestones were achieved. The Company
classified each of the tranche rights as a derivative liability on its consolidated balance sheet because they met the definition of freestanding financial instruments that could have required the Company to transfer assets upon exercise. The
Company remeasured the derivative liabilities associated with tranche rights to fair value at each reporting date, and recognized changes in the fair value of the derivative liabilities as a component of other income (expense) in the consolidated
statement of operations and comprehensive loss.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the probability-weighted
expected return method (&#147;PWERM&#148;), which considered as inputs the probability and time that a milestone would be achieved, the potential fair value of preferred stock upon the exercise of the tranche right and the risk-adjusted discount
rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Tranche Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the tranche right related to the Company&#146;s Class&nbsp;A preferred unit financing (see Note 6) upon issuance in June
2015 was $2.4 million, which increased slightly as of December&nbsp;31, 2015. Upon the issuance of the Class B preferred units in February 2016, the tranche right was cancelled and the settlement of the fair value of the derivative liability of $2.4
million was recorded as an increase to additional paid-in capital as a deemed capital contribution from the Class&nbsp;A preferred unit investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Class B Tranche Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the tranche right related to the Company&#146;s Class B preferred unit financing upon issuance in February 2016 was $0.9
million. Upon the issuance of bridge units in December 2016, the tranche rights were cancelled and the fair value of the derivative liability, which had decreased by $0.6&nbsp;million to $0.3&nbsp;million as of the date of settlement due to a
decrease in the fair value of the Company&#146;s underlying units, was settled (see Note&nbsp;6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of non-controlling interests in certain of the Company&#146;s subsidiaries (see Note 9), specifically Spero
Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., the Company granted anti-dilution rights to the minority investors. The Company classifies the anti-dilution rights as a derivative liability on its consolidated balance sheet because
they are freestanding instruments that represent a conditional obligation to issue a variable number of shares. The Company remeasures the derivative liability associated with the anti-dilution rights to fair value at each reporting date, and
recognizes changes in the fair value of the derivative liability as a component of other income (expense) in the consolidated statement of operations and comprehensive loss.&nbsp;The fair value of these derivative liabilities was determined using a
discounted cash flow model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Potentiator </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s issuance of a non-controlling interest in its subsidiary, Spero Potentiator Inc. (&#147;Spero
Potentiator&#148;), to Northern Antibiotics Oy Ltd. (&#147;Northern&#148;) in&nbsp;February 2015, the Company granted to Northern certain anti-dilution rights (see Note 9). The fair value of the derivative liability related to the anti-dilution
rights upon issuance in February 2015 was $2.4 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2015, the Company issued an additional 2,736 shares of Spero
Potentiator&#146;s common shares for no additional cost to Northern as a result of the anti-dilution rights. Upon issuance, the fair value of the additional shares of Spero Potentiator issued to Northern of $1.5 million was recorded as a reduction
of the derivative liability and as an increase to the non-controlling interest. In January and August 2016, the Company issued an additional 2,160 shares of Spero Potentiator&#146;s common shares for no additional cost to Northern as a result of the
anti-dilution rights. Upon issuance, the fair value of the additional shares of Spero Potentiator issued to Northern of $1.0 million was recorded as a reduction of the derivative liability and as an increase to the non-controlling interest. At that
time, the derivative liability related to the anti-dilution rights issued to Northern was fully settled as Northern had received the maximum number of shares it was entitled to under the anti-dilution rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption impacting the fair value of the anti-dilution rights was the
probability that the Company would fund the maximum amount of investment providing anti-dilution protection. Upon issuance of the rights and through August 2016, the date the maximum anti-dilution protection was reached, the Company&#146;s
assumption for the probability of such funding was 100%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Europe, Ltd</I>. <I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2016, in connection with the issuance of a non-controlling interest in its subsidiary, Spero Europe, Ltd. (&#147;Spero
Europe&#148;), to Promiliad Biopharma Inc. (&#147;Promiliad&#148;), the Company granted to Promiliad certain anti-dilution rights (see Note 9). The fair value of the derivative liability related to the anti-dilution rights upon issuance in January
2016 was $0.2 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative liability associated with the anti-dilution rights was
insignificant during the year ended December&nbsp;31, 2016 and the six months ended June&nbsp;30, 2016 (unaudited). During the six months ended June&nbsp;30, 2017 (unaudited), the fair value of the derivative liability decreased by $0.2 million to
$0. In May 2017, the non-controlling interest in Spero Europe, Ltd. was repurchased and the anti-dilution rights were settled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most
significant assumption impacting the fair value of the anti-dilution rights was the probability that the Company would fund the maximum amount of investment providing anti-dilution protection. Upon the issuance of the rights and through
December&nbsp;31, 2016, the probability of such funding was determined to be 100%. During the six months ended June&nbsp;30, 2017 (unaudited), the probability of funding Spero Europe, Ltd. was reduced to 0% due to Company&#146;s decision to no
longer pursue development of the licensed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Gyrase, Inc.</I> <I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, in connection with the issuance of a non-controlling interest in its subsidiary, Spero Gyrase, Inc. (&#147;Spero Gyrase&#148;),
to Biota Pharmaceuticals, Inc. (now Aviragen Therapeutics, Inc.) (&#147;Aviragen&#148;), the Company granted to Aviragen certain anti-dilution rights (see Note 9). The fair value of the derivative liability related to the anti-dilution rights upon
issuance in March 2016 was $1.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative liability associated with the anti-dilution
rights was insignificant during the year ended December&nbsp;31, 2016 and the six months ended June&nbsp;30, 2016 (unaudited). During the six months ended June&nbsp;30, 2017 (unaudited), the fair value of the derivative liability decreased by $1.4
million to $0.2 million as of June&nbsp;30, 2017 (unaudited) due to Company&#146;s decision to no longer pursue development of the acquired technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption impacting the fair value of the anti-dilution rights was the probability that the Company would fund the
maximum amount of investment providing anti-dilution protection. Upon issuance of the rights and through December&nbsp;31, 2016, the probability of such funding was determined to be 100%. As of June&nbsp;30, 2017 (unaudited), the probability of
funding the entity was reduced to 0% due to the Company&#146;s decision to no longer pursue development of the acquired technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent
Prepayment Options </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Bridge units issued to investors in January 2015 and December 2016 contained contingent prepayment options
whereby such units were automatically convertible into equity units sold in a subsequent round of qualified financing at a discounted rate. The Company classified the contingent prepayment options as derivative
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities on its consolidated balance sheet because the bridge units were deemed to be more akin to debt than equity and the embedded prepayment options were at a substantial discount, thus
meeting the definition of derivative liabilities. The Company remeasured the derivative associated with the contingent prepayment options to fair value at each reporting date, and recognized changes in the fair value of the derivative liabilities as
a component of other income (expense) in its consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these
derivative liabilities was determined using the PWERM, which considered as inputs the probability and time that a subsequent round of preferred stock financing would occur and the risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>January 2015 Bridge Units </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability related to the contingent prepayment option associated with bridge units issued in January 2015 was
$2.3 million. The option was settled in June 2015 upon the issuance of Class&nbsp;A preferred units. As a condition to the June 2015 financing, the Company and the holders of the bridge units agreed to reduce the previously agreed-upon discount to
the per unit conversion price from 20% to 10% of the per unit price of $3.90 to be paid for the sale of the Class&nbsp;A preferred units. The reduction of the discount resulted in a decrease to the fair value of the derivative liability of $1.4
million, which was recorded as an increase to additional paid-in capital as a deemed capital contribution by the holders of the bridge units. The remaining fair value of the derivative liability of $0.9 million was settled upon conversion of the
bridge notes into Class&nbsp;A preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>December 2016 Bridge Units </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability related to the contingent prepayment option associated with bridge units issued in December 2016
was $0.9 million. The change in the fair value of the derivative liability associated contingent prepayment option was not material during the year ended December&nbsp;31, 2016. The fair value of the derivative liability increased by less than $0.1
million as of March 2017, at which time the contingent prepayment option was settled upon the issuance of Class C preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investment
Option </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s concluded collaboration agreement provided its collaboration partner with an option to participate in
the next round of financing subsequent to April 2014 in an amount up to $2.0 million at 90.0% of the per unit price of the related financing. The Company classified the investment option as a derivative liability on its consolidated balance sheet
because it met the definition of a freestanding financial instrument that may require the Company to transfer assets upon exercise. The Company remeasured the derivative liability to fair value at each reporting date, and recognized changes in the
fair value of the derivative liability as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. The fair value of the derivative liability related to the investment option was $0.2 million as of
December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability associated with investment option decreased by $0.1 million as of June
2015, at which time the subsequent financing occurred and the collaboration partner elected not to exercise the investment option, which then expired. Upon expiration, the Company recorded other income equal to the fair value of the derivative
liability upon expiration of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of this derivative liability was determined using the PWERM, which considered
as inputs the probability and time that a qualified round of preferred stock financing would occur and the risk-adjusted discount rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides a roll forward of the aggregate fair values of the
Company&#146;s derivative liabilities, for which fair value was determined by Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tranche<BR>Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Anti-<BR>Dilution<BR>Rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:41.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Contingent<BR>Prepayment<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Investment<BR>Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:35.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total<BR>Derivative<BR>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed capital contribution by bridge unit holders for reduction in contingent prepayment
discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, Net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was less than $0.1 million and $0.3 million for the years ended
December&nbsp;31, 2015 and 2016, respectively, and $0.1 million and $0.2 million for the six months ended June&nbsp;30, 2016 and 2017 (unaudited), respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Redeemable Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the operating agreement of Spero Therapeutics, LLC, as amended and restated, provided for the issuance of Junior
preferred units, Class&nbsp;A preferred units, Class B preferred units and bridge units, but did not specify an authorized number of each for issuance. As of June&nbsp;30, 2017 (unaudited), subsequent to the Reorganization (see Note 1), the
Company&#146;s amended and restated certificate of incorporation authorized the issuance of 43,297,267 shares of preferred stock, par value $0.001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Bridge Units </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January
2015, the Company issued and sold 8,000 bridge units to existing investors at a price of $1,000 per unit for gross proceeds of $8.0 million (the &#147;2015 bridge units&#148;). The bridge units did not have any stated rate of return and were
automatically convertible into the same type of units issuable upon a qualified financing at a discount of either 20.0% or 25.0% to the per unit price paid by investors in a qualified financing, depending on the timing of such financing. The Company
classified this contingent prepayment option as a derivative liability on its consolidated balance sheet on the date of issuance (see Note 3), and the fair value of contingent prepayment option on the date of issuance of $2.3 million was recorded as
both a derivative liability and as a reduction to the carrying value of the bridge units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, the Company issued and sold 1,923,076 Class&nbsp;A preferred units at a price of $3.90 per unit for proceeds of $7.3 million,
net of issuance costs of $0.2 million. The sale of Class&nbsp;A preferred units met the definition of a qualified financing under the 2015 bridge unit agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a condition to the June 2015 Class&nbsp;A preferred unit financing, the Company and the holders of the 2015 bridge units agreed to reduce
the previously agreed-upon discount to the per unit conversion price from 20% to 10% of the price to be paid for the sale of Class&nbsp;A preferred units of $3.90 per unit. Accordingly, the Company issued 2,279,202 Class&nbsp;A preferred units upon
the conversion of the 2015 bridge units in the amount of $8.0 million, at a conversion price of $3.51 per unit. The conversion was accounted for as an extinguishment for accounting purposes. Accordingly, the Company recorded the Class&nbsp;A
preferred units issued upon conversion of the 2015 bridge units at their aggregate fair value of $8.9 million and recorded a corresponding adjustment to extinguish the then-current carrying value of the 2015 bridge units of $8.0 million and the
then-current fair value of the derivative liability related to the contingent prepayment option associated with the 2015 bridge units of $0.9 million (see Note 3). There was no gain or loss recognized upon the extinguishment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A preferred unit financing included a provision for the issuance of an
additional 3,295,455 Class&nbsp;A preferred units at a price of $4.40 per unit in exchange for gross proceeds of $14.5 million in the event the Company achieved a regulatory milestone. The Company classified this tranche right as a derivative
liability on its consolidated balance sheet on the date of issuance, and the fair value of tranche right on the date of issuance of $2.4 million was recorded as both a derivative liability and as a reduction to the carrying value of the Class&nbsp;A
preferred units. Upon issuance of the Class B preferred units in February 2016, the tranche right was cancelled (see Note 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class B Preferred
Unit Financing </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, the Company issued and sold 5,909,089 Class B preferred units at a price of $4.40 per unit for
proceeds of $25.9 million, net of issuance costs of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Class B preferred unit financing included a provision for the
issuance of an additional 1,609,846 Class B preferred units at a price of $5.28 per unit in exchange for gross proceeds of $8.5 million in the event the Company achieved a regulatory milestone. The Company classified this tranche right as a
derivative liability on its consolidated balance sheet on the date of issuance, and the fair value of the tranche right on the date of issuance of $0.9 million was recorded as both a derivative liability and as a reduction to the carrying value of
the Class B preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Bridge Units </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The regulatory milestone related to the Class B tranche right was achieved in the fourth quarter of 2016; however, the Company and the holders
of the Class B preferred units agreed to replace the second closing of Class B preferred units with the issuance of bridge units that would be convertible in the next qualified financing at a 10% discount. Accordingly, in December 2016, the Company
issued and sold 8,500 bridge units to existing investors at a price of $1,000 per unit for gross proceeds of $8.5 million (the &#147;2016 bridge units&#148;). Upon issuance of the 2016 bridge units, the fair value of the derivative liability
associated with the Class&nbsp;B tranche right of $0.3&nbsp;million was settled, resulting in a decrease to the carrying value of the derivative liability and an increase to the carrying value of the 2016 bridge units (see Note 3). The bridge units
did not provide for any stated rate of return and were automatically convertible into the same type of units issuable upon a qualified financing at a 10% discount to the per unit price paid by investors in a qualified financing. The Company
classified this contingent prepayment option as a derivative liability on its consolidated balance sheet on the date of issuance, and the fair value of the contingent prepayment option on the date of issuance of $0.9&nbsp;million was recorded as
both a derivative liability and as a reduction to the carrying value of the bridge units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class C Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, the Company issued and sold 24,326,470 Class C preferred units at a price of $1.7749 per unit for proceeds of $43.0 million,
net of issuance costs of $0.2 million. The sale of Class C preferred units met the definition of a qualified financing under the 2016 bridge unit agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company issued 5,321,112 Class C preferred units upon the conversion of the 2016 bridge units in the amount of $8.5 million, at a
conversion price of $1.60 per unit, which represented a discount of 10% to the price per unit paid by other investors in the Class C preferred unit financing. The conversion was accounted for as an extinguishment for accounting purposes.
Accordingly, the Company recorded the Class&nbsp;C preferred units issued upon conversion of the 2016 bridge units at their aggregate fair value of $9.4 million and recorded a corresponding adjustment to extinguish the then-current carrying value of
the 2016 bridge units of $8.5 million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the then-current fair value of the derivative liability related to the contingent prepayment option associated with the 2016 bridge units of $0.9&nbsp;million (see Note 3) (unaudited). There
was no gain or loss recognized upon the extinguishment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares of Preferred Stock of Spero Therapeutics, Inc. Issued upon the Reorganization
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, pursuant to the terms of the Reorganization (see Note 1), holders of outstanding preferred units of Spero
Therapeutics, LLC exchanged their units for preferred stock of Spero Therapeutics, Inc. on a one-for-one basis. The rights and preferences of each class of stock (as described below) were the same both before and after the Reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of each balance sheet date, outstanding equity of the Company consisted of the following (in thousands, except share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preferred<BR>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:42.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carrying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:31.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation<BR>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>Units&nbsp;Issuable<BR>Upon<BR>Conversion</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Junior preferred units</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A preferred units</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December 31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preferred<BR>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:42.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carrying<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation<BR>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>Units
Issuable<BR>Upon<BR>Conversion</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Junior preferred units</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A preferred units</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class B preferred units</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June 30, 2017 (unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preferred<BR>Shares<BR>Authorized</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preferred<BR>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:42.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Carrying<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation<BR>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>Shares<BR>Issuable&nbsp;Upon<BR>Conversion</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Junior preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,396,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,447,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,747,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,647,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,647,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,297,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,197,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,929,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Junior preferred stock, the Series A preferred stock, the Series B preferred stock and the Series C
preferred stock are collectively referred to as the &#147;Preferred Stock&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of Preferred
Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. The holders of Preferred Stock are entitled to the number of votes equal to the number of common shares into which each such
share of Preferred Stock could convert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is convertible at the option of the holder at any time after the date of issuance. Each share of Preferred Stock
will be automatically converted into shares of common stock at the applicable conversion ratio then in effect (i)&nbsp;upon the closing of a firm commitment public offering with at least $50.0 million of proceeds to the Company, and at a price of at
least $2.66 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization, or (ii)&nbsp;upon the written consent of the holders of at least 60% of the then-outstanding
shares of Series B and Series&nbsp;C preferred stock, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The conversion ratio of each series of Preferred
Stock is determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price is $1.00 per share for Junior preferred stock, $3.90 per share for Series A preferred stock, $4.40 per share for
Series B preferred stock and $1.7749 per share for Series C preferred stock. The Conversion Price at issuance was $1.00 per share for Junior preferred stock, $3.90 per share for Series A preferred stock, $4.40 per share for Series B preferred stock
and $1.7749 per share for Series C preferred stock, subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#146;s certificate
of incorporation, as amended and restated. In March 2017, as a result of the issuance of Series C preferred stock at a price per share less than the Series A and Series B preferred stock Original Issue Price, the Conversion Price for each of Series
A and Series B preferred stock was adjusted to $2.5622 per share and $2.7521 per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Holders of the Series A, Series B and Series C preferred stock are entitled to receive, out of funds legally available, cumulative dividends
at an annual rate of 8%, compounded annually, when and if declared by the board of directors. Holders of the Junior preferred stock are entitled to receive, out of funds legally available, noncumulative dividends at an annual rate of 5%, when and if
declared by the board of directors. The Company may not declare, pay or set aside any dividends on shares of any other series of capital stock of the Company, other than dividends on common stock payable in common stock, unless the holders of the
Series C preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Series C preferred stock to which they are entitled. The Company may not declare, pay or set aside any dividends on shares of any other series
of capital stock of the Company, other than dividends on shares of Series C preferred stock and dividends on common stock payable in common stock, unless the holders of the Series B preferred stock first receive, or simultaneously receive, a
dividend on each outstanding share of Series B preferred stock to which they are entitled. The Company may not declare, pay or set aside any dividends on shares of any other series of capital stock of the Company, other than dividends on shares of
Series B preferred stock or Series C preferred stock and dividends on common stock payable in common stock, unless the holders of the Series A preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Series A
preferred stock to which they are entitled. The Company may not declare, pay or set aside any dividends on shares of any other series of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital stock of the Company, other than dividends on shares of Series A, Series B or Series C preferred stock and dividends on common stock payable in common stock, unless the holders of the
Junior preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Junior preferred stock to which they are entitled. Through December&nbsp;31, 2016 and June&nbsp;30, 2017 (unaudited), no cash dividends have
been declared or paid by the Company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company or Liquidating Event (as described below),
the holders of shares of Preferred Stock will receive, in preference to the common stockholders, an amount equal to the greater of (i)&nbsp;the Original Issue Price per share of the respective share of preferred stock, plus all dividends declared
but unpaid on such shares or (ii)&nbsp;the amount the holders would receive if the Preferred Stock were converted into common stock prior to such liquidation event. If, upon any such liquidation event, the assets of the Company available for
distribution are insufficient to permit payment in full to the holders of Preferred Stock, the holders of the Series C preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series B, Series A, Junior
preferred stock and common stock. After payment in full to holders of Series C preferred stock, the holders of the Series B preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series A, Junior
preferred stock and common stock. After payment in full to holders of Series C and Series B preferred stock, the holders of the Series A preferred stock are entitled to receive such amount prior to and in preference of the holders of the Junior
preferred stock and common stock. After payment in full to holders of Series C, Series B and Series A preferred stock, the holders of the Junior preferred stock are entitled to receive such amount prior to and in preference of the holders of the
common stock. In the event that the assets available for distribution to the Company&#146;s stockholders are not sufficient to permit payment to any class of holders in order of preference and in the full amount to which they are entitled, the
assets available for distribution are distributed on a pro rata basis. In addition, solely if (i)&nbsp;proceeds are received in connection with the sale or merger of Spero Potentiator, Inc. and (ii)&nbsp;contracted distribution thresholds in
relation to anti-dilution clauses are satisfied, then distributions to the Series A holders shall be made until their Adjusted Potentiator Shortfall Amount, as defined, is met, after payments to Series C and Series B preferred stock have been made
in full but prior to and in preference of the holders of the Junior preferred stock and common stock. After the payment of all preferential amounts to the holders of the Preferred Stock then, to the extent available, the remaining assets available
for distribution shall be distributed among the holders of the Preferred Stock and common stock ratably in proportion to the number of shares of stock held as converted to common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless the holders of 60% of the then-outstanding shares of Series B and Series C preferred stock, voting together as a single class, and
holders of 60% of the then-outstanding shares of Series C preferred stock elect otherwise, a Liquidating Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the
outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At any time on or
after February&nbsp;1, 2021, shares of each of the Junior preferred stock, Series A, Series B and Series C preferred stock are subject to mandatory redemption by the Company in three equal annual installments beginning 60 days after receipt of a
notice of redemption from the holders of at least 60% of the combined voting power of the holders of the outstanding Series B and Series C preferred stock, voting as a single class at the Original Issue Price, subject to appropriate adjustment for
any stock splits, stock dividends, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combinations or any other similar recapitalization affecting such shares, plus any dividends declared but unpaid thereon plus cumulative dividends. If, upon any such redemption, the assets of the
Company available for distribution are insufficient to permit payment in full to the holders of Preferred Stock, the holders of the Series C preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series
B, Series A and Junior preferred stock. After payment in full to holders of Series C preferred stock, the holders of the Series B preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series A and
Junior preferred stock. After payment in full to holders of Series C and Series B preferred stock, the holders of the Series A preferred stock are entitled to receive such amount prior to and in preference of the holders of the Junior preferred
stock. In the event that the assets are not sufficient to permit payment of the redemption amount to any class of holders in order of preference and in the full amount to which they are entitled, the assets available for distribution are distributed
on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the operating agreement of Spero Therapeutics, LLC, as amended and restated, provided for the issuance of common
units, but did not specify an authorized number for issuance. As of June&nbsp;30, 2017 (unaudited), subsequent to the Reorganization (see Note 1), the Company&#146;s amended and restated certificate of incorporation authorized the issuance of
61,917,986 shares of common stock, par value $0.001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters
submitted to a vote of the Company&#146;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In 2014, the Company issued and sold restricted common units, which were subject to vesting requirements. In 2016, the Company repurchased
128,333 unvested common units upon forfeiture at the original issuance price of $0.001 per unit. As of December&nbsp;31, 2015 and 2016, there were 457,083 units and 42,917 units, respectively, of unvested restricted common units outstanding. There
was no unvested common units outstanding as of June&nbsp;30, 2017 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June 30, 2017, pursuant to the terms of the
Reorganization (see Note&nbsp;1), holders of common units of Spero Therapeutics, LLC exchanged their units for common stock of Spero Therapeutics, Inc. on a one-for-one basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Share-Based Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to
the Reorganization, the Company&#146;s operating agreement, as amended and restated, provided for the granting of incentive units to officers, directors, employees, consultants and advisors. Under the terms of the incentive unit grant agreements,
such incentive units were subject to a vesting schedule, with 25% of the incentive units vesting following one year of continued employment or service and the balance vesting in equal monthly installments for 36 months beginning on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the holder&#146;s employment or service with the Company. Holders of incentive units were entitled to receive distributions in proportion to their ownership percent interest, when and if
distributed, that were in excess of the strike price of the award set by the board of directors on the date of grant. The Company determined that the underlying terms of the incentive units and the intended purpose of the awards were more akin to an
equity-based compensation award than a performance bonus or profit-sharing arrangement and, therefore, the incentive units were equity-classified awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The total number of incentive units that could have been issued under the Company&#146;s operating agreement was 3,483,296 as of
December&nbsp;31, 2016, of which 971,713 units remained available for future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance as of December&nbsp;31, 2016. Upon the Reorganization on June&nbsp;30, 2017 (see Note 1), the Company could no longer issue incentive units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Unit Valuation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
fair value of each incentive unit award was estimated using the Black-Scholes option-pricing model. The Company has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected
share volatility based on the historical volatility of a set of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. The Company
has estimated the expected term of the Company&#146;s incentive units utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla.&#148; The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash
dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used in the Black-Scholes option-pricing model to determine the
fair value of incentive unit awards granted to employees and directors were as follows, presented on a weighted average basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s incentive unit activity since December&nbsp;31, 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B><br><B>of Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted<BR>Average<BR>Strike<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:41.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Intrinsic<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,448,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Units vested and expected to vest as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,456,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of awards is calculated as the difference between the strike
price of the incentive units and the fair value of the Company&#146;s common units for those awards that had strike prices lower than the fair value of the Company&#146;s common units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair value of awards granted during the years ended December&nbsp;31, 2015 and 2016 was $0.17 per unit and
$0.56 per unit, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair value of awards granted during the six months ended June&nbsp;30, 2016
and 2017 (unaudited) was $0.56 per unit and $0.25 per unit, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recorded share-based compensation expense in the
following expense categories of its consolidated statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:85.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, total unrecognized compensation cost related to the unvested share-based awards
was $0.8 million, which was expected to be recognized over a weighted average period of 3.1 years. As of June&nbsp;30, 2017 (unaudited), all of the incentive units were cancelled; however, the Company will continue to recognize compensation costs
related to these awards (see below). As of June&nbsp;30, 2017 (unaudited), total unrecognized compensation cost related to the unvested share-based awards was $0.6 million, which is expected to be recognized over a weighted average period of 2.6
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, in connection with the Reorganization, the Company cancelled the then-outstanding 2,448,320 incentive units. In July
2017, previous holders of the cancelled incentive units who were still employed by the Company at the time of the Reorganization received stock options under the 2017 Stock Incentive Plan (described below). Such stock options were granted for the
same number of shares of common stock as the number of incentive units cancelled, and the stock options were granted on the same vesting terms as the incentive units. All such stock options have an exercise price of $0.97 per share. The Company will
account for the cancellation of the incentive units and the issuance of new awards as a modification of the awards for accounting purposes in the third quarter of 2017. The resulting compensation charge related to the modification, if any, will be
equal to the positive difference between the fair value of the modified award and the fair value of the original award immediately before it was deemed modified for accounting purposes. For the portion of awards that are vested as of the
modification date, share-based compensation expense equal to the amount of the incremental fair value of the modified award, if any, will be recognized immediately on the modification date in the third quarter of 2017. For the portion of the awards
that are unvested as of the modification date, share-based compensation expense related to the incremental fair value of the modified award, if any, as well as any unrecognized compensation expense related to the original award will be recognized
over the remaining service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2017, the Company&#146;s stockholders approved the 2017 Stock Incentive Plan (the &#147;2017 Plan&#148;). The 2017 Plan
provides for the grant of incentive stock options, nonstatutory stock options, stock grants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and stock-based awards. The 2017 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board. The exercise prices, vesting and
other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common
stock on the date of grant and the term of stock option may not be greater than ten years. The number of shares initially reserved for issuance under the 2017 Plan was 10,850,693 shares of common stock. The shares of common stock underlying any
awards that are forfeited, cancelled, repurchased or are otherwise terminated by the Company under the 2017 Plan will be added back to the shares of common stock available for issuance under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Non-Controlling Interests </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Potentiator
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February&nbsp;2015, the Company&#146;s wholly owned subsidiary, Spero Potentiator, issued 996 shares of its common stock with
an aggregate fair value of $1.1 million to Northern in exchange for an exclusive license to develop and commercialize certain licensed compounds and licensed products. The Company recognized research and development expense of $1.1 million upon
acquisition of the license and recorded a non-controlling interest in Spero Potentiator in a corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the
acquisition of the license, Northern obtained anti-dilution rights to maintain its 49.9% ownership percentage in Spero Potentiator at no additional cost to Northern in the event that Spero Potentiator completed subsequent equity financings, subject
to a maximum amount of such financings. The maximum amount of gross proceeds from equity financings subject to the anti-dilution rights was $5.0 million through the date the Company filed an investigational new drug application (&#147;IND&#148;)
related to the licensed technology. Subsequent to the filing of an IND, the maximum amount of gross proceeds from equity financings subject to the anti-dilution rights was $6.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet (see Note 3). The fair value of
the derivative liability associated with the anti-dilution rights upon issuance in February 2015 of $2.4 million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2015, Northern was issued an additional 2,736 common shares of Spero Potentiator for no additional cost as a result of the
anti-dilution rights. The Company valued these shares at $1.5 million and recorded the amount as an increase in the non-controlling interest and a reduction in the carrying value of the derivative liability. In January and August 2016, Northern was
issued an additional 2,160 common shares of Spero Potentiator for no additional cost. The Company valued these shares at $1.0 million and recorded the amount as an increase in the non-controlling interest and a reduction of the derivative liability.
At that time, the anti-dilution rights issued to Northern were fully settled as Northern had received the maximum number of shares it was entitled to under the anti-dilution rights (See Note&nbsp;3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, the Company repurchased all of the shares of Spero Potentiator held by Northern in exchange for a cash payment of $1.0 million
and contingent consideration of $0.1 million. As a condition of the repurchase of the shares from Northern, the Company amended the license agreement with Northern such that the Company will be obligated to make milestone payments of up to $7.0
million upon the achievement of specified clinical, commercial and other milestones, including a payment of $2.5 million upon the closing of an initial public offering. As a result of this transaction, during the six months ended June&nbsp;30, 2017
(unaudited), the Company reclassified the balance of the non-controlling interest of $6.4 million as of the date of the transaction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to accumulated deficit as an increase to that account. Additionally, the cash payment of $1.0 million was recorded as an increase to accumulated deficit (unaudited). The Company will record the
contingent payments as research and development expense when it becomes probable that the payments will be due. For periods subsequent to the acquisition, the Company no longer reports a non-controlling interest related to Spero Potentiator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Europe </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
January&nbsp;2016, the Company entered into an agreement with Promiliad whereby Promiliad granted to Spero Europe certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a sublicense to research, develop, manufacture and sell certain compounds.
In exchange for the <FONT STYLE="white-space:nowrap">know-how</FONT> and sublicense, Spero Europe provided Promiliad with a 5% equity ownership interest in Spero Europe, with a fair value of $0.1&nbsp;million. In addition, Spero Europe agreed to
make payments to Promiliad upon the achievement of future regulatory and commercial milestones of $4.1 million&nbsp;and to pay to Promiliad royalties of a mid single-digit percentage on net sales of licensed products under the agreement. Spero had
the right to terminate the agreement with thirty days&#146; notice. The Company recognized research and development expense of $0.1 million upon the acquisition of the license and recorded a non-controlling interest in Spero Europe in a
corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the license, Promiliad obtained anti-dilution rights to maintain their 5%
equity ownership in Spero Europe at no additional cost to Promiliad in the event that Spero Europe completed subsequent funding events, subject to a maximum amount of such funding of $5.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet (see Note 3). The fair value of
the derivative liability associated with the anti-dilution rights upon issuance in January 2016 of $0.2 million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017 (unaudited), the Company repurchased all of the shares of Spero Europe from Promiliad in exchange for the return of the license.
As a result of the transaction, the Company reclassified the balance of the non-controlling interest in Spero Europe of less than $0.1 million as of the date of the transaction to accumulated deficit as an increase to that account. For periods
subsequent to the repurchase, the Company no longer reports a non-controlling interest related to Spero Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Gyrase </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the Company entered into an agreement with Aviragen and its affiliates in order to acquire certain intellectual property and
know-how related to certain compounds.&nbsp;In connection with the transaction, the Company established Spero Gyrase, a Delaware corporation, and issued to Aviragen 200 common shares of Spero Gyrase with a fair value of $1.1 million, which
represented a 20% equity ownership interest in Spero Gyrase. In addition Spero Gyrase agreed to make future milestone and royalty payments in exchange for the intellectual property. The Company accounted for the acquisition of technology as
an&nbsp;asset acquisition&nbsp;because it did not&nbsp;meet the definition of a business. The Company recorded the acquired technology as research and development expense in the consolidated statement of operations and comprehensive loss in the
amount of $1.1&nbsp;million, because the acquired technology had not reached commercial feasibility and had&nbsp;no alternative future use, and recorded a non-controlling interest in Spero Gyrase in a corresponding amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the agreement, Aviragen obtained anti-dilution rights to maintain their 20% equity ownership of Spero Gyrase at no
additional cost to Aviragen in the event that Spero Gyrase completed subsequent funding events, subject to a maximum amount of such funding of $8.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its
consolidated balance sheet (see Note 3). The fair value of the derivative liability associated with the anti-dilution rights upon issuance in March 2016 of $1.6 million was recorded as research and development expenses as it was deemed to represent
additional consideration for the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Cantab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered into a stock purchase agreement and related agreements (the &#147;Cantab Agreements&#148;) with Pro Bono Bio
PLC, a corporation organized under the laws of England, and certain of its affiliates, including PBB Distributions Limited (&#147;PBB&#148;), Cantab Anti-Infectives Ltd. (&#147;CAI&#148;) and New Pharma License Holdings Limited (&#147;NPLH&#148;) in
order to acquire NPLH and its intellectual property rights and assets relating to the Company&#146;s Potentiator Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the
Cantab Agreements, CAI agreed to submit a request to NIAID to novate the CAI-held NIAID contract to the Company. The NIAID contract provides for development funding of up to $5.7 million over a base and three option periods. Through June&nbsp;30,
2017, the funding amount of $1.7 million and the first option of $1.6 million has been committed to CAI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Consideration under Cantab
Agreements consisted of: (i)&nbsp;125 shares of Spero Cantab, the Company&#146;s subsidiary, which represented a 12.5% ownership interest in Spero Cantab, and anti-dilution rights (as described below) issued to PBB, with a combined fair value of
$1.6 million, (ii)&nbsp;upfront consideration of $0.3 million (to be credited against future payments payable to CAI), (iii)&nbsp;contingent milestone payments due upon the achievement of certain clinical, regulatory and commercial milestones (see
Note&nbsp;13), (iv)&nbsp;royalty payments of low single-digit percentages based on net sales of products from the licensed technology, and (v)&nbsp;a specified portion of funding payments made by NIAID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the acquisition of NPLH as an&nbsp;asset acquisition&nbsp;because NPLH did not&nbsp;meet the definition of a
business. The Company recognized research and development expense of $1.6&nbsp;million upon the acquisition of NPLH because the acquired technology had not reached commercial feasibility and had&nbsp;no alternative future use. Upon the issuance of
the shares and anti-dilution rights, the Company recorded a non-controlling interest in Spero Cantab of $1.6&nbsp;million. The $0.3&nbsp;million payment was recognized as research and development expenses as the services were performed by CAI. The
Company records the contingent payments outlined in (iii), (iv)&nbsp;and (v)&nbsp;as research and development expense when it becomes probable that the payments will be due. Until the time that CAI has novated the NIAID contract, CAI will continue
to perform research and development services at the Company&#146;s direction and will apply for reimbursement from NIAID. The contract had not yet been novated as of December&nbsp;31, 2016 or June&nbsp;30, 2017 (unaudited). The Company pays CAI for
such research and development services at an agreed-upon rate which takes into consideration costs incurred by CAI, amounts reimbursed to CAI by NIAID and the portion of the NIAID reimbursement the Company pays to CAI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Cantab Agreements, PBB obtained anti-dilution rights to maintain a certain equity ownership, ranging from 5% to 12.5%,
of Spero Cantab at no additional cost to PBB in the event that Spero Cantab completed subsequent funding events, subject to maximum amount of such funding of $8.0&nbsp;million. These anti-dilution rights represent a conditional obligation to issue a
variable number of shares but are not freestanding and, therefore, do not require bifurcation for accounting purposes from the 125 shares issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company repurchased all of the outstanding shares of Spero Cantab owned by
PBB in exchange for a cash payment of $0.2 million and an amendment to the licensing agreement to increase the first two contingent milestone payments by a total of $0.1&nbsp;million (see Note&nbsp;17). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides a roll forward of the non-controlling interests balances (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Potentiator</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:25.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Spero<BR>Europe</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:24.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gyrase</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:25.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Spero<BR>Cantab</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total <BR><FONT STYLE="white-space:nowrap">Non-Controlling</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Interests</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of additional shares to non-controlling interest under anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of additional shares to non-controlling interest under anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of non-controlling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of June&nbsp;30, 2017 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization (see Note 1), the Company&#146;s former parent company, Spero Therapeutics, LLC, was treated as a partnership for
federal income tax purposes and, therefore, its owners, and not itself, were subject to U.S. federal or state income taxation on the income of Spero Therapeutics, LLC. Prior to the Reorganization, all of Spero Therapeutics, LLC&#146;s directly held
subsidiaries (including Spero Therapeutics, Inc.) were treated as corporations for U.S. federal income tax purposes and were subject to taxation in the United States or in other countries. Upon the Reorganization, Spero Therapeutics, Inc. became the
parent company for Spero Therapeutics, LLC&#146;s former subsidiaries and these entities continue to be subject to taxation in the United States or in other countries. In each reporting period, the Company&#146;s tax provision includes the effects
of consolidating the results of operations of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015 and 2016 and the six months
ended June&nbsp;30, 2016 and 2017 (unaudited), the Company recorded no income tax benefits for the net operating losses incurred in each year or interim period due to its uncertainty of realizing a benefit from those items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The domestic and foreign components of loss before income taxes were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:81.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s
effective income tax rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondeductible items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net deferred tax assets as of December&nbsp;31, 2015 and 2016 consisted of the following (in thousands):
</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company had U.S. federal and state net operating loss carryforwards of $39.8
million and $39.6 million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2033. In addition, as of December&nbsp;31, 2016, the Company had foreign net operating loss carryforwards of $3.8 million,
which may be available to offset future income tax liabilities and do not expire. As of December&nbsp;31, 2016, the Company also had federal and state research and development tax credit carryforwards of $0.6 million and $0.2 million, respectively,
which may be available to offset future income tax liabilities and begin to expire in 2033 and 2028, respectively. During the six months ended June&nbsp;30, 2017 (unaudited), gross deferred tax assets increased by approximately $7.2 million due to
the operating loss incurred by the Company during that period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Utilization of the U.S. net operating loss carryforwards and research and
development tax credit carryforwards may be subject to a substantial annual limitation under Section&nbsp;382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or
that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&nbsp;382, results from transactions
increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.&nbsp;The Company has not conducted a study to assess whether a change of control has occurred or whether there
have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&nbsp;382, at any time since inception,
utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&nbsp;382, which is determined by first multiplying the value of the Company&#146;s stock
at the time of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net
operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has
considered the Company&#146;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than
not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&nbsp;31, 2015 and 2016 and June&nbsp;30, 2017 (unaudited).
Management reevaluates the positive and negative evidence at each reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Changes in the valuation allowance for deferred tax
assets during the years ended December&nbsp;31, 2015 and 2016 related primarily to the increase in net operating loss carryforwards, capitalized research and development expenses and research and development tax credit carryforwards and were as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases recorded as benefit to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has not recorded any amounts for unrecognized tax benefits as of December&nbsp;31, 2015 or 2016.
The Company&#146;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&nbsp;31, 2015 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions and
no amounts had been recognized in the Company&#146;s statement of operations and comprehensive loss.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s subsidiaries
separately file income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2013. To the extent the Company has tax
attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are
currently in process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company
has entered into license agreements with various parties under which it is obligated to make contingent and non-contingent payments (see Note&nbsp;13). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2015,
the Company entered into an operating lease agreement for office space that commenced in January 2016 and expires in December 2020. The lease requires annual payments of $0.4 million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
over the five-year term. The lease provides for a renewal option to extend the lease for an additional five years. Under the terms of the lease, the Company provided a security deposit of $0.2
million to the landlord, which is included in long-term assets in the accompanying consolidated balance sheets. The lease includes annual rent escalations as well as tenant incentives in the amount of $0.7 million, of which $0.3 million is
reimbursed to the landlord over the term of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2016, the Company entered into an agreement to lease laboratory space
through November&nbsp;30, 2019 from a sublessor, which requires annual lease payments of $0.3 million, subject to certain escalations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent escalations and tenant incentives for operating leases are accrued, and rent expense is recognized on a straight-line basis over the
terms of occupancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the future minimum payments due under the operating leases as of December&nbsp;31,
2016 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:92.45pt; font-size:8pt; font-family:Times New Roman"><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent expense for the years ended December&nbsp;31, 2015 and 2016 was $0.1 million and $0.4 million,
respectively. Rent expense for the six months ended June&nbsp;30, 2016 and 2017 (unaudited) was $0.1 million and $0.4 million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach
of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other
things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification
agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a
material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&nbsp;31, 2015, 2016 or June&nbsp;30, 2017
(unaudited). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential
loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal
proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Government Contracts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Department of Defense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
September 2016, the Company was awarded a cooperative agreement with the DoD to further develop anti-infective agents to combat Gram-negative bacteria. The agreement is structured as a single, two-year $1.5 million award. The Company is eligible for
the full funding from the DoD, and there are no options to be exercised at a later date. The DoD funding supports next-generation potentiator discovery and screening of SPR741 partners. The Company recognizes revenue under this agreement as
qualifying expenses are incurred. During the year ended December&nbsp;31, 2016, $0.3 million of revenue was recognized under this agreement, of which $0.3 million was invoiced but unpaid and included in other receivables at December&nbsp;31, 2016.
During the six months ended June&nbsp;30, 2017 (unaudited), The Company recognized $0.3 million of revenue under this agreement, of which $0.1 million was invoiced but unpaid and included in other receivables at June&nbsp;30, 2017 (unaudited). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NIAID </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2017, the
Company was awarded a grant from NIAID to conduct additional preclinical studies of SPR720, the Company&#146;s novel oral bacterial gyrase inhibitor, for the treatment of non-tuberculous mycobacterial infections. The award is structured as a
12-month $0.6 million base period and $0.4 million option period. Through June 30, 2017 (unaudited), only the base period funds had been committed. The Company recognized less than $0.1 million of revenue in the six months ended June&nbsp;30, 2017
(unaudited) under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CARB-X </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2017, the Company was awarded a grant from CARB-X, a public-private partnership funded by the Biomedical Advanced Research and
Development Authority (&#147;BARDA&#148;) within the U.S. Department of Health and Human Services to be used to screen, identify and complete Phase 1 trials with at least one partner compound for SPR741, the Company&#146;s lead Potentiator compound.
The award commits to funding of $1.5 million over a 12-month period, with the possibility of up to a total of $6.8 million in funding over 36 months based on the successful progression of specified milestones. The Company recognized
$0.1&nbsp;million of revenue in the six months ended June&nbsp;30, 2017 (unaudited) under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Collaboration and License Agreements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has certain obligations under license agreements with third parties that include annual maintenance fees and payments
that are contingent upon achieving various development, regulatory and commercial milestones. Pursuant to these license agreements, the Company is required to make milestone payments if certain development, regulatory and commercial milestones are
achieved, and may have certain additional research funding obligations. Also, pursuant to the terms of each of these license agreements, when and if commercial sales of a product commence, the Company will pay royalties to its licensors on net sales
of the respective products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roche Collaboration Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2014, the Company and Roche entered into a research and development services and support agreement (&#147;Research and
Development Agreement&#148;) and an option agreement (&#147;Option Agreement&#148;), whereby </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company was required to use its best efforts to research and develop a specified asset, while Roche would provide partial funding as well as participate on a joint steering committee for the
development of this asset. As part of these agreements, the Company provided Roche with the option to participate in the Company&#146;s next financing subsequent to April 2014 in an amount up to $2.0 million at 90.0% of the per unit price of the
related financing (see Note 3). The subsequent financing occurred in June 2015 and, as Roche elected not to exercise its option, the option expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As consideration for the agreements, Roche made nonrefundable upfront payments aggregating to $2.0&nbsp;million in 2014 and paid annual
nonrefundable maintenance fees of $1.0 million in 2015. Due to the cooperative nature of the development plans as driven by the joint steering committee and the partial defrayment of development costs, the nonrefundable payments were considered
reductions to research and development expense. Upon receipt, the payments the Company received in 2014 and 2015 from Roche were deferred and were recognized as reductions to research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company provided notification to Roche that it intended to terminate its Research and Development Agreement with Roche based
on its rights under the agreement, effective August 2016, resulting in a recognition of the remaining deferred advance research and development payments. There was no termination fee required under the agreement. Related to payments received under
the concluded collaboration, the Company recognized reductions of research and development expense of $1.5 million and $0.9 million for the years ended December&nbsp;31, 2015 and 2016, respectively, and $0.7 million for the six months ended June 30,
2016 (unaudited). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MGH License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2014, the Company entered into a license agreement with The General Hospital Corporation, doing business as Massachusetts
General Hospital, (&#147;MGH&#148;) to obtain an exclusive worldwide license to research, develop, manufacture and sell products based on technology related to inhibitors of bacteria quorum sensing and technology pertaining to the methods for
identifying compounds for treating, reducing or preventing pathogenic infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon signing of the license agreement, the Company
issued to MGH 150,000 common units. The Company also agreed to reimburse MGH for all patent costs related to the exclusive patent for the duration of the agreement. In November 2016, the Company terminated its license agreement with MGH. There were
no termination payments required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ascenion License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September&nbsp;2014, the Company entered into a license agreement with Ascenion GmbH (formerly known as Helmholtz Zentrum fur
Infektionsforschung GmbH) to obtain an exclusive worldwide license to research, develop, manufacture and sell products based on Ascenion&#146;s PqsR modulator technology. Upon signing of the license agreement, the Company issued to Ascenion 58,495
common units. In November 2016, the Company terminated its license agreement with Ascenion. There were no termination payments required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aviragen
Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s agreement with Aviragen (see Note 9) for certain intellectual property and know-how relating
to developing a gyrase inhibitor to develop therapies for Gram-negative infections, the Company is obligated to make milestone payments of up to an aggregate of $12.0 million upon the achievement of specified clinical, regulatory and commercial
milestones and to pay royalties of low single-digit percentages based on net sales of products the Company acquired under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cantab License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Cantab Agreements (see Note 9), the Company is obligated to make milestone payments of up to $5.8&nbsp;million upon the achievement
of specified clinical and regulatory milestones and a payment of &pound;5.0&nbsp;million ($6.2&nbsp;million as of December&nbsp;31, 2016 and $6.5&nbsp;million as of June&nbsp;30, 2017 (unaudited)) upon the achievement of a specified commercial
milestone. In addition, the Company has agreed to pay to PBB royalties, on a product-by-product and country-by-country basis, of a low single-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Cantab Agreements continue indefinitely, with royalty payment obligations thereunder continuing on a product-by-product and
country-by-country basis until the later of ten years after the first commercial sale of such product in such country or the expiration in such country of the last to expire valid claim of any of the applicable patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vertex License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May
2016, the Company entered into an agreement with Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;) whereby Vertex granted the Company certain know-how and a sublicense to research, develop, manufacture and sell products for a proprietary
compound, as well as a transfer of materials. In exchange for the know-how, sublicense and materials, Spero paid Vertex an upfront, one-time, nonrefundable, non-creditable fee of $0.5&nbsp;million, which was recognized as research and development
expense. As part of the agreement, the Company is obligated to make future milestone payments of up to $81.1&nbsp;million upon the achievement of specified clinical, regulatory and commercial milestones and to pay Vertex tiered royalties, on a
product-by-product and country-by-country basis, of a mid single-digit to low double-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder, with royalty payment obligations continuing on a
product-by-product and country-by-country basis until the later of a specified period after the first commercial sale of such product in such country or the date of expiration in such country of the last to expire applicable patent. Further, Vertex
has the right to terminate the agreement if provided with notification from the Company of intent to cease all development or if no material development or commercialization efforts occur for one year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meiji License Agreement </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
June 2017, the Company entered into agreements with Meiji Seika Pharma Co. Ltd. (&#147;Meiji&#148;), a Japanese corporation, whereby Meiji granted to the Company certain know-how and a license to research, develop, manufacture and sell products for
a proprietary compound in the licensed territory. In exchange for the know-how and license, the Company paid Meiji an upfront, one-time, nonrefundable, non-creditable fee of $0.6&nbsp;million, which was recognized as research and development
expense. As part of the agreement, the Company is obligated to make milestone payments of up to $3.0 million upon the achievement of specified clinical and regulatory milestones, to pay royalties, on a product-by-product and country-by-country
basis, of a low single-digit percentage based on net sales of products licensed under the agreement and to pay Meiji a low double-digit percentage of any sublicense fees received by the Company up to $7.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder (including royalty payments and licensee revenue)
on a product-by-product and country-by-country basis, unless earlier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminated by the parties. Pursuant to the terms of the agreement, in addition to each party&#146;s right to terminate the agreement upon the other party&#146;s material breach (if not cured
within a specified period after receipt of notice) or insolvency, the Company also has unilateral termination rights (i)&nbsp;in the event that the Company abandons the development and commercialization of SPR994 for efficacy, safety, legal or
business factors, and (ii)&nbsp;under certain circumstances arising out of the head license with a global pharmaceutical company. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Northern
License Agreement </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, in connection with the repurchase of all of the outstanding shares of Spero Potentiator (see
Note&nbsp;9), the Company amended its license agreement with Northern such that the Company agreed to pay Northern up to $7.0&nbsp;million upon the achievement of specified clinical, regulatory and other milestones, including a total payment of $2.5
million upon the closing of an initial public offering. In addition, under an exchange agreement the Company entered into with Northern, the Company is obligated to make a payment to Northern of $0.1&nbsp;million upon the closing of an initial
public offering. The agreement has a perpetual term and no express termination rights. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Australia Research and Development Tax Incentive
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Australian government has established a research and development tax incentive to encourage industry investment in research and
development, which is available to companies incorporated under Australian law that have core research and development activities. In September 2016, the Company established Spero Potentiator Australia Pty Limited to carry out certain research and
development activities. As this subsidiary meets the eligibility requirements of the Australian tax law, it is eligible to receive a 43.5% tax incentive for qualified research and development activities. For the year ended December&nbsp;31, 2016 and
the six months ended June&nbsp;30, 2017 (unaudited), $0.1 million and $0.7 million, respectively, was recorded as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss associated with
this tax incentive, representing 43.5% of the Company&#146;s qualified research and development spending in Australia. The refund is denominated in Australian dollars and, therefore, the receivable is re-measured to U.S. dollars as of each reporting
date. As of December&nbsp;31, 2016 and June&nbsp;30, 2017 (unaudited), the Company&#146;s tax incentive receivables from the Australian government totaled $0.1 million and $0.8 million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Net Loss and Unaudited Pro Forma Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic and
diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. was calculated as follows (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to non-controlling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Accretion of bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s potential dilutive securities, which include redeemable convertible preferred stock and
incentive units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and
diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of
diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares (as converted to common shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,929,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,465,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,684,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,061,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,014,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,929,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. for the year
ended December&nbsp;31, 2016 and the six months ended June&nbsp;30, 2017 have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been prepared to give effect to adjustments arising upon the closing of a qualified initial public offering. The unaudited pro forma net loss attributable to common stockholders of Spero
Therapeutics, Inc. used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. does not include the effects of the cumulative dividends on preferred shares or
the accretion of bridge units and redeemable convertible preferred shares to redemption value because the calculation gives effect to the automatic conversion of all shares of redeemable convertible preferred stock outstanding as of June&nbsp;30,
2017 into shares of common stock as if the proposed initial public offering had occurred on the later of January&nbsp;1, 2016 or the issuance date of the redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted weighted average common shares outstanding used in the calculation of unaudited pro forma basic and
diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. for the year ended December&nbsp;31, 2016 and the six months ended June&nbsp;30, 2017 have been prepared to give effect, upon a qualified initial public
offering, to the automatic conversion of all outstanding shares of redeemable convertible preferred stock into common stock as if the proposed initial public offering had occurred on the later of January&nbsp;1, 2016 or the issuance date of the
redeemable convertible preferred shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share attributable to common stockholders
of Spero Therapeutics, Inc. was calculated as follows (in thousands, except share and per share data): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:64.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended<BR>December&nbsp;31,&nbsp;2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:63.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accretion of bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect automatic conversion of redeemable convertible preferred stock
upon the closing of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,989,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,118,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,886,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,140,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders of Spero Therapeutics, Inc.,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Retirement Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has a defined-contribution plan under Section&nbsp;401(k) of the Internal Revenue Code (the &#147;401(k) Plan&#148;). The 401(k)
Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
established, the Company is not required to make and to date has not made any contributions to the 401(k) Plan. The Company did not make any matching contributions during the years ended
December&nbsp;31, 2015 and 2016 or during the six months ended June&nbsp;30, 2016 and 2017 (unaudited). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For its consolidated financial statements as of December&nbsp;31, 2016 and for the year then ended and for its interim consolidated financial
statements as of June&nbsp;30, 2017 and for the six months then ended, the Company evaluated subsequent events through August 25, 2017, the date on which those financial statements were issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant of Stock Options under 2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company granted options for the purchase of 9,373,425 shares of common stock at an exercise price of $0.97 per share under
the 2017 Stock Incentive Plan, of which options for the purchase of 2,353,753 shares of common stock were considered for accounting purposes to be modified options of the incentive units cancelled in connection with the Reorganization (see Note 8).
The incremental fair value of the replacement options, based on the positive difference between the fair value of the modified award and the fair value of the original award immediately before it was modified is not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase of Non-Controlling Interest in Spero Cantab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company repurchased all of the outstanding shares of Spero Cantab owned by PBB in exchange for a cash payment of $0.2
million and an amendment to the licensing agreement to increase the first two contingent milestone payments by a total of $0.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adjustment to Conversion Prices of Series A and Series B Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, after the consummation of the Reorganization, the Company sold to its Chief Financial Officer 61,880 shares of the
Company&#146;s Series C preferred stock at a price of $1.7749 per share, for proceeds of $0.1 million. Because the price per share of the Series C preferred stock in this transaction was lower than the Conversion Price of the Company&#146;s Series A
and Series B preferred stock, in accordance with the Company&#146;s certificate of incorporation, as amended and restated, the Conversion Price of Series A preferred stock was adjusted from $2.5622 to $2.5612 per share and the Conversion Price of
Series B preferred stock was adjusted from $2.7521 to $2.7508 per share. The Conversion Price for Junior preferred stock was not adjusted according to its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold
allotment or subscription. </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g431217g74a40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Merrill Lynch </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Cowen </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in
connection with the sale of the common stock being registered. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and
The NASDAQ Global Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(a) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees) actually
and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the
corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other
adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other
adjudicating court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(g) of the Delaware General Corporation Law provides, in general, that a
corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the
corporation would have the power to indemnify the person against such liability under Section&nbsp;145 of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will become effective upon completion of this offering provides that no director of
our company shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (1)&nbsp;for any breach of the director&#146;s duty of loyalty to us or our stockholders,
(2)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;in respect of unlawful dividend payments or stock redemptions or repurchases, or (4)&nbsp;for any transaction from which
the director derived an improper personal benefit. In addition, our amended and restated certificate of incorporation provides that if the Delaware General Corporation Law is amended to authorize the further elimination or limitation of the
liability of directors, then the liability of a director of our company shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The amended and restated certificate of incorporation further provides that any repeal or modification of such article by our stockholders or
amendment to the Delaware General Corporation Law will not adversely affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director
serving at the time of such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will
become effective upon completion of this offering provide that we will indemnify each of our directors and officers and, in the discretion of our board of directors, certain employees, to the fullest extent permitted by the Delaware General
Corporation Law as the same may be amended (except that in the case of amendment, only to the extent that the amendment permits us to provide broader indemnification rights than the Delaware General Corporation Law permitted us to provide prior to
such the amendment) against any and all expenses, judgments, penalties, fines and amounts reasonably paid in settlement that are incurred by the director, officer or such employee or on the director&#146;s, officer&#146;s or employee&#146;s behalf
in connection with any threatened, pending or completed proceeding or any claim, issue or matter therein, to which he or she is or is threatened to be made a party because he or she is or was serving as a director, officer or employee of our
company, or at our request as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, if he or she acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of our company and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. Article
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> further provides for the advancement of expenses to each of our directors and, in the discretion of
our board of directors, to certain officers and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the amended and restated
<FONT STYLE="white-space:nowrap">by-laws</FONT> provide that the right of each of our directors and officers to indemnification and advancement of expenses shall be a contract right and shall not be exclusive of any other right now possessed or
hereafter acquired under any statute, provision of the amended and restated certificate of incorporation or amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> agreement, vote of stockholders or otherwise. Furthermore, Article
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> authorizes us to provide insurance for our directors, officers and employees, against any liability,
whether or not we would have the power to indemnify such person against such liability under the Delaware General Corporation Law or the provisions of Article &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the amended
and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the sale of common stock being registered hereby, we
have entered into indemnification agreements with each of our directors and our executive officers. These agreements will provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we will indemnify each of our directors and such officers to the fullest extent permitted by law and the amended and restated certificate of incorporation and amended and restated <FONT
STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also maintain a general liability insurance policy, which covers certain liabilities of
directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the
meaning of the Securities Act of 1933, as amended, against certain liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;15. RECENT SALES OF UNREGISTERED SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under
the Securities Act of 1933, as amended, or the Securities Act: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2014, we issued and sold 1,531,148 bridge units to investors
upon the conversion of convertible notes in a total amount of $1,531,148. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2014, we issued 150,000 common units to MGH as
consideration in connection with entering into a license agreement with MGH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 3,438,318 junior
preferred units, consisting of (i) 1,500,000 junior preferred units issued and sold at a price per unit of $1.00 for an aggregate purchase price of $1.5&nbsp;million, and (ii) 1,938,318 junior preferred units issued upon the conversion of the 2014
bridge units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2014, we issued 58,495 common units to Ascenion, as consideration in connection with entering into a license
agreement with Ascenion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2015, we issued and sold 8,000 bridge units to existing investors at a price per unit of $1,000 for
an aggregate purchase price of $8.0&nbsp;million. Such bridge units were subsequently exchanged for <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, we issued an aggregate of 4,202,278 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units, consisting of (i)
2,279,202 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued to existing investors in exchange for 8,000 bridge units, and (ii) 1,923,076 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued and
sold at a price per unit of $3.90 for an aggregate purchase price of approximately $7.5&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units were subsequently reclassified as Class&nbsp;A preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, we issued and sold 5,909,089 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units at a price per unit of
$4.40, for an aggregate purchase price of approximately $26.0&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units were subsequently reclassified as Class&nbsp;B preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2016, we issued and sold 8,500 bridge units at a price per unit of $1,000 for an aggregate purchase price of approximately
$8.5&nbsp;million. Such bridge units were subsequently converted into Class&nbsp;C preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we issued an aggregate
of 29,647,582 Class&nbsp;C preferred units, consisting of (i) 5,321,112 Class&nbsp;C preferred units in exchange for 8,500 bridge units and (ii) 24,326,470 Class&nbsp;C preferred units at a price per unit of $1.7749 for an aggregate purchase price
of approximately $43,177,052. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, as part of the Reorganization, each of the capital units of Spero
Therapeutics, LLC issued and outstanding prior to the Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, after the consummation of the Reorganization, we sold to Joel Sendek, our Chief Financial Officer, 61,880 shares of our Series C
preferred stock, at a purchase price of $1.7749 per share, for an aggregate purchase price of $109,831. Such purchase and sale was made in accordance with the terms of Mr.&nbsp;Sendek&#146;s offer letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization, we had granted a total of 2,621,636 incentive units to our employees, directors, and consultants, pursuant to the
operating agreement of Spero Therapeutics, LLC, as amended, at threshold prices ranging between $0.21 and $0.96 per incentive unit. In connection with the Reorganization, such incentive units were cancelled as they were deemed to be valueless based
on a liquidation valuation basis for federal income tax purposes and pursuant to contractual rights under the operating agreement of Spero Therapeutics, LLC. Promptly after the Reorganization, previous holders of incentive units who were still
employed by us at the time of the Reorganization received stock options under the 2017 Plan. Such stock options were granted for the same number of shares of our common stock as the number of incentive units cancelled, and the stock options were
granted on the same vesting terms and with similar rights and restrictions as the incentive units. Effective on July&nbsp;6, 2017, we granted stock options to purchase an aggregate of 9,187,971 shares of our common stock. All such stock options have
an exercise price of $0.97. Further, on July&nbsp;17, 2017, we granted to Frank Thomas, a newly appointed member of our board of directors, stock options to purchase 185,454 shares of our common stock, at an exercise price of $0.97 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No underwriters were used in the foregoing transactions, and no discounts or commissions were paid. All sales of securities described above
were exempt from the registration requirements of the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act, Rule 701 promulgated under the Securities Act or Regulation D promulgated under the Securities Act, relating to
transactions by an issuer not involving a public offering. All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>(a) Exhibits. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See the
Exhibit Index attached to this registration statement, which is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>(b) Financial Statement Schedules.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial
statements or notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;17. UNDERTAKINGS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby
undertakes that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on the &nbsp;&nbsp;&nbsp;&nbsp; day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, the undersigned directors and officers of Spero Therapeutics, Inc., hereby severally constitute and appoint Ankit Mahadevia, M.D. and Joel
Sendek, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> filed herewith, and any and all <FONT STYLE="white-space:nowrap">pre-effective</FONT> and post-effective amendments to said registration statement, and any registration statement filed pursuant
to Rule&nbsp;462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of Spero Therapeutics, Inc., and to file or cause to be filed the same, with all
exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do
or cause to be done by virtue of this Power of Attorney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President and Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>Principal Executive Officer</I>)<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Ankit Mahadevia, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Joel Sendek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>Principal Financial Officer and Principal</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Accounting Officer</I>)<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Casper Breum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Milind Deshpande, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Jean-Fran&ccedil;ois Formela, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Vikas Goyal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Reza Halse, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Frank Thomas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Patrick Vink, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant (currently in effect).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant to be filed with the Secretary of State of the State of Delaware and effective upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.5*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Registrant to be effective upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investors&#146; Rights Agreement, dated as of June&nbsp;30, 2017, by and between the Registrant and the other parties thereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2017 Stock Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Stock Option Agreement under 2017 Stock Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Stock Agreement under 2017 Stock Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Director and Officer Indemnification Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, by and between the Registrant and Ankit Mahadevia, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, by and between the Registrant and Joel Sendek.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, by and between the Registrant and Thomas Parr Jr., Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, by and between the Registrant and Cristina Larkin.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated June&nbsp;24, 2015, by and between the Registrant and John Tomayko, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Termination and Release, dated April&nbsp;14, 2017, by and between the Registrant and John Tomayko, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lease Agreement, dated August&nbsp;24, 2015, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC with respect to 675 Massachusetts Avenue.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sublease, dated July&nbsp;6, 2016, by and between the Registrant and Tetraphase Pharmaceuticals, Inc. with respect to 480 Arsenal Street.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stock Purchase Agreement, dated June&nbsp;6, 2016, by and among Spero Cantab, Inc., the Registrant, Spero Cantab UK Limited, PBB Distributions Limited, New Pharma License Holdings Limited, Cantab Anti-Infectives Ltd and Pro Bono Bio
PLC, as amended by Amendment to Stock Purchase Agreement, dated July 18, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Assignment and License Agreement, dated May&nbsp;9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15#**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated June 14, 2017, by and between the Registrant and Meiji Seika Pharma Co., Ltd., as supplemented by Addendum to License Agreement, dated June 14, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16#**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter of KPMG LLP, dated August 25, 2017, regarding changes in the Registrant&#146;s certifying accountants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit&nbsp;5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment is being requested for portions of this exhibit. These portions have been omitted from the registration statement and have been filed separately with the Securities and Exchange Commission.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Denotes management compensation plan or contract. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX10_4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>THIS INDEMNIFICATION AGREEMENT (&#147;<B>Agreement</B>&#148;) is made as of [&#9679;], 2017 by and between SPERO THERAPEUTICS, INC., a
Delaware corporation (the &#147;<B>Company</B>&#148;), and [&#9679;] (the &#147;<B>Indemnitee</B>&#148;). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this
Agreement. <B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities
unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>WHEREAS, the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) has determined that, in order to attract and retain
qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance
has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at
higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among
other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The certificate of incorporation of the Company (as the same may be amended from time to time, the &#147;<B>Certificate of
Incorporation</B>&#148;) requires indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;). The
Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of
directors, officers and other persons with respect to indemnification; <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the uncertainties relating to such insurance and
to indemnification have increased the difficulty of attracting and retaining such persons; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board has determined that the
increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection
in the future; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to
advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation
and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; [and] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present
circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service
for or on behalf of the Company on the condition that he be so indemnified; [and] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[WHEREAS, Indemnitee is a representative of [&#9679;]
[and its affiliated investment funds] (the &#147;<B>Fund</B>&#148;), and has certain rights to indemnification and/or insurance provided by the Fund which Indemnitee and the Fund intend to be secondary to the primary obligation of the Company to
indemnify Indemnitee as provided herein, with the Company&#146;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#146;s willingness to serve on the Board;]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and
agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee agrees to serve as a[n] [director] [and] [officer] of the
Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to
continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee&#146;s employment
with the Company (or of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between
Indemnitee and the Company (or of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation,
the Company&#146;s Bylaws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a[n] [director] [or] [officer] of the Company, as provided in Section&nbsp;16 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) References to &#147;<B>agent</B>&#148; shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary
of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability
company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Include this recital and the other bracketed provisions where indicated throughout if the Indemnitee is affiliated with a venture capital fund or other entity that provides indemnification to the Indemnitee.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) A &#147;<B>Change in Control</B>&#148; shall be deemed to occur upon the earliest to occur
after the date of this Agreement of any of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. <U>Acquisition of Stock by Third Party</U>. Any Person (as defined
below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing forty percent (40%)&nbsp;or more of the combined voting power of the Company&#146;s then outstanding securities unless
the change in relative Beneficial Ownership of the Company&#146;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. <U>Change in Board of Directors</U>. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution
of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in
Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the
beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. <U>Corporate Transactions</U>. The effective date of a merger or consolidation of the Company with any other entity, other than a merger
or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or its ultimate parent, as applicable) more than 51% of the combined voting power of the voting securities of the surviving entity or its ultimate parent, as applicable, outstanding immediately after such merger or consolidation and
with the power to elect at least a majority of the board of directors or other governing body of such surviving entity or its ultimate parent, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. <U>Liquidation or Sale of Assets</U>. The approval by the stockholders of the Company of a complete liquidation of the Company or an
agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">v. <U>Other
Events</U>. There occurs any other event of a nature that would be required to be reported in response to Item&nbsp;6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the
Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;2(b), the
following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) &#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as
amended from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(B) &#147;<B>Person</B>&#148; shall have the meaning as set forth in Sections 13(d) and
14(d) of the Exchange Act; provided, however, that Person shall exclude (i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any corporation owned, directly
or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(C) &#147;<B>Beneficial Owner</B>&#148; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided,
however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(D) &#147;<B>Corporate Status</B>&#148; describes the status of a person as a current or former director or officer of the Company or
as a current or former director, manager, partner, officer, employee, agent, or trustee of any other entity or enterprise that such person is or was serving at the request of the Company. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(E) &#147;<B>Disinterested Director</B>&#148; shall mean a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(F) &#147;<B>Enterprise</B>&#148; shall mean the Company and any
other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or
fiduciary. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(G) &#147;<B>Expenses</B>&#148; shall include all reasonable attorneys&#146; fees, retainers, court costs,
transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on
Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i)&nbsp;Expenses incurred in connection with any appeal resulting from any Proceeding,
including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii)&nbsp;for purposes of Section&nbsp;14(d) only, Expenses incurred by Indemnitee in
connection with the interpretation, enforcement or defense of Indemnitee&#146;s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written
demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee&#146;s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall
not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(H) &#147;<B>Independent Counsel</B>&#148; shall mean a law firm, or a member of a law
firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than with respect to
matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term &#147;<B>Independent Counsel</B>&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee
in an action to determine Indemnitee&#146;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses,
claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(I) The
term &#147;<B>Proceeding</B>&#148; shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or
any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal
therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him (or a
failure to take action by him) or of any action (or failure to act) on his part while acting pursuant to his Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which
indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a
Proceeding under this paragraph. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(J) Reference to &#147;<B>other enterprise</B>&#148; shall include employee benefit
plans; references to &#147;<B>fines</B>&#148; shall include any excise tax assessed with respect to any employee benefit plan; references to &#147;serving at the request of the Company&#148; shall include any service as a director, officer, employee
or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he
reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner &#147;not opposed to the best interests of the Company&#148; as referred to in this Agreement.
<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company shall indemnify Indemnitee in accordance with the
provisions of this Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this
Section&nbsp;3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in
connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that
his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification
provided by the Certificate of Incorporation, the Bylaws, vote of its stockholders or disinterested directors or applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The Company shall indemnify Indemnitee in accordance with
the provisions of this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;4, Indemnitee
shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in
good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to which Indemnitee
shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#147;Delaware Court&#148;) or any court in which the Proceeding was brought shall determine upon
application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such Expenses as the Delaware Court or other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provisions of
this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter
therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or
otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each
successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice,
shall be deemed to be a successful result as to such claim, issue or matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Indemnification For Expenses of a
Witness</U>. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any
Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Partial Indemnification</U>. If Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. Additional Indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by
applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with
the Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) For purposes of Section&nbsp;8(a), the meaning of the phrase &#147;to the fullest extent permitted by applicable
law&#148; shall include, but not be limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. to the fullest extent permitted by the provision of the DGCL that authorizes or
contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement
that increase the extent to which a corporation may indemnify its officers and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Exclusions</U>.
Notwithstanding any provision in this Agreement [but subject to Section&nbsp;15(e), however], the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) (for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except
with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) for (i)&nbsp;an
accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act (as defined in Section&nbsp;2(b) hereof) or similar provisions of
state statutory law or common law, or (ii)&nbsp;any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the
Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley
Act</B>&#148;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) except as provided in Section&nbsp;14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by
Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any part of any
Proceeding) prior to its initiation or (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Advances of Expenses</U>. Notwithstanding any provision of this Agreement to
the contrary (other than Section&nbsp;14(d)), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such
advancement shall be made within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be
unsecured and interest free. Advances shall be made without regard to Indemnitee&#146;s ability to repay the Expenses and without regard to Indemnitee&#146;s ultimate entitlement to indemnification under the other provisions of this Agreement. In
accordance with Section&nbsp;14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support
the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without
interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section&nbsp;10 shall not
apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Procedure for
Notification and Defense of Claim</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee
intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature
of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably
available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder will
not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement.
The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Company will be entitled to participate in the Proceeding at its own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Procedure Upon Application for Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;11(a), a determination, if required by applicable law,
with respect to Indemnitee&#146;s entitlement thereto shall be made in the specific case: (i)&nbsp;if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to
Indemnitee; or (ii)&nbsp;if a Change in Control shall not have occurred, (A)&nbsp;by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B)&nbsp;by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C)&nbsp;if there are no such Disinterested
Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D)&nbsp;if so directed by the Board, by the stockholders of the Company; and, if
it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10)&nbsp;days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with
respect to Indemnitee&#146;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and
which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&#146; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making
such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly
will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a)
hereof, the Independent Counsel shall be selected as provided in this Section&nbsp;12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee
advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in
which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within
ten (10)&nbsp;days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; <U>provided</U>, <U>however</U>, that such objection may be asserted
only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;<B>Independent Counsel</B>&#148; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity the factual
basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel
unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20)&nbsp;days after the later of submission by Indemnitee of a written request for indemnification pursuant to
Section&nbsp;11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall
have been made by the Company or Indemnitee to the other&#146;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the
person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to
Section&nbsp;14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U>Presumptions and Effect of Certain Proceedings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;11(a) of this
Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.
Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because
Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action
or create a presumption that Indemnitee has not met the applicable standard of conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;14(e), if the person,
persons or entity empowered or selected under Section&nbsp;12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60)&nbsp;days after receipt by the Company of the
request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i)&nbsp;a misstatement
by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under
applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30)&nbsp;days, if the person, persons or entity making the determination with respect to entitlement to
indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section&nbsp;13(b) shall not apply
(i)&nbsp;if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section&nbsp;12(a) of this Agreement and if (A)&nbsp;within fifteen (15)&nbsp;days after receipt by the Company of the request for such
determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75)&nbsp;days after such receipt and such determination is made thereat, or
(B)&nbsp;a special meeting of stockholders is called within fifteen (15)&nbsp;days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60)&nbsp;days after having been so called and
such determination is made thereat, or (ii)&nbsp;if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea
of <U>nolo</U> <U>contendere</U> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests
of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&#146;s action is
based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for
the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The provisions of this
Section&nbsp;13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee
of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Remedies of Indemnitee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;14(e), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;12 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;10 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been
made pursuant to Section&nbsp;12(a) of this Agreement within ninety (90)&nbsp;days after receipt by the Company of the request for indemnification, (iv)&nbsp;payment of indemnification is not made pursuant to Section&nbsp;5, 6 or 7 or the last
sentence of Section&nbsp;12(a) of this Agreement within ten (10)&nbsp;days after receipt by the Company of a written request therefor, (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3, 4 or 8 of this Agreement is not made within ten
(10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, or (vi)&nbsp;in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable,
or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court
of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American
Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this
Section&nbsp;14(a); <U>provided</U>, <U>however</U>, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section&nbsp;5 of this Agreement. The Company shall not oppose
Indemnitee&#146;s right to seek any such adjudication or award in arbitration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to Section&nbsp;12(a) of this
Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 shall be conducted in all respects as a <U>de</U> <U>novo</U> trial, or arbitration, on the merits and
Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14, the Company shall have the burden of proving Indemnitee is not </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to Section&nbsp;12(a) of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to
make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration
commenced pursuant to this Section&nbsp;14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the
provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of
Indemnitee&#146;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent
permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such
Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#146; and officers&#146; liability
insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to
the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding
anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Non-exclusivity; Survival of Rights; Insurance; Subrogation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any
other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of
this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of
Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other
right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy
hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) To the extent that
the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the
maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer
liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee [(other than any rights of recovery of Indemnitee from a Fund Indemnitor (as defined in Section&nbsp;15(e) hereof) or under any insurance provided by the Fund or its affiliates)], who shall execute all papers required and take
all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) [Except as provided for under Section&nbsp;15(e) of this Agreement, the] The Company shall not be liable under this Agreement to make any
payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance
provided by the Fund and certain of its affiliates (collectively, the &#147;<B>Fund Indemnitors</B>&#148;). The Company hereby agrees (i)&nbsp;that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any
obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii)&nbsp;that it shall be required to advance the full amount of Expenses incurred by
Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws (or any agreement between
the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii)&nbsp;that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund
Indemnitors for contribution, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any
claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of
recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms hereof.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Company&#146;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company
as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount
Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust or other enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Duration of Agreement</U>. This Agreement shall continue until and terminate upon the later of: (a)&nbsp;ten
(10)&nbsp;years after the date that Indemnitee shall have ceased to serve as a [director] [or] [officer] of the Company or (b)&nbsp;one (1)&nbsp;year after the final termination of any Proceeding then pending in respect of which Indemnitee is
granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section&nbsp;14 of this Agreement [or by a Fund Indemnitor pursuant to Section&nbsp;15(e) of this Agreement, in either
case,] relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including
any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of
the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Severability</U>. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable
for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be
invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision or provisions
shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without
limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. Enforcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof, including without limitation any previous indemnification agreements, which are hereby terminated in full;
provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Modification and Waiver</U>. No supplement, modification or amendment of this Agreement shall be binding
unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Notice by Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons,
citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company
shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21.
<U>Notices</U>. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a)&nbsp;delivered by hand and receipted for by the party to whom said notice or other
communication shall have been directed, (b)&nbsp;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c)&nbsp;mailed by reputable overnight courier and receipted for by the
party to whom said notice or other communication shall have been directed or (d)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">675
Massachusetts Avenue, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any
other address as may have been furnished to Indemnitee by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Contribution</U>. To the fullest extent permissible under applicable law, if
the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the
circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding;
and/or (ii)&nbsp;the relative fault of the Company (and its other directors, officers, employees and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23. <U>Applicable Law and Consent to Jurisdiction</U>. This Agreement and the legal relations among the parties shall be governed
by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;14(a) of this Agreement, the
Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court
in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement,
(iii)&nbsp;appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably the Corporation Trust Center as its agent in the State of Delaware as such party&#146;s agent for acceptance of legal
process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such
action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Identical Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;25. <U>Miscellaneous</U>. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun
where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>The remainder of this page is intentionally left blank.</I>]<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties executed this Agreement as of the day and year first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SPERO THERAPEUTICS, INC.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INDEMNITEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Indemnification Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STOCK PURCHASE AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SPERO CANTAB, INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SPERO
CANTAB UK LIMITED, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SPERO THERAPEUTICS, LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PBB DISTRIBUTIONS LIMITED, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NEW
PHARMA LICENSE HOLDINGS LIMITED, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CANTAB ANTI-INFECTIVES LTD, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRO BONO BIO PLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of June&nbsp;6, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this
Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. </I></B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This STOCK PURCHASE AGREEMENT, dated as of June&nbsp;6, 2016 (this
&#147;<U>Agreement</U>&#148;), is among SPERO CANTAB, INC., a Delaware corporation (&#147;<U>Spero</U>&#148;); SPERO CANTAB UK LIMITED, a company organized under the laws of England and Wales, having registration number 10175336 and a wholly-owned
subsidiary of Spero (&#147;<U>Purchaser</U>&#148;); solely for purposes of Section&nbsp;7.14, SPERO THERAPEUTICS, LLC, a Delaware limited liability company<B><I> </I></B>(&#147;<U>Spero Therapeutics</U>&#148;); PBB DISTRIBUTIONS LIMITED, a company
organized under the laws of Malta and having registration number C 75891 and a wholly-owned subsidiary of Parent (&#147;<U>Seller</U>&#148;); NEW PHARMA LICENSE HOLDINGS LIMITED, a company organized under the laws of Malta and having registration
number C47138 (the &#147;<U>Company</U>&#148;); CANTAB ANTI-INFECTIVES LTD, a company organized under the laws of England and having registration number 8217622 (&#147;<U>CAI</U>&#148;); and, solely for purposes of Article VI, PRO BONO BIO PLC, a
company organized under the laws of England and having registration number 8705972 (&#147;<U>Parent</U>&#148;). Capitalized terms used herein have the meanings ascribed to them in Section&nbsp;7.07. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent is the owner of all of the issued and outstanding ordinary shares of PBB (Malta) Limited, a company organized under the laws
of Malta and having registration number C62504, which, in turn, is the owner of all of the issued share capital of the Seller; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS,
Seller is the owner of all of the issued share capital of the Company (the &#147;<U>Transferred Shares</U>&#148;) and all of the issued and outstanding shares of capital stock of CAI; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company is the owner of certain intellectual property relating to the research, development and commercialization of polymyxins
to treat bacterial infections, as more particularly described in <U>Exhibit A</U> attached hereto (collectively, the &#147;<U>Program IP</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, Seller desires to sell, and Purchaser desires to purchase, all of the Transferred Shares, upon the terms and subject to the
conditions set forth in this Agreement (the &#147;<U>Acquisition</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, CAI is party to a certain Award/Contract with the
National Institute of Allergy and Infectious Diseases (&#147;<U>NIAID</U>&#148;), Contract Number HHSN272201500014C, dated effective July&nbsp;1, 2015 (the &#147;<U>NIAID Contract</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Acquisition, CAI desires to assign to Purchaser, and Purchaser desires to assume from CAI, the NIAID Contract,
upon the terms and subject to the conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and mutual
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Purchase and Sale of Transferred Shares </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.01 <U>Purchase and Sale</U>. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall
sell to Purchaser with full title guarantee, and Purchaser shall purchase from Seller, all of Seller&#146;s right, title and interest in and to the Transferred Shares, free and clear of all claims, charges, liens, contracts, rights, options,
security interests, mortgages, encumbrances, precautionary warrants, executive warrants and restrictions of every kind and nature (collectively, &#147;<U>Liens</U>&#148;), for a purchase price (the &#147;<U>Purchase Price</U>&#148;) consisting of
(i) one hundred twenty-five (125) shares of Spero&#146;s common stock, $0.001 par value per share, which shares shall be issued by Spero to Seller on the Closing Date pursuant to a Subscription Agreement in substantially the form attached hereto as
<U>Exhibit B</U> (the &#147;<U>Subscription Agreement</U>&#148;, and the shares to be issued thereunder, the &#147;<U>Equity Consideration</U>&#148;), and which Equity Consideration represents twelve and one-half percent (12.5%) of the Fully Diluted
Shares (as such term is defined in the Subscription Agreement), (ii) the Upfront Consideration, payable in accordance with Section&nbsp;1.02 below, (iii)&nbsp;the Milestone Consideration, payable in accordance with Section&nbsp;1.03 below,
(iv)&nbsp;the Royalty Payments, payable in accordance with Section&nbsp;1.04 below and (v)&nbsp;the NIAID Payments, payable in accordance with Section&nbsp;1.05 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.02 <U>Upfront Consideration</U>. At the Closing, Purchaser shall pay to Seller an amount in cash equal to Three Hundred Thousand
Dollars ($300,000) (the &#147;<U>Upfront Consideration</U>&#148;), which shall be creditable against Purchaser&#146;s obligation to make NIAID Payments under Section&nbsp;1.05 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.03 <U>Milestone Consideration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Milestone Events</U>. Upon the occurrence of each of the events (each, a &#147;<U>Milestone Event</U>&#148;) set forth in the table
below (the &#147;<U>Milestone Table</U>&#148;), Purchaser shall pay to Seller the corresponding amount set forth opposite such Milestone Event in the Milestone Table (each such payment, a &#147;<U>Milestone Payment</U>&#148;, and collectively, the
&#147;<U>Milestone Consideration</U>&#148;) in accordance with Section&nbsp;1.03(b) below. Milestone Events&nbsp;(i)(A) through (and including) (i)(E)&nbsp;set forth in the Milestone Table are referred to in this Agreement as &#147;<U>Regulatory
Milestone Events</U>&#148; and Milestone Event&nbsp;(ii)(A) set forth in the Milestone Table below is referred to in this Agreement as the &#147;<U>[***] Milestone Event</U>&#148;. Payment in respect of the [***] Milestone Event is referred to in
this Agreement as the &#147;<U>[***] Milestone Payment</U>&#148;. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:52.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Milestone&nbsp;Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><U>Milestone<BR></U>Payment</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Regulatory Milestone Events</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(ii)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>[***] Milestone Event</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&pound;5,000,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Milestone Payments shall be payable a maximum of one (1)&nbsp;time only even if achieved more than one
(1)&nbsp;time with one or more Products. For the avoidance of doubt, (x)&nbsp;each of the Milestone Payments shall become payable upon the occurrence of the associated Milestone Event, irrespective of the order in which the Milestone Events occur
relative to each other, and (y)&nbsp;no amounts shall be due for subsequent or repeated achievements of any Milestone Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice
and Payment</U>. No later than ten (10)&nbsp;days after the end of the calendar month in which a Milestone Event occurs, Purchaser shall (i)&nbsp;provide written notice (a &#147;<U>Milestone Statement</U>&#148;) to Seller of the occurrence of such
Milestone Event and (ii)&nbsp;subject to Sections&nbsp;6.02(b) and 1.05(c), pay the corresponding Milestone Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.04
<U>Royalty Payments</U><U>. </U>During the Royalty Term, royalty payments (the &#147;<U>Royalty Payments</U>&#148;) shall be paid by Purchaser to Seller in accordance with this Section&nbsp;1.04. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Royalty Rates</U>. The amount of the Royalty Payments shall equal [***] percent ([***]%) of annual worldwide Net Sales of each Product;
<I>provided</I>,<I> however</I>, that if, at any time during the Royalty Term applicable to a Product, a Generic Product is sold to the general public by any person other than the Purchaser and its Affiliates or Commercial Licensees, then, from and
after the date of first sale of such Generic Product, the royalty rate payable with respect to sales of such Product shall be reduced, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis in
each country where such Generic Product is sold, to [***] percent ([***]%) of Net Sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Royalty Term</U>. The Royalty Payments
payable by Purchaser to Seller shall be paid on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of (i)&nbsp;the date which is ten (10)&nbsp;years after the First Commercial Sale of such Product in such country and
(ii)&nbsp;the expiration in such country of the last to expire Valid Claim of any of the Patents identified in paragraph 3.12(a) of the Disclosure Letter (collectively, the &#147;<U>Transferred Patents</U>&#148;) claiming such Product (the
&#147;<U>Royalty Term</U>&#148;). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Royalty Report and Payment</U>. During the Royalty Term, no later than [***] after the
end of each Calendar Quarter, Purchaser or its Affiliates shall pay to Seller the Royalty Payments payable for such Calendar Quarter and provide a royalty report (the &#147;<U>Royalty Report</U>&#148;) showing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) the Net Sales of each Product sold by (A)&nbsp;Purchaser and its Affiliates and (B)&nbsp;Purchaser&#146;s Commercial Licensees, in each
case during such Calendar Quarter; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) the Royalty Payments, reflected in Dollars, which shall have accrued hereunder with respect to any
Net Sales of each Product; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) withholding Taxes, if any, to be deducted with respect to such Royalty Payments; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) the rate of exchange, if applicable, as calculated using the average of the foreign currency exchange rate for converting the applicable
currency into Dollars as published by Bloomberg Business during the Calendar Quarter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Third Party Royalty <FONT
STYLE="white-space:nowrap">Set-Off</FONT></U>. If Purchaser or any of its Affiliates or Commercial Licensees obtains a license from a third party to an Infringed Patent after arm&#146;s length negotiations, Purchaser may offset up to [***] percent
([***]%) of any payments due thereunder with respect to sales of any Product against the royalty payments that are due to Seller with respect to Net Sales of such Product under this Section&nbsp;1.04; provided that in no event shall royalties paid
to Seller under this Section&nbsp;1.04 with respect to any such Product be reduced below [***] percent ([***]%) of the royalty rate applicable to such Product under Section&nbsp;1.04(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.05 <U>NIAID Contract.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Novation of NIAID Contract; Interim Payments</U>. Seller and CAI shall use commercially reasonable efforts to procure the novation of
the NIAID Contract, from CAI to Spero. During the period from the Closing Date until the earlier of (i)&nbsp;the effective date of the novation of the NIAID Contract from CAI to Spero and (ii)&nbsp;the expiration or termination of the NIAID Contract
(the &#147;<U>Interim Period</U>&#148;): (A) if requested to do so by Spero from time to time, Seller and CAI shall each use its commercially reasonable efforts to preserve all material rights of, and material benefits to, Seller and CAI under the
NIAID Contract, including, without limitation, receipt of the NIAID Contract Funding and (B)&nbsp;CAI shall continue work under the NIAID Contract as directed by Spero and consistent with the terms of the CAI Services Agreement (as defined in
Section&nbsp;1.06(b) below) and as otherwise provided in Section&nbsp;1.06 below. Once agreement by the counterparty to the NIAID contract for the novation of the NIAID Contract is obtained, CAI and Spero shall promptly enter into the novation
agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>NIAID Payments</U>. Purchaser shall make the following payments to Seller (collectively, the &#147;<U>NIAID
Payments</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Purchaser shall pay to Seller an amount equal to [***] percent ([***]%) of the total amount of
all NIAID Contract Funding actually received by the NIAID Recipient (as defined below) from time to time in respect of the Base Requirement, as defined in the NIAID Contract, payable in each case within [***] after the NIAID Recipient&#146;s receipt
from time to time of such NIAID Contract Funding; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of
this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Upon the attainment of the milestone of Option One, as defined in the
NIAID Contract, being exercised, Purchaser shall pay to Seller an amount equal to [***] percent ([***]%) of all NIAID Contract Funding actually received by the NIAID Recipient from time to time in respect of Option One, payable in each case within
[***] after the NIAID Recipient&#146;s receipt from time to time of such NIAID Contract Funding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Upon the attainment
of the milestone of Option Two, as defined in the NIAID Contract, being exercised, Purchaser shall pay to Seller an amount equal to [***] percent ([***]%) of all NIAID Contract Funding actually received by the NIAID Recipient from time to time in
respect of Option Two, payable in each case within [***] after the NIAID Recipient&#146;s receipt from time to time of such NIAID Contract Funding; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Upon the attainment of the milestone of Option Three, as defined in the NIAID Contract, being exercised, Purchaser shall
pay to Seller an amount equal to [***] percent ([***]%) of all NIAID Contract Funding actually received by the NIAID Recipient from time to time in respect of Option Three, payable in each case within [***] after the NIAID Recipient&#146;s receipt
from time to time of such NIAID Contract Funding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided, however, that the total amount payable by Purchaser under this
Section&nbsp;1.05(b) shall not exceed [***] Dollars ($[***]). Notwithstanding the foregoing, the Upfront Consideration shall be credited against Purchaser&#146;s payment obligations under this Section&nbsp;1.05(b) such that no amount shall be due
under this Section&nbsp;1.05(b) unless and until the total aggregate amount due under this Section&nbsp;1.05(b) exceeds the amount of the Upfront Consideration, and then only to the extent of such excess. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of this Section&nbsp;1.05(b), the &#147;<U>NIAID Recipient</U>&#148; is, pending novation of the NIAID Contract to Spero, CAI or any of its
Affiliates and, following novation of the NIAID Contract to Spero, Spero or any of its Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Offset for Upfront
Consideration</U>. In the event that the total aggregate amount of the NIAID Payments payable by Purchaser under this Section&nbsp;1.05 is less than the amount of the Upfront Consideration, then, notwithstanding anything in this Agreement to the
contrary, the amount of the difference shall be creditable against Purchaser&#146;s payment obligations under Sections 1.03 and 1.04 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.06 <U>Certain Services</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Development and License Agreement</U>. The parties acknowledge and agree that prior to the Closing, CAI shall procure the
termination of that certain Development and License Agreement among CAI, [***], dated [***] (the &#147;<U>CAI Development Agreement</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>New Services Agreement</U>. At the Closing, Purchaser, Spero, the Company and CAI shall enter into an agreement (the &#147;<U>CAI
Services Agreement</U>&#148;) under which CAI shall continue to perform all or some of the research and development activities that are conducted by CAI under the NIAID Contract as of the date hereof, and certain other research and development
activities for the Company. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.07 <U>Assignment, Novation and Termination of the [***] License Agreements</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Seller shall procure that prior to Closing the Company shall (i)&nbsp;novate the Exclusive
<FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement to a subsidiary of the Parent and terminate the <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement and (ii)&nbsp;assign the intellectual property defined in the Exclusive
License (the &#147;Assigned IP&#148;) to the Company and shall deliver such agreements to Purchaser at Closing. Seller and Parent warrants and represents to the Purchaser that (i)&nbsp;following such novation, termination and assignment, the Company
shall have no further liability under the [***] License Agreements and shall have full legal and beneficial title to the Assigned IP free from all Liens; (ii)&nbsp;the Assigned IP was transferred to the Company at market value; and (iii)&nbsp;the
Company does not have any liabilities or obligations to pay Tax of any nature whatsoever, due or to become due, accrued, absolute, contingent or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.08 <U>Payments; Records and Audit; Efforts</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Manner of Payment and Exchange Rate</U>.&nbsp;All payments to be made by Purchaser to Seller under Sections 1.02 through 1.06 shall be
made in Dollars and shall be paid by wire transfer in immediately available funds to such bank account as is designated in writing by Seller from time to time. In computing the Dollar amount of any [***] Milestone Payment to be made by Purchaser
under Section&nbsp;1.03, after calculating the annual Net Sales for [***], the rate of exchange to be used in such computation shall be the average of the rate of exchange published by Bloomberg Business over the course of the Calendar Year in which
such sales occurred. In computing the Dollar amount of Net Sales of a Product outside the United States, after calculating the Net Sales in the currency of sale, the rate of exchange to be used in such computation shall be the average of the rate of
exchange published by Bloomberg Business over the course of the Calendar Quarter in which such sales occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Tax Withholding</U>.
Seller shall be liable for any and all Taxes required to be paid to any Governmental Entity (including any Tax authority of any jurisdiction) under any provision of United States federal, state, local or foreign Tax law on any payments made by
Purchaser to Seller or its Affiliates under this Agreement. In the event that any payments made by or on behalf of Purchaser pursuant to this Agreement are subject to withholding Tax required to be paid to any Governmental Entity (including any Tax
authority of any jurisdiction) under any provision of United States federal, state, local or foreign Tax law, Purchaser may deduct and withhold (without duplication) the amount of such withholding Tax from the amount otherwise payable to Seller. In
such event, Purchaser shall notify Seller of such obligation, provide to Seller a detailed calculation of the amount withheld, and pay such withholding Tax to the proper Tax authority. Each party agrees to use commercially reasonable efforts and to
cooperate with the other party to minimize any anticipated withholding Tax required to be paid under any provision of federal, state, local, or foreign Tax law with respect to the payments made by Purchaser to Seller under this Agreement. To the
extent that amounts are so withheld and paid to the appropriate Governmental Entity (including any Tax authority of any jurisdiction) by Purchaser, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to
Seller. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark
&#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Records and Audit</U>. Purchaser shall keep, and shall contractually require that its
Affiliates and its Commercial Licensees keep, books and records prepared in accordance with their respective standard accounting procedures and in accordance with GAAP, in each case consistently applied, for the purpose of determining and validating
(i)&nbsp;the amount of Royalty Payments due to Seller hereunder, including, without limitation, the calculation of Net Sales in each country where Products are sold, (ii)&nbsp;whether or not the [***] Milestone Event has occurred and (iii)&nbsp;the
amount of any NIAID Payments due to Seller hereunder. Such books and records will be kept at the principal place of business of Purchaser (or its Affiliates or its licenses, as applicable) and maintained for no less than [***] years following the
end of the Calendar Year to which they pertain. At the request of Seller, Purchaser and its Affiliates and its Commercial Licensees shall permit an independent certified public accountant appointed by Seller and reasonably acceptable to Purchaser
(or its Affiliates and its Commercial Licensees, as applicable), at reasonable times and upon reasonable notice, to examine those records as may be necessary to determine, with respect to any Calendar Year ending not more than [***] years prior to
Seller&#146;s request, the correctness or completeness of any report or payment pursuant to Sections&nbsp;1.03, 1.04 or 1.05. The foregoing right of review may be exercised only once per Calendar Year and only once with respect to each such periodic
report and payment. Results of any such examination shall be (A)&nbsp;limited to information relating to Products, (B)&nbsp;made available to both Purchaser and Seller and (C)&nbsp;subject to the confidentiality provisions set forth below. Prior to
commencing any examination, the independent certified public accountant shall have agreed in writing to maintain all information learned in confidence, except as necessary to disclose to Purchaser and Seller the results of such examination, and
shall have executed all customary release letters reasonably requested by Purchaser&#146;s independent auditors. Seller shall bear the full cost of the performance of any such audit, unless such audit discloses a variance to the detriment of Seller
of more than [***] percent ([***]%) from the amount of the original report or Royalty Payment or NIAID Payments calculation. In such case, Purchaser shall bear the full cost of the performance of such audit. Any underpayments of Royalty Payments,
the [***] Milestone Payment or NIAID Payments shall be paid by Purchaser within [***] of notification of the results of such audit, together with interest at a rate of [***] percent ([***]%) per month for each Calendar Month since the payment due
date. Any overpayments of Royalty Payments, the [***] Milestone Payment or the NIAID Payments shall be fully creditable by Purchaser against any amounts subsequently payable by Purchaser pursuant to this Agreement or, if no such amounts become
payable within [***] after notification of such results, shall be refunded by Seller to Purchaser or its designee. Purchaser shall contractually require that its Affiliates and their respective Commercial Licensees submit to the exercise of
Seller&#146;s right of audit hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">SECTION 1.09 <U>Joint Steering Committee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Within [***] after the Closing Date, Purchaser and Seller shall establish a committee (the &#147;<U>Joint Steering Committee</U>&#148;)
consisting of [***] individuals (the &#147;<U>Joint Steering Committee Members</U>&#148;). [***] Joint Steering Committee Members shall be selected by Purchaser and [***] Joint Steering Committee Members shall be selected by Seller. Each of
Purchaser and Seller may replace any Joint Steering Committee Member selected by such party by written notice to the other party. Each Joint Steering Committee Member shall be appropriately qualified and experienced in order to make a meaningful
contribution to the activities of the Joint Steering Committee. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The purpose of the Joint Steering Committee is to provide a forum for the parties to
share information and knowledge regarding Purchaser&#146;s research, development and manufacturing activities exclusively relating to the development and commercialization of the Program IP (the &#147;<U>Program</U>&#148;) and the research and
development of Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The Joint Steering Committee shall meet as often as the Joint Steering Committee Members may mutually
determine, but in no event less than [***] per Calendar Year, unless such requirement is waived by mutual written consent of Purchaser and Seller. Meetings of the Joint Steering Committee may be held at any location mutually determined by the Joint
Steering Committee Members or by teleconference or videoconference. Each Joint Steering Committee Member, and any other individual invited to attend meetings of the Joint Steering Committee, shall be subject to appropriate confidentiality
obligations. The quorum for Joint Steering Committee meetings shall be [***] Joint Steering Committee Members, composed of not less than one (1)&nbsp;Joint Steering Committee Member selected by each of Purchaser and Seller. Each party shall be
responsible for the expenses of its designated Joint Steering Committee Members&#146; participation in the Joint Steering Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)
Notwithstanding anything to the contrary contained herein, the Joint Steering Committee shall act solely in an advisory capacity, and none of the activities of the Joint Steering Committee nor any decision by the Joint Steering Committee with
respect to any matter shall limit or restrict in any manner whatsoever the rights or discretion of Purchaser with respect to a Product, the Program or otherwise, nor shall any activity or decision of the Joint Steering Committee be deemed to
establish a course of conduct of the parties hereunder, nor otherwise be deemed to amend or modify in any manner any of the terms of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Joint Steering Committee may be dissolved, at any time, by the joint written consent of Purchaser and Seller, and shall be dissolved,
in any event, upon the earlier of (i) [***] or (ii)&nbsp;Purchaser&#146;s decision to cease development and commercialization of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 1.10 <U>Further Assurances</U>. At any time after the Closing, at any party&#146;s reasonable request and, subject to
Section&nbsp;5.03, at the requesting party&#146;s sole cost and expense, each other party shall take such further action (including the execution and delivery to the requesting party of such other reasonable instruments of sale, transfer,
conveyance, assignment, assumption and confirmation, providing materials and information) as shall reasonably be deemed necessary to transfer, convey and assign to Purchaser the Transferred Shares and the Transferred Intellectual Property or
otherwise to carry out the purposes of this Agreement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Closing </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 2.01
<U>Closing</U>. The closing of the Acquisition (the &#147;<U>Closing</U>&#148;) shall take place on the date hereof (the &#147;<U>Closing Date</U>&#148;) at the offices of Osborne Clarke LLP, One London Wall, London EC2Y 5EB, unless another place is
agreed to in writing by the parties (it being understood that the Closing may be effected by the delivery of documents via <FONT STYLE="white-space:nowrap">e-mail,</FONT> facsimile and/or overnight courier). The Closing and will be effective as of
12:01 AM Boston, Massachusetts local time on the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In connection with the execution and delivery of this Agreement,
Purchaser shall deliver or cause to be delivered to Seller, at or before the Closing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Upfront Consideration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a reasonably current good standing or similar certificate of each of Spero and Spero Therapeutics, certified by the
Secretary of State of the State of Delaware; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a reasonably current copy of the certificate of incorporation of each
of Spero and Spero Therapeutics, certified by the Secretary of State of the State of Delaware; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) certificates, duly
executed by an authorized officer of each of Spero Therapeutics and Spero, (A)&nbsp;certifying and attaching a copy of the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or the comparable governing instruments) of
Spero or Spero Therapeutics (as the case may be); and (B)&nbsp;certifying and attaching all requisite resolutions or actions of the board of directors and, if applicable, the stockholders of Spero or Spero Therapeutics (as the case may be) approving
(i)&nbsp;the execution and delivery of this Agreement and the Other Transaction Documents to which it is a party and (ii)&nbsp;the consummation of the transactions contemplated thereby; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a certified copy of the articles of association of Purchaser; attaching a copy of the resolutions and minutes of the board
of directors of Purchaser approving (i)&nbsp;the execution and delivery of this Agreement and the relevant Other Transaction Documents and (ii)&nbsp;the consummation of the transactions contemplated thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In connection with the execution and delivery of this Agreement, Seller shall, at or before the Closing, deliver or cause to be delivered
to Purchaser or, in the case of the items set out in paragraph (x)&nbsp;below, make available to Purchaser at the Maltese premises of the Company or such other location as Purchaser may reasonably request: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) one share certificate for the Transferred Shares in the name of the Purchaser accompanied by a share transfer instrument
relating to the Transferred Shares as signed by the Seller; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a signed statutory Form T relating to the Transferred
Shares; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark
&#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a copy of the updated register of members of the Company, certified by
an officer of the Company and showing the details of the Purchaser as sole shareholder of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a written
declaration, signed by a duly authorized representative of the Company, confirming that the Transferred Shares are not subject to any precautionary or executive warrant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the written resignation of each officer and director (or equivalent) of the Company, effective as of the Closing, together
with a signed statutory Form K relating to the resignations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a certificate, duly executed by an authorized officer of
Seller, certifying and attaching an extract from a meeting of the board of directors approving (A)&nbsp;the execution and delivery of this Agreement, the Subscription Agreement and the Shareholders Agreement and (B)&nbsp;the consummation of the
transactions contemplated thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) a certificate, duly executed by an authorized officer of the Company,
(A)&nbsp;certifying and attaching a copy of the certificate of incorporation and the Memorandum and Articles of Association of the Company; and (B)&nbsp;certifying and attaching an extract from a meeting of the board of directors of the Company
approving (i)&nbsp;the execution and delivery of this Agreement and the Other Transaction Documents and (ii)&nbsp;the consummation of the transactions contemplated thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) a certificate, duly executed by an authorized officer of CAI, (A) certifying and attaching a copy of the certificate of
incorporation or by-laws (or the comparable governing instruments) of CAI; and (B) certifying and attaching all requisite resolutions or actions of the board of directors and, if applicable, the stockholders of CAI approving (i) the execution and
delivery of this Agreement and the Other Transaction Documents and (ii) the consummation of the transactions contemplated thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) a certificate, duly executed by an authorized officer of the Parent, (A) certifying and attaching a copy of the
certificate of incorporation or by-laws (or the comparable governing instruments) of the Parent; and (B) certifying and attaching all requisite resolutions or actions of the board of directors of the Parent approving (i) the execution and delivery
of this Agreement and the Other Transaction Documents and (ii) the consummation of the transactions contemplated thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) all of the books, data, documents, instruments and other records of or relating to the Company, including, without
limitation, the original incorporation documents, foreign qualifications, <FONT STYLE="white-space:nowrap">by-laws,</FONT> minute book, register of members, contracts and other agreements of the Company, all laboratory notebooks and other records, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies lists, files (including patent prosecution files), documents, correspondence, creative and promotional materials, studies, reports, data (including all pharmacological, <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, analytical, quality control and manufacturing data (including batch records and technical reports)) and other printed, written or electronic materials (in all cases, in any form or medium)
owned by Seller or any of its Affiliates that relate exclusively to, or that arise exclusively out of, the Transferred Intellectual Property; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) a reasonably current good standing certificate of the Company, as issued
by the Registry of Companies in Malta; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) evidence of termination of the CAI Development Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) evidence of novation of the Exclusive <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement required pursuant to
Section&nbsp;1.07(a); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) evidence of termination of the <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement
required pursuant to Section&nbsp;1.07(a); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) evidence of assignment of the Assigned IP required pursuant to
Section&nbsp;1.07(a). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and Warranties of Seller </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as Disclosed, Seller hereby warrants and represents to Purchaser as of the Closing Date as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.01 <U>Title to Transferred Shares</U>. Seller owns the Transferred Shares, being fully
<FONT STYLE="white-space:nowrap">paid-up</FONT> shares in the Company, beneficially and of record free and clear of all Liens. There is no restriction affecting the ability of Seller to transfer the legal and beneficial title and ownership of the
Transferred Shares to Purchaser and, upon delivery thereof to Purchaser pursuant to the terms of this Agreement, Purchaser will acquire record and beneficial title to the Transferred Shares free and clear of all Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.02 <U>Authority</U>. Seller and the Company are each a legal entity, duly organized and validly existing under the laws of Malta.
Seller and the Company have all requisite corporate power and authority to enter into this Agreement, and Seller, the Company and each of their respective Affiliates has all requisite corporate power and authority to enter into the Other Transaction
Documents to which it is, or is specified to be, a party and to consummate the transactions contemplated hereby and thereby. All corporate acts and other proceedings required to be taken by Seller, the Company and each of their respective Affiliates
to authorize the execution, delivery and performance of this Agreement and the Other Transaction Documents to which it is, or is specified to be, a party and to consummate the transactions contemplated hereby and thereby have been duly and properly
taken. This Agreement and the Other Transaction Documents have been duly executed and delivered by Seller and the Company and, assuming this Agreement and the Other Transaction Documents have been duly authorized, executed and delivered by Purchaser
and, if applicable, its Affiliates, constitute a legal, valid and binding obligation of each of Seller and the Company, enforceable against Seller and the Company in accordance with their terms, subject, as to enforcement, to applicable bankruptcy,
insolvency, moratorium, reorganization or similar laws affecting creditors&#146; rights generally and to general equitable principles. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.03 <U>No Conflicts; Consents</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement and the Other Transaction Documents by Seller, the Company and their respective Affiliates, as
applicable, and the consummation of the transactions contemplated hereby and thereby, and compliance with the terms and conditions hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or lapse
of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or loss of a material benefit under, or result in the creation of any Liens upon, any of the Transferred Shares or any of the assets of
the Company under any provision of (i)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or the comparable governing instruments) of Seller, the Company or any of their respective Affiliates, (ii)&nbsp;any
contract, to which Seller, the Company or any such Affiliate is a party or by which any of their respective properties or assets are bound, or (iii)&nbsp;any judgment, order or decree, or, subject to the matters referred to in clauses&nbsp;(i) and
(ii)&nbsp;of paragraph&nbsp;(b) below, Applicable Laws; except in the case of clauses (ii)&nbsp;and (iii) as would not have a material adverse effect on the ability of Seller or the Company to consummate the transactions contemplated hereby or under
the Other Transaction Documents and to perform their respective obligations under this Agreement or under each of the Other Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The execution, delivery and performance of this Agreement and the Other Transaction Documents, and the consummation of the transactions
contemplated hereby or thereby, do not, and will not, require any consent, approval, license, permit, order or authorization of, or registration, declaration or filing with, any Governmental Entity except as may be required solely by reason of
Purchaser&#146;s or any Affiliate of Purchaser&#146;s (as opposed to any third party&#146;s) participation in the transactions contemplated hereby or thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.04 <U>Capitalization</U>. The authorized share capital of the Company is USD100,000 consisting of 100,000 shares of USD1 each,
whilst the issued share capital of the Company consists on the date hereof solely of [***] ordinary shares of USD1 each, fully paid up, all of which issued shares are owned by Seller, free and clear of all Liens. All of such shares are duly
authorized, validly issued and fully paid and were issued in full compliance with all applicable laws. The designations, powers, preferences, rights, qualifications, limitations and restrictions in respect of the authorized capital stock of the
Company are as set forth in the Company&#146;s memorandum and articles of association, a copy of which has been provided to Purchaser, and all such designations, powers, preferences, rights, qualifications, limitations and restrictions are valid,
binding and enforceable in accordance with Maltese law. As of the date hereof there are no outstanding subscriptions, options, warrants, rights, calls or convertible securities, stock appreciation rights (phantom or otherwise), joint venture,
partnership or other commitments of any nature relating to shares in the share capital of the Company. As of the date hereof there is no obligation (contingent or other) to purchase, redeem or otherwise acquire any of the Company&#146;s equity
securities or any interest therein or to pay any dividend or make any other distribution in respect thereof. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.05 <U>Subsidiaries</U>. The Company does not (i)&nbsp;own of record or
beneficially, directly or indirectly, any shares of capital stock or securities convertible into capital stock of any other corporation or any participating interest in any partnership, joint venture or other
<FONT STYLE="white-space:nowrap">non-corporate</FONT> business enterprise or (ii)&nbsp;control, directly or indirectly, any other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.06 <U>Absence of Undisclosed Liabilities</U> The Company does not have any liabilities or obligations of any nature whatsoever, due
or to become due, accrued, absolute, contingent or otherwise. Seller does not know of any basis for the assertion against the Company of any liability or obligation. The Company is not bound by any agreement, or subject to any charter or other
corporate restriction or any legal requirement, which has, or in the future can reasonably be expected to have, a material adverse effect on the Company or its assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.07 <U>Taxes</U>. The Company has filed on a timely basis all returns, declarations, reports, claims for refunds and information
returns or statements relating to Taxes, including all schedules or attachments thereto, and including any amendment thereof (&#147;<U>Tax Returns</U>&#148;) and tax reports required to be filed on or before the date hereof with the appropriate
governmental agencies in all jurisdictions in which such returns and reports are required to be filed and all such Tax Returns were correct and complete in all material respects. All Taxes which have become due or payable or required to be collected
by the Company or as otherwise attributable to any periods ending on or before the date hereof and all interest and penalties thereon, whether disputed or not, have been paid in full (whether or not shown on any Tax Return) or have been provided for
in the accounts of the Company or payment of the Tax is otherwise taken into account in the accounts of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.08
<U>Litigation</U>. There is no (i)&nbsp;action, suit, claim, proceeding or investigation pending or, to the best of Seller&#146;s knowledge, threatened against the Company, at law or in equity, or before or by any federal, state, municipal or other
governmental department, commission, board, bureau, agency or instrumentality, whether of Malta or any other jurisdiction, or (ii)&nbsp;arbitration proceeding or governmental inquiry pending or threatened against the Company, and, to the best of
Seller&#146;s knowledge, there are no circumstances likely to give rise to any of the foregoing. Neither the Company nor Seller has received any opinion or memorandum or advice from legal counsel to the effect that the Company is exposed, from a
legal standpoint, to any liability or disadvantage which may be material to its business, prospects, financial condition, operations, property, assets or affairs. There are no outstanding orders, writs, judgments, injunctions or decrees of any
court, governmental agency or arbitration tribunal against the Company. The Company is not in default with respect to any order, writ, injunction or decree served upon it from any court or any federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, whether of Malta or any other jurisdiction. There is no action or suit by the Company pending or threatened against others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.09 <U>Property</U>. Paragraph 3.09 of the Disclosure Letter contains a true and complete list of all tangible personal property
owned by or leased to the Company (the &#147;<U>Tangible Personal Property</U>&#148;). Except as shown in paragraph 3.09 of the Disclosure Letter, the Company has good and marketable title free and clear of all Liens to the Tangible Personal
Property listed as owned by it. The Company does not own or lease any real estate. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.10 <U>Assumptions, Guaranties, Etc. of Indebtedness of Other Persons</U>. The
Company has not assumed, guaranteed, endorsed or otherwise become directly or contingently liable on any indebtedness of any other person (including, without limitation, liability by way of agreement, contingent or otherwise, to purchase, to provide
funds for payment, to supply funds to or otherwise invest in the debtor, or otherwise to assure the creditor against loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.11
<U>Transactions With Affiliates</U>. No director, officer or Affiliate of the Company, or member of the family of any such person, or any corporation, partnership, trust or other entity in which any such person, or any member of the family of any
such person, has a substantial interest or is an officer, director, trustee, partner or holder of any equity interest, is a party to any transaction with the Company, including any contract, agreement or other arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.12 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Paragraph 3.12(a) of the Disclosure Letter sets forth, for each of the Transferred Patents, the name of the current owner(s) (including any
<FONT STYLE="white-space:nowrap">co-owner)</FONT> thereof (and, if the owner is not the Company, the corresponding license agreement pursuant to which Seller has the right to use such Intellectual Property) and the jurisdiction of each such issued
or pending Transferred Patent. The Transferred Patents are (A)&nbsp;valid, enforceable, subsisting and in full force and effect and, as applicable, have been filed in accordance with all Applicable Laws, (B)&nbsp;not the subject of any opposition,
cancellation, interference, reissue, reexamination or other similar proceeding, (C)&nbsp;owned, held and recorded solely in the name of the Company as record and beneficial owner and (D)&nbsp;in compliance with all formal legal requirements. All
annuity and maintenance fees that are necessary in order to keep the Transferred Patents in force have been paid by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The
Company solely and exclusively owns all right, title and interest in and to, or possesses a valid and enforceable right to use pursuant to a written license agreement set forth in paragraph 3.12(b) of the Disclosure Letter, the Transferred
Intellectual Property, free and clear of all Liens, including any restrictions, limitations and obligations (including any royalty payment or other obligations or contractual limitations (other than pursuant to the terms of any agreement set forth
in paragraph 3.12(b) of the Disclosure Letter)), and the consummation of the transactions contemplated hereby does not conflict with, alter or impair any such rights of the Company in or to any of the Transferred Intellectual Property and the
Transferred Intellectual Property shall be solely and exclusively owned or available for use by Purchaser immediately after the Closing on terms and conditions identical to those under which the Company owned and/or used the Transferred Intellectual
Property immediately prior to the Closing. To the Knowledge of Seller, no Transferred Intellectual Property is subject to any outstanding consent, settlement, decree, order, injunction, judgment or ruling, or any contract restricting or otherwise
limiting the use, ownership, validity, enforceability, disposition or exploitation thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) To the Knowledge of Seller, no academic
institution, research center or Governmental Entity (or any person working for or on behalf of any of the foregoing) or any other person (other than Seller and/or any of its Affiliates) has, or will be entitled to have, any right, title or interest
(including any &#147;march in&#148; or <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights) in or to any Intellectual Property included in the Transferred Intellectual Property (including any claim or option to any of the foregoing). Except
as set forth in paragraph 3.12(c) of the Disclosure Letter, to the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Knowledge of Seller, no funding, Intellectual Property, facilities, personnel or other resources of any
Governmental Entity or university or other academic institution or research center or of any other person has been used in connection with the conception, invention, reduction to practice, development or other creation of any Intellectual Property
included in the Transferred Intellectual Property. Except as set forth in paragraph 3.12(c) of the Disclosure Letter, the Company has not granted any license (including any sublicense), option, assignment or other agreement (including any covenants
not to sue) or any other right, title or interest with respect to any Transferred Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) To the Knowledge of Seller,
the Program IP and the research and development of Products by the Company has not infringed, misappropriated or otherwise violated the Intellectual Property rights of any other person. Neither the Company nor CAI has received any written charge,
complaint, claim, demand, communication or other notice, or is or has been a party to any lawsuit, claim, action or proceeding, where any person has (i)&nbsp;alleged, with respect to the Program IP or any Product, that the Company or CAI has
infringed, misappropriated or otherwise violated, or will violate through the Program IP or the exploitation of any such Product, any Intellectual Property rights of any other person (including pursuant to any notice or demand that the Company or
CAI must license or refrain from using any Intellectual Property of any other person), or (ii)&nbsp;challenged the validity, use, ownership, enforceability of, or has claimed any right, title or interest in or to, any Transferred Intellectual
Property, and, with respect to each of clauses (i)&nbsp;and (ii), to the Knowledge of Seller, no such claim has been asserted or threatened, and there is no reasonable basis for any such claim. To the Knowledge of Seller, no person has infringed,
misappropriated or otherwise violated any Transferred Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Company, its Affiliates and CAI have taken
commercially reasonable steps to protect, and to maintain and enforce all rights under, the Transferred Intellectual Property, including the secrecy, confidentiality and value of trade secrets and other confidential information. The Company, each of
its Affiliates and CAI require each of their current and former employees, consultants and independent contractors to enter into valid and enforceable agreements with the Company, such Affiliate or CAI pursuant to which such person agrees and is
bound to maintain and protect the confidential information of the Company and its Affiliates and assigns to the Company, such Affiliate or CAI all Intellectual Property authored, developed or otherwise created by such person in the course of such
person&#146;s employment or other engagement with the Company or any of its Affiliates, all in accordance with all Applicable Laws, and ensures that any entity conducting any research, develop or other activities on behalf of the Company or its
Affiliates does the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) To the Knowledge of Seller, all listed inventors in the Transferred Patents are the sole inventors of such
Patents, and all inventors of any inventions claimed by any Transferred Patent or other Transferred Intellectual Property have each assigned such person&#146;s entire right, title and interest in and to any and all intellectual property rights in
and to such inventions to the Company or one of its Affiliates, or, if the Company or one of its Affiliates acquired any such Patents or other Intellectual Property, then to the person who employed or otherwise engaged such inventor, and such person
has assigned the same to Seller or one of its Affiliates. To the Knowledge of Seller, no claims have been asserted challenging the inventorship of any of the Transferred Patents. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 3.13 <U>Compliance with Applicable Laws</U>. The Company and CAI are, and have been,
in compliance with all applicable statutes, laws, principles of common law, ordinances, rules, orders, regulations and any other provisions having the force or effect of law, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the
UK Bribery Act of 2010 and similar Laws of any applicable jurisdiction, (such laws and regulations &#147;<U>Applicable Laws</U>&#148;), except for instances of noncompliance that, individually or in the aggregate, would not be material to the
Transferred Shares, the Transferred Intellectual Property or the Products. None of Seller, the Company or any of their respective Affiliates has received during the [***]&nbsp;years prior to the date hereof any written communication from a
Governmental Entity that alleges that the Company or CAI is in violation of any Applicable Laws except for any such violations that, individually or in the aggregate, would not be material to the Transferred Shares, the Transferred Intellectual
Property or the Products. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Warranties of Purchaser </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Purchaser hereby warrants to Seller as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 4.01 <U>Authority</U>. Each of Purchaser, Spero and Spero Therapeutics is a legal entity, duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization. Each of Purchaser, Spero and Spero Therapeutics has all requisite corporate power and authority to own and operate its properties and assets and carry on its business as currently
conducted, and to enter into this Agreement and the Other Transaction Documents to which it is, or is specified to be, a party and to consummate the transactions contemplated hereby and thereby. All corporate acts and other proceedings required to
be taken by Purchaser, Spero and/or Spero Therapeutics to authorize the execution, delivery and performance of this Agreement and the Other Transaction Documents to which it is, or is specified to be, a party and to consummate the transactions
contemplated hereby and thereby have been duly and properly taken. This Agreement and the Other Transaction Documents have been duly executed and delivered by Purchaser, Spero and Spero Therapeutics and, assuming this Agreement and the Other
Transaction Documents have been duly authorized, executed and delivered by Seller and the Company, constitute a legal, valid and binding obligation of each of Purchaser, Spero and Spero Therapeutics, enforceable against Purchaser, Spero and Spero
Therapeutics in accordance with their terms, subject, as to enforcement, to applicable bankruptcy, insolvency, moratorium, reorganization or similar laws affecting creditors&#146; rights generally and to general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 4.02 <U>No Conflicts; Consents</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement and each Other Transaction Document by Purchaser, Spero and Spero Therapeutics does not, and
will not, and the consummation of the transactions contemplated hereby and thereby and compliance with the terms hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time, or both)
under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or result in the creation of any Lien upon any of the properties or assets of Purchaser, Spero or Spero
Therapeutics under, </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the
mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any provision of (i)&nbsp;its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> (ii)&nbsp;the provisions of any of the Purchaser&#146;s, Spero&#146;s or Spero
Therapeutics&#146; preferred shares or convertible securities, (iii)&nbsp;any contract to which Purchaser, Spero or Spero Therapeutics is a party or by which any of its properties or assets are bound or (iv)&nbsp;any judgment, order, or decree, or,
subject to the matters referred to in paragraph (b)&nbsp;below, Applicable Laws, except, in the case of clauses&nbsp;(iii) and (iv), as would not have a material adverse effect on the ability of Purchaser, Spero or Spero Therapeutics (as the case
may be) to consummate the transactions contemplated hereby or under any of the Other Transaction Documents and to perform its obligations under this Agreement and under each of the Other Transaction Document. No vote or approval of the stockholders
of Purchaser, Spero Therapeutics or any of their Affiliates is required in order to consummate the transactions contemplated by this Agreement or the Other Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No consent, approval, license, permit, order or authorization of, or registration, declaration or filing with, any Governmental Entity is
required to be obtained or made by or with respect to Purchaser, Spero Therapeutics or any of their Affiliates in connection with the execution, delivery and performance of this Agreement, the Other Transaction Documents or the consummation of the
transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 4.03 <U>Actions and Proceedings</U>. There are no (a)&nbsp;outstanding judgments,
orders, injunctions or decrees of any Governmental Entity against Purchaser, Spero or Spero Therapeutics (b)&nbsp;lawsuits, actions or proceedings pending or, to the knowledge of Purchaser, Spero or Spero Therapeutics, threatened against Purchaser,
Spero or Spero Therapeutics, or (c)&nbsp;investigations by any Governmental Entity which are pending or, to the knowledge of Purchaser, Spero or Spero Therapeutics, threatened against Purchaser, Spero or Spero Therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 4.04 <U>Solvency</U>. Immediately after giving effect to the transactions contemplated hereby and under the Other Transaction
Documents, each of Purchaser, Spero and Spero Therapeutics shall be solvent and shall (a)&nbsp;be able to pay its debts as they become due and (b)&nbsp;have adequate capital to carry on its business. No transfer of property is being made and no
obligation is being incurred in connection with the transactions contemplated hereby and under the Other Transaction Documents with the intent to hinder, delay or defraud either present or future creditors of Purchaser, Spero, Spero Therapeutics or
Seller. In connection with the transactions contemplated hereby and under the Other Transaction Documents, neither Purchaser, Spero nor Spero Therapeutics has incurred, or plans to incur, debts beyond its ability to pay as they become absolute and
matured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 4.05 <U><FONT STYLE="white-space:nowrap">Pre-Emption</FONT> and Dilution</U>. The issuance of the Equity Consideration
will not trigger any right of anti-dilution or any preemptive rights held by any holders of Spero&#146;s capital stock or other securities convertible into capital stock. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Covenants </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.01
<U>Publicity</U>. The parties agree that no public release or announcement shall be issued or any communications made to any news media concerning the transactions contemplated hereby or under the Other Transaction Documents by any party or its
Affiliates without the prior written consent of the Purchaser (for itself and its Affiliates) (on the one hand) or the Seller (for itself and its Affiliates) (on the other hand) (which consent, in any such case, shall not be unreasonably withheld or
delayed), except as such release or announcement may be required by Applicable Laws or the rules or regulations of any United States or foreign securities exchange to which such party is subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.02 <U>Tax Matters</U>. All Taxes and any filing or recording fees applicable to the Acquisition shall be paid by Purchaser. Each
party shall use commercially reasonable efforts to minimize any such Taxes or fees and to avail itself of any available exemptions from any such Taxes or fees, and to cooperate with the other party in providing any information and documentation that
may be necessary to obtain such exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.03 <U>Books and Records. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In order to facilitate the resolution of any claims made against or incurred by Seller prior to the Closing, or for any other reasonable
purpose, for a period of [***] years after Closing, Purchaser shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) retain the books and records of the Company
relating to periods prior to the Closing in a manner reasonably consistent with the prior practices of Seller; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
upon reasonable notice afford the Seller&#146;s representatives access (including the right to make, at Seller&#146;s expense, photocopies), during normal business hours, to such books and records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In order to facilitate the resolution of any claims made by or against or incurred by Purchaser after Closing, or for any other reasonable
purpose, for a period of [***] years after Closing, Seller shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) retain a copy of the books and records which relate
to the Company for periods prior to Closing (other than any such transferred with the Company at Closing); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) upon
reasonable notice afford the Purchaser&#146;s representatives access (including the right to make, at Purchaser&#146;s expense, photocopies), during normal business hours, to such books and records. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Neither Purchaser nor Seller shall be obligated to provide the other party with access to any books or records pursuant to this
Section&nbsp;5.04 where such access would violate any Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.04
<U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U>. Except as contemplated hereunder, including with respect to Seller&#146;s ownership of shares of common stock in Spero, for a period of [***] years following the Closing Date (the
&#147;<U>Restricted Period</U>&#148;), Seller shall not, and shall cause the other Restricted Persons not to, directly or indirectly, engage or participate, in the development, product design, manufacturing, production, distribution, marketing,
sale, commercialization or other similar activities relating to the research, development and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">commercialization of polymyxins to treat bacterial infections, in each case including by owning, managing,
operating, controlling or otherwise participating in the ownership, management, operation or control of any entity engaged in any such activities, whether as an employer, proprietor, partner, equityholder, consultant, agent, lender or guarantor or
otherwise. Notwithstanding the foregoing, any Restricted Person may own, directly or indirectly, solely as an investment, securities of any entity traded on any securities exchange if such Restricted Person is not a controlling person of, or a
member of a group which controls, such entity and does not, directly or indirectly, own 10% or more of any class of securities of such entity; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided, that neither CAI nor any other Restricted Person shall be in breach of this Section&nbsp;5.04 (A) as a result of CAI performing its
obligations under this Agreement and/or the CAI Services Agreement, or (B)&nbsp;anything being done from time to time by any Restricted Person excluding CAI in the ordinary course of business of such Restricted Person as such business is carried on
immediately following Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Section&nbsp;5.04, &#147;<U>Restricted Persons</U>&#148; means the Parent and any subsidiary or
subsidiary undertaking of the Parent from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.05 <U>Confidential Information</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly provided herein, the parties agree that, for so long as Purchaser has payment obligations hereunder, all <FONT
STYLE="white-space:nowrap">non-public,</FONT> proprietary invention disclosures, <FONT STYLE="white-space:nowrap">know-how,</FONT> data, and technical, financial, promotional, commercial and other information of any nature whatsoever (collectively,
&#147;<U>Confidential Information</U>&#148;), disclosed or submitted, either orally or in writing (including, without limitation, by electronic means) or through observation, by one party (the &#147;<U>Disclosing Party</U>&#148;) to any other party
(the &#147;<U>Receiving Party</U>&#148;) hereunder shall be received and maintained by the Receiving Party in strict confidence, shall not be used for any purpose or disclosed to any third party (except to an Affiliate, in circumstances where such
Affiliate has agreed to maintain the confidentiality of such Confidential Information) other than for the purposes contemplated by this Agreement, except to the extent that it can be established by the Receiving Party by competent proof that such
information: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) is or becomes public or available to the general public otherwise than through the act or default of the
Receiving Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) is obtained by the Receiving Party from a third party who is lawfully in possession of such
information and is not subject to an obligation of confidentiality or <FONT STYLE="white-space:nowrap">non-use</FONT> owed to the Disclosing Party or others; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) is previously known to the Receiving Party prior to disclosure to the Receiving Party by the Disclosing Party under this
Agreement or otherwise, as shown by written evidence, and is not obtained or derived directly or indirectly from information obtained from the Disclosing Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) is disclosed by the Receiving Party pursuant to any requirement under Applicable Law, provided that the Receiving Party
has complied with the provisions set forth in Section&nbsp;5.05(b); or </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) is independently developed by the Receiving Party without the use of or
reliance on any information provided by the Disclosing Party hereunder, as shown by contemporaneous written evidence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Permitted Use
and Disclosures</U>. Each party hereto may disclose Confidential Information to its professional advisers (provided they have agreed to maintain the confidentiality of such Confidential Information) and use or disclose information disclosed to it by
the other party to the extent such use or disclosure is reasonably necessary in complying with Applicable Laws, submitting information to any Governmental Entity (including any Tax authority of any jurisdiction), complying with the rules or
regulations of any securities exchange to which such party is subject or otherwise exercising its rights hereunder; <I>provided</I> that, if the Receiving Party is legally required to make any disclosure of the Disclosing Party&#146;s Confidential
Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the Disclosing Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such information prior to its
disclosure (whether through protective orders or otherwise), including, if applicable, by cooperating with the Disclosing Party in connection with any efforts by the Disclosing Party to obtain a protective order or other appropriate remedy
concerning such disclosure. If any such order or other remedy does not fully preclude disclosure or the Disclosing Party waives such compliance, then the Receiving Party will make such disclosure only to the extent that such disclosure is legally
required and will use its reasonable efforts to have confidential treatment accorded to the disclosed information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Publicity</U>.
At no time shall any of the parties or any of their respective Affiliates issue any press release or make any public announcement relating to the subject matter of this Agreement, save that following Closing the parties may issue a press release
regarding the transactions contemplated by this Agreement in such form as shall have been agreed between the Seller and the Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 5.06 <U>Development Program</U>. Purchaser shall, directly or with or through its Affiliates and Commercial Licensees, use
Commercially Reasonable and Diligent Efforts to [***]. Seller acknowledges and agrees that, subject only to the foregoing requirement, Purchaser has the exclusive right to determine the manner, terms and conditions of the Program, including the
determination of whether or not to [***] or the [***]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification and Other Remedies </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.01 <U>Indemnification by Seller</U><U> and Parent</U>. From and after the Closing, and subject as otherwise provided in this
Agreement, Seller and Parent, jointly and severally, shall indemnify Purchaser and its Affiliates and each of their respective officers, directors, employees, agents, representatives, partners, shareholders and members against and hold them harmless
from any loss, Tax, liability, claim of any kind, damage, interest or expenses (including reasonable and documented legal fees and expenses and the cost of enforcing any right to indemnification hereunder) (collectively, &#147;<U>Losses</U>&#148;)
suffered or incurred by any such indemnified party to the extent arising from any Claim arising from a breach of any of the Warranties contained in Sections 3.01, 3.02, 3.04 and 3.07 (collectively, the &#147;<U>Fundamental Warranties</U>&#148;) or
by a breach of Section&nbsp;1.07. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.02 <U>Indemnification Payments; Limitations on Liability</U>. The amount of any
Losses which may be recovered for any Claim under the General Warranties shall be net of any amounts actually received by the claiming party under insurance policies with respect to such Losses. Neither Seller nor Parent shall have any liability for
any Claim under the General Warranties unless the aggregate amount of all Losses for which Seller and Parent would be liable, but for this Section&nbsp;6.02, exceeds on a cumulative basis an amount (the &#147;<U>Deductible</U>&#148;) equal to
$[***], and then only to the extent of any such excess. Notwithstanding the foregoing, Losses arising from any breach of any of the Fundamental Warranties shall not be limited by, or subject to, the Deductible. Save in the event of fraud, the
aggregate liability of Seller and Parent under this Agreement shall not exceed [***]. Nothing in this Agreement shall be effective to limit or exclude any liability arising out of a party&#146;s own fraud. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained in this Agreement, any &#147;materiality&#148; or other similar qualification contained
in a warranty shall not be given any effect solely for purposes of determining the amount of Losses arising from any breach of any such warranty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If Purchaser makes a Claim for or asserts a claim pursuant to this Agreement for indemnification against Losses and (i)&nbsp;Seller agrees
in writing that Purchaser is entitled to indemnification or other recovery for a Claim with respect to such Losses or (ii)&nbsp;a court of competent jurisdiction determines in a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment
that Purchaser is entitled to indemnification or other recovery for a Claim with respect to such Losses, then Purchaser shall have the right to set off against any unpaid Milestone Payments, any unpaid Royalty Payments and/or any unpaid NIAID
Payments the amount of such Losses and, to the extent of any such <FONT STYLE="white-space:nowrap">set-off,</FONT> such Losses shall be extinguished. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any provision herein, neither Seller, Parent nor Purchaser, nor any of their respective Affiliates, shall in any event be
liable, in connection with any Claims or other claims arising hereunder for any punitive damages or for any consequential Losses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)
Payments pursuant to Section&nbsp;6.01 or arising out of a Claim in respect of any Losses shall be limited to the amount of any liability or damage that results after deducting therefrom any insurance proceeds and any indemnity, contribution or
other similar payment received or reasonably expected to be received by the indemnified or claiming party in respect of any such matter. The indemnifying or claiming party shall use its commercially reasonably efforts to recover under insurance
policies or indemnity, contribution or other similar agreements for any Losses prior to seeking indemnification under this Agreement or making a Claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Seller and Purchaser shall each take, and shall cause their respective Affiliates to take, all reasonable steps to mitigate any Losses upon
becoming aware of any event or circumstance that would reasonably be expected to, or does, give rise to Losses, including incurring costs only to the minimum extent necessary to remedy the breach that gives rise to such Losses. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The Seller shall not be liable in respect of any Claim to the extent that it arises, or
its value is increased, as a result of a change in any law, legislation, rule or regulation (including any new law, legislation, rule or regulation) that comes into force or otherwise takes effect after the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Neither Seller nor Parent shall be liable under this Agreement for any Losses based upon or arising out of any inaccuracy in or breach of
any of the warranties of Seller contained in this Agreement to the extent Disclosed or if Purchaser provided written acknowledgement of and consent to such inaccuracy or breach prior to Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Subject to the limitations of liability in this Section&nbsp;6, in the event of a Claim, without prejudice to the right of the Purchaser to
claim damages on any basis available to it or to any other right or remedy available to it, Seller and Parent undertake to pay in cash to the Purchaser a sum by way of damages as agreed between the Seller, Parent and the Purchaser or, in default of
such agreement, as determined by order of a court of competent jurisdiction, whichever is equal to the higher of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an
amount sufficient to put the Company into the position which would have existed if the Warranties had not been breached; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an amount equal to the resulting diminution in value of the Transferred Shares; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the amount by which the assets of the Company are less, or less valuable, or its liabilities greater, than the values at
which the same were included in the Company&#146;s accounts or (if the Purchaser so elects) than they would have been if the Warranty concerned had been true and accurate in all respects and not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The parties agree that rescission shall not, in the absence of intentional breach or fraud, be sought as a remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.03 <U>Termination of Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The obligations to indemnify and hold harmless a party hereto pursuant to (i)&nbsp;Section&nbsp;6.01(a) shall terminate on the [***]
anniversary of the Closing, and (ii)&nbsp;Sections&nbsp;6.01(b) shall not terminate; <I>provided, however</I>, that as to clause&nbsp;(i) of this sentence such obligation to indemnify and hold harmless shall not terminate with respect to any item as
to which the person to be indemnified or the related party thereto shall have, before the expiration of the applicable period, previously made a claim by delivering a notice of such claim (stating in reasonable detail the basis of such claim) to the
indemnifying party, in which case any such claim and such obligation to indemnify and hold harmless shall survive the expiration of the applicable period until final resolution of such claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The warranties contained in this Agreement or in any Other Transaction Document, or in any certificate or instrument delivered pursuant
hereto or thereto, shall survive the Closing for a period of [***] years after the Closing Date, <I>provided, however, </I>that the Fundamental Warranties shall survive the Closing to the maximum amount permitted under the relevant statute of
limitations. Each claiming party must give written notice to the paying party </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of any claim for breach of warranty or any claim for indemnification under Section&nbsp;6.01 in accordance
with Section&nbsp;6.05 or 6.06, as applicable. Any claim for breach of warranty or claim for indemnification made in writing by the claiming party on or prior to the expiration of the applicable survival period shall survive, and may continue to be
asserted and (where applicable) indemnified against, until such claim is finally and fully resolved and, in the case of a claim by way of <FONT STYLE="white-space:nowrap">set-off,</FONT> for the maximum period during which a payment under this
Agreement becomes due. The other covenants and agreements contained in this Agreement or in any Other Transaction Document, or in any certificate or instrument delivered pursuant hereto or thereto, shall survive the Closing until fully performed or
satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.04 <U>Procedures Relating to Claims and Indemnification for Third Party Claims</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In order for a party (the &#147;<U>indemnified party</U>&#148;) to be entitled to any payment (whether for a claim for breach of warranty
or for indemnification provided for under this Agreement) in respect of, arising out of or involving a claim or demand made by any person who is not a party to this Agreement or an Affiliate, agent or representative of the foregoing against the
indemnified party (a &#147;<U>Third Party Claim</U>&#148;), such indemnified party shall, as promptly as reasonably practicable, notify the paying party in writing, and in reasonable detail, of the Third Party Claim for which indemnity may be sought
or a Claim made (as the case may be) hereunder; <I>provided, however</I>, that failure to give such notification shall not affect the indemnification provided hereunder or damages (as the case may be) except and only to the extent the paying party
forfeits rights or defenses by reason of such failure or shall have been materially prejudiced as a result of such failure. Such notice by the indemnified party shall describe the Third Party Claim in reasonable detail, shall include copies of all
material written evidence thereof and shall include the estimated amount (if it is reasonably possible to calculate such amount) of the Losses that have been or may be sustained by the indemnified party. Thereafter, the indemnified party shall
deliver to the paying party, promptly after the indemnified party&#146;s receipt thereof, copies of all notices and documents (including court papers) received by the indemnified party relating to the Third Party Claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If a Third Party Claim is made against an indemnified party, the paying party shall be entitled to participate in the defense thereof and,
if it so chooses, to assume the defense thereof with counsel selected by the paying party (not reasonably objected to by the indemnified party) and the indemnified party shall cooperate in good faith in such defense; <I>provided, however</I>, that
the paying party shall not be entitled to assume the defense of any Third Party Claim that (A)&nbsp;involves criminal liability or any admission of wrongdoing, (B)&nbsp;seeks equitable relief or any other
<FONT STYLE="white-space:nowrap">non-monetary</FONT> remedy against the indemnified party or (C)&nbsp;involves any Governmental Entity as a party thereto. If the paying party elects to assume the defense of a Third Party Claim in accordance with
this Section&nbsp;6.04(b), the paying party shall not be liable to the indemnified party for legal expenses subsequently incurred by the indemnified party in connection with the defense thereof; <I>provided, however</I>, that if in the reasonable
written opinion of outside counsel to the indemnified party (1)&nbsp;a conflict or potential conflict exists between the indemnified party and the paying party that would make separate representation advisable or (2)&nbsp;the indemnified party has
legal defenses available to it which are different from or in addition to the defenses available to the paying party, then the indemnified party may retain its own counsel; <I>provided</I>, <I>further</I>, that the paying party shall not be liable
for the costs of more than one such </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counsel for all indemnified parties in connection with any such Third Party Claim. If the paying party elects to assume the defense of a Third Party Claim in accordance with this
Section&nbsp;6.04(b), the indemnified party shall have the right to participate in the defense thereof and, without limiting the preceding sentence, to employ counsel, at its own cost and expense, separate from the counsel employed by the paying
party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If the paying party so elects to assume the defense of a Third Party Claim in accordance with Section&nbsp;6.04(b), the
indemnified party shall cooperate with the paying party in the defense or prosecution thereof. Such cooperation shall include the retention and (upon the paying party&#146;s request) the provision to the paying party of records and information which
are reasonably relevant to such Third Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. If the indemnified party is conducting the defense
of any Third Party Claim, the paying party shall cooperate with the indemnified party in the defense or prosecution thereof. Such cooperation shall include the retention and (upon the indemnified party&#146;s request) the provision to the
indemnified party of records and information which are reasonably relevant to such Third Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.
The paying party shall not admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without the indemnified party&#146;s prior written consent, unless (i)&nbsp;the proposed settlement or disposition involves
only the payment of money damages by the paying party for which the indemnified party shall have no liability, (ii)&nbsp;the proposed settlement or disposition does not impose an injunction or other equitable relief upon the indemnified party,
(iii)&nbsp;the proposed settlement or disposition does not include any admission of wrongdoing or misconduct and (iv)&nbsp;the indemnified party is fully and unconditionally released from any liability relating to such Third Party Claim. The
indemnified party shall not admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without the paying party&#146;s prior written consent. In the event that a settlement offer solely for monetary damages is
made by the applicable Third Party claimant, and the paying party notifies the indemnified party of its willingness to accepts the offer and, subject to the applicable limitations of Section&nbsp;6.03, pay the amount called for by such offer, and
the indemnified party declines to accept such offer, the indemnified party may continue to contest such Third Party claim, free of any participation from the paying party, and the amount of any ultimate liability with respect to such Third Party
Claim that the paying party may have an obligation to pay hereunder shall be limited to the lesser of (x)&nbsp;the amount of the settlement offer that the indemnified party declined to accept or (y)&nbsp;the aggregate Losses of the indemnified party
with respect to such Third Party Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.05 <U>Procedures Related to Indemnification for Other Claims</U>. In the event any
indemnified party should have a claim against any paying party under Section&nbsp;6.01 or a claim for breach of warranty that does not involve a Third Party Claim being asserted against or sought to be collected from such indemnified party, the
indemnified party shall promptly deliver written notice of such claim, in reasonable detail, to the paying party; <I>provided, however</I>, that failure by any indemnified party to so notify the paying party shall not relieve the paying party from
any liability which it may have to such indemnified party under Section&nbsp;6.01 or for damages for breach of warranty, except and only to the extent that the paying party forfeits rights or defenses by reason of such failure or shall have been
materially prejudiced as a result of such failure. If the paying party disputes its liability with respect to such claim, the paying party and the indemnified party shall proceed in good faith to negotiate a resolution of such dispute and, if not
resolved through negotiations, such dispute shall be resolved by litigation in an appropriate court of competent jurisdiction. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 6.06 <U>Tax Treatment of Payments</U>. For all Tax purposes, Purchaser, Seller and
each of their respective Affiliates agree to treat any indemnity payment under this Agreement or damages for breach of warranty as an adjustment to the Purchase Price received by Seller for the transactions contemplated by this Agreement unless a
Governmental Entity determines otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION
7.01 <U>Assignment</U>. This Agreement and the rights and obligations hereunder shall not be assignable or transferable by Spero, Purchaser, Seller, the Company, CAI or Parent (including by operation of law in connection with a merger, consolidation
or sale of substantially all the assets of Spero, Purchaser, Seller, the Company, CAI or Parent) without the prior written consent of the other parties hereto; <I>provided</I><I>, however</I>, that Purchaser may assign its rights and obligations
hereunder, without such consent, to any direct or indirect wholly owned subsidiary of Purchaser or to an acquirer of all or substantially all of the stock or assets of Purchaser, whether pursuant to a merger, sale of assets, or sale of stock or
other ownership interests; <I>provided, further</I>, that Seller may assign its rights and obligations hereunder, without such consent, to Parent or any direct or indirect wholly owned subsidiary of Seller; <I>provided</I>, <I>further</I>, that no
assignment shall relieve any party of its obligations hereunder. Any attempted assignment in violation of this Section&nbsp;7.01 shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.02 <U>Terms</U>. As used throughout this agreement, references to a party or a party&#146;s Affiliates shall be read to include any
of their respective successors in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.03 <U>No Third-Party Beneficiaries</U>. This Agreement is for the sole benefit of
the parties hereto and their permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such assigns, any legal or equitable rights hereunder or any entitlement, by
virtue of the Contracts (Rights of Third Parties) Act 1999, to enforce any term of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.04 <U>Expenses</U>. Whether
or not the transactions contemplated hereby are consummated, and except as otherwise specifically provided in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by
the party incurring such costs or expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.05 <U>Amendments</U>. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto. By an instrument in writing Purchaser, on the one hand, or Seller, on the other hand, may waive compliance by the other or any of its Affiliates with any term or provision of this Agreement
that such other party or such Affiliate was or is obligated to comply with or perform. Any such waiver will only be effective in the specific instance and for the specific and limited purpose for which it was given </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and will not be deemed a waiver of any other provision of this Agreement or of the same breach or default
upon any recurrence thereof. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement,
shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or
remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.06 <U>Notices</U>. All notices, requests, claims, demands or other communications required or permitted to be given
hereunder shall be in writing and shall be deemed to have been duly given when delivered in person, or upon confirmation of receipt when transmitted by electronic mail, or if mailed, seven days after mailing (two business days in the case of
overnight courier service), as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">if to Purchaser, Spero or Spero Therapeutics, to: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Spero Cantab, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United
States of America </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Ankit Mahadevia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Mintz Levin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One Financial
Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA 02111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United States of America </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Lewis J. Geffen, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">if to Seller, CAI or Parent, to: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pro Bono Bio PLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Leverton House </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">13 Bedford
Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London WC1B 3RA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">England </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michael
Earl/Justin Bowen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">DAC Beachcroft LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">100 Fetter
Lane </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London EC4A 1BN </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">England </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan
Deverill/Nick Gibbon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.07 <U>Interpretation</U><U>; Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may
require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; shall be deemed to be followed by the phrase &#147;without limitation&#148;. The
word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall&#148;. Unless the context requires otherwise, (i)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be
construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified, (ii)&nbsp;the words &#147;herein&#148;, &#147;hereof&#148; and &#147;hereunder&#148;, and words of similar
import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (iii)&nbsp;all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections,
Exhibits and Schedules of or to this Agreement, as the case may be, and (iv)&nbsp;the headings contained in this Agreement or any Exhibit or Schedule hereto and in the table of contents to this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement. Any capitalized terms used in any Exhibit or Schedule hereto but not otherwise defined therein shall have the meanings as defined in this Agreement. Whenever this Agreement refers to
a number of days, such number shall refer to calendar days unless business days are specified. In the event of an ambiguity or a question of intent or interpretation, this Agreement shall be construed as if drafted jointly by the parties and no
presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) For all purposes hereof: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition</U>&#148; has the meaning ascribed to such term in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any specified person, any other person directly or indirectly controlling or controlled by
or under direct or indirect common control with such specified person; and for the purposes of this definition, &#147;<U>control</U>&#148; when used with respect to any specified person means the power to direct the management and policies of such
person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms &#147;<U>controlling</U>&#148; and &#147;<U>controlled</U>&#148; have meanings correlative to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Laws</U>&#148; has the meaning ascribed to such term in Section&nbsp;3.14. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Approval</U>&#148; or &#147;<U>Approved</U>&#148; means, with respect to a Product
in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient to manufacture, distribute, use (including in clinical trials) and sell a Product in such regulatory jurisdiction in accordance with Applicable Laws
including receipt of pricing and reimbursement approvals, where applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assigned IP</U>&#148; has the meaning ascribed to
such term in Section&nbsp;1.07(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>business day</U>&#148; means any day, other than a Saturday or Sunday, on which commercial
banks are not required to close in Boston, Massachusetts, United States of America, London, England or Valletta, Malta. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>CAI</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.05. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>CAI Development Agreement</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.06(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>CAI Services Agreement</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.06(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calendar Quarter</U>&#148; means the respective periods of three (3)&nbsp;consecutive calendar months ending March&nbsp;31,
June&nbsp;30, September&nbsp;30 and December 31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calendar Year</U>&#148; means each successive period of twelve
(12)&nbsp;calendar months commencing on January&nbsp;1 and ending on December 31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Claim</U>&#148; means a claim for breach of
any of the Warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Combination Product</U>&#148; means a product that includes a Product and at least one additional active ingredient (whether <FONT
STYLE="white-space:nowrap">co-formulated</FONT> or <FONT STYLE="white-space:nowrap">co-packaged)</FONT> other than a Product. Pharmaceutical dosage form vehicles, adjuvants, and excipients shall not be deemed to be &#147;active ingredients&#148;,
except in the case where such vehicle, adjuvant, or excipient is recognized by the FDA as an active ingredient in accordance with 21&nbsp;CFR 210.3(b)(7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercial License</U>&#148; means the contract pursuant to which Purchaser or any of its Affiliates grants a Commercial Licensee the
right to <FONT STYLE="white-space:nowrap">co-develop,</FONT> <FONT STYLE="white-space:nowrap">co-promote,</FONT> <FONT STYLE="white-space:nowrap">co-market</FONT> or otherwise has a license or other right to develop, promote, market, distribute,
offer for sale, sell or import or to otherwise commercialize a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercial </U><U>Licensee</U>&#148; means any third
party that is a party to a contract with Purchaser or any of its Affiliates pursuant to which such third party obtains rights to <FONT STYLE="white-space:nowrap">co-develop,</FONT> <FONT STYLE="white-space:nowrap">co-promote,</FONT> <FONT
STYLE="white-space:nowrap">co-market</FONT> or otherwise has a license or other right to develop, promote, market, distribute, offer for sale, sell or import or to otherwise commercialize a Product. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercially Reasonable and Diligent Efforts</U>&#148; means that [***].
Commercially Reasonable and Diligent Efforts require that the party: (a)&nbsp;in a timely manner assign responsibility for tasks to specific employee(s) with sufficient skills and experience as are required to accomplish such tasks, and hold such
employee(s) accountable for progress and monitor such progress on an <FONT STYLE="white-space:nowrap">on-going</FONT> basis; (b)&nbsp;set and timely seek to achieve specific and meaningful objectives for carrying out such tasks; and (c)&nbsp;timely
make and implement decisions and allocate resources designed to advance progress with respect to such tasks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Deductible</U>&#148; has the meaning ascribed to such term in Section&nbsp;6.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosed</U>&#148; means fairly disclosed in or under the Disclosure Letter and &#147;fairly&#148; means with sufficient
particularity to enable the Purchaser to make a reasonable assessment of the impact on the Company of the matter disclosed and to identify to a reasonable degree the nature and scope of the matter disclosed and to enable the Purchaser to have a
reasonable understanding of the issue, and &#147;<U>Disclose</U>&#148; shall be construed accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure
Bundle</U>&#148; means with reference to the contents of a CD containing documents from the virtual data room provided by [***] under reference &#147;[***]&#148; containing information about the Company, an index of which is attached to the
Disclosure Letter, only those documents which are cited in connection with specific disclosures against specified warranties and no other document shall be deemed to form part of the Disclosure Bundle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Letter</U>&#148; means the letter from the Seller to the Purchaser with the same date as this Agreement and described as
the Disclosure Letter, together with the Disclosure Bundle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dollars</U>&#148; or &#147;<U>$</U>&#148; means lawful money of the
United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Consideration</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>EMA</U>&#148; means the European Medicines Agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>EU</U>&#148; means the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exclusive License</U>&#148; means the Amended and Restated Exclusive License between [***] dated [***] (as novated to [***] on
[***]). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exclusive <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement</U>&#148; means the Exclusive <FONT
STYLE="white-space:nowrap">Sub-License</FONT> Agreement, dated [***], among [***], as amended by that certain Deed of Novation, dated [***], among [***], and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Commercial Sale</U>&#148; means, with respect to a Product, the first sale for use or consumption by the general public of a
Product in any country after Approval of a Product has been granted, or such marketing and sale is otherwise permitted, by the applicable Regulatory Authority of such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fundamental Warranties</U>&#148; has the meaning given in Section&nbsp;6.01. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Generic Product</U>&#148; means, with respect to a Product in a country, a pharmaceutical product that (i)&nbsp;contains the
same active ingredient(s) as a Product and (ii)&nbsp;is approved for commercial sale and use in such country under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>General Warranties</U>&#148; means the warranties of the Seller in Article III other than the Fundamental Warranties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Good Clinical Practices</U>&#148; means, with respect to Seller, the then current standards for clinical trials for pharmaceuticals
(including all applicable requirements relating to protection of human subjects), as set forth in the FDCA and applicable regulations promulgated thereunder (including, for example, 21 C.F.R. Parts 50, 54, and 56), as amended from time to time, and
such standards of good clinical practice (including all applicable requirements relating to protection of human subjects) as are required by other organizations and Governmental Entities in any other countries, including applicable regulations or
guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, in which a Products of Seller or its Affiliates are sold or intended to be sold, to the extent such standards
are not less stringent than in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Good Laboratory Practices</U>&#148; mean, with respect to Seller, the then
current standards for pharmaceutical laboratories, as set forth in the FDCA and applicable regulations and guidance promulgated thereunder, as amended from time to time, and such standards of good laboratory practices as are required by other
organizations and Governmental Entities in any other countries, including applicable regulations or guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use in which a
Products of Seller or its Affiliates are sold or intended to be sold, to the extent such standards are not less stringent than in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Good Manufacturing Practices</U>&#148; mean, with respect to Seller, the then current standards for the manufacture, processing,
packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA and applicable regulations and guidance promulgated thereunder, as amended from time to time, and such standards of good manufacturing practices as
are required by other organizations and Governmental Entities in any other countries, including applicable regulations or guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use in which a Products of Seller or its Affiliates are sold or intended to be sold, to the extent such standards are not less stringent than in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; means any government, court, arbitrator, department, commission, board, bureau, agency, authority,
instrumentality or other body, whether federal, state, local, foreign or other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Laws</U>&#148; means any law of any
Governmental Entity (including multi-country organizations) the purpose of which is to ensure the safety, efficacy and quality of medicines or pharmaceuticals by regulating the research, development, manufacturing and distribution of these products,
including laws relating to Good Laboratory Practices, Good </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Clinical Practices, investigational use, product marketing authorization, manufacturing facilities compliance and approval, Good Manufacturing Practices, labeling, advertising, promotional
practices, safety surveillance, record keeping and filing of required reports such as the U.S. Food, Drug and Cosmetic Act of 1938, as amended (the &#147;<U>FDCA</U>&#148;), and the Public Health Service Act, as amended, in each case including the
associated rules and regulations promulgated thereunder and all of their foreign equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>IND</U>&#148; means an
Investigational New Drug Application filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations (or its successor regulation) with respect to a Product, or the equivalent application or filing filed with any
equivalent agency or Governmental Entity outside the United States of America (including any supra-national agency such as the EMA), and all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the
foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Infringed Patent</U>&#148; means an issued and unexpired patent (i)&nbsp;that has not been abandoned, held invalid,
revoked, held or rendered unenforceable or lost through interference and (ii)&nbsp;the claims of which would be infringed by Purchaser&#146;s making, using, selling, offering for sale or importing of a Product in a particular country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all Patents; registered and unregistered copyrights and works of authorship, and applications
for registration thereof; trademarks, service marks, logos, trade dress, trade names and other similar indicia of source or origin; domain names; <FONT STYLE="white-space:nowrap">Know-How</FONT> and all other intellectual property and all copies and
tangible embodiments or descriptions of any of the foregoing (in whatever form or medium) and all goodwill associated with, and all rights related to or otherwise associated with, any of the foregoing in any jurisdiction in the world (including all
rights to collect royalties, products and proceeds in connection with any of the foregoing, and to sue and bring other claims for past, present and future infringement, misappropriation or other violation of any of the foregoing, and to recover
damages (including attorneys&#146; fees and expenses) and lost profits in connection therewith). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Interim Period</U>&#148; has
the meaning ascribed to such term in Section&nbsp;1.05(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Knowledge of Seller</U>&#148; (and any similar expression referring,
in whatever terms, to the knowledge or awareness (whatever the form of words used) of the Seller, means the [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT
STYLE="white-space:nowrap">Know-How</FONT></U>&#148; means any data, results, and information of any type whatsoever, whether tangible or intangible and regardless of the form or medium, including any
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, expertise, knowledge, practices, techniques, concepts, methodologies, methods, processes, protocols, designs, ideas, inventions (whether or not patentable or reduced to practice),
improvements, industrial designs and models, discoveries, developments, unpublished patent applications, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), assays, screens,
software, algorithms, models, data, databases, database rights, chemistry, manufacturing and control (CMC) information and data, lab notebooks, Patent data, stability, technology, test data and results (including pharmacological, biological,
chemical, biochemical, toxicological, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical test data), analytical and quality control data, results or descriptions, studies and procedures, development, manufacturing and distribution
costs, information contained in submissions to and information from regulatory authorities, and marketing and other reports. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Losses</U>&#148; has the meaning ascribed to such term in Section&nbsp;6.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAA</U>&#148; means an EU marketing authorization application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Consideration</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Event</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Payment</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Table</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NDA</U>&#148; means a new drug application for a drug filed in accordance with 21 C.F.R. Part 314, and all supplements filed pursuant
to the requirements of the FDA, including all documents, data and other information concerning the applicable drug which are necessary for FDA approval to market such drug in the United States, and any equivalent application submitted to any other
health authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales</U>&#148; means, with respect to a Product, the amount billed by Purchaser or its Affiliates or its
Commercial Licensees for sales of such Product in arm&#146;s length transactions to third parties, after deduction (if not already deducted in the amount invoiced) of the following items with respect to sales of such Product: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">credits or allowances, to the extent actually allowed and taken and not otherwise recovered by or reimbursed to Purchaser or its Affiliates or its Commercial Licensees, as applicable, on account of price adjustments,
recalls, claims, damaged goods, rejections or returns of items previously sold (including Product returned in connection with recalls or withdrawals); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">import taxes, export taxes, excise taxes (including annual fees due under Section&nbsp;9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L.
<FONT STYLE="white-space:nowrap">No.&nbsp;111-48)),</FONT> sales taxes, VAT, consumption taxes, duties or other Taxes levied on or imposed with respect to such sales (excluding income or net profit taxes or franchise taxes of any kind), to the
extent actually paid by Purchaser or its Affiliates or its Commercial Licensees and not reimbursed by a third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">insurance, customs charges, freight, shipping and other transportation costs incurred in shipping Product to such third party, to the extent actually paid by Purchaser or its Affiliates or its Commercial Licensees and
not reimbursed by a third party; and </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of
this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">trade, quantity and cash discounts, cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> coupons, retroactive price reductions, and charge-back payments and rebates granted to any third party (in each case
including by or to Governmental Entities or agencies (including Regulatory Authorities), purchasers, reimbursers, customers, distributors, wholesalers, and group purchasing and managed care organizations and other similar entities and institutions),
in each case, to the extent actually allowed in the ordinary course of business (a &#147;<U>Discount</U>&#148;); <I>provided, however</I>, that where any such Discount is based on sales of a bundled set of products in which a Product is included,
and in which the individual Discount for a Product is not itemized or otherwise determinable, the Discount shall be allocated to a Product on a pro rata basis based on the sales value (<I>i.e.</I>, the unit average selling price multiplied by the
unit volume) of a Product relative to the sales value contributed by the other constituent products in the relevant bundled set, with respect to such sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net Sales and all of the foregoing deductions from the gross invoiced sales prices of a Product shall be determined in accordance with
Purchaser&#146;s standard accounting procedures and in accordance with GAAP, in each case consistently applied. Notwithstanding anything contained herein, and for all purposes under this Agreement, Product shall be considered &#147;sold&#148; when
it is invoiced, shipped or paid for, whichever shall occur first. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For clarity, and notwithstanding anything contained herein,
(A)&nbsp;Net Sales shall not include any payments between or among Purchaser and its Affiliates, but any subsequent sale by an Affiliate to a third party customer shall be included in Net Sales, (B)&nbsp;Net Sales shall not include any amounts or
other consideration received by Purchaser or any of its Affiliates from a third party in consideration for entering into any contract with any Commercial Licensee or the grant of any license (including any sublicense) or other rights thereunder
(including the right to <FONT STYLE="white-space:nowrap">co-promote</FONT> or <FONT STYLE="white-space:nowrap">co-market</FONT> or any other right to market or otherwise commercialize a Product) to such third party and/or any of its Affiliates,
(C)&nbsp;sales by Purchaser or an Affiliate of Purchaser to a third party consignee shall not be recognized as Net Sales until the third party consignee sells a Product to a third party and so notifies Purchaser, and (D)&nbsp;sales by Purchaser or
its Affiliates of a Product to a Commercial Licensee shall not be considered a sale to a third party customer and shall not be included in Net Sales, but any subsequent sale by a Commercial Licensee to a third party customer shall be included in Net
Sales (with respect to any such sales of Product by a Commercial Licensee that are included in Net Sales hereunder, such Net Sales shall be calculated as provided herein as if such sales were by Purchaser or its Affiliates (except that such sales of
Product included in Net Sales pursuant to this clause (D)&nbsp;shall only be deemed to be billed and/or sold when Purchaser receives written notice of such sale and a copy of the corresponding invoice)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained herein, sales or other transfers of Product to any third party in connection with clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> research and trials, Product samples, compassionate sales or use, or an indigent program or similar <I>bona fide</I> arrangements in which Purchaser or any of its Affiliates or any of its or their
distributors, wholesalers or Commercial Licensees agree to forego a normal profit margin for good faith business reasons shall not be included in Net Sales except to the extent that Purchaser or any of its Affiliates or Commercial Licensees invoices
or receives amounts therefor. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Sales of any Combination Product for the purpose of calculating milestones or royalties
due under this Agreement shall be determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for a given accounting period as follows: first, Purchaser shall determine the actual Net
Sales of such Combination Product (using the above provisions), and then: such Net Sales amount for the Combination Product shall be multiplied by the fraction A/(A+B), where &#147;A&#148; is the net selling price in such country of a product
containing only a Product, if sold separately for the same dosage as contained in the Combination Product, and &#147;B&#148; is the net selling price in such country of any other active ingredients in the combination if sold separately for the same
dosage as contained in the Combination Product. All net selling prices of the elements of such <FONT STYLE="white-space:nowrap">end-user</FONT> product or service shall be calculated as the average net selling price of the said elements during the
applicable accounting period for which the Net Sales are being calculated. In the event that, in any country, no separate sale of either such above-designated product (containing only a Product and no other active ingredients) or any one or more of
the active ingredients included in such product are made during the accounting period in which the sale was made, or if net selling price for an active ingredient cannot be determined for an accounting period, Net Sales allocable to a Product in
each such country shall be determined by Purchaser in good faith prior to the end of the accounting period in question based on an equitable method of determining same that takes into account, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, all relevant factors (including variations in potency, the relative contribution of each active ingredient in the combination, and relative value to the end user of each active
ingredient). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing definition, references to Purchaser or its Affiliates or its Commercial Licensees shall be
deemed to include any of their respective successors in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>[***] Milestone Event</U>&#148; has the meaning ascribed to
such term in Section&nbsp;1.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>[***] Milestone Payment</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.03.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NIAID</U>&#148; has the meaning ascribed to such term in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NIAID Contract</U>&#148; has the meaning ascribed to such term in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NIAID Contract Funding</U>&#148; means any and all amounts paid by NIAID from time to time under the NIAID Contract, as the same may
be amended, restated, modified, or supplemented from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NIAID Payments</U>&#148; has the meaning ascribed to such
term is Section&nbsp;1.05. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NIAID Recipient</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.05(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement</U>&#148; means the Confidentiality Agreement, dated as of [***],
between Parent and Spero OpCo, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>[***] License Agreements</U>&#148; means, collectively, (i)&nbsp;the <FONT
STYLE="white-space:nowrap">Sub-License</FONT> Agreement, (ii)&nbsp;the Exclusive <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement and (iii)&nbsp;the Exclusive License. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other Transaction Documents</U>&#148; means, collectively, (i)&nbsp;the Shareholders
Agreement, (ii)&nbsp;the Subscription Agreement and (iii)&nbsp;the CAI Services Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; means all issued
patents, pending patent applications, statutory invention registrations and patent disclosures, and all reissues, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisional
applications, substitutions, extensions, supplementary protection certificates, reexaminations, extensions and all foreign equivalents of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>person</U>&#148; means any individual, firm, corporation, partnership, limited liability company, trust, joint venture, Governmental
Entity or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product</U>&#148; means a product, the manufacture, use, sale, offer for sale or importation of which in
or into a particular country would infringe a Valid Claim within the Transferred Patents, as determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Program</U>&#148; has the meaning ascribed to such term in
Section&nbsp;1.09(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Program IP</U>&#148; has the meaning ascribed to such term in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Price</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Authority</U>&#148; means any national or supranational governmental authority, including the FDA or the EMA, with
responsibility for granting any license, registrations or Approvals with respect to a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory
Authorizations</U>&#148; means any approvals, clearances, authorizations, registrations, certifications, licenses and permits granted by any Regulatory Authority, including any INDs, NDAs and MAAs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Filing</U>&#148; means the acceptance by the FDA of the filing of an NDA for a Product, the filing with EMA of a MAA for a
Product under the centralized European procedure or if the centralized EMA filing procedure is not used, the filing of a MAA for a Product in any European country, or any similar filing in any other country as prescribed by the applicable Regulatory
Authority in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Milestone Events</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.02.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Persons</U>&#148; has the meaning ascribed to such term in Section&nbsp;5.04. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Royalty Term</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.04(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Royalty Report</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.04(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shareholders Agreement</U>&#148; means the shareholders agreement to be entered into by Spero and Seller contemporaneously herewith.
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark
&#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>subsidiary</U>&#148; of any person means another person, an amount of the voting
securities, other voting ownership or voting partnership interests of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such voting interests, more than fifty percent (50%) of the
equity interests of which) is owned directly or indirectly by such first person or by another subsidiary of such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT
STYLE="white-space:nowrap">Sub-License</FONT> Agreement</U>&#148; means the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> royalty free <FONT STYLE="white-space:nowrap">Sub-license</FONT> Agreement, dated [***], between [***] and the Company,
as amended by the Amendment Agreement in respect of <FONT STYLE="white-space:nowrap">Sub-License</FONT> Agreement, dated [***], between [***] and the Company relating to the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means any and all taxes, charges, fees, duties, contributions, levies or other similar
assessments or liabilities, including income, gross receipts, corporation, ad valorem, premium, value-added, consumption, net worth, capital stock, capital gains, documentary, recapture, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT>
minimum, registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, business license, business organization, environmental, profits, severance, stamp, occupation,
windfall profits, escheat, customs duties, import, export, franchise, estimated and other taxes of any kind whatsoever imposed by any Governmental Entity (whether payable directly or by withholding), together with any interest, fines, penalties,
assessments, additions to tax or additional amounts imposed with respect to such items, including any liability for payment of taxes as a transferee or successor by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Returns</U>&#148; has the meaning ascribed to such term in Section&nbsp;3.07. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Intellectual Property</U>&#148; means all Intellectual Property of the Company as of immediately prior to the Closing,
including, without limitation, all of the Transferred Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Patents</U>&#148; has the meaning ascribed to such
term in Section&nbsp;1.04(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transferred Shares</U>&#148; has the meaning ascribed to such term in the preamble to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Upfront Consideration</U>&#148; has the meaning ascribed to such term in Section&nbsp;1.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S.</U>&#148; or &#147;<U>United States</U>&#148; means the United States of America, including its territories and possessions
(excluding all military bases and other military installations outside of the continental United States, Alaska, Hawaii and Washington, D.C.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Valid Claim</U>&#148; means a claim of an issued and unexpired patent which has not been held permanently revoked, unenforceable or
invalid by a decision of a court or other Governmental Entity of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise
(<I>i.e.</I>, only to the extent the subject matter is disclaimed or is sought to be deleted or amended through reissue). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>VAT</U>&#148; means value added tax imposed in any member state of the EU pursuant
to Council Directive (EC) 2006/112 on the common system of value added tax and national legislation implementing that Directive or any predecessor to it, or supplemental to that Directive, or any similar tax which may be substituted for or levied in
addition to it or any value added, sales turnover, goods and services or similar Tax imposed in a country which is not a member of the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warranties</U>&#148; means the General Warranties and the Fundamental Warranties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.08 <U>Counterparts</U>. This Agreement may be executed in one or more counterparts (including by facsimile or other means of
electronic transmission, such as by electronic mail in &#147;pdf&#148; form), all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the parties and
delivered to the other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.09 <U>Entire Agreement</U>. This Agreement, the Other Transaction Documents and the <FONT
STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement contain the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior agreements, drafts, understandings, promises,
undertakings or implications relating to such subject matter, whether written or oral. No provision of this Agreement shall be interpreted in favor of, or against, any party by reason of the fact that any such provision is inconsistent with any
prior draft hereof. Nothing in this Section&nbsp;7.09 shall be effective to limit or exclude any liability for fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.10
<U>Severability</U>. If any provision of this Agreement (or any portion thereof) or the application of any such provision (or any portion thereof) to any person or circumstance shall be held invalid, illegal or unenforceable in any respect by a
court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity or enforceability of any other provision hereof (or the remaining portion thereof) or the application of such provision (or the remaining
portion thereof) to any other persons or circumstances. In the event that any provision of this Agreement shall be held by a court of competent jurisdiction to be invalid, illegal or unenforceable, such provision shall be limited or eliminated, but
only to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.11 <U>Governing
Law</U>. This Agreement and any dispute or claim (including <FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in
accordance with the law of England and Wales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.12 <U>Consent to Jurisdiction</U>. Each party irrevocably agrees that the courts
of England and Wales shall have <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction to settle any dispute or claim (including <FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes or claims) arising out of or in connection
with this Agreement or its subject matter or formation. Each of Seller and CAI irrevocably appoints Parent at its registered office address from time to time as its agent to receive on its behalf in England or Wales service of any proceedings under
Section&nbsp;7.11. Each of Spero and Purchaser irrevocably appoints Osborne Clarke LLP at One London Wall, London EC2Y 5EB (or its </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">registered office from time to time) as its agent to receive on its behalf in England or Wales service of any
proceedings under Section&nbsp;7.11. In each case, such service shall be deemed completed on delivery to such agent (whether or not it is forwarded to and received by any appointor of such agent) and shall be valid until such time as the other
relevant parties have received prior written notice that such agent has ceased to act as agent. If for any reason such agent ceases to be able to act as agent or no longer has an address in England or Wales, the appointor shall forthwith appoint a
substitute acceptable to the other relevant parties and deliver to them the new agent&#146;s name and address within England and Wales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.13 <U>Remedies</U>. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity. Subject to Section&nbsp;6.02(g), no remedy of any party that is based upon the inaccuracy or breach
of any warranty, covenant or agreement of any other party shall be affected by any investigation conducted with respect to, or any knowledge acquired, at any time, whether before or after the execution and delivery of this Agreement or the Closing
Date, with respect to any facts, matters or circumstances giving rise to any such inaccuracy or breach, and subject as aforesaid no such investigation or knowledge shall limit any party&#146;s right to rely on any warranties of the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SECTION 7.14 <U>Spero Therapeutics</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Spero Therapeutics will procure that Purchaser performs its obligations under, and complies with the terms and conditions of, this
Agreement. If Purchaser fails to perform any of its obligations under this Agreement, Spero Therapeutics shall indemnify Seller from and against any and all losses, damages, expenses, liabilities, claims, costs or proceedings which Seller may suffer
or incur by reason of such failure. If Spero Therapeutics undergoes any reorganization, as part of such reorganization, it will provide Seller with the indemnity set forth in this Section&nbsp;7.14(a) from its successor (provided such successor is
of at least similar financial standing to Spero Therapeutics as of the date hereof, failing which it shall procure that such replacement indemnity is provided by an Affiliate of at least such similar financial standing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Spero Therapeutics will procure that Spero performs its obligations under, and complies with the terms and conditions of, the CAI Services
Agreement. If Spero fails to perform any of its obligations under the CAI Services Agreement, Spero Therapeutics shall indemnify CAI from and against any and all losses, damages, expenses, liabilities, claims, costs or proceedings which CAI may
suffer or incur by reason of such failure. If Spero Therapeutics undergoes any reorganization, as part of such reorganization, it will provide CAI with the indemnity set forth in this Section&nbsp;7.14(b) from its successor (provided such successor
is of at least similar financial standing to Spero Therapeutics as of the date hereof, failing which it shall procure that such replacement indemnity is provided by an Affiliate of at least such similar financial standing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank; signature page follows.</I>] </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have duly executed this Agreement as a deed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a <B>Deed</B> on behalf of <B>SPERO CANTAB</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>UK LIMITED</B>, a company incorporated in England</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and Wales,
acting by Ankit Mahadevia,&nbsp;a director, in</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the presence of:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Signature of witness: </I>/s/ Lisa Henrici</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Name: </I>&nbsp;Lisa Henrici</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Address:</I> &nbsp;675 Mass Ave 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Fl.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cambridge, MA 02139</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Occupation: </I>&nbsp;Executive Assistant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a <B>Deed</B> on behalf of <B>SPERO CANTAB</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INC.</B>, a corporation incorporated in Delaware, acting</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by
Ankit Mahadevia,&nbsp;being a person who, in</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">accordance with the laws of that territory, is acting</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">under the authority of the company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Ankit
Mahadevia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorised signatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><U>SOLELY FOR PURPOSES OF SECTION 7.14:</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a <B>Deed</B> on behalf of <B>SPERO</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THERAPEUTICS LLC</B>, a limited liability company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">formed in
Delaware, by Ankit Mahadevia,&nbsp;being a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">person who, in accordance with the laws of that</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">territory, is acting under the authority of the company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Ankit
Mahadevia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorised signatory</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a <B>Deed</B> on behalf of <B>PBB</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DISTRIBUTIONS LIMITED</B>, a company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">incorporated in Malta, by
Michael Earl,&nbsp;being a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">person who, in accordance with the laws of that</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">territory, is acting under the authority of the company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Michael
Earl&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorised signatory</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed as a deed on behalf of <B>NEW PHARMA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LICENSE HOLDINGS LIMITED</B>, a company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">incorporated in Malta,
by Richard Garraway,&nbsp;being a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">person who, in accordance with the laws of that</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">territory, is acting under the authority of the company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Richard
Garraway&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorised signatory</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a <B>Deed</B> by <B>CANTAB ANTI-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INFECTIVES LIMITED</B> acting by Michael Earl, a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">director, in
the presence of:</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of witness:</I> /s/ Justin Bowen</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Name: </I>Justin Bowen</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Address: </I>[***]</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Occupation: </I>Lawyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Michael
Earl&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SOLELY FOR PURPOSES OF ARTICLE VI</U>: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executed</B> as a D<B>eed</B> by <B>PRO BONO BIO PLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">acting by <U>Michael Earl</U>, a director, in the presence of:</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Signature of witness: </I>/s/ Justin Bowen</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Name:</I> Justin Bowen</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Address: </I>[***]</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Occupation: </I>Lawyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR><BR><U>/s/ Michael
Earl&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Program IP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Attached)
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark
&#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Polymyxin Cases</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>[***] - Link to EPO Family Information - here</I></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***]&nbsp;Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***]&nbsp;Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>[***] - Link to EPO Family Information - here </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***]&nbsp;Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***] Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>[***] - Link to WIPO Information - here </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***]&nbsp;Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>[***] - Link to WIPO Information - here </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.35pt; font-size:8pt; font-family:Times New Roman"><B><I>CAI Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>[***] Ref</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Country</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Registered&nbsp;Proprietor/s</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application&nbsp;Number</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Application<BR>Date</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Status</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Publication<BR>Number</I></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subscription Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Attached) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SUBSCRIPTION AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;), dated as of June&nbsp;6, 2016 (the &#147;<U>Effective Date</U>&#148;),
is made by and between Spero Cantab, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and PBB Distributions Limited, a company organized under the laws of Malta (&#147;<U>PBB</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to issue and sell to PBB, and PBB desires to purchase from the Company, one hundred twenty-five (125)
shares (the &#147;<U>Shares</U>&#148;) of the Company&#146;s common stock, $0.001 par value per share (&#147;<U>Common Stock</U>&#148;), which represent twelve and one-half percent (12.5%) of the Fully Diluted Shares (as defined below) as of the
Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing, the agreements set forth in this Agreement, and other good and
valuable consideration, the adequacy and receipt of which are hereby acknowledged, the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.
<U>Purchase and Sale of Shares; Anti-Dilution</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. <U>Purchase and Sale</U>. Subject to the terms and conditions
hereof, the Company hereby issues and sells to PBB, and PBB hereby subscribes for and agrees to purchase from the Company, the Shares as partial consideration for the &#147;Transferred Shares&#148;, as defined in and contemplated by that certain
Stock Purchase Agreement by and among the Company, PBB and the other parties thereto, dated as of the date hereof (the &#147;<U>Stock Purchase Agreement</U>&#148;). Concurrently with the execution of this Agreement, PBB, Therapeutics (as defined
below) and the Company shall enter into a shareholders agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Anti-Dilution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. Subject to <U>Section</U><U></U><U>&nbsp;1.c</U> below, in the event that the Company conducts one or more financings that
involve a sale of any equity securities of the Company to Spero Therapeutics, LLC, a Delaware limited liability company and parent of the Company (&#147;<U>Therapeutics</U>&#148;) or any affiliate thereof (such financing, an &#147;<U>Affiliate
Financing</U>&#148;), then the Company shall issue to PBB, for no additional consideration, that number of additional shares of Common Stock as is required for PBB&#146;s ownership of shares of Common Stock to be equal to twelve and one-half
percent&nbsp;(12.5%) of the Fully Diluted Shares; <U>provided</U>, <U>however</U>, that (i)&nbsp;from and after such time as the Company has raised a cumulative total of at least [***] Dollars ($[***] USD) but less than [***] Dollars ($[***] USD) in
one or more Affiliate Financings, then the Company shall issue to PBB, for no additional consideration, that number of additional shares of Common Stock as is required for PBB&#146;s ownership of shares of Common Stock to be equal to [***]
percent&nbsp;([***]%) of the Fully Diluted Shares; (ii)&nbsp;from and after such time as the Company has raised a cumulative total of at least [***] Dollars ($[***] USD) but less than the Financing Threshold (as defined below) in one or more
Affiliate Financings, then the Company shall issue to PBB, for no additional consideration, that number of additional shares of Common Stock as is required for PBB&#146;s ownership of shares of </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Common Stock to be equal to five percent&nbsp;(5.0%) of the Fully Diluted Shares; and (iii)&nbsp;no additional shares shall be issued to PBB pursuant to this
<U>Section</U><U></U><U>&nbsp;1.b.i</U> once the Company has achieved the Financing Threshold. For avoidance of doubt, if the Company achieves the Financing Threshold as a result of receiving proceeds in a particular Affiliate Financing (whether
such Affiliate Financing is the first Affiliate Financing or a subsequent Affiliate Financing), then the Company shall issue to PBB, for no additional consideration, that number of additional shares of Common Stock as is required for PBB&#146;s
ownership of shares of Common Stock to be equal to five percent&nbsp;(5.0%) of the Fully Diluted Shares, which percentage shall be calculated as if such Affiliate Financing resulted in the Company having raised in gross proceeds only the amount that
is necessary to achieve the Financing Threshold. For purposes of illustration only, if, prior to an Affiliate Financing, the Company had raised Seven Million Dollars ($7,000,000&nbsp;USD) in gross proceeds creditable toward the Affiliate Financing
Threshold and the Company raises in such Affiliate Financing Two Million Dollars ($2,000,000 USD) from the issuance and sale of shares of Common Stock to Therapeutics, then the number of shares of Common Stock issuable to PBB shall be calculated as
if such Affiliate Financing resulted in the Company having raised exactly One Million Dollars ($1,000,000 USD) in gross proceeds. All shares of Common Stock issued to PBB pursuant to this <U>Section</U><U></U><U>&nbsp;1.b.i</U> shall be duly
authorized and validly issued and considered fully paid and nonassessable. All such shares of Common Stock shall be free and clear of all encumbrances created, imposed or suffered to be imposed by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. For purposes of this Agreement, the term &#147;<U>Fully Diluted Shares</U>&#148; means (i)&nbsp;all of the issued and
outstanding shares of Common Stock, preferred stock (calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) and other capital stock or equity security of the Company (calculated on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis); (ii) any issued and outstanding security which is convertible, with or without consideration, into any Common Stock, preferred stock or other equity security of the Company;
(iii)&nbsp;any issued and outstanding security or other agreement carrying or including any warrant or right to subscribe to or purchase any Common Stock, preferred stock or other equity security of the Company; and (iv)&nbsp;any issued and
outstanding options and warrants to purchase Common Stock, preferred stock or other equity security of the Company (calculated on an <FONT STYLE="white-space:nowrap">as-exercised,</FONT> as converted to Common Stock basis). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. For purposes of this Agreement, the term &#147;<U>Financing Threshold</U>&#148; means the receipt by the Company of gross
proceeds in the aggregate amount of Eight Million Dollars&nbsp;($8,000,000 USD) through the issuance and sale by the Company of any equity securities of the Company in one or more Affiliate Financings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. The rights of PBB set forth in this <U>Section</U><U></U><U>&nbsp;1.b</U> are not transferable or separately detachable
from the underlying Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. <U>Third Party Financings</U>. Notwithstanding anything in this Agreement to the
contrary, the parties agree that PBB and the other stockholders of the Company shall share ratably in any dilution of their respective equity interests in the Company resulting from any Third Party Financing (as defined below), and that the
percentages set forth in <U>Section</U><U></U><U>&nbsp;1.b</U> above shall be ratable adjusted in the event of any dilution caused by a Third </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Party Financing. Nonetheless, for so long as PBB owns [***] percent ([***]%) of the Fully Diluted Shares, PBB shall have the right, but not the obligation, to purchase, at the price and on the
terms offered in each sale of any equity securities of the Company to any third party other than Spero Therapeutics, LLC or any affiliate thereof (such financing, a &#147;<U>Third Party Financing</U>&#148;), all or a portion of that number of
securities offered for sale in such Third Party Financing (&#147;<U>Offered Securities</U>&#148;) as is required for PBB to maintain its ownership percentage in effect immediately prior to such Third Party Financing. For avoidance of doubt, in the
event the Company conducts any such additional Third Party Financing and PBB does not exercise its right to purchase Offered Securities pursuant to this <U>Section</U><U></U><U>&nbsp;1.c</U>, then PBB&#146;s right to purchase Offered Securities at
any future Third Party Financing pursuant to this <U>Section</U><U></U><U>&nbsp;1.c</U> shall be terminated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. <U>Terms
of Financing</U>. The Company hereby covenants and agrees that any and all sales by the Company of its equity securities in any Affiliate Financing shall be made on good faith terms and at commercially reasonable valuations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. <U>Representations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. <U>Company Representations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">i. The Company is duly formed and validly existing under the laws of Delaware, with full power and authority to conduct its
business as it is currently being conducted and to own its assets; and has secured any other authorizations, approvals, permits and orders required by law for the conduct by the Company of its business as it is currently being conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">ii. All corporate action required to be taken by the Company&#146;s Board of Directors and stockholders in order to authorize
the Company to enter into this Agreement and to issue the Shares has been taken. This Agreement constitutes a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms except (i)&nbsp;as
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors&#146; rights generally, or (ii)&nbsp;as limited by laws
relating to the availability of specific performance, injunctive relief, or other equitable remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">iii. The Shares have
been duly authorized and, when issued, sold, and delivered in accordance with the terms of and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">iv. The Company represents that it has no debts or other financial or legal obligations, other than those obligations incurred
in the ordinary course of business that would not materially adversely affect the Company&#146;s performance under this Agreement or any other agreement between the Company and PBB. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">v. The authorized share capital, option plans and issuance, warrant issuance
and any other equity securities (including securities convertible into or exchangeable for equity securities) of the Company (the &#147;<U>Company Capitalization</U>&#148;) as of the date hereof is as set forth in <U>Schedule 2(a)(v)(i)</U> of this
Agreement, which includes (A)&nbsp;the aggregate number of issued and outstanding shares of capital stock of the Company (including shares of Common Stock and each series of convertible preferred shares) and (B)&nbsp;the aggregate number of shares
of Common Stock issuable under all outstanding options, all outstanding warrants and all other outstanding securities or obligations which, by their terms, whether directly or indirectly, may be exercisable or exchangeable for, convertible into, or
require the Company to issue, shares of Common Stock. All issued and outstanding shares of Common Stock and all issued and outstanding shares of preferred stock are validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> Upon the consummation of the transactions contemplated hereby, the Company Capitalization will be as set forth in <U>Schedule 2(a)(v)(ii)</U> of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">vi. Neither the Company nor any person acting on behalf of the Corporation has offered or sold any of the Shares by any form
of general solicitation or general advertising (within the meaning of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder). The Company agrees that the foregoing representations and warranties shall survive
the Company&#146;s issuance of the Shares, as well as any investigation made by any party relying on the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>PBB
Representations</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. PBB has full power and authority to enter into this Agreement. When executed and delivered by
PBB, this Agreement will constitute a valid and legally binding obligation of PBB, enforceable in accordance with its terms, except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other
laws of general application relating to or affecting the enforcement of creditors&#146; rights generally, or (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. PBB does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant
participations to such person or to any third person, with respect to any of the Shares, and PBB has not been formed for the specific purpose of acquiring the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. PBB has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to
subscribe for the Shares or any use of this Agreement, including (i)&nbsp;the legal requirements within its jurisdiction for the purchase of the Shares, (ii)&nbsp;any foreign exchange restrictions applicable to such purchase, (iii)&nbsp;any
governmental or other consents that may need to be obtained, and (iv)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. PBB&#146;s subscription and
payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of its jurisdiction. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. <U>Notices</U>. All notices and other communications provided for herein shall be in writing and shall be deemed to have
been duly given if delivered personally or sent by registered or certified mail, return receipt requested, postage prepaid to the following addresses (or such other address as either party shall have specified by notice in writing to the other):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spero Cantab, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Ankit Mahadevia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mintz Levin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Financial Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Lewis J. Geffen, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to PBB: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o Pro Bono Bio PLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leverton House </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">13 Bedford Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">London WC1B 3RA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">England </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Michael Earl/Justin Bowen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">DAC Beachcroft LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">100 Fetter Lane </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">London EC4A 1BN </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">England </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Deverill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. <U>Amendment</U>. Neither this Agreement nor any provision hereof may be changed, waived, discharged or terminated orally or
by course of dealing, but only by a statement in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. <U>Parties in Interest</U>. All the terms and provisions of this Agreement
shall be binding upon and inure to the benefit of and be enforceable by the respective successors and assigns of the parties hereto, whether so expressed or not. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. <U>Headings</U>. The headings of the sections and paragraphs of this Agreement have been inserted for convenience of
reference only and shall not affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e. <U>Choice of Law</U>. It is the
intention of the parties that the internal laws, and not the laws of conflicts, of the State of Delaware should govern the enforceability and validity of this Agreement, the construction of its terms and the interpretation of the rights and duties
of the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f. <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, including by
facsimile transmission, and by different parties hereto in separate counterparts, with the same effect as if all parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall
constitute one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g. <U>Submission to Jurisdiction</U>. With respect to any suit, action or
proceeding relating to any offers, purchases or sales of the Shares by the undersigned (&#147;<U>Proceedings</U>&#148;), the undersigned irrevocably submits to the jurisdiction of the federal or state courts located in the Commonwealth of
Massachusetts, which submission shall be exclusive unless none of such courts has lawful jurisdiction over such Proceedings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h. <U>Severability</U>. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction,
such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Entire Agreement</U>. This Agreement, together with the Stock Purchase Agreement, constitutes the entire agreement
between the Company and PBB with respect to the subject matter hereof and supersedes all prior agreements and understandings related to such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions
of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have duly executed this Subscription Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO CANTAB, INC.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PBB:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PBB DISTRIBUTIONS LIMITED</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 2(a)(v)(i) </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spero Therapeutics, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">875</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 2(a)(v)(ii) </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spero Therapeutics, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">875</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PBB Distributions Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">125</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated
by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENT TO STOCK PURCHASE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This AMENDMENT TO STOCK PURCHASE AGREEMENT (this &#147;<B>Amendment</B>&#148;), effective as of July&nbsp;18, 2017, is made by and among Spero
Cantab, Inc. (&#147;<B>Cantab</B>&#148;), PBB Distributions Limited (&#147;<B>PBB</B>&#148;), Spero Cantab UK Limited, Spero Therapeutics, Inc. (formerly Spero Therapeutics, LLC), New Pharma License Holdings Limited, Cantab Anti-Infectives LTD and
Pro Bono Bio PLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties entered into that certain Stock Purchase Agreement, dated June&nbsp;6, 2016 (the
&#147;<B>Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cantab and PBB entered into a Stock Purchase Agreement on the same date hereof, pursuant to which
PBB transferred to Cantab, and Cantab repurchased from PBB, certain shares of Cantab&#146;s common stock in exchange for cash consideration and increased Milestone Consideration (as defined in the Agreement) as set forth in such agreement (the
&#147;<B>Repurchase</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in consideration of the Repurchase and related transactions, the parties hereto desire to amend
certain terms and conditions of the Agreement as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of these premises and the mutual
promises herein made, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. In Section&nbsp;1.03(a)(i)(A) of the Agreement, the first Regulatory Milestone Event of [***] is increased from $[***] to
$[***]; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. In Section&nbsp;1.03(a)(i)(B) of the Agreement, the second Regulatory Milestone Event of [***] is increased
from $[***] to $[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Ratification of Agreement; Capitalized Terms</U>. Except as expressly modified by this Amendment, the
Agreement is hereby ratified and confirmed in all respects. Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Entire Agreement</U>. This Amendment, together with the Agreement and any schedules, exhibits, and other documents referenced therein,
constitute the entire agreement among the parties hereto and supersede any prior correspondence or documents evidencing negotiations between the parties, whether written or oral. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Governing Law</U>. This Amendment is made pursuant to and shall be governed by, interpreted under, and the rights of the parties
determined in accordance with, the laws of England and Wales, without reference to principles of conflicts of law thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Counterparts</U>. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit, indicated by the mark &#147;[***],&#148;
were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amendment effective as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO CANTAB, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO CANTAB UK LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(formerly Spero Therapeutics, LLC)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEW PHARMA LICENSE HOLDINGS LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ankit Mahadevia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amendment effective as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PBB DISTRIBUTIONS LIMITED</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Earl</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Earl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANTAB ANTI-INFECTIVES LIMITED</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Earl</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Earl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRO BONO BIO PLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Earl</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Earl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of this Exhibit,
indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 406 of the Securities
Act of 1933, as amended. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g431217g14o23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g14o23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[3N64&AO=&]S:&]P(#,N,  X0DE-! 0
M     "D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  -4')E971H:2!396MA
M<@ X0DE-!"4      !"/.<\/Z1LFFWP1&LNY4:S$.$))300]     !OD @
M "!N:5<     7 !< '  : !X &8 8@!U "T ;0!W &4 +0!F '  ,0 P %P
M00!: #  ,0 U #$ +0!8 $4 4@!/ %@       $$  ;< -@:4_^  0$  0#J
M"F\(9  !  \ 6 ("  $ 6 (#  $ 3 !E '0 = !E '( (  H #@ +@ U "
M>  @ #$ ,0 B "D
M             0         #     P    $
M     %!225;B,
M
M   8       0)Q G$"<  ! G          #  )0#
M             P        !$%Q  7$L# &A#!             $  0
M                * [6Q@4   #_  $ _P    ,
M
M
M
M
M
M
M
M
M
M
M                                                  $
M          #     4TU42@     0 +  6 !E '( ;P!X "  4 !H &$ <P!E
M '( (  W #4 ,  P $0 6  @ %  4P   $QE861I;F=%9&=E  !086=E4VEZ
M90!,971T97( 4&%G95)E9VEO;@  1'5P;&5X $YO;F4 4F5S;VQU=&EO;@ V
M,#!X-C P9'!I
M                          !$%P  ,4Y26 $    ,%P
M                                         &(8BD\&  $ "PD0
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M  0 $ !R '( ,0 Y #( ,0 P #0 #  $       -  8  0!O".H*%  0 #$
M,P N #  +@ P "X ,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 0 !
M                                    .$))300Z      $G    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    B %P 7 !P &@ > !F &( =0 M &T =P!E
M "T 9@!P #$ , !< $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,@ S
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG   "^@    QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P   D<    +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M  !     0'W''#^    X0DE- _(       H  /_______P  .$))300-
M   $    >#A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #-0    8              5<   (1          $
M                         0             "$0   5<
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   5<     4F=H=&QO
M;F<   (1    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   %7     %)G:'1L;VYG   "$0    -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    !3A"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M;_W?2W?;?M&_\[[1]F]'_A?T:T^LLZVYS/V6XC]'8'#V!N\C]$\OLW/]CO\
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M/;7]G+1+ Z^=Q>W_ +3L?Z?\W_A$#D@" 2-=F2/+YI1G,0)CCKC\.(\+OI+
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MMM==EN198^^SUVN?N^R46.]/&_[E,KKL_H_IUV,E$<7&!<JX/"MU\#<> D"
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M2GZJ27RJDDI__]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !2DU- "H    (  @!$@ #
M     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    #@   +"':0 $     0
M ,    #L !.O$   )Q  $Z\0   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3<Z,#@Z,C0@,38Z-30Z,#8 4')E971H:2!396MA<@     #
MH $  P    '__P  H ( !     $   (1H , !     $   %7          8!
M P #     0 &   !&@ %     0   3H!&P %     0   4(!*  #     0 "
M   " 0 $     0   4H" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!3$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    #@   +"':0 $     0   ,    #L
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3<Z,#@Z,C0@,38Z-30Z,#8 4')E971H:2!396MA<@     #H $  P
M  '__P  H ( !     $   (1H , !     $   %7          8! P #
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M4L;T/83S3RE*8?H'(M9#JFWM;9-D@.UJ5Z@DP$<17AUISI[R(OE\6?&7: %
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MP+.-1/J!M C6-K2^MPR1M[^VH'$:<\WX'5(W-*1:4A*8RT7^=Z\9O^,^D_\
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MOFFIU[>[RNOR858I-US./698A<BEI@6J-#8T+[!:AG"9PBJZ,,?V.0$-J4I
MD-/4)2*%V$@CJ5]R%IBC;M,H&MG-=572:C07MI2[X)TVK-I?4);.N4&4JHZ+
M9ER4=L96RM)JT'M(<U]SM7<681#&CL[]^E1MRLA4=<:=S7U-82@ SLV-]6DP
M7[:3+/OC>Z'MCI>K+?G=M*FP]6W]%3MB@*5MCX8X8SU.LB\"FM>,CNE]?F6O
MK:QS$LEV=%19"I:I]VSDY&R]%ZE>W8C6Z6;2S5LF5=D&V6?;$KV5#J;?:ER>
MP)):YK+UZJK! B$FH8WGEDQ$(V1.VWJ4FME&M>H#K#47D%E&WTYHMH#H=Q$/
M"PZ^^PEL?$H:H1DA&"FPW+&7<8QC&,HC\J71MQ4A>D.2UA*44:"FXA[(M)(I
M'$(2^N*&>5TSQTZ'/Z!VDD<>'- -G,<5N_MZ-82U.&E P.J%<#00APMNPY7Z
MSDL^TJ?3VCL5Y@0Y6VWU2C76"F9&?(+:3W(E;.]8BPR !9/?F<IU*[TZ#RK[
MXM=5MHOB2/@ZH]-;?8"OB"B F+E.J[R! MY2(]_9R,V[<YN:M\Y_I!_<?IA.
MDAJ2NY$[FHT"%L3JGE^B+0[NZT#>V)D;<D$M<EBI682B2ITP##AZ*)+!Z!UM
MFY2NOM]I62/8FML+E9 =Q%"T5[#$I7$G)%(K4  /,S,",1SFI:A[;6JUMIY^
M2Q:H5+-ALP,2U]BNMKFE Q ]S&&1EQ$1)%/QF9LQN9'*GN\/&"#N>S(U)9+;
M<5C=>)XHAALLASKSW7LZG@FDF0_>G8^K+M7+F:;U6X2=#ZQ]^$6&4MIK8,XQ
M V(%AYR@=FDD*VUG8NB+*X=K[((@10SR:\R:-9U@!F;.MLL\<VZ;ED1C#5KL
M*!TP%^Q88S713015W0-X!?,P]03=4"HM+JM&07?J0)36LB4#$R/E2R5C.<=>
MOBPW;M\RB?Q^^E=?TI;SU0,CZ"HPFMV^0*K$=^;G%&XUYN-V,?*6Q5 V\X3.
MP)Y&BW%Y,)S3MH])U" :H0BKM*65;B;#F>[34Z@M=4TD,&!).YO:ZQ0N,8WZ
MX=6?+0M>'Q P+"^8?V^*%6;/:RD%6N$56?@7ZMN:/UBS51=3: 1441X[0(7.
MOAWD-<TI%9(F8;+H_P#GEKR QKC&OG*.PB(L3D'KCFPC3BSQMF;7#X39>IT:
M5M:B1$*=@.]H?E#LSVF;UK8];],JF9*9*?F9F9F?XS,\SE(C C C'$#$#$?P
MB(XB/]67Y9YGN,8QC&?*N*4*$2LA(J^B5')5!299HH)^TB@PH8"56B![" [X
M#!!-^(8M!,]GL%O6M[WEIX,8ARTN]NYBF I\!#/ P@D0=XRF!9XRF#["F(+M
M[9F(G+J#6MZ6.5YU U9M1)ROS+$X(U>08D@\@Q(=XQ,CSW1$S&:RL@YCON4]
M0R>IE#C^<+!&["=)+.]+#%C64T.Y"=;^9I&I*^H.:"%+8XI!&,RXLM7Z+4C:
MF2GE*T7U'Y0;+TF]1MQZM[;HQMG\;ZDFY-O:]0P\GU HW5J?^+;1P>4Z*VU+
M2)*C8$7_ )Z:BDL%R/+^K&N]5_3K4>DNIZQ75_!.FXIQ3U73TH%%L[M)C4?A
M6K2?C"ZQ5NJZ O5R)'Y#K;7+-+_'LH0^/%Q.*1R,EB1&?8F5M:S5#>UI&-&K
M4(DA)"I:G9T&M(VT"U0 U5]$F]24^SME%B$$.A;_ %0TFM#3:C6:H)07X?1J
MU"96IIUZ',0D%M>NE6_(J"]HF[P*Y6J3D!F8CF?RUW6R+<;?9[0H>'XA>M6P
M79MNOO2I[C8I#+MC\^T2%$"?.W@VP$&41,\0F,K9H)$91-Y$>--'X='7J4/B
M@HO9QI#0P-JEU<32B=;#LXT"1(<(LK6]"-'H(-;]1:S*9C,J+\8'+E=3VO%W
M?MT5/ '_ *-[(FDOZ$(E#]7L4$]P2KY\K 54T+B;B(EQ7)(Z*K6R(//SC5)W
M1X4.@G*2DFR4UU7*V,N8QC&,9'N;<E\NV58;+;=A<\4M-K1C@D F*P936L1?
M9@TB:UI[DW"0R!R:5#F0)"O4GK$H@*=")4&F& WH0M[QC) EE@*  HH "RRP
M!++++#H "P UH(   '6@A $.M!"$.M:#K6M:UK6L8SSQC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,9";J__ $LLWC>GM?TB9??JBPWY(N_IQUZBE)P"
M4RY:QNZ8/S"7*Q259$7^/)5",U !YCJ=P4*4*E A-%J_4/\ .+W36M_=9W$W
M'"?REM?5T[%DE,'Y[BEY5G)&1D(8F#DA(!F>X>DO.HZ7]9^LOL>G]/U].4&H
M^G8TMMUQU!J].F]3;/9"$QK$;C7[%JW!8*EL65EJ>JQ8")LYM&</QC&,8QC&
M,8R&UI\,T?;5HLMIOS:K0N"94%7*F1J&2E99X<1LD24<A*^/9Y9FM%?"N/;3
M4A[FG%\:LP1@=';X;U?^CYZ?]9]7T.K]C5?7LJ:+MQKZ9 JAU$:Y"4ELP[?(
M)_3V6&532RVJ8%Y24=^=PZ1_2 Z_Z-Z2O=(ZZTE]9JI3I[]P3;>Z=!D'#1UI
M]WC()D^]"[0/759'<D8&>S)?H4*-L1I&YN2IT*! F)1HD20DM.E2)$Q824Z9
M,04$)1)!!0 %E%%A" L 0A#K6M:UG;*]=%1":M5*J]:NI:$(2 J2E*A@%J4L
M(@ 6L!@0 8@1&(B(B(SBCWOM/=9LN;8L6&FY[W&37.<TI-C6L.9-C&',D9E,
MD13,S,S.>TXK1Y)I(M[UHXHPK>]?WZT8#8-[UZ_IZZUOUUZYY:0-JM8JD4B-
ME#D$0\=PBY9+DAYYCF(+F.?CG[Y0)=I"4?<2@HY_JGG*H8MXC:8BD6B<52V/
M8RI'$^27SDPD:H,=]B]J=E\A.168J2%M84P+ 8VB72B-(5*<!;::R/)Z=6B.
M$2F&5):9,*],<+"_4T-9@#'P#-)3UM$[03,R7EVE;2:15X9F5\:JIXA"8.3N
MM>37"XHCF-SU-N9B/^LSJ6W<NS6,N.XJ^K=LMF6N&9Y66QN&<D3SF<YNW&TT
M;+NEMXT_TE*JI>YW6%3U=*F;]G-=SIJ7M=/?FO48<DHY.W&+&]>?J8NWW())
MPDQ_HF]A97Q?TJ>X_-LF]WT[+93M&+[8X58*I7ID*R_:E<KK+G@IF8+NF)XG
MC+9%!5=15D?C347T$,YGN:JQ9&R9-C]GO[P&!D8B(&)^.9S'MJ^-&)78IM9\
ML:Y+"7S*XHOS[&I;*F)LBL;/!JA769JOKFAN0MHT;<*PF2?2>*2M('1B<ED<
M3=,^D2O>E&O1A:S1(*#QIZB3U$2&?FK>P-3K]/9H.@_@Z5VK1D; 3$E(VGK@
MH7VC%0V+ A/:V0=&JMZNO97$ ZK+]BW9U;R)CF NZZR:CJ-B/I974V8EG,S,
MJFZ2CE*"M+4:7+E2:TK6>K76HE92,E,PKWF-Q*,;8F<"0DGT9T2*((1I-*/E
M4A,//",T182@@KEADBNEA$PD%LV2XYY8X]IO-KOGFR?M)#9VSE#,?=:PDN3D
MBF,*E@Y[5 *@<&K4* CA25ZK1:K0UP5'W@9K:E+"B9GAC&0/ 0(QFC+>7,8Q
MC&,UVO-5-26:Z>7H0JZ,YPY+:;$KN]V"37;<]'PF\WL4<.0L(%]<)V";L#R@
M;85."QF)WM64>@"K<D;>@4C/^8A,?C06-C;;%#')!$:"JQU:5+(MB4;I4H0]
MA1WPNL8%=K*&9@V)L,(/R1(<IW&C3UK*@>3@ZA6"G"Q@*HR6FV4G:6(SV2]@
M1-(S*(D561 3'R$+)Q>*B</4RH^4IG3NFLN[D,2EB"+1V:574,0IN.URPMD7
M9BF^O/R[#$*!M5"1D! X)E9I6SB4:PA$#>B4Y8=;)=DFHIV65F@^U[QS[S6F
MS\1;-HY)T"4S $J9E1]O'D.),N2F<P%< 2PZZC6*4(K+346 A%8!A@#Q,1$]
MAB(B _8(3,#]YRT/,;DO*6>__*58/'=ZE5A%:@@,K88[6<-M&1F3NPW"'3JT
MDLPL8JOPP/FZ-(F)V(L"PF4TP#HZM#@K;RRDAP-A%ZA+TIMZLRO[8Z1@0H7M
M='IY%,>6_+-W#"_%8KSP$:;7B/%RR3!,339'L@5B97K:9103848>9U/<WH98
MF5Z]0:8:Q%3=8 6,&_<BQW55"HA)<=T24P01R'0GD^L&H[^L&,1:EHO(:!YW
MD7.42Z0FTAFCBQV2UO?3#JWM<5,KJ)I&1>P.S?%!/S$=*AR*0-"@SY5I+:4,
M! %(O=?)6K-6'RM-+9=2VND]<\3[S/94=6_86K-B"@!72A@*J+A?E>;&**8@
M7L]I3;#PU88GN.TKI^>I;:&QXQ52]\FM%09&3DKWM3G8%SVH%'</?Y4]CXT^
M<;I/G:T.1*_B5;7U3%@2S?6G.2[<6A5HP>520*1#+S_KE(V-B?5[F$A#LP 5
MANTNBTHA!T>(&]Z];A#(E(E'$C,C,?PF)XF/]>61*#$2'Y@A@HG^J8YC_"<V
M+,\RK&,8QC&,9%?ETXV2E759YYJU4&Q+NF8V=<J3DHR5L4A&T< C)B1&4F3"
M*"C0QP32>:H")4I4MIAZH1BD9QQO(/2-A[4.O.K6'8='4_7^^*E8<H$!8T^@
ME/3>I)* 4J0%%;5338;8ESFUC8XB:1F?7/5I8:L^A>E%@A,]-=!:(;M=33>:
M-OOH?U'M1<XVM@R?9VGO%@N82I5H%I$5""PE1G7\Y'E7/E;D;U)Z0A''<'*4
MFV)WA9S!SNW'$"+))9:V-V*97Y(ERD^.R4E.D14S')@VC4%H N3=MXT^LYVG
M!F*")C+*8O'&B'1F.Q&/I"D##%6)HCC(A)*(()1-#&WIVQM2%$IBB$Q)2=&E
M))+*3D$D%@!H!119>@@TQG.XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,A.V!%,O(!)EQH=J&RD.:V1@0B*UM:WD2RXYL<^.^E1@O>G9
MI.UQ>!L?TY!.RG)7&YD,Y3K3>J2;4:NO^<]7O*?D-7HU)#CZ@BQLK4M9W?>%
MO6BFKMB.#)%F9+Z)'N[=:F-+^CYJT#,+M=<^IE[8/@OR++-1T9HPH4_$,=K+
MNJM[7J"_Y#."K)V>E$%3-E3O'-C-HSB.,8QC&,8STFJ$Y'M^8\DGW>OM^4T!
M?N]/3U]OO%KU]/77KZ?W>NO]^>3,1]YB/[9B,K%9GSV 9\??M&2XY^W/$3QF
MLB]^>RU&IY=FPN@*^.+;G->@+.%*Y'H1H$:HU.$P6@I-AT(82]"WH.]ZUO?I
MK],X6WU<OK8P(T].8 S")FR[Y[2F.?V/W\9^H5'] #I.W2IVB]0NH@*S5KV"
M"-3K9@"<H&2,3+>9@9+B.?GB/G+VN0>A?Y3_ #M65VK6-%$G.=(7P2V-)G3[
MD4A71V5/T45[2J324J@Q*M/837%*6<1\R=.J+3FFJ!DB4&]8Z<W/X]I:.T)0
MUSMBWN1#.^ --AU<NTI@9D2),F,3',"41,S,<S\$^L?IW'I;ZC]4=#(ONV]7
M0OH0C9MJ^U-Z-EJ:&V3#5 ;5BU"]@-9I ?8QBB8 +$X6,FLSN<PRMD7;<\%P
M?%>T$M<Q]9].[-#Q9L/)='+V,U6);2'"K!DD<6B+T:J>(G$RU<T*1KP!2K2V
MI:@$86(TDX-I;1F.EFOD55=[6Z8=>?/=/X=/4VHIV$L$1$B<BMM=A4KNF8&1
MI$ZR1#*BR98J^.SU-33W.LZ>QU%7URYD B\S07K*_&XBGA3+=*E8E,!!1-XJ
MZ)D%,-J^]6_TQ;@+2EE2<SUU$K1DM?\ ."^]Y09*'MR9VQ2^/[V6BINL&E<U
M%*?A>[-;8Y8ZO[DL)&E8 -4=6G)UB1T. 73+&A&W>:"*MI;.LJV%+F?>V[%B
M76MI6HJD?&=C7:E2WCWG"VW=AKJC#0MK;"K8K20:F/.(.W([%U4V07M:]6HE
M2:]RZP1(EUK6UMUZ\2L6.BK4VKU(<RJ"F>/,/8CCUS,#G6K(08UT9%(6C3V!
M+YB2XMLL37NX[1G.=.,30#6D(EM4D!<6NV%ZTXS;5+S$47;R3%B)[,13!6!1
M:LBY;]>PD#HK28GC:HD?+8V<=W$+HB)JJ5Q&#-MX+X,-/L)!\1DL65:L8BN\
MN;4;JL1]\ZQR3A"*7(#VG9<P'VB.3@1H13<*S&^LU3NRUE>,8QC&,8RC?I_F
M[RH225JSH:C\8_7,0W)Y.XPL[L#GQ]1SJM8H[&HSVZ'(7&(N2I@=T2/9(BA+
MPLZ)V6[*"J=7!>,9!*.*@7CX!>JL;EUI4_8*@ENM$%AAJEJ9[A"?&V8[4DM"
M^R(%1,-KCE/-)>::[+"D,<E@4&%#$H(:BTM);8["."<#&CYQ8Z/<,"&BD%I#
M*7%U">1N#2F-N%V+N!N>ZL;GI^=)K2O&%$NS1JT#U+*!M8E<AF4K=!!:#&]5
MHI9\S R(G09: I K7+D2C127* :>S\]MJQ(U')K5>X0K5;#;*F>YYX)ID*EL
M@5@2DD=EDN4PUJ8&.*&S)""T*F7((K/U&]B%"4DB!^E8BPV$,R8L8$")I,.X
MP*W;(N7\I3[W\5T_ZZO%[M")7#7L69K JZ$51*B+$K1=.9I5J"%38R8ES7FZ
M3HY(REUU/'@P[:9T=%2-> WZ<DP/H+98DUC7H]KL'/:UOMG[?4[HF5#BOM%N
MU*5('7IMR)B.KLPF&N1(%,.L6F#_ $LQ,BW9)U*NM*D39K4-IK07;7Y]:Y6T
M/R';LU8D#9=1,RL#AH@2%H7(Q(2<\M?GBZG5JWO-Y)%[O86"@K]?><)/T=!I
M'#%TALA_>N9')N<8CN"3,A\;V=H22D3"PERW3_'WA0(1*T]O-*TH"G#>I25>
MXAKA2RG0ZFM]6ZZLM<K\.SOZVQ0M5F]Q&)T)8Q5I4+A3UL4D.^127N;-F9;2
M!"2,;1=._JQ;LN+R^>C%U%B+? P'%\JRRH',\H)$D79Y'=ZH)>9G@#C#GCF.
M VG27.%8UK8HNK^?6L<QB[)M"]C;WN8G"=THE7SCULIP$46)2'V?T]@UO]/3
M*BF2F2GYDIF9G^,S/,_XY;$8 1$?B!&!B/ZHCB/\(S:#SS*L8QC&,Z#:LH%!
MZPL:9@+..'$H++)* I.8$E08)C85[F$!!HPB 4<+:;6BC!!$$ ]A%O6]:],U
MSK#;SH.DNI][ L.=-T]N=K ** :4Z_76;<"LRB1$YE7 %,3 EQ,Q,1FQ=(:F
M-_U9TQHI)81N>H--JI-HR:QC8;&O4DF ,Q)A$-Y(8F)(>8B8F<Z?S;$#(-1-
M7QU2+0W$$51O#V>%6>M"JD<H,.E$D6A4J=!-&%<_/+BL"'V%EDA/T2044066
M6'">EFE+I_T\Z1UC9@K,:=%Z^R',?#MGMR/;[6P+6P)R-C8WK3Q'M 0AD+
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MRG-WSYFRO3F7FN[ZJIAMY@M?='S:DTL=GT5='9A43<F9OK-+W.0+RB53$\-
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M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG@886268<<8
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MG-_?65QCL;L%"=M[)(*21Y*(:0"-.M2.3(]*]I7YL 6XM"583!JMGW0W4O\
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M&++9%?C8J+%J\;)H%89*[#[O0<]/G6K_ %37W'XC6$U>*>"75YXW2[/$(\P
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MTZ/'7=$FII? FN'#7ET1]_!#R\/N)B$^06AY.Y+8"L[\0!_J20#_ (ON:/\
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M%>PRQM;=4V0!VK2.U2JJ_P#V?Z<_XEHG_P!-WC^+,Y__ "/VO\^5_P#86?\
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MQ?<T_P#J]5E6>9>%C&?.L6)&](J7KU2="@0ISUBU:L/*3)$:1,4(Y2J5*3A
M)3ITY(!FGGFC 444 1A@@A#O>F,JG\1B-3.:<N[K]V:&YK<^XNE++OME)(96
MUM<D56(1MU8U*UN2I)))6K5&&Q2"AF"I N=@!99)-)*C2-J,L8S%3&2C[QF,
M:BW)=[-CZZ%(W2Q:QG-701I 2J6NTML&?Q5WC<0BC"UH"%2]Q=7EX7IDQ1:=
M.,M*3LY>N-2MZ54J)USJVRBOT]M@:R!9=H6Z%1<01,L7+E=B*U=*P@C-C6&(
MQ Q,#')G(@)%'8/033;/:^KG05JA5)U7ISJG0=5;ZV1J14U'3O3VWI[/<;:_
M:L,57K5*5*NUI$Q@DTX"N@6V&J4>GF#@#M88P@US#<>MC$$.MCAKF6#6Q;UK
M6Q#&6$  ZWO^D,8@A#KUV+>M:WO/F[]3^J/\Q;+_ &<\_94OTA/1 8DI]4>C
M)B(F9@=U6*9XCGX$2F2G^$1$S,_$1,YN[4;$E,"I>I84N:$K"XQ6MX2PNK,B
MT@^F;7=LCC<D=DI8FL9K<;\;D4JT8H1'')E)GO/*.. 9HT7U+JZ\U-9KZI+%
M)UZ553%#V=JV D!8,>.9">#@N9"9$IYF)F)YS\->N]NK?];=7;M%QM^MMNI=
MY?J77^X\MFG:V5EM-I1:$+(=U8E=JW@#5CVK, D9&,IY/S5,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QE"E]<>>8"XYRK<%E^>/6502,V"Y3"G6>V>:$4]?*
M_+)<5!L6<$2Y]KIX"W2YH;1)DYC^TGEK=*"S#25F]"T+<>D#TQ4LO)<[.LGL
M]Z@?&P#.!\TUV1 M4#9 9(1D>[M'NB>V,DWBK/FPBNM@ZY_ADJE@H:#"6N(F
M7!,DMG#9:2Y*"D!/B.)YRPOA&HNJ*9K:5QGJN:4),I.OG+I(HT=SW7*>LXFA
M:WT ')\$[,B6/1PE9)'F5J7E]=7?:0Y0X*' :A6J-5&&BWD6%5]IKT(6Q9U:
M\UF1)?D"I1R---543VH17K0"14 @ ]O # \9"B&S9M.80E%@A<1<<N99.3FP
M^PR?J:QO*^3,B.9&9*?G)P9&RYE+WE<HR,/LXX>O ABD+[8L>[.H*%H59;I(
MG)GC,,5J)H\/ZE!%BE1D>:E3HM3M@7J2Z; .1Z1"WH#7 ",'P&6]9'M^KNGG
M+CMFVS9HMNGYGVU;IW=M17[Y_HD%:8+36,B#[ 5S9!FE/;5L.+'3/4*6?4-.
MG0M5%Q]/%MO4_3M=C^T>)<T:9O4,GW^))N[(&)*<KT[IBC]KKOKZK5,!ESM=
M?3=K^/63\F/Z"!/K\0IC542N-J[-<6::(FP]IC22$)&*3J9(G6N[6,*4TT8R
MSDZL1FZ-#/\ .=%5 O!=UOJ1L]]M6,#CMT5KINZFC=(CXA]9<#9H"2Y.5.<8
MP,>"S*)6X(8JV7G,,J6N@G:>D \'V[;\;KS[#LCN\=J;I+W,041!()9]_DL*
M4S&'E8K'RK16B("[]:=)\WV;1NNHZ((*AU:UNX1J9A>CYB/\M*S'E1&FPD29
MO+"?IQ*TM%M0,8=A";Z>NI)R,F4C' R12,?P&9GB/[HR N"%:Q.>2@!@I_B4
M#$3/]\\YM]Y3E>5L>6"Q9;$>.I175:'GE6_U%+H9RI4Y:5(Y+5 I1=#B8T/J
M_1#8P2(9B:,5NBG<R<RU"-.2H:8XO2DKTS@H0^]C)9*G2I>1:!92GAS(B-54
MQ!8W$FP:LX:M5IJCC6ACL>:$81?VQ\D#IM,C;T"4H!KB\NJ@L  &*%&\AW[]
M765'7;K1370/<9S]YF9X!8#]S8PI@%K'DC,H&(YG-AZ5Z5WO6N^U_373=!NQ
MV^S=XJZ%_   #+'VK+2_+K4ZB!.Q;M.D4UZZV-84",Y@2DH%8%Y64U]5W_%T
M\6(9&UV0<U4R[MZ-2]UA')(-")RL.:*S21')[4FC:VMQ0FE.( (,RG*F01JE
MR5K3$VOZNI<VMY?4&W0->%+8&DUC $FT$/D9.Y:*8Y&_:6"XE<?Y*N25,R9'
MV];ZXW_3W0G3-KTG]/MJS:LO6:=CU-ZTIV'*H]4[+6"^*W3FD4)P#.E-):M6
M2BVR)+>W05>@5U5(%L\,VS.!XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC*B.IO(#-*[KBXZ_=Z]G/+-]!^O9Z5GEA(XR[4Q8@0/J<HERKRY',0*G33A
MUB1;JLC$*MP^&&@EI2-N<TBQE,3NCC ES+*:RE^:O?98UTV: 0GWLU)OH'91
MK3L]M.^Z*HV@K"LY>32J]U9;+=0&SO&BL]QM(;% :EN57N&Q5"V5!ITAO@KF
MS34%PT>X88PCPKLF%@@KV"5E;QN2'JJ3P2QG7I%=;#LQ*)6TCIYWOB/T;&;=
M<(\-@(%)3']LYX5KJU$P D&]AB:U(J&[*D7U0G/0=@3^N98 A41#!6%SW-SO
M%<NY]EQ6FE-D6C A;EDW.\4\JFO%4N?(1YB%F1V62!&=;VM3@CA79[WR6XMQ
M6)<R1UH3%+@F_7%B;(Q](QED.1<DXQC,:2"Z*=B<ZC-72JV*TC-F34H1\.KJ
M03N+,TZEI(/GT,Z,Q%Q=4T@?B@;2J=",:V]4 /TY_KO7Q&>WQ9"UIH44,>H(
M8Q*Y@VK7(L.&&L>3 )!32@BB!D5L*)X ICTXE2P<V)6EA^-;3CL6;()82L#+
M@2.":H>V)DNYBXXY,8FHC\0!_J20#_B^YI_]7JL]SS+?+?M:%495E@W'8SJ6
MRP:LXB^S23N A$Z,+:F!O/<#TZ(L\X@"MT7_  A0-#<$T)[FZ*4;>FT-2I*
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MXEV&"V4K;("%=$#C;SE[&S0N52)KBMWMAL-I BM&QI;!!G7UXJ[A;WT[[66
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M?W_?Q\?X<SQ_KG^W*$^WKCZ^1RJV'";QZ&I.-6?H2B^8'2A;!J8MU3]$UE>
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M8U5MY9JWUT5["6Q8CQQ83:AXE5:D1(TDFQV"#9A<J:PJNN*6A317%30J.U[
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MO\HFMA(51NWHJUT7MH557Y2';)Z)M- >9&3A<E/9&8>LLA$C-<*DF6/ CO\
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M?))D""7Q,H2LQ<6G! J&KA>SNL2G5[C;,U=2'Q+V(M:(Q+6=5I278D$4MO\
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MB0A*3I4I)1!)80@+ $.M:RZ9FPI-ADPR_:,RDR+B(B.2*9F>(B(^9^T1&6@
M% *U@*UA' @ P #'\!$8B(C^J(B,Y3*<JQC&,8QC&,8QC&,8QC&,8QC&,8RE
M;S?W/T93U"T45S%9K[5=BV9TM!:R"_L!;28K5(9,V/Q0&PS3RWN20)![@4B&
M(6B CT(L/]8$/NUO&M>\-WI4KGN4T-HYU>8[@L>SK+>L#B."F.8*(@2&9[N.
M?X31A(:G:6F"/>AFM$&E/'B"Q9)3BB?M'T?,\Q,?3^[YRM+MCR-]2/#;X_I+
M0MR/=>-P(MS8JZ?0L);&HW)YW?,Z2PX45=Q.#2XB*^SJ*PLX!Q:!0B,)&O-
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M&?:E=,:R;=KWC!@Y5(5_<V4"@+),K>T[X58:^O7\N@F@6S.6FZEI>HW=-7+
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<QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g431217g19n51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g19n51.jpg
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M$0'_Q  >  $  @(# 0$!            " D&"@,%!P0! O_$ &,0   & @
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MKGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S
MHK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34
MEJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3
MO)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\
MS HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q
M34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IM
ML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCV
MZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q
M+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#
MIML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KG
MCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK
M6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJ
MW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)
MKGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S
MHK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34
MEJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3
MO)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\
MS HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q
M34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IM
ML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCV
MZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW#IML3O)KGCVZ\S HK6Q
M+Q34EJW#IML3O)KGCVZ\S HK6Q+Q34EJW'*C*7XQLX7IU?2)R<YP8EU<K9R;
MCQQ%Y.:@EQ8SCCSRN5GBSC&.+L\>%&:-GYJ*<\+?R0S802   &![,]1DE[,@
M/**) A<B]R[C/ )            C3PI-XNM :RE-@-8;I^>+<Q*/2KT<6-]$
M]-)5E%\?HTS*0YGF/1GHCB]"*Y4YKFN-/E\X3)E(K3D\0\5&#;2IDSY-GP]%
M7I*QO^MFG?6EQX[)>9XV8C-6U;S#':KV)</^MFG?6EQX[)>9X8C-6U;QCM5[
M$N)8\$KAMR7"/N$[675+ZF,0L2WD\.>GQ)G#K"[TK3*/-%A(K*&2<K!\*<XM
M@_W.2%XN5G%IE$2*6?F9,M*JP6F.3XYOB6/#6;
M                                                     # ]F>HR
M2]F0'E%$@0N1>Y=QG@$@           5V]$N[FZT>V%3\JX89L9=:;FC6\S:
M_@:X(VFL "T3H6';;O/N3C_GE(8M\U=6]#)CG)KW*;!@TFX
M
M  P/9GJ,DO9D!Y11($+D7N7<9X!(           %=O1+NYNM'MA4_*N&&;&7
M6FYHUO,VOX&N"-IK  M$Z%AVV[S[DX_YY2&+?-75O0R8YR:]RFP8-)N
M
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MVOX&N"-IK  M$Z%AVV[S[DX_YY2&+?-75O0R8YR:]RFP8-)N
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M)SM-<\HV<?\ :-R=?E+QY]//)*7'Y,8QV!I-F+VFK?R/ZZD)SUS;UX)KOS!
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M9+G'(5:T$I<9X\9Y6,H49$_*QQ9QCC-DO$;/&7.>+.&J/CT#%[35L=Z&:@9
M  !@>S/49)>S(#RBB0(7(O<NXSP"0           *[>B7=S=:/;"I^5<,,V,
MNM-S1K>9M?P-<$;36 !:)T+#MMWGW)Q_SRD,6^:NK>ADQSDU[E-@P:3<
M           ?,L\:M^+"ZZ:6<^ERS8P .#IK&_VUO_$P '36-_MK?^)@ ?6D
MNBN7E(J$4+^4F>/  Y0  'YGL8SG^X 52<++HBRW!MVJ;7&* ZLF>D+"=Z9(
MSK:,3*1^\DFA6OH96)>G,9+I=E3*W/XP;"N"X3+R,F-U?D5@N?\ +&:&YV8G
M=S(66):^D?R#R2-OU57+IP\^4QV90Z1$:^6ABXM&+&*QHYSRJP@NN3$YLS<W
M-KV5JU)7<J^58E+#E$1X\?.\3$:</%\GY%5QL:G&R) C)_URCGUHG_C:R\WA
M]=_L$E7_ %')O\-??ZT^:_VQ./L-_P#?G7^E/W'1E'''CCU#(9Q^/&+<RQGB
M_7U.A_L$E7_4DF_PU]_K1_MCD_V&_P#OSO\ TI=EJBZFV)KVH78S4S+JIK<'
M8"LSJ%5,T+,QC:1*V,L4B953(8<82,IA-/"F29/@A<&Y..#3C(UF^<)=(&FT
M>M2*62F2*\1G%1XLF?-N5;1F+2LHVK&,C*M*J(L%53L$@E22Z1226(PKM)5)
MG$I1VJXRNT?NF'J,*TB(C2LHW#&1$C#(>B#\9^L
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MVF9SXU\7)F#H2:-&2#A')( >(>N
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MXF6%:X[ <R  W0."UW/VH/>UHODO&"@7*7K'/VF9SXU\7)F#H2:-&2#A')(
M>(>N                                   0IV/PE;C3>#YPY-N1\'6W
M,_P5FN[7U5C72,HK$V9'5NGXC:,8WGTT9-L]*M*+2"L,]7CGC4J:94WC=#!L
M&;G$HD592.793 R-3A00-#E:G5]M9G&UFV)L:2I%,;1.KK1"&*@QU]*W8C^;
MC3S]S42:NU:S.QK!^UDCJO'#N)XX5K'MIF8:"/A?#XG@M/X6FZ=F5.MSU88:
MSK+^<H_!1V0BRFJK:[6VD6G"VRV8U;7K=Q'7^K*1TY0I!G/25TNW-S3=2IGA
MIQGKYODSUN42J0M5+/'\<TW-P3D1"4MV:6D6L?AT_A$V^7*F$^>.C.Q:RI4^
M/[K)$BF4-C\1<9R"(JY#%K(OIHUG;=<[7W?=">&%^@3!:EL4C'9KV+<.N=K[
MONA/#"_0$%J6Q1CLU[%N'7.U]WW0GAA?H""U+8HQV:]BW#KG:^[[H3PPOT!!
M:EL48[->Q;AUSM?=]T)X87Z @M2V*,=FO8MPZYVON^Z$\,+] 06I;%&.S7L6
MX=<[7W?=">&%^@(+4MBC'9KV+<.N=K[ONA/#"_0$%J6Q1CLU[%N*^>B,7^ES
MO!]LL7#V6)D9!20K.$V;5R51<^4+/$JJ\DF,<>>;33.<WY"D-G\0S818Y,Z;
MFD,6U180]/P-? ;#6 !91T,VS0%9VI<W,_+,HE!Q5V*2*KU7"1%5"2Z1S$)G
M/IF*3^EG'Y.R,6N:OC.9,\Y->XOK+M'7ARE.6WP9BFQ@Q<X>%XLXSV<9QV/2
MS@:H+4MBFS&9KWG]=<[7W?=">&%^@(+4MBC'9KV+<,[/U]CLYMT)Q8_\87Z
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M9F,5Y=>!Q))\E[B&65B\+88J&0R$;CX]F>HR2]F0'E%$@0N1>Y=QG@$@
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MXP4"Y2]8Y^TS.?&OBY,P="31HR0<(Y) #Q#UP
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M0>]K1?)>,% N4O6.?M,SGQKXN3,'0DT:,D'".20 \0]<
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M-IOMI<O+2PBFF%_KY.WJIM_#)&6BP9]3YN]9+N/E190.9'WP 'YGTL_JS\0
MU:.BK]U0?WOZ[\\686XP(]37VFI9PL@*V86.L[K14FXF6%:X[ <R  W0."UW
M/VH/>UHODO&"@7*7K'/VF9SXU\7)F#H2:-&2#A')( >(>N
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MS( #= X+7<_:@][6B^2\8*!<I>L<_:9G/C7Q<F8.A)HT9(.$<D@!XAZX
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MR="F5I$^2Y+DR<.Q(;)<YQG)<Y*CC/%G)<9XORXQ^0(JN55)1E$R(9L()
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MR^B^!%Z%X:F]TJ7K^0EHB>EE;4YX!\W;[;7]46"U1U*G]SWW7D-PB-"K,:=
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MS/49)>S(#RBB0(7(O<NXSP"3Q[>7:\G_ &N??X-P,V,NKXH8-Y-?P4JP&TU
M >FZ?[8$'^VO\B88M\U=6] 6O(?>4_V"_$-)^@Y0  %=O1+NYNM'MA4_*N&&
M;&76FYHUO,VOX&N"-IK  M$Z%AVV[S[DX_YY2&+?-75O0R8YR:]RFP8-)N
M "#W"B_#(OV2I\B<<CPQ] 37IA."E1UC _T_.NB5XN2D2!7,L0 !,/@K?=V#
M]^W^2P+$8&^A9WTHQPCLKYAAZ9FG1CSBFR:H[ <B   #79Z,MVR]1>YFT_.<
M0+,X!.CN47MLA]P_."88O/ID]DE?OG13*._G&@ -ICH5G<FTWVTN7EI8133"
M_P!?)V]5-OX9(RT6#/J?-WK)=Q\J+*!S(^^  _,^EG]6?B &K1T5?NJ#^]_7
M?GBS"W&!'J:^TU+.%D!6S"QUG=:*DW$RPK7'8#F0 &Z!P6NY^U![VM%\EXP4
M"Y2]8Y^TS.?&OBY,P="31HR0<(Y) #Q#UP /F>?@KC]T?X@!4;L;U=6GVW<_
M'@5OY:=:)X]H8X=R>4\Y[7>84/ES ^MA^',O9;;Y8@_3(_/))[2X]ZR2F5.]
M-Y<= _U0P]C(_)$%L%RKWKO/58YJ:]ZG;B#(             //MFVM>F5"7
ML+=+GSQC)T]YGCY.5<-6RSC*>#YP;!,J82Y&#Y*;!>/E<G/%Q#:X=*_?.G*+
MBJ]>,.\94BC..TC,89X1R9PB1:89C#&:99C5C417N]!6CGHA$OQYXJ6IQ<?8
M_P#K*/\ \:/LOU.:^O,?^AK]\>A\V//Z]G_P_,_/^L(F.\Q3X92_^-#]3FOK
MK'_H:_?#YL>?U[/_ (?F>L:7X8LIL^\-:HI7#1A5FCAWET:03=XXFQT2Y3YH
MK-OGC/SN,X-SG$7D]DN>/L>;.O)YJ;9+^D_I++U/E&7>(CIICG(TL<97C63%
MR0ICE-$HD;<G=_*-/4;\I&41&<7+GBJK55GS%BQ#<HA#9],Q2F_\\8R/FC\Q
M_0      P/9GJ,DO9D!Y11($+D7N7<9X!)X]O+M>3_M<^_P;@9L9=7Q0P;R:
M_@I5@-IJ  ]-T_VP(/\ ;7^1,,6^:NK>@+7D/O*?[!?B&D_0<H  "NWHEW<W
M6CVPJ?E7##-C+K3<T:WF;7\#7!&TU@ 6B="P[;=Y]R<?\\I#%OFKJWH9,<Y-
M>Y38,&DW   !![A1?AD7[)4^1..1X8^@)KTPG!2HZQ@?Z?G71*\7)2) KF6(
M  F'P5ON[!^_;_)8%B,#?0L[Z48X1V5\PP],S3HQYQ39-4=@.1   !KL]&6[
M9>HO<S:?G.(%F< G1W*+VV0^X?G!,,7GTR>R2OWSHIE'?SC0 &TQT*SN3:;[
M:7+RTL(IIA?Z^3MZJ;?PR1EHL&?4^;O62[CY464#F1]\ !^9]+/ZL_$ -6CH
MJ_=4'][^N_/%F%N,"/4U]IJ6<+("MF%CK.ZT5)N)EA6N.P',@ -T#@M=S]J#
MWM:+Y+Q@H%REZQS]IF<^-?%R9@Z$FC1D@X1R2 'B'K@ ?,\_!7'[H_Q "HW8
MWJZM/MNY^/ K?RTZT3Q[0QP[D\IYSVN\PH?+F!];#\.9>RVWRQ!^F1^>23VE
MQ[UDE,J=Z;RXZ!_JAA[&1^2(+8+E7O7>>JQS4U[U.W$&0 #CXNSGL8 '\<XG
M_OD_XB_2 '.)_G"?\1?I #G$_P#?)_Q%^D ?V    #Q#A"]JVV>TDM\V/!^R
M;_/9+[0X]ZP2S_2.O6L?M&N\.R'TX $HN!_VZ(WVGDOE60^;Y5=%_P!X=?LO
M#SYS\V_M&-S1?4C]Z2_=D_Y<#F9XYR #''MQJ,;$S\](VFN,(.J*/$K1-/9R
M,:Q-;5CDDUY!*?D5W2;.'48(+(K/"2*S<S5)5-1?!"'+G('/ 6BM6MJX?5:Q
M0=D9-'AX]T\@)9A,-6S]-!NZ48N'$<X<I(O"-G;1P=LH<JQ4'3=;),)K)F,!
MTJVR]<-R,E%[_24"2-F;TJ/.M:H),C^Y.^9]"U)D8[\N'5F<^B&_H>!0R>56
MY]'FVAN=)R@.'9GJ,DO9D!Y11($+D7N7<9X!)X]O+M>3_M<^_P &X&;&75\4
M,&\FOX*58#::@ /3=/\ ; @_VU_D3#%OFKJWH"UY#[RG^P7XAI/T'*   KMZ
M)=W-UH]L*GY5PPS8RZTW-&MYFU_ UP1M-8 %HG0L.VW>?<G'_/*0Q;YJZMZ&
M3'.37N4V#!I-P   0>X47X9%^R5/D3CD>&/H":],)P4J.L8'^GYUT2O%R4B0
M*YEB  )A\%;[NP?OV_R6!8C WT+.^E&.$=E?,,/3,TZ,><4V35'8#D0   :[
M/1ENV7J+W,VGYSB!9G )T=RB]MD/N'YP3#%Y],GLDK]\Z*91W\XT !M,="L[
MDVF^VER\M+"*:87^OD[>JFW\,D9:+!GU/F[UDNX^5%E YD??  ?F?2S^K/Q
M#5HZ*OW5!_>_KOSQ9A;C CU-?::EG"R K9A8ZSNM%2;B985KCL!S( #= X+7
M<_:@][6B^2\8*!<I>L<_:9G/C7Q<F8.A)HT9(.$<D@!XAZX 'S//P5Q^Z/\
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M?]KGW^#<#-C+J^*&#>37\%*L!M-0 'ING^V!!_MK_(F&+?-75O0%KR'WE/\
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MW$RPK7'8#F0 &Z!P6NY^U![VM%\EXP4"Y2]8Y^TS.?&OBY,P="31HR0<(Y)
M#Q#UP /F>?@KC]T?X@!4;L;U=6GVW<_'@5OY:=:)X]H8X=R>4\Y[7>84/ES
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M-G_9&W\!+_* .HD*M R9L&>1C-4V/QF03_\ 8N C#(0J(N4ZWJ J7Z%8_P
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M80L=VHDC%-D->7%Z?*B=BJ<%/WBKM95!V\JMSGJT]B'B@CQX\7D@
M'@FZMOS6LF]0?U2H+;)P^F'SJT5>MEF)"Z*T6'AY)Y89JCL8R(?P\M/01T6T
MF2 L$S736EFQD:O4'$Q?92MU^2 PG@@[(VCM'6^+3L>+D^8ELHS=:M[Q]K=U
M#VYA/NY6334H6-=23HSK7$1#J5]I4YV]1-0V+-IK/<V^H0LJR6(L!+$
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ME"L:.:W47THWHUM([C&DC8Z^RN$5*+V"B6I1]*4D[]R"_P ?%U!+\"
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MXNM+Q=-3RD? S[\Y]65-A&J-Z%(UME?ZDZJTG:YZ&4$QRHGQH]%/BLLH Q
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M>M&U==KH:^L%4H58KVZ-+/J(GN37E&MNJ:G6$1DJU?P[O&5%I6*EM(&(
M  'DFZ]OPVE*2:V2<7(6*1D9J'J5/J<2]@(N3N5YLSKI?5JE'R]LF*]5(I_/
MR64V#%S8I^)8K/%4(]LNYEGL;'/0*NZ?K>]<*C:\/L?;5%E+[J6S7!S&+V2
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MN(E!?*[YM#>BW$56V\G+OYJQ.(*NHQ\&E.3\W)(,2.Y1ZNN(/9P
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M2^<+,I@VLI#-H85C8,5,6J)G'[RQ2LU8!*K'.J]ZQAF\6$^0(
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M6J*39LV230;MT$R)((()$PFDBBDG@I$TDR%*1-,A<%(7&"EQC&,8 @Y@
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MSADHJ MU[J]7@XY_*3LA TVI6ZP0->0G'//3EBLS^R6><$$HP
M                       1HX3.['VG:G77E6-#S-OL%K9L8ZEIN&+Z\6FO
M0_/2=]/KFFJ23"4OD_5:^T=3TO7*VG+VHU<832E3K-ON2==IEA B%K+5VSN%
M';HO9VRK@Z-J]W%Z\EYAYKC8A'NI]QS]!L<%=J18='QT6]DYBFZX5L56IVQT
MY67EZ_N*C7E&[:U=6'8M3FDK!!#*A,F7=Z-JHN;(N4M)8,&,4Q91<8S:QT;&
MM&S"/CV+=)HQ8,6:)&[1FS:MR)H-FK5NFF@W;HID211(1-,A2%QC Q/K
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MF@W;H)D10012+@B2**2>"II))D*4B:9"E(0N,%+C&,8P!!R@
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M[ @
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9I0(                           __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g431217g32y96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g32y96.jpg
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M!Q4B,H'1\!8C0E*A)#-BP>$T0U-R\1<E-41C@I)4DZ,F161SHG3_V@ , P$
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MPE.DM$Y3U]P!/?W'6O#WCWJ1XSK'K?4I[.F[=:'39+VJJ1LKH_<M^U\=:JY
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M]I-6-=]5O5#K+;]EV+A^"O/07IO4/3@[JC6L;:H3;O5C5;F?!5.O;3KFX+)
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MBS-G5E,9'BH V++2<+7"&9FP2L+7AA<&PTDJ8DIF7B8F"#$>D)60%":<?00
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MBQ;*N1(DQ)6J]6B!9FWY6RQA$*0?)1D@LL9N2F$RS&0AO&N.B,180OC\3O\
MT['_ +58.!7XO(0@6JE!F2IV^QCIS2U([=>*IBQ"/['$R1C#9=;:[?:3NA?&
M"]_K]/Z%I'_1E-QT,M2?_9[5XXRQ6,CK%>&U)5GDGR)GT+<CXGO;6;5>T_8A
M[9DI+&92NG[%Z$:F:YL-$1L2@6RQ8S%_A:7)%DZS:2!DJ<#]+8F6W2864AXX
MAYOT2RG #(G&'VTIDED)^D)V4.-;3!0[6A?JUSVGM,37QV:S7'3N: D-GCED
M /.&"1DI(),8:?!8G6>'X7FSR6:\TGV.R>0Z&8CNY9 "8WL:?NDEI8 1]K:W
MQUKHWZB]K2<2*#%VJZ6S7;Y#]@ ]4$PI@<QIG_A_.R/Z>^QHS3)C9BH_,BU!
ML8;>><!2X-GBLEP;:@JRY+(4>Q!F%-^S^\!+>9E@!A+.7F B;/LDOU'U!T>^
MPWTA9.F*N+Q>5?V%>3V^*+E:Z(Z):^J\O':&%X<Z22IL1[<90!)IPDZ Z7(O
M7$. -IG8-XUU, C(042[(8ME;LYB4]G9"TTN;SF$?+)^>'"*]BMD,HRE SS*
M&VTIY]F.; P"I/- \#J2[M8Y#YR1/^P2?./LR/ ^"WUKC&;+3R/S^,QV5@D>
M2QK8C2MTV?PQ4\A7_M+8V]X9:-MKCU>"22HVUCU+;4B)RUQO4IK]ZDP$3,#P
MC&P(BOS#-0B9? XJ/1S92B9EMN)ETN-28-G08N'%6:@4LI Q(;K-BOD++'R-
MR$'8L:[D[=D;Q$UP Z/.WZ:[8<V3FY!OJ=$$;;+\)86>M2FX2RC<C:GKNL/Q
M<]F WIH2]YYZ[.2N3/ 0Z&2F8Q8>(R]C"]KPZ\X9@D@*.< 4.<$8RV2(8&^T
M2*4.\C"V7QR&5+9?9=0I*VW6EJ0M&<*2K.,XSS< AP#FD.:0"""""#W$$="#
MX$+SE['Q/?'(QT<D;BQ\;VECV/:=.:]K@'-<T@@M(!!Z$+L<E4IPB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBBJSZ
M)TE=HHF"N.G]7VF%,=9?+B;#0JM,1Q+P[R26'GPSXI]AUUDA"'FG%HRI#J<+
M3G"L=^8TE*G,TLEJUI&'1+9((WM.CL;#FD'1ZK<U.(^(*$S+%'.9BG/&'-CF
MK9*Y!*QKFEC@U\<S7-!:2T@'1!UW+FJ^DM,TF+CX2G:EUK58>)<<=BXNO4:L
MPX$<Z\6Z>ZX")'Q@[(KCAS[QBUL(0I13KC^<Y=6I69CIU(6M9%5KQL9]UL<,
M;&MV2X\H:T =23T\3M4V^(,]?FEL7LWEKD\X FFM9&W/)*&L$8$CY9G.>!&U
ML8#B0&-#?N@!1',=&&A+!*2\W,5R3+E;+.6&QVTUN>D8]RURUGH>V-7RI<RB
M+<"9\]S7^Z;S56RHUN.-3&KK?C)<(IM4?B,A:G9_7K\Q^ME<YG2!J.0D(.5/
M=NIIU?K(E5 61;I%P;  ]H>N9).8WMB+9D)>Q+%/EB0@A$E>[(T=++(PZFG"
MA;L/H"A1\;JD*&5/04AI6%,K.O+)%RRF[!%5B5C8^(FZX:22P4%-PLX!#PWO
M(&9 .;5)0<#8!?2V."AY<$BS >IP(ZRS%I!N&P&SYV7KLF<._:238Y U;2AL
M>$%#,:?;;ASQT>FDQW\DO/(?.*&($E3RY%PBY)S4=;G9>XS;QUA!.OL16*]9
MU1DF@5J0KM619FA(3RU"NX9".8N%@9DG6LI/<]:T^&:$6!'D"D_7JHKL'2)J
MJ6DIBPQK,C#60]P@Z.*]2HZ$BI7$) P<8]FNJ4,,9&1HE7@&_<ZB1V2AP7&%
MOMJ+?>R19>D].<57=)QNDY^S'V&%"3-LE$1\3%5\&2 L+$L-,0TA776YV-FX
M:2:G)5R2#MJK.Y)'F+DCBB#6 WA2DGKON_R_7ZZ+X%Z4-- 4^_T8"&DA*]LF
M2H$G9&O>SYARUZRJ6N*-3Q!I622;)8CX^L:HI4>\(828@YT$Z1,R])S4N884
M;/Z]5MD#H+5]>KD+3!X#,E3*Y W:IP%0L!9$_6XFHWPH-Z6J8D3+**&_#D;'
MAIK-6B7DNBU6F//TV"0%65IBT$_7Z_75?5'T)K+6TA6#Z/!?AMNH1^U8N#BX
MY[+40*)NB\P&QKZCT/@RC.9"UUF&-"RE2,10XR@ ,,A/OLN$6MR/3%K&8.BS
M))F8<1 VBY6N#%$E2 &PC[_N*D;^M2'7ALI**3(;9H4+9&G,OM/!"^?""+:C
M7GFG2+Z:Z7-.C$090L+-J?K\F)+A*E[G<K1E\V,N% V##)/)M$],23P<->=7
M46SQ@8\@(T(=#E,-91'6&S!S)/U^O52U1J;$T"K1=4A<ON!QWK7W2BUI69)2
MDM(ES,Y,&J;0VSZV9FY"0E3$CLL"H),=0*..,EIALBVSA$X1.$3A$X1.$3A$
MX15MZN_X>-A?Y3_GBM<J9]X?C\BJ7_=/X?,*2=-?V0:I_P -J-_*\7R#WGXG
MYJ1W#X#Y*2>0I3A$X1<!3RQQB'VAGS7&&'7FPQ<CI)+6VVI:!AU%OBB)??4G
M#362BAA\.+3EY]EOQ.)(HZTPM3FI=;.*:<84NDUM:F7<MY=94J*&5EIS++CK
M67&\Y\"\M.N-^+&? XM/969/>?B?FH'</@/DH0DJ1J+I67:]R@HM\E:K>\[!
MLP'OTN9E-@VZSRS9T77XB+>3G!M@EIE&?3$>%>0!7)(Q]38+9KF+'&OT@.Q/
M#\<N49'/'6EKU,/C:5=HO9')3--:ABJ#&[?)-:<0SD +61L=8EU' ][=APEP
M:_-9KV;'N[ R1S6LID+<SO8L=CH")KN3O/<0V."LS;BXD.>]S((]RS,:[0)_
MIFLD[K6_[.L0@TIU:6$7-VJ]AA3D1S^O+/ 1[RZ10*-+J4E T#"M>&'EO5.Y
M"N19)Q=@=>'>%<"\8N_1YD+O#^;XBR$4=GZ3[T?UQCK].9L#\%D:,#CA\)A;
M3B&QTJC=5;7:O['+3232WG.C?$8?6:7T@4*>?PO#]&22O]&E&3ZHR%&W"9V9
MS'79VC+YG,50-RW+3MVJW9M[;%Q1PQTFMD;()JSZ]ZECJ16G*[[1.ERTO)G3
MC<KK,BY:GAI4AR+7AZ/LK^6&(QB/::A"T!JSE :9E8DLW@=!P*PD-\QP5],?
M$_ M2S7^E6;B+&7KT\<F&LLQCJMBU1#GQWFS&@VK&^&C.(9 Q\9LEEEIB;-$
M8@WI^,/HEX>XTMP6/HJ9@K]*E7?'F:_UI[1!7ND-DHF+VY]F1LMV S,+FR"L
M'UG"1T,HE+K<;5TIKN.I+VZM&5$P/9@ L%9=<RVN13#'#W"1@XZ*%:K&5/PC
MM5+@S$LR8+,4PVS!8>4PA"FDMK^N^'^))<L*4%S(PW,#DH!)));>UL4M2PSV
MMEEEHAL_;/);+!(Z0N=*YO-WG7RUEL,,<^T8Z<E;*T9G1=G$T]I'9@?[.^!T
M.W1\C"'1RL#=!C7:[EE]8=2,C%U"O#=0M/O&LI]D9B+D+I9ZL8'2YN1'PAC!
MQ$N&.H>N%2.,8*?9FA(B,20M],>4ZRC#;5S)</QR6YW8*W2R,!<Z2.I6LM?;
MAC=MW(V)Y#K#8_NAT+I9"T O8#U-NIDW,@C&2AL59  QT\L+A!(X:',9&C41
M=WD2!C=_=<>X64K]RI-^:G1:W/0=K%B26X><3'$,28"'3XL23;&<=1Y@9HQ4
M;(L*\T=9 ;F5$"*<R2*6PSSMFE:J"(6ZTL G8Y\;9F%A>QLCXG[8[J-/8YI:
M\!VM.URN:3MH+44KBZM,USH7MV^)_5C]-D86O:>_1:YKFDZ/<=@ZJ/)],.R:
MQN,.[:/V-'4&CM!2!J:)(#S,G5XZ8+0$B2A@ZF/(B1B:[:WQT24BZ$3&DPYK
M&'8T9;C,<H;GG8ZQ';;-4G;#"&N/8D/=&UYUS,$8<&]G*1S.(+2TC[(/V2/2
M8>+\3;P$F.XAQ,N3R+I(HSDHGUX;LM>,R&&=]U\,DQM4FO,40D9,R>-VIG@.
ME#Y<^*^SZ7^SVKJ"3) :^ERZZ@(=OD%E./J64;5768^]1 [:.ZG?(BI]MOPY
M_P"*6GNI.3[38A_VFJXM_P"-5W,S7FZ/0F:-=^FO \RM)]2XC(=<+G862N[L
M?G6MQEGKW,CNATN-G>3H-YIZQ._N#N,DTS:^M]A#OD4ZYP,WD-"W#PF34C2\
M8EKOYOO:$.P+,1.6^V?,3(@BJ1VSXL8[9[9$-FO."8I6/U]X Z<W_F8[3V_^
MYH6IOX7+8M[67\?9K\Y CD=&7P3%WW>PL1\\$^_ Q2/!4@(6AU"'&UI<;<2E
M;;B%86A:%XPI*T*3G*5)4G.%)4G.<9QG&<9SC/+ZUA!!((((.B#T(([P1X$+
MZX4)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+
M\SW[9[=LY[?+&<]L9S_=WSVSVQ_Y]L]O^V>$5)MG[>ZP*K2;)+Q'334I*3:#
M<#B$5/;4K=YMF1D%I  DQZJQJ>-7+CQ;Y#<H>&Y(1Z' 12$+*9SG&>>=9G.\
M>TL=<G@X0H33",QP"CG)\C9;+*>RBF92;@X>W; YXFEC,L0,;' O;WK#EEMM
M8XBNPG6AR2%[@3T!Y>S'-H]2.G0+H:/VWUA6FD55ZV].L %)B)#@[)+W/94E
M1+%)DQZ!AI&S9IJ]7'MBHDDY7(-#!R;H;CZG6!W&$(\EFUPWG./KN.I.O\*5
M(IH^SK7)\AEYL;;F?$&,EN?5_P!2R-8)AN5K(YC&7%S&EH'*V(9;;F-YH&@C
M37%\A8XD:!=R]F=;[^G3R4/KZJ^HFOV\"%G**;8JU6]^]0,=)3]6IAI)6W=)
M0FH^H38VEF*$H=9L:BWC6S5PNJ+PXPC+TI90*M(QP$0-M>!!9]*6?H?T'CW=
MP.^GOZ>7CU4KG]:4L(;#QH^HO>A<[24W"/>CKG(%0ZL'[,.I5>&5.,Z_<CR@
MIZL@$WAB2AG)=X1L*2B"8Q+ K,Z84:Z;_7<%M9^\KE8 NFB5<%<T_3=QTRQ6
M:_6\I@:?SK^XAUVLR52U<]*3D0+"Q;UF/E[2O%FLD (@[%!=J84=$VBY0RP"
MC]:]5MU'V-9A-FW&O7:U1<W3VJ[J..KMC$B X0)G:LY)7:#N-/)%0^[*0TD>
MF.I$I'5J==DCQ")@QY,P@*6B(2,(HLV!N#=D#M>X0L8Y!.ZN]]TR('NU>:Q9
MEZI!_#TV5:\[#@'ZV 4):9>VAUN+KC0M@LD215[;B5+CZ^5$#$6$BUVL=:.R
ME2%?A;YT]D5TYR.KS=M('N1C;T+8#*'6K'80\1,G2QHL8>%LUF8J[JSKFEEA
M$78CBCT.PS84F4]//];^?C_FMME>H^[7+IG!W+KZ+J4-83[6L=%<;O</-^KK
M,%/GO2\:%=#:Y^#JML"P4V'(.K\7?XZ/KXUBD(JEV.>KA\HBP11-==?Y>[_+
MQ]R@V8Z@>JEZ*W?<*X/EJG4&5US"QC%FHT?6[N\[>-9=)-N!Q!U<MTYP26%L
M.R-YP][1<'RX>M$158K\:43+UBX%Y)Y?U]3Y*;*!M#>MEKFH;E(ID'YIV/V]
M);*T_&TH2*EO24!RXQ8-:E9RP8'1'[2%L<GJJL2;,&0'2;)*#W:TTPF1H14.
M<(36OZ?U_P OUKJMDTIN+;%SLFKXN]P.:\BS57JI/M$>;5RH$X6;U5O;7U(U
MQZ;#TM)8 !F*3/6*09$?>,(G6PTRXQBQPB,K)_I_4?KX>*Z4KU06VOS=9CR-
M6ES@UHV%MBKF>BDSPY6IQ&O^H&A:%KA:(ABLS&;$5=1;LQM=ALB0KOIZ8#,N
M@>]6@&'R"C]?/\EAB>IK:$Q<]6A16F+K6:989B0B;;^(X*Q0-W<,(NFGZ7".
MUF+M%0$$+@X839E@OMW<,:CROP?0)^1K<@8NOV,)DIUZ^OGY;]RM)J:WR5\U
M[7+7+QR8V0E&3DO(:0XV'((CI4Z+&L$4AY2W40=H%"9LD"EUU]S$-*@X600K
MN^X4*1>$3A$X1.$3A$X1.$3A%6WJ[_AXV%_E/^>*URIGWA^/R*I?]T_A\PI)
MTU_9!JG_  VHW\KQ?(/>?B?FI'</@/DI)Y"E.$3A$X119JUA\K3='&%+6 21
M0H=@<YM"77 GWH9IMDMMM?9#BQW%)>2A>?"M2,)5\LYY;L,?)%/''*89)(Y6
M1S- <Z%[FN:V5K7?9<8W$/ /0D:/17*[V1RPR21B:..2-[X7$M;*QKFN=&7#
MJT/:"TD=0#L*E?2-T:;$U'?['?MV7"+OL@(\;FA-LS=BGT!RTNK+,[=R&IT<
M-B/L$E&-LQ:7FVCC_2DGMO'(1AKS_!/HO^B?.\+YN_F^+LI6S4\+IOJ4,N7[
MHBM6CRW<Q(V['$R&]8KM97#VMFG[.2=KY@.7G]U^DSZ4\'Q-A:.%X2QEC#02
MLA&9+ZE&D9:U4<U/$L=3DE?-2KV'/L%CG0P]I'"YD))=R=^8]HQ2(?JL:Z5'
M=<VIZ?=O<'0\6QN3B$PV#9P>/?9.R$K/KO2L9D4(<1W\U7EK4G'SPGGUC'P;
M:DP)SPNUQ$*DMOV<LE[7DA+P6\^N3F/(2/#JOBV?Z6<=!QN."3B;KK1R=;&>
MW": 5^TLLB<V7LS^\Y&]J 1OF.B1Y*U&Y^G/46_VJ\UM*KJGE5<DI^&(&E9:
M&+';/]-B1"65$&!/O G^C%R0PXO/A6.TZ.MA[&7,^.\6<!\+\;MHMXCQQN''
M22/J21V;-25C9NS[>$RU98GNAG[*/M&$]"QKF%CQS+Z'X5XYXFX+=>=P[D!3
M&1CC9:8^M6M1O=!VG82B.U%*QLT/:R<CV@;#W->'M/*O*N\Z#ZONDVW7#<FH
M[*Y?:DTXNN0T/ZZUW:R"4@UI8L B:JA8JV#F:2,+&Q[);<A(H#4T'()$Q'>\
M&A/FO,<%?2E]&64RG%?"^0=FL6QYH5:O;9++Y&/#S-,=%MO&2Q.9,W$1LKP-
ME;/,(2R*<1"N9VQ?1>(XS^C'Z2<9B^%N)J#<-DW-;?M6NQQN)H2Y>)PDNFID
MHI0^%V6?)/.^-T$!F#Y83+[1V#I?0?IKZCH_:=+KU9VT3$U#>3X)3%HUQ/QD
MA4I4]K)QC$;)1=>M XCTJ)-PB 9,A,/F3"'=,>&4IG",CM>Z?1Y](4>?QF.I
M<13P8;C=K'^W8.U#9Q%V0MGE;5MTZ>0;#+.RU5;!:)IF>*)\KF!S.7D;XE](
M' ,F!R60N</0SY?@PR,]AS=6:OE:<?-!$ZS5MVZ#YHX'U;3IJS1;$$DC(FO(
M?S<[M?U[TBZ]KLA/6/7&Z]J"&R!)(\@54[?4V8UF7:*]4M!T9"UAN&,="<>>
M;Q$RH9 @K1;J4!LN99=:]U?QR,S Q@JX#(P59'0.<QK[9C>QH9)"9Q<DDAE
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MQ\DEYIEI"<K<6E.,YY4QCY7MCC8Z21[@UC&-+WO<>@:UK07.<3T  )*D D@
M$D]  -DGR '>N"O6*OVV%CK)5)V&LU=F!TEQ,_7I,*:A9012E(25'2D:^2":
M.I2%I2\,^ZWE258PKNG.,52Q2P2.BFCDAE8>5\<K'1R,/DYCP'-/N(!0M+26
MN!:X=""""/B#U"YT3$0XV&\W*QKC,B4X#'NH.&6V<:SZGS0PUI=RDDIKT9?F
M#L96\CTI/B1CR'?#;4+)<(L?)RT5"BY.F9./B04NLL9,DS!@!</$NI8'9R04
MXTSAU]Y:&66\K\;KJTMHPI:L8R1<Z'@RE)2AT8E:&QS4)0MIY2&2?.2*6G&,
MJREM_P HA([^.R7?+>PVM7@7V(O@J1CP6WW33PPVA4,N$NE%,#MCMDN*9'6^
MMY:$LH?>2IIE3F4I=<2IM&5*QG'"+KEHA9QF7KYR(N8'=$4!/0A:1)!EP"5&
M<;6%+QKV'D+$D@UNH4,8SEDP93B<H<:4K&2+X@J_ U>,&A*U"1%=A@DY0'$0
M4:'$Q@B%9RK*1@ &1Q&$Y5G*LI::1C.<YSG'?A%PEVBLQZSFS[%!!+BU#(DT
M%R\>,N.6:AIP-!R7B$9$46AYE8R2,-Y?0ZTIK"L.)SDBYD6"!<)-#;FXAPR-
M%2=(BHD@E$@!*:0^DLUA+V7115,N-O)(?2VUEI:',+\"DYR1<P,Q$28PAL;*
M1T@&>MYL$L$X8L8UP?SL/MB/CNN-$K8R,1YR65K4WY#WCPGRE^$BYV<A80HL
M?(N&SUL$**9RUA!KCS0XPSZGD?22MUAL4=AW*EJ6T@=IM64);3@B["DI6E2%
MI2M"TY2M"L84E258[*2I.>^%)5C.<9QG&<9QGMGY<(NJ(0 [A8X+X;B0E9%<
M8$=97@13&<M9&6TRK.&%,Y1EK+*DHRWE&4>'&4]L$7<X1.$3A$X1.$3A$X1.
M$5;>KO\ AXV%_E/^>*URIGWA^/R*I?\ =/X?,*2=-?V0:I_PVHW\KQ?(/>?B
M?FI'</@/DI)Y"E56N_6-IC7*YG-S+GH0.MS%CB[')O1@SX$$)5[MK+7\A89!
M8LB^_B"=LFW:6P(Z..1(K$)DSWXT<:&DECD6K2?7EHN#,LL7.IN,-,TIVF@W
M.&.A8[)U8F]E5.T776->D<BSA(9$QL.$JA>:VW$ER0:)"2@XN<-ACI-IA)2
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MI%/T1U-FFP^!-P+B(3%)3$38'Q-V%*RV;%([--NTL0S/)K\-D]F*@/14VMV
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MD=)[31,F,OQM<3RAMJ R1V!&TAK#<KV7N#6\\A[UF?B)NJE?3L74B;?&-_\
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M<(RI,=,3MG2RB'D*M8I%#0<9+(KT$"EB6C#EGJ&;?6]YMB_ILS47'5[A[C#
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M2UMBN\1\\ICY8W S#JS>^MMN1,<96[%&LS98J'3J;(R 0UMAB?#^W$/A5/\
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M-H=:=0IIUMQ"5MNMK3E*VW$*QE*T+2I25(5C*5)SG&<9QG/*7-:]KF/:US7
MM<UP#FN:1HAP.P01T((T0I:YS7!S26N:0YKFDAS7 [!!'4$'J".H/4*MTSTQ
MU 62+LVHIRP:(MQ;N22C]<.C#568*QCZ%V?7$BR72)Q&59RMYW$0!*/*5G/O
M1"NRL<!;^CO%Q6)<CPO<O<%Y25QDDFP#XV8RU+X.R/#]ADN'NMWLO=[+!8?L
M_P!I:>J[VK](.4DKQ8_B>I1XRQ<;>SCASK9'Y&K'UV,?GH'19>F[1TUIM35V
MZ ]F(Z*M?4;U"]6G3520C)*D:RO^"IP6,%VA"C6EF*2-EE]>![3KQLQLJ#FI
M)3*?32 %R-@<N>:.AALET8;' <><=?2;]'^(BELX?AW-]I<BKQ<1U&9)M7L^
M5Y[/)8)LK9*=NP6CLYX,O-2+N>-L;9'1QKO.!N"/HUX]RTL5?+\084QTY+$G
M#UM^.=9,G,P=ICLX8G1VZE<.=VD$V*BN!O(\O=&V216IT%U 5'=M-K\@U,5T
M"_N0XCURU^Q+-9GZO-I:PF3#*A2U,S0XK1*7<C/%"8PIC*<9><6A:N>D\$\;
MXOB_$TIVVJ,.;-6-V6P;++?;L;<#0+$4E24MMLC;('&-\D6BPC[;B'%><\:<
M%9/A+*7875;TV%%J1N*S;ZSA2R-0N)KRQVX@ZH^1T>A(V.7H\$AK6D!3_P [
M=<6L'8*Q6[8"N+M%?A;'&N=_&!.Q8,L&KQ8[9SD8]A]GQ9Q\O%X._P#VSR]!
M9L57B6M/-7D'<^&1\3^G^)A:?ZJW)%%,WDECCE;_ "R,:]OHX$*%E=.-5AE*
M(UE9[[J,GOEQ M+LQ+U86_W[H412;,B?JBFL9^2F1(L'Q)RK"7$96I6=O]?V
M9NF1KTLH-:YKE=HLAOCRW*_86=].]\K_ (+"^K(H^M66Q3/?J"4F(GWP3"6'
M7N:QONTH=WCL?=?3_0RY>URFJ]MP$D2W70$S5=EJI8RY&1'*=:0?#1A,S69X
M,8<4@H]EK-:P\.PZEM2'766L;/%8S"<0V_9HH,ACGACI9F-FAN5.Q8YH<!),
MV*>(O+VL9SBP 2.;8!<L2W>R>'B%GMJ\Y:]K89&MEK66RG98X=DYS'%@:7$M
M,)Z'1'0+M-;AZ:MV0=?D-M4ANIJGAVEP4ILZL8BP"%)6ME>:ULL9"XEK(Y+3
MC./*L$3)H6C*701W4.-MZS)<'6FRS1-BJY8USI_L;FRVH1H.:7UOLVXR6D.!
M8QS#WMD<-$[G$<8VJ#8WT[]_%";J&/>^.I,>H(=LNIS#>P1*"? M!Z*31=.6
M"$&9/TWNZWPD:ZVEX&"MA ^VJ.Z+V\3# *I\C%H"#5\DI<C+@A*6^V6V\]E8
M7RKJ,]=Q;!9G@<TZ,-@&=C2#]WEEU*SR($@UY=%U;>(J-X#ZXP.-O%PW[;C=
MX>\XGOD<^FUU&9WC^]HNV>]WB.?\>;VIWRO.I(^\QS7S>L>F9Q!!F&_W84Y0
MKDY$RN',?UEM15@G5XQGLVESP]U1VUR+^^JMF;_/4?MVO?#+RN_!KW]/-3]6
M\-W_ /P[-RXZ4]&U<_6+(]^.LE0$\.O .GJU@=;.M]-AK?4'J6R'IA,VEJL6
M;/A2NIWL(^BV9#V<^'+"(FTCQ;QKJ5=\9S&Y-:SVSE#BL8SG%<=ZK([D[3LY
M/^%,'0R;\@V0-+O_ &\P]ZQK?"^;J1>T>Q&Y3[Q=QLD62J%NM\QGI/F;&".O
M[[LW>;0IHQG&<8SC/?&?GC./GC.,_NSC/,M<^G")PB<(G")PB<(G")PB<(G"
M)PB9[]L]OEG^[.<=\=_[N^.^._\ ^.^/_P XX14UV+&=<K%,L[U+N6BY.QHC
MWLPH$-KZQ0TT0_E:,>&+DK9L.;K(LDAC+C@F9R-+C'"4-LE80VYE]ORC/5OI
MD9B<@[$9;@RQ?$#O9(:F"OT[CWEP!%:QE,]<QT5@1\SHC=KRUG2!K).5KB]O
MJ>"L?1"_*X]F5Q7&%>B9V>US6LY1MU&,T3NQ7QN"IY"2N7\K9?8[$5AL9<^/
MF<T,=U]01W7,_3*H1LBVZ9C9O..\]&SM%EYBTI%2>[A.)"5IE\A*@N4?CL-K
MQ[IB6Q!U+:;(\\ELEQ=OA:#Z8WXG&OS^3X3KV_\ SE>[A;5O)"(3.T)[6)S=
M/%FR^ -(]FJB.,EHD[21LCC7Q//]$#,KDF8+&<5V*G_D[%/,U:N.,AA;OL*V
M5PMS)BLR?F!]IM&633G,Y(S&!!"]F];M>MT>*[5+Q=JA6M^]0,J&8/1H"*.V
M_I4[474):M,46=>35V5:_>I&V*A4-=9LKD;6S;="2^G)\JQV$BWW-HCUM>5]
M/AW>/0'Q/IZ'I\)7/ZB^H)@V'BX[2<E,JE:2F?S80]<;C"@1Y:2V8= 0@;XE
MCKT!-QYC>O@%V2SU6=$AYF E2!6VSI&)+!,-*->_W>'E\>[?C_T6UGWS=D\%
MTT2TQ#W775;NM,L<ENI=#I!5AMU2V9FNUE^F54JO2]8N,U!TLDTF_ERLNN >
M("G:W2825EVXJ>DAI@H\_P!?K_5<FI=@;FC;Y;83<<78BZP1--U^D6-%1D1D
M ^FF1JQ4TRR(*N8CIHO9\*E&S)ZS D,U[74D9*TF=%K" (ULHIZ?K]>'=Z>]
M:IL"[]3R=Q72(C*E?Z[IX4?5#0=MKM>HUH('C,D[N1<YJG"!DVNSSMEGYH;4
M ,M%2U56/6*:HLYN(ACEN6&<)TUZ_P"7^NE%\)MGKMK\)&2UJUM[ZN94%+,7
MVJ,4\Z5IM0M"IFHLT%=#.JV!).U1DO4WKI-7A>;'.CPE@ CH=9=?44,&^30\
M^G]3[]'7Z[MJ4:3U/;/F=F:RUI<-?B5&3LYEG+MF2ZUL!!$76F"KV/33,-/
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M<4NN-V0KQL$T3+8:T<SX9.68:'BR0-;*X=W,U[2[6^796/=AX2RUNQ)C;MC
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MY8Y!X.7E/2/9G[3T'O\ ?ZC=/[&I%QDX.SWB=K&N]A!VT%L^%N EAB'(28V
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MR7&:]_@#ZZV/P_7NF^6ZM]8P1;$9-1=]B)U^ +L*:[*51Z.G&AQ-@+UND4D
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M\?4>VOQ1C\GPA9<X,#\Q 'XB5Y(&J^>I.L8IS>HZV)ZLG7K$U3=8=WZ7J,7
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MK3KNV ?!69J\%AH9/%',P.Y@V1H< X @. /CHD;\B5I9^@=(R<8-#FZHH3H
M3>6@4(K,4P0$VIQ3N4AGCC-'B=W%K7W');SXE9SW[\S&9S,1R.E9D[P>\[>3
M9E<'G0'VV.<6.Z #[33T5EV.H/8(W5*Y:WHT=DP%OC]EP </P(6L_P!'6!B?
MG0[_ +;UUA'U,A5^_2DQ!MN8^>,_A^\8MD3AOOVPIED9A/@_9MY;3V[9'U]/
M+_MU'%Y#?>^>C%%,1_\ WT_99=^\N<3X[5GZLC9_L]FY6\FQV'R1[_\ Z[';
M,_  #RTGX8ZD:_\ .%VA0+^SCY>DV#12:V?X<?NQ[^HLF@/S%?N4YFIJ2GYY
MPRK.?D]HX?G_ +['7J+OYJ-QMAF_']Q=C+]>0%D'_$G99.+[ENO9'E9KF)W_
M -RN\-^),)\>BU:S2MREAO1[@Z5(V]QK*<MNGTV;I>Q&>V?WO"05R'J$ZSC*
MNZT(&9)>;[85ASS/#CEN3$8.Z.6++U]G[L66H30:]QFA%V$$;^\7,'P'59E3
M-YW%N[2O'=JN!VZ7%7R"=?X.>M([>M%NG;'3KW*)FWNG&!<2U%6[='3#)K7C
MM''.7^C0:7<Y_9^9%7./G-;N,X5\L-BH\E2.ZDYPG.'.8AX-O$%^./;L'7FQ
M&1@M-.O_ .,)9'CW@UV]VN_:WH^D*673<U7Q^0WT_P"_<0V.< ]^LA RK9V?
MYO:W===X4OU\K=#PWK-=[MU!N^*2G"L-V2*8BI##6.W@3BTZVD3HI3CF,>'+
MS]/QCQ?/*>_?/-3/1S-%W+-W_P##O5):LG0=W,T ;/OA6;'D>#<B-OQ]_'.U
M_>X;(Q9&OS'Q-6^.U#1_*W(;]ZV'XP[$KWT[ T%>1&D_)4OK>1A=GQ6?#_7>
MR$"]#6UIKM]6$_AAYWY^'&%]LJY8]KG9_?T9FC^:!S++?B0WDD \?[LJY]18
MNU_X9Q-C9#W]AEHK&'G'DWM)6V*)=X$^VM'CT[EFH+J(TK8RO=3=]AHB77CR
MUU^XH+I4YXU]TJ'S#V\6&-><[^)&4,,/)5V5E&5H^KEQEZI(>43,:[^27<+_
M (<DH8X_@"L>SPMQ!59VQQEB> =19H<F1KZ'7F[>@^Q$T:Z[<YNNXZ/13*+Z
M;TP^ O(]'AEI(N!?+]-@=*,89P/Y7[+#.&\)PUAOZ,(QC"?I[<RAK0UK6NFN
M[7AKW+0OY^=W:<W:<Q+^??/S$_:YN;KS;WO?7?>M-=UAK5]0:W]>49Y4<4>=
M'J=J4 XH$V5'L@DH8'E<?G(I4D+<K>,>0QE#I@]JLC)"W&YR325*I6&8T=I0
M5<<X-I_5H[D/$A0$2MC7]3:7%P4::7)1T+'*;B$Y"B0)&0//"C1LM!BFFEE,
M,MODO.+(M@+UUKX^%@ZV=1*:;7:P\P16H$NL0A,+7B!1"0!7X.+>!6#$O# F
M%A,.@,#K9$*)';4EE]U"B+X=UOKYXSWBND51,AF7AIY1[,!&,'.S5=7YD#)O
M%L#-D/FPZN_NY]YQ:Q$Y4AG*$*RG)%S'Z]H,J[,O2E'J$D]8U"KL+I]:A3'9
MU0/HO1*F7" G%RB@_=D=Z7)V7\C^[PO*RCTK'ED7$?K?7<JY(/2E"I<D]+/1
MY$JZ?5H,QR3?B!U"13\@L@%Q1KT8*M8T>X3EQ80ZU,C*:;5E.2+2$=/&H1[_
M %[9,?2H2)L=7!>"A,1,7%Q\?'+(*D"WI"/%&!0J)E"URTBU+F0ST<NR"O#"
M6?$T/$0C<:1;D_K#6A1!Y9.O*,05*2<9-R9+]2@'2)&9A)Y%JAI<]YR/4X9)
MQ%H;;LD8>0IPH">;1,"NM2*4D8(NZJAT9<YFS+IE359%3 MB5855V'5.*L 4
M 75 YW,MD/)^9@2K'G5H63R1ZT> ,+AFGT1Q#PRR+*-UZ 98AQ68.':&KS'I
M8 =N,"0Q!BXCUQ.!H=E+&&XQC$6XN-\D)+#?N]:P_#Z=66\D6/Q2:BW%5N#&
MKD.##4YP%RIQ<8 /%@5K$='$0PC$$+'H&9B@VX0PZ!6"$AD,B!/D(,AAV*.+
M#>(N:N5&ITX#W54:Q7:M&96PYF-KD+&P8'F"QX,2,YZ.,&%'\8\5&1L8PKR_
M$S'QX(;>4C",-MD73B:#28 J-+@:K P;D,)( Q3<-&"Q8<<-*IBVY' @ #8X
M++I;,)$C.DH'P3Z0!@1+J1DY:41;=PB<(G")PB<(G")PB<(JV]7?\/&PO\I_
MSQ6N5,^\/Q^15+_NG\/F%YZ=06Q:91VNGYO<_4CK?5FJ5=,]&LU9H%]U<;LN
M/F-OU&6K\K"S4F)"5>.M#KDS'X:@:/3ZANS7]RV#;8Q5?K-9O><2D>/![S\3
M\U4T;:!K9Z>FOUUUT\5[%PQBY&(BI!S#B7#HT$Q:7@"HIY*RA6GU8=BS5N&Q
MKF%+SA8!;CA0:NXY"U.MK5F$4+[_ -#1'4'7(>HV&<.A8$-R_HE4Q0S2Y.1"
MV#I3:6DI <,Y][R8M\*'VI*3(I2P9'"I&-!:6/Y"W_$0=.JKQ-] 53L-QS?I
M*^3.+*[O"A=1Y2@XEMB*>VUJ\W8[])(;CWI4ET:F,!;"Q'SM4;.R3-8KH![5
M@C)&2G"9$IV?Z:_7Y]ZM15=8Q5$U-\.F%$V 0:.L3YCI 0A+\O+V"2E+),$,
MQ1#N 4MESTJ:_'0[I'HQ&%C1V25,,^=DH/7?]/'X=_E[UC^GRO0T%J*@.Q44
M+&$2E.K!DJI@1D1XPW,0-XWS&V,J;]1W6OQX0M:$*4I*%93VSF7=Y^)4-[A\
M!\E(]NMU8H-8G;I=)V,K%4K$85,S\_,E-!1D5&!-9=)++)=SA#;;:,=DIQW<
M=<RAII"W5H0JU++'#&^65[8XXVE[WO(#6M V225ETJ5O)6ZU"A7EMW+<S(*U
M:!ADEFFD/*QC&CJ22?@!MSB "1_,KM7ICVY)W_;OM>:@N,K=;IE_AMXZKU-M
M*!EXJP[!U]38V(9=M4WF-D,%U%B=3&>]:G '"9EIJ&?;)E'ZPI\3U/GMG'6G
M3VN*(BUD<4[+M>K88X23PPM:#([E<#$'AG-%&X%[VG;C'L;^L\-Q?A(L;A/H
M1O"6U:OXV?AW,9O$689JN,R=^6<BG7[6(LNNKF8PW;,;^PKSM+(FW.63D]*?
M9K>T3L769!;9D]K0VM]<$T&7J0$,U!2IP;4LQ/ASI!KA";)+%N+<#7%#I1D1
M:4823G#J>^49ST/#^=DRS++K+((# Z)K0QSAS!X>3OM''NY1W>:\I^E?Z+ZO
M =C"PX:QE<HS)079)S8ACD,+JTE=D8::L# !()G[YP3MGV3WKU?:=:?:;>9<
M;>9>;0ZTZTM+C3K3B<+;<;<1G*5MK3G"D+3G*5)SC.,YQG&>=*#OJ.H/4$>*
M\9(+26N!:YI(<T@@@@Z((/4$'H0>H*Y.%"<(G"+5+C1:7L*'>K]ZJE?M\(_W
MRN,L<2#+AX7E/AP\TT:R]A@E&/FT2QY9#*L)6TZA:4JQA7\;C\K7=5R5*K?K
MN[X;<$<\>]:Y@V1K@UP\'MTYIZ@@JE[&2#E>UKV^3@"/Z_-4IW/J^_=/&NIZ
MX=+]NV]ZT# 8D1I-F*.W;537) QD/PP4-.MREIJ T<V\_*/DQ$]B(%:$\K,.
M^EQ(K_GG$.&R?"N)LW^#+V=[6+DCK\.MADXBHR&61K-5J]D37:#(@Y\[GP6A
M78&:]G?L,=A3125XR^L^;8T!#HS-.SUY0[;F:V3L.T-=W@>[J;JGVVU08">Z
M@.F_;%0;R-D*6N%=K9L^ALN,5D4^9LVNV @;_5 S,M9DFG0*]8H?TSZ5,2*4
MH=9'N8/C3.MQ=6SQ1PEG* Y.SL7ZE22T&OA/)+8N8IL<>4I1R<O;!T52W!RN
M^S* "ULQ6I1&UT]>5H[B]K2[J.A<Z, /8#K?1KAU'7OU;+7^V-:[5CU2FNKO
M7+>*SVP6B'DF'SXY><]O(EHI2D2D03C/R4+*!B$HS\E-8[XYV^+SF(S<1FQ.
M1J7V#[XKS-=+$=ZY9X"1- \'H631QO![VA94<L<HW&]K_/1ZCXCO'P(!4A<V
MJN+5;G1J7L>O'5+8%2K=VJ\FCP2%>M<+'3\,7C&,X3E^.E!RA5K;\6<M.Y:\
MQI7UM+0O&%8O06)ZLK9JTTM>9G5LL,CHY&_!["'#W]>OBJFO<QP<QSFN'<YI
M((_$=5Y"]9/LX=NR6M(VK]$.X=A:]@DV@*0F]'SNX+<+K5J/8'+2,71BC<3$
MW5\Q\@^DLBHMS;--,:RV<'&!RD+&-D]O@>*:++CIN(*-6U)V+F1Y".C"ZV7D
M@D6 .2.;G:.43F,S@_9<]S'OUL*]R/G)LQL<>70E$;>?PZ/UH.V!][7,.[>B
M5/FK-\[TZ:M<TJ@=7NE]H3GX,KL;7Y3J1U2\_OVGV-N('2,Y:+I&0$:!MRLO
MK&0RN0.DZ%,-$O)?,*F7GW'5YUES'8_*VK%G"7JD?M$SY(\5< QL\7.>810/
MD>ZE*.8D,:RRPCH!&!I6I(HIWN?7EC',21#)^Y<-^#228W>X!X\M!74U7O'3
MV\(=4[J/95.V%',X3ZS-9G I V*<5GM@:;BD.XE8(S&?DL&8"!,;SVPMA.<X
MYH;F/O8]_9W:D]9Q^[VL;FM>/.-^N21O^*-SFGS6-)%)$=2,<P^',"-_ ]Q'
MO!(4J<PU;77+#$D!2 3Q1S0BV5CE!EL-$BDL.IRAQD@=Y*VGF7$YRE;;B%(6
MG.<*3G&>W*FN<QP<QSFN:06N:2US2.X@C1!'@1U5$D<<K'QRL9)&]I:^.1H>
MQ[2-%KV.!:YI'0@@@CO7EQU3>RQU;O4^M2>KY2 Z?R8U^P$V46NTA^8@K,_,
M8AO1E,UH.WU:OUTT#,:9ZLV+C<$S:3V4R#BL1@G;N\%QY?Q<<\>0CFS#7B$0
M.FMMBE@$?:\S3.^M8FF8_M&\K)'\L7(>0#M'+Q?C7Z%<+Q++3GPLU7A9\3[;
M[C:F-=8K77V/9^1[:<=^E5JR1]B_M)88N>SVC1,3V,>I=H5<ZM^FJD5&@QU>
MUKU+:\HM<AJO#KK1I.F]KCQ$( P"-AR(M,E:*%9'1A1DM-Y_%E5)+SA"G/&Z
MI2LZ^W-P[F[5BV^:]@[EJ:6>43L;D\>Z25Q>[4E=E>W!S.<2?[-8:WPT%OL7
M4XZX/QM#%Q5,/QABL93KTH#3D?P_G&05HFQLW7NS7<9<<QC T?VZD^0Z)VXD
MJ1Z]UD:7,EA:Q?R[)HBZ%K\IBI;VKQ>N"2W>^$X3#V.24[1K'AQ>? .JNVJ5
M\_/A\M.?&CQ84W#63;&Z>FV'+56]38Q,S;K6CSD@9JW#H=7":O'KQ[BMM5^D
M#AV2=E+*27.&<C(>5E'B:I)B'R.\!!;FYL;;V>C?9+LW,>X=1NTS#[!3+1(S
MS1 [[:'F'V'$.LO,N)PMMUIUO*D.-N(SA2%H5E*DYPI.<XSC/- 06DM<"UP)
M!!!!!'>"#U!'B"NU:YKVM>QS7L< YKFD.:YI&PYKAL$$=00=$=0N7D*I.$3A
M%^9QA6,I5C"DJQG"DYQC.,XSCMG&<9^6<9Q\LXS\LXX(WT/4'H0?% ==1T(Z
M@CP4 6CIBTW8Y-RQ@5IZ@W!?B5BZZME9'7-HP\K.<Y?).JA$<Q+.9SG/B3."
M2C*\?);2L8QC'#Y'Z.N$[]EU^#'OPF5/7ZWX;LSX#(\V]\\DV,?79:=YBY%9
M:1T+2%VN/^D'BFC7;1FOLS6+;K>)XBK5\[CRT?P1PY*.=]9OOIRUWCO#@5KO
MX+ZFZ#]5*VC5]P0C/R;KFY87%>M*!F\=TL"[&H8;0A9;F,>!+\Y1B<J5V4^7
MC"LK1@?5'TAX3KB>),=Q539]W'\65/8,D(V]0V/B#"1-BEE</LA]S"R[/WY>
MO,W.^M?H_P UTRW#V0X7MOUS7^%;?MV.,CNA?)@<S*Z2.,?>+*>8B &PR+P,
M+;HZ[)K0D7"HV-TZWB%M,R>Z.,&[:JP53#P0VVUR!D'>(?WNN0)%P0)G$4=6
MX<S*"$+(])A*L<Y/BSZ9K?!=>HW/<!YBGDK4SF,B=DL=)B)X8@TSRTLQ4]J=
M/)%VD7]FGQ]24B0%_9Z('5\*?0]4XRL6C@^.<1;QU6%KY)68[(1Y6&:4N$$5
MO$6O96P1R=G)_:8<A:B!80SM.]6TU5NS6VY*W"6&D6N"DG9>' E2*^S-1)5B
M@7#!&B7HN>B@C22(^3CEN*%.'=3V;?:<\"UM^%:O3>&N+^'^+,?3O8?)TK#K
M56"S)19<JRWZ3I8FR.K7:T,TCX+$!=V<S'#[+VG1+=$^:\1\)Y[A:_;HY?&W
M*[:UJ:LRZ^I:CHW6Q2.C;9I69H8V3UYP!)"]OWF.;L!VP)7YTRYM.$3A%QNM
M-/MK9>;;>:<3E#C3J$N-N(5CLI"T+QE*TJQ\LI5C.,X^6<<D$@@@D$=00=$'
MS!'<A (T1L'O!ZA0_8.GO2=F(];)ZTJS4EXLJ][P@'X8FL+S_P#,Q-5I<3*^
M9C_I<]9XT_\ 2K'-K!G<O7;R1Y"R8_\ A3/]HA^'8V!+%KW<FEA28VC(>9U6
M$._GC;V3]^?/%R/W[][6O_ >2A?KH.ZMOU++?R'CY2P!;$@&48_<SB.O\;/&
MX93C&$I0Q+C^%/?LK"NRL7_KN.;I>Q&*M;^])' ZA.3Y]I1DA9L^)=$[:M_5
M[F=:]Z[#Y-?(VS&/=RV6R.T/(2#QZ^*P<]2]\D!YC9U&AMWPJ/$I0-WJ4K3I
M(A.<?6WXQUWJO*=4G&$X7F&$;4KZE^!/9":'CAFX")JN2I$]P:^KDZ[3UZ\D
M[*DNM?\ JO/A[U?K6N(,=():5Z+G'^\A?:QU@Z[@)*\DC=^_E W\>D,.TH.K
M..$9T#O73A3BE+5+].VP&+/!*SW[J6NKQ4TPTZSA7U)9>UVXISY8R.I.,8YB
M'AG$RG>-SM6)Q_@E=;Q3_<.65LM+PZ_OM#NVN@''>?T&9C&Q9>,  >WTJ67/
M0?\ U+!#DP==-MD#CX:*[<=N.9AB6P(;J6IQY?\ RVZKU*:ZDM9SB,)SC'D+
MLP3%,PZ2G/9K+ZJW)86OZN[ZLX3RB3ACB:!ID@:,A".YT38;K2WS[;&R/UT\
M7P[Z;("J;Q'P1=(9>Q5K#S'JY^.ORQ#F/A[#FHY>@[^6.ZP'H 0.JF>.W1L@
M,5LRR:4D+#$Y^C\3Z6N%=V5%$9QCOY[,24Y5[*EI6.R_+'C9%U*<XQC+B\X3
MG422WJSS';QTS'-Z'L7"0CXQ2"&8#X,<>BSFXC WFAV*XHJ NZM@S%6?'. _
ME]J@-^DYWAMT\33W_9"V&*ZD],R!C<7(W!NF3:_I5![%C9;7LHAWOVRQAFWA
M0[)#OBSA.,!ODI4K.$H4K/RY#;]1QY72]D_^2=KH';\OWH8#_P"TE43<)Y^*
M,S14'7ZXZ^T8J6#*0EO\W-0DG+6__P!C6$:)( "FL0P0\=HP H8T1].%L%"/
MM$CO(S^Y;3[*EM.)S_<I"LX_\^98(< 6D$'J"#L'X$="N>>Q\;W1R,=&]ITY
MCVEKVGR<UP!!]Q"[/)5*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JV]
M7?\ #QL+_*?\\5KE3/O#\?D52_[I_#YA>0'6A3Q)2U=(]SN&F]K;>U-2NG&D
ME[$AM9;\JF@UN(.\Z,JIY=PMG7;TG#PDO6;@? E5Z1&HNRFY-R:/KA4U59&0
M@'7(=WGXGQ]ZK9]T=0.@.B"?#OURN_R7O;31T"5"JBM1QD.T-6X,=N(D7_52
M$6AF+%;1''E9SG))@*4X&*?SG/G/M+<[_5R%"V3A$X1=&4;4]&2+*&2"5N@E
MMH'#.=BRWU+'<2ED638?&?CB'<YPA@YDD=T1U22&WVEMX<210M2AIM_IL@ Z
M[@QBQO:>8&@TM']CV9MRIY:C,-RCY"<X,;.RQA![Q2>SV,$.$8^;G*)P\QS"
M/?:%D@9HZ/.6GET>FCO6CL:67C70,O4'V@TU66ZKK(>TO88&S,,P<P!Q>TQA
MW,T-)<-C1WI>*_0;T?\ 6U==IGD>T2-W9:-4U"/B[73J)LK<X>P:':-CQDN/
MF&?LE9$N=H3*#UQA14T" >,Q%/2K(+YV"TB-AN\3A<7EY;#CG3;DK1-;)%!8
MMMGADG:X<ADC;++SB,;< [32[1/-K2^D_I'XXX H8>-OT7QX"GF+TLU*]D<5
M@9,9DJF*FA=V[:EM]&GV+[3@RO)+&YT[872"+LR\R-_H4.CP)0(F-D@A)&.-
M86,8 <,R6$6,ZG*'!R12$.,/L.(SE*VG6UMK3G*5)SCY<[AS0X%K@'-(T6N
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ML5>D#UBKD&R&EM&();\]</I+PO$_98ZK>XFX;@A%6%V8R.)K22B9L,\D[K,
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MT\UDJ,?8167/JG[U.RUEJFX>(-:PV2(;'0EC6NUW.! 5Z.Q-&.5KR6'OC?\
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M&/N.M1]W97HXKS".[6K<<Q UT^R0=>*P78NBXES8!"\_QUG/K.WY[@<P'O\
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MQ2LU+.B":MNO#/KF+6.;&\MN+JK:E"W;K^N;2UA/HM%#MHY95>GD1TO$ID&
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M3_\ )18J,3,U]UY:<9QYKE)$:RYE/=+*$J4I[#])V+_V3.\,\50CJ8\YB[.
MOD#^!M_"R7*+G.'\3L-$WFU]QNR7MWT:Y/\ VK!\2<,3'IVF%R=?.T 3_&:&
M8CJ76M:?X&Y>1VM]7'0#X][ K7T[.Z;]HP;>/ZTUKAZ$W%7TMI_YA"T5HD&Y
M,LIQ]6/.I:7/!A2E(3C&,J?MMG,?TXB^C_B2FWQMX!]/BND /O/+<=)#EF-'
M?]K$ \H)('C/[&82_P!>'^/.';CO"IG6V^%KI<?NL:[(1RXI[CT'V<L1LZVM
MHJW4WH6WF>ZXO9]:"F_%AM5<M+Y%)LR7<_+R?P[<1X*:4ZG/R4E *_\ OCOC
MMGFQQOTB<%92;V:MQ%CX;G0>P9)[\/D X_P^P96.E;+O @0DK79'Z/N,\7#[
M38X>ORT];%_',9EL>6]_-[=BWW*@:1XF8>1Z]%.B%H<0EQM25H6E*T+0K"D+
M0K&%)4E2<YPI*L9QE*L9SC.,XSC/;G9@AP#FD$$ @@[!!Z@@CH01U!'>N/((
M)!!!!(((T01T((/4$'O"^N2H3A$X1.$3A%H=JU;K:\)<Q<*%4+*MS&<*(F:]
M%G&)[X[94T:^*LQASM\O,9?;<QCOC"NV>9D&0O51RU[EF%A!!C9-((G-/0M?
M%S=F]I\6N:0?)67UX)'![X8W/:06R%C>T:1W.9)KG:X>#FN!'@57N6Z'-$/F
M9E*H);]:3&.^6Y77]QF(HIE><]\*8;DG9@0?"<]LX;&&9;QV[X3A7U<LRR5[
M!YK6.QTS_P#BLK"A/O\ F=/BW499' ]>:5\A/<[8T%NZV>SU.,0PYF^^N-#V
M6_(S+U.4=.1M;,1WX8V$=.6)D>A]W1ZKY8TIU(4OMF@=3)ED":_Y<#MZIAV3
MSL)Q]&";8(1B=Q_]*_(';\7?QY[YQC'+#H*Y_N+%^J3UU(Z#(P[_ )6QRLJV
M6M/FZ](X>]98S=*?ID^',5.=Z[;%/M8*P >]Q;$^[CW.!Z@#'1MZ:Z;)688V
M!U357LBYZ.J=]&;^9,SJ6]L@K0A/[ULUF\MA2!:U?W,LR"5X5\L84GZL67"W
M'U K6F^ C?)6FU_BCG:ZN#KKH7"#W [T%<%;A:W_ '.2RF(D\69.E'?K;/=J
MYC'BQR^;G8MI_P .AM9H?JDUT'E+5\B-AZF)5G"<(V10Y^& 4K]RLHL  TM6
M\M8S\L/JET-*_N5WQE.+1NQL_OXYZ_OEB<8__O1=I#_^3YA5_LGD9QS8NSB\
MTWOUC,A ^P!K8W1LFK?!([A[,2IDK-]H]T:P]4+C5[0WE'C\5?GHN7RE/]_F
M) *?6WE/[EI<2E2%8RE>$JQG',F.2.5O/$]DC?YHW![>OO:2%HK=&[0?V5ZG
M:IR=1R6H)8'G7DV5K2?P^*VSE:Q4X1.$3A$X15MZN_X>-A?Y3_GBM<J9]X?C
M\BJ7_=/X?,*B'7,JDR/2!TO5.^&[+$K]E,J2),G4$L W>80:+Z==CRL?:<52
M1'4+>*Y#V@2NL3D&7*5P)CWB'+OS+BXYJ$F8/>?B56SH ?(#O[O7P]WHO52@
MX"Q1:7B-=-?CL5*N8 ?DV@F)%X+W.'Z5V09C4ICF37&/+66T E(3;^7$"IPQ
MAO'(4+;>$3A$X11OIW^RG77_ *-KW_M@_)/>?B?FH'</@/DO+6J;0VEUY]4F
MPM [3T_:=9=-O3S:G;#:("3CW/.VI8X0R#QKJG[2DUR'NEROGDYD-FC5FM,S
M,198L.!9DS38D5J5F?5+..QW!G#E'-XW*5LAG\Y6$%>:-XUC8)F3>W6L=&(^
MT$[&]GCW6+#HI:\CYC&ULCC'%Y]#=N\49NWBKU":GA\3.99XGLZWIHW1>R5[
MKR_D[)QY[HAA$C)HQ"'N<P"23V'+ !/ *BS1!BXTT1X L AEMT0D$EE0Y CX
MZTY:<&>86MEQE2<MK:4I"DY3G..>6->]CVR,<YLC'![7M)#FO:>9K@X=0X$
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M$LU^[5Y9"\>%B*2OPH=K['AK(?W%FU@K!_W-YIR&/+CT#66Z[&VX6[[S-5F
M'?)WD6O:^/\ !]+N/QW&5%G?:P[VX3.!@ZE\F+O328RW)K>FU<C4+S]R '33
MN%(ZMM(7*::J!]B.UIL)SPI5K;<,+(:QNWFK5X4L@1MI:"#L65?UD/561G1'
M$?6T0M&,YQC6^'<K5B-ED++U,;_MN-E9?JZ'4E[ZY>Z'7B+#(G#Q 6PQW'7#
MF0LMH2VY,/E7=/JC/UY<-D>;^6*&ZV..T3T(=2ELL<.K7D*RW-&NP3A$X1.$
M3A$X1.$3A%J]IH]+O 7NZZ5&LVT#LK& [+!1DX,G"OW^!F3%);1G/[_$A*58
MSVSC.,XQGFMR6'Q.8B[#+XO'Y2#1'99"E6N1Z/?IEB.1H_  K8X[+Y;#R]OB
M<GD,9-L'M<?<L4Y#KNV^O)&X_ DCP4%KZ3=91:U/ZXE=C::*6K*U9U;?[!!Q
M*E9^:?,J,F1-TIQM*OJPRJN>5G/]9.>R>W&GZ,>':Q+\!9SW"4A.S^S><O4J
MI.]CFQ=A]S#N:#UY3C^4^(/378#Z2N(+(#,]6P7%48  _:+"TKEH#6CRY.!E
M3+!Q'\0O\P\".N_G\&=4U2^=8W'0]GAI^E$7MNAKKDKAI/\ 53BX:V*#%4]G
M'A1E\FC%9SV4M:75J[ICZH^DG%_^'<5X7B.(=&UN*,*:%D-'</K7A^6*,O/<
M7R8:0_Q$.<=A]:_1UD__ !#A;,\/2GJ;'#69%ZMS'O/U7GHI9 P=X9'F(_(%
MH'5\:]O5?Z=D=-=TR,CZ%SNG[#7]J1KBD_);_N1QRIW9EE6/K2TU6CWDX5AM
M/GJ2I6'[7\4X[IQ!]'V7[-O0W>%;U'B6NXCO?[&78S,-:>\-;CIG]0T<Y4_L
MGPQD>N!X]Q0D/VA3XHHW>'+#0>YGMC6Y+$.>.XN=D(6G[QY1I9J!ZJ="3AZ(
M9_84=4; KLE5<V,'*ZVG4/9SVR.F.O(, Z2]A7T>$+U*5JQG#2UXQWYETOI*
MX*N3-JOSL&+O'H:&?BL\/W0_N,?L^9AI/>\'I^Z[0$_=+EB7/HYXSIPFTS"3
MY.D.HO8&6MGZ9;W\YL8>:ZR-NNO[WLR!]X!3Z,4,:.T4&0P6*^C#C!(SK;X[
MS:OZKC3S2EMN(5_<I"LIS_=GG;QR1S,;+%(R6-[0YDD;FO8]I[G->TEKFGP(
M)!7%R1R1/='*Q\4C"6OCD:YCV.'>US' .:1X@@%<_*U0G")PB<(G"+\4G"L9
M2K&%)5C*5)5C&<*QG';.,XS\LXSCY9QGY9QPBAFV=.^D;NZHFPZSJKIZE>/,
MM%@?AV;\SOWPY[[KRXN6RXC/U(7DS.49[Y3V[Y[XSJ=9SNT[%K)!_O(MPR?_
M '(BQ_\ _I;VKQ-GJ;.QAREIT&M&M9<+M4@>'LMQL]?7N[-1T_TTS\%XG-6=
M06X:,M/_ (6+G9<?9-6#PGYH0/!6QMQU+>/W+0J44E:>W?&%=U9K:RQ'_=VW
MO'BVW'%;#AX RR-;;&O LLM('0$!7CF\?:W]9<.8R4GKVV,=8PE@.\7<E21V
M/)/CSXYP)V2"2L._GK;I7?+'P<W5&MX^25-R-!MI7A_\LOLU8;S,?_<>[+S_
M -*,?5=%AP_O\?')X<V/N/KD?XC7O1VP\Z_A%V(;\1T5!J\-6O\ 9LKE,2\]
M>3*T(,I7V?X!;QDE&=C0?XCC9G:UT<=K#/\ 6!8Z9WQN/IQVU166OI(F8(82
M[5MI6/DMQ<TQB'#PWCME>4L.E.81V\*7?ZV;HDQC] W9J+CTUDZ$\4?-_*+&
M/.3@UY/E="T]YY0J#PWE).N.EQ&<!ZM9BLM7;;Y? NH988JYS>;(HIG;^RWF
M*W^I]9/3=;_*0'LZ'ARG,8\0MJ8/JZF<J_<EPR:%$BU9Q_>ID]U&,_+*^_,Z
M+%6[+2^C[/DV ;WC+=:^X =_-#6EDG9KQ$D32/$;6DNQV,6_DRM.]BG;Y1]9
M4K5)CCO7V)K$4<,@)[G1R.:? J>0;I3Y146B,M5=DE3;I#$-B/FHX[WJ\*&[
M($M1^127<&+'!8>,>2QE>6AFEO+[-IRKF')6L0ES9H)HG,T7MEC?&YNR .8/
M (V2 -JU'(R5O-$]LC?YHW![?+O:2._IW]_3O4)=7?\ #QL+_*?\\5KEMGWA
M^/R*E_W3^'S"\SO:85.BV#HAZ49*]R>N:U%PMPU2.3;=DAPWNF(CI_3ELBW
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M!78\AA[]K'78ONV*LKHGEI(+HY #RRPOT!)#*U\4C?LR,<WHJ@?";J=Z9O\
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MA_LMRSA+#NZ#)--RB7'^%E^JP6(FCSGIO 'WI>\JW[?Q[A.F0Q6/XNHL[[N
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M\21[E.9O5H5JO$_&LRL$LFSDZT14DV(=^7BR<V1T_$@2.3@CPD/N\OZZ_--
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M&PO\I_SQ6N>7L^\/Q^17T>_[I_#YA23IK^R#5/\ AM1OY7B^0>\_$_-2.X?
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MB5'J%?8DKEEE6%,YM9S4>DFQ9:5C"FLR[IGEJQC*>V>$44]7?\/&PO\ *?\
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M[?\ NMLG\\VC]4XT/(>@39\SZE/C+M_[K;)_/-H_5.-#R'H$V?,^I3XR[?\
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M[?\ NMLG\\VC]4XT/(>@39\SZE/C+M_[K;)_/-H_5.-#R'H$V?,^I3XR[?\
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5QM7EO-MNI[+0E6&AY#T39\SZK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g431217g41w64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g41w64.jpg
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M 0$! 0$!_\  $0@!' '> P$1  (1 0,1 ?_$ !\  0 " P # 0$!
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MJB?G;,"V?Q4]> G+]JD=F<!'QF'A,K:;&95(G,NCCM(''!>F=GYLKEDT>/\
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M5KD)(V$A-$)5^#=$,Q-,02[U8&.P0W16*.2N6/XAJ+M1#*J^J22E@TGZJI<
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MC.E:.-\L)XI("-9[.KQ3M5Q.5HN1?DDQF@AM#G7\02$Q7=)..IJ.-6J@X?\
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M<[D\CU^F-N6WQ*ZOV?QW1^S6[4MTMTM?W3S8BB@\W /9RK7U1$4'">JZ;H=
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M6T$:H\\A-5Y$;&G/<=WFZ)=3;7J]@$/JJ"Q&M:^ L8Q"()'1,4BD?&IY39"
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MKSS654U+4Y^<R5I:% V/>LWEYR.LSYHB/ )0_HFA1T?;;#& 86!8[(S O))
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M1!!%/7_9HDDGKJFGIC_Y:Z:XQC_Y8]S))<2YQ+B=R2223XDG<K=      #8
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MF0'&_7IY'QZ;CIYK&NN^7^L.K:\#U5N"YBKVN(K9/-,["PIO.YQ*6!1*E;B
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MY[F"N8]S#47"L:PM>;?"6L,3<M[:30YI9JIYEQ-\ XDK6\/4P'HM)(RINU<
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MY:/&;M+1=J[:N$MMTEV[A!319!9+?9-5+?7?3;;7;&<PK*!G=UY=)\W4]?\
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MDY ZGIU]JR;F?MRM^E)Q.:K8@)+7]JP"OZ<MDO!)?N%6(.:TO>((3" R<8^
ME"@Y]ELFH[C$S'I+Y4C$P%NV.JQ0$^C<C/E!&/5G&?,<Q]]%2E_:.O\ ?SXA
M/^8!"_\ WF#>+)%S=_H/S"Z?/%B3Q$\1<R7S\=A:A6L.Y5B1#51;58;/K020
M5S]%%]\;*0J+O/QYQMC5!IEU+2#177.F5'$.=Z9QMKGZ9&#K[EC>>0]JG_\
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M,)+_ #X14K-KB1W1>S]<(17C#EDR@T&0RRB006T9K)N&>1;EL4V2:JML9-1
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M\ZJQQLX9B9J@JJFHT<[I+E=@'YM301R!SX;'W\O,<BHV_$U4%15SU@.7YO\
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M[YA7*^A63Q$\10@^0OJ/')W,LMFP,2G*[8F[T;4-"0#]9,@YGUTV-NJ#A0%
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MDF6"LP$G;!(WP<?(\U3K\0\ZX"EW?$>UI7KWMKY ;>Q5EXDHU,NB]9^RAW.
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M'E9OG.U5.KE* 89*(8@?5U359O'#*I]IX_;:)ZK+,64@&+;ZI(%VFRY1W=+
M[_,[/JV'+F-_+H56K\DB'R_I7;\9F?DK><WN85GMNL\5EK1^NFI364?U;#/Y
MG)W[6K?_ %#(G\.&OUSM_K'W?X8_V^+*SL^]HSG2>?AM_9=[_B^9/$3Q$\15
MZ?(3UU).=H-$:QHT2A-^P.DS:U:\V0#Z)+X3/N$M<';.DR*FJB32"U@-<?U
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M[\^2@\O7M[_IS4NJ,J"*4!3]<4O"4?Q1FMXD(BPY39/1)<AL/;ZX?FGVJ?\
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MQC(XV#46ND?U_#?#\7#]&^ 2^D5$[Q)43:=#7%HTLCC9EV(XP78))<YSG..
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MM>,:9:ES@#EDC(W+XY.(JBX/=3\-T1N#@XL?<JC7!:H'#()[0@253FD=Z.$
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M\8\0U%CCM]!P]1TG#L-^LE#>[F+?"8;@:BX]LZ2CEJ<]K%!#H_"AA['0UY:
MV,]FIX;L\-T=5U=WJIKK);+G56RC]-E[2E[&D$894LA_*^275WY)#('%H=N\
M:U,\_P!,-25+NZ+C7]G+^06M8J7(!WTED$$'V<C8TM1!K9>LP\FL&3\LRB3$
MP.2VK0TH'R^29:DQS!5NFW02W;J^0ESB=1)).Y)ZG?<^)W.Y7H A8!I#V >
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MEMG6W'CT]ZV5_E_.SO\ @+?(!_T"UO\ MI\4=F/ZC/>/JG^7\[._X"WR ?\
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MYU''@? ^)\OJMO\ &/:%%=X47&[[H229*QTOML,D<;)ZHLIG7,S9(I*'(%/
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MKS$X%-GHC W%E38)!VL\G Z.J-C#F'Q!4W@Z:9,7PIR729)@FYH(X*I%F12
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M8!"Q'0MK(2:9R./+GQH,%I*0-2"9@2=H5U7!63ATSBD:BXR/#2+QL,57%M6
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..1/$3Q$\1/$3Q$\1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g431217g42o58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g42o58.jpg
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M 0$! 0$! 0$! 0'_P  1" %X B # 1$  A$! Q$!_\0 '@ !  (" P$! 0
M          4'!@@" P0) 0K_Q !L$   !@$" @0%"!$2 P4%!@<! @,$!08
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M)&0R'I(YH:>K25T]JX/XLXAI?'K/9*ZZTL;S$R2&EJ)6%\?SFB2.-S"]F=V
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MP@-L(  B/(!V(.@] 7A_N\HAL'=OR$>0[>40[AY=_+"E $![A ?+W^0.\?<
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M"U7.=L5JAYNM5>*85>0;QB\C$VZ7F7;IV]A(NP,Q0C'U+@DB-#,)9%)RJK*
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MV<9V'3HLGS&.,@ENK&LXUO9_P;]\L(/J.R'L\EKM_OBX8Z]-)&_8IY;E5XX
M#8/5!,@ !R#V-@N\-O='W1WVWS8RN!H('L;I/CU<,.>YPV92]>A(VZ$[]ZNE
MY#!H SJ.0XN+",=K0=^NP.1WY6/'(4X"&P<_)Y/Z=_\ T$0S55$3*J*1DT-.
M\O&,.A9)"X9W;)#*'L<W&1TZ[JEKG-W$LT1SD>+2NIVM/:0(R-SC&^1A9=IS
M<:II;;VUTL2+=K&%8/8J1D2HMR'8ED5&@)NQ$3)BH45$ 06*!Q6,"^Z::Q@$
M@Z2VV^S\(\5T/%ELX6CFU4=5;[M\B45*VXPQSMC$5724D0I^;$QP?X[H=S&0
MX>UKSEJ[.W7JJN-LJ+-<;U-R8G0S4++E5S.@=('.YC'R.+F,+6D&-SQI!ZG<
ME6C:.D+IS?+)!*UI^@[@VS!W'JV,HE*U&3DE(]RRCU@W%PW;J%0,=%TX3115
M<*(]2)D^L$>HE\*]HH/"/9HKQ:;GP_8;I:W6JAXHN\+:"CK;D97RTM%.YQ<:
M:EGYP9;IJHP^,5(JF-B;RP7[FFX>J*JSUT]#5T=SK*(^-36RAJ&S3FF>W2^:
MGT_<ZFH!:2^"GU/T#42#L,M'R<]^7W_Z/I\N7/EOWY[\P/$<1=R_*C#VZ.UC
MB2#G8N:?O':6AVY Q@GBBUP\MV?+W P=(QV-?T>6YTO  T.!:1G<_F5*$PB8
M1,(F$3")A%)P?LW'?5R_>/DCJ/2/>K3^OJ^LJ)3^0+[F0KJYX1,(F$3")A$P
MB81,(F$3")A%)2_R^?ZUCOQ!ODGKZA[@H'3UGWE1N0I3")A$PB81,(F$3"*O
M=2M0V&FD WGY&/=R2#B4;Q14&1T4U2JN&SUT5417,4G5E*R.40 >+B.78-@'
M.-XXXRI.!K1#>*RCJ*V*:X0V\0TSXV2-?-!4SB0F4AND"E<TC.<N&-@5B5M6
MVBB$KV.>"\,PT@')#G9W[/)*HS]5Q5OH4G_A,=_BYY1_LB[#_P 7KO\ T]'^
M>M7\OP?B\O\ .8N1.ES5BG(;U)SX\)BFV[3'<]A ?GN0?U1=A&/_ (>N^YQ_
MEZ+\]0;_  $$<B7?_29\5W.^EY5EG3E8*G8"@JX64 !<QVX =0Q@ ?UWO#?;
M)'ZHNPG?];UW_IZ+\]3\O0C;D2[;?.9V+S_JN*M]"D_\)CO\7'^R+L/_ !>N
M_P#3T?YZ?+\'XO+_ #F)^JXJWT*3_P )CO\ %Q_LB[#_ ,7KO_3T?YZ?+\'X
MO+_.8GZKBK?0I/\ PF._Q<?[(NP_\7KO_3T?YZ?+\'XO+_.8GZKBK?0I/_"8
M[_%Q_LB[#_Q>N_\ 3T?YZ?+\'XO+_.8GZKBK?0I/_"8[_%Q_LB[#_P 7KO\
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MD\1ZUE:W3SSMAM+OGE=NVV-N_L3+<?-/\X]0!D].W/FPH3MU>^AL_P =._\
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M?S(7XP=?FQMW'V_X)OWCV?XJ1E7,5VTP*0Y5#]G8CQ]M63]:+)N)"\)" 'K
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M'-'(QVAS)8G8?$<Y+-?SV@N;L%ZD_D@]PW]4<S(^WU?6J.P^D>XJ%KW_ "_
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MJU5*F6IFA1XQK-INFBAK)'UI^Q;M(M\W51%BX(V#:-\(OFYE ?))K-EE4FK
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M-2MX,B((BB54RKGB*L8I1*64)/9U[N_Z?3U[E9*?6<! 5$@J@4H*"D!@3%0
M]>*8'W-P<6_!Q<^';?GA2N>$3")A$];L(\1?MA[FVV^_?RW_ #AE>&.9Y&#(
M.K!44TDOI%.V0.Q__E]"AHD?U#XOX\.?9B9H/H+AT(R$#AV$1'N[Q >0?9'V
M^>P\N?+;RY :YK=4C'B,-),Y8^*,8&3@N:^G=CS5>2=L*ML4DGDQOA>[IC5&
M:C/GHJ:>KD ],_L6+RMVJ$(822=CBVRH;_L;M:"SH>[<0:H*J.QVW#<$VZH^
MWP\M_,^)O#+X)^#GNBXC\('#%#4M_P#PSY3IYKSGL;\CV]UQNNIW1K?$@2=E
MTELX,XGNH'B=GNM2TX_;0M<L-MWSTKG5$S.S][[^W ,/+ZO5-9T=:,3G9@IF
M[(I 9P,@T*;JV2"8[.)M.);F 3D/Z[K";%VY"/,>0?\ JA>%:Y@DX4X6\)'%
M\<F&PU-LX)NMKM;GG#8]5YXN;PS;@PN+0Y\<LF!E[6N PLJ;@RIH9A!=K]PK
M:) X<V"6^0W*OC9J\MSK5:(JRXLP,X$M.S!P'$;K!I#5NPB188FG)H%(0YTU
MIJ62XS 4!$/V'&HNP%0>6R8O  P[ )@*(B''\2^&/POMMERK;'X,+-PS3T=%
M55(N/%?&=)=*\"&&23F06'A:AN>J=FG5'!/<!'(\!CWM:XN6QMMIX"^4*2BG
MXIN%XJIJJGA;#:N'IHZ(/DE:T"JGO%102FGR0)#!3R2Z-6EA=@':&RT33ZNT
M=_>T9%V$JA#MWY+,>77>FF 024<L(Y9LJZ41>,G;EZL5E'H-R$9F?&".*T4Y
MYWE^I[)P5PO/QRV_\0">AY=TJ*M]TN=^?>YWOAD%KFMKZ]\=U$[GNIZ6FBQ+
M2Y#:6>C<S(PX75MXN+;(^DH&1RS.I T6VF@^36ZG,%3)*R&.9G);F0ODF=D-
M\IKQUP.&EXN=CD92(>(OF3CBX%T3"( 8H\)T5B&*0Z"Z1@%-5%0H'*<-S%*!
M@ /3>%N*;#QE8:/B#AVY4UXMM8=,5?;W\ZB=*R,&H@UN#)HY:>0F.2.6)D[)
M 8YJ>%H$SN<NUKFLM746^MBEI:J"8-,<^-)8XXC=%*&M95"<8<Q\.&QY <';
ME2F= M:F$3")A$PBUEZ5W[V\9_UA&?V3.YX7^J#_ -Q-#_VDH?\ V^[+2WW]
MQL_E#/[.5?/'/C-<BF4N^]_C!%F\%IO?K5$RUAK=.L<Y!PHKC*2T9$O';!F+
M='M+@BCE)(R9E6[82N'"29CJH(&(LJ0B9RF'=V[AR_W6BJ;A;;/<:ZAHFN-5
M5TU)-+3P\N,2R-=*UI:7QQD22,:2]D9:]S0UP)R&4U1*V22*&21C"=3FL<6C
M&YW Z@;D#<#<[+H:Z?7E[(5^):5*P.9.UQ9INM,$8MVH[G8@J+IR:2BD"I"H
M]9E;LG:XN$ .F"3=53BX2".4Q\/WR:HM])%:;A)576E-;;*=E+,Z6OI R:0U
M-*P-+IX1'!,\OC#FZ(W.SI&52*>=SHV"&0OE;KB:&$F1F"=3!CRFX:3D=@*D
MX#274^U,&\I6Z#;)R->-'CYH_C(.0>,W35@\6CW:C=RB@9)847S=PT%-,YE3
MN$%D4R'.D<I<J@X2XGNL$=5;;!=JZFFAFGAJ*6AJ)H98H)GT\KHY6,+'ED\<
MD6EI+S(Q[&M):0*HZ2JE:'QT\SVN#G!S6.+2&DM<00,;$$><@@;A===TIU*M
MR*3BLT2U3C9=6003<QL*^<MQ6BNH"12%=-$4B*,S.FR:Q#G*8JJZ2( *IRD&
MFW<*\2W9C)+98KK71R/J(VR4U%/+&7TG+\989&LT-="98FO#G A[VL^>0$CI
M*J8 Q02O!U %K"1EF-6^.S(!\Y ZKIK>F6H=PD)2)K%*LTW(P:AT9IFPAWJJ
MT0N111$S>3+U( Q<]<BLD#9T*2YE$5B%3$R2@%HMO#7$-WJ*JDMEEN=;4T+B
MRMA@HYWOI'M<YACJ1H'(EUL>P12Z9"]CVAI<QP$14M1,YS(H)7N8</:UCLL.
M2,/V\DY!&#@Y!'8N43I?J-.R4I#P]&M,C*P;YI&34<VA)!1Y$/WXNBLVLFWZ
M@%6"KCL3P2 Z*D' U<'$0(D<P32<,<1U]354='8[K455#/#35M-'0U!GHZB?
MFB&*JBY>NG>_D3$"4,VBD)P&DB64M3(Y[&02N?&YK7M#':F.=G2'#&6YP>N-
M@3T!696;H]ZHU2D5.^2=<?FB[6H\2!DWCI<\K J)2C2)BBV!NI')(,C69=X@
MI6RH.71I-$Y1*":AR)&W-S\'W%%JL=JOU3;9S2W5TS1!'35AJZ!S:J*DI6W"
M)],QD!N<DT;K:(Y)C4L<"-+B&&]+;ZJ&"*=T;M,NH:0U^J/#PQG,&D <TN!B
MP3J"P*W:?W>A*,$;I5)VKJ2B*CB.)-1SE@+Q)$4RKBAUY"@<[<RR(.4@'K6X
MJI L0@J$XM!=K!>["ZG9>;57VMU4QTE.*VFEI^<QFD/,?,:-1C+V"1H\J,O9
MK#=3<X\U//3EHGBDB+@2W6TMU 8SC/=D9[1G=8?FH5E,(OJ=H5^]-2_>]U_:
MC[/OSP3_ .]YPQ_(Y_\ U]6NYM?[@IOXA_\ .Y6UGHBSUL-I#["2/OE^3I85
MYGS1Z_>5;6%4L?M,^E5X"2G56JSWL*:0(LD#IIJO'CIPBR8M"*K"5)#M+UPW
M0,NJ/5(%4%93UA!# W^WM4$X!*AKPX8M&5;>2S:05:I76H(B>,F'L8=E(RDP
MWAH9PX*S6:&F(WP[)1S5_%.1,S<-'"CERV7(U[.>1]1^WL0]F>\=OJ]?7V+.
M<A2F$3"*+G#]5"RZ@CL"<7('$1\G T5-O]C;-=>':;1='$X#;=7.)[L4TIRL
MJA&JMHV]=553C'?F5@7Q@TL3 E*BE=N;HAEQ$0YCN4B9?(&PE*D4OT@#D&?"
M/@0D>/!APN2 72T4I&!L6RU]1*]^YSJR-CG '7.5]/<=3.'%=>QH&AH,3\@D
MM+.C0=@-\9ZYV]5AYZNN/3")A$PB81,(F$3")A$RA_3U2?V4BI=][_UD7]HQ
M9$M_RLP]_)7\0A,V!_S7!_+ZS^SIU:/[ND_D5'_:5:QW,)7U!V"M0UKCCQ,Z
MR*^9*'*IU8F.F<BI ,!%$U4S%43.4##L8ABCSV$>'<!Y[B;A6S<7VYUKO-N;
M<(0XSQ N<SD/8TATK7LP]KM)P-+V[]=0V6ZL-[N-AN,==;*N2DJ6LD#7-#',
M=Y/22.1KFO ZC(."JK3K$+I/*-9.);JI5F=*VAYI550SI:(D1<'+%RBBZQ3K
MEC'*BQFKY(JG5-SE;N1*'7% OGMCM-I\$%Z@?04LS.$^)S1VZIJ7.CE?;;W$
M9&T?C51RV/937!TSXC43.DCIC "6YD)5CCJ.Z>%&QF>>J=5<3<-"MKC2M\GQ
M^V%L7C/BM,W[F:BF9"R0,@:UTK'NU \O*MCGY0V^D/> ^4!VW#VAW 1 0'EG
MT&&OTB0_Y-_D@??QR,QS8GD;$LU,+7C >QS7@8*^5G- R0]K@7'#0#J:!T.2
M?+:=VZ@!Y;9&=6G#"I3"*-E7P1S-9R+-^^ .K3ZB.;]J<_KIA+Q@@!BG,1/Y
M)0Q=^$O,=@YY<CWSZNOK10M(D!D:O"*"RD&/9XB):=7(MNS'7ZF-:CVM .(W
M6-5N/9(_MD.&X[<DOS_MWE%EF6T3")DC3OF-CR>U^HX] U ?0H:UC7F30TO<
M "7#/3;;?;9>IAN5^Q53.L@LDX(*2[9=9JY2$XE(84G+=1)PEQ$]88J:A2G*
M.RA3  ;:^LME#7F)]9 99J?4*:I;-44]91L<^-[XZ&LII8:J@9(Z(&44<T!E
M+I'2%[GDK-M]QK[7*^:@JG0.D+2]O*II8I-/02PSP2Q3#& !,R32  W3@+P
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MBL/+R;]VI?2>%BOE)OOA@KK=1;XMG _#%GX=I6GM!J+M^N&N)[G-JF$'< '
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M%0.I]/U!0.8*E8PVW&X2VV^Q:W70$=AX?9*U@( ;Y$=A*8!V$=A 0'GRS*F
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MI&-W0M?D>1E==<G6UBBT))LF= 3\2+MFJ(]HCW[<>K>,7!1 !!9!8!XMP 1
MQ1$-A#?MN';]0<26>@NUN<T1ST[65-/IT3T-PA<]E;053/O*BFFSD. +HY(G
M=,+YUXHX=K^%KY76>Y-^[TKVM;,S>GK("T.@JZ5W1\,T;FC4/^$9(WJU3N;Q
M:!=:W[DK]3/_ %1PBA:M_P M5S_I^%_LYOD#J?3]013V2B81,(O4Q^7&OUPC
M^$+A%Y [Q]W^X,(OW")A$PBP^S 'A&F?3MZ>_P!BKVCG[OT_M;9E!QT/ PW7
M&QA+6@$!N!EI():YVY>X;N).54'D9SAP.D$. =D,^:-QT;V8QT"R\O(I=O(
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MQRK'=I,]VB@J'9^A9MM87W&@8!DOK:5@'3)=/& ,^?*^2D 420D04P=T4PV
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M#L<M+FFW-#'/&Z*5NICNH[0>P@]CAV%:'WS3V4H4MV=?B=1+HYS14H4FQ'!
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M'-R2-3A%B/N(\O3TSL"HDE9JC9'&]Q( >[R&$$;G2TRYD&>A&G+=R =E-E
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M>:6BJ*.&T>.SN,EMJ)XZF1SP#B:>FTQO8:4R!FHL.0&85TZB0-SHTO#,Z>E
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M#A.\!NB#HX=VQW($ZXX<Q^2./>/MCF%%;+;!.ZJAM]#%4O:&NJ(Z2G;,YH!
M!E$8?L"1USN>]93JZM?&(7UE4^%I!;$ZHE=&".A#"\M&/,%Z@Y!L'=L ;?2
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M[!U#4 <'O&>W==B7-5/?RJ$W^GN8-_MY)W>)#N\9PX_.&H@NP>OE$#/?C="
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MPND,UHWIZX5TAH;Q Q5VMGU%91IF,[-(BF%0T[9S+Q ZLS+P?5=[<:NAAL/
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M\(0SLO<FS#R<I"+#E[7)WCRN_P#\0^*JR.X_S3\%^A#O2@!2D:      2,8
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M!^S.[D'V@Q@]X_G#XID=Q_FGX+\\#/!,!Q39B< $H&\(Q?$ &V$0 W:]P 1
M-P =AV#?NR=\8SMW:ACWID=<'/\ %/P6AFI/0??ZY:HN+SJBTT3CD(6;1F*K
M.T:FHI:H3:]86>N=*U+W<IZT/&YV^GS]PTFCQL'%HJV*7C63<9F%J2DQ4YOO
M+9QC\A6MM#:WW>1TT#H:J"NN41M<#:IL;;J*&CIX6.U7"-KX!)/*X4T,CW"&
M:K$-7!KY*/GRF240C#@YCF1.YKM'^2YCW$[1G!PT>41U:TN:<HZ/?12ONG9-
M(W&J5JHUE6T#TF::/Z2P5#BS5RN0\>,7 0MAO4P$W:)Q[*7:RQ=8B(Q#J!8Q
MU6B5)]@Q\)*V23?#B\0\24EQ-W;:Z2KIFWZ[/O%VGKZN"HJ9I.;434]!#R(8
M&145-+532NU<R2JE$$C^4*:)BKIZ9T?),KFN\7BY,+8XWL:T$-:Z1P))+W!K
M1W,&H#.HD[Q042\3F8Y4_9 (5<HF_;".-RV,'R)'1SCS\A2&^_MQ:V3<%O3?
M??2?AV*)"(? &W"TY<N4E&;"&P#_ -[#;??N$ $/*& #CL[>T=_G*H<1J.Q[
M/O3W>A<20KI(H$229)D#?8A)"+(4-Q$1V*5V !N(B(\N8B(]^5'43DG)[RX$
M_253D#H#_-/P7Z6%=E,<Q4F93*"!E#%D(L#',  4!.(.]S"!0 H";<0  #N#
M&YQDYQL/*&WHWV3([C_-/P7+P0]Y>M:\N8?ME&<O)R_9GM"(?9R,'S>T?%,C
MS^P_!:W](OHJ1_2*9Z>J/;S>--+3I3>$M0Z#=--['3VLQ#65*'DX$RKAA:8J
MTUV5:JQ<N^;F2?0RBZ0*F[*Z;IJNDW'2<.<25'#K[@&4-NN=)=:$VZOHKDR9
M\$U,9HJ@!KZ6II:B)XEAC<',F#3CRFN(:6XU33LJ1'E\L3XI!)')%@.#@TMW
M#F.:1AQ&X]!ZYK^*_P"'_I<L[5GM4)N_:[W9_/4:;G+MJO?(=Y)SC73:2D9Z
MDTU["5)O4J8EIU!6F37MH45E66L!+V="/F[&VFGT<S62V$W'-X#!3VN"V6&A
MCIZZ""AM--HB@=<XXX*ZL9/5S5=8;C/2Q-I/'GU+JB&E=)!3.A9(\&T*&$^5
M,Z6H>7,+I)2<N$9+F,+6-8SEM<=>C3I+@'.R0%NAX(>CWE:CW#[)1GDYA_[Y
MY!YAG%X/F]H^*SLCS^P_!/!#[YEK\91GIF,'S>T?%,CS^P_!?G@A[MMP--O:
M\(QFWXYD[]<[_P 8?%1MTQM_%/P595K0JK5?4.]:KLX_M^H6H2,3&S=HFI]G
M*2#.M02!4X>FUSM#WJ:Y4&+D74N,%$)-6SZ=D'\W*"^E' NB[.JN]=56Z@M3
MY&,M]N,TD%-"UD4;ZF=Q,U94Z3FIK'MTPB>8N='3QQP1:(FZ5;9%&R224!QD
MDP'.()(:WHQNWDL!R=(V+B7'+CE6=X)??,M?C*,],S5X/F]H^*NY'G]A^">"
M'WS+7XRC/3,8]'M'Q3(\_L/P4C*Q3PSXQB]E,'9V)?9!@7F1DW*/[HY(([B
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M9CCF0CF#8K+A_P#3['+EW^U]O?/2<-TL,;&QQD$L:(G1.#02#S ?G/U Y<W
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MTHJK?!'4>,>*6]O)I&3034K9&M?,QQ9&"EIZB*EIJ>F:Z1K',;4".40RO8&
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M_E#!+9+J]\KH>E R%_[9-%2*V:9S'4CGT;2,,9/"SQ@@]9BY^KE[#$0 U?\
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MM/DJ_4W&WQTLU+;::MB-2(S5>..BE>61N#Q'') QD3FZFMQ@:LC?L7B'_?\
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:$3")A$PB81,(F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g431217g58u08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g58u08.jpg
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M1K57XJ:<4IQ2G%*<4IQ2K/[M_@?'_P!N0O\ A"'*T[_V?^HJA^[]O_H:T?\
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MUVHU]QV4'37I+KF BW) !*GE)!OK5VJ>#I5)D*2-<RJ%A3[V<,]KJ_.@3L-
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M)&+RFV62.*XQ"CQ!3;C<MAO'FZE9QB%W*-U1&\8=?-83BF9B82VU 0O';R?
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MXG>(T\._^U0S^56QWLSX68C[O'@+$ZL.Q*I$ZVI5I)3)'*W=A)2)-IXCF_\
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M$NWYB(21[<25]B+.XM#;&._2Q,,L[VSQPR79PDLNO:+^W62/3*OEM6$]I/\
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MO.9NA!&3TT]^VSF=;[3Q?>K_ +!H _>:Y:UE?FW8ZV0DL<ZQ8)AB--96.FN
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M9C)9O?&6XAFN))&AM#EKF( 09J5$DVXZXQ8 2'%P_ 9 +NF.K&B]97U2W5J
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M9=D29,AU#$>/'80IUY]]YU26V666TJ<==<4E#:$J6M6$XSGD$@ DD  $DDZ
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MESS0^OXF$6FH@28J5.92B.+D96B(O:WD-N,9=P3R/':BPGAFE +2);BW9))
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M/*GE#2*0MZ !),9')>01_!GQ4V@ QE-21H1\8UE7U5;AO'4II/7&B^EX1O\
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MT[9^5/9I*GE,XD,^'[.&RF.D+L^0M;IIYH[N:5I(K4Y&XMP!#FY8MP\&SXP
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M!J\H?^@+U,?X#X][-W^D<!]>XS[13MT7]5=_1)_\%/LJ6H?@U>4/_0%ZF/\
M ?'O9N_TC@/KW&?:*=NB_JKOZ)/_ (*?94M0_!J\H?\ H"]3'^ ^/>S=_I'
M?7N,^T4[=%_57?T2?_!3[*EJ'X-7E#_T!>IC_ ?'O9N_TC@/KW&?:*=NB_JK
MOZ)/_@I]E2U#\&KRA_Z O4Q_@/CWLW?Z1P'U[C/M%.W1?U5W]$G_ ,%/LJ6H
M?@U>4/\ T!>IC_ ?'O9N_P!(X#Z]QGVBG;HOZJ[^B3_X*?94M0_!J\H?^@+U
M,?X#X][-W^D<!]>XS[13MT7]5=_1)_\ !3[*EJ'X-7E#_P! 7J8_P'Q[V;O]
M(X#Z]QGVBG;HOZJ[^B3_ ."GV5+4/P:O*'_H"]3'^ ^/>S=_I' ?7N,^T4[=
M%_57?T2?_!3[*EJ'X-7E#_T!>IC_  'Q[V;O](X#Z]QGVBG;HOZJ[^B3_P""
MGV5+4/P:O*'_ * O4Q_@/CWLW?Z1P'U[C/M%.W1?U5W]$G_P4^RI:A^#5Y0_
M] 7J8_P'Q[V;O](X#Z]QGVBG;HOZJ[^B3_X*?94M0_!J\H?^@+U,?X#X][-W
M^D<!]>XS[13MT7]5=_1)_P#!5V^GOKZTOU'[4,:5K-3W[KW98?7[NT55?>N@
M]FZ4G$Z-'L8ZIR3P1.P (;!6+'/EH(]S,3S^UYQS#?>>%E=SBW^#O,?:I>22
MV,]L\XMN;97UM>JLYC:41OV>1]A,:EAK\FGE&MR&ZBF<QJLJN$W[98I(M5U"
MZC>HUZD#I6;G--633BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI5HM[ZC&[VU5:M5EB3@>#:4"4NE&(,<B_"4*.##:%LQ)*VF7%
M.K&XC*RIQ&4-OK5C.<X\W*I!T.M:?-G=---7U5S:HYUOF*B7+7VP[&M-7L0_
M8(?%=@3$[;W<&B5:Y+L,/6DK;=7J5A-LU,O)+"GJ3HC2.MGG-9V>'K J8)*G
M7IW?)IKZ ?U#_P!3W]34[,=%FBMR["V1FO==-@.GKS;[3@N%B7FM%K0_;K5T
ME:DI )#DVN'J^]82M1IH:@;F .0QB%MQIP-:_-@QVB3JG=\G<-/6?W]WIK/S
MI:Z:2/3:/VA");;N6W'MC;,.[!03N3A!4\2T87YZ1S^91XS$GE$^=EHB>&Q:
M]'+1XPQM8**Y [Z0J"=?DT_S_G]]>3JBJ&E[J5T%#W)LNJT:%6-L2+J K]B,
M"Q$K813%"N&NHH$6\0*P%MXBE]EA)TEYF(6;DR,#JZY%:?L4.4UJ<K#93MCU
MO;F*!8KPSQQR.B&X?L\]J(U+.O<]TC$@."=L9 ,BL/2/<]R?%6)MN,Y>%L#D
MLO+D.&TQ-[>V-K<7,>$MCF<7G)+VX6"VG!YEM@+J&-6EM6C0SWRRLEC+&^+?
M3YJ6I5[:](O5*Z[1-ZKIF]FQCNM@!:(P(V5=JKH2I:^-@L-P=BD6+#900W6[
MMT.Q"(FQ2@D& VQ$A!98>78I>IQ]K#'>07$&>2XBDN)$-JC@+<SPX^*V= %N
M6$DL:VQGD#)*45= $9#(WH7&O$F2O>&\MA\M[CUSA[ZUP]G<)GKVVE:ZP&(R
M/&62S=I=ZS8*W>RL+V?/)B;.6"YL8[N68O)+=QW<=C%M8YUE?.E1VH?P4K7^
MP1/_  #')/>?UG]]4I\4?M_>:D7(JJM76_\ IM&:ZHCLT-U$/:3;)W+>141D
M</L=:@EKEMRZD-M A3+]'/MJAN@188M23)TI5KRI6KIEOR""U4C(])1N6R&-
M6W@W)DC9!I[YTVK+&KS7<S7<: P2>+RU1X'D:&?\5,W+2)CO'T)P9QW/G,RL
M=WP.G%IM\7PA;W*SS6%_+;8OAG$P\-7EPZ9>R82K>W%U;9:UM+?(8@#B&+&"
M\N\C G(DJ3'3F%)5S40VQ=8+A4J,M).\UZ,T3$D:R142#6BW28](R<M!?8"8
M*::<<FOSBNP[0.=K8YLE $A1LKN&JQCHVBM$DRY=EE>:,;D:)MZ2S$0<R5[C
M3DR;B7N)5,:[E1%;08S\<W4%]Q-/8^YBMM;W..M\1?.UO<07\ M[K'8U'RW8
M\?:X4S'*V:Q+%;83'SK?SM!-<W5Q'O:>ZDZ/+=KN^ZYO375!L>ZU>J0!ZY=.
M-R#Q,/:9'J?JNOB!AHE,O9/N,6JTA2NSS<:=%L N27/,,#XT"<):L4V_:8>:
MWN+:<92YGBB5287,C)*>QQ6[.&,[:<V5'NG#"12\@VA602'4<2^Z?C,YALYA
MV]S[ XG(9&:8192T2SM[K'1^^C(YN"U:"+#V^_P=CKJVX>M)(9+*XCM;-VG>
M:&Y:QBSVYOZ\;IQ2G%*<4IQ2G%*<4K$+=O3X>M^Q8^WJ&9K-2MP;6ABJMFIC
M;HTN_,EW:@%Y"TV>*,)R:TF=KH%L'7K=OAPB!VG1[Y),A(,MQAZ(_I[['R37
M(O('BAF2V>(2-JKDF>W=OA K&/=;1W%N)@&DA%P7C4Z$'TSA/C6SQF#DX9S-
MMD,EC+K/6N1:TB99[5(HL5FK9 <?)<6\=_R<Y>87-MC)98+/*/AH[6[FC5UD
M3'#7>M>J+8M3VWF?U44^PTTS3CM"$6T.;%7P%9'I.M]>"WBS/H-N!#U\FM66
M)L?Q5@ADY=GLB[7Z5,5T.U7*ZW+UUM;92XBNRV5ADA>&2!94=)XY2;:V4L-F
MU;?E2BYUD#&67G;WBC$<8/=9S/>Y[@\EPUR?<[REEE+7*6F9NL9=6ESA[RQ6
M//9NX2V;MAFES1R&/DP7+LI;>/'V QW9K2^NFO[YHOI?3+U=09]RATGJ2@AW
M9;CA(>/9=)#PZZM8]PVN\("IE1 $V2&-2 .9M>D6^#$GE8.2,N7"\0M]YQVX
MV+S"QN(,FJ;I9F5075.5)="XV:B-BDAC)B,RAG&I*]YUP8?= ]S*:[M7RW 4
MMR(K#'0SW++!/=^$++AWP/VDQR7L,=W9Q7R1W\>+FD@MIN4D<Q4*BILQKD,J
M.KP$>>**.'((87#,FU,QXRC!6+!88(E%1XC$6*PHA,0]+RS&BQH[67O,989;
M2EM/11AUCC61]\BHH=] -[A0&?0  ;CJ=  !KT '2O$;Z6VGO;R:SMQ:6DUU
M<2VMH'>06MM)*[P6XDD>21Q!$5CWR2.[;=6=F)8UGE=8M.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE1RN?O#7\HS'^_3Q4#N_:?WFM='E2?X"]''_ 'F70)_Y
M_5SG2<,_ELO_ .&\]_T^6L2]^+;_ /?+7_S5K$7RK/E3]_\ 1-O>C:?TQ3]0
M%8)O4@C9)LULL!<K'+=EG;C>*O%%BX]8OU&8@1H+-*7+D/2\E'9KI-"&\040
ME9F>H>Y)[DV-]T/'Y>_R.5OK 8^\@M(8K*.W8N9(3,\DCSK)Y45555TT8ECJ
M /'/=7]U7(^Y_?XFQQ^+LKXW]I/=RRWLDX"!)A"D<:0-&==0S,[.VNJ@*-"3
MK!_;!G75^ _2G_5KMG]?O/7?P9.&?G%G?_T>/^SUY-^$IQ+\WL'_ /I+_P"T
M4_;!G75^ _2G_5KMG]?O'X,G#/SBSO\ ^CQ_V>GX2G$OS>P?_P"DO_M%9V>3
MB\L+U*]57514-%[@I>CH=6N(&Z262^O*U>JR<$DZO5REJ8DO/V395W'3ATA@
M-)@2(6!T*0ER6Q-;)(1#=AS/-_=2]Q?$\"<-)GL=F,C>R#)6UE);WL5L$:.Y
MCG.]'@2-E='B7HP=64L/%(!KT7W,/=CRO'/$<F#R&(Q]G'X.N;V.>SEN=XDM
MY(%V.D[R*R.LK?%*%6 .K D5N0KW79TG'V/$/;IJU.;>'J.B\;.\?JMVQ5/T
M$'L[%YK#&Q(=:>L5$E@+ %)Q;B(1+K[K)*(WF>F2ZEGGSM7T'I5=D]9O2A&3
ME>>H;4,A*)4F)*S#OM<EX'K'CIA@LZ2\.07Z.C@Q$%\L>D3.Y;"C%19Y-46+
M.A.R%-/\^K]]=LOK Z;$ 29\)MRIWMD2K7")0K6<[&R+,I>W;'7*EK7$:KTI
M)L])3<#]L 0!#C(];3OCO$.+:C1I;S"IT/\ GS=]><#UH])EC 1;*-ZB-1MB
M9-1!7M:R]V"UZ:.J5DP%P(-'1!^4,+5Z.^_80\&0V=@CI XI+R*),Q"4:5%8
M4T/D-<P.L_I3($#PQK?VK8\NN2V(9%)&WB!;:W)%)#;$;=&O$9,9HO$S4C;!
M)4P8N5&2X/L0_+OI&K62*+4T/D/HKA?6ITAMK>:7U-Z*2XP. EG49VA3_.2.
MM,3$^LRO-]+=JD6&'GQ 5*/.<)M]N82'NS.,*:'R'T57A/53TWG[!)JX#=NM
MSYN##V&1)Q@5I&&6 T'4S@5G9,LX1&O2AH./3'[$&CG'2\R$B+)F8C=JGV)3
M;*FA\GD]?4>FH&CKPZ2?<6)O<K=E5%"#(WTM&&'$DPEQB0TN$FI.3=#*P(ER
MKCPY0<FHRQ8 8QT&Q"?E&4P(J,O<4T)Z"JZ_UG=+4:SU:GO;PH.+!<200*$A
MM&X\IK)RS5^3:JX#*38F7X( J>K\1\B'B'9 Y9%'AX\3+LR>/CRE-#Y*R( G
M0MH!AK-6RH\[7;$*''0)L3+9GBC(4M$9GBRHR=&6Y'FCR,&0Q+A2X[BV),9Y
MMYI:FUI5E455>*5K'D_^V8"?]V/:/_FIJ'.D'_"#_P#B2+_IDU87_:(_[D?_
M #Q6SCG-UFTXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*5@I!\HUTN2+XNB$+81K;N:0SL*#8[- BB !NKDK"Q6ZT2KT=XDJTGH
M-SG3A#=/,"ZS*KYXD;$U"*7]WTK-2;5.T_Y\OD_9\OI[JQMV'"\GYU'[M&H3
MU)6BPWG>QJ'6JE5]57%I\"B_YZ==RUX-L8'/!52>^P3A:-7M&!#+&+&3UVAX
MI ?G@G3\^M2%*GQAW]P^0Z=VH[_E[ZLC>-3= _0]M^DILD_J?A'-8I8WI3
M\; .4JY&*M7=$ZE,DAC$.JP91PM5ZC6=</%UQ98L4B$NWQ $^881:0,-3J=?
M1W]P[_E/7Y>_7NK8N0Z[]/,S7X8*M;=N*(^VK!I1R57==$&DKOE>U'7MY/1X
MD"R2J\;)!"FLCZK57[,,%3 )P($-GA\]ZN,P#)%4:>W]FNGR?_6KJ&M>UO<Y
M75N[:;L>T@6VJCG <S3/<R^-O6MKP5HE\4,GMVNKV!V+ -/4VNNM% .09YD7
M,)QF9[#\J-)@8=Q9B>>"X$\T,D*O&>5RB)89)8)7B<2Q2Z!FMXQOCV2!2X#
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M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2HY7/WAK^49C_ 'Z>*@=W[3^\UKH\J3_
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M@BIJ?W^OOJHS>@_I ( VJW+T'1EA6!P<3&A(8(Q\0X%>L)6U@6H4B.0:E0G
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M9>PX!2@N$*U9Z8X'U]- 64,_3PN:K<K&$FL"%,3K Q/;EVL@>*#A<^$IJ?\
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MOT\5 [OVG]YK71Y4G^ O1Q_WF70)_P"?U<YTG#/Y;+_^&\]_T^6L2]^+;_\
M?+7_ ,U:V=<YNLRL;>K+JRTAT3Z2L/4%U!VA=5UQ6R5=#RI<2&LH7GE;0:A@
MQ0T(&86F87G*>EJGR8L/#CT8/ *%7$8B#I+B%2 2= -360 <P*L(@4? DH)D
M&<&P3 8N,E,S1I443C-31Q(?-CK<CRX,Z&^S*B2F'%LR&'6W6EJ0M*LJBJEG
M/9]O/VL8^WG.?]'%*P)K?E)^E6XU:RVNHV:TVZ)7+60J6(-/I)ZY334ILW"
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M4K=GLMB,D\I^*^TW$-SD;#MK6MU?7-HINMB1"\8/&KQM;S0SR6<@#PS21:N
MD<Z2QQQJMH6&Q&2&8QB2.))#LU9C&-"0P9642#HRANAU*E69B?F]^1YJ6S7;
M*.MVX$C:1:]?OCI=)UUJL11Q@';*^E(=T<0[]3,JM1Z+7J.$U&)@*!ZC=&E(
M\*Q1T3'KG+%]H?DP<6S6PC:&TW317 837%T\[26GA1LN;>;X*,R3O=.V^[W*
M6C) A5]'$OCU?<&DT1DTVH@3:_(%ON7QB @0#;&00& \;:-M9^])?3BUTO:L
MF:[18Q%B>+7R[; FXJ=(AZQU^"GW8PLM*KVN-:#S-BAT2G0',]]% LGR_GE9
M9<N[,R\4<9:T.5R'A.Z%QRWC"P0P#FS&YG<0IL$EQ<LD9GF;Y9"B^*$331=3
ME6\/(CV:@ZLS':NQ 6.I")JVQ=>NFIZDGY:R<YK:O4XI3BE.*4XI3BE.*4XI
M3BE.*5^/C_E#7_TMM1?_ )= ?_F7L[GVW_HS_P#!F;_\3W'_ $K$U\6?Z2/_
M !GA_P#PQ;?]5R]8C+Z*=/FJ)IB""V\BL;HVI3-=W:,'MMA%'@LH79*=<;==
M)+U2J-57<Z4)J$.MPEP3)B6>39<DL0A\'$A&74=H./<W!D<])<81KO!8>^R=
M@T]E:S6\ZS6M]8V5@BWM[>"POYKU[IQ)! EL;3E<R63:=#QQX%PL^/P:6^9%
MIG,O98V^6&]N8;B!X;JROKR^<V=E9F^L(;)+5"D\[W/:N;LBCW D0Y_R>]KC
M@Z]:\[BU3(JY:EN;')R1[]E*60!1IE6'W6K&Y%%& IENFNV6N&!$C Z(*5)!
MS9BHIO,2/'<G<SA[I=FUQ<V?@/,+=PWXQ<2R+:PVMQD8[R6PO+=<A-<)9(MK
M=03+S7FVW"(&MP[,(ZP6]SF\6"VN_#6':UFL3E)FB:[FN;;'O:Q7UI.]A#;/
M>.UU:SPL(DBW02.4N#&J&2J^]T#-2JJ.EP+PT)-,!8Y>U&;4Q8QP 0D/7>N6
MX6_+%4506+XACW.](2%#(QF&*LHHJ8D#3%:?>G936<9?='9;V1),>9K=KAH+
M."T:UEN9C/<>Y]9V6Z\\)-CMW:N-M)F@>:UFA@66"[58_P ;R&]ST-9QR1WX
MAG6!9KN>[6ZBMX1#:\?7UX5LSCER 4VW!@Y2S)%=0S3M'-:LTFEKXR?D]K#!
M&HD.;!K<=F 1+125DCCK_:H9ALB:U4$UZFOTBHZ[*7M#YU_:0QTGCP)=V*AM
M^.W#;*-C1AZY%[IEM)*5&-NF,D4+Q6K2XVS> Q09B?)FYR%[DX<<5MTQ$PB^
M$@5R58R&%I9;>B7W.+F.(,<C:J(Y)DENECR-W',)9\1;XT6]A98R;(!KALM$
M9?@YRH#*$$PBAN8\3Z&R]0U(4VK;KB,DL.Z>L5\$U\"@A"/ ;8 E]/4]=:NX
MFPAX<V#'?J>_0Y!C+;<27+E1<38F':Y*#%S^5#[H,%]FHL/96,RLN;M<=-=7
M!C>VN;.YCXFC%UCYK:=XY&6]X;GB;4O&B-RWTNDG@ML:7@*:SPTF7O;V)@V$
MN<C#;6XD2YMKRV;AJ4VN0AN84>-6LN(X)%T".[KS$W6K037. W/1J\]IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*O3H/J VCTT[&$[/U-87 =@'?YO.AO87) V8
M*ZZTY.K=H%8=::+ R'=-Y>CK6U)BR&HQ,7+'EX, A%YWBCA7"<8X>YPF>LTN
M[*X&JGHMQ:S@$1W5G-H6@N8M24==0P+1RK)"\D;;_AKB;,<)9:#,X2[:UNX?
M%=>K074#$&2UNX=0L]O+H-Z-H58++$T<T<<B?M\Z:MQDM_Z/H&WBVO[#K&?<
MQ.)[U2LB<8D->8KNTE@[V?,DS:J<QCTC624^&-FD1+K$M<'$=V-+E_F%Q[PO
M;\&\4Y/A^UR]IFH+*7:EW:MJ4#=>S7:@&..]M_R=S'$\B)("NX.&C3]&."^(
MI^*^&\;G;C%W6'EOHM[6ET--=IT[1;,='DLKC\I:RR1Q/)$0VPJ5=[Y\XZNI
MJ$WE3F%@O-5:<=W'>>C^ 80I+<O$N2G#NL.W[<W=/=94D>.=[6%53)5_.//;
MQSU;@4#P7=?[!XUTZOS6.ICY<)*YW3\GPP3H9IE\87_(7N)KSCC$L,A:]<CH
MMNK((44@2\R4!N'R0>;Q7MU$$#>(<:;E^]:U1[2ZI^H.L=9L/I]U7K8+?J>,
MK/3K;3R]?U^WDKS5QFX=C[BK6S;M3;M&--4BFWNG4K6#MBM->L( I.V 7BVV
MKA9(Y^$B6QTL]U<]K[-#;AXD2U>\?+0LEE/;3R2Q1IF+H2HD6$LVBY^&)1GF
MC>W"[GD K26UI:=A[5-=;)I)+Q+&/"W$;WUO<6T4,TLF#M#!))-GKY93;YS1
MTCAE2Y+;8XV:K0TGRLE7;TCK+8^Q]-W&KVLM2]77:TUS4A2CSV:?5MG:G#;.
M)7OIV'.74J;]SJXQ"3#WP.L"%D:NEV!'M$RO2":5-88S>VU#W-O-<7$D%G)(
MEXF]<B'ACDYN? </);VS2+[U&0(S QO-T(+YQP!>[,5I=06]M'/?11/8ORVQ
M9CN)8N3PZQ0QQ7-RL3^^\.7 ;F)!M;=LEIKRJVLJ_!LR,Z9W*_::I?R]%':\
MU^#'3;-. 0*]NNU2[EI ,LCWS^B+&#T!L1^U6-Q4T+8Y*(30*P*8:MLNH9$N
M8@1IPT-W(5N(XB<A$HEN9"DLBRY_QE_UU"D+G!<H<H[-&+<N0ICQ8*X<6Q2X
ML(U:VEE'@Z9C!9Q[X8VAX</+?_4<[W$:\0\T\X!B4"\R%6RMMV\[6&W1TP44
M%3 ZM>[UA79HA;<RB40N&:":SLU^@5N@5=<5AUCIL>P&CKV;8K!)1-'X?)#8
M MZ6S-F#,F6>=;NUB"J8+AI6DDNW9;SM4<9>)KZ 1A%XV"C_ %?'S-A+6R\L
M[RZX4-O;O97DS.RW-JL2116<2-9=DDEY4R8^X,A=N!"SCPC)R=X"W3\Y=BQM
ME!]K'VNQKL\'X3_)Y_S'T1V]N(BU_=QT18SG/98_^G9F]^GSOM8SS-_M?E>9
MXPTD[1_6#_\ RCI_[G^1Y6SIUT.#_9TY/*Z?D>S?U9.G_P!DO_X[\MS=W730
M45C"L+PO$1251VXSN#JLM"5CT9QEABWN)SA4?I@1GL]7YE'^=2I/ATN9[,\:
MG4$<P$.SCLH#7(F.FYL<I^-QT?\ M>V.L:('(\\'30@B$@QJC=L.VV,"Z;4R
M1 U3W/A_V+=#X223EAB=37"\87AW#V(:TNM,M2L7E>8PEV,UYOA4;F6C/:/U
M2UGLSIJ<SV.D).(.'NWSL\@="I4R JS,G@H;[A78#F'AI2-)>("/^)8FU6*/
MFE/)4G0A@PB(9%$GA@\NV:-?R:\5$=8>'%/_  O*FC32<H/KKU^E]KGB._\
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M9K:.[BGM+JRGMY))(ED@NXC#*O,B*R(2I(#*0PU.A!T86;B'GH%#F-ED217
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M/#[*?L1O*!_ZVK9GZ'_2#^K_ (\+8+YJVOUME_M-.1=?GS?1X?93]B-Y0/\
MUM6S/T/^D']7_'A;!?-6U^MLO]IIR+K\^;Z/#[*?L1O*!_ZVK9GZ'_2#^K_C
MPM@OFK:_6V7^TTY%U^?-]'A]E/V(WE _];5LS]#_ *0?U?\ 'A;!?-6U^MLO
M]IIR+K\^;Z/#[*EW3YT5;1UGU'E.IW>/5Q=.IN_O:1EZ' MG]3:EU8-KU/GW
ML/L&4M$;5P0(R4G*-!T):?(,+=:CRY+>77$8CH8M7^9MKG'+C;+$PXV 7HOG
M,=U=W+22K ]N-3=22%5V/W*0-0.G?K,5NZ3&>2=IGY7*&L:( N\/_,TU.HK8
M5S05ETXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7X^/
M^4-?_2VU%_\ ET!_^9>SN?;?^C/_ ,&9O_Q/<?\ 2L37Q9_I(_\ &>'_ /#%
MM_U7+UHJ19[*W-'DD6$X@B)'MB!4]!:>F:,$M1G830P?*Q(P_#'MPY#\1N%&
M<;C(C/.L):PTXM"OH4VEH8Y8C:VYBFE,\T9ACY<LQ=9#-*FW;)*9%5S(P+EU
M5B=0#7@(NKH/'*+F<20QB&*032;XH0AC$4;[MR1A&9 BD*$8J!H2*D8[:^T@
M^*LD3LJ_BTT;!#%)2.N-BA8I^"R%H*XJV(Q%K%?P30XM!# GPGC4+6F3WF%9
MQG%EPV'G[9S\5C9O"'*[?S;&UD[=R"##VS?$>T\D@&+G;^60"FFE9467RT'9
M.3E,C#X/YO8.5>W,?8N<")NR;)1V;F@D2\G9S 3OUUJGYV#?LM.1\W>WY8=9
M=CNLYLIKNG8[\2S0'V'&_&^8MEZ#=+C"=:4G*'(ELLT9:<LGBB)5SP9C=P?P
M?8[U8.&[)!N#*]I(K!N7J&62PL9 0=0]E:,#NMX2EKPCD-I7M]YM*LI7M4^T
MJR7<;*1OT*M'?WR,.XI>7:GQ;B8/[X.U=H"Y7CAFR+\.F^ ("_&0;A88DKT8
M6CP8A0=XB.1;>\ 2BBQD8A#\_P /,CCH+,AMQN)'2W;DP^(F3ES8K&RQ\R.;
M9)8VSISH6D>&7:T17F1/+*T;Z;D:61E(+L3<CR^5B?F19/(12<N2'?'>W*/R
MIEC2:+<LH;ERK%$LB:[76*,,"$4#I([-V28%PP9?8-X*A!X=->@!R-L/3A<$
M GT?YH.&/DSW8D8.GT2*\T8RRB%CT8/[&/\ ,HW=U18G%03/<08S'PSR3FZD
MGBLK:.:2Y/,UN'D2,.\YYTVLK,9/A9/&^$;6F7*9.:%+>;(WTL$<(MHX9;NX
MDACMQRR+=(VD*+"###I$JB/X*/Q?$72#\V%8-.*4XI3BE.*4XI3BE.*4XI3B
ME.*5SC&59PE.,J4K.,)3C&<YSG.>S&,8Q]O.<Y^UC&/MYSP3IU/0#J2?DI7Z
M-?)O^2CQ'] ;]ZJZYA3_ /FIG7VE#D7M2WV^9(@6;9PZ0G[:L?Y.2+H<MO/G
M9[I^W-8;PY77_C[W9_=[$/:^$^!;L-*=]OE>(K=]1%WI+:8F53H9.])<@AT3
MJMHQ;2=?JSW)/<2+FUXGXTM-(_$GQG#]RG63N:.ZRT3=0G<T6/< MXK78"ZV
M[?HB^[SXQ9BQ+,2S,22S$DDGJ22>I)^4FOK0    :    =  !H !\@ Z ?(*
M<BE0F\(=RX!\UNS9[Z.]'C9@R4H2_,5+DK3%UKVY_P";=Q9:2IR"8<\UINK)
M*1<K\YW&,^K<"D>"[KK8^+=.[\U"2D8CA4R9O^NX;#$":W&K&^Y#Z:*:\WXR
M#>$+71<@=]NL<?*D 5Y3)*1'@?ZCB@J"T-TVBC'"XCUU:K5Q@ 5!F8?A!8N+
M%88D !--4:##'6T]#K3Q>4.!ZV+]RB9'V-7I!X])V._.?5"=29L2QZ4.%)BG
M^V/BZEN6 BJ\AR0YEND;D<M^(5&O:.'WZ>]Z!?&MWY98#0Z<@-6VA!*Q=W2(
M8H\JYDD37FIPTQ.EMQ%&/^)KEM%N8Q*%)UZP(EH[2EEA01I74&J;".>:@QQ(
M^H:^J>1\EBK#%!H+/3G$("'&*VFL!E."MRMN-MHF!531XW"(KF6LVS!"@7?!
M&G8]FWPTB3=C$B&*+WV;5//62,F+A+D_[+JJMH-5J\+FX<N4GED-\7+'!RO
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M;$_HK_9'LIX.'_%(WY!KZ/&]_P"DW]H^VFQ/Z*_V1[*>#A_Q2-^0:^CQO?\
MI-_:/MIL3^BO]D>RG@X?\4C?D&OH\;W_ *3?VC[:;$_HK_9'LIX.'_%(WY!K
MZ/&]_P"DW]H^VFQ/Z*_V1[*>#A_Q2-^0:^CQO?\ I-_:/MIL3^BO]D>RG@X?
M\4C?D&OH\;W_ *3?VC[:;$_HK_9'LJ@56/'>K%==>89===""W''7&D+<<6N$
MPI2UK4G*EK4K.<J4K.<JSG.<YSGDEVU/C-WGY3[:I55VCQ5^7Y!Y:K_@X?\
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MG]PJ/E/ZA^\U(^14TXI3BE.*4XI3BE.*4XI3BE.*5@;/U3U0TZW6\KJN[29
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MSQ34>4>D4]U=6_"0!^>!WUGBFH\H](I[JZM^$@#\\#OK/%-1Y1Z13W5U;\)
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MNMPO,+ 7HN02<?X0V&UN!;F/F<ODI?!6MFN6;I'%J#(2JJ=6&M/;%YO*V?\
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MH^/&U](UO5;39;)KZVPG4I=9LT232;16'G6WDQ&;*+R,5YSLACSJTX4O9%R
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M6VN)+9Q\&A'P@4]RAAH@,BR%5\74*S Z@DZAV'RC3/#3.I*WHW7P_6]2FFR
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M]?XK[73]EAT=?"5Z:/ZY-6_XCX]Y/&?S1XG^H,K]DI[]N#/G=PQ]?XK[757
M]2'2Q:C ^NU??6@++8"\A,02!K^T-=FC126O"E(BCA0TY)G3I*TI5E+$5AUU
M6$YSA&>S/,>ZX3XIL;>:[O>&N(+2TMT,L]S<X;(P6\,:_&DEFEMECC0?*SL
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M.D)!$K+J(]#O*UBR7UC"95FO+6)H'ACF62XA0PR7'6W24,X,;S@_ J^C2_S
MU?2S%):R^EPI5FU1BK *2E<X2C,<W*\WPP9_"G<9:*R/.3W ]SS9;OG)[ME7
M;CE0L+YMI6SNB'MVND(MYCOM4UWW*Z)XUNFAW3#6-=#JPJDY"P4L&OK-2EPE
MHX-S""EW)\2U8%_%N'U&R$Z2-KT4UQZ9I&%>9DK5<+R<]R^$^.$>=FR^;A?N
M=\WO>WTYYN<*]$]GC_-SC/A^S/;R>P7VFO8KO3LO;M>SS:=BUT[9\3_9=>G:
M/R.O\^GA''ZZ=NL]>U^#].TPZ]O_ #+3?_M?_P"&_+?_  5RV8I+JV6VBE6<
M<DE) ..AN<)6M\W#QG,L.RE+N5.E(N$JS('HPJ6QC&<N,I[,\@V-\H9FL[I0
MD"73DV\P"6TGY.X8E-%@DU&R8Z1M_-8U*Y"P8JJWMHS/</:(%N826NXQK):J
M ^K7$8&KPC61!U911@Q292X3<4I5I+A*7-'CD,3A+RR$\;A2B,*$EMU694N!
MA"\S8S&''HN$JR^AO"<]A["^C$I>SND$$<4TQ>WF40Q3:"&64E!RXY=1RG?1
M9-1M)J$R%A(8ECOK-VGDEA@"7,+&::#4SQ1!7)DDA )E1-6CT.\"OB*<HL[T
M;X(Q4Y?IG!%0CPI /(]*I$>=Z6R-[IY?CL#/,7Z1S%[W$+S5>)[KS<]E4F/O
MXN?S;&\C[-R1<\RVF3LYN-.SB?<@Y7/U')YFWFZC9NUJ(\ECY>S\J_LI>U\X
MVO+NH'[3V;7M'9]KGG<C0\[E[N5H=^W0T8-T:4F&N*7J<E!&%+)#U,3P[R9P
MZ!G*9T^&IMU6)4*$I.4RY3&5L1LXSAYQ&<9Y#X^_C,@>RNT,,L<$P>VF4Q32
MC6*&35!LED!!CC;1W!\4&I3(X^01&._LW$T4D\)2Z@82P0DB::(JYYD41!$D
MB:HA!#$40<HKB&W&S%36V\(?L#*T$ ZD.@8N<XDFVU)>RE8B/G&</DDYS#:S
MC.''D\DX^_!938W@*W"6C VTP*W<GQ+5@4U%P_\ ,A/PC?(IJ!DL<P!%_9$-
M;/>J1=0$-9QDA[L$2:&V0@AYQ\$I!U<4R<HN$^?DQ4\(P#39LKR0#X3BMK7E
MM%A\[ONST&M>,H26[? *7C*<2,Y^UQX/OR=.PWFO:C8Z=FFU[:!J;/39_M0'
M4V_Y4#KLTIX2QX&O;[+3L@O]>U0:=A)T%[KO_P!D)Z"Y_(D]-^M'3=&83(4^
M7J;*8@R.:E*=GAVTQ@TM6$Q2TC*W<89&259PF//<\V*\K.,-NJSGD+C[]R@6
MRNV,D[VT86VF)>YC&LENFB'=.@ZO$-9%'QE%2V1QZ!R]_9J([=+N0M=0*$M9
M#I'<N2XVV[D@),=(V/16-)!RBQ,$%2S%3BI$QH4THJ00#LX&PR64X'2R&7'D
MXAQI^5HQ"?D=VU*RM.&%N>=CME,??R&(1V-XYN'EB@"6TS&:2#7G1Q!4/,>'
M0\U$W-'H=X&E0^2QT?.,E_91BV2*6X+W4"<B.?3D23;I!RDFW#E.^U9-1L)U
M%5&,[6YDR>.AN!)9 5X7!2#&7 ?F#<SF/$P<3XK65/P_&1O\XB^(0WXAC_*L
M^>W^ZY9>WGCCBFDAFCAN.9R)7C=(YN4VR7E.RA9.4_B2;"VQO%;0]*OI<6\L
MLT$4\,DUOR^T0I*CRP<Y.9#SHU8O%S4\>/>%WIXRZCK7O]'#_P"(P_YLS]#E
MFKU/1P_^(P_YLS]#BE1ZNP8*D&?.AQ5>;82Z4^='9SYJ</)[$X[4?:3C_1C'
MVL?Z.*@?^I_>:D/HX?\ Q&'_ #9GZ'%33T</_B,/^;,_0XI3T</_ (C#_FS/
MT.*4]'#_ .(P_P";,_0XI3T</_B,/^;,_0XI3T</_B,/^;,_0XI3T</_ (C#
M_FS/T.*4]'#_ .(P_P";,_0XI3T</_B,/^;,_0XI3T</_B,/^;,_0XI3T</_
M (C#_FS/T.*4]'#_ .(P_P";,_0XI3T</_B,/^;,_0XI3T</_B,/^;,_0XI7
MJ0A#:4H;0E"$X[$H0G"4IQ[$I3C&,8_ZL8XI7UQ2G%*<4IQ2G%*<4IQ2L&>N
M3I$-]7%6H@(+:=:U]ZEG3AG#&SM4$-BCUS#->E A]CJQ^F[#U%M76UXJ#TE9
M$#8Z%LH(R1CODP5G&&($Z*\*W6%RR8J2=WBN9!,B)K;72V[:)(':.5)K>[M;
MB"4#:\<]LY4A7C9"K!\6ZMS<*H#(-I)\>,N.HTU4J\<B.O>K(X^4,#J-+(ZY
M\EAK^N$]I7#9^P[1O/9]S'Z\;J6P+X0NKGN7L]%Z0];]++^R#]%3?Y.O+KLT
M\[2S]]>OLZM0;6/7<7Z]$,92*8+R,VXXFN)%MH;:WBLK:%K@RV\"P_"1SY:X
MRG9XY^0+B&V031P"!96B80ARGCE!;2Q16=W=I7;9M9BWBLEND&\KO*,[;2V[
M0,-VW7IK40UUY*"%JC7>R-74G<BF:QN;IXZ?-&;*D'J@6LMG<]5$F('V<Y2K
M87V!(/U+6V[-?2;0%E:A3.)5NA6ZPS+I5I6/'&P1>]<<4M=7%O<S6>LEGD+^
M]MPDJQQ?C0+6W.B2 1RW-E.(G%WM$L\4:PRC14=*5L0B2(LGBRPQ1.2I+>)T
M?:Q<E$E4L#&"51CN7Y0TPZF_)[;,ZG]H;'*6[?%%B:4/Z,M.F-2ZT5I>Q3+)
MH.5;*1(#&M@4FS0MUA:05M9ZU>BWK#.LNJB)!6L!2]5U0I3XYZS60S9QN?ML
M9;6RPV,QO8[V*\N[GMD8COQ%.'2WFC-F\Z1)%N$8BNE7M+"ZE28QQ1I5-:/.
M[EI$Y1B:-$,;%HMR$%E(E"%BVFI,>O+!C4KN8G,+I=T6;T-1+4(MMO%WF];&
MVYM+=-\L->K,RFU=RU;2MDVQS!E6JY&R7$D'  X;T +!;)6@V0FY@.E)<M+\
MY<9C49*]2^GB>*)H8+>UM;.".2032\JVB6,-+*L<*O([!G8K$BKN"@:+J<B"
M(Q(P9@S/))(Y5=J[I&+$*I+$ :@=6).FI[]!DCS7U>IQ2G%*<4IQ2G%*<4IQ
M2G%*<4K\O?\ RC[_ *5T>?\ X???^\TUSZU_T7>[C?\ 7PY^[.5\H_Z3?Q^"
MO_EXB_?@Z_.YC2.X%:WQN%&L[L[JO*7',[!9KA-ZIMLLG,UAV0\::CKA,146
M/'H!4IYUN/@RIL;WOC'6V5?3GA_"#*'!G+6 S&H'@UKJ);TLUOVL*MN6$C.;
M7\9V*"W(!ETV L/FOP%FO!GAH8J_.(ZGPD+68V8 N.R%FN IC51=?BV]F"\\
MB+7F$*;7<V]:FI:FAW1=6]VZ:N;S4/-F+Q9/1\C 921Q,,&GY1/RC#"_!EK"
M"'R?,7G+,LM!97YJI#>,X7A&P%YX/[7!VW5 ;7F+SP989YX]8]=PWPVUQ*FH
M\9(9&'1#69X/O>R=N[+/V/1R+GEMR"(I88)-)--IV37,$;:'Q7FC4]6%4;T*
M6]"XL?HZ7Z"R4R%P6[E7@<EDQ$SE#L/]GF>+Q#4F3EGM\[#*L+[.S/+_ &B'
MG]EYJ=HY/:.3J.9R2YCYNWOV;P5U[MW2K'(FY':>6_9^;R.=M/+YVSF<O=W;
M]GC;>_;UKM UT[:)[@NN""!LBR*/'78(R*[,DMAJL")6>R$ULLI4M,$'70Y4
MV4D9QW4,8/ES'E(98<6F+FZM[.,374\=O$9K:W$DKA$,]Y<16EK$&8@<RXNI
MX;>)>]Y941=68"IM[:XNI#%;0R3RK#<7!CB1I'$%I;RW=U*54$\NWMH9IY6[
MDBC=V(52:HW+]6:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KT1)<L?+BSX
M$J1"G0I#,N',B/.1I<27&<2]'E19#*D/1Y$=Y"'67FEH<:<0E:%)4G&<4NB2
M(\<B+)'(K(Z.H9'1@59'5@5964D,I!!!((TJI'>-UDC9DD1E='1BKHZD,K*R
MD,K*P!5@000"#K7Z>_)P>52A[1] Z&ZF#D8=LQ7AA%%VD2=:B#=B+_<LP@%P
MDK[N..O;N?,8'&W,M0+DYE$6:J+:U,NVKXE]V?W!7QG:^*^"+5I,;X]QE<#
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MMK:RPLV'N+U(,@MZ'OK^WFN9],Q@LHYN)%QT<3S3C#/%+((0&:[+N'Y;";P
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M['(Q<?:A[C%83AL%K/"<1R[2&W%Q5Y7GD:!0%"QH%C-@$C;?%'!)H6PL3_\
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MNEK!(0\MCC+KQC<8R\U$T]Y)I<&76*U94^%7*GG!5Z)4<KG[PU_*,Q_OT\5
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MVBVT%J;F-3J83<))(\2R:;7>->8$+<MD<JZ[LJUI*N4VO!:E4D#*U5ZX.CB
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MO*7(U6XN"'C=2=($)UKA6AH"//S LQ(0ME*5@G!4./&<J1%W_P!;FJNIQU_
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MGXY!+S7AUQ<Q)DOI['(17_/Y22+V>18G+KHK,T23>(?YP"R*&U (;4:$:,?
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M\*TZXVQYB%JQGK8X88BQBBCB+Z;S'&J%MH(7=M W;02!KKH"=*^;[W*Y3)+
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MG>_,;6)/&DZ^.WB]7\9O&.I\8]>IK9KF\RA@*9;)J;:V[';%;^Z4V]IXGXK
M1*.5;?!1? 1[8O@T\7Q%TI-)J5."3K$8#5>MB"TLZ>8E%!@,9 (R8\DGDC(8
MD38L5J2\S((+7.>;<=4AV8M4I:5/*RO-2PPQL72*)'((+HB*Q#-O(+* 2"Q+
M$$]6))ZU9GRF3O($MKO(W]U;1.K16]Q=W$T$;11BWC:.*61HT:.!5@1E4%(E
M$2D( M7&[Q'WV.7*PJ=XC[['%*=XC[['%*=XC[['%*=XC[['%*=XC[['%*=X
MC[['%*=XC[['%*=XC[['%*=XC[['%*=XC[['%*=XC[['%*=XC[['%*=XC[['
M%*=XC[['%*=XC[['%*=XC[['%*=XC[['%*HGBT^WY,_1XJ-1Y1Z17PY*RIMQ
M*%^:O*%80K.,X\U64YPG/;A&<X[,]F?M8S_V<#S]U-1Y1Z:U\KU%UNN^Y#Q7
M4& EMAJK;XQF.U,]$)EVDPW;PU<\R2+U8Q(+5L$%DT@LXX>S*LKMF&''6"C2
M946;C?"\PHYVEA(-\L10Z;ML2<EY.CW)"2.XF7Q"(Q&R J="*Q-EQXOPRG0-
MKU ZG<!W("54;3U);<#U^6O57-9=<[QQTE<]_5:,Q*)4!CLJBQSN1%:$DB4F
M\H'B"VF&J[.LAR ;ECQQ4@-\-ED4#<EPXTN+&ECTEUA!'MAL)"0MP09=PWR.
MJB#<R7AD6.,H&9%8G5WT8J2K MP3JTR#XGQ2.@!._0&/0D@]"1\@_9TA!OE
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MP T"L=24Z:*RL?(&4GH14<Z(]TB'_P#F'G'[P1^PU]2]_P"I8M?L5H1LFGE
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D5\_%*=VGV9^,KY^*5VMH3CM^U[/].<^WVYXTU_\ J1^ZE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g431217g74a40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g74a40.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\T4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP"   "   < E  #5!R965T:&D@4V5K87( .$))300E
M       0EEA8R+2\4M&!=SFNZ7%GM3A"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              %\   #R          $
M                     0              \@   %\
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   %\     4F=H=&QO;F<
M  #R    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   !?     %)G:'1L;VYG    \@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ /P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M .0G7RQG[? 0;X;Z7_C*]57;VW1^LX'6<%F=@O+ZGR' B'L>/IT7L_P=K/\
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M4XKV-Q;K@+K3OK#-OTSI[[&._P"BK'3[#9;U%YK=476 FM\;A^AK^EL+V_\
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MGN^B@59'4F4L:S!#]K  1>R# '&GYR-&,MY5PC7A,M>*?[JMC]$EY_ROB_\
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M?4UC<9CP]S:P?IV'^6[]WV(BQ("-D&1XK&U_I1DK^+__V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !2DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    #@   +"':0 $     0   ,    #L  ZF    )Q  #J8    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,C$@,#<Z
M-#<Z,S( 4')E971H:2!396MA<@     #H $  P    '__P  H ( !     $
M  #RH , !     $   !?          8! P #     0 &   !&@ %     0
M 3H!&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!3$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    #@   +"':0 $     0   ,    #L   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,C$@,#<Z-#<Z,S(
M4')E971H:2!396MA<@     #H $  P    '__P  H ( !     $   #RH ,
M!     $   !?          8! P #     0 &   !&@ %     0   3H!&P %
M     0   4(!*  #     0 "   " 0 $     0   4H" @ $     0
M       #P     $   /      ?_A/T)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-RTP
M."TR,50P-SHR,CHR,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@5V]R9" R,#$P/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$W+3 X
M+3(Q5# W.C0W.C,R*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q-RTP."TR,50P-SHT-SHS,BLP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@5V]R9" R,#$P/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^4')E971H:2!396MA<CPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @
M(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D1",#A%144P,38X-D4W,3%"
M-C-%0D9#04-!,T,V134Y/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D0Y,#A%144P,38X-D4W,3%"-C-%
M0D9#04-!,T,V134Y/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z1#DP.$5%13 Q-C@V13<Q
M,4(V,T5"1D-!0T$S0S9%-3D\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.D0Y,#A%144P,38X-D4W,3%"-C-%0D9#04-!,T,V134Y
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#$W+3 X+3(Q5# W.C0W.C(W*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1$$P
M.$5%13 Q-C@V13<Q,4(V,T5"1D-!0T$S0S9%-3D\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3<M,#@M,C%4
M,#<Z-#<Z,S(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.D1",#A%144P,38X-D4W,3%"-C-%0D9#04-!,T,V134Y
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#$W+3 X+3(Q5# W.C0W.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D1!,#A%144P
M,38X-D4W,3%"-C-%0D9#04-!,T,V134Y/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D0Y,#A%144P
M,38X-D4W,3%"-C-%0D9#04-!,T,V134Y/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M1#DP.$5%13 Q-C@V13<Q,4(V,T5"1D-!0T$S0S9%-3D\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 7P#R P$1  (1 0,1 ?_$ !\   ("
M @,! 0$           @)!PH&"P,$!0$" /_$ $80   & 0,"! ,& @<%!P4
M  $" P0%!@<($1()$P 4(3$*(D$5%A<C,E%"81@S4G&!D=$9&B178B8G-9:A
ML=@V<H62\?_$ !T!  $$ P$!              4#! 8'  (( 0G_Q !1$0 "
M @$# P," P4$!@0)# ,! @,1! 42(0 &,1,B00=1%#)A%2-"<8$(,U*1%B2A
ML='P&&)RP1<E-%-5=(.4TB8U0T145I.5HL/3U=3A\?_:  P# 0 "$0,1 #\
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M#1>@W@TK*)+N KT,I/J$K5YG&S5@NX>16-YZT?9S1(ZSO@1,QTZ]U[Z?=R:
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MM?!"B8^A_5H4I0$3&-IIS.4H  ;B(B-+     1$1] #U\!_]->W/_O5]/O\
M\\P?_P#+Z<?A<P^,:7_\&7_X>A]ON-,@XDL[ZBY?Q[;<8V]JP1=/:CD*GSU/
MM#)J^;HNV+UY7;+&,Y!&.<-ED'BJKJ/,F[AU%C,".'2[(JA+!US3=4.S%U#M
MK5E9"QBT;+QLZ5HQ(L4CN%EE5<==S)+)M8ARL:@R.JGQHLJ'W-#+'S0;TY5H
MUN'PMWMX%@718A0QZ9ETJ.IE>M!^;&E?LTX]D=+.5+5%L\T463<RTRQIQI$\
M;$R>9ZJR12G7(66MQQ&[F8CF<'8I7)U/9#17 24U!8NL56JSZE_3?#U[#R,O
M3X(_VOBP.\,<2PK)*J43CSH(UD,<S,/3>;)"P3R%P[0;XIR>GYZ(XCDD503[
M@7"E?NU&R-O(("BU ! ;E=BZP5)L1R*Y0053*?\ ,65$HE<J$%!8IG!E?1;T
M313*N)2G!0@=TPB1OQ6,,8^5+.&8(8V5E=_:C*59SMVJ%"[39)%+R11!$L;W
MB@=U4;0W?'/(O@63XH ?8CH0-;6N#$FC? N6LN66:A;--X[AXHC'&C6TLXFQ
MV6X7!9\QH%7(+9O*S<66Q/XR4?.Y1C S<C#TVMW>YQ\%/(TZ1CS2K0.W-6U_
M,Q<; P<R<9(>198,+(RD&/$46?( BC</#$98D9_[KUIH(7=/6#!C/D0P EY$
MM0+5W6[:]HHD<M7'S0)HUS31C9F*SXWMG5FZJ+Z9RM&6Z6FL>Z/-(U<?RM4:
MYJL\/)2;8M.JI"-I69K&F/%"J3Y6>EXDKU_<KNZL"MVE;K>TS5;+][0X TN.
M/MSM#.@TO,QH)Y>Z^XILZ/'AT?&B>1)L#-R(5QY9-:RLG&V1Z:[W$(45L6+%
M1\G3V*E\A&FG">ENVQ*H9#*PH-M(W@(B-N(_B;<22:#LOI'2KUO]02)H][U_
MYF=:;L Q7V#8*#HQQM6(:OP&.*,P0E4ZY78G%B:K>AXH=UJNRA(Z"G;S$9,R
M['QD@]HUZA8Y2 2(>-9'U&[*[/FSX^U]*R-;UAEGDRM:[Q?3,J!0@'J9R3X3
M)F9$;SARTC9&'&BKZR2.)"D.WX261"TS[%# 1QQK:A:/%,0!0JJ4LQX*\;FD
MB7Z#G3=A8:DL6EFU47,V0;E&U!K;X7(-73FJJ,Q 2MCCMX!OB^+K[,CIF[A7
MJ4>M2"F<5V6;V#@O$_\ %GAVK_VCN],%L')S-*T_(Q=0FQL/$BT#!U6? J57
M,.0RR:V%.[8:FA9_4 (56 /6CXL"^B$,E2R"/>Q "[PUD$)\<<! "IOF['IJ
M=(O5]H3\W?NF)JGL%EJ@.2RUCTF:CTHJ7H.26Z\7&FM#5TYCF<5CAW/6L\!#
M0D4_<5/&$I&QLU-=O,-,C"2+I^4;OO1>YUC3NG3(=/FF6H<[$ @RL=MP$8*2
M2RY<:K3/)%')DAY%0&"5I %<1P3Q@F)BZC^%A['%"]K#VD'P"0G\7N4#HJ],
MO4[:2#:LGR+7;E0:"I>*G@W,$/DY:>F,MZ)M1L\[1KE,QCJ(=239C=+5AG-+
MI%I6\)ZH++$HK(WM(D)EB5&P33B#IT=U70EBE$6*R960Z>ICMA(CXVJ06M9&
M"L:M%%D(6O)PHW8.I5\=?3=7+J![)+>Q: I^&1MWY3N(L'RKG\W*M7)Z=[&+
MIG$#E3(7\M4$!#<0%OW2\BDXJ&;D4(X!5!T#,5R.!;MW:JQ"KM4QADQVMM!M
M_P Q4?FK[[>&VFP>0*NCR#TYKFJKX^U>//V^_7J^8('H)TP$/<!, " _4!#E
MZ"'U#PS.= I*M+$""0070$$<$$%[!!X(/CK*/V/]!TECX@^;>Q72_P P1S9$
MJK.U7/$%<F53$7.9I%GR- S7F$NP B53[1A8]N!C_EB5<Q! 3&*4;A^C.'!F
M=]X"SFA#BYTL8L#?(8#!MY!O]W/(PH7N4'@ D#=5=DPW*BR7C'\J;=?D?*@#
M]2!\]:\PQ5H]1!0G=3.=JV7$[850*1)ZDOW50!!VQ=JI!%+*NW39NLIYY$#-
M':)V#IQX[1U;;AM#+$I/$84K07U$D;E2IC+;60[E5R77AAL9K@Z6<CDT&W*V
MZR0+4<C:0+)%%O:*+?F1;VH^E3'&+L28#Q!CK!RL0]Q#6,;5=G09V"6@7<3:
MZVJQ2>1U\/*U9%E7;!,9%%TYO4U:(B/02LTI/O9AV=9RY[A_G#W1FZOJO=FJ
M9^:LD67E">7,67\4B8^6<M]^$B3/)+"N&M8T6.[L\4,"I>U5 LN)(HH45*90
M%"$%2'7:*?V@ D^2W\1-B^B =M3+IE*H<HI]PIQXF(<$Q+N9-4Z2Q3I'*FIP
M$H&26X*\%"I@8A5$PL46H1S!S,A7G@23U1!!%4!R"11XH]8_ILM40WW 7]?Y
M_IY'GGR!U$7]';!RF8FNH!7%%&#-C&MO*NADLD"S^]JL Z<13U1NZF.P1:34
M05BF";)\[\\^BT"G91SUFT>O6[F02:KJ/[/. ^9D'#4F5<7UG:!6 :]L=TH)
M);: HW,S42Q8H+$BR;]J[FI-W\1!(\G_ &_\:ZFE$0$IRF'8QTU%" ;T5,&Y
M!5.<-@ /G4+N   % 2@(![ +@/J1L2#6^OB_ //D??\ ITK)Q?V('\Z/'S_L
MZUS/78(0>JIJL,;T '.$T]AV]PTY8?$/<-MMM]__ &\=W_0^*$_3C3Q)04YV
MHL2=OD9+(![A7A/'^7V$-U:OQ,GF@\?\Z,8/_?T7GPQ0)AKSRSMMR_HE7W;?
MCMN.8\![#Z>N_P"WUV\1C^T D"]CZ;LV5_IAB #V6&&CZU54/L!7S?3_ $@V
MS??TVL_IN%_U/S?R!U>O5#D4I3[&^;<Y1 # 8@E,7@8#;B "(@/MZ[;>PB'C
MCPN%W'^)5+<>17/'(-_[.?O74D7_ "'@'X'C[?I?V_GTL+JWX'QQG?0%J32O
M4*DK)8MQ/><NT.<8N&;6;@KEBVM2]OA3L)R11(E&MY96*<5>=!9P5-W7YR6C
M>(N'B)B2KZ<=RY^G=RX$N*9(Q+G08F1$0_IRQ9$BQ.2JM9DB)$J5M.^,;V$0
ME!:9\*20N&H^UF%G\K*"11H  GVGYY-"^M;*B4AF_  -W$RKD$C<AD4N)#*-
ME"G(]+WB$/'%.A&(*B#DKM-9(Y>Z=(/'T,QO]<P8]RA5]-6V $4.4 "W(12C
M: 5*BK9N 1"<E%!!L$EZ)X)OEO) _BYN[\_<CJ['@RQ3EG^&7G9"PRSR:D&>
MG34)6$';Y<%G"$#3<QY*K%4B?<3%1A*M%0T&U((_EL8UJ0"@7AXXSR\98/K1
MZ:C:!K6,> !RV-&['A0"2Q)8UR;\D$]2>$G]G*3R?3(_3AV'_/\ (=4ET4E%
MSF(F4QC%8@.Q0,(B!$0^A0$1]/?T]_V\=IL391?)TP[1^K-0\<W9XH7U%]GJ
M9K+]DWT?'ML<\'[_ /\ OK9#=$L4QZ7.DDY3;\JA; Y;EVW+D^\D'<0^H"40
M]_00, ^VWCYY?428KWAK1E#;CDQ@@#P1C0 7N-C@#^GZ=3G#6L6( B@GR>3R
M3_GTU+<A1W,9(!$0#D<0 1W]@ 1]P_T'Q"6.,I]1A"&:EWD1AC?-%CR?'B_C
MIU? HM?\^/Z==@HD  _JS"(; )=AWVW'W^H>OI_+?PJ-M6@4_P#9H_I\=:GG
MSS_/GK@$Y5  2=L2F#F4Y-A Q1#D @8!$# (#N AZ#Z#OXT1Y"Y5EI0I-[6'
M-@59->.?OUFQ5Y%WX(-<??BK'(ZU@_4S 1Z@>M/8!';4YF<P[!OL4MJFA,8?
MV*4 $1$?0 #<?3Q]!?ID:^G_ &Z3P!B8Q)/Q_JHZ@VJ?^5M^LC ?J;CX'5@3
MX57?S6O'8#^B6F HB3Z&*KJ)$Q1'Z" '((E]P Q1'W#>D/[1RELWM@ E3^'U
M.RIH_P!]B\6/]W1W1.$EL \)PPL<F0@U_GS]CQU;L=E.=,HB)?D5 2][8 *8
MQ#IE.4YR*=M4HJ;I&*7D94"H\BE4,(<RA9$-^M]P0TC41\@^.CWL^% (KX _
MRX/\_'CI(77WPACS(_3ZR-DZT0,0>^X)EZ5;\:7-\UCBS5=>R>1J35[#$LY5
M1!J]^S+K OEV<K5&8JQTW-MZP^$AW43&BK;'TEU7)T[O328H7_<Y\HP\J-0S
M"2)V28,H5EVNLD,7[RU;TS)$=P8KT.U11^$D/!*LI4@\_'/QQS6WR6KBUM=?
M?&M@=)+F'@B7R8G;BJ(KMR+E(D5\=<I4U#K*"N5J\!L7=1-,Z7H!% Y]P8L7
MXA\N9JWRPM$H*[R&D)8EMQ]WNC5@"P(4U_$"(+Q^(LW3,;_[-A5 XL"MP('!
M-FSM)ZV,.FG4O 86Z.&$-2U\9-1;8ITA426,QD;0:)=VF=I],CZ/4HU>S2IQ
M60L&2I^*B8%)\J1PL^E)Q=)-.05=^3<<$YFAS:SW[E]OXS?O-0U_)PPTD?JK
M$D^7(97= EM%!$TDI&W\J@?P[^K!Q)5CQ4D>@/3]U4/T %B@21Q=@L5-=5CM
M8A<LYSC^F3I=N=Z<O<R:WBQ&L'-61E)J9<TVWW[6[<(_%V!W4_2'C0[-DC@+
M$5=98W;P$"1O!U^F*NH*A,&/?,ZD;V^F^#'VYB?435'598^TH]2T2& Q1^K%
MCZ$)\[-C0MZ*SQY[J'GC<XI9XT=Q:P#& 9JM/-$@NW_>AN6MI&VQ.1M)5HE4
M!2&8;3M6K;>]:HX%KUOU963,#*AR%GINC2+8:.NFKB=,MO3HT;;<4TV&)F#/
M5O9V]RI59=*A9,F6F&&N1X^>*_02QZ\VJ3O)6-L;SR/.O=?>N9I>B' *Y>5G
M][:M^)U3+TI(I,QY]5CF;'_$O'D0-#A1$2Y>2RQ/Z4LZ(OK19>0O1:,*J (I
M;:Q$2<TNT>YZ<_%!=Q/"@\#:@5@%MS^Y#)K^!K%<R'-3,(C98)K48)200<9
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M29TYY+LB\O+33W(E2K#^5C,7Y<=/IF(CG9#7".@K%73*R#V7G[2\H3_(L_\
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M !T05\P!ZE..HJ2X;_0"[X)$ -[B&P_40W\"/^CCEN_I'5\78%W!VQY=A/@
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MV<*S2J&2-8EZF&C9#20N&+$Q^VS5D&]I)\D@A@20IH*=MDGJKMUW!,7JN:K
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M6:;+F]2.27]SD8_X>.)II2(VCR']264K(;=45-L4[273M-&&YG)7>5*; 0
MQ1B6*A?.Q10.T!?.XGIQG5-+VNG1K(1*B9--' 5P(7=/LIIE%J44&J*8JJ&$
MS=MVB.#!LW%<1%OQ4.[22K#Z?2E_J)H$?G;E)N;[ON:R#_$#N))(XX YW=/L
MRSC3$^3S_N\?IQ?''VZUG0 0JA.?L=LD4!$2E  42X*"8QMBE*"(J& 3>@"
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M2)*I/IUN_,'3BS5?EL"N;H"K%\GK8+LB*E#BH4Q.:)3"B?\ ,%!8PK++@"P
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M1&5BH)"&"6,A#&4>-RW* ?N+-1AE(9TW$[U_);!6*  !Q#1-LD'$JG%+MIN
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M%4B>QA ?F, B4 #</F'TXA[CN&P>OC:658@FX@>I(L2V0+=[V@61;&N +)^
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M@!R&&@/JAVMHO9>7@Q:2VL31Y#94<W[1.))*)(3$RF+\-CXBB,K(0Y922ZV
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M\)+T]K:*U>))S<59!M#-X"'AWXF>1IX@BK<4I.:B7AW;I6=8(M2( L98Y#)
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M4\AMIYIP?!'7<R_DN)Q#0IN^3;5\]C(4J"KQM&H-G+]1%=T@T$&J#E]'$44
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M 98U!W>0HMN$'RU%OR@U\7A%'U*X'N-P:412LRN/;(Y>LDHUA?Z4QJ@3)70
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MNF#6OIQB9N)GPG*^H>@!CG00+AA&R%B=KFFNE]9>:8!/5!^+"ZK"K?@"\D8
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M[E!,$:]X^_YGIZ^OR^VP>_\ =XNG,)6&6K_\DD''GA&_Y_SZD^1^0?\ ;4=
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M1(:/"[@.0:QY)V4&39RPY%[K-'@^17\[O]#QT\[X1M^3\E:?[G$2\"TAL67
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GU6- M$L_3^P3_P#4/%EF&$DDQ1DDV244DD^237)/1.S]S_F>O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g431217g74g36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g74g36.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M     "D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  -4')E971H:2!396MA
M<@(X0DE-!"4      !"/.<\/Z1LFFWP1&LNY4:S$.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  0/      0 !.$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              @    .K          $
M 0             #JP   @                       0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   @      4F=H=&QO;F<   .K    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      ,)0    $   "@    5P
M >   *,@   ,"0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 5P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M224_5.X>?W%+<//[BOE9))3]4;AY_<4G.$=_N*^5TDE/_]D .$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      4I-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    X   "PAVD !     $   #     [  9!D   "<0 !D&0
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C(U(# Y
M.C(S.C$U %!R965T:&D@4V5K87(      Z !  ,    !__\  * "  0    !
M   #JZ #  0    !   "           & 0,  P    $ !@   1H !0    $
M  $Z 1L !0    $   %" 2@  P    $  @   @$ !     $   %* @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 4Q-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    X   "PAVD !     $   #     [    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C(U(# Y.C(S.C$U
M %!R965T:&D@4V5K87(      Z !  ,    !__\  * "  0    !   #JZ #
M  0    !   "           & 0,  P    $ !@   1H !0    $   $Z 1L
M!0    $   %" 2@  P    $  @   @$ !     $   %* @( !     $
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MG.>+&,8_5@)  V'</</BEF[RZ=U4K?8<9ZL$G8> \A'>73NJE;[#C/5@C8>
M\A'>73NJE;[#C/5@C8> \A'>73NJE;[#C/5@C8> \A'>73NJE;[#C/5@C8>
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M"._P'F?JCI.W]5(_RG+^#!'?X#S/U1TG;^JD?Y3E_!@CO\!YGZHZ3M_52/\
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M3\9,A550%4!54;!5   'N  [@!X"><1)F9Z9_9/KO_*,)YDD$33 B B B B
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M]-?Z:Y'/U;_NK4__ ,?F_P#MK)2S^3L_]#?_ *F?.@?G><J B B B B B B
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M/[OJCH&>Z\3G9E4_  C8^)_=]4= SW7B<[,JGX $;'Q/[OJCH&>Z\3G9E4_
M C8^)_=]4= SW7B<[,JGX $;'Q/[OJCH&>Z\3G9E4_  C8^)_=]4= SW7B<[
M,JGX $;'Q/[OJE:J$+,K5YDHC<)AHF961P5!*/K:B9,EDWA39*=Q"++9YPQ3
M*&P90V,&/DI,%)@I<) '<.\^[^KZI9>@9[KQ.=F53\ "3L?$_N^J.@9[KQ.=
MF53\ "-CXG]WU1T#/=>)SLRJ?@ 1L?$_N^J.@9[KQ.=F53\ "-CXG]WU1T#/
M=>)SLRJ?@ 1L?$_N^J.@9[KQ.=F53\ "-CXG]WU1T#/=>)SLRJ?@ 1L?$_N^
MJ5JGPLRM6XI5&X3#1,Z2N2MT8^MJ)I<3E?&<%.XA%ELXSG&3?TBI\XR;.,9Y
M.,8PD =P[S[OZOJEEZ!GNO$YV95/P ).Q\3^[ZHZ!GNO$YV95/P (V/B?W?5
M'0,]UXG.S*I^ !&Q\3^[ZHZ!GNO$YV95/P (V/B?W?5'0,]UXG.S*I^ !&Q\
M3^[ZHZ!GNO$YV95/P (V/B?W?5/1E(*<)&2)CW6:5*5B[,9,T;5RE4+ANIG)
M#&)!$/@I\?S<Y(8I\8SQE-C/%D(V/B?W?5/6K\'-J0,(HG<YI!,\1&G(@2-K
M!B(D,S1R5(AE8-14Q4\9P0IE5#J9QC&3G,;C-E( [AWGW#P^J2_0,]UXG.S*
MI^ !)V/B?W?5'0,]UXG.S*I^ !&Q\3^[ZI!V>$FTZU85%+E,N$TX.6.HW4CJ
MR1-<A&#@QD3G1@TUBD5+C)#&2434*4V<D.0V,&QS]6_[JU/_ /'YO_MK)2P?
M!OWG\1O#\D_U3@\?G><N B B B B B B B B B B B B B B B B B B B B
M B B B=J:VAYAQ1Z\LWMLLP14:*Y39MV%=510QW6XQR"*.X9PY-C.<9-QJK*
M&XS9QC/)QC&/O'2O\W],_L7_ ,>V=*D?!)WGW?U>)_JEXZ!GNO$YV95/P >@
MF78^)_=]4= SW7B<[,JGX $;'Q/[OJCH&>Z\3G9E4_  C8^)_=]4\=$(9.LM
M2'5,L<DA8"'6.5,IU3%L,K@RIRI$32*93.,G,5,A$\9SG!"%+Q8P@>[])^DR
MX!)@(D27W=6^26WGCL(DL$0$3.-P;-A-+ZMO^V+*UD'L#KRJ3-MEF<2FDM).
MV4*R5>+-F*:ZJ"!G2^$^:1Y]9%$IS8,JJFG@QL58D&I%4N]^1BXE2@@<K\S)
MJQ:%+'954W7(&=B%1=V;N!F6FKMK G((.-CLS D*E5;6N=E!9B$1ME4%F.R@
M$D3#MN<):YT^]0.K]2:!M>]M@/*0TV19XB)N=)HD73J8_EU(./=OK!<7[9E(
MR\I(LIA&*A8],ZCOHATHLZ:(<2N!;_:,NE073!]7.1<-A_O;9@QEJJ8BRU[!
M@Y#%=E"*J\FY,%F($=AB7$\7S>V]7J()]G&7%;)>VQ0U=8K]=QU4;L;&=N.R
MH6FQZ5VW![OUU#["@HR9@DWSV?@YBMV)NDUGZO:JC8).J6VLS"3=9RUR_@K'
M#2<:JNS<N6+S#<CQDX7:KHJFRLJ;5656I?1?37?1<FX6RJU0RDJP#5V(=Z[J
MG >FY+*G')#(]L/;5;6U5U%C56UL5;BR@,"&4E7KLK9+:K%)6RJQ'7N83512
M3 1 1 1,STS^R?7?^483S)((FF!$!$!$!$!$!$!$J='][+#]]*?ZL^"0/</F
M'T2V!)@(@(@(@(@(@(E3HWO4A_W*_G;@) ]P^8?1+8$F B B B B B1TQ[DR
MGR<]\V5")ZM:][E?^1(KS! ) ]P^8?1)L),!$KUN]ZEG_P O37^FN1S]6_[J
MU/\ _'YO_MK)2S^3L_\ 0W_ZF?.@?G><J B B B B B B B B B B B B B
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M/F'T2V!)@(@(@(@(@(D=,>Y,I\G/?-E0B>K6O>Y7_D2*\P0"0/</F'T2;"3
M1*];O>I9_P#+TU_IKD<_5O\ NK4__P ?F_\ MK)2S^3L_P#0W_ZF?.@?G><J
M B B B B B B B B B B B B B B B B B B B B B B B=[ZJ_9]6/\$KYZ
MZ'WCI7^;^F?V+_X]LZ='\DGS?YF:"/03+ 1 1*G2?>\E\J6/_<<L$@>[])^D
MRV!)@(D27W=6^26WGCL(DL$0$0$3/JOLBN7>?V16*XI)+/\ 6%@9U&T/5(Y1
M".1LKZMQ-IZ,C'3GDIRCB/AI^%<OSHD,T05D$6N5U%R.4T*,'?&-U?)5L.55
M18 A9GQG:BVRM'(#)7DK90&?BCW47)N0C&6[DN6IP"171>RG?B*[RQK5F7W,
MR)S*K[2UO6YVYKOGG!<M+RX:<AY64V=.;<F&UDV! S=QLM)@M=S_ $S6KY8X
M"2K<K4:TBC#1KJGNHY2K96985)*I1"<P9RZ,_P N%,@*M1AVIQ*78.+:MBLS
M=OSI7G<P8[UV-8'%U'=V%RV4E5-9 BP%,G+K(XFK*M3LO?V*^RU=:O[[D-3)
M;7>?Y:NQ;5V5E ]3A6;QLO!VTK=-L5C6+_:#BG0,U8I"+1L4-5HJ+B("*=S$
MA)SLO)'</TVG<[,[1HW@(*P2;J2<-$3,6[,SF0:T4[Y&)21Q3(RL7'>X]ZU#
M)RJ,4;(N[V6LUX-:;+6>+FVZH <L^/1V[\ WML>-: ;L[%6;<D[*E:!2;&)+
M $!$=CL*GO7A#W775PTO1*)5M7RT]MR$O$X1[MG:LEJVM125+2IILQ[:5B]?
MW]U*2TJK;TTV3+$6TP8K)4W/9,<I,9 C-DY6.G ^JTI<26(LM[3*]51*JPIY
M,&]MO:&R^[<^_7KV?"3+/(&R_%I"*H9%]8Q<O)+/867B%]5[-?8/-K!^+MW]
M20"\TY@XAQ8V<5'V!>-9+33&"DW,W"LY11NF=\VB9A[%PCN4CD7&5$V;]U#1
M:[MN5-=6/:'/E DN$#L*RY0'V2ZA'_\ \E#. =_B#&54L5!8*#W_ (K%E]YV
MV)"GW;;]W<=QN=MS+BDM,QTR8OZ*->?SB^]&$_KQX$D$33.63X1?G8^T(CED
M^$7YV/M"(Y9/A%^=C[0B.63X1?G8^T(CED^$7YV/M"(Y9/A%^=C[0B.63X1?
MG8^T(E3I!BXK+#C,7']-)_UX\;/@D+[A\PELY9/A%^=C[0DQRR?"+\['VA$<
MLGPB_.Q]H1'+)\(OSL?:$1RR?"+\['VA$<LGPB_.Q]H1'+)\(OSL?:$2IT8Q
M>]2'_G%_]E?^O'A;@) ]P^8?1+9RR?"+\['VA)CED^$7YV/M")67EVJ,>Y69
MO;'#M7;<_-KMUWR":J1\8QG)3D,;&2FXLXSQ9_ZCF7:UI./:]-^HXE5M9XV5
MO>BNC>_9E)W!V/NE#96"074$>\$SUOTA4?K7!=HM_OC%]\&A_P#-<']HK^N1
MVM?Y:^<?I"H_6N"[1;_?#[X-#_YK@_M%?UQVM?Y:^<?I"H_6N"[1;_?#[X-#
M_P":X/[17]<=K7^6OG/GWP]^%EN[4M=ID3P6]:-]NSUO4GBV>81BI"SQE2BH
MTD81N@=I"2319.4FSR#@K51]@S0K5B\,B55SC!F_T#H-O1SK-V>_576>F:/C
MXJ4#%I.I8F+;EVW=KS8/D*X-5"UKR%?ME[$Y$+W-Y?J76-6T^O&71< Y]MS6
M&ZP4V7I0E?#B.-3*0]I8\2WL\5;;<[;=3:!W,WM^EM96/8#=AKR[2=0B#VBE
MR+S"#NOS2#?#1ZS.BZ/W4BF95#+ALDZ_XE-LNB1Q_3%./*Z[JG2VGZOJ&%IO
M4>G:E@8^397B9R9-++DT=QK?DAX,W$A7*>P75BOL[3M:;FV9.!B7Y=7JF3;2
MC7XS;@U6>YEV;V@-QNH;V@I ;OWFO?I"H_6N"[1;_?')^^#0_P#FN#^T5_7-
M[M:_RU\X_2%1^M<%VBW^^'WP:'_S7!_:*_KCM:_RU\Y!V>]TUU6["V;V>%6<
M.(.60013?H'45658.$TDDRX/QF.H<Q2E+CV\FSC&/;R-'4]=T:W3=0KKU/#>
MRS!RT1%O0L[O18JJH!W+,Q  'O)E7MK*. ZDE6 [_C(,X4'PV<V B B B B
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M9U"^BQ;:;<@M78AW5UXJ-P?C&X,Y]I#6,0=P3W'] E/''F. B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B=[ZJ_9]6/\
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MUT5TBQ]VOX=NS,UI8]9#')@(@(@(F9Z9_9/KO_*,)YDD$33 B B B B B B
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M>,G'S@T:U0[E?R#=ZV<.'F64<5N=?G9O86$M7;A HJ[)B5YP%K.Y#;G+!(9
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MRG?8@[CN.Q'S@@@CW@@@]XDH*RTXTG_V ZA^3H/_ $)<>!](/_=N%_\ ??\
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M\*);UD/6Q\FR_P!0?KC\#&1_2;Z&?[Q--^QCV0C;XG.$'_"B6]9#UL?)LO\
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MD-K/;S=L5VR9UU:#BAP]-R>()(6W(H<7%=R>*NU0MX#9%9VX*JD*O8(B3 1
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MPB2P1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g431217g74p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g74p02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  -4')E971H:2!396MA
M<@ X0DE-!"4      !"/.<\/Z1LFFWP1&LNY4:S$.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  0/      0 !.$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              @T   3Z          $
M 0             $^@   @T                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   @T     4F=H=&QO;F<   3Z    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      .YP    $   "@    0@
M >   'O    .RP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 0@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]3+&$R6@GQ(2].O]T?<%)))3'TZ_W1]P6;EOR7YSL:A[,=E=3;7.],6%Q>Y[
M-ON<S;M]):BSLO'S&YKLG'K9<VRIM3FN>:R"QS[-T[+-V[U$V>W7?HD(?1ZA
M_P!S&_\ L.S_ -*)>AGS_3&_^P[/_2BJY&=ELSFXCWT8UGI[Q2+6O>[7W.]V
M-<_V,_X/^6K&'9U:W&KL.,QY</IFTUDZF'&OT/;[4VO[W_/7:^'_ #7"ZS]?
M'=%OJQ+>GMR['UN>ZUM@J'MMOQ?YOTKO^X^_Z:J4?XSK,A_IT=#]6R)VMO;/
M(;_W'_><U:W4OJ#B=9LJRL_)NIR&,<PLQRS9#K;LK_#5/?N;]HV*JS_%9TEC
MMU?4,YCOWFNJ!\>6T*UC.'VX\0/'6OS;H-66O_XXN;('_-YTEXK:/6;)>=GZ
M)OZ#W6?IJO9_PBE_XXW46.#/^;]C7%P;M]<#W.,-:[]![7._EJR[_%G@N@NZ
MKU%VTAS9LKT</HO;^A^FW]Y5>I?4+H/3L6S+ZAUG-JI:"2Y]M?N(#G[&!U/Z
M6US6NV5M_2)P]D]/^G_WR-%S_C%ZB\[?^;]CC)]OK@F0"YWL]#=[&M?N_MJ/
M_CBYL3_S?=$D ^NV"1MW;7>AM=MWL^BBX?\ B_Z-ETMR<+K6==4Z VRJZIPE
MOMV[F4_2K^BC#_%G@  #JO40&_1'J5P.?H_H?Y3D+P]A_P __OE:.?=_C0=1
M:ZF[H?IVLT>QUX!!C=K^KK2Z)]=Z>LX^6UF,S%S:75FFEQ]0&JQU6/ZVZ*]_
MI7V?I&;/]!_I$)_^*OI+W%[^H9KWGESG5$F--7&A7NF?4G%Z+B9;<)[LC)R+
M*WMLO@.].IU=K<;>QK6>ZQECM_I_G^_^:3<IP^W+@!XZTJ]TBK#?+LMMOHG.
MQA89(8:!N(!VN=M^T;E!K^I.N-7J!H !]0XL,,S[6O\ M'TFQ[E#-R;J2TVX
MK,>VQP#+'V5.=MW,]<L;M<]VROW/^GL_G%G?5_J^19C5BVW[4;?4+#:\"S=]
MINH97N]+=NV>BST[?H*EP93J9\(!VB)^H'OQ_P!U=IX?\UW<*V_[8_$R37=^
MB;<VQE?IQ+GUECF[[?W%H>G7^Z/N"H85&4<Y^7?5Z#?2;2QA<'DPY]CG[F?1
M^DM%30NNOU62W8^G7^Z/N"08P&0T ^("DDG(?__0]522224I5,G/]"UM0IL>
M7:;V@%C=-VZPS[6_F?UTL_+NH].O'J]6Z[=M$AH :-SG.+R%EEO4R27423J2
M;:__ "29D$C'T2X)?;_TDBNHMI.Z-F?;B]EH;CV9'VFU^[Z46?:&6-Q_3WU]
M1K]F%]H];[-9A?SG^!IKW!U&NN\5$G<\%VT-,0"-WOC8UWN_.6<RGJ+-T4$[
MG%YW7,=J>0W<_P!C/Y"<5]3!>?1)#R"&FVN&P(VLC;[?SO>HI'-Z1",8&4B<
MAOWAY^J>&7^*NTZZ]OT?^^=YCVO:'-,@J2Q*+>J8[]PQMS?SF>K7K\/=]):]
M%S;Z*[V AMK6O:#S#ANU5A8@R,XT6;?LU]K8$/J:' S_ &MWM5/J#\7JN,_I
M^9A91Q[7,]5NR X->U^USFN_F_;^DV?X-4\C!IQ;#4]E/J.]U>RG(< TEWTO
M2>]N]K_3V*)QL5I])U=>H(MC'RB/4V_X-V[VL;[/H)76J6_@7T=/Q*L'&PLM
MM&.!74TLF&^XL;OW?08T;/?_ -<5ZG+-MSZO0MK#!/J/: PP=L,.[<L'T*G5
M6#;0&O=O>#C9+1N ?Z3W>_V;:Q9_KZ:+BX5.7=^B;2=I:ZUQJR*W0+/\"ZY[
M6L_1,9]'\_\ X-)3T*B][:V[G& HY%S<?'MO>"6U,<]P')#1N]LK'R+.J7/W
MOQPT#Z+?5K@?]+Z2!(&I-(;=[V7/;86 V5SZ3X&YLZ/V6?F;V_3VJGAU654U
M5OMNI-5KK0WUFV;];/T=KO3;OI?ZGJOK;[_^$0:Z\ZVSUJZ=YV[(;>PMB9GT
MVOV;]W^$3OQLRQS'OPV/?4=U;G65DM)$;F.)]JK&$YS&6)B)0],8\?%BE']9
M'7]5Q\7ZQ?8 X>_AJ[M-[;1'#AR/XHJP0WJK"'MQ]I'T7>K7_P"26I@Y=F0'
MLNJ]&ZDM#VR' [AN:YCF$JTL;22222G_T?4+'WM<!74'MTD[@._A"@;<N3&.
M" =#O&O_ $54LQ*:W[#EY;3H&PYS@)T'YK]W_7$QIH <TY>7.W83+]/SMX_1
M_3]J:2/WJ^Q=0[_@OEOO=E8I->QX]4;1^DTVM]WM-:E^G_</_;3O_2ZRNN]*
MQNIT8N)9D7[/5LL-KH#]P;]#]8])GI^]88^J70CD'%'4KCD EIKFF=S1N?7N
MW>GZK&>]]._U=B;+4Z$G3I_Z"S8L>"4;GG..5_+[9GIWXN)[#]8_</\ VT[_
M -+IYO\ W#_VT[_TNN4_YB]-_P"YF1_G8_\ Z42_YC=-_P"YF1_G8_\ Z43?
MJ5_L\K_XJ/\ X3+_ +]ZH_:(/L/!_P $?#_CU9Z9_P FXG_$U_\ 4M7%N^HO
M32T_KF1P?SL?_P!*+M.FF>G8I\::_P#J6I\.K%FABC7MY3EN^*X>WP]FRJ67
MB8[6795AM=#'.<QMKP"&C?[6;PQGT%=5?J'] R?^*?\ ]24]A1XN'1^AR6NN
M)#!L;9:]X@M_.:][FO?_ "U<0<3^B4_\6W\@1DE-7JG_ "9E_P#$6?\ 4.5<
MNN/+"?\ K3__ ":L=4_Y,R_^(L_ZARXT_43&9#3EY0^/H#_HNN#E'DVH[&P6
M;##%*_<R^U5</HEDXO\ %;WUHI%703715]G8,K$.VFM]/TLFK=_-/;]+?_G_
M /"+=>^[>Z&$ZG7TG^/]=<;U/ZJ=,P.G/NMNR,A[;L=KJGGTW-%MU=#'>S]&
M]F]_\XKEWU&Z<ZUYKSLF-Q&RMAL#2/I,]7:[W-<FB51$1$Q ,O5Z1CE\GR^K
M_N63VN6,B#S)JA4O:EK_ ,YWZ\9E5S[ZZ"VVV-[O3LUVC:W0V;?HHN$^X9&6
M6U[G$U>TS7IZ?/OWKF/^86,>,O-/_6VC_JB%J]$Z33TW'R,(WY :VYMC;?HV
M!SJ_SA7O:YGM_.0Q0A"Q"(A'^H.&/[J,L,(%PSG+*ZHXY1T[\4G=-N7 C'!D
M2?>-#^[]%3JLO<XBRKTV]G;@[OX+/%%#2UPS,R")#27F?C-?\E3JQJ;'L8S+
MRB6#4%S@'0X/]Y<P?O;?;^8I01?S?DP4._X/_]+U5))))32RFAW4,,'PM/S
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %*34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    .
ML(=I  0    !    P    .P 'M*@   G$  >TJ   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HR,2 Q,#HQ,CHS- !0<F5E=&AI
M(%-E:V%R      .@ 0 #     ?__  "@ @ $     0  !/J@ P $     0
M @T         !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !
M0@$H  ,    !  (   (!  0    !   !2@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0%,34T *@    @
M" $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    .    L(=I  0
M   !    P    .P   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-SHP.#HR,2 Q,#HQ,CHS- !0<F5E=&AI(%-E:V%R
M      .@ 0 #     ?__  "@ @ $     0  !/J@ P $     0   @T
M    !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,
M   !  (   (!  0    !   !2@("  0    !              /      0
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M 0$! 0$! 0$! 0$! ?_  !$( /H"7@,!$0 "$0$#$0'_Q  ?  $  0,% 0$
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M]0]X[AV?&'I#4:DQ.I,<)D1), 3PX[>?:H@]WV^P/HK4V-\8E,!34.C%,/8
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MGD[Q=W^(U$V'S^+,!M\?_P"R\WG]&D@R)$CB)&WG[OAIH5[E7H/JK7R<XPV
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MDI0EQ>0P]TJ+199J\M-<:.FZ@IKMG,U'-UT5"]ADU457)5$CE'L,0Y2F#N$
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M?9R#"0YW4'S-[T?-Z3JCE!QT8&WYHJ="<_, VP\WG;<X0-MOS3;-3PW*1!W
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MY*4E(&8NDB$DR1-UE,Q,JX3&Y)\IXUE2E8B-G&@L95FB^:B8BG0K@(D*H3G
M10O-,4P')SS<T0,'8.P[AN ]IG?H^RCTCX*O ,Z8-:X]A3BDN>"7B=2$.)3<
M)0XB"-+B4W*P%;F GN,\Y8W]SASXN;5PMN!)3()&QX\"#\]4N;&E&-L/BXQ
M0W$!*9T':)1+N "Y$ $ ,.P@ "'FV[=_&![#GV-[>OJ.B_ [8N1K4R[B"5%.
MH*+9)O#^#*D@E,;P-]A&Z5F_'U&3?N;&0-OMY/-6X,:47S5E@&X  ["Y#NV
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M@'I$._Y=6W02A0$28C5XOC#CN-J<Q_23_M"L5_#JA&*\H]<ADH%U.G2Q^*S
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MJBRLE12DY0AR?C\@ "UF8MU   .B[2>LW*9N: B1=JZ;H.$%"CN!TEDDU"&
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MMB"1LW(8ZBQBHI%,JL! 55,"92F45 A$R HH.YC@1-,H&$0*0H;%"M)U 'O
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MB =P#QVB/L=QM!J:G)(\&/$#R=66.)#AENB[B]\/5J6A,KX+RLT1229OGZ!
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MSLU69T@53=D<$4%NHU40.59-P!Q2,B(*@?F>^U!,<>^*#>1W?;[#C7?*NF8
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MIE9AD.MPJ$Z-JEF6-&SB<F4IX'UPM3.1B'"MTQ)V/+GSY\N?(<120J3PGR_
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MH32)1$R0&YJ;XH .ZJ&X; H!0%11N \X! QB;DWYL@CCW^0^;[>3S4JYH#N
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M$F#&GQX@\^4#<U3PUJH&$IACR&,F83D.#E<1(82&)S@_3AYH@0YR[EYH[',
M]@[!X*U["3V*-NE?59<2IQR!X3:8^4=4G4%CK$&_*'&TD)6MMQ"D'3PCAO\
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M*G.15*50A@"QCG^$CZ',LXG>X/C^3.E/#<3P]U5K>V-S@>"M/6MT@J*E+_\
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MXNQA2*U"UR"M$%;*Y::A4Y2[.AZJU@GJ=0%>1DX<\;)(F4&=((/<HR1RF(W
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MU]I>Q(]C_B?L<^CO%LEXOF/"\Q7F(YFN<>-QAME>VB0'[2WM"8NW7$]7HM6
M$- 0H%:CJ6K5Q><<Q-YCQ9%TTSU3;5LEIN?&T@R4DP-7:DR=^7 5ZGAHO[,=
MO.&YMA^7MU]2+3UB%-K*E-+@.,DRRZ 9TNMF4.)X@A0(()' FN6"E)*2DE*D
MK2M*DF%!29@@C?GPX5L\+H[@;8NX=WO V\_F[O/^YYM: Y2RN74/?<[@NMNX
M\*2/:RSTE_JG60M22R0K2AU>D'9*M*@ I(-92K^^5JF\NCJ5J/X=SCPV[6P
M$ <!6GA5$!W "AW]Q0 .WO[OF^34?<CE4(2VC+F!M(3<^%!+6%6+8UP4J00A
M@2RX@EMQDRVM!TJ3%4B\NQ,75S)()/7NC?R0L 3S@0:W>&$^_< '<1W H ;<
M=MQYP=NX[=^^LBTR[@=@^U=6>%8?;W3-QX4BZ:L[=%QU_5ELK+R6PX=22=0*
MH425$3O4+N[MQIQERZN%MNZ0M*GEJ!T^+Q)(B(D;D<9WK=X:+^R'YS?ZVMU6
M/3PT7]D/SF_UM*5R)3YT%$UD%U454CE4252.HFHFH7[51-0A@.0Y![2F*("
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M&^P34URZ4II2O!M-EAZ96;%;[$[!A7ZK!RMCG'PIJK RAX1BO)2;L44"*KK
MV9-EUA202464 G,23.H)2BI6%;-W*?XAOW/K].E;4SIWO>LNU:=:$'<^<H&
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M?&+96A/$+S%*UUU4',6WC(6WMF,#-SCIBQWKQ6T+4CB?,)\O&#OY/^W"J5\
M 1Q5Y8[HCT[^:I"8EO7$T[XD&5>O#7($IC>5QU!/W'7\;)4FO5&7+0:N_>.)
MQX:J240_GY>X&L+59C4\W6EQ"N7@0KVF,XZ%+9EKFT.GL\3'J!VV&_KJA7_E
M:23V1)[CON?*1\YVBK*+S_%91GMRA*[+Y_D'),KYZE:>FMA]E:X>V6F1RX9]
M0*79;&K2TVU=PP^QQ*,9IA<X^1B8YHZ?SL2%YC7E/;5!*A(@C8Z=0WVF#$_-
MPV\^\4))6J=P4GS:NZ9^VXG:!>3-N4,XQG$PG0<=RMZ6:Q>/\$VMA3*MCB'M
M-8GY*W94R; 7LF0K>^C%75)@?$2I'<Q3]6;K+8TM$%%E)/G^\%+(EQ1(_!\Q
MP)CN[S.T">?'@:Q'5H[^X<?WGY@.>\;162S/QY2,#?ETF&;(-)K*8VEX5*7P
MK+.+08TJAE)M=:)"NXSAM<,VK>-E8O'BB\H2@9(A&9'2C5/(_@:>"V1=6\R(
M"8X<Y\W<!5'+B?F\I[OW>@\9=X)OG$K,<1%DA<F1-\3QY(4-*<CVDE2"5VM4
M68%G3%6D XFPHK:-LEA6</K,DN]JN6+JU5.S=]?K%4(TCQ<50-"Y.X CR\9^
MW_2J#)6W$D=K48VV B3&Q)^"1PV(.1  #8.P.X/-JA/BC[<ZN5NU52FE*:4J
MQW$[]S9Q"_M'99_Q"G]*5#KA" /<P8)[ _WMJYYO_= UH"I6ISM'^<5S/?68
MV!H3L.'=4C=@] ?,&DGO/I-5P.X>@5J4I1'80[//L :HU2IQ+FLH0@+A.HJ)
M)*1 &Y)5 $<3 \\$  F!M$\-O/W ]Y\L;U2+^]T^,=K,'\VT;.FY^8N@<JHG
M1/L!A(H)&YP X )1,4#B8O.YH@!@, > 9H]E#T$9-QJZR[F7I#P["\8P][P?
M$\,6\5/6+Q0EP,O!-@_I<ZIQ"UH+JU(*BE>A0*$[ZURMC]XPU=VN&];;O J:
M<4A7:"5*03'#QDD Q!$$;&O.\JF/ND%$+5$]*0Y$S)<]3I"G.F95,AD^@YY3
MG23.J0H@!C)D.< YI3"&'_*Z]CR+9-V.E/!4V9:<>1<+PK$5,^#LW#=FZX;D
M8*65H9NG6K5YY*RVFY<0TI0<6E)O_<7F*0DX9B(6J"$IOK9 ,B>PVI06E)XI
M21(3L>%=@N2*0H8I L<?N8P$#;I@]]SN;S=S-P*'OO>CN(  [[ZHMO9?^QQO
MKIBP9Z7<MN7%TZVPTRW;7+#KCCR@E"$.NX8RVVM94 A;CK: 2"I0%0YDO,++
M:WG,*Q0--I+BU*NF'4!"1J)4V@E2TQQ2G=0X<:K;WHE X"!RF#<#;=P &_S"
M&X[[?-KZ&M+AJXMV+NVN5W]K=H#UO<F4EII:>L3UB?Q=:"-.K3(A0D5SBP4.
M=6I&F"092=E"9$Z0 ?(=Y\NP; /;L&W=OMV;]@[;_((#\@@/<(:RDKUB4*UC
MA*5:A/=()J(2.(3\U-@] ?,&FH[C5N.(GA/?4P.X>@4V#T!\P:F3WGTFD#N'
MH%-@] ?,&DGO/I-('</0*;%] ?O:E.I4Z=2H5I.D*4 J)TDB>U&^GQHWB*B$
MR4]F4@%0VD \"1Q /*>-:!S1'8.:([ .P  CL(B &_N=P$-^[<![>P=6^M3(
M <224A8 6"2A2^K2L"9*2X"V%#8K&D'5M4!39X*;/F*3]%:[!W<WT_V/H[_-
M^]JXG6LP@+6H:@4H"E*!0HH4"$@D:5@H5([*P4F%"*$M@22@#O)2!Z3M6FQ?
M0'S!YM4A<S"ITDI._!23"DGN4D[*2=TGB!4C08C29&H1&Z>\=X\O"M=@] ?,
M&ID]Y])J8'</0*A+QT 'B5@SL#[JS!X_,^G!#YA[M9%BHFX=!)(TIV),<*L/
M@!(@1N.'])-9@2?:%_N0_@UMA^\_2:QZW:FE-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI4!N4]^X=S?_ /(H?^4^DZCF/,?I%*K"H_UJ5C_F
M]"_]VMM:%?\ /O\ ],?[(K.1XH^'Z350ZBJJ:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2H;9T^ZVX OVR<F_XD1^LC#/&<_]?_U*QG^*?,?IK+CK<58I
MI2FE*:4II2FE*:4KS9AZ:.B9.0*( 9C'O'@"9/I2@+9NHMN*0*H"H <SM3!=
M$3_:@JGOSPI4K2DJ[O\ M2L;DARAB#?&\O9XW$M\L,C&TH[J-L9FM.KM(L^2
M$,"PO$$>FM&CK(DC9XH#4.4=2RSQVV<1#4T2^A4;!(RPL22"(*5+V6H2!Y.<
M1/(;R1]%0@ZTJ4B5)3 60( )B!OOQ(X2/+$FI$8[XHHC(%SCZ8I0KY64I5:R
MPD+:YM"M'J\W=:&FGY0J6P7AK/+RR<I47!)-HN^?Q+.O32D%-*UN:F&K(B[B
M2 1O&WG'P^COB@,D2#!F3 VCX?W']U1^K7'3:5;P[C+?A.T0U39/+"PD9*+<
M5.5>5IM$9^L>%6=PGU"7@J:U<<.8V+*\C()G*6E"2/+.6T0Z@F:3]6E)AI;J
MU0E"],D$S($1&J?/L/-SJ5&I03ND& ?3OYN[GQVJ]&">,_%W$#,WUA4&M@8H
M4-IX8/,3#>'-%SU9ZP\9EL$:>$G)EU')'<,5Q"'LS:!L8M56KWP.#=43DJWT
M3P.\ [*CD2.':Y;^0@53.\<^[O\ +]MZMW;.4,QS1*94[K;,=Y3@POS]4],@
M)2.IL?*V6H)5V'M?C]%O7MU0K2T$>!GHI8(GPZ%Q+)N3P2M:3EFZS5.D'Q$F
M 5\9V [P8F#'=MW>22>7P1MMQ/PQY*N-A7B*FLJ9/MU2"+B4:W$H6E]"2+=K
M)-I)XPA[3%PT6J]0?.?TI1VPD#.720-4E$W)2I<Q$"*$U4A,H4%;%*B )XI!
MV.WP<Q ^ &A:QUR4(@I+843PTK@2C?C!/&-_AVEBG$QQ9)>;".8I3+EHTCG,
MFFU;ED'4<P5>.&+%R]*GUI=FR<R,@NT;*K&1:K/7BJ!$SNES*35=>GI2FE*:
M4II2FE*:4JQW$[]S7Q"_M'99_P 0I_2E0[X0ON8,$_M;5S_L@:Y\^.Y_\1?T
MUFM^(GS5(W2JZW /8(;[;B7<=MQ  ,4>S;;S />.WR=NK;B5*3"%:%*+22KN
M0+AA:C\"4J5Y0-I,520=+X]VEL)',E*E$_ )G?X)X5%VUXXM[VUS\BPC6KIE
M(2"[ENL=ZU3,9-4><7GIK*E,40^U'WO;W[[=H_AE[('V%/3QG;IEZ0\VY;R_
MAU]@>/9DNK[#7W\9P^V?>M5MLH2ZXR[VVRM2%%*5J*M&DD)F![A@>;L!L\'P
M^UN+MY+[#)0XE#;I2%=8XK8A!'!0F#$]^X&-*[\GOQ$S-_ELBPMJAEGUPLLG
M8;?#*6BPT8Z3B'8V" Q0XKMRI3SQA9.:+5;/*Q#LH(-TITAD455$T!<=-] Y
M2Z&^DO"LEV&2\6Z$TJM<'RRQE_"K[[HLH9B96]=KPF]S,[BF6,>MT8*[98MB
MF"LWENI;N(.L..)<ZAMZ'&]3=XWA#UVN[;QAY*EN%11U=T@D)*@T.L;05#0A
M2A"=,B"9VJ?4/B+(R$1#Q\F@E)2#.-CF<C,+.(QJI*OFK-%N[E%6C=P=%J=Z
MX34>G;-^<DB944DC' I=_D7$/8,^R%Q'-R\4L\CX/@^&/XVB^M;=K'L-<3AE
MCX=UZ+;2"E3[C#2@A.A2 \&P%J"E$UT3.=, M[30J^>>>ZO92FWH*PDQJ(:$
M!2A*HF KR&NEQY<;]&X%<).\AV&+?W"Z2*;J.QW08M%X(V*;013YKV=DFS9P
ME7*A$**H*SLX]%(2@JV81A',J^:-]?T/='^4+S'A@>"/.LLN6K.&6CUU;E+=
MN^MBS0TZ@()2LJ4M);2-/%6J=.]>%.DW%T\].E"KA]SJXVT**BD@C;?5/(G@
M>58WN2:Y7V9XL9^3P?Q(M6<;E]U)24G0;O7H1RQJ-N82+M[(M:-(-6;99C6[
M% M"J,ZXX>.TTK9$LP2,<]C9KK3_ *3TD]&K.72Q?81=)\%=8*.I!2E76,P'
M7(.DJ3KA*B!*2J1*#V86C0D2(),Z=R8.\DC:.[GS,;S] /\ M_MM_P#?7CC&
M[8*MURH+/>08&_/G_P!JM\SW?]_^E-7J4TI5F\SRTK$P\.>+>NV!UY,2KK,U
M54#BF1L8Q2'52V,4HF !YG. JFP=^VOSE_PB>=\[Y*R%DYW)F.XS@=WB.9E.
MW5Y@:[AE:;:VM'$H+CS(E$.A$D'42-MJ]#Z.;##[J_Q%&)6[;Y=:3U*7=)!@
MC8 JG9/'@8CNK'UQ&YASY5:M$(X7"ZW"]R<PLY(RCW#%P@W@*S&/;#)(/U['
M/0,.T2M+YI#44BWA,9ED2U.)R#CY!Q"+))_ G0%TI](.:L9QF]Z3>GO.V7\M
M6&%.6[3EWG+,B'KF_OB;2Q;MT6-P]>*5A[JG<<TI95;.FQ%M=N(:NM_0\7PV
MP89;3A^!63[CAESJ@Q"$#QM6M:4[D!.QE(6%I$C?R^'?B*RUD\+=XT/;9%1\
M?.6%[7W[]C<*M(EA'V3,C1E9K\W&6%A%<^:8T6!J4VJZBBN&[AC8&*KDYS*(
M2$IN^GG.'2;T>6V7,1RWT\=(E^]BEI:)Q>QM\^W>)-)Q%C+V7KC$L:8<M,1O
M%M6>(8W=XRVFVNG=;5U9/(MTMVVEJWPL!M\/O#<-WF#V(TEQ*0I"4F-;B$!0
M4?QD!"P4B>V).KM*R(86F9:7:6 9.4>R96SIB#4[YPHY42Z=-T9<I5%3'.!3
M@F@82<\2@/VH=^OL[_!PY]S[GG+?20[GC-V/9H.&XO@;>%JQS%+K$%L"\L+A
M_$0R+I2EC2^EI#CDP5$I25)WKD^D>SL[-[#T6=M;L)#9"RP$B5 >*H)/XL[;
M;[D[U>W7Z65YE4)>.C^LK!O_ $K,(?\ ;9S618?^(>_HH^BK#_BCSC_:368
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M;J"-0(/.G"H^APJ8'"K!2PQZT\6 =KO_  4,[:1)UQSB4,%K+]9&<%[SCXI
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M@DV;O%5E3 0!-L1,Q@ .<&PE 0[7HUQ6R&=LO-,8I9JZ[$6AU+5]:.J4HI4
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MB"!$DF('D._'[32G3$^/YM2""2.8B?A[J4Z8GQ_-J?@^CUTK07"8"!=QW'M
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M"".() /S50M24I)6%=7P6I*2K2#L-@=1DG\4$U="B</?#N^J5<6=XCQ2JY-
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M<VK%MC%U@MQ=/6BF4/(;8O&$-K;<#;P+@*FTZ70UM?<=\2Q28E4JL\)FUO\
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MGM!@?YIL_0[_ &M/#4S\+2?^'NOY736?)\_KI[08'^:;/T._VM/#4S\+2?\
MA[K^5TUGR?/ZZ>T&!_FFS]#O]K3PU,_"TG_A[K^5TUGR?/ZZ>T&!_FFS]#O]
MK3PU,_"TG_A[K^5TUGR?/ZZ>T&!_FFS]#O\ :UD?Y*)V[><;&%A=.G#GF6]
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M)V98@[1NM<31= TDG[EN#A)-98B:P)@H0BJA2F #F <[#W777E:W%D(2D@2
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ML#86XKB(I+](! Z,3YEK:>#:MP=7,'?D9/<3S'TGA\P>R-]D'A73=;9=9PK
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M%*TDLO.;<061'DW>23/&8[]^55'[I#+'X(69_1_Z4I?UOJW]WN8/\VV:N_\
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ME-*4TI32E-*58[B=^YLXA/M>W!^6 ]\.Q>VAS_:8=AV .\1V[M-MI(2)$D\
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M1&J3UKSRT; F2#Q\G/?:L,/]#<WF]9_F.+)/.%SMN7PK4=B-2O\ E'L4K</
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MB[)4EIUXND=I2E:20)"E*,CB 8JXE"4K+@\8]^J?25*5&PD$G@G<<J=>\,$
M^B'$4I*+I=<CF4:Z>LXQNTD#I-IFURSE5!R54YF[EZ2U+M 7$%10ZJBX.FN)
MSI!8=R9ASC;B$#0I2 SK(WT J,R._6>_X>%4%M._E[MOQEJ/PGK% G?X1M7C
MU?A0B8)J=N_L+J<55:R;15Q(QSM^'-?R=->)J)>')J:>)F1;4MHS42!_U90S
MQ1PU29)((M"6<,R+AM@E(< N E&G?5ON@GQRH[Z!Q)\@   %N9W)D$;DD?\
ME]Y)X-I'C;<HVCGDN%QO(/9E0EJ6:1<VM*NG#!&M1XN4'+J9NDU&@UE3N.N-
MFD>YNCM-TS3("<DW9)( JR3=O@<RYDJV<#J>N[#I7*=/!*BX0D'R!PCE,"8!
M-0II)6LR=*TF=DDS+BA"N(W=5MW;2-P>I.<*C>;MIK$M:72<>6.\&-X,T,#E
M)NV6JS.KND$E#RB3%-DL5DC(]6;0[9P9V90K][(H%:D8XCF2+=>)KQ J5H4I
M=NXSI/;MBQ9MH"3JB I@GLH' 3J@ 2NW;4AH:O$@C\:)24$1,)&F. D_C2 #
M7H)<+L:ED2+O25AE&Z3*</-K0:!)!O'K&0M$S:XELD@QF6<>3JK^973>+245
M,%=H)I=3;Q+@[APM=8R3:6^,LXFV51;?AT(A0!>1>OW"  E02.R\>*53Q3I,
MS*F4+!/-2DDB2/%)6# 4!LHGQ@?)!WJV_*:D%/@<S@ %,'ZFH6V_> !E"DE[
M>P W[O0';YMPV[G= <<2E2E+)<*0#J*B!V0)X[1',U*I"(&X2D@#R1YJV1O%
M!E"H5"FEE>%Z_"B^85N$A54[-4#+2[URP:(LT(]F@_<NW:K@A3N13004%!LF
MJNX%)N@LN3R_%\^X[A3JTJR/B]VVNZ3:VCHNK.S%PM?BI:1<JZQXD\T(@';E
M5LNJ3Q8>.X'8ZI9,D#8!W5\T\X@$UZ=YXMLB8VIMKR'>N&"\UFFTFOREJM,_
M(W6BD80L!!L5Y&5D71BR!U!(U9MUU1(F4ZBHE!-(#G,4ILZUS3F^\NK6T:Z-
M,>-Q>75K:- 8GA2E(-VM+86J%R$I62%0#JB!!DU6EQ>PZI:0J0HDL[#O,.$D
M1R&\G;G6!<G'GQ9\H#Q",\:,Y_.'!9B.XTMKD# ^-L8,ZE4LV\16.U7+M%>\
M-<S9#2.Q: (-A<>*E"BWBJ4<9<QPE$8U>P.?9\?<=R-AEK>X;DEGI O4.M'&
M+NWQAMVRRZZ[(7:WEFPLLW)2X(4ZXM:5J$(@0FLE90PD+0%O$IGJD!N9'(ZU
M(B(/BJ"AOQD%-]'.'>/;#-C3-PJYTXRYJ_,(XEC>8CXM;OC'B'QE;XDKPZ)V
MDZ_;M:U9,=(S*YEF[*<A9 'ZJK0Z,<@(-'*[?SFWZ7V;_&!@>8>B9^RUI;>=
MN<!O!U]I9OOA@7P90ZI!#9*U--NITNK1H ,$#'-THJ#:;-_6H$]L-!*$@B2X
MI+BBD"1 ,%128DS4X.'_ )3&W9;I=M?V'A:N=5R/AFUFQOG2BC<:P+JDY,;@
MV35AV+5V="7FXNP'=HN*8^:M5QL*"P-V'7'+1;?!Z0,4Q?)>*6Y:RK?Y@P2[
MP]O%<(QRUQ*UM3<6[SW@Z;6XMG8'A32W-+K06L)6(B152W@TVKLN'\503H.\
M[)3K=;)*N(TH))@#C%2^)Q#YK,B1;W(F1B$.4#EYUPHZ8\TP 8NY%'X'(;80
M 2F I@-N40 0VUI&<YYI>9ZX=&^-H3IU0O%<*2J ),I*I&P)C?AZ+76+][O?
M_L?[7ES[N=>'!\4V4;2206@>%+(<HWBY)U$.W32VTPS,)%D(%>-F[T[L&K\S
M17=N[.Q6<)-G::S)8Y';=P@CB6G2#F.\ZQ5MT<8T\VVLMEY&*84MI3B3"D)6
M' DE!V7!,$B:@.J,PP]L8D]4 2..DEV% ':4DB11QQ49083D965^%/((3LRW
M=.X^)3M]+</5F;(/U6_51;.U.J1[<QDD3OW@HM.LKHM>F!RNW26+Z0,R)NV[
M+[W&-=>X@N!M.*X5KT:BDJ*0LD)D1K,"=MZ@O*!2DL/2J8CJCPXDPZ=(X"3
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MC.1'G\JI;]K5):CJF[V[2DQI4=*X[2>((@22!/=QJ!LA&\@:@F?<I40.&TQ
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M>O,O6;S6(73RBM^X0^BT<?2X\M14XEU4:E'3J@K5MSBN(+3J.)7B"=)@/+T
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MK4-^*/.K_:-6#Q/G/TUS:KJ*:4II2FE*:4II2FE*:4II2K'<3OW-?$+V /\
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M03:85:+M\.-S=2E27@^D )9T()"UCQ2)K/QI5P PBW0%J=64*4HP&FX7*U?
MF!(V)W$[5*7BYY5V X,^AX=\,T//>,,CU#,_#_:+U7LN51O6'4S4J&]>V3)D
MZRDFMGFFLDRRZ[CJQ7F_@==>MRU>8RD@UD%T'XMU=!T.=";.#*Q%EJY;5@EW
MA5L+?J75W#KN-)8N47V(7"BC2BXO77&5W*"N4^#MA"#'9BPPSJDO*!"4RDJD
M[*6H*U.)VXP " 3$)($E59N,(<=^/N.NJ5G(>&<39^3QE3\HTQT\N%_H+.J5
MRXNRR[B%;Q=*>)V"5>6IY4[*ZC;'-+1D>>&C$JZY:2<RR?BW9..<S]EJ^P)6
M#6UP[;O.V6,6=R];6[RW7PTT7$I"I;0$J"E(4VE1!*4$G2(FA]!9*25)6%*W
M""3QV'+\51"XG?01.\5E0%N#EIT1P**:Q#$4((B)3$/SBG#]\1 /3V#MW:R5
M,I=:6VH'0ZVM*D\% .$DCX-54\#L9CG]OGK"%QHDY0;AGFL0W7A0=3%TQG6J
M]>V&5*&UK36_0411ZA:"2U4D!@7[BOR[VR(T:97B"-JW-0\U/!64V_75E&XR
M.M=@^'.X=9ILWG$+2V]<*;+15_,+<6IE!*@DE:$%*5&(D&"1!J@:@F#N9,<-
MDZCI!V!,)(&PDQO/&LE>%[55LW+T;B,Q7<XBV8]O>-&\<]D8TRY23+^/DDWD
M*H,8ITZD'(5]:0M\;-QKQZ,DP>NPB9%N9Q' HA2<->3C3>)-+;#'@)M7FU%9
M=4H.:VU)A.GL@J!)7._#G4S*E*!V5Q'&2""DSMND%0/?,1M5W\J51Y=*1+0<
M4Y28SG21TG79%<YR(QMAA9%K+0T@J*:+@QTFC]FBJL@**A'*(*-C@!%3&*S#
MA[V*8/>V-LI"+EU#:K=;A(0AYEYMYM1(!.RFP=AOPYT()B#!!!23R4#(//@=
MX(@USV"X0E10APG'@D=S,@TAHEDT;KNW\K++%$1;Q\<U*N[< @W26?O#))G3
MCXQL[D'RB#-FY72JN\1M,,2PF[4$N72TA#:4J6MQZ$)(0E(49 3))( 2%'48
MFI)YD[3'E)X[#B>9[P 28 KHXTJ+ZEM+/%*N6ZL0[N$Y.UIJB*AU(R*G54Y1
MTQ<+*II&44&><S+U(@ <K1J\;L2+*D;%-JS@&&OX4S>VKBD+97B%U>6BDE4I
M9O%EXM+U =MMPKF)$* !,4($F.!X"!V1 D2 )!5J(XP#$[5"WE+?][7 7_2Z
MP=_UMFUOJ@\/A'TBLC1/M"_W)?X TJ:W:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*@-RGOW#V;_\ BU$_RHT?2H/ ^8_14S:'_613_P#F
MO7_^Z&>E356:4K3F@/:(;_[!YN[S!\P:B./"#RC[?12N,J0%W[=]Q 1W#T?)
MV?%V@.@GR1Y!'[S2N7;;N[-32FE*:4JQ/$[D.;Q'P[9VRM6BQI[%C7#V2+W!
M$F457$2:7J=0F)V.\)MT7+-9>/ZVP1ZZDD\:J*-Q.0CE Q@5+0M6A,U4A(4J
M%&!'$=_VBH,9MY1..Q1D,\'26.-LF0">)JIDT9D<N1\%'S2KD_$(O9J91U(J
MO6UO:\EO6^&D(JH5$'S )F>DTVCM]$%:NG#IJ,P(,I61QXI\&$&)]\23R"1W
MS5/! 5'XRQ\ X'X?75$6'E6I.'E7L6CB;'S<1EG)X]:SYN-71CH>/@^(^9=U
M&[HCCQ^>K9T<!PX2C>-Q:091!<UZJ9U;0CS7A1JGM(3MVN)W('#GS]7<:I*H
M,0>?';@"?3M])Y5X\_RHMS-/5AS7L*(*0"=^N)[35T;,O-918XSQ]4N(N2N+
M"W51.#C@QSEQ!7!BMTJ-*ZW;@N5;,>O>$(20?&E&%"E*3 T\DDS*2)2PKR[?
MA3OS"9C>*JGB.XQ(,@PMU!CR@-@QPDD3(KO3W*S/H->T%>88KT:BXI-2NF(4
MI;)L@>2R!&7NYX\@JI(6)M 8]G6>,H]_ 9-K4XLA=9&,F47+A!%M&O:^[&TM
M*BJ%!.V\QYX[N[[343V=4<ICO_=W<^?GBW<CRA=#XF<<Q-AN/#QB)XQ@[1AR
MSU&&R[F>)BO$B^JTVE9/-?+H];TZ80IF.8IW:DJE1LCQRL['W:V,%X*1C(1G
M+)",DP4ID .!P3/#0RXX1$\26X D3N>4&8\;GIU;<^RM2=Y\6=,\X!W\M5V;
ME2KQBUI=D+1B.HS\P_L^3BX>4:Y">UV,L$!1LW7G&PQE\>O*I)Q=.FFT; 1X
MQTNVEYFNV1R=>2D7M0:KI-DK;:@0A(X]4'#,CBXZV/@_!$DQQ,;Q4:AV)D%>
MOE[D@>;>1Z^%<Z_*B6^P)T6P0V)ZA6Z[E%G?F=$F;QEA6$K,.XI XL=O9[+$
MZA1'C.H1;HM[7KU;"&<V9.=MB]?@W2L8,Z@^CZEK2@&9D:=HV,M7+LR2( %O
M$[^-/+>40N"/=*'E[+C#6PC<DODQ/BIF9,5(#@,XY+1Q0."4ZWT.+B)V%PMB
M[(DK;:W,.%HB0F;9#Q_AUB[K<G'LWM:1?2Z[N5I ,)2WQ\K5$CN'TRPD6Y6;
MJN0>$Q)B1!V)&]4:CIF!,3MPXQ'(\/GGNKUN+WMXK^3L'TY.RS_B/$Z5761K
M2E-*4TI32E-*4TI32E-*4TI32E8].5(^XTN/[;?"9_G=X*UM,%_RFS_H^(_[
MNNJR+;^>1_2_X5UD%0_6RZU#?BCSJ_VC5@\3YS]-<VJZBFE*:4II2FE*:4II
M2FE*:4JQW$[]S7Q"_M'99_Q"G]*50? Q]R!PZ_M65G_LFI/$^<_34#@/,/HJ
M5NHJ::4II2K5YFQ/3LU8ZLN/+ZK-MZS.,%DWCZM66;IEAB5$RBJWEX6TUQ_&
MS4+)QJA0<MGC1XF4#%,FZ3<M%%VZM32UMN!:=*B#(2I(4D[[ C>0>%!7P"H\
M#?$T[SK&\3CTO%S[B][Q#LL=%XF%[A(CG=O@$EU)!-LHK21EC61O1QK8DD/'
M?P*2I)-$Q<)E*S!(ZGT$YF3 A@1P8)P=6)(PIO$T6(MFU6MMBUBR7DVK:5 H
M?<NW$PXA2@L$D'K.>U==;ZG0$RM$G8[*GB28CL^,(@D2/*?K,Y33%E5P[R1'
M$]CVDEF/%^MXA18,EK!89NVV!\(VFN=8D9JRV-_)S<U)OEA4<O'S]ZNHJHH8
M$NB0!))/R?)[UP_G/!WG"@+=Q-OLLMI;0E*RH*2AM(2@#22( 3'=WX;!*WVX
M DJ)CEL"8X;#R<*PP_T*R &F^- H .QXG"H]G:/O7>2"#VAW[; (^C</W?0>
MFD-NC D!*DLJ1B!/!/:)M&3"@=0D6X5YUD<A6;B:%(*"2)V@C>-@1MN"!\Y'
MGK))QE\FMB#E">)B]9=XBLTRL#B[#-5@N'6@T[&JJD?+U_(,@R)=9^V9$GIZ
MOOHYNH1[DNOFBX>+;+Q"L;'Q4E8;$W)U^';<!EW.MUE3#_ L+2V?";QBZN57
M&M>M-NE3;;"(*5H"TK/6.:Y)T0.R*P$/+0-, F#O)![03.P@;A*8&\1MQ(J?
MW C56G#?PN8<P-=LUXUR*M2"VZC8VO<+9(M%+(-%J$S*+5\S9BN_6_W>J-6%
MK!6R,BGLPVB7<$Z7%\9L<#$Y_&+MK%,3O,0#75"\>5<EE2RXEIU>[B4.$)U
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MXG2JJR-:4II2FE*:4II2FE*:4II2FE*:4K'IRI'W&EQ_;;X3/\[O!6MI@O\
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M*7>*NM36GP<(&K6!/BR8)V.]=%E1249API;G5=4+MKK"\4A 23OJU I(B>,
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M&PS,($BWZ)9Q"OUV;)XK$N^L1_7V+)^FW3>M6[A$'' V6@M0;*@LMZCH*P"
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MQ+)^ ML8IA6-*-CBV,XE8"]M3CKERO",(N[=EG"7+V[Q^XN,34'GA>-VUDS
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M$DDDB 1---,D$4B9"$*!2D( %*  !0   -*B//Z8^B*Y?L;\9^%QQL_GN/\
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%*:4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g431217g78m75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g78m75.jpg
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M  ,! 0$           D*!P@+! 4& @,!_\0 7!    8" 0$$! D'!0H+!@<
M @,$!08' 0@ "1$2$Q0*%187(3@Y=WBTM;:W&#$V-U%U=B(C-7&6&1HF05)8
M88&7IR0E)S(S-%99D=3F1U3"T]76<IBAL<'7\/_$ !X! 0 !! ,! 0
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M.1A/+R<+/@E'%&R5=&*E*45:XXZB$5-*"YUJZ4U7:^0S?R),< < < < < <
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M.G4<HA8$LOV7FV7!M6B;TC38%;L!MR-PU]>D/%AQ8YR8C009EJTJ1/ 9#&I
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M+C:A<3A6ZJ#KL:/N*Y&WITUTX/7*TZ,C)D!:@EX.5' (+R,6)<+(0=\8>\+
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M/G7!O*. >_BGZ4QO]_L_VBFY=D=GD^%E^FC&Y9[3Y5\6V[V6:=,'F[9^4$<
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MA-&#9#@>8^0>YECE26M%*_%ZG3RTIYR^3TT<=G3BZ?\ C]FDNJF/@^''P43
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M#@#@&*IT6J'-JD$37R:6$ER)\$JE!V<8-KX&8XM"!V3_ ,V/&!.9F<-HLC$
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MYL^9#*EJ*)Q4A3CC56[DKR83F>.YQP#^*@K!Y!Q&1FE8.),*R808(D\O!@!
M[Y)P.P11H.WO%F!SW@#Q@6/AQC@%07IJ:BIJMVVU*FKYHMJG7]BH'&2@DNP\
M8ZD\KOZ[W-]64399<B?UM0*IF?&9)))>:)<*8Y:FUP0,1;@]O[2V(T+64H;1
M=BB332C;6J'1HL=SNIQ<Y-1LCIWL%;'4JT4W(AYE.$UAI^Q7RR.[!)9W-FR>
M3;W\5PI@BY4VM[75#_'F?V1-4!<4J=5(UOM&65E.<?'Q&X,)$5$E#'#?6+1I
MLN==ON-6'?HPNKA.9!"RYE#@ZS2KJLLW5+=P&J7SWCEO2: +D#[0Z>-@C^8X
M.,N]AB1N">;8FB9>WP@Y8R@BYCNF3.B@--W:FH=#DV\=+O/N)_1@ 8 99@ F
M%F!$ 8!AP( P"QD(@#"+&0B"(.<X$'.,XSC.<9QV<$#ES>DDQR/Q3JV7LS1A
MB9XXS$0NCC4[2PMB-G;"!J*AB!J@9*!O(3)2A'GB,..$65C)IHQF#SDP0L\'
M+D]9RLZ('3/QV=.'I^X_9I)JGC_<1 ^#C1==%WSYR"3J+JTB#TD/I?JUSK"6
M1(3JO:PCG2QBBCH4C#F+[7 P8_E'.306-*(8@E$X&Y)<86#39P,6<8+&)P]B
MCXX>=$Y!SXU)5^<*W5$QY;E[:!TQ:[@TK0PL;B^MH&M/M)CWH8R].DQ&867K
M.()7>9U![9CPCA!PF.%OIYO=K/."]-:<YORK=$3(%"Y1Q$Y&6LO:ES?#U[D[
MTL%KC>S8,67G+U=TM$N1AUU<0!.RUY7L^ E*Q&)2)&'3GPNP73="!U_5R=5T
MK;R3D%S(Q0WFTFF=42QT;E,@@ZXV8:B+B8MML)+.I$8_;%N2%8G?(&\@;SBD
MM9">$^5Y92U&Z2P7)79%RZMT6%V!8/TW^*'JM]&^COPQB_!;>+XWSE"[TN;Y
M2>F_H35K^..QO!R9'6/OGS(JT<%X< < [&JOU-[O=-_6UENU>FXD%49:&]L2
MNBHNPW3W?JPDP1S$VG$EHVYT (U0<L=,'M@1) IC2<J%28PN4/Z5U>I==UZO
M,:]5]+_*;A\B2(Y=B.IK3>M5J/51S"G-MY<_,2)E7*GZK-;YW/(0K+?&M*[I
M@-$M;BBFMW,3)U9:9RRW#4$H',I6UGG!7H5B<CZ[).9F4<L6&7;[/E#(,B5-
MBF0PRK;EBRV6TPN5,BEQ?&2(VXY=7"W!II.*!PQI:$4+?'F6B&7$X'!-B:I?
M# W#>JW.JKR:[L37"-]=O4N9(#G2(4YNS*FQ,XKVA0XQO5F:/B%.ZM9XDKFV
M'*VM4J3E.#<I").N1&&!4I#PY*4%%F8R'&7G<&67K/$H+1;\W)$;@AF*"=EN
MS2HG!&M*"-0QJ%N"-7PQ)4B5Z;1;5MEO""<UM4NM^S'43"PV4(IQ$(I-&U"]
MMC=+XVQRAO;9,S+XY)&]$_M:5V2H9!'G4E.Z,+VD(5ED.K,Y)R%[6O+4(5A)
M2@@P ?@+1)BLUHGV>.*5''9YTV3%')F03I,<4J.*"**5.EMP3943A;ES(&X(
MX&HH6TTSEIZ23555)WJCO5;T[T]JU'TG+)4< < < < PW8OJOV_I7SL]<HLL
M]J)#EKC*-,XG))Z?[+KL'-;B>D-+2(R6PG.7 HYS <0:9VI" !5*"C026$5U
M;E?LOQZ<I&*E8+Z7NBVW8%0_KI?'S>/FKKCZJY\UDX5.ZR9] L7HQGO;^3R^
M;G8OKCG3ZVQD.?.N#>4< ]_%/TIC?[_9_M%-R[([/)\++]-&-RSVGRKXMMWL
MLTZ8/-VS\H)5!ZE%V;,H^H-9M7UKLK<E4Q)J@\!>D+'#YU+6QA2GJ(?&35WE
MF1ID#0B3F+E;@:L4GEXP(U1D8S C&:(>-?\ /;*F6X,[[=8;%EK*5@L\%FLD
MR"59K7:)<J%NRR(H]&5+G2X4XXHG%$U2L3;=6SV3^"OF%P3S?@SYI9WYU\%&
M8V>66K;G#G)D^T90RYF]D6UY1FRY>6\K0V?XW*%LR9;;1-@L\BRP2)4J)T@E
MZ,,+AA@4+U&-G>Z1Q9A)V]6PYI1H!E&EF3R?# 868'(1@&$4\S@0!ASD(@YQ
MG&<9SC..S//G7;<YFFGG5EAIW-.UVMIIXIK^5G<\&0N :7%#'!\';@P@C@B4
M<$4.;N;BBABA:<,4+6;E4TTFFKTU4^;AJK:>NHRU0R [BW7"XBQEGDLT8B\H
MF+$PM12E6H7J"FYJ;9LF1(RSUJI2K- 026$Q2H..%C)A@Q9LV:9EZQR)=FLF
M<>4[-9Y2:E2)$^TRI,M11..)02X+5#!#6.**)T2K$VW>V93+JX(,Z,K6S+V<
MG 9F#E[+>4(Y<RWY6RODG(>4,HVR.5)EV>5':K9:L@3;1/BEV>3*DP13)D3A
ME2X(%2&&%+S%=][F0265D<NW-V$DJ)\L2+LBQM4V1.TR8U*I<B!J * FRY>6
MI(/* -.:G,)P PLT6!YR'M"*;ROG)99]B<6<N6)T,VV2)<4$5MM4,+A<:;42
M=HC42:5&FJ--U+5GX.^ K.3(V=LNS\!'!GDFT9/S6RQE"1:Y.:V;LV;!.DV6
M9#+BE.#(EFCE3)<<<,V";#,TH8H%1)T:N)SWU-[^* \Y9;M&GCR=L^IJW2)'
M0YJLP/LVU>L3G96D. UHQ0M/@#N@"[$GB5'J1A;LE'%'9'M,L'=LOV?Q/SZO
M%7[;MI2=ZWOREM_?NVG_ ,%J_P"=99Q]M[3WLCU$L\^.'C\Z&<'@<C?8F3R)
MWF#.GQP#+FO_ .OBD_G<K?[Y,W+]E^4V?P\KUD)F<W.Z'(7CG)?MT@Z<G.X3
MU/' &> 57]0]$K,UQW7T]5VOKMTE-37A Y2Y_BR[7Y3L>X[ V5@JD[,C+S6L
M.?K':D]?2-[*:W=;)9\F22MVD:"/,"F0X2+6U06I6"[%%5-**-[:I4QUT?DK
MK+4'!:' ,(V)L34=66;1].3.4EM]D[$R61Q:J8L0C6+US\NB4+D,^D*Q5E(2
M:2SL[;'XTX9&ZNAB5*<XFHFQ,,Y6J"6$5HVF]2QY70Y^_I+U8P [?[8:QS4^
MQ69RGA=%%DJ$E,LJB@< Q!X2TXPNMT5A%/"4[U::8$108&=C$GRF8N_D@X3F
M6.1);T:=32KUW^2GOY-MYSIH_!TX^G_C'YL:2ZJ=G;CL_P#83 _\7P]G]7;G
MLY18+BUG'BZZ+C>/&00]1MQ"T>D@=,!Q')H3#@I=5[6'F36.APY0EI[T8VN+
M\>0(<R.)84)3._Y8D.9&U]U8<F'XQG=\ ZI<A[%'QP\Z)QE2\+,N/\27ML.]
MD7!H).Q:\O22D-39E;ZV%DH=I"P[49S9[K:V3L)M9SRDJGW=*5K8 Q,9DKU6
ML%O[MF--EVK7RWGG"7A9SDIADL;HCB*NT6CYRBU98DE3?5ALH=Z2"37^S:8&
MSYV;/N^T?.A+UUF)13H&""?V0L9+CE86WV4'3GW8+7TI"'U_">]TK[X2=Z7*
MQ0U52,;/9E4_2ODAI\UPEFHCP&NMM#2K_LG-N;%/Y?\ AI [-)C[N3'ZQ4NK
M.*4(\2DB2V^+DKKX>5\=T2NNPZ;E80TW^*'JM]&^COPQB_!;>+XWSE"[TN;Y
M2>F_H35K^..QO!R9'6/OGS(JT<%X< < [)R4$@'7&IWJ.MV&?D%K:O,?5[V0
ME/.KYFQ CPJ)RR94FE"3/+88(I*G5$8..P4M.3%DY,5 -*DJ=5>U==37>KGS
M\AC7JNK?Y".3J*=<FG^G1?;=04[I&RK#>G&NX]8H'Z)/,7;VLM#(G>2-!#<,
MAX/+5Y5IS8V><:9@/@B+4DX!G(@CYV1FEP:90SNR7'E2S92L=DEP6N;9/BI\
MN='&XI4N3,<=9:T=%J<DECU+VG%GVR&1'H."*)Z*=4TL:FAO]]>ZU_YJ]X_V
MG@7_ )OGU']!F6/[<R;_ -"U?<6?]I0?JHOWE]QH]H#Z0E1^GU,2VL)30%JR
MYPD5Z7-;!#FP/T12(D[99TQ525O:CBW%0 \2YL3J IEAH,93F'!R(@609QSZ
M3.G@HREE_*,BVR<JV&SP2LF9.L+@FRI\43CL5FAD1QIP*FC&X=*%8I8WEF1;
M894#A<$458XHJII=<\,#>'^^O=:_\U>\?[3P+_S?/F_Z#,L?VYDW_H6K[B]_
MM*#]5%^\ON+4C(Z%O;,T/1)0R"G=L0.A1)F0B,)+7I2E8"C,A_DY&6$W !9#
M_)R+&<X^#G2$R!RYDR6W5RXXH&U@W#$X6UQT,BG5)[4GY3V?(%1P!P!P#%\W
M ]"F=4B;8*SR=O+D#V)ZDC@4G,7P1-F.K0IW1F-., :F4.1XL-J@T@!N3$X\
MIA ",\HTNJP=]+KEM=5_$HZU5%6^][%3$I]]=+X^;Q\U=<?57/FLO"IW63/H
M%B]&,][/R>7S<[%]<<Z?6V,ASYUP;RC@'OXI^E,;_?[/]HIN79'9Y/A9?IHQ
MN6>T^5?%MN]EFG3!YNV?E!*A/46^5-M[YK:_^YT*YKIGIW=Y1^A6/V2S'MC\
M&/YGV8_UQSE^V\X#"O,4?;C@&';2_I^F/G>B'UT/,?;>RY.\86?TC[O,WM=G
M[]1LN^H+K\Q+D K@ID;?6[#(V M+9'M#8B\A(8^UL,;$VX:26 \TT"I."9*L
M&-+J%(2=XZ9*5@_)197:/;%8.^F%VW^&\_.V\5=MOV%(3K>_*6W]^[:?_!:O
M^=99Q]M[3WLCU$L\^.'C\Z&<'@<C?8F3R)WF#.GQP#+FO_Z^*3^=RM_ODS<O
MV7Y39_#RO60F9S<[H<A>.<E^W2#IR<[A/4\< TUW:DFZ<7KZ!+M%8'5MC6NH
MM1"BE,<N1V7,,#S6@X%82AV7.+TU*TCLW*TLJ30S#88W#-.4+C24*@D3>J6#
M *JGZ5:;L31RJ'WK&V!L'KN5MOK'II$Z,B]E/<ID\QIRP9E+)]%5I=/VFP,#
MBUMLC<Q(B4JYYD"./.JTDA2K*;7M22 H)*A0H)$GH4='%755)+%;&]1\=M\\
MRN.]<KI#,#5/;$3P^QXGNTZ2ZO\ ,]EAE<.3I"-<9"GC3KBOA.V8>G=FX+NY
M#PZD,P'(\U5DQ0J-R41@H5A743'K6AZ1$I)-P+^*76)M:4^R(-QQ/TDMGT]9
MD 5JT)@=8&:N5\'_ "<QMX3,$>Q+RB/4.;NPE)BTBVPS<3_RX9:2G="A+15R
M_P#:TF]][K[B;K9/13:J=;S:V[5U_>\6>8#4MRR"S':LI1 69 ^Q>/EZ^R2K
MT$.B<P*5*%TK;90[/3RG,:W<Z+M\,.G\JFS4:L?LG@<A!1)0M4Q5//6KXO.5
M*NK?UI.I1*:]O'IN;K:N:[4=(9@UUNHG*.%+9!(98P($\AA=O150U2!HN6P8
M.:)V+96;S0.UR&2WKE28TM$XAP).+T$N&JBAB;2>RA>+Z:(_$Z<?3_'GX,CT
MFU4'G&/\7>HF!Y__ )X+$5T42_Q/G((NHN]&1WTD/I?O14K8(,8@U7M8T,KE
M#.HD# S9'%]KB?,.3.E>XVH7$FX,RE 66]M^0'GE&Y-&$O))@G#V*/CAYT3B
MFR)QCZX./:53 O81>WI<^W$I?IP&C<3I];2<M]UEAV,,#=:R[ J<IJ>5@3K@
MT^-P2>*0 M,-O4BW=TU\5UQYP']P8#VTWVD403V)<(]%<JIQ)7R<)*5Q-G>E
M "K"YDF-A%.+IL>Y,.QY=46+X3N75>'Y.6=A0 Y:AGH=.?=@NFZ$#K]C6*.E
M;=[<>AEQ@( .E(D)C7V*ZOKC08W28:AR/%27NK6W9/B+ZMZ4&'J9Y%[DPS/1
MD5B.'F,8DZ)1*G!\M 7)79(>7ENBO5V'3BL):;_%#U6^C?1WX8Q?@MO%\;YR
MA=Z7-\I/3?T)JU_''8W@Y,CK'WSYD5:."\. . =C!P]E?=]IG[2SB00Y3B25
M.*,HV,A8>1,9#[OU@$D5?,I ""F:%Y8SAJ%*O.$H<E!3F8QYG!I4E7JJ*O4W
M[E57F-=*PWTOZ=/O*57I0?RC\8^C!6/WUM3FU7 MW(3O'5M]FL)AK?\ */V(
M?>5S.=N'"' ' .Q' ?T$A7\)1S['1\\_K5\IM'AYOK(CZ:#K(>]AYD?6\L$A
MP!P!P#"]C^SOO!I'UO+7I@=L2B19CC&W%*C&^6+/99<%6A>3"0B)3IT2465)
M!BK/=&:/*<&.\?DTJ2K2*BK<JO6KUA[]Q&*E8*MJ]T6UTUE1/KI?'S>/FKKC
MZJY\UDX5.ZR9] L7HQGO;^3R^;G8OKCG3ZVQD.?.N#>4< ]_%/TIC?[_ &?[
M13<NR.SR?"R_31C<L]I\J^+;=[+-.F#S=L_*"5">HM\J;;WS6U_]SH5S73/3
MN[RC]"L?LEF/;'X,?S/LQ_KCG+]MYP&%>8H^W' ,.VE_3],?.]$/KH>8^V]E
MR=XPL_I'W>9O:[/WZC9=]070; ]E/?YKWZUG$@9)3A%;GLI"F\A88PS@O,9:
M?7ID@/)!E&G%&46"G%JPM$#*A4:/";.3"A!%MBJT=UUW)L]Y^=MXKEY>F)2B
MZWOREM_?NVG_ ,%J_P"=99Q]M[3WLCU$L\^.'C\Z&<'@<C?8F3R)WF#.GQP#
M+FO_ .OBD_G<K?[Y,W+]E^4V?P\KUD)F<W.Z'(7CG)?MT@Z<G.X3U/' /X*C
MA)TRA0 @U4,@@XX"4CN9/4B*+$,)!/B" 7XIV0X++[XP [XL=X00]N< 54&3
MK07^X0.N(5+]B=(4EBV'L]K#4*FX:BBUN&,560*8D3A?L&7;+#>C;!HH@M"J
MT,,85TJ.0NC6PL#3/QJ76+1/#8U+'$7-%5N3IHMWZ]C5+]&_\2:LC5"N-G[,
MU&WZF$ML1!<U6UD2_P!38B3Q'V^#0]-<U>(D-B(D,;=(H[FO2"7M+JK1*S)8
MXOSFA3G%Y9E[6<E1F)Q"K2:U/%<6&^X^K6=/+61=;HK>415RRJ,V$9MME$#
MYE K=5M#'H*JKEHO8^/X0^>S-TD85?\ 5RWDN**)(F23=7&CYLG#(>!I/;JT
M>2M:<5?NP-X."AR_?2:,=G5^OO/^5!Z(SG_8]$ _LQ_BQ_I_K_Q8'+D]9RLZ
M$_3/^#IP]/['[-)-4_P)@?!Q8NNBXWOU[2"KJ(.WJ+TDGI=NWM$GB7DM6;7,
M]HE;*?(D[7WXMM>5XQK*F.3GK\&>)Y?!19P,@$=@[.<A+SC(N0]BF<</.B=$
M3@;'UQ'>/60?$#6IDP\N2UYF6*5]N7MO* BD802X\-OF7'YCPH^K !<&J,+
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M$4@.M[\I;?W[MI_\%J_YUEG'VWM/>R/42SSXX>/SH9P>!R-]B9/(G>8,Z?'
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M\[Q2>,HNO)T6TBR0L:18V0?>PMS3*75 0H;Q2.@W1%'0+BC3P&)!/JTLU(S
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M"\)#S1'8/!KW03O%EI]?9#IE2,R9 D-6 CI\=*8#71Q#,BG<90750WAC:P:
M$<"/&3!K K Y&JPF[#L)@Y$9_P #PKYYOW5CK6NJG'K-G76L-*8NM=E-13WZ
MZ7Q\WCYJZX^JN?-9.%3NLF?0+%Z,9[V_D\OFYV+ZXYT^ML9#GSK@WE' /?Q3
M]*8W^_V?[13<NR.SR?"R_31C<L]I\J^+;=[+-.F#S=L_*"5">HM\J;;WS6U_
M]SH5S73/3N[RC]"L?LEF/;'X,?S/LQ_KCG+]MYP&%>8H^W' ,.VE_3],?.]$
M/KH>8^V]ER=XPL_I'W>9O:[/WZC9=]07;I4=/@6C5!3"IBI<$.33[,_3.HR
MRE2:6SM^8KF* 'CQS"R'/)XGWR^<! B$5E1V]I/-L52CVW4\M]3\[;K5;+Z]
M.F!1UZWOREM_?NVG_P %J_YUEG'VWM/>R/42SSXX>/SH9P>!R-]B9/(G>8,Z
M?' ,N:__ *^*3^=RM_ODS<OV7Y39_#RO60F9S<[H<A>.<E^W2#IR<[A/4\<
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MI_L16DBFJ225XE2E3R>S"LI5%6,F.+)B58*TI6E@[FD5N+7"W!,D6*D  >9
M:<,@0JM%K6XDZ;DG]_F*@75LZYLWV I2]=*[VZ8 M6;KGK97'K273RQC7"RX
M2C9I?";):%!\9>J#A;\H(D+"P$-:/OR-L !J>0K2A*DQ>$2D7X):342CJEL5
M//4NO=-(6!]./0 >,=F!Z3:JBQC]F!45 \XQ_J[>S@L1==%WSYR"CJ(),KO2
M2>EXD"SRY_R=JS:X<,\$D^89+5W9%MKQ>&RR?$JA.6A0' ?%-/\ :EG\1*6>
MF\P9XWECQ.'L4?'#SHG(]=!?%R,(),=-\S9:4:276<V.AP[I]CWMNP:KUPQG
M;!/[IFVH/#S^4(A$E(]ZQ"9P2A1N>%OJI<+?3^-WDV'G)G@+X>QD@DATWS-5
M+1(B4=:S(Z(KKG+BSM303+$UW/SM,'%74_5OB^'?$ &6;FTO%<RL-K_B1";K
M/#S<?$]VO4R#OK_2<#CTJKD,#8</?,3XFEYH2K1'FK66^"FJ;ZC-HKCU@91W
M_9>*AH2+"> QF:UX.-G#?K"E3/-</A'G3);< N2EU:NPKR717.['IQ6#M-_B
MAZK?1OH[\,8OP6WB^-\Y0N]+F^4GIOZ$U:_CCL;P<F1UC[Y\R*M'!>' ' .Q
M4ZBAH:_TN]K(E(I.J'*:E!$U3"><01&9/[OEHT4@?L%#!A2S(R@'^93&=H!9
MR$\7> G&2=*&O54=.IOWJJN1C8OT>^12P]*#^4?C'T8*Q^^MJ<VJX%NY"=XZ
MMOLUA,-;_E'[$/O*YG.W#A#@#@'8C@/Z"0K^$HY]CH^>?UJ^4VCP\WUD1]-!
MUD/>P\R*1_7$^6-CWT6H5]>G_-M. KN7_P":Y0]393J[A2[13_#V+UK--.=Z
MFN0X!JCN+^JIN_C1I^RG[G!RAV!>$AYHCL'@U[H)WBRT^OLATHI^*+XG5!X>
MXV]O+P.1/V(N[-AQI;='%V(@L&L5O90!A H3*D@,E)RQX_FSB\J,"[I(R3O.
M"_JZ.FW?U2N3Z5-G(J5@JF[[J:KL65'^NE\?-X^:NN/JKGS6/A4[K)GT"Q>C
M&>]WY/+YN=B^N.=/K;&0Y\ZX-Y1P#W\4_2F-_O\ 9_M%-R[([/)\++]-&-RS
MVGRKXMMWLLTZ8/-VS\H)4)ZBWRIMO?-;7_W.A7-=,].[O*/T*Q^R68]L?@Q_
M,^S'^N.<OVWG 85YBC[<< P[:7]/TQ\[T0^NAYC[;V7)WC"S^D?=YF]KL_?J
M-EWU!<[L,4-QL%KJ%XB<B=I>)%<.8;*FY0<7'XD6&,-'M$"1)P&!*4"?4 B4
M+0(X _ 5@'D&,"-P(.V2ZV+DYS\[3ZZ';?S%*CK>_*6W]^[:?_!:O^=8YQ]M
M[3WLCU$L\^>'C\Z&<'@<C?8F3R)WF#.GQP#+FO\ ^OBD_G<K?[Y,W+]E^4V?
MP\KUD)F<W.Z'(7CG)?MT@Z<G.X3U/' ' ' -!KGT51W)N;K1NFLMZ41V8ZHM
MMC-%7PALC<95PY6AMN)'0V?^V!B\DV0.ZIS:5)P6P]L=V$MF&6C&4G4&DJCE
MHDHFDUJBI7'5AKYZGP"_I5Z^N%LJYT8N?P0)RW.9>H0Z4\ IN]FU^V;%!E<(
M3S4UWR1EV]DUQRDJ?N\)'@P+A8Z),[">RHT-9$%0:3I^SH_LUK3\=EQ)QP1.
M7[Z31CLZOU]Y_P J#T1G_<[#P_\ P\'+D]9RLZ$_3/\ @Z</3]Q^S235/\"(
M'P<:+KHN^?.04=1)")R])'Z7B$+ ]2@2C5BU@888])3(>].79%MKQ^$@DA3S
M'C&HP'=\<9P7E!DPDHQ/X@\'9),$X>Q3..'G1.;E>L?EQ 1.KA.\3A:E.,!&
M7YSAGOQQ#'MN[JRM_P#EA38I]-3&"N]8:$1*/%M%)%)&$[D%;E&H%OI_%I7U
MU'FDKEC\<T$B<U\\Q-UC))#4<9?'*&GW:*)NU-!#95>*<VV3BIH=4@?%#/J]
M'@OWJA+7@R@> O"A++!3IQ$'G7_D"M;TJKI/.G*%U#8&*5FAKAA$N$@V .:9
MMJ0TAN:L6A184H!2T$B@G11$7JL3&HDV1221%3(*C!@5;[,Q=E=?#R\ESQN\
M_16"]-_BAZK?1OH[\,8OP6WB^-\Y0N]+F^4GIOZ$U:_CCL;P<F1UC[Y\R*M'
M!>' ' .RDA,E8*WU2Q&; C,'3&*:P+DZ&1*$2=1.X[F!GC60N.!5HU8E<@<#
M0$*TJ1()&JRG0JE1:P'E,DGU6NZMUV[>S'.MUZ2K?OW(I$>E!_*/QCZ,%8_?
M6U.;5\"W<A.\=6WV:PF%M_RC]B'WE<SG;APAP!P#L1P']!(5_"4<^QT?//ZU
M?*;1X>;ZR(^F@ZR'O8>9%(_KB?+&Q[Z+4*^O3_FVG 5W+_\ -<H>ILIU=PI=
MHI_A[%ZUFFG.]37(< U1W%_54W?QHT_93]S@Y0[ O"0\T1V#P:]T$[Q9:?7V
M0Z8,I'(PR>HPL\S8(XU&.[H&1QYU.2EN<V1AC*L:1LCY1Z8XY4L;E0<.:HE*
M<D&6C*,5C-,"FP0;YOW=755V/9?T1L[%6L-&E?>GKNP14 ZZ7Q\WCYJZX^JN
M?-9.%3NLF?0+%Z,9[V_D\OFYV+ZXYT^ML9#GSK@WE' /?Q3]*8W^_P!G^T4W
M+LCL\GPLOTT8W+/:?*OBVW>RS3I@\W;/R@E0GJ+?*FV]\UM?_<Z%<UTST[N\
MH_0K'[)9CVQ^#'\S[,?ZXYR_;><!A7F*/MQP##MI?T_3'SO1#ZZ'F/MO9<G>
M,+/Z1]WF;VNS]^HV7?4%V.7F2L-N4Z6U6!&8_%C4MB^UD"<U"(N2V"86R-V6
M$Z,)SD9RQ27$5HC7-[$B5HL)DBHG*G"HLX("]L5@[ME'LXS\[;Q5^V[;]]"D
M!UO?E+;^_=M/_@M7_.LLX^V]I[V1ZB6>?'#Q^=#.#P.1OL3)Y$[S!G3XX!ES
M7_\ 7Q2?SN5O]\F;E^R_*;/X>5ZR$S.;G=#D+QSDOVZ0=.3G<)ZGC@#@#@&.
M7VWZIC%@0FIY%9$'9;1LKUOFOZY<I0S))S,RH^R.LC?5,;BIRP+X[HF=C8W9
MS<UR-":C0I4)PE)Y>>X$0K1TK1T6+U(]8;>],$V2"GCK/A)=GF*R&T$('(&\
M+]EZ4QU1,$L=RDR=_)E"J'(UDR2Q<0\2%3$$BJ4D-AC G.<0"E'B:/3?J;P"
M$[6*=<54*6JF5FV3U[U(DU@@?PEJ6VZ]E*5L"ZX&D0Q3U*84Y15(V16+1AZ>
MLR9(X$R*<"P2R"1198>Z"6C=R.+D3I[F5>_24---AG"U=F-NDFD-/.5"-<4H
MU,NW+46_,D]LM!P2Z^@HDJ6J"]E4<15%@DRU/ <&&Z[+Q98UQSWD\2XD$J2B
M]*B5RTVG5]33'EI[RW+TT\9QTY- ,9QV9QI-JKC.,?#V9Q14#QG';VY_-^;\
M^?Z\\(L1=<^-\Y!)U%6KUYZ2+TOFKV;'+O.:L6L7[.%R Z+#=>[%MKS?!#($
MYI!S9DON>8\8LT&1X)R1G.<&YQD7(>Q3..'G1.>>@5OZX??3JIWB=KVQ0>$)
M[U"\7=[$/C:82N#G!Y(:=]S."/&&B#Y0-MX19*&%4!6+&1:Z=.G&>;A"K?CD
M11B=5.<3=RCDH4)<'/$+]])D,=J9R796%.#B?="&HL(C._7O:E!:>&\WQ4ZH
M*Y9@P5Z<]W+RD'_I "M7_<K+U7&R(]3BP%%(S!2ZF,#DG!?2AJF.I3"7;V&Q
M5D15)^R^!J(7[J^XC')#' Z783#/0+CA"Y*Z^'EYHO+QE@C3?XH>JWT;Z._#
M&+\%MXOC?.4+O2YOE)Z;^A-6OXX[&\')D=8^^?,BK1P7AP!P#L9+@1X5>Z:^
MO:]?9T?B15/EB7,JEQ3DP5ZQ7ZP2:9O(4 1 5M+: )I2A(X9+0"RH"H-,\1,
M42=*'"*^G4W[U57>6F\QKQANK?Y.FS<4J/2@_E'XQ]&"L?OK:G-JN!;N0G>.
MK;[-83#6_P"4?L0^\KF<[<.$. . =B. _H)"OX2CGV.CYY_6KY3:/#S?61'T
MT'60][#S(I']<3Y8V/?1:A7UZ?\ -M. KN7_ .:Y0]393J[A2[13_#V+UK--
M.=ZFN0X!JCN+^JIN_C1I^RG[G!RAV!>$AYHCL'@U[H)WBRT^OLATJ)T%ES-J
M*RY0IWDCAB0/?J20MYZXI#"E/LDLRH<7<E-C*940X$!\D04OR HLW&510\FD
M!).\X+^KHZ*^N^_#IQ&SD5*P75=;MUV/%^!49ZZ7Q\WCYJZX^JN?-8^%3NLF
M?0+%Z,9[W?D\OFYV+ZXYT^ML9#GSK@WE' /?Q3]*8W^_V?[13<NR.SR?"R_3
M1C<L]I\J^+;=[+-.F#S=L_*"5">HM\J;;WS6U_\ <Z%<UTST[N\H_0K'[)9C
MVQ^#'\S[,?ZXYR_;><!A7F*/MQP##MI?T_3'SO1#ZZ'F/MO9<G>,+/Z1]WF;
MVNS]^HV7?4%T.?!CV;ZU^$X5Z^R%_"BMOV>GZ%2XE,E>!S&FG#L4_)DP<MRH
M4M2Y UM8G,81)E*<8D(1FFF9!MDNMBOV777W^75J/SM/KH;MM_(4H.M[\I;?
MW[MI_P#!:O\ G6.<?;>T][(]1+//GAX_.AG!X'(WV)D\B=Y@SI\< RYK_P#K
MXI/YW*W^^3-R_9?E-G\/*]9"9G-SNAR%XYR7[=(.G)SN$]3QP!P!P"O_ +G,
M[&W]>[HQ.J%K:4+P^P??<Q]<4B)&F<GD2#7%Q1-ACLK)* J<!(TH!)$(UAAV
M4Z<&4Z?("PY!@7(>QS/V/29#E*$-YY8K.:^Q[#L2;Z61&%L>!GS'KK#<;69[
MC#UZ0.?Y\$)#7@0KD)HL89RZ_"8,WNLN#<<$KKMGQ-[QH[UZ7G+-]C=->JI[
ML*\;"AD+TUN[W<U/[*N45*3)!M:[8&@J8L*D*KF8G,6<JT;*U1N;MCT[1Q.D
M$8YRR"1=U [I$)TC9W\6])TIN:Y&Z].-D(MW]%SK3;(U;*J5O#JX1&Q:MFQ;
M25*H8]UNN*;'HMC?6N3M(%1C:QH5P<(GYE:W(K)"HK.3T96!]\K(RQBXID":
M:EI;Z_@?5P+I*==*L8-"ZU@?6*C<9@U>Q..P:&1M!6IYB&/Q2)LZ-@CK(C&J
MCIZH:1J:&]&@3C4GG*!$IP9.-,,R(>13XR#]4O+^!A&RN@'U8;ANB#;#V9U1
MH#+KIK6-N$0@M@.5<O('B.1IU*D)#@THBD;8F;AIU14KD(!B4H3SL8=%&0&A
MR$G)8K\9#1KXM4>*TMG(9@=>D#UPWP<F,=NL%&%HYBHC"N3"-K53C+PHABE.
MKBYJGPV '8)G4I$QJ;!/A!$(H.#L&AR+&133@_5+][\".C0"FNLEU)6?:-R8
M.IZ9!R:IV,25Q.2);#4KN.:3.KRXZX1R7(Q-4>+PB2MID=8,H4@^X/ VLG*@
M!H1&8,$XG!"H?]VGI*N.%;Z:]INA<_0DZO>P\#L"L;HZJT(L"!6I((Y*;!C3
MQ7#J4AE$@B*:-HXVZ+QMS2B5 4-*6(1LE/A*H3E""TIO&+-SD[)@BID"=5+H
MU_BX]V\S)%^E/UX(5&8[#8MUDX^S1B),31&8XSI:T-$F:F%A;T[4T-J<1\<-
M.$0A;TJ=*5DXTPW)90<F&#'VBR*:<'ZM?O?@:<[+>C2=1C<2>-=G;,=1FL;=
MGC+$T$&:I+(Z]DI"Y%$FMW?7Y R% 9DS8ERE3.\E?5Q8AIQGY-<C\".$7@H!
M8DIRAN4%%WWX&O/]YZ[(?YXM(_V#GG_F."OQ_P#@_P WX$<W35Z!MN=2BK;4
MM&$7]7-:(*KNZ2TDX-4JC$F=U;JZ1J.Q21'OB,YH- 22WJ296G3%)SL94 -2
M'#'GN#!V"4<W1:6C6L*>-,:[B1G^\]=D/\\6D?[!SS_S'!'X_P#P?YOP)5D'
M2XZ^3.W-+.T=9MB2-;.F1MR%(77)Y1:-N0)/*)""L8C!HE ""2R20$J!X#D.
M/%$9DPL.!"&G!^J7[WX&GNP7HVW4FVJG2>S-A.I#6EHSM+'V^*IY(_UY(R5Q
M4>:E;BN;VL(&I(W)?+I5;LXGEYRGR;D:LSOF"#@& _1Y)SNSCR'978\DY6M%
MBLL4V.>Y,J&2X7-CA@ACCK,E1Q5BAEP)WTZE78EF.79ID6E'9X8HJ4KIQ*Y<
M5#!O]Z0[9?Y[=,_V!FW_ ,SF3_I&SV_O#;/W++_H$/Y/8_\ AH?WX_O(YNF)
MT.;^ZG%!2R_(+LI :P:(G<$FJ!0P2V+R%Y<E;E&8M!Y2>\$JFC($P$*I/-TJ
M4I./'C@.0J!CSW#"^Q_2-GM_>&V?N69\\@E'9;'"Z?R:%W)]=$L=R9(S_>D.
MV7^>W3/]@9M_\SC^D;/;^\-L_<LO^@1_D]C_ .&A_?C^\D^1=,'KZMR-(WHN
MM R)T:%,0C2$ K/.0$)DQ0"2"0Y%&1"R$LH  ![PLB[ X[<YS\//BHHG%%%%
M$ZQ1-Q1-ZVW5OE9R5'+5RE*BW_@:FVWZ.QU0+WM BZ;=ZF-=3FT4T=21,B9.
MU=OY;F7'4(UIB1J"6@0(T7ER!N*T0!92Y.[5 ^\9G& ]WZ7(^>.<V0+/_),C
MY7M-@L_QD<[XJ3#)</QDQ0PQQUF2HXJQ*"%.^EV!CLHY,R7E:3%9\HV"7:I,
M3@BBES(YBA;ENL#ZAPOJ7>J/C/BU_HUO450(5BX?45K$P"-*H5" &O9)@0PI
MR1G" '.4W9@0L SC&<_!C.?AYE_Z4,_O[S6_]VS?^.8+^8V9W]WK)_U+3_JD
M??3)Z5^\O4SUS<-BX-NI%ZQ96^RY-6HXY+(DY/+H8NC+1&'<]S"K:48$H4BH
MN3$$E$YQXH!I31#SV#!V/Z3\_O[S6_\ =LW^@3CS$S.ABI_-^R.[^O:%S3C>
MR4>BZ[YS1N TRCJ!50\MQ:HI<6D4U]*PEA5DEG$E'XR044/O +4' Q_*[O89
MGMQG/9G$8^$W/N8M&/.2W1*M:."RN_;\G.58,U\V\F3G:+!D>SV:?%+BE.9+
MF3G$Y<44,44/53(E1Q00O"MV)(#GID]?X.2 E]:-E\,O/9G_ ).#"^X#!0@A
M[ !BX@G_  ]T/<-$$(<9R;@61EA"+X0^ATY?ZO\ S/[C5BW_ $>KJG7Y,3;
MN#J=U].ID<W(6DU^=J\?BE8VYL"8! DR!O;T2?PTP33, S@C \][/>$+X.S
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M=.#]4OWG]QIY;7HX_4SO:>O-GVWU*:WG$^D);84]29UKN0EKG MF:D3&UA.
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MU_O^^F9O]F7_ *8YE#L33@_5+][\!_<S>O\ ?]],S?[,O_3' TX/U2_>_ M
M\%H< PY)==M?II/&NU)C1=.2RSV3R^66QY+6,)?9XT92%8(2Y:Y>Z,BJ0H/+
M$XP2G\HXE>"5C!9?=!CLX%=6H^A,J2JC9\5:IM:0 RSR2@$DV,9#X\.=%%%M
MBEE+ 7+!-V7X 2V98L:"^ZOQW&I6J;@=B-0<2,#(7 ' ' ' ' -+-,]"J'T2
M;[A;*+Q,\)KQM-UN&<>V,B*D)F9>\D%IUGJ@938V8;VOPRP^$B$%2( NW.5
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MRL^30>,)6).H&I7'+7DN,M9@5I<89ER]2-O0G^(K-5.BA<N4BUS:EL-AN .
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MB-MSD\QB36)+G]IGD@BU9PET@#3,).P59%CYM8[LSGV9-8!%U)<1BQ G5:W
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MDTK?F:,1QE2C7/$@D+HA961I1%=GBK'-U<CTR! E+[<=]0J/**!VX[P\=N.
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M KD6]U,MUFNV-D)%KJ"+VU(])[AL2,;5=.&7PQO8[3=M;V68+PUQLWK-8+*
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M;9GR8"BK6V)!$-+83EOCS:/SAC8@$88N<7E_<'R0/ BW5X4W;#83@H. . .
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MT3(I='1,S(CUZIS>RXRW/<@?W!G:E[LMPD.=EJC(LJ51XQ"V?9< < < < <
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M22GW0OVN<W8$Q1(620/#,Y'(6H]WPO0$O3&R/SJA$7#2J;O3I3WUP) ('6L
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M#4C3M[6U-;>G+2(&UM0)"R4B% A2$E)D:-,44G3)RBR22P%@"' MGL. . .
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M"<X!S('(2]>N&:$18M-UXL::KZ5YC9<LL!0 %%  666 )9998<  6 &,!
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*@#@#@#@#@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g431217g81r65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g81r65.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M(5\S-ZLOXPYO8-=R^O)-#8ZG!]]/,9/;4;6@, PJ"4A7R,[8VD82?0&X)QT
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M\?&&\ !+^$ D=A/7T5-1ON$]73QT+(N^=5.E9W'=8X@]L@):X.&.#A)+R0&
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M!T LD@@H("BBBPZT$!980@ '6M!UK6O3-G:UK&AK6AK6@!K6@!H Y  8  Z
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M29.!G=<+F\$CG!X;VB_,>4IQ^I3=PA&"A^OH%8OOJ3+2=;_Y4B5D1C$'Z?\
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M'/N=TDTRD+%!AB9YZ[N*YJ>PL93<H0.KCM"5W'!._AD8VY?'W*0=)<Q<Z/\
MY(O(5#%](55J,PVIO&O(H>S(8'&&U'#WUF6=+R%L=XL2@;$X8ZX)WB-,*[2I
MITD--,:$.CA&%IRP!*"3PC<\W<_4 5'#QQ<IRRRJFXXL^&1VHZ<CU#=A=J3]
M^MB&.CCJ\+5AB;HWJZ"#H=U86ZO8^S-M:O[H_M"R1?>MDRU)MMKZ,@;HH2Y'
MHUL8@?,_G\N2DD;YR26M] SAOY;CE\%T<9*HF$3"*FGO?A9_LVRYST[)O)SV
M7Q11$1J*.&2:/TC?[_7E>L3O$UTJ.E\]>VQ:)7'V9O71A1$2#1-)*'WN#,[N
MCD$]0Y?%PK-/(<+7$GJ#G?D-B%D? 7&XZ"NRUIDW^07I#M]+'F-SHZ<,W25L
M*[0>J8L8H^N[("RQS>RP)(\H?X@^,KK+D!I9"T]-N$*@B5IS/1$1QR .%K>H
MP.?,=2?WE6YX55A5@P"/V=%U\-E1LB#'G8(B7=-&9=*(2N<D1A!Q![:H?H:[
ML,A*;E0#MA6I$;JE+7%ATF6?'2#/3FD6G97Q]SE+(?5,%%6+)%8_11JXRERJ
MZ&LKA95A;M$7R O:.#KX2H8U;"VOL+DK[''IL2&A;W-"XC,5)C%R9"K2E.3N
M<\^>=\^O/J6XJWKF#5! 8=5M91AJA=?5_'6J)PV*,A&T[4PQYD2%(6QM1EB$
M8:(!"<D&AGJ#3E2HW9BE6>>I.-.&4'?<\RN>7PF_\1;S^_\ 6;$?^ZNC\@<O
M:?S*RO\ L1>IWR6>>>>0O["DY:VQOCPS;5*;ITJVTN:UN^9^"557P?C_ "9Y
M/QOA?%-^%\3W?#^(9[/3WB]?I#Z/E-3U$FK/*((9^!ECX.^B9+P\3KMQ</&U
MW#G SC&<#/(+Q'M@GFA;I[N9I8N)UUXN[D?'Q8%NQGA(SC)QGED^*I+YEG5S
M+.BZ+20F8'+)BIMJOT\623J0RDZ%J'\Z4-A;23+"6I6-S-CIBX1 7DMO )8-
M!L\*8.SM@UGNNJK?9&:9O[ZZB:RB99[BZK?04U(*YM,VDE,SJ-TS!$VI$8<8
M#(> 2<)=YN5Y18:RZOO=H;253G53KE1MIVU<]0:5TYJ(Q$*D1N,A@+\"4,!<
M6<0;NNKK^Z=TE:?^-T;V5/"VM1OWGUUS6T(*7C1 !?\ UFQ3,=!>)U(FL_7J
M X*Y2WGC)WLO0P>HA;^0_P"+],6GS=,Z)MYE;LVY:HFDOE42.4K:+^1;Z:5O
M,&-LK0=\'DOHK^'+[<=[YJBL$9YT-AC9:H!SS&ZJ_FU<\;AL0\QG&1GJJP.B
MH%7<EO,_QM>-. 19@Z#<FU"^=C=H.J158KYQU4T@UZJ M4WE:QX=0](6>B$H
M(@T=:G9M<&%*>*2>UF"67)(KTEWUUJR]L[FNO=9Y+C@%%2.;;Z%L?2/R2A;3
MP/:T;-[QCW8YN)R5W%MTGIVU$3TUKIN_SQ"HJ&NJZI[_ +S_ "BJ,TK<G)=P
M.:"<C'13RA'A4\=T!B4<A['3+D%%'F5K:1K]V#.D3D_K$"!.C62:0B9WYL0K
MY/(5! W:0NA:%-]X.JI2H"006,L@OG6/M)U?IRVPVFSW&&EH8'RR,B-NM\SN
M.>1TLCGRS4TDLCBYQ +WNX6!K&X8UH'"NVBM.WRNDN-RHY9ZN5L;'O%961MX
M8F"-C6QQSMC8T-:-F- ))<<N<29.\_\ "G,O,$O=)W2\$71>3/,;51-P7JIC
M,)"6<Q+'-I>%"32.0OCFC*&-P8VT[2DH@"D&B!%!-T4<< ?'U%K_ %3JNBBM
M]\N$=72P53*R.-E%14Q;4,BF@:_CIJ>)Y CJ)6\)<6GBR1EK2,META8=/U,E
M7:J1]//+ ZF>]U54S@PNDCE<WAFED:,OBC/$!Q;8!P2#+W-,6S)A%@VZPK7?
MUW7D&WO?UWO<38/K_P#Y^<_ZUN?_ $C7_P"F5'_^BX?U?;_\AH_]&A_]"R1H
M8F2/I1HF!G:F1$8<)2-(T-Z1M2C4# 66-0-.B))*$<,LDHL1NP;,$ HL.Q;"
M .M<::HGJ7A]1--.\-#0^:1\KPT$D-#GN<0T%Q(&< DGJ5R(H88&ED,4<+"2
MXMB8V-I<0 7%K !D@ $XS@ =%]7,*R+271RVX$-)6+N@HYJ47 MCREI@B ;P
MQL1*%Z=Q ;0R$YQD3@VM8 QE.J/?RTQRC8EZAN)0 +%\SO8>JO;KDVU5OU1!
MW]R?"Z.D:9(H@R67#._+YGQLQ '&8-+LO+ P#SMMX[-H-&SZYTW_ ,(-R-KT
M;!<8JN_SMHZZO?/148=4FW,IK=3U-43=)(H[>Z5D>*>.I?4%P[H \?%&\%=U
M268.UB4]!2E<HI.Y'*,N$A_M"KY&)JM6N7)N<G0I*I=I0F ^A:W,Y)\9T;Q+
MVA:?\PG+6*1%*0 ^<+3I'5<]3)66VE#I[5<WT[YO+:-ICN%$]CY UTDX[WNW
MEN9&\<;SD<3B' ?LCKOM_P"P:V6:DTYK*_/AM6N-%TUTI[;_  YJ*9M7I/4M
M+4TU*^6*CM4AH354K)N"DJ!!601]W(Z&(/B+NTJ#.4G>89%76;1S40F+A'VE
M7*HL%P0.Q<?D)R$D;RTD.C6K7-[BE1.&U!"5:E5'%J4X"CM[",8@!^G*1\\M
M-3R54'DU2^&-U13A[)!#,6 RQMDC<]CVL?D->UQXF@'8G _$N^TMKHKU=J2R
M7+ZYLU/<:R&TW4T]12.N-N9.]M%624M5#3U%-+/3B.26"6%CHI7/8,AH<<JS
MD+JDPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M<6?4-872P)
M(M;$&CE@1U [D/R-FD[<4YH$SRE1KF].Y$D':V$"LE$YN"4L[7ZP25AX-?0S
M>=G:KS=;'4OJ[17U-NJ7PNIWSTLABD= ]\<CHBYNY8Y\4;B/Q,:>BX-PMEON
ML+:>XTD%; R1LS8JA@>QLK6O8V0 \G!DCV@^#B.JT:5P1QB0:4>3S54A9Q)@
M#2C 11%H19A8M# ,._3Z""+6A:W_ *;UK._=VA:W<"UVJ+P6N!:X&K?@@C!!
M]!&RZ@:.TLTAPL5M!!!!%.W8C<'V%2YS35LJ]98C1N*-4WN"5,N0+DQZ-<A6
M$%*D:Q&J*$0I2JDQX1DJ$R@D8R3R#@#*-*&(LP(@"WK9%H6,\D\J0M1&%<.Y
MEY\B:J$NA;Y#%,9IBN&%1$7LH:@PIXC!S7&TIC Z%C5JAEN#4)(K -2H$$[6
MSC-B)D^//FL];*>J-EFDLL=FJRN6FPYZA2M<ZGK9"(R@FDT;$(#2T+=+)0E;
M"GR1H499YX$J1X7+$Z<!QH22P!,'K9,G&,[>'1>W7E6UE4,?W$ZGKJ"5A%MN
M#@[;C5>1&/PJ/[=794:N=7/;-&F]L;MN#FM..6."SY;YE8J--4*3##3!#V0D
MGF<^M9WA$PB8106\G%<RNWO'SV%5T%2MBV93ZA)_%HPC>9''(@U*WMX9SDC>
MF72>7.K'&&-.<H, 6)Q?'AN;D_NT)0K*!^MA2TX<TGD"#[BM><#(T4>LSO,"
MF55^Z*+BZ^=KOKU%$['@<V<'FK=<Z<PUGN6JFZ'R)\6L*4,XALA8A(Y"0U.8
M349"K:+2!R;%2PI.X;Z!@^OB<?R*LLPJJO[R6]8V#Q5S,.^X+ E,U:V&SJP:
M+9>$L?<Y@95%(OLH3)+2M\,.9W%G7RA1"8WH\QO:_O=M;B75<@=7U3]P-KH2
M<5F@$X)QX>D]!GIGQ5=5<^6:VK8D/+U708^H7L_L"_.Y6NBK]:FMP=8[(^7N
M2*J<YW&;#?ZU*ER=UBUD3Z7Z109WC;ZZLIZ!K8I#)Q1"-J'QD:&@K%F X[^:
M&Y'I)Y>[<;>CU_<A?VA_B&/<N\FWCT^^R"IICTQ5KS-RHC%H)-9VTH76#3R2
M53/24+FRMC@(EK(GT.D!;(2YF_>(VCY(U3LPS8S1$[MQ<X-&>$^('JYX46?L
M\=Q03H'K[S;W763@K=J^M7IBK[ ACDN;5K.L7QF4O71;FS*U+6XE$+F\\](8
M 9J-624H3BW[#0!'K>L@?,_$Y5I!AL8/, Y^"O![-X2KCMDJNBK!ETVBNJV,
MEAC3N&FL1>UVY>&-A7:<?OMF=];TFU&4GRGRVD_I\=3\;XOJ5\/?=$:_N>A3
M<W6VCH*LW048F\M%0>[\C-28^[[B>'[7E3^/BXOLMQC?.FZITA0ZK%"*VIJZ
M?R$U)C\E,(X_*>XX^/O8I?L]PWAX>'F[.=L17JGPPT'4EG5]:3):%ON3S74R
MC<U:F]U40P38M<(R[)'A(E< I(FE5;1GGI %*=)E)!^RA#T4<6/T'K;;OVX:
MBO%JN-IGM5EB@N=#54,TD+*X2QQU4+X'OCXZQ[.-K7DMXFN;Q 9:1LM=MW9;
M9K;7T5PBN%SDEH:J"KC9(ZE[M[Z>1LK6OX:9KN$N: [A<#C."#NLG\@/:5F1
MB91#A+B)(U3'O.^F<]<WKEQ85\,Y8J(1H4$AZ/N#8"59")$S .&3 (XN(.-E
M<G^4+ W/  HX])?%EZ@UHQQ.V:/>X^ ^9Z*3O$/%M9<-TLFJV"*W26RI_=UT
MYN:XI88);8=X6W(1?-2ZRIT[GG*UBQS>%XC-($1RU64R-0$K80H4B)/6*BAS
MBX[^P= .@"F'A0F$3")A$PB81,(L+LB;-M:UY/+%>-ATTP.&R:9.7N%[-;0Q
MEE6O2H/N_P!-C)1# 'TUO>Q"UK6M[WK6<6NJF4-%5ULG_)TE-/4OZ>9!$Z5W
MO#2N[TU8ZG4VH[!INCSY7?[U:[+38'$1/=*V"BB..H:^<$], Y("BOXZ84XP
MWCVGU+][C)38C6Z7#*UAH/8H7O5LO3A._F%0=_4*@IK>VU"((O080HP!'KWZ
M%G0:+I7TNF[:9=ZBLC?<JAQ&'/EN,KZO+O[PCE8S??#1G?*]7^D??*>]=LFL
MHJ##;5INJI=&6F%IS'3T.D:*GL'=0GK&ZJH:J<$9!,SBT\)"FYFTKPU,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")O>M:WO>_36OKO>_IK6M
M?MWO>$4&%/DNX42_'T9TC!1"3?%T8$@F0J!"V3[O>$GX#(9H_>]AWHOX.QZ-
MWZ?#V+W:]=4=KC2;<YO=)YN<X$SN7/&(CGT8SGHO=XOHQ]O,O=\/9I?@).#A
M+W6Z, /Q@O[RN;W8&<NX^'AWXL8*K>XM\O$0E=M=$I>CYFG@<$DTH%-Z77/P
M%AJ2-L*<**,Z@!VVY.NV2H,94+$_EZ*)*1J'O\LG PS2ES* 9I.F.T:FJ+C>
MFWNJ%)23U'E=K?,'%L$+>"#R,]VU^'&)D,PP UTOE3R<O /TKVV_0\O%HTCV
M<3=FMDDO]_MEJ%CUO!;W0LFN=PD,US_B%@J98..-M;/7VYW$]\T5#]2TS6F*
ME>YMOE.]<<W] 2!QBM-VW&)[(FEG,D#BT,_WD!8F925J)N.<A%KT"/0TQ2YQ
M0)C1E"'LLU61H>M:,#O?H]MU%9+Q,^GMEQ@JYHXC,^.+C#FQ![&%_GL;YH>]
MC3C."X>*^.]9=D':5V>VZFNVL](733]MK*UMNIJRM\F,,M<^">I93!U/43$2
MO@IJB5H<&\3(9"">$J0BH*H:52!"<G3K1)S@HU"I,8L2D*A%BTG.4HR52$U4
MG*-V 9R8I<C,/+"(H"I.(6C@=TO-U1&1Y1[ZB?.7*G4UC0RI7&L;*O:UX'T<
M7%(_,V1;4=/U]=\AHTRWX^N<[ DNG)/&7%"R36=MRYH. EB*A_.1GI],.UJP
MK<(.0.?"",]3@$C]/Z[3+N7L.P8SW7RSR76[!"U$0MLFS=6G8\D2/3XJ8'Z)
MU8[6I'85#D#+(&!#I^%'F9*[2XY]5*?NMCGD!<&YM6A<5'M(!D$YW'3V@?,?
M%;'X0O\ L;I:F9)9%E)H2@=VN]^B*E0H8,R/K,V_=E&79.J>3NJL+_*Y6J/7
MR/4*_* XLE0E3MNW+[K %;\I]X*2@C!]C3[P#\U-+"A,(F$59/E;IF5=(\GN
M-85Q13)U1)D=RT\].5%O=G K")2E%%9,TS![9K"E)2]O^[V3\F?1RTVJ5R,U
M4L51Y8G K,VB2+2LTX.<XY[XRH>^*CF"><W7/8TBG7C,HSQ[,4DK5)'DTKJS
MH4^Y@60^GSB-EM48? F256WQP]":JV)B <U"7R!8ZGI&Y<#Y)2C5/9C]^A6>
M01L]SM_O=/:K^,+&HC=C<RN74$-JAE9YL7#W2H.BJ:Z(0('9J/?H78*JH)"8
M^DUW83*F<6M0LBK^,W2DM42H/-C\G:XW*0-CR)CTT+BD'&?2"/>JY:Z\+,:I
M^80Z[:SGL<C=TPCJ;K_I"-LB.&J4%*1ED['J0%-R^G(U$V]Y)<&R.0EB9X4_
MQY^)/*$Y2"-NA.HY'F23)VZ+E)>2,>+0/<<@^GPW_16"\F\,TERGS#1_,;;'
M6"PV6E(:*-(I3-(HPKG9[=75X<I5,)!M.K3N 6@,FF+Z^R#;0E5*"&_;CI(%
M2J^!\R:0N))/+/@J<O!ZW-[3Y"?/FV-2%&V-J#L6&)$+>WI2$2)&E(D_1P"$
MR1(F 60G3D@UH!1))8"RPZT$ =:^F0/F?S*N_P"Q'ZC\E?M?O0M*<MU?(+GZ
M"LB-U7648TGT[2J3J32DVE*PSX2%L;4*,E6[/KVXFZV4V,+&@<7ER-T(M"A4
M#"(.I6, DX R539-O/YRI;\*U _',[N/5W9%DR5/6M(TD=7]DP9/N3NR)>KW
M8T\7S:,Q5*AJ:"M+>NE$P=$;B$X")"% M4,"=4L?6<K]VX?:\T#<G8^['4]%
M/#Q^\+)./X;+Y;8DO-NGKN_W@B>]3=#NY7J[V#-QE"^6CD=T:208P59 B#AL
M-?1-&G;V]O:R=K MB ]:-$E*A.?4-@/1^IYGT^C 5A&%"81,(F$3")A$PB81
M0!\E;NX&\S'54Q*!II/T99E7\_1XPO\ 6'\>P)8B^^M>S7^^6.)M4A+-WO>@
M +&(PS?M#O6]/UQ(\V)UOA=PSWJNH+/"1XUE0SO?8:>.8'H <G887T']&6CI
MV=I[-65\;9;7V;Z8U3VAW%KMF]WIVT3^1'BZ.%VJ[<YG5SFAK1D@B=C,TM[
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MK9<*ZGA,-'1R59IXVMD<*Q]-4-,9IAQ4Z59X5.J:CL>$V;&+FHW;[!Y(UR-
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M[Q<+JG2@3WI<<UN UC4(W9.6< Z,*YH?'RUY:@T#PF;R7,25L-4#0$E!.3[
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M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814'>5SBZ7.@I5V
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M>>29L8C1$[MW$YH&>'U#GRYGJH?_ &>ZVX!?'8_F_N2JWT4FKFS^GJSGD(D
MVMX9!/,5DSYT8XLCF)ID#>UO;;M8C, =M$ZMR%P3>OPU24@W6P:@?,_$Y4R
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M8"@ **  LLL 2RRRPZ  L -:"   !UH(0!#K00A#K6@ZUK6M:UK"+FS\)O\
MQ%O/[_UFQ'_NKH_('+VG\RLK_L1>IWR72?DK$F$3")A$PB81,(H$=87C-G*2
MM'(G.!Y"CH*T6<Y5))4(O:MFH&JE&](WNRY-LO>@A>SR#A(H.R#,*/7.QZ98
M/>M;:DKQJ&H;K5/GCTY9'--YKXRZ>H(XH[/;W'AEKI\;=Z6DMI8B07R%KO\
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M:"D=.FD;MEO:&%N0O\7^[T4MV6A>TKFCTFT\ TFT!0>$TKM=@/RX[C;<\_\
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MK.RGY"9G&[$B$6G<0<BG>,3.-,$OCKB4$9?ST?E#2D?&-?L@X(#R KFQ<F5
M+/++-" W6A@"+6]:*JRC")A%5[)?)E 8+UG950VJ1"Z!YOIUJ30R6=,=$6"Q
MTXU3KI*1(H-,(_4]*L,R-;#9^S1^LI,.3SN8)3P(&XUXC>T^RVDU(Y2$K<.P
M(W)Y ;[;[G'IY#UJS9O<$#L@0NK4N1N;6YHTS@VN3>I)6H'! M) I1KD*Q,,
MQ.K1JTYA9Z920882>28 TH8P#"+957N81,(J7*&\P%6/MOSB$=82NH.2S)O9
MP()RA3-AS+0.A)!'X^ZNT-?9C>[(A&Y1>IC)S-V\1%<1Y_=F=>>W)511OWD#
M;8]/17+3CS07;9) .!UP/8=U='A43"+'9<]K8U%)-(FU@=)6XL3 \/#?%V31
M0GF2+FUO4+$C"U:/&6GTXO"@DMO1"4&%IP*%!8CS"R=#&$BKM\>7D30=?IYY
M3MPP,_G;N"@%>F3HKFB0*PF.#(>$9)2.P:]6F&FZF-5R<*E$K:7]N4.)3;MQ
M0)52]Q;72,224%9S<8(.6GD[Q_0^A6:854PBASVK:?3];5["&KCVKJ]M"^;5
MLQ)7<6!;K\[QZIX0B(@L]L5^G%@*8[LN1+6=&SU\K8&]J8U"5P7221,8=*-)
MP'E&E(QG<X'HY^Q>GQ=U#);\IR#.%Z0QGI3HQ2^W'7]@U"G>@NB)//* L%;7
M-C*H0Y&F&"?8H>L):I*S'E*7 PIAD2#_ #[J4F.=3R$ '8Y'0^L94TL*$PBK
M-\E/473?(\=I*VJ#J%+>L(:[!?S^BJR;2#!V6_U(T09\?GA54IFE19!TSBB%
ML=IS]S&HU@WYJBJ]  28O9XS"LP!Q()QML?3D8]_)2>Y1ZYH'MFHF^\>;IR&
M?5VN<3F,UTVS/C"J;)$B;FMS=(ZYMK^W-RLEU:"7E"4XA(+4(RU0S""%B@1)
MFPE!!!P1@J2F%"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB\1C 4 9
MA@PEEEA$,PP8M    -;$(8Q"WH(0A#K8A"%O6M:UO>]ZUK"*J_M?L'H")UA$
M[W\?$9J3L2"5#.5\AZGB4%L)BE4P?:L9&PUM?H+5Q454/0!6:E,>1SHLH\PM
M6G(@?W22TR$Y]VP+2LT G#MLC8^!VP3Z,*N"Q.=N >YFV&^0^IJ9Z%\A1=YR
M%LB=1<_0JZ%5503E*PWTQWE%KV0^(44WABJEGTV=F@?;=D_QY:L03Q^:Y4PL
M+@*0H'XXK9<W+"0W&<GJ1X>G(Y#8>E=(->,C_&H!!HY*WXZ52F/P^,LDDE"@
M0QGR1_:F5$@>'X\9A91@SGAQ(4N)@AE%C$-0+8BP;WL.BQK,,(N>;RC7Y=D8
MZFB'."+H&4\@"NNKX^X\47RH(8G;F>=]#,C[+D%E\V=21R3QY^:G!OL9D<*_
M*C+NJ*&F8_G$GR*-<K7.C*_ED:!PDXXL'<;Y Q]H$>WGLO\ 6JFFQ_(8R5HX
MW5X[Z#A=^1FS55;]O7_,'1H9[/H"WN:'V%R*&*J *319^GDM*G#$O9YK5[LW
MV(V0:(I9">->XS1H4G[EA0?-SAQ(Z>!!YYWVZCQSX=.A3"HF$7'-UK>O6%W2
M3M*C6J7S5^NNH%%SQ'JWQLSQ2T?DAU7P_)'=],A=_<1/*AA%(8C9$7J9VCKC
M]W,BIT<#WYM;']P:'YU$HC,\+, !PGH1D/'W7>#AR(SXC?QQRL,\:7CFFD96
M<A]#V?-JGLYNH&N3=\J=!PB/R.N[]L[F2VJD=66(TSU##?D!PUW305KES-(X
MN^(Y5)G=J=HVB0:_6<7YV<WA^_?G_?\ %5<[F!D9YC.1D'F"3G<Y\%T&X6-8
MA8".9.,&E[=7;JU,,\<8X\-\.D#XC-<F>/21<A.2L\@<VLD19KNB8UQQ+JH9
MP'I!.Y:/;;I<@^:^<((J3N->X)I4=O.OC\\IYT.BO5S!%1MM0])N9*%CK3N*
ME4JM02U.S&[K@)4)-EI-J3B997AHPJESJ>Y*6QOTY#=D.BNX CB9GAZCF6G]
M.6#U]8*D!XO>2^FZ(CLGLWK.SC72RIW!ZIJF*45%%2453T%2E$-CRP55%&S9
M UNY!8RQO>W1ZL:6E.BE M>78;6W#6HFM.YJRAQ'3TY)YDGY>'OZX%L&%50E
M[<I+HWH6*UY5]"]%2_EMG=IHO7VW;-:-S,NLQ+%6J(2!3'8_%E+V>04S)'J<
M?D^*1.K9H;UMN0A:4^R6UV=E!16:0-R,^&>7[_?I%+B5EK.>2VFHY<]#<\]X
M^9:,U+?-:)6ZX'%/&:Q?*]YQZL>*._MRL..:C,XB4/D]@0HHRQ&!X<H8&1R-
MLBKW$(T\-AA3.@5E;)WPXM9GIN>6< 9R<';GMUZKH8YZJX5*TK757#+CB8V(
M1\I">VPMO4L\%8E"E2I<E,:KYE6GJEC%7<8/6F1Z ,*I2H4,D.;&1J./.,1B
M,$6,G)S^_P!^GJMRX14"VQYE9I4$NL.SC:<CUG\@49T#/.;NK3*^5R(OIKD&
M0Q"?O<,CUK637ZT*YHGE-V6T-2";QF0Q8# 6B;GL3$:O<WMF]CP5PS.V2"1E
MNVSMN7K67S.NJHZ!O^^*]XJH?GEKE%RH:REO</4-TTQ-9 WSRD[QJM/^23MS
M%(TB'\B;)F2V,-X3US>XR5@@3)*50I0\,,VD"F8E%E'(#)SC. #N,'?/4?-7
MC$D@3DE$%^[X9!19(/>,9H_86#0 ^\PP0C#!>T.O<,P0ACWZB$+8M[WA57^N
M$3"*!?1'CTI'HSI/G;J%_#((9:-!J) 4=,*VD;[ Y?9$-=FA8WIZGG4BB[@U
MKWJL_O%S5/;BRJ3AGJ=%J8\0H3QR52Y ZE8.(!'0]#O[1X'IGY@8GIA53")A
M%6G57CN:8YW%:?;MIS]XL>1 =9"AY8KP1RE%!><HC/V!LU;3LU-!>R$SO9=I
MRPZ2G2.5+"CS4T4/:8\E.-*3!^4*W%YO"!CJ3U/A[E99A53"*-75O,<:ZTJL
M=42F<637;::^HW0Z35/(RHG,MM9S<[1B7QI.^F('$U USJ R:6P9]/0E)W0A
MHD:Q2U+T+B2F5%DY+YW+?%?,W%C1.X[S'5[=4\<L>5(YG)HZR.L@6,8W]#&V
M>+%*6IL>75R2LA9C8RI3%:=I+2%+7 U6X*PG*5 AZ*22>9SZ3S]_-2FPH3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$4()?<W-G:$-Z4Y!JGI:$"M60
MU!/8%(F^&2E&*QH&W6+#%T=06&SL/S2)W<6EN!(D#PT2=GTH8%8S&T:9WV%:
MF&84X(P2/?R]7]%SS<\0?JN.]O599,FJ:9<Z^1.!V9754=BHX=!9,#DOR:<I
MR&8-,.E/2$7D\>8M5XW6]6L<<S;-D93F>S*#S6(U>!"@>DSA$8\_?]?FLA+>
M$CFW<MSCB8?#'@?1Z_%=)_/O&'/',DVO.R*BKJ/16<=$V$XV)9CZU-J= )>X
MK )RB6MK1IPZ2LC*#Y73HX(&PM.2]2E<\2=R :XN6_@%C)) !.PY?OVJ5.%"
MH!\T-B2*JY13#I;<KO>L.+[&8G.M9#TOSC.K!A<[XPZ.-D*)?5MYRMO@STUI
MIQ6LB1JCXG(624(G=$A):U'W,- ^O"5LE!78,\L%PW (!#AU&_7XXSOX?)H&
M*=@]N4O'.6NQ6/D_H&.4-?S(UWY:%@P]7.H;UYRW(ZT+F%+WCSP\Q01+!'K6
M=27X@ER>R!MOW0I;]NFG%.O4.L=<R'A!RW(R.0.[7<B#UQC/K5[-;UG!ZCB;
M="*]82X_&VLLDI,D^=<W9:=\ND2MZ<YS>WQ:Y/KTK(;D*!M)6O#DN6%MJ! W
M@/TC0I""2HL[PBY0>R[#Z@;>[K!I=EO6P^6NRRY2?:OCLL=]L*5@X[[>J)8@
M:E2OD"T:]?WHZJ&6R(L]A<HS'G8EE:5STZGI%+L,IX>(\_R1^_\ ?^_RWR #
MAXL<3>3A]YI\0?CX=#XBSJH*9>^_9C0W8/4%$T4SPI'SS GJN8V='9S&^M*3
MZ4+>W,NUV4ZTFMS9SC:B*%]X-S.Q%+]Z?1"(6N3(C#\\>^E4^:"T$\]_PD#&
M-O'/CZO%6\-[>@:4"%J:D21L:VQ&F;VUM;TQ*- WH$1($R-$B1IP%ITJ1(G+
M+(3)B"RR2"2P%% " (0Z*JQZ?H)4ZP2:M<$>$T>F[E$I(@AK^L("J1L<J6,Z
MQ/'GA6F&4>%0F;'<Q&M/($2<$XH@1>RC-"V#9%R-\R]:])PZZVZUH!)K=;K"
MJZP(13_E=\8=U6-,[*<XG^4DD98*H[,Y%46(_221'0U4ZO3=+7UDC#N>W%DJ
MDI*HY?$W%E?U)92UN,'&-RQ_+_NNV^)W]A7255M#V#,%T2L3M5OHJR[HIRU+
MB?J%D-:Q9Z2,,"@LV5D-D16A(F7S;FGLQ%"DVV9[>&TXM"0!>I2I#G105]_*
MBQDCIL"!G._R\5,?"A5[>3Y[O")<D2R=T7!WZUE\ D<3F%G4_$))*H;-[8HU
ML<ME6Q#(-+8.O:YA'Y;J,*SY(S*HZN"YJSX]MH*0O8'$Q@=2LW!.#MGKX'H3
MZ,\_0J@O']T#U:ZAE5=<E]%E]4<R=-4W9LXX4N_IM:_SJP^3+_@9#*JD?+76
MRA I73A6A8D$@TLC[PZ*GDY2C9V\^-A?&9R-3[*S@!CB&' @. ^\.?$/#P\.
M6,<E>)RWQY7'.SK9MM:CL<4])='N[9/.D[.:4ZD0)5/-M2(IT9X?MTT8Z1ZK
M6AV X'PV)&'FF(R%9BYY5.C^K7N:@J$].G0?OJIA84)A%6'=_B]K&Q>GA=@U
M78$JH.Z97%S*ZOE)'62,3*I>G:O5-X&9=#+UJF6H5#'*QC9"2&A&_IE3:YI4
MB9$)1\^J:V90VE;B..'8CF/$'Q&%/JI*RBM*556E-P4A4EA-30"'5I#TRY2)
M:M3Q>"QYNC# 2L6"" 2I44U-:4"A3L -G&A&9[ >[VZ*IWW6PL(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB\1C 6 1A
M@@@+ $0QC&+00  '6Q"$(0MZ"$(0ZWL0M[UK6M;WO?IA%H>WN@J)K*A'N][#
MG\?!21\51NQ,N97#\H$,P:):F((C*.""C9BU7,W><C<T#="&N)Z<725.+HVI
M(^4L5+4P1D]"Y*X+S-U7)7BMH09!;,<>A>,W*-N7CS[KB"%DD,UC,22L[',V
M_P >7DOCT!?) LK1_;H)*6R'.BN;F;CT9 _*C%#VMA3B\JIL67B !QC!'G-/
MC^)GKZ>[P76O17/<.Y\*M<J'R"Q9 &X;HG5Z205B3I[G(VF56 -N&[,D/&]&
MF[C4(0?=B?3%%T/^4;?B*1Z,.-4&&;+&3GV#'(#EZN?K.ZWOA0F$7R7UA8Y2
MS.D<DS*TR*//:%0V/3"^MR-W9G=M6%B)5M[HUN!*A"X(51(A%*$BL@T@\L0@
M&EB#O>L(L9K>K*QIR+IX14-<0.JX6D4JEJ6(5O$(_!XNF6+1!&M5IV",-S6T
MDJ58PA&J/+2!-4""$1HQ[UK>$))YG/K6>81,(M<V;3M1W6PD1:Y:LKFVXPE<
M"'5-'+-A$9GK"G=$ONTF<B&B5-CJWE."?0A:(6%IPJ"?<+X9@?7>$SCDL[;V
M] TH$36UHDC:V-J1,WMS<WIB4:!O0(R0)T:)$C3@+3I4B5.660F3$%EDD$E@
M** $ 0AT1>WA$PBU:_T;2DKL&-VU*:?JV2VK#"]$P^S'^OXF\V#%"0B,'HJ-
MS-Q:%,C8B]#--'H#6Y)0Z$88+6O48M[)GX\_2MI81,(F$6K8=1M*5W+9;/Z_
MI^K8+.Y\9\6=36'5_$XQ+9J;\?YGXLMD;(T(7B1F?,_YCWO"Q8+X_P#B^OQ/
MUL(MI81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3"+0O2UZ(.=*A?++/CJJ:/7WS#(1!("W+B6UTL&R[,F+
M%7E=0AN7')EH41TCF,E9T"EQ^07A9VT:YY/1GI6\\.%(&2JBV[DSYRT)WQ0U
M3,-:3OG-V=.C/'U8+XV.$WCU<\[]#S)$@LM9!JR6OJ&".EW\JR@NR*RI*:2]
MOD>Z>B-EU*N3,RA*[*4QQ3TSMOL1UR,XSZ#UP=R-]\*X:@* K#F6L&.I*D8S
M&>,,YBYQ7+G%<I>I3,)2]*1N$HGD\E#@,UWE\[E[N:H>93*7E0H<G9R4&&FF
M ) 0024$DG)6Z,*$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPBAWUOR>Z=3GT5\E?%C4<FI6U3K6VHK1G@;B^2-WU!Y7"&H!:ZP8U,&5C6,*
M:8NSHRN^XT\'M3P)(^-1""3,\>?V4I!QG;.1CXC],+-*/Y.I3G]>ZR2%,;\^
M6)(DHT<JMZSYI+K9M^4)SS4:E6D=K&L-YD4F*9U2MO0*]QAH7-<32&H&\+<P
MHB&Y 2F)D_O;\E)#"A,(F$3")A$PB81,(F$3")A$PB8149<]=_7\Q>32PN,.
MGW2&K:DM"*V[*>.[%1QM/%7ER<>?K,E\/LRO)HX)5H65[E)$6CZJ='*F]J9D
MK>QM:0\28L3UHHHK\(+.(9R#AWMY$>A:EJSR(=8W'T]Y4Z\%)8G!J[Y+YP@]
M\<\H6NOV]1(5J&S*B)MV#&6:JD2ER-7#-CXVL4CC[<G85B-8\N380ZI3&Q,H
MPA: UKM\DD'<=/#;]5K:J/+ST;(^-?%XO7'0-]Z_\HUW2NNF!Z7Q#:"JZ8@L
M&M=1 Y[.TD-:'9&\2IRCD>41M8RQYVEA!3S)7E<N5N9+,U CJPK%@#G_ (6
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9(F$3")A$PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g431217g96e78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g431217g96e78.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2'B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP"   "   < E  #5!R965T:&D@4V5K87( .$))300E
M       0EEA8R+2\4M&!=SFNZ7%GM3A"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              18   (2          $
M                     0             "$@   18
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   18     4F=H=&QO;F<
M  (2    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   $6     %)G:'1L;VYG   "$@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 5 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_66YN\GI.>YK)@LJW$QZF[VN<S_1U?V[_P!'OKKMM5S$OQ,5K<5V..GF8:R
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M&-W^JW^1?78I?8[,CW9S_5G_  #9;2/Y.SZ61_6R/^V*E:KI;6P,K K:.&M
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M66M?D[+_ /M-53DW_P"#1L/J&$:A[?LM-=-5K/4VM8*[)96UNT[6^FYGI?\
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M_OKM].IM.S_M[T(<G)\7JA(7*SPE?'FS'TR@>$:"4?5_C?NN[E4 B@>-S?\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %*34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    .    L(=I  0    !    P    .P $NO
M   G$  2Z\   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-SHP.#HR,2 P-SHU-SHP-0!0<F5E=&AI(%-E:V%R      .@ 0 #     ?__
M  "@ @ $     0   A*@ P $     0   18         !@$#  ,    !  8
M  $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !
M   !2@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%,34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    .    L(=I  0    !    P    .P   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HR
M,2 P-SHU-SHP-0!0<F5E=&AI(%-E:V%R      .@ 0 #     ?__  "@ @ $
M     0   A*@ P $     0   18         !@$#  ,    !  8   $:  4
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M\!@E<M'A,S548I+2\1DF)S0V-T-$14=3@N+_Q  = 0$  04! 0$
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MN!YG6;8$WOZBY%^N+V-]@UUDP-+9HR"WJL4LN9W)5RD2"ZTU/"ITG$E@N[]
MDT5-0HG_ )=6;4U<P&$DH=XJ(]/S7Q5XV<6\1Q34&45+9+12L]Z:I,TE1,K
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M40+Z!4L-K;;8[UXSG<9V2F0\CBV2I\M2U$.(I>FK1;B#(0@!U)(!&?[.DJD
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M@TPP:88-,,&F&#3#!IABVH4QA*)1 ..KGD1#\Q>/8!]-4871@/>(%O3K??\
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M2MP 7'X0L\TDOE)<A!^DGDL615T7\4P"!3@01 PF*4S#$F6B1$ (BB4"(D2
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MHJ*)IE24KN&8D1GG30Y?YADULHV_(<:L=0 %;Y CT=:((G.PQ+'3#%LRR9!
M#' !$0  'GD1,;I  #CGN80#]Q /?5AD4;$[FUMCO>_3[OEAA/6>WU6F0C^Q
M6ZQ0U8@8U$59"9GI%I%1K),?I*9P\?*H-TA4,(%1*=0#+&$"I@81 -7K=B
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MC&[SZ..<PTW(NUK+_BD9_@C.L"K 0MC=B<O"F.LDMG#['=Y:NC\JL4HN>1L
MM3D.^@8Y?Q6J<"2,HS#J Q /J =C;XCZ8EI/&X%S9K D$$;]P+];8G[YMN(
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MC.S-3M5"/ 1Y(W6*X!0Q1(("PQJ(?+^/)^;DZ]#VJ#?R,/7Z]:'XMY)NJQ+
MVES-M824;2:0GCWK1VM7)@AU&KE46HMT?-%1\VWZV&-P7(-/,V<.PL]8\LSC
M3S+YR-CB?+,8E)T[9*RKQQY@4VT8D[9.D%'RXIH)JM'B)S%7:J(Z88T:V9<:
MH7:(QR:X0(W2<BI6:C((DD@=PY8PSN!9OA*H03(%= K9H,S9@=4KYX@^!TV;
MJM6[E=%AC8+9.I:18KIGXIV>:=G9QI8U\A)E<J)F735.0\>9R4&[=5LNW>.S
M<,V;M(S1PX(L*15&&,&D9CQMD;S(TRWP,\#:>L5<,#*3;'46E*H_2B[ FR2Z
MP-(-XY^X:H*OF/F&)@=-CD<F\P@51AASM,,)"]V=A2JC:+C++H-(FIUJ=L\H
M\<GZ$&K& C7,HZ67, &,1%)JV<*J' !$B1%#  \<:88:;:]5W=:P)C0))#RL
MW.0)+Y8VHD4*8MFOSA:ZV(I_%-XA5334V\.L*O4<%CKB8 Z^DK%!TZ?0;]?S
M_OA\9";813-9_).$&+%J@HZ>/72Z;9FS:HIJ*N';IPX%(B#1 B9CJ.5NA$I
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M8=-_4G_>^,DD7R4! "^_H0/N.L9D]6/XC\,7^SI\/N_UQ>&- 0$ )P/W]?\
M#0R@][?('%YB0BUOR_3%DT8 !WZ0Y[=R!H'N=F/X_P!\6>SIZ#[O]<8JD23@
M> */7V/P4  P>P' !Y,4HB(@!OI 1$1#OJ[F$=_COZ][6 &]OG]U\4-.MK"W
M;MM]WKT^[",L-&K]EC'\)9("&L<'))*MG\%.P["6AG[=;J\9N^BGR"\>Z26,
M<XJIJMC)J"<YE"'4,)]9 T3C2;&XWZ$DGKU^)/6YWVQA:&5+L-0';;L=Q87
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MW=K7(VOTV/R^O3$NV$40A"E!,"@7H*0H#TD(!"\% A X*4I2_0!2AT]/T\<
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M=")'N.4"#$Q*ARI8==(-B-B+W>*%"SJB@+8E5(-V\HL1>Q-QN1WVZBW)O?\
MXQ,?,.+)NBW\F/;IE>MV&.N2]CB5)RI+U3&2<9Y";09M'T?)C;O/75G$-VB#
MMVPE(U<XR!&!6)%'W/<:IDDG#^6Y_FN235$U/,PC@IV6.T;:&;7S$G\K:26
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M:T1O\RJWW@'^^/ )%T.Z?Y79=_\ I)']L/AJ[%F,=1;H,)0$H#P \"4YA !
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MX7'">99=QA7R-(^<PK2$2:69)YE:G0$J\K$D.I4L;D%22"2,3W2A"F*02I
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M@8[A/O,\G:EJLHJO>#PP,]2-XFD(34>;<QDDD_UEC>^-.D?+DS.(+[E55(H
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M*FG<^RU<E*[M$ID=8G,21DF\DA<  +YBQV47 $:2IAD2149&;25.DABI%QN
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M,Y3+1$RI4E6ME?O)Y(62+B+<0#=E(M9!KV%?Q)Q%D'%<>4Y@KR053EY$EYA
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M3[9(=6GI>20@W[;$;;7^[#^WBHW[(&PC!]1QM,UF!N%C_P"CS"QLC;9&0CH
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MH$V7[=2!S_\ =+0?4/3BKQX?_#]-?<%."((0>O*2_P ](OCY/EWEE_\ V/\
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M<Q,LP?Q[T@*&!)RS<$$P@F8Q6&-N$NQ,) *\9GZUQ:EZ'*1@%T7H*9OV,/\
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M"\169HMFGF8L\7%*H++ZVE.:5=+399/6Z9S,?;(&("TTAL5!:P+60:FL  6
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M?'8\!L3G494%@&BN0"?ZQN;7 W%[?0=,(5*'+V*(%$W!2]/2 CR4O(@ >O4
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M@7%C>QQU7"G'$_%/"59FE1<&@J"G,D9U1UCD0-H:0!BEM0-P#J.EEMNV9?\
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M&3F:]MJR!@+#TWCW(D]#>!?PR;!96E(B>K;C&3"Q$C_PY#L24AZYE)6P-$[
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MB"8GOW?O]_=AAN-[,$T<;0-P[$B""+9+"F0D46Z")4TDDB563$B2*9 X(0>
M*5,H<$*/27MJ%F3M'E];(@NZ4L[*!U+"-B+?&_3$JB(%92EN@J(B=^P<=?A;
M'$BP;,(.P0\4\-'I&,M"QBRA#-2 HD*L>V.)E.P'+SU!P4P@8W4 @ @'(?).
M89Q5)GLQE#+N20Q86OI'^6USUZ#U]<?2V7&"3)X%N/=&X87[_$ _B#\<1%OG
MP\HQ\=R PI'*"P]2C=9HB9LL1,QC)E.1=N[ W<PCW0]! >H0Y#6PH>)J^CS+
MVNF?3&L)C9@Y7SFY^FQ&Q'K;UQ=F^6&NRZ.D&6+F$3,'=S"9-!&VBXBD'_5U
M[[@WQ#6\?#G6CE <U]D]KSZ-\P,4\KIEJ\\BC..I)UY%_#>170([0.HD]21(
MW!SU&!95=,QR&Z3A'Q-XCX=SJHS.&2579)N6PED3S,C@:6"GKJ&PL?GMCE>*
M_#3@GBC):;*\PX.H:V;7 O(J:&FEAD8.AT3)-1-'RBR^;6I7L1AAH3;-G;"L
MM8I7&-YN=07GO "PI^=7F&5G4:&_V-S--Y(TD=P^9H%%LUE2J-WGE#$:+)*$
MZQ+ZIPK_ !#\99=7UE14%G2< GG3N0S;;D-$P+ +;>]A:UNN/*N-/X7_  VS
M_+J*CFH*7A=:;RI_*:2EBY":F=TC]D:BT(7)9@I )9B=R;F+LB[QMM079E5Y
M8;_$WZ85L-CCKCYV,?,YXS!I&.9>%DXMJ[:'0D64>P0>13Z)3*FFT*LW>>,L
MH5/N>%/XD*^D?-)L^RM\TEFS)JJG=YY&,<')B5(T/L4K!1('8"ZK=R"IOOY3
MQU_!WD&:TV4Y/X<\;YG'-#EI&9$4,LL;KSVYBRJV>&(R,ATEK#2@4!0=\.)M
MV^(KN"P#6,DT>]X_6GXFXWBT7UI)4IVLJE&/+0HBYDXFPQTJ+)RZ.F_(X493
M*0E_D*-4#$3*W  ]$X:\??#WB3,9GSO(8:.HA9IDD+( "GVH#B3+TN0Z&[W5
M0/Z;KOYOQ+_#!XL<-Y/24_"&<+4\.A(J.OYSI'(*B33 U1&BUS64(T!,;<R5
MI%+<_P XTO?M=^,/6L/XGRIC[+49-8SE;?DF\W@[RQ)E48VQO;Y0\E'&;SD>
M,A&C*M6RR,/Y)RN"Z;.-9I-$S'$Q1[#*.,/#?B+B6;.I*VDIM#F:(K- R^1O
M*I(,?NH0H-A?OOCS?B3@?QG\-^&Y^&<MR3,>):;.5$9K8*6JWDF1(Y);\JKU
M<QAS"O.95#>4Z5)+*;</BI6&A2^Y@\)C7)#VA91N#&Y-I6(AI4(H'32!;UZ0
M6?10M4)-(9=&+9K-W:: I/F[$@+&\5,PZR3>*'A94<1YK45M11$T#0+1O[13
M7D70PD(+(=V,:MY!92P)\QN:T7@IX^9;P/04&6+F-1%FIJI\]HC!6M_+&DDY
ME/&T:3>13')(J\[E%Q 2JE25B0N'=[VZF,R?G#(M)PI-R%-R.6 35,,VA$6$
MB=9))ECGXQANINNF]-.R1O**N&+N-;H-P*99TY=%3YNN_B(\,ZW./9)11\J,
M+'&WM,&H!-M0?D;AC:X/4J+W[=IDW\)_BI-P7%'P]QG-DN;R23SU<4U/)RY'
MJ2"\34[9S2&-D\P#*22Q!6VGS:K%][^(!+Y:R7F.HUJ!K9+A"1\$^J-C+)F<
MN6<0_=/8YR$Y'M3-FLBFO(R*SE$(V58G%=-("J.$S21N-S3^*S+HL[%4G#<<
ME-"HA2\AWBCNJ$2?RT^\ #>Q!4A1L+GO>'?X$\ZDX/?*<ZXQDR#BB1WJ#420
MQP^TN]@76GDSFF)2=5#J&D;<B5M9L!D4;!>^VZ96G\PO[Z[QY:'L4I IQT8R
M*ZK;N+!8CP6,HA(&/(2YC/44W1GZ;N(50.0GE4#% 2#Q.=?Q9UM3GL=?EV4>
MP *L32),Z1R0J21$;4$(8#WM.I@W^46OCNLE_@<R).%8^'<RK3F&=T]6:RJS
M.2GBDEGB95C%I!6L;:[E09Y-(.POYBIZO\/#/%YR,MDS)F6;>SMS=HY91<[6
MGRT(DR;K&$R[1O%,'"3$&KI?H5>@_-,K/@31!P8!23*GQ?$'\37%5=G]-FB-
M+H@T!=%3+956PL&$ "BUK6L!W&/3N&OX./"W)>&:G*,V2EDDGNSK+0TMY).S
M/KG<LWFM<F_6U^N')K/PHV$S;W-GRK99G(3D4BI,7DR^-\SBR)G+X9(IVBW
MD "0% 4U(--BH8Q2F<BKP(#Q7$WC9QOQ!F]/7IQ--#&K&1(S7RDP*UB(Q_Q$
M84*!:P1;=-(WQVV0> O /"N719-P]P5P])D=5!&F<2"BRU!5N%TRS3HM'()'
MDU.QYTCD'JS6N7\H?PL<45FPNIMXD[L)'I? >%G7#R<6=H (BFW6>S#Q\_59
M% PD*U<K+M2' 3IM"@8=<OQ#Q]Q7FF84M9-GLF81H@C,/M<DMW(4"0CGR#R;
M]4)'=A<8[O(_#;@+AN.7+N&.%\ER?*9HI):FHHJ6@B9:H;K'_P /2P;2%GU
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MO54TI(B@OTL--[].^C\S^(Q45%*1]JZ"WJ1;K;N1?M\.^]KX6+&@"4%#^ 8
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MK;4;=?CMO\,9:B0/3M/%Y@$1@.S68]Q_V_GZ8SL;'YQMC?L $&@T_K-SW+Q
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MM(X[@I^D7:</7X07;9Z[CVECM%89QHL6!OG$R1E$M8DZS9W)*BGX@'YGB_\
MAW67+HN(Z/,ZQ9ZO09*&3+T18V8L++*)68[+T,8))!O;%.&/X@89<TJ.'YZ*
MC6.F,FBKAS RM(JB[%XS$@# E=-I"J@L 1<77D;\73%,+8!I>YS;QFC;S:DV
M;ITN=XE6,BP"A(\Y22 ,WU6F"33YZS*)E1A&< ZGW""9E&,<]\-<$O(<_P#
MCC+*:),PHG]HH);-)4-&Z%)R2.2JB)E/D"L+NINQL"!?'K&1^.V055><M:O-
M'6Q^Y2*('66$6O4M)+(KH"Y90JJZ@(=5BPQ)G'>\'8MN"7&*QGN QK-SH&1*
MYKDRO+46SM@<%6.F+BMWZ'K,XF"A$TQ()XWZC', =?2/' 9EPKQ)E5+":RBJ
M8M;I%'+'"[(\K, MV**H5BW4%AI-P#W]!H>.:#,JF9:;,8*O3&[RHSPQ2I$J
ML79.29'!32QO=0"+:@V'HEL*0<HW!TT8-GK5S]23MJ9HX;K)"'(*-UTE1*L4
M?<2B !SZ&#D2\_5_S2$)'(DD)3JZI8G;H=2C\+_#KCJZ*LR]ASXUCKBZ_P"'
M-4.P7:YW\_P^?QWPR5CVS0#SQ#BP0$1 P"4$R\]_^(3D+P//?@H&#N ]_366
M'.'I98VEK)(V$>CV=H86$@N?M"[,&!)NEE!MI]ZYMC:)'+&PJ,JCI:5CM,L<
M<<A=-CR];QE@N_4&Y]+G$:K7LPKCP%N&"8 ?JY*3G@1 1'I'L)1 !#L =''
M<"'ME3-J@S/-"X42*X8J &TL&4VL!>X-QON=\1GHJ":9SF4,R4S(Y]ACJJA8
M6GTMRYB1)&0R2<M]%BI,8!!!L8%[HMF-;KV*)"45B"&%&W8]2 QBI<D%]>X)
MHIT\%YZSHJG3$3]?J(F#[[7(\_$$KPQ35:@(=[$$BQZ^?:YM8CJ=CB'G5+#-
M2Y0$6&*++S$I5J:&<SZ.5;6TRETV2VS-;4=]AB9N.]ME+K%?:,XVN,$$73=,
M7"8I<^)U 8IA/]78Q^1$XI^&4PC]28\!K03YH\N9U#ZYUY+@.KNZ\_43:]F_
MI"V'I<;XZZ):2.-:BECCCCS"./VNEY2/$QIP50J6#%-0D<'0%N+7!L+//"86
M@8LHI1D*R8HJ /B)H-TB <.1$>0(!"^HCSR7D1[B(B(B,&9(9*CVD0Z9!8FT
M[[D#K>^YV]#Z8R%,F,>F/+EB?O)'43K<^ND,%%_Q/RPNXO&35N7I(R2*7C@2
M@D0#&#GU P 4.0'_ -4>>VKOYG)+$8I*NQOLQBB)%B; _3IOOU^&,!JZ/E6S
MV#^858-HJQII:5E2Q$:\JG*H>6EE#$W-M1%^JS9XZ(!2CX/28![' B8>OT@7
MC@"ASSW$3??C[:K/5K+2QT[R7T2:UE6.-78VMIV \O?KU[=L8XZN*,!XI3%8
M^_JUM*HM:(ER?*+!R1<@]L*]CCLXE(!FQ1,'0)2E !'@PFZQ,4.GD"!TFZB\
ME-R!>OL8 L2I?D&G6D,MP?MCU (&X4+IVMZV^!VQ"DJDFJ!+5+>)3<CF,-0'
M8^Z+&]OA\,*#\"M(YOYB2,VCV_3R=T]<%9-^0[B BY\'@O83=0"*10 1!50H
M ;62ER6M="/Y2\@F\ZS<RI4D-N&"!-*ZEWLMP#L"18XB5&<Y1EHFDJZCV.FG
MD8K&E2SB16)*[O*@7RD[ D+T %KAN;)F+;5CEHY>7?.>(*PT:$.LX7ELBU5
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M;$K[P-RW 5'A7P55<,UE)PI.F2\1SEY#+3EX;5#"30RQQO*B%&D<(5@!0-9
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M:@"+5E'"#- 44R& B_EP$HHH*)C9P=3Y=7YC+F6:,\G)6>20 L9&Y27TJ-:
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MF;,9?S?C#P#R*',Z"!!"DD] DB+S*GJTTHZ$'?RWZ&P^F/2. _'K/\PRO/\
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M= I"_KSW$! >1 H% PB7_?Z0X$P" ]^?7C@;7VZ8MU,V[=?V=MSMOC*
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MCP&:]ODHF,08,(.NQC&(-"J)S)L&N-MP; G>_>_4[7[>IWQ+@@T7U"_6U][
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MTUD5'+#<DB]MSMMT&_QW ^[>V**\:FY6V]QT&XO:_P >F-"]>D 0ZQ)P GY
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M_+]>0_PTPPU&6<-4G-%:_#-WC5'";9ZE*PLY%O74-:*K.M0.+"QU.PQYDI*
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M;?7_ $.,AD%]]S\+$?V_+'OFBCV W<?3DO ?Y:<L#?K;M=3?Z8M+@@]?W]<
MN!#U,7_#5+C_ "'_ -(Q9=O4_?;\SC'.[^H?J*/IZ<?8/UUF2,,H.D]^P_0X
MH6ML6_\ =_KC7KR(#S]9NWIT@)AX]>0  $1].?I P^_';5XC[ ??]WRV^([6
M^5O,4'WOQ^8_=OIC0N98A"FZ#&'@IA,($-R(%].P@!A$P=P I1$"E$3=/O)2
M(( 3:UQOU]=Q\]A\R+8C2SDW"@D[^[_ON-[['XXBM+YOF\AS#NF;;H1IE&RM
M%E6$_=EU7+3#N.U/J!0UEMB2?3;)@ Y!*D44D_.IJE2&<<4YL[9R;K#/.J$*
MEQ=02?COTW[BU^E]KXMAA:8%C:P8KN+;C2?J.F^YN".O1ZL/[<X_'TN\R#:9
MUUD3,5B9I-;'D>902;G:1Q5"+I5.A5Y(RT;1*0Q.0A$(6+.J[E5R#,VN2L4^
MY=RBT"265KA2--NAV/Y6_3XXG1P(@!(NW6]SZWL+6Q)<O7_O"4?OQ_IVUA\_
M[M_;?&<V[=/CBO63#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@T
MPQ;6)XB2A.DINLAB@4PB!1$0$  PAR(%^_ <\>FJ&]CIZ]K],-CUZ=_EWQ%7
M*VW,T]8U,M8MG6^,,V$:-V+JQ),E).I9 C&9%$VE;RK5TW,?^(HM(#%^63\<
M^B;K6CD(G 3B3!:1AY7-#*4(UV(M8V %OBNWX=/IC#+"IORQ\M1._P#W=1ZW
MZ??AM:KGM6%F6&/LYUW^#F3';@&,4UE'R3VB7\R70@$ACJ_))H0LNFJ8!#\+
MROR2ZQ0 1-W7"M%&+Y[M8I(I4)!868@ZNI-AO:Y(OT'4$[XULT=0C+J*6MM8
M=.W91?8GO],2?:RJ8E#A00,'!3E$!+T\_E$1-P'!^>0 !$0[=0$'MJUX"=_+
M8[^H/J0!?<=^WQQ>E1H%FO<6'0[?E^%[_.^-ZA(%'L)A'@./;GOZ>@@(\#_X
M^VH+PW-U&W0V[_+<CZ?[8F+4\SJP^MOS Z>OX;XV"3KGGZ@]O4 Y]^?3_75K
M*JVLI-_@#T_???UQE);;=?H;??<XO Z$1$ $.WZ!W_;D=6[?Y#O_ -(_8^N+
M+GU/WXJ\R3C\X"/V /\ +D U7D_/[QC)K'Q_#]<6SO2E !Y]1X[@7_OU1D$=
MK@M<VV%[?'H+#%K."-C;YD#^^^,99V!@ >>_' >@=^_KP/IK(@!_I()^ &U[
M7^?7%NY&Y^A)_+&J7D (4>HX%*0HB)AXX  #OSP'MZC^GKZ:SJE]E'7J?]?R
M_9Q@>4)?<?3M?U'P/Y]+X15EN,#6X>2G+%-1\##13<SN2E)E\UC(]BW)^95X
M\=+)(-B<B'(K'3X 0$0#6<((1S)#Y?=LMR;[;[@"WQ^E[XBZWJ'Y2 AK:KL;
M+MU%QN#\+=O3$;$K;E7<(X(PP<T<T7%C@BZ$AN&MD*9!_*(&%,KTN%J1/%0?
M3;Y,R:@Q]\N4(C2$%$D)& CKTT%0I,$M1'OH![[6^.W0[6'J=[_,&1'33+[S
M*3ZWO;UMY0>OK?ZX>O;-BNKX[QW(Q%;05*J?(V4#35B?G"0MEQDHS)%GB2V2
MWV%R4[Z?L#Z/CT@7D79P /$$C9LS22;(MH$C,SD] ;$];]!VZ#<?'$Y%TJ ?
M>!-]OB;;]>GPQ*/5N+L&F&#3#!IA@TPP:88-,,&F&#3#!IAC&7:(N1Y5(53@
MAB 50A%"<&$!'DARB \\<"'( 8.Q@'@.&&(FVK:7549.0M.&K'+X'N4H[&1F
M%::@P7HES?%,=0%[OC2106J<P^$QS :>CV<-;#IG,DI/J)=*9:QRR*VY.D'8
M=-OG]_3X8QO"C;V&HW-[=_CO8_':W3KA".+'N1QH $R%B9ME*(2$"&O> W[=
M=^5$."D/.8FN+J&FH\ +_/<$I5FOA3*IB8&+,.4B;6.JB90C?^ZXL 1O<:KF
MUP-KD$WQ!DI9 "RD6%NAO^%A8>HV%AC)B-UF%GCM.(E[TQHT\H)BA7LDMI/'
M,N)DQ ITTFUY8UTCLQ3"!148JN4BG$I#&$3)F4NO#W'7X7^^Q/[Z8P!)?Z6^
M'?\ (@7_ #.'[8SR#]JB]CG"4BS63!5)XP-YUFNF8.H#)/&WB(F#CL)R@=/D
M/I,8.!&X1JVZA0#L+V!N-CM??X;C%#)(NQ!)!W\MQ:U]R!U_?3&R"8'@/H$
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M3YG5FKI46C= IB&95F\).75_JS40#I02?.;G&Q*1$V\?"-$B^7"7'4N"-1)
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
